sampleid	sample_name	run_prefix	experimental_strategy	cgc_base_name	filename	analyte_amount	analyte_A260A280Ratio	aliquot_concentration	cgc_id	cgc_filename	vital_status	gender	race	ethnicity	disease_type	data_subtype	tcga_sample_id	cgc_case_uuid	sample_type	cgc_platform	gdc_file_uuid	primary_site	age_at_diagnosis	cgc_sample_uuid	cgc_aliquot_uuid	tcga_aliquot_id	reference_genome	tcga_case_id	investigation	days_to_death	knightlabID	data_submitting_center_label	tissue_source_site_label	country_of_sample_procurement	portion_is_ffpe	pathologic_t_label	pathologic_n_label	histological_diagnosis_label	pathologic_stage_label	PlateCenter	PlateCenterFlag
13722.58cfa82fe4b0c9d6adf6b62c	58cfa82fe4b0c9d6adf6b62c	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.bam	237.4	1.9	0.16	58cfa82fe4b0c9d6adf6b62c	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-50-5941-01A	F3F024C2-52F1-400E-946C-398F5B72E6DC	Primary Tumor	Illumina HiSeq	f7c353bf-7be8-42d0-88d0-e89032718c2f	Lung	55	91719392-76CE-479F-BA05-E43BF0201CC4	666720AF-64D9-4A63-BE57-2B8E49E79413	TCGA-50-5941-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5941	TCGA-LUAD	NA	s11128	Harvard Medical School	University of Pittsburgh	United States	NO	T2a	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5e0	58cfa82fe4b0c9d6adf6b5e0	TCGA-50-5941-10A-01D-1751_111007_SN590_0110_C003AACXX_s_4_rg.sorted.filtered.	WGS	TCGA-50-5941-10A-01D-1751_111007_SN590_0110_C003AACXX_s_4_rg.sorted	TCGA-50-5941-10A-01D-1751_111007_SN590_0110_C003AACXX_s_4_rg.sorted.bam	30.7	1.9	0.16	58cfa82fe4b0c9d6adf6b5e0	TCGA-50-5941-10A-01D-1751_111007_SN590_0110_C003AACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-50-5941-10A	F3F024C2-52F1-400E-946C-398F5B72E6DC	Blood Derived Normal	Illumina HiSeq	30af8e89-edaf-467e-a92e-6c6387c651dc	Lung	55	F5FA8534-1CE2-4D90-A6EF-9EF5D49F1666	9A9FA257-23B4-4B19-9CF0-26E9E13EB6C5	TCGA-50-5941-10A-01D-1751-02	HG19_Broad_variant	TCGA-50-5941	TCGA-LUAD	NA	s10785	Harvard Medical School	University of Pittsburgh	United States	NO	T2a	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1751-02	TRUE
13722.58cfa82ee4b0c9d6adf6af8e	58cfa82ee4b0c9d6adf6af8e	TCGA-05-4405-10A-01D-1853_111204_SN208_0256_C0562ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4405-10A-01D-1853_111204_SN208_0256_C0562ACXX_s_3_rg.sorted	TCGA-05-4405-10A-01D-1853_111204_SN208_0256_C0562ACXX_s_3_rg.sorted.bam	43	1.9	0.14	58cfa82ee4b0c9d6adf6af8e	TCGA-05-4405-10A-01D-1853_111204_SN208_0256_C0562ACXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4405-10A	F587C9AB-2949-4410-80D6-A050865D48AA	Blood Derived Normal	Illumina HiSeq	5ba6a451-8249-4373-b08c-91c603ad51bc	Lung	74	202767FD-8637-4451-A049-568E10E752D2	13562942-715C-494C-A79B-212EA8BCC2D0	TCGA-05-4405-10A-01D-1853-02	HG19_Broad_variant	TCGA-05-4405	TCGA-LUAD	NA	s11221	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	TRUE
13722.58cfa82ee4b0c9d6adf6af20	58cfa82ee4b0c9d6adf6af20	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted.bam	143.7	1.9	0.14	58cfa82ee4b0c9d6adf6af20	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4415-01A	D15B7B29-C5C5-41D8-B83B-7CC12FE92820	Primary Tumor	Illumina HiSeq	ae778c61-5e62-4f34-9b62-f28d9acf21b1	Lung	57	57E160F5-45FC-44EF-95C6-54E112E3B7F5	4CD99514-20D0-439F-9B9F-BDDCEE5D950F	TCGA-05-4415-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4415	TCGA-LUAD	91	s11220	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b669	58cfa82fe4b0c9d6adf6b669	TCGA-44-6775-11A-01D-1853_111207_SN590_0112_D09CDACXX_s_6_rg.sorted.filtered.	WGS	TCGA-44-6775-11A-01D-1853_111207_SN590_0112_D09CDACXX_s_6_rg.sorted	TCGA-44-6775-11A-01D-1853_111207_SN590_0112_D09CDACXX_s_6_rg.sorted.bam	16.7	1.9	0.14	58cfa82fe4b0c9d6adf6b669	TCGA-44-6775-11A-01D-1853_111207_SN590_0112_D09CDACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6775-11A	3C4FF061-D214-4D1C-8D2E-3034F207C252	Solid Tissue Normal	Illumina HiSeq	5628940b-6674-4130-b526-a3c2921984c9	Lung	72	3F3669E8-F8AD-4267-99C8-D221774CC859	13D5FBFA-D5A3-4195-9756-91151ECAA5CF	TCGA-44-6775-11A-01D-1853-02	HG19_Broad_variant	TCGA-44-6775	TCGA-LUAD	NA	s11551	Harvard Medical School	Christiana Healthcare	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b67c	58cfa82fe4b0c9d6adf6b67c	TCGA-44-6778-11A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-6778-11A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_7_rg.sorted	TCGA-44-6778-11A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_7_rg.sorted.bam	84.7	1.9	0.15	58cfa82fe4b0c9d6adf6b67c	TCGA-44-6778-11A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_7_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-44-6778-11A	5D5CC436-6E57-4D23-A164-7F5153C2E666	Solid Tissue Normal	Illumina HiSeq	8e94334e-a21b-40fb-9b54-bc9af6bcb7c8	Lung	59	2D27ED82-5872-4628-B6B3-A3DEECCEB0DF	9E581E04-C431-49E6-8C70-DC84FBF35F00	TCGA-44-6778-11A-01D-1853-02	HG19_Broad_variant	TCGA-44-6778	TCGA-LUAD	NA	s11339	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b690	58cfa82fe4b0c9d6adf6b690	TCGA-44-6776-10A-01D-1853_111207_SN590_0112_D09CDACXX_s_8_rg.sorted.filtered.	WGS	TCGA-44-6776-10A-01D-1853_111207_SN590_0112_D09CDACXX_s_8_rg.sorted	TCGA-44-6776-10A-01D-1853_111207_SN590_0112_D09CDACXX_s_8_rg.sorted.bam	620	1.9	0.17	58cfa82fe4b0c9d6adf6b690	TCGA-44-6776-10A-01D-1853_111207_SN590_0112_D09CDACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-44-6776-10A	C2A1DE2E-6451-4C95-8CE6-263F2B7E6EFF	Blood Derived Normal	Illumina HiSeq	043a1a5e-6327-41d8-838f-0af474ccf4ce	Lung	60	0DD94B00-F572-4650-B646-6B71685FA36C	9BFD050E-38C6-47A0-8DDE-B6D3D8FEA0C7	TCGA-44-6776-10A-01D-1853-02	HG19_Broad_variant	TCGA-44-6776	TCGA-LUAD	NA	s11341	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5f1	58cfa82fe4b0c9d6adf6b5f1	TCGA-38-4629-11A-01D-1203_110712_SN590_0096_A80WMCABXX_s_4_rg.sorted.filtered.	WGS	TCGA-38-4629-11A-01D-1203_110712_SN590_0096_A80WMCABXX_s_4_rg.sorted	TCGA-38-4629-11A-01D-1203_110712_SN590_0096_A80WMCABXX_s_4_rg.sorted.bam	113.9	1.9	0.16	58cfa82fe4b0c9d6adf6b5f1	TCGA-38-4629-11A-01D-1203_110712_SN590_0096_A80WMCABXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4629-11A	127BF818-F7E5-46B5-A9DE-39F6D96B8B83	Solid Tissue Normal	Illumina HiSeq	364e81ba-b440-470b-a9e4-8e3795d66795	Lung	68	85C1E746-D2E4-4BCE-BBC3-11FEB9CE4C28	D2150D6C-5E42-49D0-B65F-59A3004B1A17	TCGA-38-4629-11A-01D-1203-02	HG19_Broad_variant	TCGA-38-4629	TCGA-LUAD	864	s11446	Harvard Medical School	UNC	None	NO	T3	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b686	58cfa82fe4b0c9d6adf6b686	TCGA-44-6779-11A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_2_rg.sorted.filtered.	WGS	TCGA-44-6779-11A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_2_rg.sorted	TCGA-44-6779-11A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_2_rg.sorted.bam	222.7	1.9	0.15	58cfa82fe4b0c9d6adf6b686	TCGA-44-6779-11A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-44-6779-11A	CBBEA9F1-396A-4BF3-B67C-2CAC3394DCEB	Solid Tissue Normal	Illumina HiSeq	85ba6328-d485-4bdb-8720-4dca67560048	Lung	50	D6833663-C9ED-4BAE-A0F3-A92B18B21577	E4E0BE5A-9D60-4224-B4B6-EEC24899D791	TCGA-44-6779-11A-01D-1853-02	HG19_Broad_variant	TCGA-44-6779	TCGA-LUAD	500	s11124	Harvard Medical School	Christiana Healthcare	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6d8	58cfa82fe4b0c9d6adf6b6d8	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.filtered.	WGS	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.bam	168.4	1.9	0.14	58cfa82fe4b0c9d6adf6b6d8	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5942-01A	75DD635E-8E0C-4C0B-B21C-20F77770218D	Primary Tumor	Illumina HiSeq	915fe8ed-278a-43fb-90cd-986d5c65e9ad	Lung	67	AED669E8-23B6-4786-9398-6BB048815DFA	8DC8F884-F58B-4EFA-AE96-C87AB7F6D991	TCGA-50-5942-01A-21D-1751-02	HG19_Broad_variant	TCGA-50-5942	TCGA-LUAD	NA	s10794	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b648	58cfa82fe4b0c9d6adf6b648	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.bam	237.4	1.9	0.13	58cfa82fe4b0c9d6adf6b648	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-86-6562-01A	DCD066BA-5894-453E-B1DA-82092858C3DB	Primary Tumor	Illumina HiSeq	71d960e2-40e8-4084-bcc1-5ebbefc183af	Lung	52	DE4BB1D0-8BD9-4614-85CA-C39D8C636BCC	3AB9FD95-4329-4DD3-823D-F2E050CBA3C1	TCGA-86-6562-01A-11D-1751-02	HG19_Broad_variant	TCGA-86-6562	TCGA-LUAD	NA	s11014	Harvard Medical School	Asterand	Russia	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6c1	58cfa82fe4b0c9d6adf6b6c1	TCGA-44-6775-10A-01D-1853_111207_SN590_0112_D09CDACXX_s_5_rg.sorted.filtered.	WGS	TCGA-44-6775-10A-01D-1853_111207_SN590_0112_D09CDACXX_s_5_rg.sorted	TCGA-44-6775-10A-01D-1853_111207_SN590_0112_D09CDACXX_s_5_rg.sorted.bam	489.3	1.9	0.16	58cfa82fe4b0c9d6adf6b6c1	TCGA-44-6775-10A-01D-1853_111207_SN590_0112_D09CDACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6775-10A	3C4FF061-D214-4D1C-8D2E-3034F207C252	Blood Derived Normal	Illumina HiSeq	797b054a-91c8-4360-8f90-8f4aea0d25cd	Lung	72	18129C77-70F2-4DB9-9B5B-39E6D9C429A0	93BC6F55-FDB1-4BCA-B07B-3370CBD8D402	TCGA-44-6775-10A-01D-1853-02	HG19_Broad_variant	TCGA-44-6775	TCGA-LUAD	NA	s10658	Harvard Medical School	Christiana Healthcare	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b60d	58cfa82fe4b0c9d6adf6b60d	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted.filtered.	WGS	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted.bam	387.4	1.9	0.15	58cfa82fe4b0c9d6adf6b60d	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4631-01A	2483621A-4DB3-41AB-AA33-B9427EA8A0AF	Primary Tumor	Illumina HiSeq	b1dd06d4-cd7d-4e62-8deb-12fed31731b5	Lung	72	13B0D336-205A-42AC-8A50-DB0EB065013D	B1FA802A-C88E-4B8D-88FF-4545DCF326DE	TCGA-38-4631-01A-01D-1751-02	HG19_Broad_variant	TCGA-38-4631	TCGA-LUAD	354	s11229	Harvard Medical School	UNC	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b748	58cfa82fe4b0c9d6adf6b748	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.bam	142.7	1.9	0.15	58cfa82fe4b0c9d6adf6b748	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-44-6776-01A	C2A1DE2E-6451-4C95-8CE6-263F2B7E6EFF	Primary Tumor	Illumina HiSeq	bb5d193c-cc97-466b-9b28-bdbf5cf255e8	Lung	60	64FB8EBA-A055-4128-92CA-695A3A6F8EBD	5BC01EC3-A1C2-41BB-A9C5-95946A066FA6	TCGA-44-6776-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6776	TCGA-LUAD	NA	s10660	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b71e	58cfa82fe4b0c9d6adf6b71e	TCGA-64-5815-10A-01D-1623_110826_SN590_0103_AC005WACXX_s_6_rg.sorted.filtered.	WGS	TCGA-64-5815-10A-01D-1623_110826_SN590_0103_AC005WACXX_s_6_rg.sorted	TCGA-64-5815-10A-01D-1623_110826_SN590_0103_AC005WACXX_s_6_rg.sorted.bam	171.4	1.9	0.14	58cfa82fe4b0c9d6adf6b71e	TCGA-64-5815-10A-01D-1623_110826_SN590_0103_AC005WACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5815-10A	A65700C2-E58C-4FD4-AEB1-5686B8F4D212	Blood Derived Normal	Illumina HiSeq	9ed58ced-f480-42df-be0a-fdc8a5c298f7	Lung	74	E34398CE-FB59-4BB7-919A-AE03489EC54A	F1EC082F-85F1-478A-A2F2-8FD6296977CB	TCGA-64-5815-10A-01D-1623-02	HG19_Broad_variant	TCGA-64-5815	TCGA-LUAD	NA	s10909	Harvard Medical School	Fox Chase	United States	NO	T2	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b680	58cfa82fe4b0c9d6adf6b680	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted.filtered.	WGS	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted.bam	195.4	1.9	0.14	58cfa82fe4b0c9d6adf6b680	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4488-01A	D721BFE0-90E3-415E-B9F3-1A270EFA5FBB	Primary Tumor	Illumina HiSeq	26421230-2518-42aa-85ee-f9c83d47a6ba	Lung	74	1AEA8530-43FD-47EA-A2F1-377267DC9D33	DA0D3199-053B-4789-A217-CA2BFB83D57E	TCGA-49-4488-01A-01D-1751-02	HG19_Broad_variant	TCGA-49-4488	TCGA-LUAD	869	s11236	Harvard Medical School	Johns Hopkins	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7ca	58cfa82fe4b0c9d6adf6b7ca	TCGA-50-5930-11A-01D-1751_111007_SN590_0110_C003AACXX_s_2_rg.sorted.filtered.	WGS	TCGA-50-5930-11A-01D-1751_111007_SN590_0110_C003AACXX_s_2_rg.sorted	TCGA-50-5930-11A-01D-1751_111007_SN590_0110_C003AACXX_s_2_rg.sorted.bam	131.4	1.9	0.15	58cfa82fe4b0c9d6adf6b7ca	TCGA-50-5930-11A-01D-1751_111007_SN590_0110_C003AACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5930-11A	368E23F0-E573-4547-BF5A-14080BAF737B	Solid Tissue Normal	Illumina HiSeq	8e682cfc-cf44-4c71-b08e-152f8539f402	Lung	47	4CDDB392-FC4B-4400-A44F-2E92A78B3E97	A3426EEB-C297-4456-B368-6A366350FBF6	TCGA-50-5930-11A-01D-1751-02	HG19_Broad_variant	TCGA-50-5930	TCGA-LUAD	282	s10788	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b880	58cfa82fe4b0c9d6adf6b880	TCGA-A5-A0VP-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0VP-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_6_rg.sorted	TCGA-A5-A0VP-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_6_rg.sorted.bam	13.28	2	0.16	58cfa82fe4b0c9d6adf6b880	TCGA-A5-A0VP-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0VP-10A	2DB0FB62-64CE-457C-9E22-DD05EF59F684	Blood Derived Normal	Illumina HiSeq	704b6bd0-471d-4b24-8b66-d1e9cba7e424	Uterus	74	75E2A958-78F2-42A7-BEF2-1C2E68DC2BBF	C52324E4-AF6B-478B-BDA8-D0CF8A811C09	TCGA-A5-A0VP-10A-01D-A101-02	HG19_Broad_variant	TCGA-A5-A0VP	TCGA-UCEC	NA	s4776	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8dc	58cfa82fe4b0c9d6adf6b8dc	TCGA-A7-A0D9-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A7-A0D9-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_6_rg.sorted	TCGA-A7-A0D9-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_6_rg.sorted.bam	338.66	1.9	0.15	58cfa82fe4b0c9d6adf6b8dc	TCGA-A7-A0D9-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A0D9-10A	17BAEF7C-D97D-4B98-AB53-503EF856523D	Blood Derived Normal	Illumina HiSeq	4d84158c-282c-48bc-ae3d-55ada9b30f29	Breast	37	70B623D6-E6A5-4BB6-A1BE-62E8EF235FE5	34D29129-A82C-477F-8D08-DC972D08AC45	TCGA-A7-A0D9-10A-01D-A060-02	HG19_Broad_variant	TCGA-A7-A0D9	TCGA-BRCA	NA	s5797	Harvard Medical School	Christiana Healthcare	None	NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8c0	58cfa82fe4b0c9d6adf6b8c0	TCGA-49-6743-01A-11D-1853_111218_SN208_0258_C054RACXX_s_3_rg.sorted.filtered.	WGS	TCGA-49-6743-01A-11D-1853_111218_SN208_0258_C054RACXX_s_3_rg.sorted	TCGA-49-6743-01A-11D-1853_111218_SN208_0258_C054RACXX_s_3_rg.sorted.bam	219.7	1.9	0.14	58cfa82fe4b0c9d6adf6b8c0	TCGA-49-6743-01A-11D-1853_111218_SN208_0258_C054RACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-49-6743-01A	A391D49F-A822-460B-981C-6FBE1868EE38	Primary Tumor	Illumina HiSeq	8b2cdd00-4024-407a-94a7-dbfe5eaa6cd1	Lung	81	5D7DAE28-FC9F-4160-83AA-122F999668B0	3B48B0C9-B9B9-4926-97CA-7232A360A0EE	TCGA-49-6743-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6743	TCGA-LUAD	NA	s10998	Harvard Medical School	Johns Hopkins	United States	NO	T1	N2	Lung Clear Cell Adenocarcinoma	Stage IIIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6fc	58cfa82fe4b0c9d6adf6b6fc	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.bam	218.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6fc	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-55-6712-01A	F17D3463-AF6C-42C2-A8E9-FAE45F69286F	Primary Tumor	Illumina HiSeq	fb1682cf-0fca-4bf1-963d-67a3a177fe98	Lung	71	EA75499C-7BF0-47BE-9B09-3C12AAA22F12	61ADB041-60CE-4263-BEB3-33A4DBBA217B	TCGA-55-6712-01A-11D-1853-02	HG19_Broad_variant	TCGA-55-6712	TCGA-LUAD	NA	s11345	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8d9	58cfa82fe4b0c9d6adf6b8d9	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.bam	853.7	1.9	0.17	58cfa82fe4b0c9d6adf6b8d9	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5055-01A	CC3D9750-7CE0-489F-86D4-8017B7EBED29	Primary Tumor	Illumina HiSeq	97723d64-755b-4f00-b641-95ad083c397e	Lung	79	68D19E88-7FBD-48CC-A09F-55C47BFAF6E7	323E338B-1BA7-49E2-811B-C1FEE673A926	TCGA-50-5055-01A-01D-1623-02	HG19_Broad_variant	TCGA-50-5055	TCGA-LUAD	NA	s11008	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIA	1623-02	TRUE
13722.58cfa830e4b0c9d6adf6bc48	58cfa830e4b0c9d6adf6bc48	TCGA-AO-A0JJ-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_4_rg.sorted.filtered.	WGS	TCGA-AO-A0JJ-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_4_rg.sorted	TCGA-AO-A0JJ-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_4_rg.sorted.bam	96.1	1.71	0.17	58cfa830e4b0c9d6adf6bc48	TCGA-AO-A0JJ-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JJ-10A	BEF7B135-A727-45E8-850A-CC4CD56C49AA	Blood Derived Normal	Illumina HiSeq	335753c7-066c-41ad-8616-f9ec5f6b22e8	Breast	54	57F491FB-7CAD-4BC8-B55B-2231AD16A9E3	8A9F1058-6930-4942-879D-6633DB1848E0	TCGA-AO-A0JJ-10A-01D-A060-02	HG19_Broad_variant	TCGA-AO-A0JJ	TCGA-BRCA	NA	s5959	Harvard Medical School	MSKCC	None	NO	T2	N1a	Infiltrating Lobular Carcinoma	Stage IIB	A060-02	TRUE
13722.58cfa82fe4b0c9d6adf6b766	58cfa82fe4b0c9d6adf6b766	TCGA-67-6217-10A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_4_rg.sorted.filtered.	WGS	TCGA-67-6217-10A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_4_rg.sorted	TCGA-67-6217-10A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_4_rg.sorted.bam	124.7	1.9	0.15	58cfa82fe4b0c9d6adf6b766	TCGA-67-6217-10A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6217-10A	108A71CF-B9DB-47CD-AA74-C03EC989B41B	Blood Derived Normal	Illumina HiSeq	868f0059-3a66-4f4c-a285-0b547b522450	Lung	73	EAC9B8A6-1569-4CEC-A266-AD10C42226FD	5E6CB91C-E92E-4605-9CBB-291FF6611FB0	TCGA-67-6217-10A-01D-1751-02	HG19_Broad_variant	TCGA-67-6217	TCGA-LUAD	NA	s11243	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9f0	58cfa82fe4b0c9d6adf6b9f0	TCGA-A5-A0G5-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0G5-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_2_rg.sorted	TCGA-A5-A0G5-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_2_rg.sorted.bam	16.99	1.85	0.14	58cfa82fe4b0c9d6adf6b9f0	TCGA-A5-A0G5-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_2_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G5-10A	4806D9A6-E65D-4A82-B422-1B287980A0C6	Blood Derived Normal	Illumina HiSeq	a28c40ec-cbba-4ed8-ace9-208d66dc0e8b	Uterus	73	F15B93DA-B9EF-4DD7-92E9-B6A8926A3A75	3554D67F-1ED4-4F7D-AB2E-83DD0B79F8BC	TCGA-A5-A0G5-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0G5	TCGA-UCEC	NA	s4587	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bb6a	58cfa830e4b0c9d6adf6bb6a	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted.bam	267.4	1.9	0.15	58cfa830e4b0c9d6adf6bb6a	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-6205-01A	9A63F744-4ED4-4B4D-AAC6-F9BDA66AA563	Primary Tumor	Illumina HiSeq	ccc090ad-afab-4e7d-b71b-dcd39a87e359	Lung	NA	D845174B-1A04-4D22-B34F-C48D7AE35233	A5D194B2-0A92-49A1-9AC3-FC4C1B6ADE92	TCGA-75-6205-01A-11D-1751-02	HG19_Broad_variant	TCGA-75-6205	TCGA-LUAD	NA	s10666	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa830e4b0c9d6adf6bdce	58cfa830e4b0c9d6adf6bdce	TCGA-BH-A0H6-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BH-A0H6-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_2_rg.sorted	TCGA-BH-A0H6-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_2_rg.sorted.bam	18.64	2.08	0.16	58cfa830e4b0c9d6adf6bdce	TCGA-BH-A0H6-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0H6-10A	AEB6A3A6-B57A-4C53-90E6-E833777DD2A1	Blood Derived Normal	Illumina HiSeq	f8cb702c-5eff-49df-98b0-e1404066dc8f	Breast	82	9269A6CA-6D25-4815-8BB2-6AB526262266	3DDCCFEC-A269-41AB-B274-31E992F98878	TCGA-BH-A0H6-10A-01D-A060-02	HG19_Broad_variant	TCGA-BH-A0H6	TCGA-BRCA	NA	s6125	Harvard Medical School	University of Pittsburgh	None	NO	T1b	NX	Infiltrating Ductal Carcinoma	Stage I	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bdd4	58cfa830e4b0c9d6adf6bdd4	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.bam	18.62	1.9	0.15	58cfa830e4b0c9d6adf6bdd4	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0BM-01A	C2AEEE6C-BA10-4CF9-B560-C739580F7BF3	Primary Tumor	Illumina HiSeq	46f039c4-a705-4933-bf85-0e96e80e5024	Breast	54	5423B7F8-D2BB-47C8-9AF8-3D3E1276888C	FA99DD38-37F1-4B24-960E-617F92CDADD0	TCGA-BH-A0BM-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0BM	TCGA-BRCA	NA	s6772	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6f8	58cfa82fe4b0c9d6adf6b6f8	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted.bam	245.4	1.8	0.13	58cfa82fe4b0c9d6adf6b6f8	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6593-01A	E10568FE-0436-43F2-9F0F-48F9903868C4	Primary Tumor	Illumina HiSeq	f552d49e-eaf1-4d8f-bd11-0f2017c95ba3	Lung	49	3B2ED302-D8F1-4078-95F0-3B5C5B322DEB	BC00F0B2-D91E-444A-91A4-08AC5F09CA1F	TCGA-50-6593-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-6593	TCGA-LUAD	336	s11456	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1751-02	TRUE
13722.58cfa830e4b0c9d6adf6bdd0	58cfa830e4b0c9d6adf6bdd0	TCGA-BH-A0GY-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BH-A0GY-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_8_rg.sorted	TCGA-BH-A0GY-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_8_rg.sorted.bam	8.18	2.06	0.13	58cfa830e4b0c9d6adf6bdd0	TCGA-BH-A0GY-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0GY-10A	7D9D3522-EC3B-4EFE-8C8E-C0E675276EF5	Blood Derived Normal	Illumina HiSeq	2e13622c-8cd4-44aa-a010-0de1e4dbcbee	Breast	67	CD531C9F-A0E9-498A-9032-42040EC975DE	A9C89A38-C132-4BA7-A2D4-26B3184AA047	TCGA-BH-A0GY-10A-01D-A060-02	HG19_Broad_variant	TCGA-BH-A0GY	TCGA-BRCA	NA	s6918	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bd7e	58cfa830e4b0c9d6adf6bd7e	TCGA-AP-A05P-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_6_rg.sorted.filtered.	WGS	TCGA-AP-A05P-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_6_rg.sorted	TCGA-AP-A05P-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_6_rg.sorted.bam	37.05	2.21	0.15	58cfa830e4b0c9d6adf6bd7e	TCGA-AP-A05P-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_6_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A05P-10A	3CB83517-78A4-47B8-8B1E-57E765DBDD2E	Blood Derived Normal	Illumina HiSeq	ecfa17c8-9981-4618-a559-0a1b0b8639a3	Uterus	54	C1E003DF-12D0-4E77-8C6E-C52615CBAB96	EE0D1DC0-B5AC-4558-8EBD-C3A5E721DFEB	TCGA-AP-A05P-10A-01D-A043-02	HG19_Broad_variant	TCGA-AP-A05P	TCGA-UCEC	NA	s5200	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6be94	58cfa830e4b0c9d6adf6be94	TCGA-BL-A13I-11A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BL-A13I-11A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_5_rg.sorted	TCGA-BL-A13I-11A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_5_rg.sorted.bam	9.8	1.98	0.16	58cfa830e4b0c9d6adf6be94	TCGA-BL-A13I-11A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A13I-11A	EBC094A6-CDC9-4C02-B8EC-A181B25A364D	Solid Tissue Normal	Illumina HiSeq	18c5e150-2417-4ca7-88c8-d147dfb43853	Bladder	57	DD38F3F6-5A39-41B7-B2EA-8917298E76D2	325DC686-E598-42C6-B2E7-3AE19B1EA4F9	TCGA-BL-A13I-11A-11D-A13U-02	HG19_Broad_variant	TCGA-BL-A13I	TCGA-BLCA	223	s3082	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba37	58cfa82fe4b0c9d6adf6ba37	TCGA-A5-A0G2-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0G2-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_2_rg.sorted	TCGA-A5-A0G2-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_2_rg.sorted.bam	18.79	1.89	0.17	58cfa82fe4b0c9d6adf6ba37	TCGA-A5-A0G2-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_2_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G2-10A	4ABBD258-0F0C-4428-901D-625D47AD363A	Blood Derived Normal	Illumina HiSeq	07955d67-db65-4ccd-a245-1e9981824904	Uterus	57	D6272155-71A9-4B3F-A2E7-4D45E945236C	89A3BA3E-D1A7-4B9F-8F59-CA715A1266BD	TCGA-A5-A0G2-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0G2	TCGA-UCEC	NA	s4586	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b988	58cfa82fe4b0c9d6adf6b988	TCGA-67-6215-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_5_rg.sorted.filtered.	WGS	TCGA-67-6215-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_5_rg.sorted	TCGA-67-6215-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_5_rg.sorted.bam	156.7	1.9	0.15	58cfa82fe4b0c9d6adf6b988	TCGA-67-6215-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6215-10A	DBD5B0DE-94C9-45DD-AFB3-6820A7ECACA2	Blood Derived Normal	Illumina HiSeq	30aaa08e-3e7d-4c12-8452-ae8bfb552ef2	Lung	52	BCCA4C61-554E-4521-8F3B-018F28E10559	000520ED-D9C8-496C-84B2-5F483AB271FD	TCGA-67-6215-10A-01D-1751-02	HG19_Broad_variant	TCGA-67-6215	TCGA-LUAD	NA	s10911	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa830e4b0c9d6adf6be88	58cfa830e4b0c9d6adf6be88	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.bam	30.94	1.89	0.15	58cfa830e4b0c9d6adf6be88	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A291-01A	D4C68C1C-A3F3-4E0C-B555-D457378A1D24	Primary Tumor	Illumina HiSeq	bb0bf0e4-e29d-422a-879e-b8dc7f5c720b	Thyroid	56	D1612961-A709-487B-A4D1-CE42F0B9AA54	E28A1E8B-41A3-44C0-ADBC-6A203C92DDF5	TCGA-BJ-A291-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A291	TCGA-THCA	NA	s11990	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6becf	58cfa830e4b0c9d6adf6becf	TCGA-BL-A13J-11A-13D-A10R_120920_SN1222_0151_BD1D5CACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BL-A13J-11A-13D-A10R_120920_SN1222_0151_BD1D5CACXX_s_2_rg.sorted	TCGA-BL-A13J-11A-13D-A10R_120920_SN1222_0151_BD1D5CACXX_s_2_rg.sorted.bam	13.33	1.94	0.14	58cfa830e4b0c9d6adf6becf	TCGA-BL-A13J-11A-13D-A10R_120920_SN1222_0151_BD1D5CACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A13J-11A	556FCBC8-172A-4AF1-8822-AE036E8D68E8	Solid Tissue Normal	Illumina HiSeq	477877cc-b9b8-4869-b082-7dc505705bcd	Bladder	65	2A834A44-9490-4C60-B587-EBE890C3FB0A	9B4FFD23-8B53-4DFC-A98E-E4C70F7680F0	TCGA-BL-A13J-11A-13D-A10R-02	HG19_Broad_variant	TCGA-BL-A13J	TCGA-BLCA	81	s3081	Harvard Medical School	Christiana Healthcare	United States	NO	T4	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6bee4	58cfa830e4b0c9d6adf6bee4	TCGA-AP-A0LJ-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-AP-A0LJ-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_8_rg.sorted	TCGA-AP-A0LJ-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_8_rg.sorted.bam	33.9	1.8	0.14	58cfa830e4b0c9d6adf6bee4	TCGA-AP-A0LJ-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LJ-10A	B4A520AE-F259-48C8-823E-C10B9B8A133A	Blood Derived Normal	Illumina HiSeq	621545f7-ce7d-481d-95ca-f241098c48d1	Uterus	42	6E436D9F-6DF5-4414-BD68-CF6607D24E28	20DB61A1-BF33-4A14-B10C-2DF57BFC6824	TCGA-AP-A0LJ-10A-01D-A043-02	HG19_Broad_variant	TCGA-AP-A0LJ	TCGA-UCEC	NA	s4426	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6beea	58cfa830e4b0c9d6adf6beea	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.bam	106.84	1.77	0.15	58cfa830e4b0c9d6adf6beea	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LL-01A	D17668C4-5D66-4E16-8B70-B54616581AAE	Primary Tumor	Illumina HiSeq	0ea2fbb0-cc11-44d9-9706-2523b9d268be	Uterus	56	488A7462-8348-422C-91D3-7D9F0C39D25E	0D29C555-7C7C-4BBB-A4C6-E554CC758CA7	TCGA-AP-A0LL-01A-12D-A101-02	HG19_Broad_variant	TCGA-AP-A0LL	TCGA-UCEC	NA	s4595	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bf28	58cfa830e4b0c9d6adf6bf28	TCGA-BR-4187-11A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-4187-11A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_8_rg.sorted	TCGA-BR-4187-11A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_8_rg.sorted.bam	249.9	1.9	0.16	58cfa830e4b0c9d6adf6bf28	TCGA-BR-4187-11A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4187-11A	12071070-D06B-4C7B-A7B1-77C84963ABE6	Solid Tissue Normal	Illumina HiSeq	6ba29a1c-c406-4572-bb2e-69bb70f46dfa	Stomach	56	5B3D227E-A9B7-4A5D-859B-27065CC14C6A	2E462096-2631-4956-B78C-84460306B288	TCGA-BR-4187-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4187	TCGA-STAD	NA	s15376	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf50	58cfa830e4b0c9d6adf6bf50	TCGA-BR-4279-11A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-4279-11A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_2_rg.sorted	TCGA-BR-4279-11A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_2_rg.sorted.bam	7.9	1.9	0.16	58cfa830e4b0c9d6adf6bf50	TCGA-BR-4279-11A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4279-11A	117EB38B-0C62-4336-A866-FA5BD013256A	Solid Tissue Normal	Illumina HiSeq	1fc5b32a-8266-4f98-8444-a219ed9631a2	Stomach	43	B87F1A8B-9A6A-44AE-BB89-686186F2FD2D	BB0A8962-7A53-4786-B7E5-ADE753A3D009	TCGA-BR-4279-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4279	TCGA-STAD	NA	s15101	Harvard Medical School	Asterand	Russia	NO	T2a	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bcc6	58cfa830e4b0c9d6adf6bcc6	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted.bam	93.54	2.18	0.15	58cfa830e4b0c9d6adf6bcc6	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0L9-01A	7B9947D5-E86B-4006-8890-EA5209584A88	Primary Tumor	Illumina HiSeq	df10c3ed-7978-4d58-b4f6-52a76db0994a	Uterus	71	53D0521F-10D6-4F70-9277-D99025A6B963	DAA573AF-564D-456D-8181-DF4C07B77672	TCGA-AP-A0L9-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0L9	TCGA-UCEC	NA	s4423	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bf44	58cfa830e4b0c9d6adf6bf44	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.bam	115.02	1.84	0.16	58cfa830e4b0c9d6adf6bf44	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A2HD-01A	A8DEF1A0-A136-47F4-9AD9-60EBCF9B726B	Primary Tumor	Illumina HiSeq	b9d10df5-eb11-4976-b3dd-10e970fc715d	Uterus	69	5A2EDE97-0CF7-44D7-A789-92EE9BDA3D6C	C24E7F27-2155-4727-B6D8-8E5BC16D9197	TCGA-AX-A2HD-01A-21D-A17E-02	HG19_Broad_variant	TCGA-AX-A2HD	TCGA-UCEC	NA	s4428	Harvard Medical School	Gynecologic Oncology Group	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A17E-02	TRUE
13722.58cfa830e4b0c9d6adf6c062	58cfa830e4b0c9d6adf6c062	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.bam	78.5	1.92	0.14	58cfa830e4b0c9d6adf6c062	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RI-01A	BFD55808-DDDD-44C3-97D7-41600497B992	Primary Tumor	Illumina HiSeq	9283f68e-d261-4afd-b0eb-0a29fdda83ca	Breast	44	973EE776-E287-4568-A43D-7B16CC0094A9	71542129-1393-4608-B81C-1767A5051763	TCGA-B6-A0RI-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RI	TCGA-BRCA	NA	s6273	Harvard Medical School	Duke	United States	NO	T4b	N1b	Infiltrating Ductal Carcinoma	Stage IIIB	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6c134	58cfa830e4b0c9d6adf6c134	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.bam	40.26	2.11	0.15	58cfa830e4b0c9d6adf6c134	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RG-01A	9B13927C-7357-44FD-8385-92AE6A656B7D	Primary Tumor	Illumina HiSeq	b38ff19d-a769-4388-81e2-03263bba7985	Breast	26	B98AA84F-5144-4062-BADC-32E89368D684	E71ED8ED-7371-4423-83C8-6075A6FC7C39	TCGA-B6-A0RG-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RG	TCGA-BRCA	NA	s5640	Harvard Medical School	Duke	United States	NO	T3	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6c128	58cfa830e4b0c9d6adf6c128	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.bam	49.61	2.14	0.16	58cfa830e4b0c9d6adf6c128	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RE-01A	08DA7C4C-3067-4BCF-9D7A-78566DF72E69	Primary Tumor	Illumina HiSeq	f7dd44eb-562f-4d27-8c45-5ec7fbf49448	Breast	61	270BE245-2239-4E96-A917-79CCA40868BA	D5CE279A-3A7F-43E7-894C-265E9504C3FD	TCGA-B6-A0RE-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RE	TCGA-BRCA	NA	s6769	Harvard Medical School	Duke	United States	NO	TX	N0 (i-)	Infiltrating Ductal Carcinoma	Stage X	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bf55	58cfa830e4b0c9d6adf6bf55	TCGA-BR-4255-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-4255-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_8_rg.sorted	TCGA-BR-4255-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_8_rg.sorted.bam	70.9	1.9	0.15	58cfa830e4b0c9d6adf6bf55	TCGA-BR-4255-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4255-11A	956017BA-5E4B-42C7-B93D-42316874BA93	Solid Tissue Normal	Illumina HiSeq	9a506d86-f850-4a34-a336-6a7ac27b7aad	Stomach	76	14C7AEAF-97D3-48B6-BB08-B38D7D3E12ED	80DCF338-52AA-4563-A7A3-6111C1247354	TCGA-BR-4255-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4255	TCGA-STAD	NA	s14816	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6c02e	58cfa830e4b0c9d6adf6c02e	TCGA-BJ-A0ZC-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZC-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_2_rg.sorted	TCGA-BJ-A0ZC-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_2_rg.sorted.bam	65.57	1.93	0.17	58cfa830e4b0c9d6adf6c02e	TCGA-BJ-A0ZC-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZC-10A	6675C581-297D-44CD-B80F-AE7E53D48228	Blood Derived Normal	Illumina HiSeq	58e1cb0c-b7b5-4c66-accc-3ad21f51a8a1	Thyroid	55	CF4CE78D-BB15-494E-80E0-6EFBC987D617	E18B064C-F6BD-4625-A065-722412F92FC8	TCGA-BJ-A0ZC-10A-01D-A13U-02	HG19_Broad_variant	TCGA-BJ-A0ZC	TCGA-THCA	NA	s12506	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6c1a0	58cfa830e4b0c9d6adf6c1a0	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.bam	411	1.9	0.14	58cfa830e4b0c9d6adf6c1a0	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-B7-5818-01A	6E03B415-84A1-4B91-8717-1A41EDD4A255	Primary Tumor	Illumina HiSeq	9924779b-8261-4ea6-9925-28dd5a0aed8a	Stomach	62	FD97CDF5-0F7F-48A2-B5DA-5C5F56A89166	0EBF1A63-C6E4-49FE-B21B-AE46FF14261D	TCGA-B7-5818-01A-11D-1598-02	HG19_Broad_variant	TCGA-B7-5818	TCGA-STAD	NA	s14963	Harvard Medical School	Cureline	Russia	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1598-02	TRUE
13722.58cfa830e4b0c9d6adf6c136	58cfa830e4b0c9d6adf6c136	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.bam	125.71	2	0.17	58cfa830e4b0c9d6adf6c136	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UJ-01A	FF82548A-F1BB-4DAA-A8F7-B3831B5843AD	Primary Tumor	Illumina HiSeq	094adbd4-f2af-42bb-9509-0dcfa2c6672f	Uterus	68	2EA1339F-A5EB-4552-AC13-858FA70E606E	15FDA615-0A79-4211-B5DE-F61741E8937A	TCGA-BS-A0UJ-01A-12D-A101-02	HG19_Broad_variant	TCGA-BS-A0UJ	TCGA-UCEC	NA	s5221	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c1a6	58cfa830e4b0c9d6adf6c1a6	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.bam	58.9	2	0.14	58cfa830e4b0c9d6adf6c1a6	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HB-01A	0C1023C0-D2CE-4940-8047-7642F1DC3965	Primary Tumor	Illumina HiSeq	c9a434dc-8ce3-485f-88aa-a2373f6cdfac	Breast	55	19193B8F-1E1B-448C-B934-93F25E60D45B	49556237-D73F-4DE9-B5D9-7169DB7A53C5	TCGA-BH-A0HB-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0HB	TCGA-BRCA	NA	s6275	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6c138	58cfa830e4b0c9d6adf6c138	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.bam	110.21	1.89	0.17	58cfa830e4b0c9d6adf6c138	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UF-01A	F77D7256-2CCF-42A7-9B30-332AC24CA812	Primary Tumor	Illumina HiSeq	33e84ef1-730b-4f0b-9967-bca62c9f631c	Uterus	65	C805F55A-322F-4A11-AE0C-4BBC365D1BD6	D1F78FB2-7BB7-4BF7-8EC7-E2E08F579A38	TCGA-BS-A0UF-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UF	TCGA-UCEC	NA	s5220	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c1d4	58cfa830e4b0c9d6adf6c1d4	TCGA-BB-4225-10A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BB-4225-10A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_4_rg.sorted	TCGA-BB-4225-10A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_4_rg.sorted.bam	71.4	1.4	0.13	58cfa830e4b0c9d6adf6c1d4	TCGA-BB-4225-10A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4225-10A	C1F50A22-38DF-41CC-A1F4-F7985504A7AC	Blood Derived Normal	Illumina HiSeq	4d810623-2a13-4ed1-ac3c-9582a8e96048	Head and Neck	73	F50A9185-7AF4-4EB7-8866-AA3FBBBC3BAB	27BEDA53-5C52-4515-9125-702366FE2B4A	TCGA-BB-4225-10A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4225	TCGA-HNSC	NA	s16315	Harvard Medical School	Johns Hopkins	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c1e1	58cfa830e4b0c9d6adf6c1e1	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.bam	93.28	1.98	0.17	58cfa830e4b0c9d6adf6c1e1	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MT-01A	082E32C5-7F82-466A-B52D-A3293A8F8E57	Primary Tumor	Illumina HiSeq	3499ad67-e5ed-4030-9fba-fac9fa52f9c5	Uterus	64	91F629F5-6938-4F5C-BA2E-1F519CE6B255	23FB2C48-BE95-4169-BB10-00EA361C5687	TCGA-BG-A0MT-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MT	TCGA-UCEC	NA	s5217	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bf40	58cfa830e4b0c9d6adf6bf40	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.bam	100.97	1.91	0.17	58cfa830e4b0c9d6adf6bf40	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A1CJ-01A	ABAF757B-F79F-40BD-96E3-E2C0F63061F0	Primary Tumor	Illumina HiSeq	f42806a5-e473-4ae8-bb1a-aa11fe2dde53	Uterus	59	72D06DDF-9FB2-4577-BFDB-B0E463105B4A	A4EE1BB7-59FF-4034-ABA1-9AF4F62B42B0	TCGA-AX-A1CJ-01A-11D-A133-02	HG19_Broad_variant	TCGA-AX-A1CJ	TCGA-UCEC	NA	s5388	Harvard Medical School	Gynecologic Oncology Group	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A133-02	FALSE
13722.58cfa830e4b0c9d6adf6c202	58cfa830e4b0c9d6adf6c202	TCGA-BA-5558-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BA-5558-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_8_rg.sorted	TCGA-BA-5558-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_8_rg.sorted.bam	317.4	1.9	0.15	58cfa830e4b0c9d6adf6c202	TCGA-BA-5558-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5558-10A	6A1AA50C-097C-4E04-8DDD-12D50F8A5AC2	Blood Derived Normal	Illumina HiSeq	da16b0c3-9934-4caa-b4ca-5e4c5d9a4494	Head and Neck	65	160DD4E9-A8C0-42B3-BF9B-747D5AC25922	730EC759-9CC9-4F3A-96D1-C11101CBE3B3	TCGA-BA-5558-10A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5558	TCGA-HNSC	NA	s15611	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1509-02	TRUE
13722.58cfa830e4b0c9d6adf6c208	58cfa830e4b0c9d6adf6c208	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.bam	252.7	1.9	0.15	58cfa830e4b0c9d6adf6c208	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5558-01A	6A1AA50C-097C-4E04-8DDD-12D50F8A5AC2	Primary Tumor	Illumina HiSeq	4116c10d-23f4-49f2-bd5a-9b9466f08bfb	Head and Neck	65	EB749281-B3DC-43E4-812E-F5F5004A21ED	41737268-345A-4F87-B2DB-E184247E1396	TCGA-BA-5558-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5558	TCGA-HNSC	NA	s15610	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1509-02	TRUE
13722.58cfa830e4b0c9d6adf6c232	58cfa830e4b0c9d6adf6c232	TCGA-BA-5557-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BA-5557-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_7_rg.sorted	TCGA-BA-5557-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_7_rg.sorted.bam	209.4	1.9	0.15	58cfa830e4b0c9d6adf6c232	TCGA-BA-5557-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_7_rg.sorted.bam	Alive	FEMALE	Not available	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5557-10A	7E0575CE-670B-4035-8A90-4D35279707B2	Blood Derived Normal	Illumina HiSeq	11ddaf7c-cee4-47b6-a167-60967da1bd66	Head and Neck	41	C56044D3-D6D5-41CD-B9A0-62EE45944B88	5F826C70-5AA0-40C4-8ACC-A7C17A74B457	TCGA-BA-5557-10A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5557	TCGA-HNSC	NA	s15878	Harvard Medical School	UNC	None	NO	T1	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1509-02	TRUE
13722.58cfa830e4b0c9d6adf6c236	58cfa830e4b0c9d6adf6c236	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.bam	64.48	1.98	0.16	58cfa830e4b0c9d6adf6c236	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z3-01A	331CAE6E-2868-4C58-9302-709A9FF7D025	Primary Tumor	Illumina HiSeq	ddae4f5a-aed4-4466-9434-23f6ed312d19	Thyroid	33	6BF032C1-B7D5-4B1C-BF41-C9BFEAFA5E7A	3D0982B1-944E-4C03-AAA4-F8FD4602D4C9	TCGA-BJ-A0Z3-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A0Z3	TCGA-THCA	NA	s12628	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6c234	58cfa830e4b0c9d6adf6c234	TCGA-BT-A20R-11A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BT-A20R-11A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_4_rg.sorted	TCGA-BT-A20R-11A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_4_rg.sorted.bam	17.44	1.78	0.18	58cfa830e4b0c9d6adf6c234	TCGA-BT-A20R-11A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20R-11A	F8780A4B-7F55-41D1-BF92-8513955D150E	Solid Tissue Normal	Illumina HiSeq	81815e13-7a11-4252-9fea-8006d97d9a9b	Bladder	79	4F6353E2-FB61-48B7-B784-3C0D391D708B	B2AEED65-1A63-4712-A8E1-22C91A2C690B	TCGA-BT-A20R-11A-11D-A16N-02	HG19_Broad_variant	TCGA-BT-A20R	TCGA-BLCA	154	s2865	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6c286	58cfa830e4b0c9d6adf6c286	TCGA-BH-A0HB-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BH-A0HB-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_6_rg.sorted	TCGA-BH-A0HB-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_6_rg.sorted.bam	10.32	1.88	0.16	58cfa830e4b0c9d6adf6c286	TCGA-BH-A0HB-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HB-10A	0C1023C0-D2CE-4940-8047-7642F1DC3965	Blood Derived Normal	Illumina HiSeq	6c213158-4cff-4e3f-a2fe-79b1eb8349dc	Breast	55	12ED991B-96F2-4A0E-AA8B-8345573A8E57	3F02CEB5-9B6C-453C-8A81-00D2B609B742	TCGA-BH-A0HB-10A-01D-A060-02	HG19_Broad_variant	TCGA-BH-A0HB	TCGA-BRCA	NA	s6917	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6c23a	58cfa830e4b0c9d6adf6c23a	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted.bam	26.04	1.91	0.17	58cfa830e4b0c9d6adf6c23a	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20R-01A	F8780A4B-7F55-41D1-BF92-8513955D150E	Primary Tumor	Illumina HiSeq	e997f623-927f-4dae-8fe9-590eef9a9f59	Bladder	79	20231B7F-CB6A-4CD0-9C46-10D4E959D483	78460059-E3A1-40F1-89B5-2F69C6E2E0F1	TCGA-BT-A20R-01A-12D-A16N-02	HG19_Broad_variant	TCGA-BT-A20R	TCGA-BLCA	154	s2696	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6c29c	58cfa830e4b0c9d6adf6c29c	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted.bam	66.31	1.98	0.16	58cfa830e4b0c9d6adf6c29c	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted.bam	Dead	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0T9-01A	4EB95566-0E73-4260-853E-F7DF650667A0	Primary Tumor	Illumina HiSeq	2c61f255-688e-4a53-83fd-bea3b66d5a15	Uterus	39	3C9FF865-013F-427A-8D4D-C8E60EA346A1	CB5B905D-7287-41B3-9B49-B2F7FF7D2173	TCGA-BS-A0T9-01A-11D-A12F-02	HG19_Broad_variant	TCGA-BS-A0T9	TCGA-UCEC	1428	s4260	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa830e4b0c9d6adf6c2a8	58cfa830e4b0c9d6adf6c2a8	TCGA-BR-4184-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4184-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_3_rg.sorted	TCGA-BR-4184-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_3_rg.sorted.bam	257.9	1.9	0.15	58cfa830e4b0c9d6adf6c2a8	TCGA-BR-4184-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4184-01A	0D4D23BA-066B-4244-A3A5-922CDCAAA28F	Primary Tumor	Illumina HiSeq	efa9bef0-628c-4883-8eea-34f0690acc42	Stomach	70	5DB02C36-DCF0-4311-AD90-754E4EC579EE	501F74C8-6E77-429C-99BD-739D45A74ED1	TCGA-BR-4184-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4184	TCGA-STAD	NA	s15102	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6c2aa	58cfa830e4b0c9d6adf6c2aa	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.bam	204.9	1.9	0.15	58cfa830e4b0c9d6adf6c2aa	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4201-01A	8520654B-2192-46CF-9D72-1DDB885A7C55	Primary Tumor	Illumina HiSeq	359db0d8-a78f-4d9d-9a3e-9f1a04472df0	Stomach	66	B42CC87B-4BB0-433D-8AFB-CB314B8CBA30	FE12C75F-5A26-40A8-BEF0-742FAD4CD0E5	TCGA-BR-4201-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4201	TCGA-STAD	NA	s14529	Harvard Medical School	Asterand	Russia	NO	T2a	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6c25a	58cfa830e4b0c9d6adf6c25a	TCGA-C4-A0F0-10A-01D-A10R_120926_SN590_0181_AC19HCACXX_s_6_rg.sorted.filtered.	WGS	TCGA-C4-A0F0-10A-01D-A10R_120926_SN590_0181_AC19HCACXX_s_6_rg.sorted	TCGA-C4-A0F0-10A-01D-A10R_120926_SN590_0181_AC19HCACXX_s_6_rg.sorted.bam	17.76	2.02	0.17	58cfa830e4b0c9d6adf6c25a	TCGA-C4-A0F0-10A-01D-A10R_120926_SN590_0181_AC19HCACXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-C4-A0F0-10A	40398C03-A9CC-476B-9EE9-AECF161BE43F	Blood Derived Normal	Illumina HiSeq	c5e7b6e1-16a2-46ee-85ed-49e5092c1e70	Bladder	60	2F276A79-5F80-4FEC-842D-F4ADC4163F26	AEB2BBE5-2FD5-4747-B39F-17ECD434B4E8	TCGA-C4-A0F0-10A-01D-A10R-02	HG19_Broad_variant	TCGA-C4-A0F0	TCGA-BLCA	NA	s2857	Harvard Medical School	Indivumed	Germany	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c34a	58cfa831e4b0c9d6adf6c34a	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted.bam	563	1.9	0.15	58cfa831e4b0c9d6adf6c34a	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5718-01A	D5C58161-05ED-4472-81ED-176216F49929	Primary Tumor	Illumina HiSeq	98032563-24e7-466c-9f90-1ba67975f2f9	Stomach	78	5865A287-63C4-44F7-92D5-C4F3C323AF89	1A108108-EEAC-4EE8-AFD7-871AFA69054B	TCGA-CG-5718-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5718	TCGA-STAD	NA	s14903	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa830e4b0c9d6adf6c2db	58cfa830e4b0c9d6adf6c2db	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted.filtered.	WGS	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted.bam	13.51	1.77	0.15	58cfa830e4b0c9d6adf6c2db	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-C4-A0F0-01A	40398C03-A9CC-476B-9EE9-AECF161BE43F	Primary Tumor	Illumina HiSeq	38f56daa-7d69-4fe0-8895-10e22397ee2a	Bladder	60	54234A11-8674-4B01-B2EF-A4C6D772AA43	5584A4A7-2EA1-46D8-8960-8905689D5720	TCGA-C4-A0F0-01A-12D-A10R-02	HG19_Broad_variant	TCGA-C4-A0F0	TCGA-BLCA	NA	s2862	Harvard Medical School	Indivumed	Germany	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c31e	58cfa830e4b0c9d6adf6c31e	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.bam	67.64	2.28	0.18	58cfa830e4b0c9d6adf6c31e	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A27C-01A	7FEE9D6F-C0EA-43C2-89C2-66D965A077A8	Primary Tumor	Illumina HiSeq	ecc65751-9b59-49c3-a142-7a4c61174649	Bladder	52	EAD6792B-4E52-4C28-891C-6D8696873A13	1E553EB3-8C42-48A1-87A7-BFA8541CE568	TCGA-CF-A27C-01A-11D-A16N-02	HG19_Broad_variant	TCGA-CF-A27C	TCGA-BLCA	NA	s2873	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6c389	58cfa831e4b0c9d6adf6c389	TCGA-CD-5800-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CD-5800-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_5_rg.sorted	TCGA-CD-5800-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_5_rg.sorted.bam	214.7	1.9	0.15	58cfa831e4b0c9d6adf6c389	TCGA-CD-5800-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5800-10A	EEB114EA-ECEE-49EE-A162-B3B7BC0A60CD	Blood Derived Normal	Illumina HiSeq	f7df3714-78fc-460f-8d69-6870f63c1f49	Stomach	51	7FA0B096-DD41-4BD1-B826-00A265F4857D	CE784634-F5A7-4317-A7AD-BF5098E2247C	TCGA-CD-5800-10A-01D-1598-02	HG19_Broad_variant	TCGA-CD-5800	TCGA-STAD	NA	s15318	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Papillary Type	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c366	58cfa831e4b0c9d6adf6c366	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted.bam	135	1.9	0.14	58cfa831e4b0c9d6adf6c366	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5720-01A	7C9EA4FA-4CBC-4941-945A-E531E1D48304	Primary Tumor	Illumina HiSeq	6cf7bbf9-63f5-40e8-b595-c9012a1825ba	Stomach	71	1B2E1B50-8D4E-4E62-9B1B-B484936BD6EB	98CE6D0E-465C-40FA-9408-33AA7A25FBB2	TCGA-CG-5720-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5720	TCGA-STAD	30	s14984	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3b0	58cfa831e4b0c9d6adf6c3b0	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.bam	20.53	2	0.15	58cfa831e4b0c9d6adf6c3b0	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0H7-01A	2021ED1F-DC75-4701-B8B8-1386466E4802	Primary Tumor	Illumina HiSeq	d5ab471a-88d1-4966-865a-f7fa29214fe4	Breast	65	69BFA6CE-ED46-4321-A107-347C49D68951	E0E60B71-1EFA-4896-B89F-D05974CDCF48	TCGA-BH-A0H7-01A-13D-A060-02	HG19_Broad_variant	TCGA-BH-A0H7	TCGA-BRCA	NA	s5801	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A060-02	TRUE
13722.58cfa831e4b0c9d6adf6c37e	58cfa831e4b0c9d6adf6c37e	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted.bam	46	1.9	0.16	58cfa831e4b0c9d6adf6c37e	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5719-01A	263F67E0-0A28-42E6-B3F3-1DDD0D397220	Primary Tumor	Illumina HiSeq	e6237df3-92e8-4e8b-92a4-b09d3515f16f	Stomach	54	606573EE-ED11-4DB5-ABAF-E842EC575EEE	9008E364-B8F3-4923-B0CC-6ED34AA7BAC3	TCGA-CG-5719-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5719	TCGA-STAD	NA	s15247	Harvard Medical School	Indivumed	Germany	NO	T4	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3b8	58cfa831e4b0c9d6adf6c3b8	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted.bam	362	1.9	0.15	58cfa831e4b0c9d6adf6c3b8	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5724-01A	0B4E8D73-459D-4930-9D1A-ABB8D53E1844	Primary Tumor	Illumina HiSeq	b1cebb86-fe73-4b53-899d-9e6a4caa800b	Stomach	59	4D624B21-5AEE-42B8-B192-8AFECB51434D	8611C0AC-38E4-4BFD-A1C4-56CABFCF6374	TCGA-CG-5724-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5724	TCGA-STAD	366	s15248	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3ca	58cfa831e4b0c9d6adf6c3ca	TCGA-CG-5724-11A-01D-1598_121011_SN208_0434_AC18MYACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-5724-11A-01D-1598_121011_SN208_0434_AC18MYACXX_s_8_rg.sorted	TCGA-CG-5724-11A-01D-1598_121011_SN208_0434_AC18MYACXX_s_8_rg.sorted.bam	261	1.9	0.15	58cfa831e4b0c9d6adf6c3ca	TCGA-CG-5724-11A-01D-1598_121011_SN208_0434_AC18MYACXX_s_8_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5724-11A	0B4E8D73-459D-4930-9D1A-ABB8D53E1844	Solid Tissue Normal	Illumina HiSeq	4289e6b1-841a-44f2-adf3-c4729a04518c	Stomach	59	4074EB62-5EBC-4305-A437-7689B76E6F71	5216A2FE-BD9F-47F9-899E-4531A80AF2FC	TCGA-CG-5724-11A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5724	TCGA-STAD	366	s15194	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3d6	58cfa831e4b0c9d6adf6c3d6	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted.bam	206	1.9	0.15	58cfa831e4b0c9d6adf6c3d6	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5734-01A	2A227292-C73D-45FC-AB68-CDFAF7AEF9E7	Primary Tumor	Illumina HiSeq	4cac9679-5c5e-4b51-b7a0-0d82ab2c2237	Stomach	68	A0237637-3859-47D9-A60E-0AF8C6884B4A	12BCC59A-0A89-4087-B976-A22F66D8190C	TCGA-CG-5734-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5734	TCGA-STAD	243	s14990	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3dc	58cfa831e4b0c9d6adf6c3dc	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted.bam	217	1.9	0.16	58cfa831e4b0c9d6adf6c3dc	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5726-01A	863AD936-E2A0-471C-8D95-3A548BB94AFA	Primary Tumor	Illumina HiSeq	87491384-bbcf-4127-8cf0-59e692b8e37b	Stomach	73	C881739A-982C-436F-9BE2-4638DB792C53	D472F361-BC94-44A5-9158-5BD999C96C27	TCGA-CG-5726-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5726	TCGA-STAD	881	s15130	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3f0	58cfa831e4b0c9d6adf6c3f0	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.filtered.	WGS	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.bam	82.12	NA	0.18	58cfa831e4b0c9d6adf6c3f0	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LX-01A	B82F4C6D-530F-4B0E-8F33-995633CB254A	Primary Tumor	Illumina HiSeq	ef574f7b-2b69-4be8-83f3-cc02df579a0a	Cervix	54	41BEBEA3-11C2-4748-8E60-082CFB8E0251	F4772B1E-699C-4C3D-9E0B-1BD4634A7F36	TCGA-C5-A2LX-01A-11D-A18I-02	HG19_Broad_variant	TCGA-C5-A2LX	TCGA-CESC	NA	s1175	Harvard Medical School	Medical College of Wisconsin	United States	NO	T2	N1	Cervical Squamous Cell Carcinoma	Not available	A18I-02	TRUE
13722.58cfa831e4b0c9d6adf6c3fc	58cfa831e4b0c9d6adf6c3fc	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.bam	257.7	1.9	0.16	58cfa831e4b0c9d6adf6c3fc	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5788-01A	C039014F-821C-43D6-9D3C-914F9C8D98FA	Primary Tumor	Illumina HiSeq	8bd51d54-e1be-4a0a-bad5-3b8013692b90	Prostate	69	144E0265-C04E-4538-A721-94DEF2570486	ADB6611D-7A44-4FFE-A48B-FF8E24696B38	TCGA-CH-5788-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5788	TCGA-PRAD	NA	s3595	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c444	58cfa831e4b0c9d6adf6c444	TCGA-CH-5744-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CH-5744-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_6_rg.sorted	TCGA-CH-5744-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_6_rg.sorted.bam	130.4	1.9	0.15	58cfa831e4b0c9d6adf6c444	TCGA-CH-5744-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5744-10A	4E76DE8E-CB0D-4B83-8AB4-53BC67A7A9D3	Blood Derived Normal	Illumina HiSeq	7e3d3253-ca6c-4dbf-97ea-4d9126f9acad	Prostate	64	3F028008-19E4-400C-BADC-5540E6C4A242	AC85C5E7-0716-4375-AC65-56D632C858D1	TCGA-CH-5744-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5744	TCGA-PRAD	NA	s3414	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c39a	58cfa831e4b0c9d6adf6c39a	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted.bam	211	1.9	0.16	58cfa831e4b0c9d6adf6c39a	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5721-01A	588ABAEA-AB16-42F4-9457-5901EE791B5F	Primary Tumor	Illumina HiSeq	450e30b5-bcb4-4169-a48f-bbf3db7feda2	Stomach	58	B79123B9-5094-426D-8267-FD4A1C9F2778	8DE4E4AE-4C98-4D4E-BC77-2C205D817E01	TCGA-CG-5721-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5721	TCGA-STAD	NA	s14555	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c481	58cfa831e4b0c9d6adf6c481	TCGA-CG-5725-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-5725-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_5_rg.sorted	TCGA-CG-5725-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_5_rg.sorted.bam	14.7	1.9	0.13	58cfa831e4b0c9d6adf6c481	TCGA-CG-5725-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_5_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5725-11A	129D95CA-71EF-44AA-A93D-F87803C37C9A	Solid Tissue Normal	Illumina HiSeq	42216242-2d3d-4bb9-9b00-f0d50042790a	Stomach	72	0529F76F-29A6-4640-9DFD-447AA67EF836	9539B3CF-4AB9-468B-A80A-D91F624DD650	TCGA-CG-5725-11A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5725	TCGA-STAD	457	s15067	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3fa	58cfa831e4b0c9d6adf6c3fa	TCGA-BT-A2LB-10A-01D-A18D_120904_SN1120_0186_BC1911ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BT-A2LB-10A-01D-A18D_120904_SN1120_0186_BC1911ACXX_s_7_rg.sorted	TCGA-BT-A2LB-10A-01D-A18D_120904_SN1120_0186_BC1911ACXX_s_7_rg.sorted.bam	69.79	NA	0.16	58cfa831e4b0c9d6adf6c3fa	TCGA-BT-A2LB-10A-01D-A18D_120904_SN1120_0186_BC1911ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LB-10A	D17A5AB1-3789-4652-AFF5-D8F4F2291F9C	Blood Derived Normal	Illumina HiSeq	832b34b6-3018-44f5-b83b-4b2b9f5f032f	Bladder	73	46DEE0FD-8287-40CA-BE34-7E93A66CC23B	B13D2A50-787D-44AD-9E6A-EF40BC09E23D	TCGA-BT-A2LB-10A-01D-A18D-02	HG19_Broad_variant	TCGA-BT-A2LB	TCGA-BLCA	NA	s3088	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A18D-02	TRUE
13722.58cfa831e4b0c9d6adf6c488	58cfa831e4b0c9d6adf6c488	TCGA-CD-5801-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CD-5801-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_6_rg.sorted	TCGA-CD-5801-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_6_rg.sorted.bam	269.7	1.9	0.16	58cfa831e4b0c9d6adf6c488	TCGA-CD-5801-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_6_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5801-10A	DF822EA3-E0E6-4AD3-A228-E20E3A737DAC	Blood Derived Normal	Illumina HiSeq	0127bc2c-34be-4051-8211-7ccdc8529b37	Stomach	69	524D40B6-5811-49E4-AF3A-C8C70B2D0F7B	6CD1E3D4-E1D8-42F2-AE17-3DE6CBEC983F	TCGA-CD-5801-10A-01D-1598-02	HG19_Broad_variant	TCGA-CD-5801	TCGA-STAD	NA	s14976	Harvard Medical School	ILSbio	Vietnam	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c4ae	58cfa831e4b0c9d6adf6c4ae	TCGA-BR-6566-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6566-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_3_rg.sorted	TCGA-BR-6566-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_3_rg.sorted.bam	174.7	1.9	0.16	58cfa831e4b0c9d6adf6c4ae	TCGA-BR-6566-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6566-10A	43F0421C-6578-4D77-9314-EF0305C7EFBD	Blood Derived Normal	Illumina HiSeq	929fba9b-a5db-4260-beee-93a5f1be80ac	Stomach	64	81E4E4F1-AAF2-494F-A128-9070D2E0DE53	604D30E0-231B-491C-BE4B-7A750BE8CFE5	TCGA-BR-6566-10A-01D-1798-02	HG19_Broad_variant	TCGA-BR-6566	TCGA-STAD	NA	s14472	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c53a	58cfa831e4b0c9d6adf6c53a	TCGA-CH-5767-11B-01D-1784_130115_SN590_0208_BD1TAGACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CH-5767-11B-01D-1784_130115_SN590_0208_BD1TAGACXX_s_2_rg.sorted	TCGA-CH-5767-11B-01D-1784_130115_SN590_0208_BD1TAGACXX_s_2_rg.sorted.bam	98.4	1.9	0.15	58cfa831e4b0c9d6adf6c53a	TCGA-CH-5767-11B-01D-1784_130115_SN590_0208_BD1TAGACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5767-11B	8DC53431-44AB-485E-B4E6-C3D06509506D	Solid Tissue Normal	Illumina HiSeq	1cbd34c5-4fa8-46ee-b97f-ccbd7b816165	Prostate	66	FCBBC85A-D75B-4280-B6FB-643C8643E2F7	137B56C8-7D2A-4E33-9732-8D1B067F6C1C	TCGA-CH-5767-11B-01D-1784-02	HG19_Broad_variant	TCGA-CH-5767	TCGA-PRAD	NA	s3772	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa831e4b0c9d6adf6c57b	58cfa831e4b0c9d6adf6c57b	TCGA-CG-5728-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-5728-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_4_rg.sorted	TCGA-CG-5728-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_4_rg.sorted.bam	103	1.9	0.16	58cfa831e4b0c9d6adf6c57b	TCGA-CG-5728-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5728-01A	1286AC33-A466-4F58-900E-F6B13FE9C25A	Primary Tumor	Illumina HiSeq	557597f6-e3e0-4ac2-a626-902dc5b8709f	Stomach	88	CC525529-8511-41B1-B6C9-BF51DF484B7B	CC47C834-085D-407B-8F82-70FCF2402BAF	TCGA-CG-5728-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5728	TCGA-STAD	NA	s14418	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c594	58cfa831e4b0c9d6adf6c594	TCGA-CG-4469-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4469-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_7_rg.sorted	TCGA-CG-4469-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_7_rg.sorted.bam	23.9	1.9	0.15	58cfa831e4b0c9d6adf6c594	TCGA-CG-4469-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_7_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4469-10A	2AC986F6-CD6F-4CA5-90CC-7A105CFE85EA	Blood Derived Normal	Illumina HiSeq	e07b3b35-5adb-4abd-9750-e316a6f53fff	Stomach	70	0279401D-8BB4-4E90-AB5B-E0BC1F6C1709	725941B2-EABE-486D-B19D-FD215B801A8E	TCGA-CG-4469-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4469	TCGA-STAD	215	s14905	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c5c8	58cfa831e4b0c9d6adf6c5c8	TCGA-CG-4469-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4469-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_7_rg.sorted	TCGA-CG-4469-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_7_rg.sorted.bam	298.2	1.9	0.14	58cfa831e4b0c9d6adf6c5c8	TCGA-CG-4469-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_7_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4469-01A	2AC986F6-CD6F-4CA5-90CC-7A105CFE85EA	Primary Tumor	Illumina HiSeq	ed99ca3f-0ae6-43ab-a171-dc2774cf52e2	Stomach	70	2A3D7538-D377-4D94-BB61-BF77BA56BE1B	9BAFEA4B-CCC4-4F5D-8BFE-BD13D56741F6	TCGA-CG-4469-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4469	TCGA-STAD	215	s14988	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c5b3	58cfa831e4b0c9d6adf6c5b3	TCGA-CG-4436-10A-01D-1154_130815_VM001_0003_VMR0003CXX_s_6_rg.sorted.filtered.	WGS	TCGA-CG-4436-10A-01D-1154_130815_VM001_0003_VMR0003CXX_s_6_rg.sorted	TCGA-CG-4436-10A-01D-1154_130815_VM001_0003_VMR0003CXX_s_6_rg.sorted.bam	108.9	1.9	0.16	58cfa831e4b0c9d6adf6c5b3	TCGA-CG-4436-10A-01D-1154_130815_VM001_0003_VMR0003CXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4436-10A	7938CA55-766E-4277-9E7E-603FFA02E570	Blood Derived Normal	Illumina HiSeq	3eeefb8e-1bd7-4739-b4c3-b7695bedf7d3	Stomach	57	5B54776F-F475-4EFC-93A3-D6B54C954F2F	C2FA7041-FFB4-4296-8E12-57045F98BD17	TCGA-CG-4436-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4436	TCGA-STAD	NA	s14758	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c576	58cfa831e4b0c9d6adf6c576	TCGA-CN-4725-10A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-4725-10A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_4_rg.sorted	TCGA-CN-4725-10A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_4_rg.sorted.bam	274.4	1.9	0.14	58cfa831e4b0c9d6adf6c576	TCGA-CN-4725-10A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4725-10A	3BE2ACE5-1C2A-49E9-8DA9-CEED6119530B	Blood Derived Normal	Illumina HiSeq	bf165379-dbd3-45a0-b736-21fb5757d11a	Head and Neck	60	53B7BCFC-B007-436C-A375-4CBA7DE5BA1E	CCEF4FE6-7FAB-4F31-914D-44F1D42AAE7D	TCGA-CN-4725-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4725	TCGA-HNSC	NA	s15622	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c4c4	58cfa831e4b0c9d6adf6c4c4	TCGA-CF-A27C-10A-01D-A16N_120920_SN1222_0151_BD1D5CACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CF-A27C-10A-01D-A16N_120920_SN1222_0151_BD1D5CACXX_s_8_rg.sorted	TCGA-CF-A27C-10A-01D-A16N_120920_SN1222_0151_BD1D5CACXX_s_8_rg.sorted.bam	178.36	1.89	0.18	58cfa831e4b0c9d6adf6c4c4	TCGA-CF-A27C-10A-01D-A16N_120920_SN1222_0151_BD1D5CACXX_s_8_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A27C-10A	7FEE9D6F-C0EA-43C2-89C2-66D965A077A8	Blood Derived Normal	Illumina HiSeq	0152aa29-570c-4966-b98d-5b7f4cf31305	Bladder	52	1C4C59DC-B0B3-48B0-9888-42891CF1E8F8	6D4B14CF-5E4E-4DE2-B809-79CBAC40F7B8	TCGA-CF-A27C-10A-01D-A16N-02	HG19_Broad_variant	TCGA-CF-A27C	TCGA-BLCA	NA	s2878	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6c518	58cfa831e4b0c9d6adf6c518	TCGA-CN-4729-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-4729-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_4_rg.sorted	TCGA-CN-4729-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_4_rg.sorted.bam	948.4	1.9	0.14	58cfa831e4b0c9d6adf6c518	TCGA-CN-4729-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4729-10A	2FC960BD-01B0-422D-AD33-34520FA3DF0E	Blood Derived Normal	Illumina HiSeq	a038764a-307f-4a6f-8fd0-5ad2d2e2c05e	Head and Neck	73	818173B3-BD9D-44DD-B1C0-6CBF552C51D7	21E11B04-9295-48DE-A5C2-2796A44698EE	TCGA-CN-4729-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4729	TCGA-HNSC	NA	s15621	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5b8	58cfa831e4b0c9d6adf6c5b8	TCGA-CN-5360-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-5360-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_5_rg.sorted	TCGA-CN-5360-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_5_rg.sorted.bam	98.4	1.9	0.14	58cfa831e4b0c9d6adf6c5b8	TCGA-CN-5360-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5360-10A	5793879B-F663-4A10-9BD9-1ACD2E189650	Blood Derived Normal	Illumina HiSeq	e5e36209-eb45-4a7f-b70a-547a36daace6	Head and Neck	68	9439BC03-9D26-454A-BA80-A0F5A4585656	E8A06D37-CC48-46E7-B1DA-C9B8A9B2A462	TCGA-CN-5360-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5360	TCGA-HNSC	NA	s15890	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5e2	58cfa831e4b0c9d6adf6c5e2	TCGA-CG-4300-10A-01D-1154_130815_VM001_0003_VMR0003CXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-4300-10A-01D-1154_130815_VM001_0003_VMR0003CXX_s_4_rg.sorted	TCGA-CG-4300-10A-01D-1154_130815_VM001_0003_VMR0003CXX_s_4_rg.sorted.bam	136.6	1.9	0.15	58cfa831e4b0c9d6adf6c5e2	TCGA-CG-4300-10A-01D-1154_130815_VM001_0003_VMR0003CXX_s_4_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4300-10A	8ED901F6-D1BC-48B1-8514-6E8C066DC160	Blood Derived Normal	Illumina HiSeq	059e7973-6498-492c-b3a6-9adc84950f18	Stomach	79	D3396AE2-DF13-47B9-B955-ACBA8C222255	295E29A6-5CA9-4C89-84C4-679AC988A1F6	TCGA-CG-4300-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4300	TCGA-STAD	609	s15393	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIB	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6c214	58cfa830e4b0c9d6adf6c214	TCGA-BA-4077-01B-01D-1431_120310_SN590_0145_BD0RGYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BA-4077-01B-01D-1431_120310_SN590_0145_BD0RGYACXX_s_7_rg.sorted	TCGA-BA-4077-01B-01D-1431_120310_SN590_0145_BD0RGYACXX_s_7_rg.sorted.bam	246.33	1.9	0.15	58cfa830e4b0c9d6adf6c214	TCGA-BA-4077-01B-01D-1431_120310_SN590_0145_BD0RGYACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4077-01B	4BFBCE2B-9D0B-4E8A-950F-FD8E0BA3E05A	Primary Tumor	Illumina HiSeq	4f243210-88ea-4d9f-88fd-faf45b45d38e	Head and Neck	45	327BBCA7-FA25-4A92-BE27-21A4C184C760	8428602A-5EEC-4D09-B187-02B1CFF24EB5	TCGA-BA-4077-01B-01D-1431-02	HG19_Broad_variant	TCGA-BA-4077	TCGA-HNSC	1134	s16314	Harvard Medical School	UNC	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5f4	58cfa831e4b0c9d6adf6c5f4	TCGA-CG-4465-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-4465-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_5_rg.sorted	TCGA-CG-4465-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_5_rg.sorted.bam	110.9	1.9	0.14	58cfa831e4b0c9d6adf6c5f4	TCGA-CG-4465-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_5_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4465-10A	C9AB5BF4-092A-420F-9B90-87DEEA58104C	Blood Derived Normal	Illumina HiSeq	fac76410-c449-448e-8f7c-c33a3e3cadc5	Stomach	69	85ED773E-80B5-407A-9B44-E9D333716079	597C92D7-94B4-442C-925D-882BE837B5F6	TCGA-CG-4465-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4465	TCGA-STAD	274	s15126	Harvard Medical School	Indivumed	Germany	NO	T4	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c61a	58cfa831e4b0c9d6adf6c61a	TCGA-CG-4305-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4305-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_1_rg.sorted	TCGA-CG-4305-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_1_rg.sorted.bam	264.2	1.9	0.13	58cfa831e4b0c9d6adf6c61a	TCGA-CG-4305-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_1_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4305-01A	E0E35051-FBB4-4389-AEDB-87BDE84D21AD	Primary Tumor	Illumina HiSeq	dad3a237-d784-4731-bbef-c4d3dce49fa2	Stomach	69	6B64B4A0-EDC8-4DC3-B527-D320DED81351	A01B1633-2A30-4379-80AC-72799C14B5C7	TCGA-CG-4305-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4305	TCGA-STAD	NA	s14981	Harvard Medical School	Indivumed	Germany	NO	T2a	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c5da	58cfa831e4b0c9d6adf6c5da	TCGA-CN-5366-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-5366-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_5_rg.sorted	TCGA-CN-5366-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_5_rg.sorted.bam	31.4	1.9	0.15	58cfa831e4b0c9d6adf6c5da	TCGA-CN-5366-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5366-10A	30EB06A5-8E88-4C46-BEBB-FB93CA07F108	Blood Derived Normal	Illumina HiSeq	8d6d4c85-46e4-449c-9bc1-f75a4af110a6	Head and Neck	51	111AD944-F78E-4EC6-967B-F05C49B49B1C	1683419A-F9D7-4484-A65B-B5A1DE47D1EB	TCGA-CN-5366-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5366	TCGA-HNSC	360	s16322	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5dc	58cfa831e4b0c9d6adf6c5dc	TCGA-CN-5364-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-5364-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_8_rg.sorted	TCGA-CN-5364-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_8_rg.sorted.bam	38.4	1.9	0.14	58cfa831e4b0c9d6adf6c5dc	TCGA-CN-5364-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5364-10A	13F63218-0949-41E6-A661-C844414C45B5	Blood Derived Normal	Illumina HiSeq	2dc9d158-11f1-4d04-a6e6-8075121def2e	Head and Neck	55	7CFD419C-8485-4080-BDB3-18B33964FBDF	31CB16D7-5896-4895-AE00-46DD28092923	TCGA-CN-5364-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5364	TCGA-HNSC	493	s16185	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c670	58cfa831e4b0c9d6adf6c670	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted.bam	18	1.9	0.14	58cfa831e4b0c9d6adf6c670	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	Not available	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-4944-01A	64CD17EB-C778-45E9-B994-02B68182E51B	Primary Tumor	Illumina HiSeq	c266d33e-c72f-4059-b287-2f1bbd6fd48b	Brain	50	F1AA24E4-BC7F-427F-9CEB-8CAAFABFE535	63B56E68-639B-483B-B777-EAD4BDDC112C	TCGA-CS-4944-01A-01D-1465-02	HG19_Broad_variant	TCGA-CS-4944	TCGA-LGG	NA	s8127	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Astrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c65d	58cfa831e4b0c9d6adf6c65d	TCGA-CG-4465-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4465-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_2_rg.sorted	TCGA-CG-4465-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_2_rg.sorted.bam	110.9	1.9	0.14	58cfa831e4b0c9d6adf6c65d	TCGA-CG-4465-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_2_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4465-10A	C9AB5BF4-092A-420F-9B90-87DEEA58104C	Blood Derived Normal	Illumina HiSeq	6109b58f-b3ad-4763-a565-ff5c8665b31a	Stomach	69	85ED773E-80B5-407A-9B44-E9D333716079	597C92D7-94B4-442C-925D-882BE837B5F6	TCGA-CG-4465-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4465	TCGA-STAD	274	s14982	Harvard Medical School	Indivumed	Germany	NO	T4	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c5ed	58cfa831e4b0c9d6adf6c5ed	TCGA-CG-4306-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4306-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_3_rg.sorted	TCGA-CG-4306-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_3_rg.sorted.bam	213.2	1.9	0.14	58cfa831e4b0c9d6adf6c5ed	TCGA-CG-4306-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_3_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4306-01A	73D177F7-8C0A-42F6-A73D-8073C0E6142B	Primary Tumor	Illumina HiSeq	97a524b1-432a-4c20-adcf-5e45ee168834	Stomach	90	78785DB9-C3D5-4C26-BBEF-E741C4AAE429	42E4D7EE-860D-498E-AA00-D2AB42EB4ECA	TCGA-CG-4306-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4306	TCGA-STAD	31	s14827	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c61d	58cfa831e4b0c9d6adf6c61d	TCGA-CN-4740-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-4740-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_5_rg.sorted	TCGA-CN-4740-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_5_rg.sorted.bam	38.4	1.9	0.13	58cfa831e4b0c9d6adf6c61d	TCGA-CN-4740-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4740-10A	E37C83DC-C2C4-4E5F-A57B-39FFCF9AA3CF	Blood Derived Normal	Illumina HiSeq	d36d8c79-6394-457e-a92f-c582f98097a0	Head and Neck	79	533B0EC7-41DD-405E-A6B5-6E82CB689CDE	A820807E-4D6F-4481-BD39-C29522B3C3FE	TCGA-CN-4740-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4740	TCGA-HNSC	NA	s15886	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c63c	58cfa831e4b0c9d6adf6c63c	TCGA-CN-4741-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CN-4741-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_6_rg.sorted	TCGA-CN-4741-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_6_rg.sorted.bam	84.4	1.9	0.15	58cfa831e4b0c9d6adf6c63c	TCGA-CN-4741-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4741-10A	277B02E9-DED5-4980-845D-AF53690000AC	Blood Derived Normal	Illumina HiSeq	ada75f19-f08c-4bbe-a617-4f070b55e658	Head and Neck	75	8D8DDCA2-6461-4A8B-A696-DA0906661B9E	CAA37FFF-7EA8-4980-A7FF-FF228F2B432A	TCGA-CN-4741-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4741	TCGA-HNSC	NA	s15626	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c6de	58cfa831e4b0c9d6adf6c6de	TCGA-CG-4443-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-4443-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_4_rg.sorted	TCGA-CG-4443-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_4_rg.sorted.bam	80.9	1.9	0.16	58cfa831e4b0c9d6adf6c6de	TCGA-CG-4443-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4443-10A	8CB0144B-BE6B-40A1-86A2-708F96D9B615	Blood Derived Normal	Illumina HiSeq	d8d4539e-9091-4761-ba28-e83c2f89a9f3	Stomach	68	5F5EB83F-C6C8-409B-A8CE-89AF811FE35E	C3189796-A375-481F-9F34-1013B41FD585	TCGA-CG-4443-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4443	TCGA-STAD	NA	s15191	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IA	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c671	58cfa831e4b0c9d6adf6c671	TCGA-CN-5363-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-5363-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_7_rg.sorted	TCGA-CN-5363-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_7_rg.sorted.bam	15.4	1.9	0.14	58cfa831e4b0c9d6adf6c671	TCGA-CN-5363-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_7_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5363-10A	291B069C-9DDE-4E1E-8430-85146BC94338	Blood Derived Normal	Illumina HiSeq	97348237-93c4-44d0-9bb6-3c2ee7ac10a1	Head and Neck	48	591E99EC-46F9-442D-AC20-745DCCC8A52B	559D615C-BE5B-4AD1-8860-B633A0B361B6	TCGA-CN-5363-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5363	TCGA-HNSC	253	s16324	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N3	Head and Neck Squamous Cell Carcinoma	Stage IVB	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c6e7	58cfa831e4b0c9d6adf6c6e7	TCGA-CN-4742-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-4742-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_4_rg.sorted	TCGA-CN-4742-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_4_rg.sorted.bam	41.4	1.9	0.16	58cfa831e4b0c9d6adf6c6e7	TCGA-CN-4742-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4742-10A	444E5BFC-D4E5-4B0D-B96D-88ECEA8873E9	Blood Derived Normal	Illumina HiSeq	2f928254-a183-425a-b4d0-4a9317c432fd	Head and Neck	48	580D4B59-8FB5-49BC-8030-56524652DDC3	80CAB596-28EA-43F4-BFEB-98599A3494CF	TCGA-CN-4742-10A-01D-1509-02	HG19_Broad_variant	TCGA-CN-4742	TCGA-HNSC	397	s16175	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa831e4b0c9d6adf6c6e2	58cfa831e4b0c9d6adf6c6e2	TCGA-CN-5355-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-5355-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_7_rg.sorted	TCGA-CN-5355-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_7_rg.sorted.bam	15.4	1.9	0.14	58cfa831e4b0c9d6adf6c6e2	TCGA-CN-5355-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_7_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5355-10A	45A10908-19E6-421A-8903-1440BFA57C9D	Blood Derived Normal	Illumina HiSeq	b41ec820-7463-4bef-84a1-09d5c40fc499	Head and Neck	64	C2EF7833-C2FA-446C-A12E-F353C744B1E4	75ACDB7E-80B8-41DA-B105-F57F4BE1E9F0	TCGA-CN-5355-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5355	TCGA-HNSC	NA	s15764	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c73a	58cfa831e4b0c9d6adf6c73a	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted.bam	274.4	1.9	0.16	58cfa831e4b0c9d6adf6c73a	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6524-01A	7EF3F065-1928-4A58-B5A6-76DDDB8488CF	Primary Tumor	Illumina HiSeq	67f702e7-84ad-4d23-90e7-03040d417e4d	Stomach	53	6F14723A-AF83-402D-AB98-B4ED29A93AAF	48540EAA-46FD-4C0A-9893-1FF69D205F79	TCGA-D7-6524-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6524	TCGA-STAD	NA	s14557	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach  Adenocarcinoma  Diffuse Type	Stage II	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c6be	58cfa831e4b0c9d6adf6c6be	TCGA-CN-4742-01A-02D-1509_120420_SN208_0285_AD0T5JACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-4742-01A-02D-1509_120420_SN208_0285_AD0T5JACXX_s_1_rg.sorted	TCGA-CN-4742-01A-02D-1509_120420_SN208_0285_AD0T5JACXX_s_1_rg.sorted.bam	52.7	1.9	0.16	58cfa831e4b0c9d6adf6c6be	TCGA-CN-4742-01A-02D-1509_120420_SN208_0285_AD0T5JACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4742-01A	444E5BFC-D4E5-4B0D-B96D-88ECEA8873E9	Primary Tumor	Illumina HiSeq	e655fe0a-a859-4967-b69c-4c8d36a8a7e0	Head and Neck	48	507B9A1D-BFBF-43F8-86D2-665A488441AF	A9768535-FE1C-4B4F-B709-DED0809BA592	TCGA-CN-4742-01A-02D-1509-02	HG19_Broad_variant	TCGA-CN-4742	TCGA-HNSC	397	s15892	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa831e4b0c9d6adf6c6fe	58cfa831e4b0c9d6adf6c6fe	TCGA-CV-5970-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-5970-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_7_rg.sorted	TCGA-CV-5970-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_7_rg.sorted.bam	37	1.9	0.13	58cfa831e4b0c9d6adf6c6fe	TCGA-CV-5970-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5970-11A	1F6167D9-C99D-4873-8D6E-E62A1C964135	Solid Tissue Normal	Illumina HiSeq	004bd2ad-a03c-45c2-9e51-6051014fe91b	Head and Neck	59	EF1AEFD1-1B8F-4840-9037-282DE48ED7F7	B31C32DB-0966-4A8A-AD18-0F5EDAFBBCCB	TCGA-CV-5970-11A-01D-1681-02	HG19_Broad_variant	TCGA-CV-5970	TCGA-HNSC	406	s16337	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c6f2	58cfa831e4b0c9d6adf6c6f2	TCGA-CV-5976-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CV-5976-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_6_rg.sorted	TCGA-CV-5976-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_6_rg.sorted.bam	37	1.9	0.14	58cfa831e4b0c9d6adf6c6f2	TCGA-CV-5976-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5976-11A	23062172-7361-4E61-8EE6-B0A613D72A24	Solid Tissue Normal	Illumina HiSeq	f5c4e8eb-c5ca-4eb2-b92d-a5a054c4a0c6	Head and Neck	50	B721E292-1D8D-451C-BB08-77BC2A61A1B0	662DE6A8-5889-4EB1-86D6-7C5E4012F914	TCGA-CV-5976-11A-01D-1681-02	HG19_Broad_variant	TCGA-CV-5976	TCGA-HNSC	NA	s15642	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c6f0	58cfa831e4b0c9d6adf6c6f0	TCGA-CV-5439-11B-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CV-5439-11B-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_5_rg.sorted	TCGA-CV-5439-11B-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_5_rg.sorted.bam	32	1.8	0.14	58cfa831e4b0c9d6adf6c6f0	TCGA-CV-5439-11B-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5439-11B	3EE863DA-7991-414F-82D8-2B6502D4C061	Solid Tissue Normal	Illumina HiSeq	f81e667a-9c30-4093-8e59-c8fa7f8b772c	Head and Neck	62	23F2A9BF-D544-407E-A074-AD7CA9614D7D	82E05280-64DC-4926-931F-B24196B966AF	TCGA-CV-5439-11B-01D-1681-02	HG19_Broad_variant	TCGA-CV-5439	TCGA-HNSC	546	s15513	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c702	58cfa831e4b0c9d6adf6c702	TCGA-CV-5966-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-5966-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_2_rg.sorted	TCGA-CV-5966-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_2_rg.sorted.bam	99	1.9	0.14	58cfa831e4b0c9d6adf6c702	TCGA-CV-5966-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5966-01A	0D0731E2-8D82-4B6D-9258-2896A770A868	Primary Tumor	Illumina HiSeq	a774b0c6-39f6-4601-9c2a-5a81369b9f87	Head and Neck	63	E71C33E9-1F74-4CF6-B6BF-985D0C96F71E	84D0CA61-132A-4B85-A343-0C55DE088B0C	TCGA-CV-5966-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5966	TCGA-HNSC	545	s16335	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c740	58cfa831e4b0c9d6adf6c740	TCGA-D3-A3C8-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D3-A3C8-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_6_rg.sorted	TCGA-D3-A3C8-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_6_rg.sorted.bam	18.14	NA	0.17	58cfa831e4b0c9d6adf6c740	TCGA-D3-A3C8-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A3C8-10A	16182443-12A1-4B0F-A6AB-33C2942E2991	Blood Derived Normal	Illumina HiSeq	8cb73a3e-5bb3-4c87-9f23-3c223fc0af0a	Skin	58	5DBB9CC8-5C79-4C61-B414-39C9030AB221	FFE107B9-1019-47D7-90DC-3900385015A8	TCGA-D3-A3C8-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A3C8	TCGA-SKCM	NA	s8000	Harvard Medical School	MD Anderson	United States	NO	TX	N3	Not available	Stage IIIC	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c784	58cfa831e4b0c9d6adf6c784	TCGA-CN-6013-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-6013-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_5_rg.sorted	TCGA-CN-6013-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_5_rg.sorted.bam	492.7	1.9	0.15	58cfa831e4b0c9d6adf6c784	TCGA-CN-6013-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6013-10A	714496C5-D221-4397-9C5A-CD2D22603E6F	Blood Derived Normal	Illumina HiSeq	6b051d97-36f0-4a18-80f9-60c27c73c081	Head and Neck	56	8B510BC8-7B3C-4861-9A40-C2C30B7099E0	762CA7DA-6D6E-4709-B1AA-13621D962D35	TCGA-CN-6013-10A-01D-1681-02	HG19_Broad_variant	TCGA-CN-6013	TCGA-HNSC	NA	s15889	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c7aa	58cfa831e4b0c9d6adf6c7aa	TCGA-D1-A17R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A17R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_1_rg.sorted	TCGA-D1-A17R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_1_rg.sorted.bam	76.31	1.88	0.16	58cfa831e4b0c9d6adf6c7aa	TCGA-D1-A17R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17R-01A	73A0DD38-115D-48FB-B683-04AA5D612F2A	Primary Tumor	Illumina HiSeq	5425360b-22c2-480d-aa90-d7b4b67dad49	Uterus	58	205DE3E7-B078-4904-82C3-3D0F757D94A8	DF3E4C9B-67D4-46FF-BFE0-4F55A72CA179	TCGA-D1-A17R-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17R	TCGA-UCEC	339	s5227	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c7b1	58cfa831e4b0c9d6adf6c7b1	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted.bam	155.7	NA	0.15	58cfa831e4b0c9d6adf6c7b1	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6996-01A	49B94421-FE82-4F24-8EF2-820674142418	Primary Tumor	Illumina HiSeq	533cea76-ea79-4b37-8e72-5626bc894990	Head and Neck	58	2C3790CE-A54D-431B-B76C-FA25441AA41C	5367CF72-E404-4203-AD7D-CF7663072EA7	TCGA-CN-6996-01A-11D-1911-02	HG19_Broad_variant	TCGA-CN-6996	TCGA-HNSC	NA	s16180	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c7a2	58cfa831e4b0c9d6adf6c7a2	TCGA-CV-5971-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-5971-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_8_rg.sorted	TCGA-CV-5971-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_8_rg.sorted.bam	30	1.9	0.15	58cfa831e4b0c9d6adf6c7a2	TCGA-CV-5971-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5971-11A	1465B7EC-8D2B-47DD-8387-977EED44CC86	Solid Tissue Normal	Illumina HiSeq	1ceeef7f-0aec-40ec-b515-3b369cde02e2	Head and Neck	60	925E85CB-0CEB-44B7-A745-7B7C21427DF8	27495DD9-B50E-4C66-AFF3-C910D0DCC72D	TCGA-CV-5971-11A-01D-1681-02	HG19_Broad_variant	TCGA-CV-5971	TCGA-HNSC	NA	s16046	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N2a	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c7c8	58cfa831e4b0c9d6adf6c7c8	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted.bam	56.36	1.95	0.15	58cfa831e4b0c9d6adf6c7c8	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17K-01A	5C22C8D6-5805-455C-8E1C-E6B8006738E4	Primary Tumor	Illumina HiSeq	312dd86a-5fc1-4446-bfd6-fe867e3617f2	Uterus	74	CA213835-EFC5-4216-A762-A6B320B516BF	3E67F5BD-C5A6-4CDD-8D71-78038D316447	TCGA-D1-A17K-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17K	TCGA-UCEC	NA	s4617	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c78a	58cfa831e4b0c9d6adf6c78a	TCGA-CV-5439-01A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-5439-01A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_1_rg.sorted	TCGA-CV-5439-01A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_1_rg.sorted.bam	262	1.9	0.17	58cfa831e4b0c9d6adf6c78a	TCGA-CV-5439-01A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5439-01A	3EE863DA-7991-414F-82D8-2B6502D4C061	Primary Tumor	Illumina HiSeq	e10c02de-cabd-4311-baab-3bb90e13717f	Head and Neck	62	C94D8E61-8A15-4702-90EF-37616F1C015B	A1170138-A1B1-4D13-B66B-0507D3DE897B	TCGA-CV-5439-01A-01D-1681-02	HG19_Broad_variant	TCGA-CV-5439	TCGA-HNSC	546	s16194	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c7de	58cfa831e4b0c9d6adf6c7de	TCGA-D1-A17B-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A17B-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_3_rg.sorted	TCGA-D1-A17B-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_3_rg.sorted.bam	44.38	2	0.15	58cfa831e4b0c9d6adf6c7de	TCGA-D1-A17B-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17B-10A	E55DD65A-C75E-4A3C-BB24-8B3AF4D65321	Blood Derived Normal	Illumina HiSeq	1b9457d8-9c16-4247-b276-1ead20efc5dc	Uterus	69	131CB413-EA4A-4DCB-B0F5-8F4BC66D8D08	7520530E-39A1-4666-A534-CCC41B2EF335	TCGA-D1-A17B-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A17B	TCGA-UCEC	NA	s5229	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c7f7	58cfa831e4b0c9d6adf6c7f7	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted.bam	46.77	1.95	0.15	58cfa831e4b0c9d6adf6c7f7	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17C-01A	6F4F0CDD-8387-45D0-A9E8-EFCE6260159D	Primary Tumor	Illumina HiSeq	554e5953-4680-4681-a963-fcc940b3f448	Uterus	78	2D5AC7FC-BED4-4C7F-927D-9B44846324C4	99444E9D-219B-4653-9410-B258D28DEEB7	TCGA-D1-A17C-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17C	TCGA-UCEC	NA	s4801	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c803	58cfa831e4b0c9d6adf6c803	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted.bam	99.18	1.97	0.15	58cfa831e4b0c9d6adf6c803	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16N-01A	DBBBDDAE-D711-40F5-BD10-863735885B1F	Primary Tumor	Illumina HiSeq	0cea9a43-7170-4273-879f-084cb6e14196	Uterus	51	6D916A47-DCFF-4C98-9E88-348AAA353F98	133CBA56-19C9-47AE-AB5E-37FF35A7E71E	TCGA-D1-A16N-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16N	TCGA-UCEC	NA	s4263	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c822	58cfa831e4b0c9d6adf6c822	TCGA-D1-A2G0-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D1-A2G0-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_6_rg.sorted	TCGA-D1-A2G0-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_6_rg.sorted.bam	11.63	NA	0.15	58cfa831e4b0c9d6adf6c822	TCGA-D1-A2G0-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A2G0-10A	6F661F0D-F08B-486E-8BD7-4306E1593EB9	Blood Derived Normal	Illumina HiSeq	e49e2287-a4cb-4280-ad97-698435bac987	Uterus	70	87CB512B-1C17-4C8C-93DB-7B7E62880924	330535EC-19A5-4FB7-821E-58A8AD25060B	TCGA-D1-A2G0-10A-01D-A17E-02	HG19_Broad_variant	TCGA-D1-A2G0	TCGA-UCEC	NA	s5228	Harvard Medical School	Mayo Clinic	United States	NO	Not available	Not available	Mixed serous and endometrioid	Not available	A17E-02	TRUE
13722.58cfa831e4b0c9d6adf6c7fc	58cfa831e4b0c9d6adf6c7fc	TCGA-CV-6959-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-6959-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_8_rg.sorted	TCGA-CV-6959-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_8_rg.sorted.bam	79.7	1.9	0.14	58cfa831e4b0c9d6adf6c7fc	TCGA-CV-6959-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6959-11A	EF3CE0E5-D2E8-4616-8B1A-A78C591CF235	Solid Tissue Normal	Illumina HiSeq	e12b73cf-efab-4371-8449-776e46f7949c	Head and Neck	48	C6706A96-631D-43D0-9A08-0BBE9D6295FB	556078E9-11DC-4089-9520-D5D5C49E42E0	TCGA-CV-6959-11A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6959	TCGA-HNSC	256	s16203	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c836	58cfa831e4b0c9d6adf6c836	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted.bam	131.4	1.9	0.14	58cfa831e4b0c9d6adf6c836	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6521-01A	6DE6B8E2-03EB-4F32-B5A3-BEA73FC632B4	Primary Tumor	Illumina HiSeq	72a895e9-b1b0-4b79-a5e6-6bae340e8798	Stomach	65	C3D9FC3B-EF2A-4D02-B7A4-5D1463AD5EF3	0F49F6E2-C6C8-4F3E-8755-BAA962453E71	TCGA-D7-6521-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6521	TCGA-STAD	NA	s14838	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2b	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c885	58cfa831e4b0c9d6adf6c885	TCGA-D7-6521-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D7-6521-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_2_rg.sorted	TCGA-D7-6521-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_2_rg.sorted.bam	415.7	1.9	0.15	58cfa831e4b0c9d6adf6c885	TCGA-D7-6521-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6521-10A	6DE6B8E2-03EB-4F32-B5A3-BEA73FC632B4	Blood Derived Normal	Illumina HiSeq	eb009690-3197-4b8c-9b74-0020480845fb	Stomach	65	F7C9FE46-4828-4C41-A15B-6D6B8BE59DA2	A2ECB6E3-ABF3-46A7-A4C6-505FC39A8CDC	TCGA-D7-6521-10A-01D-1798-02	HG19_Broad_variant	TCGA-D7-6521	TCGA-STAD	NA	s15403	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2b	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c82b	58cfa831e4b0c9d6adf6c82b	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted.bam	77.69	1.86	0.16	58cfa831e4b0c9d6adf6c82b	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17Q-01A	CA8DBBFD-8928-4E25-94C6-B875DE631BBD	Primary Tumor	Illumina HiSeq	77e56615-42dd-4c50-a518-cc93c3b80107	Uterus	54	B6ABEB01-B6EA-4AB4-AA00-AE16CFC88B7C	59FB249D-4C77-40B1-A557-98281869AC91	TCGA-D1-A17Q-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17Q	TCGA-UCEC	NA	s4442	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c82e	58cfa831e4b0c9d6adf6c82e	TCGA-D6-6826-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D6-6826-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_7_rg.sorted	TCGA-D6-6826-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_7_rg.sorted.bam	405	1.9	0.16	58cfa831e4b0c9d6adf6c82e	TCGA-D6-6826-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6826-10A	31243867-8E9F-46E9-A213-B83544EB8028	Blood Derived Normal	Illumina HiSeq	cb6e32f1-cfa4-4387-a53f-e7a562ac45d9	Head and Neck	64	7AA13049-917A-4D7A-BCEB-3C718EC8FB7A	A6B7AC7D-425D-4741-BE71-3E3FA167AEE8	TCGA-D6-6826-10A-01D-1911-02	HG19_Broad_variant	TCGA-D6-6826	TCGA-HNSC	NA	s15913	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c848	58cfa831e4b0c9d6adf6c848	TCGA-D6-6823-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D6-6823-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_5_rg.sorted	TCGA-D6-6823-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_5_rg.sorted.bam	658	1.9	0.15	58cfa831e4b0c9d6adf6c848	TCGA-D6-6823-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6823-10A	FBDAB01C-191C-4AEF-9451-CA3AFEC55FA1	Blood Derived Normal	Illumina HiSeq	60900e52-222a-400c-9981-8ea2dfba4553	Head and Neck	50	3CA51C87-28F6-4269-A387-D9D89E8FBA56	0B3ABCE7-4747-4354-8481-EEB667C705EE	TCGA-D6-6823-10A-01D-1911-02	HG19_Broad_variant	TCGA-D6-6823	TCGA-HNSC	NA	s15654	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c85a	58cfa831e4b0c9d6adf6c85a	TCGA-D6-6825-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D6-6825-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_6_rg.sorted	TCGA-D6-6825-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_6_rg.sorted.bam	530	1.9	0.15	58cfa831e4b0c9d6adf6c85a	TCGA-D6-6825-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6825-10A	42BC2336-2408-441A-83B9-AADC9700F750	Blood Derived Normal	Illumina HiSeq	dac94d31-7c1f-4e4b-98af-a3a585b86fae	Head and Neck	73	2D4DD757-4C4F-49E4-B5BA-84BCAE21C5FD	222663D9-DF98-4A0B-88EB-83FCB81BCB0A	TCGA-D6-6825-10A-01D-1911-02	HG19_Broad_variant	TCGA-D6-6825	TCGA-HNSC	NA	s15656	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c867	58cfa831e4b0c9d6adf6c867	TCGA-D6-6827-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-D6-6827-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_8_rg.sorted	TCGA-D6-6827-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_8_rg.sorted.bam	876	1.9	0.14	58cfa831e4b0c9d6adf6c867	TCGA-D6-6827-10A-01D-1911_120518_SN1120_0143_BC0VN6ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6827-10A	3C5BC678-41E9-46B3-9686-5CD95659AB71	Blood Derived Normal	Illumina HiSeq	aef80235-e93d-436c-8a32-888344249391	Head and Neck	55	2EF80E58-961D-45D6-AC3A-A520BE3728C9	E38F279E-881E-4A80-806E-50B316E0741D	TCGA-D6-6827-10A-01D-1911-02	HG19_Broad_variant	TCGA-D6-6827	TCGA-HNSC	NA	s15653	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c8c4	58cfa831e4b0c9d6adf6c8c4	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted.bam	165.7	1.9	0.14	58cfa831e4b0c9d6adf6c8c4	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5373-01A	546F01D5-AED5-4FB8-91C0-0FD5E0FDE935	Primary Tumor	Illumina HiSeq	22213a76-97e9-4565-8074-c3046269b70a	Head and Neck	55	9D73D061-F1E1-47BA-929D-FEEB6C191279	3FE7F18F-8AA4-4AFE-8AF0-256876F7E86E	TCGA-CN-5373-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5373	TCGA-HNSC	NA	s16035	Harvard Medical School	University of Pittsburgh	None	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c8eb	58cfa831e4b0c9d6adf6c8eb	TCGA-D7-6524-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D7-6524-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_6_rg.sorted	TCGA-D7-6524-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_6_rg.sorted.bam	156.7	1.9	0.15	58cfa831e4b0c9d6adf6c8eb	TCGA-D7-6524-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6524-10A	7EF3F065-1928-4A58-B5A6-76DDDB8488CF	Blood Derived Normal	Illumina HiSeq	53a3658a-e190-413c-904b-1f8bf1ddf4ee	Stomach	53	87288983-703E-485D-B236-7EBACBFE9086	CD98C312-9C0F-4923-BBCA-7BCF722DE68B	TCGA-D7-6524-10A-01D-1798-02	HG19_Broad_variant	TCGA-D7-6524	TCGA-STAD	NA	s14420	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach  Adenocarcinoma  Diffuse Type	Stage II	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c8e8	58cfa831e4b0c9d6adf6c8e8	TCGA-CV-6441-01A-11D-1681_120427_SN208_0287_AC0J25ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-6441-01A-11D-1681_120427_SN208_0287_AC0J25ACXX_s_2_rg.sorted	TCGA-CV-6441-01A-11D-1681_120427_SN208_0287_AC0J25ACXX_s_2_rg.sorted.bam	46	1.9	0.14	58cfa831e4b0c9d6adf6c8e8	TCGA-CV-6441-01A-11D-1681_120427_SN208_0287_AC0J25ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6441-01A	59398D50-45CF-4812-A24E-0C00C0199971	Primary Tumor	Illumina HiSeq	4df6f8df-9255-4e46-8936-baeab0ed20c2	Head and Neck	60	192C9F36-08EC-4F7F-8137-1A9BD0282D98	FE879D88-4817-4ED8-9FB2-EE92AF1A582F	TCGA-CV-6441-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-6441	TCGA-HNSC	292	s15779	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c85f	58cfa831e4b0c9d6adf6c85f	TCGA-D6-6517-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D6-6517-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_4_rg.sorted	TCGA-D6-6517-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_4_rg.sorted.bam	367	1.8	0.15	58cfa831e4b0c9d6adf6c85f	TCGA-D6-6517-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6517-10A	EBE99910-E9F2-43DC-AD57-AC2F610B60C8	Blood Derived Normal	Illumina HiSeq	019b158f-ce54-4f1b-9db2-b82383657121	Head and Neck	59	A2DD87A8-E0D1-47C1-A8D1-70B9730AA4BA	81C11B09-5291-4389-977F-904F11E62597	TCGA-D6-6517-10A-01D-1868-02	HG19_Broad_variant	TCGA-D6-6517	TCGA-HNSC	NA	s15530	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6c91f	58cfa831e4b0c9d6adf6c91f	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted.bam	43.47	2	0.18	58cfa831e4b0c9d6adf6c91f	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AB-01A	F027D254-EC01-4882-A8A7-964AE90B7D49	Primary Tumor	Illumina HiSeq	a5005e15-2ada-4bf4-9a61-0febc81a99ca	Bladder	74	253F84AB-FCE2-4E2D-955B-0B8D13A9E4F0	D1F85B58-EBF8-4A73-A5E0-8DFE62CF1164	TCGA-DK-A1AB-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AB	TCGA-BLCA	NA	s2707	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c8f2	58cfa831e4b0c9d6adf6c8f2	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted.bam	135	1.9	0.15	58cfa831e4b0c9d6adf6c8f2	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5976-01A	23062172-7361-4E61-8EE6-B0A613D72A24	Primary Tumor	Illumina HiSeq	ef7745ae-17be-41bc-a3a5-c24eeda89075	Head and Neck	50	EEF68956-D624-4CD0-9C48-28FAF052C5F9	2581BC16-0DEF-40BC-8A97-54A1AE577E26	TCGA-CV-5976-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5976	TCGA-HNSC	NA	s16041	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c91d	58cfa831e4b0c9d6adf6c91d	TCGA-DJ-A13R-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DJ-A13R-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_4_rg.sorted	TCGA-DJ-A13R-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_4_rg.sorted.bam	60.3	1.88	0.15	58cfa831e4b0c9d6adf6c91d	TCGA-DJ-A13R-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13R-10A	3E787A0E-B5D2-401E-B1E5-077376090B3A	Blood Derived Normal	Illumina HiSeq	ed7404d8-0429-4aa7-9487-9ed11a162c7a	Thyroid	50	4CD78789-F3CE-423A-A09E-0514C295A475	BCD273B7-C1C8-40BD-85EC-674E75F3F46C	TCGA-DJ-A13R-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13R	TCGA-THCA	NA	s12511	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c9ac	58cfa831e4b0c9d6adf6c9ac	TCGA-DB-5279-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DB-5279-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_8_rg.sorted	TCGA-DB-5279-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_8_rg.sorted.bam	70.7	1.9	0.15	58cfa831e4b0c9d6adf6c9ac	TCGA-DB-5279-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_8_rg.sorted.bam	Alive	MALE	Not available	Not available	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5279-10A	85F77526-791E-47CD-904D-D1DBB49EAEAB	Blood Derived Normal	Illumina HiSeq	767a0a89-778e-4312-bd3b-123ddca4d6e2	Brain	59	9F564BDC-2E24-4A53-A50B-B23522CD7798	390161FE-0819-43C8-B4DF-C591B46E51F2	TCGA-DB-5279-10A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5279	TCGA-LGG	NA	s8752	Harvard Medical School	Mayo Clinic - Rochester	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c931	58cfa831e4b0c9d6adf6c931	TCGA-DQ-5624-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DQ-5624-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_6_rg.sorted	TCGA-DQ-5624-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_6_rg.sorted.bam	33	1.9	0.15	58cfa831e4b0c9d6adf6c931	TCGA-DQ-5624-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5624-10A	B4A41682-4ACA-4F1D-BACD-66F5E6EC7466	Blood Derived Normal	Illumina HiSeq	72bf54c2-0056-4578-8448-34fb30ed8b3a	Head and Neck	43	A782129D-F444-45AB-AFEC-0F45B369B258	55E14906-C54C-495E-B360-0384B230200D	TCGA-DQ-5624-10A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5624	TCGA-HNSC	NA	s15786	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6c93f	58cfa831e4b0c9d6adf6c93f	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted.bam	61.12	1.95	0.15	58cfa831e4b0c9d6adf6c93f	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AC-01A	36C14E9D-1863-4C55-BBBB-F8C9DD418932	Primary Tumor	Illumina HiSeq	befc5d25-55df-4a22-b4e4-25508f3935c9	Bladder	72	CD2FB6B8-5DB9-42B4-A407-A5B6F7B8665F	221E5DDE-BAB0-456C-87BE-DB54998FE197	TCGA-DK-A1AC-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AC	TCGA-BLCA	NA	s2884	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6cad0	58cfa831e4b0c9d6adf6cad0	TCGA-DU-6402-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DU-6402-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_3_rg.sorted	TCGA-DU-6402-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_3_rg.sorted.bam	41	1.9	0.15	58cfa831e4b0c9d6adf6cad0	TCGA-DU-6402-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6402-10A	152F028E-EE29-40E0-8E75-5CAFFFACBD45	Blood Derived Normal	Illumina HiSeq	3cd68c5a-a87d-41a1-97aa-29c156e57988	Brain	52	3C6F9D48-F638-4D28-80AC-0A6A276ADF87	1383A087-72C2-4BA9-B4E8-EBE3C80206B5	TCGA-DU-6402-10A-01D-1703-02	HG19_Broad_variant	TCGA-DU-6402	TCGA-LGG	214	s8346	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6c9c1	58cfa831e4b0c9d6adf6c9c1	TCGA-DK-A1A6-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DK-A1A6-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_8_rg.sorted	TCGA-DK-A1A6-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_8_rg.sorted.bam	67.49	1.93	0.17	58cfa831e4b0c9d6adf6c9c1	TCGA-DK-A1A6-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A6-10A	9C274536-3CA1-4F0E-93A8-1688074D862F	Blood Derived Normal	Illumina HiSeq	bd7ea8ac-238d-4a6d-8a48-5d2ce8a29981	Bladder	53	E1FD80CA-0A44-4604-8B6F-283C56824721	4CC13FCD-6F52-4B4C-AFAB-DC292E41F30A	TCGA-DK-A1A6-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A6	TCGA-BLCA	NA	s2888	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6ca71	58cfa831e4b0c9d6adf6ca71	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted.bam	91.81	1.77	0.15	58cfa831e4b0c9d6adf6ca71	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DO-A1JZ-01A	169F045F-1739-4B0B-9BDC-028AACA420F8	Primary Tumor	Illumina HiSeq	a349224e-f179-4a21-ae6f-5807917a484d	Thyroid	23	2EEB72CD-8A11-4ED1-87B0-3CF0C1BF1FB5	C69C86EC-D4E4-422B-88F8-AF3CE8B14148	TCGA-DO-A1JZ-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DO-A1JZ	TCGA-THCA	NA	s12377	Harvard Medical School	Medical College of Georgia	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6cace	58cfa831e4b0c9d6adf6cace	TCGA-DA-A1I5-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DA-A1I5-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_6_rg.sorted	TCGA-DA-A1I5-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_6_rg.sorted.bam	20.69	NA	0.15	58cfa831e4b0c9d6adf6cace	TCGA-DA-A1I5-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1I5-10A	E2271488-1A7D-4733-A1EA-38BBAEB97B4C	Blood Derived Normal	Illumina HiSeq	3112c5a0-bd63-4479-bcb0-203b6585ee22	Skin	27	7D0CBB6F-9BF0-437F-A1C2-47FA839A2DCC	792F1ED6-B16E-4BAF-9013-E91D77B22C89	TCGA-DA-A1I5-10A-01D-A190-02	HG19_Broad_variant	TCGA-DA-A1I5	TCGA-SKCM	NA	s7835	Harvard Medical School	Yale	United States	NO	T1a	N0	Not available	Stage IV	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ca93	58cfa831e4b0c9d6adf6ca93	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted.bam	93.33	1.39	0.17	58cfa831e4b0c9d6adf6ca93	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16R-01A	40F43483-B504-4EA7-AD24-40682B10CAAC	Primary Tumor	Illumina HiSeq	3574ade8-f6bc-44dc-94ce-8ea657978707	Uterus	39	F57EB4ED-4393-4DC3-9362-A4757EF8B21D	93FEF054-0782-4A27-A27B-22176874E805	TCGA-D1-A16R-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16R	TCGA-UCEC	NA	s4618	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6cb25	58cfa831e4b0c9d6adf6cb25	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted.filtered.	WGS	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted.bam	17.09	1.94	0.18	58cfa831e4b0c9d6adf6cb25	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-E8-A242-01A	4D9DE9A1-7DF1-412E-9F16-15DD51B4C5F5	Primary Tumor	Illumina HiSeq	0e5bb14f-1671-4b8a-9a38-e1d389ecd440	Thyroid	56	225B76AD-DB11-457A-9A77-E1F333895E5C	EA178797-16FB-41AB-B71F-3B397153CE63	TCGA-E8-A242-01A-21D-A16N-02	HG19_Broad_variant	TCGA-E8-A242	TCGA-THCA	NA	s12378	Harvard Medical School	Asterand	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6ca01	58cfa831e4b0c9d6adf6ca01	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted.bam	154.7	1.9	0.15	58cfa831e4b0c9d6adf6ca01	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5625-01A	53D9A130-4A3A-4491-85CD-9A44415A1632	Primary Tumor	Illumina HiSeq	33b84364-a81e-48fd-89d6-552802c7ff18	Head and Neck	52	74856E66-109F-4A68-A496-8FA66729FE1F	9641D13E-BE95-46BB-8330-6128EE15D47C	TCGA-DQ-5625-01A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5625	TCGA-HNSC	NA	s16058	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6cbf7	58cfa831e4b0c9d6adf6cbf7	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted.bam	72.21	NA	0.16	58cfa831e4b0c9d6adf6cbf7	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2PL-01A	45CADCF3-EA98-4063-9255-5C18D6A5CBAB	Primary Tumor	Illumina HiSeq	ca898dd4-73fc-4fa3-8d2b-3d4f27be4736	Cervix	36	6EE33187-69A7-4328-9521-173CFCDE7A1B	2AC0C1AB-11A3-4806-82FE-08529AD8BBDD	TCGA-EK-A2PL-01A-11D-A18I-02	HG19_Broad_variant	TCGA-EK-A2PL	TCGA-CESC	NA	s1187	Harvard Medical School	Gynecologic Oncology Group	United States	NO	Not available	Not available	Cervical Squamous Cell Carcinoma	Not available	A18I-02	TRUE
13722.58cfa831e4b0c9d6adf6cbd9	58cfa831e4b0c9d6adf6cbd9	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted.bam	150.7	1.9	0.14	58cfa831e4b0c9d6adf6cbd9	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5515-01A	19CF56B2-A85B-43E7-971F-5680B9B1A67A	Primary Tumor	Illumina HiSeq	25dbfef2-277f-4974-a326-2747d9494a2d	Prostate	60	5FBA6E4A-3D7D-478E-AFA6-E66C816E7852	C124D41D-EBD2-4DAE-A344-8518DB3354A4	TCGA-EJ-5515-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5515	TCGA-PRAD	NA	s4132	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae56	58cfa82ee4b0c9d6adf6ae56	TCGA-05-4395-10A-01D-1203_120305_SN1120_0119_BD0REAACXX_s_6_rg.sorted.filtered.	WGS	TCGA-05-4395-10A-01D-1203_120305_SN1120_0119_BD0REAACXX_s_6_rg.sorted	TCGA-05-4395-10A-01D-1203_120305_SN1120_0119_BD0REAACXX_s_6_rg.sorted.bam	146.9	1.8	0.16	58cfa82ee4b0c9d6adf6ae56	TCGA-05-4395-10A-01D-1203_120305_SN1120_0119_BD0REAACXX_s_6_rg.sorted.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4395-10A	762DEA8A-5B41-4058-979A-B7876ED13D7E	Blood Derived Normal	Illumina HiSeq	4e22fe2c-0d95-4a62-9b9b-af0b7b0839c1	Lung	76	440ED729-AF4A-44C2-AF41-AB7CD2D6B796	7F0B8263-9D74-429A-80EB-26F498240727	TCGA-05-4395-10A-01D-1203-02	HG19_Broad_variant	TCGA-05-4395	TCGA-LUAD	0	s10901	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1203-02	TRUE
13722.58cfa831e4b0c9d6adf6cba8	58cfa831e4b0c9d6adf6cba8	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted.bam	333.7	1.9	0.15	58cfa831e4b0c9d6adf6cba8	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5525-01A	554A7381-46FD-4301-B91B-5AF7F173C350	Primary Tumor	Illumina HiSeq	10ab041f-88f9-463c-873d-508073d1672b	Prostate	67	351AF15C-B213-4621-8BCB-3F4DDCF72553	333DDE15-F4B2-4301-A6AC-59C7F4CD6639	TCGA-EJ-5525-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5525	TCGA-PRAD	NA	s3602	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cbfc	58cfa831e4b0c9d6adf6cbfc	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted.bam	238.7	1.9	0.15	58cfa831e4b0c9d6adf6cbfc	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5506-01A	E5E4D3B6-8E58-4DCF-8F67-A00E656A8E27	Primary Tumor	Illumina HiSeq	bd66d4a0-aa1a-4bf3-a764-cb7292bc89b1	Prostate	67	9EBDA113-B0FC-4233-87AC-DAD0E7D033DE	CED987BC-B780-487A-A82E-2EB589AD3796	TCGA-EJ-5506-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5506	TCGA-PRAD	NA	s3780	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cc23	58cfa831e4b0c9d6adf6cc23	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted.bam	172.7	1.9	0.16	58cfa831e4b0c9d6adf6cc23	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5503-01A	AA252F78-EBF3-42F9-86AF-BB6E57345706	Primary Tumor	Illumina HiSeq	4eba210f-0895-487c-9b48-db8a8c629cc4	Prostate	50	627B9FF8-2557-4470-824A-B76A8BCD1E9F	68211C41-2971-4B41-8EEE-75FFB78175BC	TCGA-EJ-5503-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5503	TCGA-PRAD	NA	s3782	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cc94	58cfa831e4b0c9d6adf6cc94	TCGA-EJ-5502-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-5502-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_6_rg.sorted	TCGA-EJ-5502-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_6_rg.sorted.bam	121.4	1.9	0.15	58cfa831e4b0c9d6adf6cc94	TCGA-EJ-5502-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5502-10A	48E83A4C-C602-494A-80CD-E2F4B4DD701E	Blood Derived Normal	Illumina HiSeq	ba38e3c4-9b7a-47f3-819a-86b4b443cdd3	Prostate	50	E5B3D936-B458-4E11-8CE2-707E2B73233C	27D1AFF1-E0BC-43C5-9C8C-209B685B2A96	TCGA-EJ-5502-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5502	TCGA-PRAD	NA	s3952	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cc08	58cfa831e4b0c9d6adf6cc08	TCGA-EE-A2A1-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EE-A2A1-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_3_rg.sorted	TCGA-EE-A2A1-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_3_rg.sorted.bam	55.01	NA	0.17	58cfa831e4b0c9d6adf6cc08	TCGA-EE-A2A1-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2A1-06A	A92E70E1-C57D-45EF-A822-33B361C22291	Metastatic	Illumina HiSeq	d2b1ca54-da4a-4eba-8e02-a1cc07f55639	Skin	46	70BEAF75-9B5D-47F7-AC73-AB7C99984C8B	BD64EE85-341B-4D5A-8DDE-17898F3CDC99	TCGA-EE-A2A1-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2A1	TCGA-SKCM	NA	s7332	Harvard Medical School	University of Sydney	Australia	NO	T2a	N0	Not available	Stage IB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc0f	58cfa831e4b0c9d6adf6cc0f	TCGA-EE-A29E-10A-01D-A190_120730_SN1222_0141_BC115GACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EE-A29E-10A-01D-A190_120730_SN1222_0141_BC115GACXX_s_4_rg.sorted	TCGA-EE-A29E-10A-01D-A190_120730_SN1222_0141_BC115GACXX_s_4_rg.sorted.bam	26.22	NA	0.17	58cfa831e4b0c9d6adf6cc0f	TCGA-EE-A29E-10A-01D-A190_120730_SN1222_0141_BC115GACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29E-10A	83D05B9A-F409-4169-BEF9-E772D2CFBFAF	Blood Derived Normal	Illumina HiSeq	e4cd78aa-d008-4138-ba8e-f9435d69a2ba	Skin	54	D422B04A-2EC6-4769-8546-425772FB812E	93EB9265-C790-4980-B305-4E0240791242	TCGA-EE-A29E-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29E	TCGA-SKCM	NA	s7683	Harvard Medical School	University of Sydney	Australia	NO	T3a	N1b	Not available	Stage IIIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc76	58cfa831e4b0c9d6adf6cc76	TCGA-ER-A194-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-ER-A194-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_4_rg.sorted	TCGA-ER-A194-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_4_rg.sorted.bam	30.36	NA	0.17	58cfa831e4b0c9d6adf6cc76	TCGA-ER-A194-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A194-01A	2BBF00F4-7798-4DAD-9894-96202C9132BE	Primary Tumor	Illumina HiSeq	40a52169-d476-4650-a043-d5fda21a4213	Skin	77	EA15A5B0-8BA7-4114-853F-E3396E81CCEB	411370DC-4C66-484F-AC7E-42A19E486DFC	TCGA-ER-A194-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A194	TCGA-SKCM	1354	s7693	Harvard Medical School	University of Pittsburgh	United States	NO	Not available	N0	Not available	Not available	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc7a	58cfa831e4b0c9d6adf6cc7a	TCGA-ER-A19E-06A-11D-A18Y_120723_SN1120_0177_AC11GTACXX_s_2_rg.sorted.filtered.	WGS	TCGA-ER-A19E-06A-11D-A18Y_120723_SN1120_0177_AC11GTACXX_s_2_rg.sorted	TCGA-ER-A19E-06A-11D-A18Y_120723_SN1120_0177_AC11GTACXX_s_2_rg.sorted.bam	30.72	NA	0.16	58cfa831e4b0c9d6adf6cc7a	TCGA-ER-A19E-06A-11D-A18Y_120723_SN1120_0177_AC11GTACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19E-06A	3FEA3F02-2DB3-44E0-984E-C61130D92C9B	Metastatic	Illumina HiSeq	d3874936-da5d-479f-8c3c-1f3d9306dde2	Skin	36	96BB672C-48FB-4AAE-9FA5-7CEAF98E5348	189A39F9-D385-4DBE-9DE6-0CDBB00E0BDA	TCGA-ER-A19E-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A19E	TCGA-SKCM	396	s7859	Harvard Medical School	University of Pittsburgh	United States	NO	T2a	N0	Not available	Stage IB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6ccb6	58cfa831e4b0c9d6adf6ccb6	TCGA-EE-A2ML-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EE-A2ML-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_3_rg.sorted	TCGA-EE-A2ML-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_3_rg.sorted.bam	60.49	NA	0.15	58cfa831e4b0c9d6adf6ccb6	TCGA-EE-A2ML-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2ML-06A	01CFBFAE-F344-439D-AEAB-A9E15D636325	Metastatic	Illumina HiSeq	2336ae9f-4b2d-45d1-853f-e0ed0b651e71	Skin	35	0CD2BB77-7E7F-4CA7-8E5F-87BC5B46C550	A77E44A0-C4ED-45C0-B21A-1B6DEE9B1EFB	TCGA-EE-A2ML-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2ML	TCGA-SKCM	NA	s7688	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage II	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cce2	58cfa831e4b0c9d6adf6cce2	TCGA-EM-A1CS-10A-01D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EM-A1CS-10A-01D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_7_rg.sorted	TCGA-EM-A1CS-10A-01D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_7_rg.sorted.bam	29.7	2.03	0.15	58cfa831e4b0c9d6adf6cce2	TCGA-EM-A1CS-10A-01D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_7_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CS-10A	E92BDB0D-969A-4D98-ADA8-5DFEC68119B5	Blood Derived Normal	Illumina HiSeq	2a0f4d5d-c751-4c68-9f40-28b07dae7b03	Thyroid	55	3929AAFB-3850-4F1A-A883-CA904D6CBC69	9EA0BB57-C503-4043-BEB0-3939368D70D9	TCGA-EM-A1CS-10A-01D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CS	TCGA-THCA	NA	s11999	Harvard Medical School	University Health Network	Canada	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6cd76	58cfa831e4b0c9d6adf6cd76	TCGA-FD-A3B3-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FD-A3B3-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_8_rg.sorted	TCGA-FD-A3B3-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_8_rg.sorted.bam	14.2	NA	0.16	58cfa831e4b0c9d6adf6cd76	TCGA-FD-A3B3-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B3-10A	4B5D873B-BFDA-482E-92A0-BF84C0F9032A	Blood Derived Normal	Illumina HiSeq	675113cf-e818-448a-a767-827cd45c7827	Bladder	74	9E9FD5A9-9BBE-484F-90EE-6E35E49908DF	6FAB5B8D-8E7A-4099-9495-F38CF408E273	TCGA-FD-A3B3-10A-01D-A204-02	HG19_Broad_variant	TCGA-FD-A3B3	TCGA-BLCA	NA	s2722	Harvard Medical School	BLN - University Of Chicago	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A204-02	TRUE
13722.58cfa831e4b0c9d6adf6cd97	58cfa831e4b0c9d6adf6cd97	TCGA-FE-A238-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FE-A238-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_1_rg.sorted	TCGA-FE-A238-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_1_rg.sorted.bam	84.67	2.14	0.16	58cfa831e4b0c9d6adf6cd97	TCGA-FE-A238-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A238-10A	DFFC4F7A-C67A-4AC5-A338-717DFFDE686D	Blood Derived Normal	Illumina HiSeq	b306d369-9c40-4392-866e-ac180ee999fa	Thyroid	36	526E831B-6E71-4816-B132-36B525A351B1	3FBBAA9D-89F1-429B-8FEB-FF4D1AF32980	TCGA-FE-A238-10A-01D-A16N-02	HG19_Broad_variant	TCGA-FE-A238	TCGA-THCA	NA	s12255	Harvard Medical School	Ohio State University	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6cd96	58cfa831e4b0c9d6adf6cd96	TCGA-FE-A230-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FE-A230-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_4_rg.sorted	TCGA-FE-A230-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_4_rg.sorted.bam	53.75	1.88	0.15	58cfa831e4b0c9d6adf6cd96	TCGA-FE-A230-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A230-10A	B1D71782-2443-43F3-BD0E-8B7220515CB6	Blood Derived Normal	Illumina HiSeq	95f6440a-f378-4551-859b-3c4c64c419f6	Thyroid	30	33613A27-3E77-4ED8-AB5F-A9DE98431149	D31A8255-C4C9-4512-9333-5B97C8A70936	TCGA-FE-A230-10A-01D-A14U-02	HG19_Broad_variant	TCGA-FE-A230	TCGA-THCA	NA	s12529	Harvard Medical School	Ohio State University	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cdb6	58cfa831e4b0c9d6adf6cdb6	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted.bam	7.3	2	0.13	58cfa831e4b0c9d6adf6cdb6	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-5963-01A	68F550CA-3A33-45E4-B1C9-14F99E543263	Primary Tumor	Illumina HiSeq	11f814ba-95e7-4824-ab33-1e14947dcbd5	Brain	23	41C647E8-6A53-464B-9EFC-78547C514519	166F687B-F395-4AC7-A06A-78826A0722E7	TCGA-FG-5963-01A-11D-1703-02	HG19_Broad_variant	TCGA-FG-5963	TCGA-LGG	NA	s8148	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa832e4b0c9d6adf6ce22	58cfa832e4b0c9d6adf6ce22	TCGA-EJ-5524-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-5524-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_8_rg.sorted	TCGA-EJ-5524-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_8_rg.sorted.bam	437.4	1.9	0.15	58cfa832e4b0c9d6adf6ce22	TCGA-EJ-5524-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5524-10A	4048C139-1329-4E6A-8D2F-C0AA104A68EE	Blood Derived Normal	Illumina HiSeq	f7ef709a-7e6b-4b7e-9827-28d64d2cedb3	Prostate	57	330555E0-0B47-46B8-BDB6-125675717E3B	6D03C8FA-1441-410F-B980-CABF11F60930	TCGA-EJ-5524-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5524	TCGA-PRAD	NA	s3945	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cdba	58cfa831e4b0c9d6adf6cdba	TCGA-ER-A19K-01A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_1_rg.sorted.filtered.	WGS	TCGA-ER-A19K-01A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_1_rg.sorted	TCGA-ER-A19K-01A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_1_rg.sorted.bam	38.56	NA	0.15	58cfa831e4b0c9d6adf6cdba	TCGA-ER-A19K-01A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19K-01A	F9E36BC2-484F-48E8-82BA-99026957277A	Primary Tumor	Illumina HiSeq	7f909731-9b4e-45a5-b8e0-ae6d67969159	Skin	79	E358B11D-2A35-45AE-8910-AE2DC06D39F4	EB5E15F5-55E7-433C-8DD2-AA3DF568F0CF	TCGA-ER-A19K-01A-21D-A18Y-02	HG19_Broad_variant	TCGA-ER-A19K	TCGA-SKCM	469	s7862	Harvard Medical School	University of Pittsburgh	United States	NO	T4b	N0	Not available	Stage IIC	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6ce8a	58cfa832e4b0c9d6adf6ce8a	TCGA-G2-A2EL-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G2-A2EL-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_5_rg.sorted	TCGA-G2-A2EL-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_5_rg.sorted.bam	27.96	NA	0.16	58cfa832e4b0c9d6adf6ce8a	TCGA-G2-A2EL-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EL-01A	30C7445E-D0C4-4A0F-96A4-27E4259EE10B	Primary Tumor	Illumina HiSeq	15128dae-4500-4372-9676-d23d4c116527	Bladder	77	90F1D206-3E97-4C88-922C-FE4773C37CAA	D850DDCD-6E04-4EB4-887C-E1AE410C301C	TCGA-G2-A2EL-01A-12D-A18D-02	HG19_Broad_variant	TCGA-G2-A2EL	TCGA-BLCA	819	s3122	Harvard Medical School	MD Anderson	United States	NO	Not available	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A18D-02	TRUE
13722.58cfa832e4b0c9d6adf6ce66	58cfa832e4b0c9d6adf6ce66	TCGA-GN-A266-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-GN-A266-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_4_rg.sorted	TCGA-GN-A266-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_4_rg.sorted.bam	37.9	NA	0.17	58cfa832e4b0c9d6adf6ce66	TCGA-GN-A266-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-GN-A266-10A	3429967F-4F77-4894-BF27-C4A22698CA92	Blood Derived Normal	Illumina HiSeq	59df09f9-be81-41ce-bb63-1a6f3ce58efc	Skin	45	35D85937-9F8A-4DFC-8CE2-FA6E913AF9F3	7F4405F2-9D42-405C-8291-5C332DAD2591	TCGA-GN-A266-10A-01D-A190-02	HG19_Broad_variant	TCGA-GN-A266	TCGA-SKCM	308	s7375	Harvard Medical School	Roswell	United States	NO	Not available	Not available	Not available	Not available	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6ce96	58cfa832e4b0c9d6adf6ce96	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted.bam	18.46	NA	0.18	58cfa832e4b0c9d6adf6ce96	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EC-01A	28E25FFB-8B0C-4839-A735-ED7B78E3213A	Primary Tumor	Illumina HiSeq	0d4b7559-34dc-4690-a8e9-144698537cdd	Bladder	58	2DA969E6-9A63-4C03-8347-01A51496C224	09ED2111-236D-47C1-A82D-7919C8EEA5B2	TCGA-G2-A2EC-01A-11D-A17R-02	HG19_Broad_variant	TCGA-G2-A2EC	TCGA-BLCA	NA	s3303	Harvard Medical School	MD Anderson	United States	NO	Not available	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	TRUE
13722.58cfa831e4b0c9d6adf6cd7a	58cfa831e4b0c9d6adf6cd7a	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted.bam	63.8	1.81	0.16	58cfa831e4b0c9d6adf6cd7a	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-EY-A1GC-01A	EBC25A41-BECB-4395-AE33-483A304B07D8	Primary Tumor	Illumina HiSeq	e6c7f95a-f103-4fbc-a123-91eefcfbf4c2	Uterus	62	06BE0E15-E48E-4243-AD8D-86CCA9DA68F9	C8E60958-98D8-4EE6-BAA1-DEEEECFF141F	TCGA-EY-A1GC-01A-11D-A13I-02	HG19_Broad_variant	TCGA-EY-A1GC	TCGA-UCEC	NA	s4620	Harvard Medical School	University of North Carolina	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A13I-02	FALSE
13722.58cfa832e4b0c9d6adf6ceb1	58cfa832e4b0c9d6adf6ceb1	TCGA-EM-A1CW-11A-12D-A13U_120706_SN1222_0122_AC0WPYACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EM-A1CW-11A-12D-A13U_120706_SN1222_0122_AC0WPYACXX_s_6_rg.sorted	TCGA-EM-A1CW-11A-12D-A13U_120706_SN1222_0122_AC0WPYACXX_s_6_rg.sorted.bam	36.84	1.82	0.15	58cfa832e4b0c9d6adf6ceb1	TCGA-EM-A1CW-11A-12D-A13U_120706_SN1222_0122_AC0WPYACXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CW-11A	22EB9F00-6869-4D8F-B657-DFD64F81E9E9	Solid Tissue Normal	Illumina HiSeq	835978aa-a34d-4803-8f67-b150df22dbb1	Thyroid	39	66990135-F339-4195-855B-A95AB74B4FE4	87592E6E-4EF0-4D83-B2A5-4B52FA10B36A	TCGA-EM-A1CW-11A-12D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CW	TCGA-THCA	NA	s12110	Harvard Medical School	University Health Network	Canada	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A13U-02	TRUE
13722.58cfa832e4b0c9d6adf6cecd	58cfa832e4b0c9d6adf6cecd	TCGA-EK-A2R7-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EK-A2R7-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_7_rg.sorted	TCGA-EK-A2R7-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_7_rg.sorted.bam	14.04	NA	0.18	58cfa832e4b0c9d6adf6cecd	TCGA-EK-A2R7-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2R7-10A	D7A75BF5-5189-4978-99D9-FCEF91C9FBD2	Blood Derived Normal	Illumina HiSeq	86ab2e15-4d96-4350-b5cb-99b156e7ea61	Cervix	45	6064867B-CA99-4158-9E01-A8A37A0F955C	3FD8793C-06FE-4899-9BCE-87814C4AC594	TCGA-EK-A2R7-10A-01D-A18I-02	HG19_Broad_variant	TCGA-EK-A2R7	TCGA-CESC	NA	s1527	Harvard Medical School	Gynecologic Oncology Group	United States	NO	T1b1	N1	Cervical Squamous Cell Carcinoma	Not available	A18I-02	TRUE
13722.58cfa832e4b0c9d6adf6cec0	58cfa832e4b0c9d6adf6cec0	TCGA-EK-A2R8-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EK-A2R8-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_8_rg.sorted	TCGA-EK-A2R8-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_8_rg.sorted.bam	21	NA	0.16	58cfa832e4b0c9d6adf6cec0	TCGA-EK-A2R8-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2R8-10A	D4510801-8CE4-4F10-8B31-25C0A39B5135	Blood Derived Normal	Illumina HiSeq	8498b73d-be83-4863-bad7-ddd22874d071	Cervix	48	0C67F012-629A-478A-8836-646272637695	F4A6EA47-F2FA-4101-9229-D35ACA3A39B3	TCGA-EK-A2R8-10A-01D-A18I-02	HG19_Broad_variant	TCGA-EK-A2R8	TCGA-CESC	NA	s1528	Harvard Medical School	Gynecologic Oncology Group	United States	NO	T1b2	N1	Cervical Squamous Cell Carcinoma	Not available	A18I-02	TRUE
13722.58cfa832e4b0c9d6adf6cf46	58cfa832e4b0c9d6adf6cf46	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted.bam	59.4	2	0.17	58cfa832e4b0c9d6adf6cf46	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6371-01A	D5C43A14-21AB-4178-AE33-2D8B7BAA256F	Primary Tumor	Illumina HiSeq	46c365e2-d78e-45ed-8356-c9ad57629c34	Prostate	58	2F91086C-ADCD-4A79-96AA-58819AB28A57	570A6B67-7527-4F71-B37F-5D9102648470	TCGA-G9-6371-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6371	TCGA-PRAD	NA	s3798	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf7a	58cfa832e4b0c9d6adf6cf7a	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted.bam	62.7	2	0.14	58cfa832e4b0c9d6adf6cf7a	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6499-01A	ACD5CEEF-C5CF-4E95-9394-C50FDBC70C8D	Primary Tumor	Illumina HiSeq	db7d4277-9d52-4996-ab7f-5e6ddc01c234	Prostate	66	424FB9D8-F70E-4A36-B895-A766176EEE7C	24062AD0-10DD-4BFB-B805-CA18C57D1FA0	TCGA-G9-6499-01A-12D-1957-02	HG19_Broad_variant	TCGA-G9-6499	TCGA-PRAD	NA	s3459	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cf7e	58cfa832e4b0c9d6adf6cf7e	TCGA-G9-6363-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G9-6363-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_6_rg.sorted	TCGA-G9-6363-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_6_rg.sorted.bam	8.7	1.9	0.15	58cfa832e4b0c9d6adf6cf7e	TCGA-G9-6363-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6363-10A	B5B3871C-078C-46A7-AC50-EF916D4A6781	Blood Derived Normal	Illumina HiSeq	2a69deb3-9543-4506-b9b1-31593b6cb7d5	Prostate	64	B7119CE5-584D-4696-B5B3-EDD5B6ED5F98	C835BA0A-5D30-4D36-B233-F0212B0322A6	TCGA-G9-6363-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6363	TCGA-PRAD	NA	s3454	Harvard Medical School	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf2b	58cfa832e4b0c9d6adf6cf2b	TCGA-FS-A1ZP-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FS-A1ZP-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_5_rg.sorted	TCGA-FS-A1ZP-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_5_rg.sorted.bam	39.25	NA	0.15	58cfa832e4b0c9d6adf6cf2b	TCGA-FS-A1ZP-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZP-10A	4CDB18F5-47BF-475F-B34C-FA4912515268	Blood Derived Normal	Illumina HiSeq	c45fbf32-91bb-4076-a1d5-62da08774f63	Skin	52	7765773F-AD0D-438F-A5B0-9DF496DA22F7	E5CD2522-30A3-4CA0-B342-942D98E02F97	TCGA-FS-A1ZP-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZP	TCGA-SKCM	2273	s7871	Harvard Medical School	Essen	Germany	NO	T3	N0	Not available	Stage II	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf82	58cfa832e4b0c9d6adf6cf82	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted.bam	59.4	1.9	0.14	58cfa832e4b0c9d6adf6cf82	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6348-01A	8AD78C4F-C84C-4F9E-88C9-42A05EB65498	Primary Tumor	Illumina HiSeq	32ce4cfa-ee58-4c85-8e6b-9e7fd9bb6b8e	Prostate	68	A692E125-CCFC-4376-9CEA-2410511882BF	68D451D5-F3A1-46C9-BD28-05D71D2C94FC	TCGA-G9-6348-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6348	TCGA-PRAD	NA	s3447	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cfa2	58cfa832e4b0c9d6adf6cfa2	TCGA-G9-6333-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_4_rg.sorted.filtered.	WGS	TCGA-G9-6333-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_4_rg.sorted	TCGA-G9-6333-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_4_rg.sorted.bam	14	1.8	0.16	58cfa832e4b0c9d6adf6cfa2	TCGA-G9-6333-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6333-10A	64BF32C9-9466-404A-A147-E7A0B9E91E34	Blood Derived Normal	Illumina HiSeq	ead27538-b8e3-4f26-905e-764c0be3f524	Prostate	66	5AC98B24-4104-40D1-8E73-1CB0EF6D343C	30D073C8-EAF3-464B-8089-007CD94FEECD	TCGA-G9-6333-10A-01D-1957-02	HG19_Broad_variant	TCGA-G9-6333	TCGA-PRAD	NA	s3613	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cfae	58cfa832e4b0c9d6adf6cfae	TCGA-G9-6342-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G9-6342-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_8_rg.sorted	TCGA-G9-6342-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_8_rg.sorted.bam	45	1.8	0.14	58cfa832e4b0c9d6adf6cfae	TCGA-G9-6342-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6342-10A	00E41E6A-9FE7-44F9-978B-7B05B179506A	Blood Derived Normal	Illumina HiSeq	28236670-c301-4b5e-a898-f0d264f00b8a	Prostate	61	B9CBE7E7-9C36-4964-B2CD-085B261F6BC3	D34FDC30-1501-4986-83AB-BD5F2872240E	TCGA-G9-6342-10A-01D-1957-02	HG19_Broad_variant	TCGA-G9-6342	TCGA-PRAD	NA	s4150	Harvard Medical School	Roswell Park	United States	NO	T3a	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cfdc	58cfa832e4b0c9d6adf6cfdc	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted.bam	168.3	NA	0.16	58cfa832e4b0c9d6adf6cfdc	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7232-01A	CE3585D3-7388-4D05-84C8-64E0883003B3	Primary Tumor	Illumina HiSeq	26e5268d-e95b-44da-ae7c-dfb6fe50a127	Prostate	66	0F4B7D00-1C4C-4634-A45E-10F8949ABB43	E847C3F1-CE33-494C-8D95-F82314C95F01	TCGA-HC-7232-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7232	TCGA-PRAD	NA	s4156	Harvard Medical School	International Genomics Consortium	United States	NO	T3b	Not available	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6ce32	58cfa832e4b0c9d6adf6ce32	TCGA-ER-A2NF-10A-01D-A18Z_120516_SN1222_0107_BD12HYACXX_s_4_rg.sorted.filtered.	WGS	TCGA-ER-A2NF-10A-01D-A18Z_120516_SN1222_0107_BD12HYACXX_s_4_rg.sorted	TCGA-ER-A2NF-10A-01D-A18Z_120516_SN1222_0107_BD12HYACXX_s_4_rg.sorted.bam	15.51	NA	0.17	58cfa832e4b0c9d6adf6ce32	TCGA-ER-A2NF-10A-01D-A18Z_120516_SN1222_0107_BD12HYACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A2NF-10A	D32A4219-4CCA-470F-B6B3-11447D9F5E0B	Blood Derived Normal	Illumina HiSeq	d65224cb-bbae-42de-884a-9a237085e215	Skin	53	C3CE1857-971F-4416-9F5A-2AA029C6C75A	F621CC23-047B-4E89-B6D6-B407FF00C7A3	TCGA-ER-A2NF-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-ER-A2NF	TCGA-SKCM	NA	s8020	Harvard Medical School	University of Pittsburgh	None	NO	T4b	N3	Not available	Stage IIIC	A18Z-02	TRUE
13722.58cfa832e4b0c9d6adf6cfaa	58cfa832e4b0c9d6adf6cfaa	TCGA-FS-A1ZS-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FS-A1ZS-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_7_rg.sorted	TCGA-FS-A1ZS-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_7_rg.sorted.bam	30.03	NA	0.17	58cfa832e4b0c9d6adf6cfaa	TCGA-FS-A1ZS-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZS-10A	31E94518-F6DD-4458-94D8-DDA3CC7A0831	Blood Derived Normal	Illumina HiSeq	d805072e-bd81-4372-8429-4d37de4b4efa	Skin	54	B2F92369-CCF6-4B10-9D8E-5843C15B48B9	2BAB4819-3BC4-4970-AD50-71C1977724CA	TCGA-FS-A1ZS-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZS	TCGA-SKCM	NA	s7699	Harvard Medical School	Essen	Germany	NO	T2	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d018	58cfa832e4b0c9d6adf6d018	TCGA-FT-A3EE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FT-A3EE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_1_rg.sorted	TCGA-FT-A3EE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_1_rg.sorted.bam	35.79	NA	0.15	58cfa832e4b0c9d6adf6d018	TCGA-FT-A3EE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FT-A3EE-01A	CCE62116-3DCD-400D-ADA0-9839CA02466E	Primary Tumor	Illumina HiSeq	7bd31003-35c9-4165-b964-e3d1e803dbe9	Bladder	80	2356F78C-0653-468F-83DB-6CF6107BD259	0C871E11-F5FB-4B9E-B286-163187A68992	TCGA-FT-A3EE-01A-11D-A204-02	HG19_Broad_variant	TCGA-FT-A3EE	TCGA-BLCA	99	s2913	Harvard Medical School	BLN - University of Miami	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A204-02	TRUE
13722.58cfa832e4b0c9d6adf6d006	58cfa832e4b0c9d6adf6d006	TCGA-FS-A1ZF-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FS-A1ZF-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_8_rg.sorted	TCGA-FS-A1ZF-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_8_rg.sorted.bam	48.76	NA	0.17	58cfa832e4b0c9d6adf6d006	TCGA-FS-A1ZF-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZF-10A	E0D36CC0-652C-4224-BB10-09D15C7BD8F1	Blood Derived Normal	Illumina HiSeq	33a85bcf-963a-4790-bd1f-1c7d28f1db24	Skin	78	1F3F382C-3210-48A1-9C02-772321216C5C	3A3F2B88-9E3A-4B69-99E2-D6B98C5F465A	TCGA-FS-A1ZF-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZF	TCGA-SKCM	470	s7369	Harvard Medical School	Essen	Germany	NO	T4b	N0	Not available	Stage IIC	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d03c	58cfa832e4b0c9d6adf6d03c	TCGA-G9-6336-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G9-6336-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_6_rg.sorted	TCGA-G9-6336-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_6_rg.sorted.bam	16.7	1.9	0.13	58cfa832e4b0c9d6adf6d03c	TCGA-G9-6336-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6336-10A	59207BCD-F127-481F-B576-8716DA7D7D97	Blood Derived Normal	Illumina HiSeq	1b1f382a-4dbf-432b-88ed-e94a3d9a55b3	Prostate	57	71864139-EC05-4BB1-9DF7-27954283261E	C92E8498-68AE-4F04-81C6-1F8B028F2403	TCGA-G9-6336-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6336	TCGA-PRAD	NA	s3450	Harvard Medical School	Roswell Park	United States	NO	Not available	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6d04e	58cfa832e4b0c9d6adf6d04e	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted.bam	41.7	1.9	0.15	58cfa832e4b0c9d6adf6d04e	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6329-01A	A08FD0A6-A89A-4ADB-B641-D4C1238ABB71	Primary Tumor	Illumina HiSeq	1971b9d7-8a67-4447-835d-23525622c037	Prostate	67	E004F38D-C874-4E03-830B-4E554EF3E274	46BEFA09-3AF0-415C-994E-330B07586058	TCGA-G9-6329-01A-13D-1957-02	HG19_Broad_variant	TCGA-G9-6329	TCGA-PRAD	NA	s3796	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6d07a	58cfa832e4b0c9d6adf6d07a	TCGA-HC-7077-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-HC-7077-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_7_rg.sorted	TCGA-HC-7077-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_7_rg.sorted.bam	76	NA	0.14	58cfa832e4b0c9d6adf6d07a	TCGA-HC-7077-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_7_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7077-10A	92252560-5984-41F6-A4B5-A3AA8654C0C8	Blood Derived Normal	Illumina HiSeq	dd0dd624-e056-45af-8e61-7badb7a7fe56	Prostate	64	766EEC0B-6346-4A94-9F1A-2AD9364CE165	60A6879B-1737-4351-B658-6283F73F8393	TCGA-HC-7077-10A-01D-1957-02	HG19_Broad_variant	TCGA-HC-7077	TCGA-PRAD	NA	s3982	Harvard Medical School	International Genomics Consortium	United States	NO	T3a	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6d044	58cfa832e4b0c9d6adf6d044	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted.filtered.	WGS	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted.bam	40.79	NA	0.16	58cfa832e4b0c9d6adf6d044	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A2C5-01A	5D54C742-5A8E-4C40-8D62-95E75E210AB8	Primary Tumor	Illumina HiSeq	27e88ee3-dcb4-43c4-9653-c55aa1851cb1	Bladder	53	2CD62676-762C-461D-B111-1F81E7CD5877	EEB315EA-D1B6-4F92-91B0-9AAAC7083D68	TCGA-GD-A2C5-01A-12D-A17R-02	HG19_Broad_variant	TCGA-GD-A2C5	TCGA-BLCA	NA	s2920	Harvard Medical School	ABS - IUPUI	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17R-02	TRUE
13722.58cfa832e4b0c9d6adf6d188	58cfa832e4b0c9d6adf6d188	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted.bam	207.3	NA	0.14	58cfa832e4b0c9d6adf6d188	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	Not available	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7233-01A	E2B33861-2247-413F-B2E5-9BE3B604666C	Primary Tumor	Illumina HiSeq	b16d1760-889f-44f7-a1c1-1dfa3f31efc3	Prostate	73	848C2C7B-918E-4A09-BAD9-3B3D59BBC101	8262CCFE-6E66-412E-A8C8-E4FA91979764	TCGA-HC-7233-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7233	TCGA-PRAD	NA	s3813	Harvard Medical School	International Genomics Consortium	Yemen	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d10e	58cfa832e4b0c9d6adf6d10e	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted.bam	56	NA	0.14	58cfa832e4b0c9d6adf6d10e	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HW-7489-01A	6957D45E-7CCB-457D-800D-C2A2037F4F01	Primary Tumor	Illumina HiSeq	e81e0ec5-b546-421b-a1ee-5adf17fd07c0	Brain	38	B4E032D1-B12E-4DC0-8978-899760F0A245	BBCC5F2C-08F5-424D-8A66-099084F3C47E	TCGA-HW-7489-01A-11D-2022-02	HG19_Broad_variant	TCGA-HW-7489	TCGA-LGG	NA	s8578	Harvard Medical School	MSKCC	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d194	58cfa832e4b0c9d6adf6d194	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted.bam	95.7	1.9	0.15	58cfa832e4b0c9d6adf6d194	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6377-01A	007F9081-5093-4323-B4F8-CD510BF20705	Primary Tumor	Illumina HiSeq	126d92ca-d172-491d-9366-11555d88901b	Prostate	61	8F105D0D-0630-46FC-8168-DCBA11A5197F	811D74B4-6F98-4B1F-9ADD-CB949E4B5B20	TCGA-G9-6377-01A-11D-1957-02	HG19_Broad_variant	TCGA-G9-6377	TCGA-PRAD	NA	s3977	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6d1c8	58cfa832e4b0c9d6adf6d1c8	TCGA-HI-7170-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HI-7170-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_6_rg.sorted	TCGA-HI-7170-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_6_rg.sorted.bam	157.6	NA	0.17	58cfa832e4b0c9d6adf6d1c8	TCGA-HI-7170-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7170-10A	6394E00A-1F6F-4EA2-B885-373BBB59DEF9	Blood Derived Normal	Illumina HiSeq	3469af72-4b83-4fe2-bc08-221168d68d84	Prostate	58	B42AA0FA-0368-4D18-B827-1CCDB894700C	F187CCC7-3C46-4C3E-B97C-A16CDB4B00D3	TCGA-HI-7170-10A-01D-2111-02	HG19_Broad_variant	TCGA-HI-7170	TCGA-PRAD	NA	s3632	Harvard Medical School	Fox Chase	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d1d3	58cfa832e4b0c9d6adf6d1d3	TCGA-HI-7168-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HI-7168-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_2_rg.sorted	TCGA-HI-7168-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_2_rg.sorted.bam	130.6	NA	0.16	58cfa832e4b0c9d6adf6d1d3	TCGA-HI-7168-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7168-10A	25D70934-01A5-45A2-9960-68D3058B6965	Blood Derived Normal	Illumina HiSeq	ab5dab2c-9975-4682-921c-6e013cd929bb	Prostate	62	5C923E40-E32E-4656-8FF6-E3DB3B28CE2D	2B30D8C9-1DBE-4E62-9973-8819115CD82C	TCGA-HI-7168-10A-01D-2111-02	HG19_Broad_variant	TCGA-HI-7168	TCGA-PRAD	NA	s3815	Harvard Medical School	Fox Chase	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d1dc	58cfa832e4b0c9d6adf6d1dc	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted.bam	122.7	NA	0.15	58cfa832e4b0c9d6adf6d1dc	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7473-01A	DBFACCB0-E8C0-48E8-9AEF-570267574822	Primary Tumor	Illumina HiSeq	0c3613f1-9a5e-42d1-a1a9-884cf56894f4	Brain	28	D302390B-4B66-48E6-92DE-612504B34FA3	A664FDA7-9BF1-4016-A16A-BCA75C6D139C	TCGA-HT-7473-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7473	TCGA-LGG	NA	s8154	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d1ce	58cfa832e4b0c9d6adf6d1ce	TCGA-HT-7473-10A-01D-2022_130913_SN1440_0167_AC2A6PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-HT-7473-10A-01D-2022_130913_SN1440_0167_AC2A6PACXX_s_7_rg.sorted	TCGA-HT-7473-10A-01D-2022_130913_SN1440_0167_AC2A6PACXX_s_7_rg.sorted.bam	246	NA	0.16	58cfa832e4b0c9d6adf6d1ce	TCGA-HT-7473-10A-01D-2022_130913_SN1440_0167_AC2A6PACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7473-10A	DBFACCB0-E8C0-48E8-9AEF-570267574822	Blood Derived Normal	Illumina HiSeq	2b1e29cb-e83c-4e25-a643-1ded3bbcccb6	Brain	28	996FE719-74D2-433B-9E73-76ED2775DDE9	8CDB3395-5562-4FAE-89AF-2980F5F9B09B	TCGA-HT-7473-10A-01D-2022-02	HG19_Broad_variant	TCGA-HT-7473	TCGA-LGG	NA	s8152	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d1b5	58cfa832e4b0c9d6adf6d1b5	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted.bam	96.3	NA	0.15	58cfa832e4b0c9d6adf6d1b5	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7170-01A	6394E00A-1F6F-4EA2-B885-373BBB59DEF9	Primary Tumor	Illumina HiSeq	4eefa9f0-575b-4039-912a-7c0e58f4e508	Prostate	58	70BF0C3E-0C06-4168-996C-46783752FA37	1C5E0781-5295-427A-B94A-062B2708B62C	TCGA-HI-7170-01A-11D-2111-02	HG19_Broad_variant	TCGA-HI-7170	TCGA-PRAD	NA	s3629	Harvard Medical School	Fox Chase	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d208	58cfa832e4b0c9d6adf6d208	TCGA-HC-7232-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HC-7232-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_5_rg.sorted	TCGA-HC-7232-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_5_rg.sorted.bam	170.65	NA	0.16	58cfa832e4b0c9d6adf6d208	TCGA-HC-7232-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7232-10A	CE3585D3-7388-4D05-84C8-64E0883003B3	Blood Derived Normal	Illumina HiSeq	650b3a4f-0196-40bf-88c0-7b01ad67b377	Prostate	66	28553F1A-F11A-4876-9BEF-B16AFFFFBDA5	E8BDB147-E6DD-4755-B088-684DB3A94E2A	TCGA-HC-7232-10A-01D-2111-02	HG19_Broad_variant	TCGA-HC-7232	TCGA-PRAD	NA	s3628	Harvard Medical School	International Genomics Consortium	United States	NO	T3b	Not available	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6ceea	58cfa832e4b0c9d6adf6ceea	TCGA-FS-A1Z4-06A-11D-A18Y_120711_SN208_0414_BD13L5ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FS-A1Z4-06A-11D-A18Y_120711_SN208_0414_BD13L5ACXX_s_5_rg.sorted	TCGA-FS-A1Z4-06A-11D-A18Y_120711_SN208_0414_BD13L5ACXX_s_5_rg.sorted.bam	67.34	NA	0.15	58cfa832e4b0c9d6adf6ceea	TCGA-FS-A1Z4-06A-11D-A18Y_120711_SN208_0414_BD13L5ACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1Z4-06A	8465257B-7212-44A3-BD9F-1F7D017499AD	Metastatic	Illumina HiSeq	0161c7e1-fed0-4d34-8c99-afa6e680230c	Skin	62	9AFE3E49-19FE-426F-ADCC-9A017F42DC45	7D7EB9C0-01BF-46E1-8107-F17852714D60	TCGA-FS-A1Z4-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1Z4	TCGA-SKCM	854	s7528	Harvard Medical School	Essen	Germany	NO	T1	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d288	58cfa832e4b0c9d6adf6d288	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted.bam	31.7	NA	0.15	58cfa832e4b0c9d6adf6d288	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7476-01A	27D0D3CB-16C0-4BA8-9662-95917F665004	Primary Tumor	Illumina HiSeq	8eda6747-01ab-4378-b3c9-6f638de37412	Brain	26	50823838-03B8-4CD8-A40D-8439011C9B38	06ABBC57-F759-43B4-AD0A-3CEE74E012B5	TCGA-HT-7476-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7476	TCGA-LGG	NA	s8370	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d1ea	58cfa832e4b0c9d6adf6d1ea	TCGA-ET-A25J-11A-01D-A16N_120718_SN590_0169_AC0WL7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-ET-A25J-11A-01D-A16N_120718_SN590_0169_AC0WL7ACXX_s_3_rg.sorted	TCGA-ET-A25J-11A-01D-A16N_120718_SN590_0169_AC0WL7ACXX_s_3_rg.sorted.bam	24.02	1.62	0.15	58cfa832e4b0c9d6adf6d1ea	TCGA-ET-A25J-11A-01D-A16N_120718_SN590_0169_AC0WL7ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25J-11A	618A1C29-5C26-46DB-83D5-4799F9043CD3	Solid Tissue Normal	Illumina HiSeq	5656cb7c-7e70-4014-b67f-5aedc6553483	Thyroid	40	52B6215E-6DC4-412C-931A-2FFE3E949DA3	93B1148E-E39E-4920-8736-F922C80C59DA	TCGA-ET-A25J-11A-01D-A16N-02	HG19_Broad_variant	TCGA-ET-A25J	TCGA-THCA	NA	s12646	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6cf0a	58cfa832e4b0c9d6adf6cf0a	TCGA-FS-A1ZA-06A-11D-A18Y_120712_SN1222_0124_AC11GPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FS-A1ZA-06A-11D-A18Y_120712_SN1222_0124_AC11GPACXX_s_1_rg.sorted	TCGA-FS-A1ZA-06A-11D-A18Y_120712_SN1222_0124_AC11GPACXX_s_1_rg.sorted.bam	50.34	NA	0.16	58cfa832e4b0c9d6adf6cf0a	TCGA-FS-A1ZA-06A-11D-A18Y_120712_SN1222_0124_AC11GPACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZA-06A	177B515E-BCB9-4A08-9B38-3CCDEC0E293F	Metastatic	Illumina HiSeq	d159fb2a-3b27-4d7c-a951-5d250e812f94	Skin	45	2202923F-63CB-4EDF-BF68-8898E974BEA0	9D3074DC-AEFF-47FC-AF7F-843CE639D00E	TCGA-FS-A1ZA-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZA	TCGA-SKCM	843	s7868	Harvard Medical School	Essen	Germany	NO	T4b	N2c	Not available	Stage IIIB	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d0d5	58cfa832e4b0c9d6adf6d0d5	TCGA-FS-A1Z4-10A-01D-A190_120711_SN208_0414_BD13L5ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FS-A1Z4-10A-01D-A190_120711_SN208_0414_BD13L5ACXX_s_6_rg.sorted	TCGA-FS-A1Z4-10A-01D-A190_120711_SN208_0414_BD13L5ACXX_s_6_rg.sorted.bam	127.26	NA	0.17	58cfa832e4b0c9d6adf6d0d5	TCGA-FS-A1Z4-10A-01D-A190_120711_SN208_0414_BD13L5ACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1Z4-10A	8465257B-7212-44A3-BD9F-1F7D017499AD	Blood Derived Normal	Illumina HiSeq	95ed4f71-803b-44ac-a13b-342354376a61	Skin	62	FC080989-3E83-45CE-A52E-52BD231F2B1A	FDA54930-6F29-4C59-AE0A-721F9BAADB89	TCGA-FS-A1Z4-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1Z4	TCGA-SKCM	854	s7367	Harvard Medical School	Essen	Germany	NO	T1	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6c4	58cfa82fe4b0c9d6adf6b6c4	TCGA-44-6774-11A-01D-1853_111204_SN208_0256_C0562ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-44-6774-11A-01D-1853_111204_SN208_0256_C0562ACXX_s_8_rg.sorted	TCGA-44-6774-11A-01D-1853_111204_SN208_0256_C0562ACXX_s_8_rg.sorted.bam	115.7	1.9	0.14	58cfa82fe4b0c9d6adf6b6c4	TCGA-44-6774-11A-01D-1853_111204_SN208_0256_C0562ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6774-11A	33C71EAD-4C2A-476D-85EF-885DBBFC2CBD	Solid Tissue Normal	Illumina HiSeq	b2c21986-7ec8-4686-89b3-45fc5f257b49	Lung	56	09584CAC-EED9-458E-842B-C2FF06DF64E1	43FA0F12-DABE-4C58-BFE0-4ACD6543EBCC	TCGA-44-6774-11A-01D-1853-02	HG19_Broad_variant	TCGA-44-6774	TCGA-LUAD	NA	s11000	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	TRUE
13722.58cfa82ee4b0c9d6adf6b092	58cfa82ee4b0c9d6adf6b092	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted.bam	184.7	1.9	0.16	58cfa82ee4b0c9d6adf6b092	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4417-01A	A244A99A-D7CC-4FB1-BC76-B66886481621	Primary Tumor	Illumina HiSeq	f4f3791e-3b72-4f33-986c-dca1cf3ada94	Lung	51	9AB40E48-6979-43CB-9ACF-1D4F474CAD4D	B7C6B0BD-AB9E-4211-8B3A-786B45C43F3D	TCGA-05-4417-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4417	TCGA-LUAD	NA	s11437	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b62e	58cfa82fe4b0c9d6adf6b62e	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted.bam	304.4	1.9	0.16	58cfa82fe4b0c9d6adf6b62e	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-6206-01A	C4C1469D-752F-42B6-8686-714AD4A8AC97	Primary Tumor	Illumina HiSeq	2b0c2142-3073-4443-9998-a7e909add85d	Lung	NA	4AFC6152-819B-4E55-817D-DF8A42EB0D36	B6836DCC-F7D7-45BF-AE7C-DE6F2140779E	TCGA-75-6206-01A-11D-1751-02	HG19_Broad_variant	TCGA-75-6206	TCGA-LUAD	NA	s11131	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b861	58cfa82fe4b0c9d6adf6b861	TCGA-A5-A0R9-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0R9-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_5_rg.sorted	TCGA-A5-A0R9-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_5_rg.sorted.bam	17.82	1.84	0.14	58cfa82fe4b0c9d6adf6b861	TCGA-A5-A0R9-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R9-10A	284174FD-1320-4617-9E99-75BD75DF9BF3	Blood Derived Normal	Illumina HiSeq	7dd18801-cadc-4e38-9c58-382d556d861e	Uterus	51	A1B31C24-B03A-4305-89DE-5E1EE65405E6	53D8A79C-1D94-4E9C-A398-65E638DAE589	TCGA-A5-A0R9-10A-01D-A101-02	HG19_Broad_variant	TCGA-A5-A0R9	TCGA-UCEC	NA	s4986	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82fe4b0c9d6adf6b696	58cfa82fe4b0c9d6adf6b696	TCGA-73-4658-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_6_rg.sorted.filtered.	WGS	TCGA-73-4658-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_6_rg.sorted	TCGA-73-4658-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_6_rg.sorted.bam	21.4	1.9	0.15	58cfa82fe4b0c9d6adf6b696	TCGA-73-4658-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4658-11A	AFB91740-2668-46D7-BA01-BB26153AD1C7	Solid Tissue Normal	Illumina HiSeq	154d1467-8cef-484b-b813-86a414c476d2	Lung	80	0E18E1B8-3E7A-43FF-BB86-F097EB9BABC5	27CFDE2F-DC0C-41BF-B179-411D1A3E025F	TCGA-73-4658-11A-01D-1751-02	HG19_Broad_variant	TCGA-73-4658	TCGA-LUAD	1600	s10912	Harvard Medical School	Roswell Park	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b701	58cfa82fe4b0c9d6adf6b701	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.filtered.	WGS	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.bam	237.3	1.9	0.16	58cfa82fe4b0c9d6adf6b701	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6775-01A	3C4FF061-D214-4D1C-8D2E-3034F207C252	Primary Tumor	Illumina HiSeq	c17b3c9b-e41f-48e2-9cde-facc8537afbc	Lung	72	7C606F64-69A1-465C-9F4E-2EB1EBEDA5D7	8B286297-0077-44ED-9093-6F13E2CA4EBA	TCGA-44-6775-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6775	TCGA-LUAD	NA	s11454	Harvard Medical School	Christiana Healthcare	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b885	58cfa82fe4b0c9d6adf6b885	TCGA-A5-A0GX-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-A5-A0GX-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_8_rg.sorted	TCGA-A5-A0GX-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_8_rg.sorted.bam	16.78	2.02	0.17	58cfa82fe4b0c9d6adf6b885	TCGA-A5-A0GX-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GX-10A	553F0CCD-4E6F-4AE2-9B39-97529EB3D826	Blood Derived Normal	Illumina HiSeq	70c8aa33-5105-415c-b6a3-a247449de2dc	Uterus	53	FF637ADE-4B5A-4A0A-9712-4FF2FC5E5B9D	351BBF18-3B64-4A6D-B8CD-D7C3B97D0539	TCGA-A5-A0GX-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0GX	TCGA-UCEC	NA	s5196	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b894	58cfa82fe4b0c9d6adf6b894	TCGA-A5-A0VQ-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-A5-A0VQ-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_7_rg.sorted	TCGA-A5-A0VQ-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_7_rg.sorted.bam	21.48	1.91	0.16	58cfa82fe4b0c9d6adf6b894	TCGA-A5-A0VQ-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_7_rg.sorted.bam	Alive	FEMALE	Not available	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0VQ-10A	23489245-48D7-4F19-8A42-E23B1181412B	Blood Derived Normal	Illumina HiSeq	454b7f4f-321e-4a19-b484-bdb2279d3b74	Uterus	62	AE0455A3-3C16-4A66-B282-65C8108A9481	06276560-9149-4373-8466-CF72D191E234	TCGA-A5-A0VQ-10A-01D-A101-02	HG19_Broad_variant	TCGA-A5-A0VQ	TCGA-UCEC	NA	s4988	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8de	58cfa82fe4b0c9d6adf6b8de	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.bam	59.5	2.02	0.17	58cfa82fe4b0c9d6adf6b8de	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A0D9-01A	17BAEF7C-D97D-4B98-AB53-503EF856523D	Primary Tumor	Illumina HiSeq	43dc32db-2202-486d-82f4-388e37224379	Breast	37	C144AE50-ED29-4E27-BBEE-FA81E79AC7DB	7CD9AC40-F6B5-4C68-9D9A-D57845B812DB	TCGA-A7-A0D9-01A-31D-A060-02	HG19_Broad_variant	TCGA-A7-A0D9	TCGA-BRCA	NA	s5638	Harvard Medical School	Christiana Healthcare	None	NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8d4	58cfa82fe4b0c9d6adf6b8d4	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.bam	743.7	1.9	0.16	58cfa82fe4b0c9d6adf6b8d4	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5049-01A	9944F46F-9FA8-4E2C-A806-776BEC7F8803	Primary Tumor	Illumina HiSeq	16ea05eb-f830-4b36-83bb-989c8de99568	Lung	70	21B2F32E-CCEA-4B20-86D3-6647E99825CF	26ED24EC-1AD1-492D-B2CB-46314B47919E	TCGA-50-5049-01A-01D-1623-02	HG19_Broad_variant	TCGA-50-5049	TCGA-LUAD	NA	s11457	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b896	58cfa82fe4b0c9d6adf6b896	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.bam	39.7	2	0.13	58cfa82fe4b0c9d6adf6b896	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-6742-01A	21FB46F9-4BBB-441C-AF19-A687E9138344	Primary Tumor	Illumina HiSeq	eeeb9a6f-97a9-4db9-aeb9-c5afaf9d0153	Lung	70	F0A4AE58-D5BC-4AB0-B1CF-0D951EA91FC7	04467FAB-BB2F-4F26-AF9E-39C09D920A63	TCGA-49-6742-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6742	TCGA-LUAD	NA	s10655	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N1	Mucinous (Colloid) Carcinoma	Stage IIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8ec	58cfa82fe4b0c9d6adf6b8ec	TCGA-50-5049-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_4_rg.sorted.filtered.	WGS	TCGA-50-5049-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_4_rg.sorted	TCGA-50-5049-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_4_rg.sorted.bam	96.4	1.9	0.15	58cfa82fe4b0c9d6adf6b8ec	TCGA-50-5049-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5049-10A	9944F46F-9FA8-4E2C-A806-776BEC7F8803	Blood Derived Normal	Illumina HiSeq	3a6b8979-927a-418d-971c-e268a67a00c1	Lung	70	507A2EAF-BCE2-48EE-8D87-7DCE6D49879F	234C1669-E9DF-4C3A-9BC0-D44365EC4A2C	TCGA-50-5049-10A-01D-1623-02	HG19_Broad_variant	TCGA-50-5049	TCGA-LUAD	NA	s11006	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8f2	58cfa82fe4b0c9d6adf6b8f2	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted.filtered.	WGS	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted.bam	289.4	1.9	0.15	58cfa82fe4b0c9d6adf6b8f2	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5932-01A	EBCBA7F2-CE13-4BAE-97CD-91A6B1DCD465	Primary Tumor	Illumina HiSeq	a1be116a-f392-49b3-97c6-b674ac8dee93	Lung	75	7ECB9621-7A1F-4876-9DFB-9B77CC4CB7B4	B9ACEF1D-8029-47AB-9830-06B2FF147CDB	TCGA-50-5932-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5932	TCGA-LUAD	1235	s10661	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b697	58cfa82fe4b0c9d6adf6b697	TCGA-44-5643-01A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-5643-01A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_7_rg.sorted	TCGA-44-5643-01A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_7_rg.sorted.bam	672.7	1.9	0.15	58cfa82fe4b0c9d6adf6b697	TCGA-44-5643-01A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_7_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-5643-01A	27FCEEC1-3298-4CDD-A4E6-8F5CF34604F0	Primary Tumor	Illumina HiSeq	d7fc0a17-7a0f-4345-904e-dd40d39ebbc3	Lung	53	ED5B47C1-569F-492B-8D6C-155E3BA79ACB	98EAE374-5F58-4544-BB02-BF605A09AD15	TCGA-44-5643-01A-01D-1623-02	HG19_Broad_variant	TCGA-44-5643	TCGA-LUAD	NA	s10778	Harvard Medical School	Christiana Healthcare	United States	NO	T2b	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b942	58cfa82fe4b0c9d6adf6b942	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.bam	65.96	1.81	0.16	58cfa82fe4b0c9d6adf6b942	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GN-01A	A2A2DBDA-D10C-49C4-86A8-61BAF6160CDA	Primary Tumor	Illumina HiSeq	7270b44f-635f-48bf-b3c4-8042b4557613	Uterus	65	F6F9C40B-1E58-47A3-B518-9694FB5FF2CF	41896FDE-677E-419C-B8B9-0171D6669A4A	TCGA-A5-A0GN-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GN	TCGA-UCEC	NA	s4589	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b904	58cfa82fe4b0c9d6adf6b904	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted.bam	180.7	1.9	0.15	58cfa82fe4b0c9d6adf6b904	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4512-01A	A1E65587-24C1-4B41-92A7-4E1F15FFFD78	Primary Tumor	Illumina HiSeq	bfba789d-2b84-4c34-89f9-7a38586facf6	Lung	69	D809A778-D1AC-4406-AB09-67CC70F1F0C2	6D2569C8-4E18-423B-852D-315DDC3AE2F7	TCGA-49-4512-01A-21D-1853-02	HG19_Broad_variant	TCGA-49-4512	TCGA-LUAD	905	s10780	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b66d	58cfa82fe4b0c9d6adf6b66d	TCGA-50-6597-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-50-6597-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_4_rg.sorted	TCGA-50-6597-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_4_rg.sorted.bam	14	1.8	0.14	58cfa82fe4b0c9d6adf6b66d	TCGA-50-6597-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6597-10A	0D66BF6C-EED0-4726-BD5B-3BF6D610B4E0	Blood Derived Normal	Illumina HiSeq	cf5182e3-08aa-45af-8c6f-2d6afdf01d08	Lung	79	254F2707-C4FB-41DA-BFC0-2190EB9368D5	6E660AAE-3656-424B-966A-DEC114CCCBCE	TCGA-50-6597-10A-01D-1853-02	HG19_Broad_variant	TCGA-50-6597	TCGA-LUAD	NA	s11129	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9ea	58cfa82fe4b0c9d6adf6b9ea	TCGA-91-6835-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_6_rg.sorted.filtered.	WGS	TCGA-91-6835-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_6_rg.sorted	TCGA-91-6835-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_6_rg.sorted.bam	327.7	1.9	0.13	58cfa82fe4b0c9d6adf6b9ea	TCGA-91-6835-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6835-11A	2F09479F-87FC-4C34-8E2C-333E970A3681	Solid Tissue Normal	Illumina HiSeq	842df4e9-6924-416b-bf5a-773944b4ba5e	Lung	81	D6EF8F0B-39AD-42BD-B2BD-62B42BBB69E2	2E6A7A9B-AE70-4871-856C-1D139C570919	TCGA-91-6835-11A-01D-1853-02	HG19_Broad_variant	TCGA-91-6835	TCGA-LUAD	NA	s11252	Harvard Medical School	ABS - IUPUI	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6a0	58cfa82fe4b0c9d6adf6b6a0	TCGA-44-6778-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_6_rg.sorted.filtered.	WGS	TCGA-44-6778-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_6_rg.sorted	TCGA-44-6778-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_6_rg.sorted.bam	179	1.9	0.15	58cfa82fe4b0c9d6adf6b6a0	TCGA-44-6778-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_6_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-44-6778-10A	5D5CC436-6E57-4D23-A164-7F5153C2E666	Blood Derived Normal	Illumina HiSeq	81a9ac95-7603-496d-a966-9fa6ebf33f49	Lung	59	BEBC6D2B-2535-4ADD-8F65-95C1666A5B1D	014CA609-0E9A-4A43-A9DD-25BBBE06FAE7	TCGA-44-6778-10A-01D-1853-02	HG19_Broad_variant	TCGA-44-6778	TCGA-LUAD	NA	s11343	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8f0	58cfa82fe4b0c9d6adf6b8f0	TCGA-75-5122-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_2_rg.sorted.filtered.	WGS	TCGA-75-5122-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_2_rg.sorted	TCGA-75-5122-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_2_rg.sorted.bam	194.7	1.9	0.15	58cfa82fe4b0c9d6adf6b8f0	TCGA-75-5122-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_2_rg.sorted.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-5122-10A	78AE716B-0CA5-4C01-A053-D41288385FCD	Blood Derived Normal	Illumina HiSeq	b223fc0a-cce3-4c35-8a1f-fb5fceca402e	Lung	NA	EF7E95DC-5686-417E-AD90-239CA31826C5	99190FE2-C307-4217-A0F0-71F8820D31B9	TCGA-75-5122-10A-01D-1751-02	HG19_Broad_variant	TCGA-75-5122	TCGA-LUAD	NA	s11558	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9dd	58cfa82fe4b0c9d6adf6b9dd	TCGA-91-6829-11A-01D-1853_120305_SN1120_0119_BD0REAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-91-6829-11A-01D-1853_120305_SN1120_0119_BD0REAACXX_s_3_rg.sorted	TCGA-91-6829-11A-01D-1853_120305_SN1120_0119_BD0REAACXX_s_3_rg.sorted.bam	267.7	1.9	0.16	58cfa82fe4b0c9d6adf6b9dd	TCGA-91-6829-11A-01D-1853_120305_SN1120_0119_BD0REAACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6829-11A	1427CD18-5AD3-491A-9981-908E31AE49DB	Solid Tissue Normal	Illumina HiSeq	a1eb6a43-9ab8-4c52-a1e2-a18576cf662c	Lung	78	EEDF6790-10F7-4C33-A1A6-7857AD23F7E8	33A1760A-4C6A-4B3C-86F2-530E6F3867C2	TCGA-91-6829-11A-01D-1853-02	HG19_Broad_variant	TCGA-91-6829	TCGA-LUAD	1258	s11359	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N0	Lung Bronchioloalveolar Carcinoma Nonmucinous	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba08	58cfa82fe4b0c9d6adf6ba08	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.bam	104.46	2.03	0.15	58cfa82fe4b0c9d6adf6ba08	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G2-01A	4ABBD258-0F0C-4428-901D-625D47AD363A	Primary Tumor	Illumina HiSeq	f5289cfe-4208-4623-896c-ec78fb5f7dc5	Uterus	57	771811E3-740E-42FE-BE9C-FD485997EAAE	579C21E4-83BD-4DAE-B030-53E0930DEACA	TCGA-A5-A0G2-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G2	TCGA-UCEC	NA	s4773	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba48	58cfa82fe4b0c9d6adf6ba48	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.bam	83.98	2	0.17	58cfa82fe4b0c9d6adf6ba48	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G5-01A	4806D9A6-E65D-4A82-B422-1B287980A0C6	Primary Tumor	Illumina HiSeq	db20abab-2eed-4958-a741-e31199adb617	Uterus	73	FA7392E8-335E-4465-9272-4A19DC99412E	EDFD99A3-38A2-4E43-A3D1-B1D19EA818E5	TCGA-A5-A0G5-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G5	TCGA-UCEC	NA	s5382	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9c6	58cfa82fe4b0c9d6adf6b9c6	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted.filtered.	WGS	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted.bam	150.4	1.9	0.15	58cfa82fe4b0c9d6adf6b9c6	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4658-01A	AFB91740-2668-46D7-BA01-BB26153AD1C7	Primary Tumor	Illumina HiSeq	9ee6d96c-98e7-4829-94dc-f41e5f078854	Lung	80	BFDE37F2-AB6F-4426-A33D-EF9D21772F02	6A3AFDA7-56BB-4120-AB92-6EDA217BC214	TCGA-73-4658-01A-01D-1751-02	HG19_Broad_variant	TCGA-73-4658	TCGA-LUAD	1600	s11130	Harvard Medical School	Roswell Park	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b67a	58cfa82fe4b0c9d6adf6b67a	TCGA-44-6779-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-44-6779-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_1_rg.sorted	TCGA-44-6779-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_1_rg.sorted.bam	330	1.9	0.17	58cfa82fe4b0c9d6adf6b67a	TCGA-44-6779-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-44-6779-10A	CBBEA9F1-396A-4BF3-B67C-2CAC3394DCEB	Blood Derived Normal	Illumina HiSeq	f0c8649c-84d2-4fca-a36b-589106e28853	Lung	50	6E64FD37-19C0-442C-A490-3BCCBEB84597	09A8A60E-F929-467D-A666-B61F784A1E74	TCGA-44-6779-10A-01D-1853-02	HG19_Broad_variant	TCGA-44-6779	TCGA-LUAD	500	s10997	Harvard Medical School	Christiana Healthcare	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9ce	58cfa82fe4b0c9d6adf6b9ce	TCGA-67-6216-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_6_rg.sorted.filtered.	WGS	TCGA-67-6216-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_6_rg.sorted	TCGA-67-6216-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_6_rg.sorted.bam	261.7	1.9	0.17	58cfa82fe4b0c9d6adf6b9ce	TCGA-67-6216-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6216-10A	CCECCE70-DD54-4C5B-BF9F-CA87D290CB00	Blood Derived Normal	Illumina HiSeq	ca8f48ed-992b-4763-ad25-7d8f16528337	Lung	57	E196675A-2C83-4726-9D0A-E633E5D8E9B1	08670F63-D3EA-4C70-B74C-34ECBD0B5205	TCGA-67-6216-10A-01D-1751-02	HG19_Broad_variant	TCGA-67-6216	TCGA-LUAD	NA	s11247	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T1a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	TRUE
13722.58cfa830e4b0c9d6adf6bbb6	58cfa830e4b0c9d6adf6bbb6	TCGA-A2-A0EU-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A2-A0EU-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_2_rg.sorted	TCGA-A2-A0EU-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_2_rg.sorted.bam	21.31	1.91	0.13	58cfa830e4b0c9d6adf6bbb6	TCGA-A2-A0EU-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A0EU-10A	C0427237-B476-4AF4-B664-7BD479922EA5	Blood Derived Normal	Illumina HiSeq	bbc2932c-4507-4111-a367-ba914dfe257b	Breast	79	7B9319B5-3093-4E22-94B2-E7A956BDC271	11E97514-242B-4CE1-99EA-3830E6902EE3	TCGA-A2-A0EU-10A-01D-A060-02	HG19_Broad_variant	TCGA-A2-A0EU	TCGA-BRCA	NA	s6768	Harvard Medical School	Walter Reed	None	NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bbbc	58cfa830e4b0c9d6adf6bbbc	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.bam	40.68	1.8	0.14	58cfa830e4b0c9d6adf6bbbc	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A0EU-01A	C0427237-B476-4AF4-B664-7BD479922EA5	Primary Tumor	Illumina HiSeq	f8f8a691-8930-46b3-9cd7-1b8ac6895baf	Breast	79	69DBB2AE-3F19-4C29-9C24-810AE60312F3	7F0FA628-7A18-4E52-81CC-3E213C431D3E	TCGA-A2-A0EU-01A-22D-A060-02	HG19_Broad_variant	TCGA-A2-A0EU	TCGA-BRCA	NA	s5489	Harvard Medical School	Walter Reed	None	NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bc7a	58cfa830e4b0c9d6adf6bc7a	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.bam	48.13	1.89	0.13	58cfa830e4b0c9d6adf6bc7a	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JL-01A	D5D8E76E-2F2A-49BC-BA0A-D51283611B16	Primary Tumor	Illumina HiSeq	b39a31b9-dd85-403d-ac11-d7b6dd2703a6	Breast	59	834D2E25-DA72-413B-BB0E-3BEB24D46472	A34C3F47-AD37-4777-A733-07AE8F4B4BFF	TCGA-AO-A0JL-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JL	TCGA-BRCA	NA	s5639	Harvard Medical School	MSKCC	None	NO	T2	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bd78	58cfa830e4b0c9d6adf6bd78	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.bam	29.04	1.87	0.14	58cfa830e4b0c9d6adf6bd78	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JJ-01A	BEF7B135-A727-45E8-850A-CC4CD56C49AA	Primary Tumor	Illumina HiSeq	6d955c96-b34d-4aea-961b-378e856ae8cb	Breast	54	008DAFDD-A3D1-4801-8C0A-8714E2B58E48	ED24B69D-599E-42ED-BBE3-5C4F59FABED4	TCGA-AO-A0JJ-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JJ	TCGA-BRCA	NA	s6271	Harvard Medical School	MSKCC	None	NO	T2	N1a	Infiltrating Lobular Carcinoma	Stage IIB	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bdcc	58cfa830e4b0c9d6adf6bdcc	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.bam	71.16	2.03	0.15	58cfa830e4b0c9d6adf6bdcc	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0H6-01A	AEB6A3A6-B57A-4C53-90E6-E833777DD2A1	Primary Tumor	Illumina HiSeq	9c69c17b-33de-4bb8-be9f-7e0dcde9db0a	Breast	82	B2921C9D-C655-46F3-86E5-2FC2BED1ED33	57D73BC9-950E-42A3-B9FB-6045117112B7	TCGA-BH-A0H6-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0H6	TCGA-BRCA	NA	s5963	Harvard Medical School	University of Pittsburgh	None	NO	T1b	NX	Infiltrating Ductal Carcinoma	Stage I	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6ba9b	58cfa830e4b0c9d6adf6ba9b	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.bam	92.8	2.11	0.16	58cfa830e4b0c9d6adf6ba9b	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GJ-01A	94817E78-78F5-4556-9394-610DF65605E2	Primary Tumor	Illumina HiSeq	d5b73d0f-c14a-4a54-a8e1-14bc027cfef5	Uterus	44	48FA5B7D-E488-4743-A7CE-ACEB9945F00B	A5D63CC4-892C-4357-B8A1-2BF50CF425DC	TCGA-A5-A0GJ-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GJ	TCGA-UCEC	NA	s5384	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bc74	58cfa830e4b0c9d6adf6bc74	TCGA-AX-A1CJ-11A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-AX-A1CJ-11A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_6_rg.sorted	TCGA-AX-A1CJ-11A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_6_rg.sorted.bam	73.42	1.95	0.15	58cfa830e4b0c9d6adf6bc74	TCGA-AX-A1CJ-11A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_6_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A1CJ-11A	ABAF757B-F79F-40BD-96E3-E2C0F63061F0	Solid Tissue Normal	Illumina HiSeq	c62b26b6-8926-42d4-8602-bb8462ef7956	Uterus	59	210AE0CA-30CB-48EE-AE34-9228DBB7EE19	B3D0D218-03CC-4922-BB97-CB8415CC7B69	TCGA-AX-A1CJ-11A-11D-A133-02	HG19_Broad_variant	TCGA-AX-A1CJ	TCGA-UCEC	NA	s4998	Harvard Medical School	Gynecologic Oncology Group	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A133-02	FALSE
13722.58cfa830e4b0c9d6adf6be20	58cfa830e4b0c9d6adf6be20	TCGA-B6-A0RG-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_4_rg.sorted.filtered.	WGS	TCGA-B6-A0RG-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_4_rg.sorted	TCGA-B6-A0RG-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_4_rg.sorted.bam	7.45	2	0.15	58cfa830e4b0c9d6adf6be20	TCGA-B6-A0RG-10A-01D-A060_130807_SN590_0235_AC29RAACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RG-10A	9B13927C-7357-44FD-8385-92AE6A656B7D	Blood Derived Normal	Illumina HiSeq	5ad51bb7-5bcd-42bc-b3ad-64bb242f91b3	Breast	26	3EBECB70-9957-4BFB-8E69-DC6F157C3F08	6F602AEF-51FE-40AD-9984-0F95D27A4078	TCGA-B6-A0RG-10A-01D-A060-02	HG19_Broad_variant	TCGA-B6-A0RG	TCGA-BRCA	NA	s5962	Harvard Medical School	Duke	United States	NO	T3	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bddc	58cfa830e4b0c9d6adf6bddc	TCGA-BG-A0MU-10A-02D-A101_120406_SN1120_0131_BD0UK4ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MU-10A-02D-A101_120406_SN1120_0131_BD0UK4ACXX_s_1_rg.sorted	TCGA-BG-A0MU-10A-02D-A101_120406_SN1120_0131_BD0UK4ACXX_s_1_rg.sorted.bam	10.2	2	0.17	58cfa830e4b0c9d6adf6bddc	TCGA-BG-A0MU-10A-02D-A101_120406_SN1120_0131_BD0UK4ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MU-10A	A7329910-B1C7-4A18-B28E-8FAD79121339	Blood Derived Normal	Illumina HiSeq	56dc6ee6-2816-48fc-b41d-acea5bdb9330	Uterus	78	AE04F86F-3927-4E5E-BC46-997CD6BED18A	37E6CE2A-F097-4D62-B8BE-2C790F76774F	TCGA-BG-A0MU-10A-02D-A101-02	HG19_Broad_variant	TCGA-BG-A0MU	TCGA-UCEC	NA	s4790	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6becb	58cfa830e4b0c9d6adf6becb	TCGA-AO-A0JL-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_2_rg.sorted.filtered.	WGS	TCGA-AO-A0JL-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_2_rg.sorted	TCGA-AO-A0JL-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_2_rg.sorted.bam	42.91	2	0.14	58cfa830e4b0c9d6adf6becb	TCGA-AO-A0JL-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JL-10A	D5D8E76E-2F2A-49BC-BA0A-D51283611B16	Blood Derived Normal	Illumina HiSeq	4db7f9bb-a3b8-4b87-b98c-8ba5be69963f	Breast	59	6F0C9CAE-2A0F-4512-9B36-E94917CF2561	5159552D-2BC4-4C78-A5FD-3B34084C6A4E	TCGA-AO-A0JL-10A-01D-A060-02	HG19_Broad_variant	TCGA-AO-A0JL	TCGA-BRCA	NA	s6122	Harvard Medical School	MSKCC	None	NO	T2	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6be41	58cfa830e4b0c9d6adf6be41	TCGA-BJ-A28R-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BJ-A28R-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_8_rg.sorted	TCGA-BJ-A28R-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_8_rg.sorted.bam	60.26	1.93	0.17	58cfa830e4b0c9d6adf6be41	TCGA-BJ-A28R-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28R-10A	524A39EE-8FA3-418E-98A2-A6A90E9C8064	Blood Derived Normal	Illumina HiSeq	22696c6b-bf53-4670-9518-1526986414a8	Thyroid	38	576D5B97-6871-4E32-8A11-14ECAE9D490C	90BB8D84-280A-4E9C-8F10-4003DCDCEF31	TCGA-BJ-A28R-10A-01D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28R	TCGA-THCA	NA	s12355	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6bc86	58cfa830e4b0c9d6adf6bc86	TCGA-AX-A2HD-11A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-AX-A2HD-11A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_2_rg.sorted	TCGA-AX-A2HD-11A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_2_rg.sorted.bam	26.63	1.83	0.17	58cfa830e4b0c9d6adf6bc86	TCGA-AX-A2HD-11A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A2HD-11A	A8DEF1A0-A136-47F4-9AD9-60EBCF9B726B	Solid Tissue Normal	Illumina HiSeq	39807b39-505a-406e-a14a-07c227eae42f	Uterus	69	26BC3B4C-B0BC-4D05-9DBF-334F27F1CB89	693C4452-359A-4876-88F6-E99BB600FD4F	TCGA-AX-A2HD-11A-11D-A17E-02	HG19_Broad_variant	TCGA-AX-A2HD	TCGA-UCEC	NA	s4780	Harvard Medical School	Gynecologic Oncology Group	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A17E-02	TRUE
13722.58cfa830e4b0c9d6adf6bf5c	58cfa830e4b0c9d6adf6bf5c	TCGA-BR-4292-11A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BR-4292-11A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_4_rg.sorted	TCGA-BR-4292-11A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_4_rg.sorted.bam	193.3	1.9	0.15	58cfa830e4b0c9d6adf6bf5c	TCGA-BR-4292-11A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4292-11A	703D3E86-32F4-44AE-BD88-C02378FC2269	Solid Tissue Normal	Illumina HiSeq	763db891-de7a-4a7f-8608-d70ab806e102	Stomach	73	1351C1B9-3E15-4FE6-A8D4-F3376E3561B4	94341BBF-538A-498F-860C-0A5B2F1872AB	TCGA-BR-4292-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4292	TCGA-STAD	NA	s14878	Harvard Medical School	Asterand	Russia	NO	T1	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6be6c	58cfa830e4b0c9d6adf6be6c	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted.bam	57.46	1.9	0.15	58cfa830e4b0c9d6adf6be6c	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A13J-01A	556FCBC8-172A-4AF1-8822-AE036E8D68E8	Primary Tumor	Illumina HiSeq	58daf5d5-0c54-4a8c-b756-35565cdc9671	Bladder	65	CF23846D-A7D2-40A9-8B51-49A27967D101	782CEFE1-C28F-40BA-93A2-66279184EEF6	TCGA-BL-A13J-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BL-A13J	TCGA-BLCA	81	s3080	Harvard Medical School	Christiana Healthcare	United States	NO	T4	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6be5a	58cfa830e4b0c9d6adf6be5a	TCGA-BJ-A18Y-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A18Y-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_2_rg.sorted	TCGA-BJ-A18Y-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_2_rg.sorted.bam	40.18	1.88	0.16	58cfa830e4b0c9d6adf6be5a	TCGA-BJ-A18Y-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A18Y-10A	ACB3B9DB-16E9-40F5-87A9-9DF9D4CEEE54	Blood Derived Normal	Illumina HiSeq	bfbcbb41-3d4e-4ee9-9fe1-af5d464bba4e	Thyroid	29	13867A18-2AA2-426C-A515-69AA1DABE296	6CB890E9-E04E-4FDD-82F4-8B38870D1C30	TCGA-BJ-A18Y-10A-01D-A13U-02	HG19_Broad_variant	TCGA-BJ-A18Y	TCGA-THCA	NA	s11985	Harvard Medical School	University of Pittsburgh	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6be7a	58cfa830e4b0c9d6adf6be7a	TCGA-BJ-A190-10A-01D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BJ-A190-10A-01D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_8_rg.sorted	TCGA-BJ-A190-10A-01D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_8_rg.sorted.bam	60.56	1.93	0.16	58cfa830e4b0c9d6adf6be7a	TCGA-BJ-A190-10A-01D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A190-10A	04FFF86A-B6F5-4900-9E37-C1F0B881B160	Blood Derived Normal	Illumina HiSeq	e22bc87d-3dff-4873-8313-a7893de7d0c6	Thyroid	55	953F9755-A3DA-446C-980F-1679C19138EC	58A913F6-CD46-45AB-83EF-DE29953A07B3	TCGA-BJ-A190-10A-01D-A13U-02	HG19_Broad_variant	TCGA-BJ-A190	TCGA-THCA	NA	s12236	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6be82	58cfa830e4b0c9d6adf6be82	TCGA-BL-A0C8-01A-11D-A10R_120926_SN590_0181_AC19HCACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BL-A0C8-01A-11D-A10R_120926_SN590_0181_AC19HCACXX_s_1_rg.sorted	TCGA-BL-A0C8-01A-11D-A10R_120926_SN590_0181_AC19HCACXX_s_1_rg.sorted.bam	69.7	2	0.17	58cfa830e4b0c9d6adf6be82	TCGA-BL-A0C8-01A-11D-A10R_120926_SN590_0181_AC19HCACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A0C8-01A	A6003B1C-56A9-430A-A5E2-B70AF3F81BDB	Primary Tumor	Illumina HiSeq	19df03d2-75d2-408e-86e2-482ddeed9736	Bladder	73	5FEED572-07C0-4DA0-8649-CA8F8682657A	AB020F79-BA66-457C-9D77-DDD87C799538	TCGA-BL-A0C8-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BL-A0C8	TCGA-BLCA	NA	s2690	Harvard Medical School	Christiana Healthcare	United States	NO	T1	NX	Not available	Stage I	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6bedb	58cfa830e4b0c9d6adf6bedb	TCGA-AP-A0LP-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AP-A0LP-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_5_rg.sorted	TCGA-AP-A0LP-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_5_rg.sorted.bam	34.3	1.91	0.13	58cfa830e4b0c9d6adf6bedb	TCGA-AP-A0LP-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LP-10A	EFAE3940-D3CC-4988-BDB4-FA05D977AFF5	Blood Derived Normal	Illumina HiSeq	2b1e3b74-bf9f-487e-a763-3ceecfb24090	Uterus	76	67F90A95-8C23-45EE-82CD-A0F24058D35A	5A346376-940C-412D-9B0C-E4DE7CA6D733	TCGA-AP-A0LP-10A-01D-A101-02	HG19_Broad_variant	TCGA-AP-A0LP	TCGA-UCEC	NA	s4779	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bfd2	58cfa830e4b0c9d6adf6bfd2	TCGA-BG-A0MS-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0MS-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_8_rg.sorted	TCGA-BG-A0MS-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_8_rg.sorted.bam	6.56	1.86	0.16	58cfa830e4b0c9d6adf6bfd2	TCGA-BG-A0MS-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MS-10A	A798A8CC-4E72-4A8C-9E20-74A14DEAFD12	Blood Derived Normal	Illumina HiSeq	8c7d0948-d0c3-4bd5-bd25-bf8b70f1e346	Uterus	53	13F70704-8617-4547-BD50-A41C1DB3C6B2	F25B6FF4-0207-428C-8FF1-DD40235D0D0C	TCGA-BG-A0MS-10A-02D-A101-02	HG19_Broad_variant	TCGA-BG-A0MS	TCGA-UCEC	NA	s4602	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c02c	58cfa830e4b0c9d6adf6c02c	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.bam	26.88	1.91	0.16	58cfa830e4b0c9d6adf6c02c	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZC-01A	6675C581-297D-44CD-B80F-AE7E53D48228	Primary Tumor	Illumina HiSeq	a470b305-96a5-43a8-b1f4-db15c7b0b4d5	Thyroid	55	1F945AFF-7BC2-40F5-87DB-92313E541243	0E4A0528-883D-47A5-B399-57B1B15EC412	TCGA-BJ-A0ZC-01A-12D-A13U-02	HG19_Broad_variant	TCGA-BJ-A0ZC	TCGA-THCA	NA	s12232	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6c054	58cfa830e4b0c9d6adf6c054	TCGA-B5-A0K4-10A-01D-A043_120504_SN590_0156_BC0H68ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-B5-A0K4-10A-01D-A043_120504_SN590_0156_BC0H68ACXX_s_4_rg.sorted	TCGA-B5-A0K4-10A-01D-A043_120504_SN590_0156_BC0H68ACXX_s_4_rg.sorted.bam	29.97	2.03	0.16	58cfa830e4b0c9d6adf6c054	TCGA-B5-A0K4-10A-01D-A043_120504_SN590_0156_BC0H68ACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K4-10A	A8F38E37-978B-4435-B676-E8D4C34DA909	Blood Derived Normal	Illumina HiSeq	36d00246-213f-4c95-a5a4-f558597a08ba	Uterus	51	94FDE18C-1E3B-46CA-88F4-E41566384633	569A4D40-7177-4D9F-BE01-EC38E2277D5C	TCGA-B5-A0K4-10A-01D-A043-02	HG19_Broad_variant	TCGA-B5-A0K4	TCGA-UCEC	NA	s4599	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c122	58cfa830e4b0c9d6adf6c122	TCGA-BS-A0TE-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0TE-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_3_rg.sorted	TCGA-BS-A0TE-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_3_rg.sorted.bam	18.46	2.12	0.13	58cfa830e4b0c9d6adf6c122	TCGA-BS-A0TE-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_3_rg.sorted.bam	Dead	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TE-10A	09066FBF-6A1D-46C9-A4C5-C53340C3D1BA	Blood Derived Normal	Illumina HiSeq	f8af36b9-66a9-43c7-91f7-de5b728f0d49	Uterus	35	0DBD157F-3CC0-4364-B76D-5E6775BA82BC	63677E1D-5D49-47A1-BF72-32377846EEE8	TCGA-BS-A0TE-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0TE	TCGA-UCEC	146	s4794	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c10c	58cfa830e4b0c9d6adf6c10c	TCGA-BS-A0TA-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BS-A0TA-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_8_rg.sorted	TCGA-BS-A0TA-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_8_rg.sorted.bam	15.24	1.9	0.15	58cfa830e4b0c9d6adf6c10c	TCGA-BS-A0TA-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_8_rg.sorted.bam	Alive	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TA-10A	AD3D8420-F562-4CBE-AC82-C968BD4F782D	Blood Derived Normal	Illumina HiSeq	eefab396-34cc-4190-9980-99576677cbaa	Uterus	58	435C97F0-2223-46D6-A682-7113C7071D35	BD02B371-649E-449D-B86C-F0B30FDEAADA	TCGA-BS-A0TA-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0TA	TCGA-UCEC	NA	s4262	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c10e	58cfa830e4b0c9d6adf6c10e	TCGA-BS-A0TI-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BS-A0TI-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_5_rg.sorted	TCGA-BS-A0TI-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_5_rg.sorted.bam	6.8	2	0.17	58cfa830e4b0c9d6adf6c10e	TCGA-BS-A0TI-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TI-10A	DF857BC6-FD6A-4713-BEF9-6EE1301E5FB1	Blood Derived Normal	Illumina HiSeq	6c79babf-5d05-4b25-be49-7ca0b6cd759a	Uterus	64	F4052639-340A-488B-810A-8403FC796000	3CB294E3-4240-49DE-BA0E-8F802CF741CF	TCGA-BS-A0TI-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0TI	TCGA-UCEC	NA	s4605	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c120	58cfa830e4b0c9d6adf6c120	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.bam	37.3	1.98	0.16	58cfa830e4b0c9d6adf6c120	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZG-01A	A3810F36-D2B4-4A45-AD08-A4DBFB9D27AA	Primary Tumor	Illumina HiSeq	44c5a52a-3434-4e05-a510-33799f327c93	Thyroid	80	3AC025C9-FEC6-4997-8630-085750DC84E0	D030DC18-6E50-4679-8BF9-26A1DAEC8F79	TCGA-BJ-A0ZG-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZG	TCGA-THCA	NA	s12101	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c112	58cfa830e4b0c9d6adf6c112	TCGA-B5-A0K9-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_2_rg.sorted.filtered.	WGS	TCGA-B5-A0K9-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_2_rg.sorted	TCGA-B5-A0K9-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_2_rg.sorted.bam	59.37	2.1	0.16	58cfa830e4b0c9d6adf6c112	TCGA-B5-A0K9-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K9-10A	4485CC98-5D58-4EB4-8325-7D1A617B6461	Blood Derived Normal	Illumina HiSeq	285455ac-3652-45e6-9634-9b705defc33c	Uterus	88	23D730B3-A4B4-4FEC-916A-67DC5C79241F	5F225516-70A5-4A2E-8F28-B91932006218	TCGA-B5-A0K9-10A-02D-A101-02	HG19_Broad_variant	TCGA-B5-A0K9	TCGA-UCEC	NA	s4600	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c132	58cfa830e4b0c9d6adf6c132	TCGA-BS-A0UM-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0UM-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_3_rg.sorted	TCGA-BS-A0UM-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_3_rg.sorted.bam	20.2	1.94	0.13	58cfa830e4b0c9d6adf6c132	TCGA-BS-A0UM-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UM-10A	A7C565FC-C711-4B63-9549-4CD74D1F57C2	Blood Derived Normal	Illumina HiSeq	e06c3a0d-7216-434e-aea1-0b79cfac3269	Uterus	64	D5EF6EF5-A2E1-49A9-BFCB-C6BB41424676	7E557D99-F492-4067-B0A4-A70485952689	TCGA-BS-A0UM-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0UM	TCGA-UCEC	NA	s5007	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c13c	58cfa830e4b0c9d6adf6c13c	TCGA-BS-A0UF-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0UF-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_1_rg.sorted	TCGA-BS-A0UF-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_1_rg.sorted.bam	16.27	2.03	0.16	58cfa830e4b0c9d6adf6c13c	TCGA-BS-A0UF-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UF-10A	F77D7256-2CCF-42A7-9B30-332AC24CA812	Blood Derived Normal	Illumina HiSeq	4901eca0-dc95-4a8a-b119-955bac45c497	Uterus	65	283B4B89-BABC-45E1-AE18-04E258DA434D	4FD6E229-6662-4039-A2EF-225350AC231C	TCGA-BS-A0UF-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0UF	TCGA-UCEC	NA	s4435	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c1be	58cfa830e4b0c9d6adf6c1be	TCGA-BS-A0UT-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BS-A0UT-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_4_rg.sorted	TCGA-BS-A0UT-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_4_rg.sorted.bam	16.38	1.9	0.16	58cfa830e4b0c9d6adf6c1be	TCGA-BS-A0UT-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_4_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UT-10A	E2B1D0DE-5221-44A1-8FAD-9708A3CADA14	Blood Derived Normal	Illumina HiSeq	ce5e4242-4066-48c3-bae1-a64cba28a927	Uterus	62	452C7150-C00B-4945-9564-92D26805F128	6A617CA5-0762-4337-9B3F-F7BF10416751	TCGA-BS-A0UT-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0UT	TCGA-UCEC	NA	s5016	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c1a4	58cfa830e4b0c9d6adf6c1a4	TCGA-BA-5559-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BA-5559-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_1_rg.sorted	TCGA-BA-5559-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_1_rg.sorted.bam	94.4	1.9	0.15	58cfa830e4b0c9d6adf6c1a4	TCGA-BA-5559-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5559-10A	17B17D91-C3DF-4B89-9C10-4DB069AFF656	Blood Derived Normal	Illumina HiSeq	e4331399-eb06-4ee0-a375-64ffa929d8e7	Head and Neck	71	43FBB037-8BA4-4BA3-8458-71A027EDA822	673B6C98-3F56-42D2-BFF8-2E68992864F4	TCGA-BA-5559-10A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5559	TCGA-HNSC	NA	s15491	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1509-02	TRUE
13722.58cfa830e4b0c9d6adf6c193	58cfa830e4b0c9d6adf6c193	TCGA-BA-5555-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-5555-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_5_rg.sorted	TCGA-BA-5555-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_5_rg.sorted.bam	64.4	1.9	0.14	58cfa830e4b0c9d6adf6c193	TCGA-BA-5555-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_5_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5555-10A	8970F713-4A7A-4125-892C-6A34139371D8	Blood Derived Normal	Illumina HiSeq	cb082daa-fb68-4836-bd36-abeed40b581c	Head and Neck	54	99CA3C12-0D63-428F-8B1B-03E4A3E8E233	8837A50C-34E3-471D-89FE-D9444255804B	TCGA-BA-5555-10A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5555	TCGA-HNSC	NA	s16317	Harvard Medical School	UNC	None	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa830e4b0c9d6adf6c1f0	58cfa830e4b0c9d6adf6c1f0	TCGA-BG-A18A-10A-01D-A12F_120626_SN590_0163_AC0VU5ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A18A-10A-01D-A12F_120626_SN590_0163_AC0VU5ACXX_s_8_rg.sorted	TCGA-BG-A18A-10A-01D-A12F_120626_SN590_0163_AC0VU5ACXX_s_8_rg.sorted.bam	43.15	1.98	0.17	58cfa830e4b0c9d6adf6c1f0	TCGA-BG-A18A-10A-01D-A12F_120626_SN590_0163_AC0VU5ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A18A-10A	FEB3E930-3638-44B4-AC0F-A5DCB01FED76	Blood Derived Normal	Illumina HiSeq	dd3a2d63-837e-4868-bd5b-558c9555fa7b	Uterus	74	4AA1EED0-0890-4FD8-9367-07DBCBC4BF11	50671901-C77B-4E88-8A99-5F1CF123F00C	TCGA-BG-A18A-10A-01D-A12F-02	HG19_Broad_variant	TCGA-BG-A18A	TCGA-UCEC	NA	s4251	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa830e4b0c9d6adf6c192	58cfa830e4b0c9d6adf6c192	TCGA-BA-5149-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BA-5149-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_1_rg.sorted	TCGA-BA-5149-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_1_rg.sorted.bam	277.7	1.9	0.15	58cfa830e4b0c9d6adf6c192	TCGA-BA-5149-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5149-01A	CB99FB14-641C-4FB3-BF1D-17EFB8CD982A	Primary Tumor	Illumina HiSeq	88e71e4f-d4a5-4136-844d-883107af63b9	Head and Neck	47	E5A9FE30-E292-47DC-8EF5-565894B02A62	0F1EEC01-B772-47F6-8A14-0F651FC2F84E	TCGA-BA-5149-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5149	TCGA-HNSC	NA	s15616	Harvard Medical School	UNC	None	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa830e4b0c9d6adf6c218	58cfa830e4b0c9d6adf6c218	TCGA-BT-A20X-11A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BT-A20X-11A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_6_rg.sorted	TCGA-BT-A20X-11A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_6_rg.sorted.bam	9.27	1.77	0.15	58cfa830e4b0c9d6adf6c218	TCGA-BT-A20X-11A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20X-11A	BE8B3F36-AAA1-4302-B28E-DE1996FACEAF	Solid Tissue Normal	Illumina HiSeq	85b68bda-849a-4597-8161-176a8ad06f09	Bladder	56	F949B635-1BF1-457F-B72A-02F59753E467	4200DE6A-AE4E-42DD-8AB5-1B78298A2A22	TCGA-BT-A20X-11A-12D-A16N-02	HG19_Broad_variant	TCGA-BT-A20X	TCGA-BLCA	251	s3091	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6c254	58cfa830e4b0c9d6adf6c254	TCGA-C5-A2LX-10A-01D-A18I_140206_SN1222_0239_BC2RAKACXX_s_7_rg.sorted.filtered.	WGS	TCGA-C5-A2LX-10A-01D-A18I_140206_SN1222_0239_BC2RAKACXX_s_7_rg.sorted	TCGA-C5-A2LX-10A-01D-A18I_140206_SN1222_0239_BC2RAKACXX_s_7_rg.sorted.bam	24.64	NA	0.16	58cfa830e4b0c9d6adf6c254	TCGA-C5-A2LX-10A-01D-A18I_140206_SN1222_0239_BC2RAKACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LX-10A	B82F4C6D-530F-4B0E-8F33-995633CB254A	Blood Derived Normal	Illumina HiSeq	2ae4bce7-ffc3-4bce-a766-63d284bcab75	Cervix	54	9D41477D-8B08-46BA-ABDD-865BBAAD1F81	A7161C5A-7BA3-4DD8-9403-28B22C2E7147	TCGA-C5-A2LX-10A-01D-A18I-02	HG19_Broad_variant	TCGA-C5-A2LX	TCGA-CESC	NA	s1172	Harvard Medical School	Medical College of Wisconsin	United States	NO	T2	N1	Cervical Squamous Cell Carcinoma	Not available	A18I-02	TRUE
13722.58cfa830e4b0c9d6adf6c228	58cfa830e4b0c9d6adf6c228	TCGA-BT-A20X-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BT-A20X-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_5_rg.sorted	TCGA-BT-A20X-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_5_rg.sorted.bam	38.54	1.64	0.16	58cfa830e4b0c9d6adf6c228	TCGA-BT-A20X-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20X-01A	BE8B3F36-AAA1-4302-B28E-DE1996FACEAF	Primary Tumor	Illumina HiSeq	256c8b67-1fea-4666-b42c-21e8860946e3	Bladder	56	4D7D3354-6588-4E02-9354-AB5044BA1AB3	B9EE2E33-FF09-41FE-901C-453588041DCE	TCGA-BT-A20X-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BT-A20X	TCGA-BLCA	251	s2692	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6c2e6	58cfa830e4b0c9d6adf6c2e6	TCGA-C5-A2M1-10A-01D-A18I_140206_SN1222_0239_BC2RAKACXX_s_8_rg.sorted.filtered.	WGS	TCGA-C5-A2M1-10A-01D-A18I_140206_SN1222_0239_BC2RAKACXX_s_8_rg.sorted	TCGA-C5-A2M1-10A-01D-A18I_140206_SN1222_0239_BC2RAKACXX_s_8_rg.sorted.bam	14.69	NA	0.15	58cfa830e4b0c9d6adf6c2e6	TCGA-C5-A2M1-10A-01D-A18I_140206_SN1222_0239_BC2RAKACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2M1-10A	8911C80C-C903-48E4-AF5B-FFEDEF9ABC47	Blood Derived Normal	Illumina HiSeq	78a6a70e-fe67-4b95-a5eb-6bff4842969c	Cervix	37	D54090CA-8F9B-4F5E-BA79-92CADB9BD6A7	106D9368-DD47-43F6-AA1A-A469376469BC	TCGA-C5-A2M1-10A-01D-A18I-02	HG19_Broad_variant	TCGA-C5-A2M1	TCGA-CESC	NA	s1517	Harvard Medical School	Medical College of Wisconsin	United States	NO	T1b1	N0	Endocervical Type of Adenocarcinoma	Not available	A18I-02	TRUE
13722.58cfa830e4b0c9d6adf6c298	58cfa830e4b0c9d6adf6c298	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.bam	48.65	2.08	0.16	58cfa830e4b0c9d6adf6c298	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0GY-01A	7D9D3522-EC3B-4EFE-8C8E-C0E675276EF5	Primary Tumor	Illumina HiSeq	bcac7e1b-ddeb-43d6-ba44-db40336bf564	Breast	67	A7E71EAC-1768-4FC2-8EBA-1576D22E0F43	F5C72179-9BDA-4BC6-B006-93EB616804BC	TCGA-BH-A0GY-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0GY	TCGA-BRCA	NA	s6771	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	TRUE
13722.58cfa831e4b0c9d6adf6c32f	58cfa831e4b0c9d6adf6c32f	TCGA-CG-4474-01A-02D-1154_130815_VM001_0006_VMR0006CXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4474-01A-02D-1154_130815_VM001_0006_VMR0006CXX_s_3_rg.sorted	TCGA-CG-4474-01A-02D-1154_130815_VM001_0006_VMR0006CXX_s_3_rg.sorted.bam	112.2	1.9	0.14	58cfa831e4b0c9d6adf6c32f	TCGA-CG-4474-01A-02D-1154_130815_VM001_0006_VMR0006CXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4474-01A	39DD61A8-CD17-4DF3-AE17-61E239EB00BD	Primary Tumor	Illumina HiSeq	2b986f51-b858-4e25-a6f7-cbc49e180234	Stomach	67	68D21E75-16AC-48D0-B7CA-ABFDE13DED29	A3D7BAF1-387C-4094-957E-24BD2A78ED8D	TCGA-CG-4474-01A-02D-1154-02	HG19_Broad_variant	TCGA-CG-4474	TCGA-STAD	NA	s15399	Harvard Medical School	Indivumed	Germany	NO	T4a	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6c240	58cfa830e4b0c9d6adf6c240	TCGA-BS-A0U8-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BS-A0U8-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_8_rg.sorted	TCGA-BS-A0U8-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_8_rg.sorted.bam	17.81	2.05	0.17	58cfa830e4b0c9d6adf6c240	TCGA-BS-A0U8-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0U8-10A	FB7475DF-30CC-4316-B9AC-37CBEEB6BA2B	Blood Derived Normal	Illumina HiSeq	2ab387c8-839e-4435-9f0a-51ea04594026	Uterus	55	5CA13FB8-860E-4126-B510-BBF920500533	B02F987B-C5A1-4724-8B56-3C7EA9240B73	TCGA-BS-A0U8-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0U8	TCGA-UCEC	NA	s4606	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c12e	58cfa830e4b0c9d6adf6c12e	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.bam	107.99	2	0.17	58cfa830e4b0c9d6adf6c12e	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UM-01A	A7C565FC-C711-4B63-9549-4CD74D1F57C2	Primary Tumor	Illumina HiSeq	942f9e1e-4e57-4325-a7d0-0a464cda140a	Uterus	64	6F70F18E-5C53-4F1F-A63D-62BD27039B8D	6CD1B997-3123-4934-A06C-14A5CF1BEBFC	TCGA-BS-A0UM-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UM	TCGA-UCEC	NA	s5009	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa831e4b0c9d6adf6c32b	58cfa831e4b0c9d6adf6c32b	TCGA-CG-4474-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4474-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_2_rg.sorted	TCGA-CG-4474-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_2_rg.sorted.bam	15.9	1.8	0.15	58cfa831e4b0c9d6adf6c32b	TCGA-CG-4474-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4474-10A	39DD61A8-CD17-4DF3-AE17-61E239EB00BD	Blood Derived Normal	Illumina HiSeq	a149db78-b4d7-497e-a6a0-de097c1710fc	Stomach	67	A546EC24-E8CE-4B04-B25F-A230A5EA1067	90FBAFC6-E6C2-40D3-A0A3-D1ACD2D19E64	TCGA-CG-4474-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4474	TCGA-STAD	NA	s15128	Harvard Medical School	Indivumed	Germany	NO	T4a	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c332	58cfa831e4b0c9d6adf6c332	TCGA-CG-4472-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4472-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_1_rg.sorted	TCGA-CG-4472-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_1_rg.sorted.bam	157.9	1.9	0.14	58cfa831e4b0c9d6adf6c332	TCGA-CG-4472-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_1_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4472-01A	306F0222-8734-44CA-9A31-86E4E62B0A1B	Primary Tumor	Illumina HiSeq	74cc19cf-8ff9-4786-87d9-936dcbb9196e	Stomach	49	A474CFDD-0822-42E8-A478-C0895A409CCD	8363DF43-B859-4A78-8CDE-3E06C6230EB2	TCGA-CG-4472-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4472	TCGA-STAD	NA	s14640	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Not available	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c33c	58cfa831e4b0c9d6adf6c33c	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted.bam	128.2	1.9	0.14	58cfa831e4b0c9d6adf6c33c	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4475-01A	CAD2ADC1-0F41-4651-9C80-AE9961E2DC8D	Primary Tumor	Illumina HiSeq	8d322c4d-bfdb-40cc-a222-87ff33a87718	Stomach	76	3E5D09C6-8F98-4701-BD24-FCA581343DE8	86D8A371-57BB-4DC7-9872-0EB4542208DC	TCGA-CG-4475-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4475	TCGA-STAD	NA	s14706	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Not available	Stage IIB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c33e	58cfa831e4b0c9d6adf6c33e	TCGA-CG-4474-01A-02D-1154_121026_SN1120_0198_BC188JACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4474-01A-02D-1154_121026_SN1120_0198_BC188JACXX_s_1_rg.sorted	TCGA-CG-4474-01A-02D-1154_121026_SN1120_0198_BC188JACXX_s_1_rg.sorted.bam	112.2	1.9	0.14	58cfa831e4b0c9d6adf6c33e	TCGA-CG-4474-01A-02D-1154_121026_SN1120_0198_BC188JACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4474-01A	39DD61A8-CD17-4DF3-AE17-61E239EB00BD	Primary Tumor	Illumina HiSeq	65c20199-b73c-42b2-b95a-3995b59e5d20	Stomach	67	68D21E75-16AC-48D0-B7CA-ABFDE13DED29	A3D7BAF1-387C-4094-957E-24BD2A78ED8D	TCGA-CG-4474-01A-02D-1154-02	HG19_Broad_variant	TCGA-CG-4474	TCGA-STAD	NA	s15326	Harvard Medical School	Indivumed	Germany	NO	T4a	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c35c	58cfa831e4b0c9d6adf6c35c	TCGA-CG-4475-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-4475-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_8_rg.sorted	TCGA-CG-4475-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_8_rg.sorted.bam	45.9	1.9	0.15	58cfa831e4b0c9d6adf6c35c	TCGA-CG-4475-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_8_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4475-10A	CAD2ADC1-0F41-4651-9C80-AE9961E2DC8D	Blood Derived Normal	Illumina HiSeq	8e28c3d4-9556-49b7-bde1-8f7fe76e98fa	Stomach	76	5CEA6C63-C68C-41ED-B064-9941E60F64BD	0404F559-4DA5-4935-ACB5-D2F2F7730F30	TCGA-CG-4475-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4475	TCGA-STAD	NA	s14705	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Not available	Stage IIB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c342	58cfa831e4b0c9d6adf6c342	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted.bam	128.2	1.9	0.14	58cfa831e4b0c9d6adf6c342	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4475-01A	CAD2ADC1-0F41-4651-9C80-AE9961E2DC8D	Primary Tumor	Illumina HiSeq	77dce8cf-5642-43d4-8111-4f72d2ef30ef	Stomach	76	3E5D09C6-8F98-4701-BD24-FCA581343DE8	86D8A371-57BB-4DC7-9872-0EB4542208DC	TCGA-CG-4475-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4475	TCGA-STAD	NA	s14639	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Not available	Stage IIB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c354	58cfa831e4b0c9d6adf6c354	TCGA-CG-4476-10A-01D-1154_121029_SN208_0438_AC18NJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4476-10A-01D-1154_121029_SN208_0438_AC18NJACXX_s_3_rg.sorted	TCGA-CG-4476-10A-01D-1154_121029_SN208_0438_AC18NJACXX_s_3_rg.sorted.bam	67.9	1.9	0.16	58cfa831e4b0c9d6adf6c354	TCGA-CG-4476-10A-01D-1154_121029_SN208_0438_AC18NJACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4476-10A	442D7415-D095-4962-8296-A14390BAD40A	Blood Derived Normal	Illumina HiSeq	3ed041fd-9dd4-4ac6-8681-f69faacd1552	Stomach	69	15D8F5B3-63C4-400A-83C3-49B0A68CA1EF	E6AEDF0B-5818-444A-A4F0-D374F531BDB5	TCGA-CG-4476-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4476	TCGA-STAD	NA	s14415	Harvard Medical School	Indivumed	Germany	NO	T4b	N3a	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIC	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c34c	58cfa831e4b0c9d6adf6c34c	TCGA-CG-4476-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-4476-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_8_rg.sorted	TCGA-CG-4476-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_8_rg.sorted.bam	67.9	1.9	0.16	58cfa831e4b0c9d6adf6c34c	TCGA-CG-4476-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_8_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4476-10A	442D7415-D095-4962-8296-A14390BAD40A	Blood Derived Normal	Illumina HiSeq	a6ccc4b9-9b2d-4960-900b-4e637c691eee	Stomach	69	15D8F5B3-63C4-400A-83C3-49B0A68CA1EF	E6AEDF0B-5818-444A-A4F0-D374F531BDB5	TCGA-CG-4476-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4476	TCGA-STAD	NA	s14829	Harvard Medical School	Indivumed	Germany	NO	T4b	N3a	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIC	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c38c	58cfa831e4b0c9d6adf6c38c	TCGA-CD-5803-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CD-5803-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_8_rg.sorted	TCGA-CD-5803-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_8_rg.sorted.bam	493.3	1.9	0.17	58cfa831e4b0c9d6adf6c38c	TCGA-CD-5803-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_8_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5803-10A	33901C6F-9180-4A19-866C-F4AC6BEC76DA	Blood Derived Normal	Illumina HiSeq	c5245994-d084-4ea6-b869-e4f9a02b9ad8	Stomach	78	903B78B4-31A7-48AD-825F-294F31A91BDA	773B46FD-7ED6-40A1-9434-CA1DCC7B3334	TCGA-CD-5803-10A-01D-1598-02	HG19_Broad_variant	TCGA-CD-5803	TCGA-STAD	NA	s14977	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3aa	58cfa831e4b0c9d6adf6c3aa	TCGA-CG-5723-11A-02D-1598_121011_SN208_0434_AC18MYACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CG-5723-11A-02D-1598_121011_SN208_0434_AC18MYACXX_s_6_rg.sorted	TCGA-CG-5723-11A-02D-1598_121011_SN208_0434_AC18MYACXX_s_6_rg.sorted.bam	393.3	1.9	0.14	58cfa831e4b0c9d6adf6c3aa	TCGA-CG-5723-11A-02D-1598_121011_SN208_0434_AC18MYACXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5723-11A	0F00AD32-E4BE-49D4-A02A-D233BFC913C5	Solid Tissue Normal	Illumina HiSeq	6bd76290-af9b-4812-8b89-e9a8f8416fbc	Stomach	83	CDB68733-745A-4DA9-BF49-B0E0E74A3332	E9EA0FC9-4BF4-40E1-9AA8-D3D278CD630E	TCGA-CG-5723-11A-02D-1598-02	HG19_Broad_variant	TCGA-CG-5723	TCGA-STAD	NA	s15329	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c39e	58cfa831e4b0c9d6adf6c39e	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.bam	54.44	NA	0.16	58cfa831e4b0c9d6adf6c39e	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2M1-01A	8911C80C-C903-48E4-AF5B-FFEDEF9ABC47	Primary Tumor	Illumina HiSeq	374c6310-126e-48e8-8b83-145f75714a4b	Cervix	37	065BB06F-5BB7-4F79-B374-97A3011F22AE	E2DAD681-2B26-43A0-804B-0F2DD17B1EFE	TCGA-C5-A2M1-01A-11D-A18I-02	HG19_Broad_variant	TCGA-C5-A2M1	TCGA-CESC	NA	s1518	Harvard Medical School	Medical College of Wisconsin	United States	NO	T1b1	N0	Endocervical Type of Adenocarcinoma	Not available	A18I-02	TRUE
13722.58cfa831e4b0c9d6adf6c388	58cfa831e4b0c9d6adf6c388	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted.bam	224	1.9	0.14	58cfa831e4b0c9d6adf6c388	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5723-01A	0F00AD32-E4BE-49D4-A02A-D233BFC913C5	Primary Tumor	Illumina HiSeq	9e55e0ac-b9dd-42dd-afe7-d6f93c1dcc88	Stomach	83	4CCD9CCB-BF50-44EB-AA55-133D8824C433	9A2DC75A-E7BE-4226-9D8C-940946F75958	TCGA-CG-5723-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5723	TCGA-STAD	NA	s14417	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3ac	58cfa831e4b0c9d6adf6c3ac	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted.bam	195	1.9	0.15	58cfa831e4b0c9d6adf6c3ac	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5722-01A	F35E8FEF-F61D-4614-B73F-F7E1D0F21F52	Primary Tumor	Illumina HiSeq	05762233-5294-478d-b462-14b931579f63	Stomach	67	30D63C9D-E36A-4654-86B5-5D7A622089C2	F262DDED-846F-4DEB-8FC3-EF0DF814ECA4	TCGA-CG-5722-01A-21D-1598-02	HG19_Broad_variant	TCGA-CG-5722	TCGA-STAD	NA	s14642	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3ec	58cfa831e4b0c9d6adf6c3ec	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.bam	196.7	1.9	0.14	58cfa831e4b0c9d6adf6c3ec	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5748-01A	0AF98331-9305-41E9-AF55-30390016D65E	Primary Tumor	Illumina HiSeq	02aa8440-93b8-43d7-a58b-6c4421e05321	Prostate	64	A499BF51-B137-4DA9-87A3-D1B1A0F04695	24A0496A-CA69-4AE3-BF8A-92289C738E9F	TCGA-CH-5748-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5748	TCGA-PRAD	NA	s3413	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa830e4b0c9d6adf6c210	58cfa830e4b0c9d6adf6c210	TCGA-BA-4077-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BA-4077-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_8_rg.sorted	TCGA-BA-4077-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_8_rg.sorted.bam	58.03	1.9	0.14	58cfa830e4b0c9d6adf6c210	TCGA-BA-4077-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4077-10A	4BFBCE2B-9D0B-4E8A-950F-FD8E0BA3E05A	Blood Derived Normal	Illumina HiSeq	b95aebf7-d49b-41bd-86d3-66e2ef172c88	Head and Neck	45	8C074534-49B5-4D4A-A9C8-59BFEF52A800	0687CAE5-A756-4B2F-9DA4-FD4E9C4B91B2	TCGA-BA-4077-10A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4077	TCGA-HNSC	1134	s15879	Harvard Medical School	UNC	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c3dd	58cfa831e4b0c9d6adf6c3dd	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.bam	249.7	1.9	0.15	58cfa831e4b0c9d6adf6c3dd	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5744-01A	4E76DE8E-CB0D-4B83-8AB4-53BC67A7A9D3	Primary Tumor	Illumina HiSeq	b48809ce-93ac-45d2-b127-bf6ee8bd6870	Prostate	64	DCCEAF54-0BCE-4650-9980-9843ABCE0C41	B3198EFA-5613-4B16-BA05-4F0AACCCC00F	TCGA-CH-5744-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5744	TCGA-PRAD	NA	s3771	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c3da	58cfa831e4b0c9d6adf6c3da	TCGA-CG-5726-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CG-5726-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_6_rg.sorted	TCGA-CG-5726-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_6_rg.sorted.bam	291	1.9	0.16	58cfa831e4b0c9d6adf6c3da	TCGA-CG-5726-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_6_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5726-11A	863AD936-E2A0-471C-8D95-3A548BB94AFA	Solid Tissue Normal	Illumina HiSeq	3c2e1753-936d-4794-bf43-9af5aa4b97ce	Stomach	73	EFCE3117-E72E-4E8A-BDD0-3B375C32DC4A	40A968A5-738C-441A-B374-AECE5647A083	TCGA-CG-5726-11A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5726	TCGA-STAD	881	s14836	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3fe	58cfa831e4b0c9d6adf6c3fe	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.bam	61.7	1.9	0.17	58cfa831e4b0c9d6adf6c3fe	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5792-01A	8A5F2D7F-835C-4726-B238-F82D6A7F25BD	Primary Tumor	Illumina HiSeq	1c4a46f6-fc5f-44b1-b30a-5baaa806e78b	Prostate	57	DA5F8107-7B69-45B5-8BEB-21D17B066CB4	5975F57F-2918-46C2-B59F-38FAA67A49BA	TCGA-CH-5792-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5792	TCGA-PRAD	NA	s3933	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c440	58cfa831e4b0c9d6adf6c440	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.bam	148.7	1.9	0.15	58cfa831e4b0c9d6adf6c440	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5789-01A	BE5411DC-3CAA-4B25-9B94-CE463E8E52B4	Primary Tumor	Illumina HiSeq	fc8da645-2fde-4ef8-9ee7-8b8101580793	Prostate	61	3C42EB4B-DB63-4F81-8D28-A439E932C716	1D569000-EA8E-4D54-A581-AEE36E66688E	TCGA-CH-5789-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5789	TCGA-PRAD	NA	s3779	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c45f	58cfa831e4b0c9d6adf6c45f	TCGA-CG-5728-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-5728-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_8_rg.sorted	TCGA-CG-5728-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_8_rg.sorted.bam	309	1.9	0.15	58cfa831e4b0c9d6adf6c45f	TCGA-CG-5728-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_8_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5728-11A	1286AC33-A466-4F58-900E-F6B13FE9C25A	Solid Tissue Normal	Illumina HiSeq	db35e103-ab69-44f7-b5c2-913ab5032554	Stomach	88	AE411D6A-4E7B-4B8D-B41C-5153FB5D4D25	F3D1F1F3-EECE-45D5-96AC-16FF3D85F025	TCGA-CG-5728-11A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5728	TCGA-STAD	NA	s15461	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c467	58cfa831e4b0c9d6adf6c467	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.bam	226.7	1.9	0.15	58cfa831e4b0c9d6adf6c467	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5751-01A	721E76D0-4B1D-4E78-ADB8-1344B8030062	Primary Tumor	Illumina HiSeq	c152f07f-eb7f-464d-ba51-ce1b55777952	Prostate	68	6D8CE214-3A06-4F7C-858B-709A40EBBE25	FC06702A-2C27-42FD-A925-D0DB20C358E7	TCGA-CH-5751-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5751	TCGA-PRAD	NA	s3425	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c476	58cfa831e4b0c9d6adf6c476	TCGA-CG-5727-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-5727-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_3_rg.sorted	TCGA-CG-5727-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_3_rg.sorted.bam	269	1.9	0.15	58cfa831e4b0c9d6adf6c476	TCGA-CG-5727-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5727-01A	B75EB694-8E9D-4DBB-B536-7D278C728CBB	Primary Tumor	Illumina HiSeq	3488abf3-f0fd-4eff-a75b-32457ccff3bd	Stomach	66	CD194D5F-3814-4E5E-88B6-6CF4CF491146	D2CC734B-DEE5-4345-98B0-BCCB42941669	TCGA-CG-5727-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5727	TCGA-STAD	NA	s15327	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c446	58cfa831e4b0c9d6adf6c446	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.bam	300.7	1.9	0.16	58cfa831e4b0c9d6adf6c446	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5750-01A	DC40CF49-B208-4F59-B5F0-CFBDD02970B2	Primary Tumor	Illumina HiSeq	d0338227-feec-4f2e-bcfa-89c723bb89b5	Prostate	72	0386D0E9-7BD8-467F-BA97-A379C1D67A83	E1FEA0C9-E1D6-49C2-9DFF-9DC87F7776E9	TCGA-CH-5750-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5750	TCGA-PRAD	NA	s3591	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c4b2	58cfa831e4b0c9d6adf6c4b2	TCGA-BR-6706-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-6706-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_6_rg.sorted	TCGA-BR-6706-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_6_rg.sorted.bam	471	1.9	0.15	58cfa831e4b0c9d6adf6c4b2	TCGA-BR-6706-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6706-10A	93AEBBD4-19CF-495A-B8CE-3C4A3FEBA152	Blood Derived Normal	Illumina HiSeq	f98df3e1-6bfd-4745-9c3b-412598e8d952	Stomach	63	3F76462F-9485-4382-B825-09570F0AB41F	1428A4F7-A164-4CB4-97CC-F637E6FD4FD4	TCGA-BR-6706-10A-01D-1880-02	HG19_Broad_variant	TCGA-BR-6706	TCGA-STAD	NA	s14689	Harvard Medical School	Asterand	Ukraine	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c420	58cfa831e4b0c9d6adf6c420	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted.bam	59.68	2.07	0.17	58cfa831e4b0c9d6adf6c420	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20T-01A	096B4F32-10C1-4737-A0DD-CAE04C54EE33	Primary Tumor	Illumina HiSeq	e605a62d-c633-415e-bba0-2174fd3ad94e	Bladder	63	52F538EF-B05D-4C76-9976-CE6D49158016	3929BC99-B4FC-4EB9-BDEA-1986EA49AF2A	TCGA-BT-A20T-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20T	TCGA-BLCA	453	s2871	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c590	58cfa831e4b0c9d6adf6c590	TCGA-CG-4472-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-4472-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_4_rg.sorted	TCGA-CG-4472-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_4_rg.sorted.bam	157.9	1.9	0.14	58cfa831e4b0c9d6adf6c590	TCGA-CG-4472-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4472-01A	306F0222-8734-44CA-9A31-86E4E62B0A1B	Primary Tumor	Illumina HiSeq	f1d39d03-103f-46f0-8fbf-ef9e944d68ad	Stomach	49	A474CFDD-0822-42E8-A478-C0895A409CCD	8363DF43-B859-4A78-8CDE-3E06C6230EB2	TCGA-CG-4472-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4472	TCGA-STAD	NA	s15457	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Not available	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c4c0	58cfa831e4b0c9d6adf6c4c0	TCGA-BR-4369-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-4369-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_8_rg.sorted	TCGA-BR-4369-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_8_rg.sorted.bam	67.3	1.9	0.14	58cfa831e4b0c9d6adf6c4c0	TCGA-BR-4369-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4369-11A	FE9A5FCF-FF99-4DD1-8CC7-ED9F4B9D952B	Solid Tissue Normal	Illumina HiSeq	d5894343-a206-49f1-adce-53c336fec1ee	Stomach	75	08591D7E-0482-494D-A75A-5F5201BEC02F	91E85E65-7D7D-45B1-A0B4-4CE2E1311499	TCGA-BR-4369-11A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4369	TCGA-STAD	NA	s14532	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c596	58cfa831e4b0c9d6adf6c596	TCGA-CG-4469-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-4469-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_8_rg.sorted	TCGA-CG-4469-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_8_rg.sorted.bam	23.9	1.9	0.15	58cfa831e4b0c9d6adf6c596	TCGA-CG-4469-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_8_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4469-10A	2AC986F6-CD6F-4CA5-90CC-7A105CFE85EA	Blood Derived Normal	Illumina HiSeq	8c7f32c0-34e4-4aea-8603-cce8acbc1b82	Stomach	70	0279401D-8BB4-4E90-AB5B-E0BC1F6C1709	725941B2-EABE-486D-B19D-FD215B801A8E	TCGA-CG-4469-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4469	TCGA-STAD	215	s14762	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c574	58cfa831e4b0c9d6adf6c574	TCGA-CN-4738-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-4738-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_2_rg.sorted	TCGA-CN-4738-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_2_rg.sorted.bam	52.4	1.9	0.15	58cfa831e4b0c9d6adf6c574	TCGA-CN-4738-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4738-10A	97640EF0-0259-4244-95BA-48D28C60B372	Blood Derived Normal	Illumina HiSeq	6420a19a-13dc-4a15-9792-d6c02672c4c8	Head and Neck	53	51622170-A903-43CB-BC38-4D40C7EA170F	0487F393-1CF0-4CB4-864F-FA2C895E2E07	TCGA-CN-4738-10A-01D-1509-02	HG19_Broad_variant	TCGA-CN-4738	TCGA-HNSC	436	s16182	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa831e4b0c9d6adf6c558	58cfa831e4b0c9d6adf6c558	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted.bam	7.7	1.9	0.14	58cfa831e4b0c9d6adf6c558	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4733-01A	DEDD71B4-8537-4947-839E-90ACEDDD0893	Primary Tumor	Illumina HiSeq	c1887d1c-970a-4e8d-80df-a16844daef9f	Head and Neck	61	A1FD1C9D-C763-488A-8649-FF069F56D2BE	1CB41C9B-FB04-438D-A9FB-89D6186E0D37	TCGA-CN-4733-01A-02D-1868-02	HG19_Broad_variant	TCGA-CN-4733	TCGA-HNSC	NA	s15880	Harvard Medical School	University of Pittsburgh	None	NO	T1	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6c5e5	58cfa831e4b0c9d6adf6c5e5	TCGA-CG-4306-10A-01D-1154_130815_VM001_0001_VMR0001CXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-4306-10A-01D-1154_130815_VM001_0001_VMR0001CXX_s_4_rg.sorted	TCGA-CG-4306-10A-01D-1154_130815_VM001_0001_VMR0001CXX_s_4_rg.sorted.bam	97.9	1.9	0.16	58cfa831e4b0c9d6adf6c5e5	TCGA-CG-4306-10A-01D-1154_130815_VM001_0001_VMR0001CXX_s_4_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4306-10A	73D177F7-8C0A-42F6-A73D-8073C0E6142B	Blood Derived Normal	Illumina HiSeq	c0a0bf03-12bc-447d-9f12-b8881dee8f37	Stomach	90	75F42FE8-877E-4A9C-A27D-D89E05A00B5D	8263E2A7-C76D-43CB-9229-4909E8C6BF40	TCGA-CG-4306-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4306	TCGA-STAD	31	s14702	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6c0fe	58cfa830e4b0c9d6adf6c0fe	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted.bam	31.24	2.03	0.14	58cfa830e4b0c9d6adf6c0fe	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K4-01A	A8F38E37-978B-4435-B676-E8D4C34DA909	Primary Tumor	Illumina HiSeq	a95ec772-f010-453f-b4a3-20abf1f681e3	Uterus	51	A4AC1F6E-3411-47AE-9592-513B3D32223F	4612DB59-3A8E-4F32-968A-76BCE0D4F042	TCGA-B5-A0K4-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K4	TCGA-UCEC	NA	s5389	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa831e4b0c9d6adf6c572	58cfa831e4b0c9d6adf6c572	TCGA-CN-4736-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-4736-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_3_rg.sorted	TCGA-CN-4736-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_3_rg.sorted.bam	557.4	1.9	0.14	58cfa831e4b0c9d6adf6c572	TCGA-CN-4736-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4736-10A	0FB3E5FF-54F0-43C5-9322-541BB7825E7F	Blood Derived Normal	Illumina HiSeq	c96f69ef-daa9-46cf-b34f-d7c328956edd	Head and Neck	70	206FA54C-7FB3-442A-9A50-09C5CEA8A6C7	10D1A9FE-CB75-426B-9D1D-55F21CD1A5F1	TCGA-CN-4736-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4736	TCGA-HNSC	395	s15619	Harvard Medical School	University of Pittsburgh	None	NO	T1	NX	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c616	58cfa831e4b0c9d6adf6c616	TCGA-CG-4305-10A-01D-1154_130815_VM001_0001_VMR0001CXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4305-10A-01D-1154_130815_VM001_0001_VMR0001CXX_s_2_rg.sorted	TCGA-CG-4305-10A-01D-1154_130815_VM001_0001_VMR0001CXX_s_2_rg.sorted.bam	25.9	1.9	0.15	58cfa831e4b0c9d6adf6c616	TCGA-CG-4305-10A-01D-1154_130815_VM001_0001_VMR0001CXX_s_2_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4305-10A	E0E35051-FBB4-4389-AEDB-87BDE84D21AD	Blood Derived Normal	Illumina HiSeq	a9425aae-9f82-4927-bef0-4b29926935d2	Stomach	69	E585C25B-2247-4E71-B847-3D6D73B77D26	FEA37E9C-C745-4688-96F3-77E8A42137E2	TCGA-CG-4305-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4305	TCGA-STAD	NA	s14756	Harvard Medical School	Indivumed	Germany	NO	T2a	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c650	58cfa831e4b0c9d6adf6c650	TCGA-CG-4455-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_6_rg.sorted.filtered.	WGS	TCGA-CG-4455-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_6_rg.sorted	TCGA-CG-4455-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_6_rg.sorted.bam	67.9	1.9	0.16	58cfa831e4b0c9d6adf6c650	TCGA-CG-4455-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4455-10A	8A173D98-20A1-4C84-86C1-97818E1C665A	Blood Derived Normal	Illumina HiSeq	761098d4-2b01-462b-95d1-962819d14226	Stomach	72	DDD0129D-79B1-497A-BB38-60745BD9DEB4	7E88B22D-C19E-45C9-AD0C-4951B5A361A0	TCGA-CG-4455-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4455	TCGA-STAD	NA	s14412	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c680	58cfa831e4b0c9d6adf6c680	TCGA-CG-4455-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4455-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_3_rg.sorted	TCGA-CG-4455-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_3_rg.sorted.bam	67.9	1.9	0.16	58cfa831e4b0c9d6adf6c680	TCGA-CG-4455-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4455-10A	8A173D98-20A1-4C84-86C1-97818E1C665A	Blood Derived Normal	Illumina HiSeq	b2384b4a-3f8b-482e-baa3-8ce2f162c4fb	Stomach	72	DDD0129D-79B1-497A-BB38-60745BD9DEB4	7E88B22D-C19E-45C9-AD0C-4951B5A361A0	TCGA-CG-4455-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4455	TCGA-STAD	NA	s15244	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c648	58cfa831e4b0c9d6adf6c648	TCGA-CG-4466-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CG-4466-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_6_rg.sorted	TCGA-CG-4466-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_6_rg.sorted.bam	67.9	1.9	0.15	58cfa831e4b0c9d6adf6c648	TCGA-CG-4466-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4466-10A	2F1B96B2-7031-4F7D-9490-14728D320F3E	Blood Derived Normal	Illumina HiSeq	af58bea8-9aeb-47c8-946e-6b197b06ea79	Stomach	81	2775F741-265C-4B56-9D75-AF665CCBFC8A	45323803-2E2E-4A6F-B8C7-1D74C29E9C84	TCGA-CG-4466-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4466	TCGA-STAD	NA	s14761	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c5a8	58cfa831e4b0c9d6adf6c5a8	TCGA-CN-4731-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-4731-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_8_rg.sorted	TCGA-CN-4731-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_8_rg.sorted.bam	550.4	1.9	0.15	58cfa831e4b0c9d6adf6c5a8	TCGA-CN-4731-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4731-10A	50E25A4B-2EB2-4770-9A2D-8922A1E0AB56	Blood Derived Normal	Illumina HiSeq	bb50f6f4-9a32-49a6-a81f-dca3c16699cd	Head and Neck	63	C01EE9F4-05A4-438A-BA60-0F5A92864398	C54FB259-8BCF-495A-B96B-40266CAD460F	TCGA-CN-4731-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4731	TCGA-HNSC	NA	s15756	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c690	58cfa831e4b0c9d6adf6c690	TCGA-CS-6290-10A-01D-1703_130808_SN208_0487_AC28U7ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CS-6290-10A-01D-1703_130808_SN208_0487_AC28U7ACXX_s_8_rg.sorted	TCGA-CS-6290-10A-01D-1703_130808_SN208_0487_AC28U7ACXX_s_8_rg.sorted.bam	127	1.9	0.14	58cfa831e4b0c9d6adf6c690	TCGA-CS-6290-10A-01D-1703_130808_SN208_0487_AC28U7ACXX_s_8_rg.sorted.bam	Alive	MALE	Not available	Not available	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-6290-10A	42FE260F-520B-4FAC-8C09-D2B31AED59FB	Blood Derived Normal	Illumina HiSeq	5e2f3e2f-546e-4dde-b8c7-ab81ce38c575	Brain	31	51465F70-FF73-4028-90E4-92583EECFB27	48B76CCA-E836-4296-81BB-BE7B2C5AA9F5	TCGA-CS-6290-10A-01D-1703-02	HG19_Broad_variant	TCGA-CS-6290	TCGA-LGG	NA	s8750	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6c6ea	58cfa831e4b0c9d6adf6c6ea	TCGA-CG-4442-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4442-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_1_rg.sorted	TCGA-CG-4442-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_1_rg.sorted.bam	165.2	1.9	0.14	58cfa831e4b0c9d6adf6c6ea	TCGA-CG-4442-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_1_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4442-01A	8FCCFF71-3710-4CB9-B8AF-61707AEBE5D8	Primary Tumor	Illumina HiSeq	3a08f497-17a4-4b39-87b6-680e2fa13379	Stomach	85	51927F82-2585-465B-92ED-36EF46D44FAB	7597FC80-5A3C-4999-97B2-4DCB55609CC2	TCGA-CG-4442-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4442	TCGA-STAD	NA	s14635	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c6e0	58cfa831e4b0c9d6adf6c6e0	TCGA-CG-4442-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4442-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_2_rg.sorted	TCGA-CG-4442-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_2_rg.sorted.bam	57.9	1.9	0.16	58cfa831e4b0c9d6adf6c6e0	TCGA-CG-4442-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_2_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4442-10A	8FCCFF71-3710-4CB9-B8AF-61707AEBE5D8	Blood Derived Normal	Illumina HiSeq	c3e26eec-0792-4737-ad87-9d9a95fa438f	Stomach	85	85F0304A-7ED7-4715-B1B3-655DF4C87FBF	A0B6BE92-8B83-4971-B845-D3A5DAB98106	TCGA-CG-4442-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4442	TCGA-STAD	NA	s15322	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c720	58cfa831e4b0c9d6adf6c720	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted.bam	84.4	1.9	0.13	58cfa831e4b0c9d6adf6c720	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6527-01A	CB622CD6-776D-4681-8A67-4ADDD61C66B8	Primary Tumor	Illumina HiSeq	d1534b7a-a5b2-4083-9736-d1ad62a97ad2	Stomach	62	8461CE68-3A6F-4343-8977-78448123F373	F91DFFCE-5185-4555-92EA-919E94EB9569	TCGA-D7-6527-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6527	TCGA-STAD	NA	s14496	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach Intestinal Adenocarcinoma Papillary Type	Stage II	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c6a2	58cfa831e4b0c9d6adf6c6a2	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted.bam	325.7	1.9	0.15	58cfa831e4b0c9d6adf6c6a2	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6223-01A	D9E8C707-E61A-4813-8DC0-2472E9CCF12B	Primary Tumor	Illumina HiSeq	d12d744d-5a58-4e30-bcb7-b8c033a8255d	Head and Neck	69	775DB365-3533-41D9-B635-582292B22700	6CE8A7EC-2730-49E4-81F0-47B03A54EA1A	TCGA-CQ-6223-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6223	TCGA-HNSC	NA	s16038	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c6e6	58cfa831e4b0c9d6adf6c6e6	TCGA-CN-4734-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-4734-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_1_rg.sorted	TCGA-CN-4734-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_1_rg.sorted.bam	850.4	1.9	0.15	58cfa831e4b0c9d6adf6c6e6	TCGA-CN-4734-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4734-10A	B80FDC9A-341D-4277-9664-8E8F770D9DDD	Blood Derived Normal	Illumina HiSeq	dc55020c-4480-41b1-ad6f-0295abea2b6c	Head and Neck	70	782C9013-4F6F-461B-AA33-5E60D38BFCCC	67C9A43F-0254-47C0-9AE7-B3328D75CBFA	TCGA-CN-4734-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4734	TCGA-HNSC	NA	s16321	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c6ad	58cfa831e4b0c9d6adf6c6ad	TCGA-CV-5970-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-5970-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_3_rg.sorted	TCGA-CV-5970-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_3_rg.sorted.bam	115	1.9	0.15	58cfa831e4b0c9d6adf6c6ad	TCGA-CV-5970-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5970-01A	1F6167D9-C99D-4873-8D6E-E62A1C964135	Primary Tumor	Illumina HiSeq	e7fcc1c5-e66d-4024-adb8-45def5252f1a	Head and Neck	59	4DF92618-5E63-46D7-8526-846932BCE3C2	7EBDEF16-0A0E-4DB2-AB6A-7B6115A7B739	TCGA-CV-5970-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5970	TCGA-HNSC	406	s15509	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c6fc	58cfa831e4b0c9d6adf6c6fc	TCGA-CV-5431-01A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-5431-01A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_3_rg.sorted	TCGA-CV-5431-01A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_3_rg.sorted.bam	464.7	1.8	0.15	58cfa831e4b0c9d6adf6c6fc	TCGA-CV-5431-01A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5431-01A	64BB5550-2735-4401-A0DB-58EC1020A32D	Primary Tumor	Illumina HiSeq	0cba1ad9-9899-40b0-9fa7-dc39030c04e7	Head and Neck	73	BE567C0A-3833-45D7-B846-D229A8E16E16	D751368D-5948-42EF-8C61-D24595CAC1E9	TCGA-CV-5431-01A-01D-1509-02	HG19_Broad_variant	TCGA-CV-5431	TCGA-HNSC	522	s16334	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa831e4b0c9d6adf6c76e	58cfa831e4b0c9d6adf6c76e	TCGA-D7-6518-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D7-6518-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_4_rg.sorted	TCGA-D7-6518-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_4_rg.sorted.bam	192.7	1.9	0.15	58cfa831e4b0c9d6adf6c76e	TCGA-D7-6518-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6518-10A	40E507FB-E285-424B-A98B-362E47A53E4A	Blood Derived Normal	Illumina HiSeq	3158223f-89b3-425b-8b91-8b386fd4e604	Stomach	75	5D912F1D-3670-4A62-802F-F0AA3CECC6A9	529E5313-06C5-4F25-91A1-C76C0AA4FBA3	TCGA-D7-6518-10A-01D-1798-02	HG19_Broad_variant	TCGA-D7-6518	TCGA-STAD	NA	s15132	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c748	58cfa831e4b0c9d6adf6c748	TCGA-CV-6959-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-6959-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_4_rg.sorted	TCGA-CV-6959-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_4_rg.sorted.bam	264.7	1.9	0.13	58cfa831e4b0c9d6adf6c748	TCGA-CV-6959-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6959-01A	EF3CE0E5-D2E8-4616-8B1A-A78C591CF235	Primary Tumor	Illumina HiSeq	ff9553cc-07a7-497f-be70-1ad5b8e09130	Head and Neck	48	07FB167A-3F61-4517-A79E-BA2042F10A3A	E1D21CB1-4329-447E-AC5B-EC31BF045495	TCGA-CV-6959-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6959	TCGA-HNSC	256	s15903	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c7d4	58cfa831e4b0c9d6adf6c7d4	TCGA-D7-6519-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D7-6519-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_6_rg.sorted	TCGA-D7-6519-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_6_rg.sorted.bam	331.7	1.9	0.15	58cfa831e4b0c9d6adf6c7d4	TCGA-D7-6519-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6519-10A	E37CAE9E-0656-4B89-B326-739A5CC859E0	Blood Derived Normal	Illumina HiSeq	95e3ee3b-6ed5-4d0d-a7a9-64ae3139dab4	Stomach	64	AC4792AA-4989-43F5-A9D2-B82B25490F38	5820AD02-BC44-4840-A3EC-5749EBC0C719	TCGA-D7-6519-10A-01D-1798-02	HG19_Broad_variant	TCGA-D7-6519	TCGA-STAD	NA	s15330	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIB	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c79e	58cfa831e4b0c9d6adf6c79e	TCGA-CN-6019-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-6019-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_8_rg.sorted	TCGA-CN-6019-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_8_rg.sorted.bam	473.7	1.9	0.17	58cfa831e4b0c9d6adf6c79e	TCGA-CN-6019-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6019-10A	EE3061EC-273C-4BEF-A325-35E9C469BF01	Blood Derived Normal	Illumina HiSeq	7b49ae2c-674f-4f8f-b99b-fd2884c78a1b	Head and Neck	61	71ABA174-1006-4B0E-96FA-EF1BF171314B	2138A253-33D1-4402-8F65-BBE6F609AB58	TCGA-CN-6019-10A-01D-1681-02	HG19_Broad_variant	TCGA-CN-6019	TCGA-HNSC	NA	s15761	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c7a6	58cfa831e4b0c9d6adf6c7a6	TCGA-D1-A174-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D1-A174-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_7_rg.sorted	TCGA-D1-A174-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_7_rg.sorted.bam	25.16	1.39	0.17	58cfa831e4b0c9d6adf6c7a6	TCGA-D1-A174-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A174-10A	FC7315B0-9F48-4206-B197-2268C0518EB4	Blood Derived Normal	Illumina HiSeq	7bc53b59-d263-430d-89c8-bd97fad697f4	Uterus	51	DF9A1F44-9B3F-48B2-96AF-54AAABDFD243	0182D4E1-F835-46B5-A8F0-53DECF5868DE	TCGA-D1-A174-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A174	TCGA-UCEC	NA	s4799	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c7fb	58cfa831e4b0c9d6adf6c7fb	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted.bam	423.4	1.9	0.15	58cfa831e4b0c9d6adf6c7fb	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6526-01A	A28E57E2-9071-4558-856A-162F7A837380	Primary Tumor	Illumina HiSeq	0a9e4a52-46b9-4c50-9dd3-9418ed5569e2	Stomach	67	DDCEA84E-3135-445C-BA0D-62F686463797	737041EA-9798-4D2E-9C0B-371F533E058F	TCGA-D7-6526-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6526	TCGA-STAD	NA	s15251	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c792	58cfa831e4b0c9d6adf6c792	TCGA-CV-6003-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-6003-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_8_rg.sorted	TCGA-CV-6003-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_8_rg.sorted.bam	35	1.8	0.14	58cfa831e4b0c9d6adf6c792	TCGA-CV-6003-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6003-11A	417B357E-C90E-4B63-AE7A-4B782038FFD3	Solid Tissue Normal	Illumina HiSeq	ee070c27-f11a-4e98-9b45-ccc7d38c8241	Head and Neck	50	2B487266-919F-45DF-B7DD-1E60E063FF80	921977EE-19C0-4DEF-BF18-3493D6054677	TCGA-CV-6003-11A-01D-1681-02	HG19_Broad_variant	TCGA-CV-6003	TCGA-HNSC	NA	s15510	Harvard Medical School	MD Anderson Cancer Center	None	NO	T2	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c814	58cfa831e4b0c9d6adf6c814	TCGA-D1-A16R-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_8_rg.sorted.filtered.	WGS	TCGA-D1-A16R-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_8_rg.sorted	TCGA-D1-A16R-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_8_rg.sorted.bam	13.73	1.9	0.16	58cfa831e4b0c9d6adf6c814	TCGA-D1-A16R-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16R-10A	40F43483-B504-4EA7-AD24-40682B10CAAC	Blood Derived Normal	Illumina HiSeq	45cdae94-4e58-421e-8995-cd60304a0aa5	Uterus	39	14C95800-0B29-4BF0-BD36-1401A542E859	1073455E-5418-45D4-9D15-08EDE3D0248F	TCGA-D1-A16R-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A16R	TCGA-UCEC	NA	s4265	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c889	58cfa831e4b0c9d6adf6c889	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted.bam	198.4	1.9	0.15	58cfa831e4b0c9d6adf6c889	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6525-01A	82F9A197-040D-4C5E-89D9-D87A7AA0168D	Primary Tumor	Illumina HiSeq	03097d75-d0ad-4e1e-8a9b-5157a768cc05	Stomach	58	C1AC6717-828B-4289-9755-7C56A6FC1392	26A09728-CA75-4E29-A222-0826899E0800	TCGA-D7-6525-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6525	TCGA-STAD	NA	s14493	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c7dd	58cfa831e4b0c9d6adf6c7dd	TCGA-CV-6933-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-6933-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_3_rg.sorted	TCGA-CV-6933-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_3_rg.sorted.bam	361.7	1.9	0.15	58cfa831e4b0c9d6adf6c7dd	TCGA-CV-6933-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6933-01A	2A749317-0156-4213-8482-B2C2D6E52E9B	Primary Tumor	Illumina HiSeq	76d94513-c228-445e-91f7-474a75422b69	Head and Neck	53	8C57C9E6-75BD-442C-984D-3709D2AC4CEC	662EA9EC-86E3-46EE-91C9-6972DA5B5CA1	TCGA-CV-6933-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6933	TCGA-HNSC	2741	s15516	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c834	58cfa831e4b0c9d6adf6c834	TCGA-D1-A17D-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_8_rg.sorted.filtered.	WGS	TCGA-D1-A17D-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_8_rg.sorted	TCGA-D1-A17D-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_8_rg.sorted.bam	28.05	2.02	0.17	58cfa831e4b0c9d6adf6c834	TCGA-D1-A17D-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17D-10A	7DDEDDD1-B2AD-425F-94A2-9C476B959F2A	Blood Derived Normal	Illumina HiSeq	4d8ddec6-ce87-4279-80bf-9cbbee45d1e7	Uterus	58	E1C4F986-0667-4B47-9BEE-2C6BF81A45EE	CE8CB6B1-B049-43B7-BDB4-8038DC57CF25	TCGA-D1-A17D-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A17D	TCGA-UCEC	NA	s5225	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c83f	58cfa831e4b0c9d6adf6c83f	TCGA-D1-A177-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A177-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_4_rg.sorted	TCGA-D1-A177-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_4_rg.sorted.bam	21.02	1.36	0.17	58cfa831e4b0c9d6adf6c83f	TCGA-D1-A177-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A177-10A	E8C58D8B-51D7-4599-AF79-469EE6F269DB	Blood Derived Normal	Illumina HiSeq	ab2de74e-7320-4840-9096-c45534d1108c	Uterus	70	AAD4247B-3621-4856-8A51-46D2BA4EF136	2F3DDA0F-FFD2-4847-B352-83C8708B5B2D	TCGA-D1-A177-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A177	TCGA-UCEC	NA	s4802	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c844	58cfa831e4b0c9d6adf6c844	TCGA-D1-A17U-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D1-A17U-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_6_rg.sorted	TCGA-D1-A17U-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_6_rg.sorted.bam	26.88	1.95	0.17	58cfa831e4b0c9d6adf6c844	TCGA-D1-A17U-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17U-10A	6397C4A1-0A29-4C2C-B8CB-CE73AF93DD0B	Blood Derived Normal	Illumina HiSeq	02e3a4e4-e14c-48a7-9e6a-b797f4038cd9	Uterus	53	B0D7D8A8-D95E-48C0-A830-2C819403A91D	335F31BC-2F12-4A6D-9E5E-F91338544F54	TCGA-D1-A17U-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A17U	TCGA-UCEC	NA	s4804	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c8a6	58cfa831e4b0c9d6adf6c8a6	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted.bam	266.4	1.9	0.14	58cfa831e4b0c9d6adf6c8a6	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6519-01A	E37CAE9E-0656-4B89-B326-739A5CC859E0	Primary Tumor	Illumina HiSeq	66b2b99b-ac75-4068-9d05-34e6dbe9721d	Stomach	64	FA7426E1-FCFB-4B08-AD50-1D9E903A81FB	D7D0FD1C-F540-4BE1-A10B-160F59970FFF	TCGA-D7-6519-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6519	TCGA-STAD	NA	s15249	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIB	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c902	58cfa831e4b0c9d6adf6c902	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted.bam	64	1.9	0.15	58cfa831e4b0c9d6adf6c902	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5273-01A	AE2DB022-EB4F-4B65-89B6-9FD4439DDEEF	Primary Tumor	Illumina HiSeq	844bcbca-fe48-4dee-be69-4cef2ac59e27	Brain	33	4BA48810-3915-4567-9D35-615DF00006E4	6F0ACC8E-2A73-4B08-AAA3-A29EBE61E6B7	TCGA-DB-5273-01A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5273	TCGA-LGG	NA	s8751	Harvard Medical School	Mayo Clinic - Rochester	United States	NO	Not available	Not available	Astrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c870	58cfa831e4b0c9d6adf6c870	TCGA-D1-A16N-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D1-A16N-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_6_rg.sorted	TCGA-D1-A16N-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_6_rg.sorted.bam	29.65	1.35	0.18	58cfa831e4b0c9d6adf6c870	TCGA-D1-A16N-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16N-10A	DBBBDDAE-D711-40F5-BD10-863735885B1F	Blood Derived Normal	Illumina HiSeq	698a6ab3-cc32-4d8b-b438-d175d822590a	Uterus	51	4FF10030-A754-4B81-A6FD-A78C95B29CA8	2804E329-FB93-4BD5-9DCC-30DD37FA1ED5	TCGA-D1-A16N-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A16N	TCGA-UCEC	NA	s5397	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c8a0	58cfa831e4b0c9d6adf6c8a0	TCGA-DJ-A1QH-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DJ-A1QH-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_8_rg.sorted	TCGA-DJ-A1QH-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_8_rg.sorted.bam	61.2	2.13	0.17	58cfa831e4b0c9d6adf6c8a0	TCGA-DJ-A1QH-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QH-10A	F3C73DC9-6280-4619-A629-B575FDBDB0CA	Blood Derived Normal	Illumina HiSeq	46267199-5c17-4cc1-bf0e-2637d85dd2b2	Thyroid	58	933EC9D6-5A60-4969-B718-68D1A98B672E	EC86C465-E3B7-44A3-8A2B-D5326717A4E5	TCGA-DJ-A1QH-10A-01D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QH	TCGA-THCA	NA	s12375	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c8b6	58cfa831e4b0c9d6adf6c8b6	TCGA-DO-A1JZ-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DO-A1JZ-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_7_rg.sorted	TCGA-DO-A1JZ-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_7_rg.sorted.bam	15.3	1.84	0.18	58cfa831e4b0c9d6adf6c8b6	TCGA-DO-A1JZ-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_7_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DO-A1JZ-10A	169F045F-1739-4B0B-9BDC-028AACA420F8	Blood Derived Normal	Illumina HiSeq	b48c4339-fe64-4f48-a8d8-ab17a38fdb94	Thyroid	23	E85615F8-007A-4BF9-BD95-DC75A3D544A7	86EC9DCE-0309-4F8E-8340-6CF31CB6F4E0	TCGA-DO-A1JZ-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DO-A1JZ	TCGA-THCA	NA	s12244	Harvard Medical School	Medical College of Georgia	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c908	58cfa831e4b0c9d6adf6c908	TCGA-DK-A1AA-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DK-A1AA-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_4_rg.sorted	TCGA-DK-A1AA-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_4_rg.sorted.bam	46.88	1.88	0.15	58cfa831e4b0c9d6adf6c908	TCGA-DK-A1AA-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AA-10A	56D8A1B8-1268-4362-A7F1-77B76FBF1B59	Blood Derived Normal	Illumina HiSeq	c6b09f3f-3fe9-4d73-a1d9-c6ce0084ac1e	Bladder	57	C976B658-9A59-4205-93FF-E1AAD1995C49	EB9F2A7C-67B3-4B46-9196-6596C8C5832B	TCGA-DK-A1AA-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AA	TCGA-BLCA	NA	s3283	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c90d	58cfa831e4b0c9d6adf6c90d	TCGA-DK-A1A7-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DK-A1A7-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_2_rg.sorted	TCGA-DK-A1A7-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_2_rg.sorted.bam	64.01	1.91	0.17	58cfa831e4b0c9d6adf6c90d	TCGA-DK-A1A7-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A7-10A	3ED614E7-F356-4D87-985B-D3BBBAE3BB40	Blood Derived Normal	Illumina HiSeq	28afea94-fe9b-4212-8f6a-5b75af1905dd	Bladder	67	7C9BD4C3-A3EF-495E-B37C-5CD329D16A18	8781CB17-9E67-45BC-9B5E-2B9B41C297C7	TCGA-DK-A1A7-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A7	TCGA-BLCA	NA	s3106	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c8a2	58cfa831e4b0c9d6adf6c8a2	TCGA-DQ-5631-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DQ-5631-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_2_rg.sorted	TCGA-DQ-5631-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_2_rg.sorted.bam	207.7	1.9	0.14	58cfa831e4b0c9d6adf6c8a2	TCGA-DQ-5631-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5631-01A	10B3F56A-E61E-486B-8D3C-176668D5DC34	Primary Tumor	Illumina HiSeq	9aae2925-69ec-44f9-bc1d-bfefd16ce242	Head and Neck	52	2E4AA773-6094-46BD-A97F-9694E80C71CF	5B9E894B-444B-4DCF-9E6C-C1F398A52A81	TCGA-DQ-5631-01A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5631	TCGA-HNSC	548	s15916	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6c8c8	58cfa831e4b0c9d6adf6c8c8	TCGA-CV-6952-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-6952-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_1_rg.sorted	TCGA-CV-6952-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_1_rg.sorted.bam	111.7	1.9	0.15	58cfa831e4b0c9d6adf6c8c8	TCGA-CV-6952-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6952-01A	7ED006E8-461F-4664-BFFF-55FA6812743C	Primary Tumor	Illumina HiSeq	7145e1a2-e609-45d9-a111-efe59656286d	Head and Neck	65	18E70193-5D78-41DD-9FCA-AF5E54594AD3	EAA6BAF6-1D90-471D-BBFF-2230B87339E4	TCGA-CV-6952-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6952	TCGA-HNSC	185	s15647	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c90c	58cfa831e4b0c9d6adf6c90c	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted.bam	16.46	NA	0.14	58cfa831e4b0c9d6adf6c90c	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2HX-01A	C728FAC9-5452-4759-A4ED-A366E0F757CB	Primary Tumor	Illumina HiSeq	17e4edb9-ac80-43de-a7c1-66edf1201ac0	Bladder	80	537F3FE6-4E8E-4570-827A-0F5CAB193BE0	4BAFEFB4-28D5-4126-B6B7-AE5B0D03F05D	TCGA-DK-A2HX-01A-12D-A18D-02	HG19_Broad_variant	TCGA-DK-A2HX	TCGA-BLCA	NA	s2712	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A18D-02	TRUE
13722.58cfa831e4b0c9d6adf6c912	58cfa831e4b0c9d6adf6c912	TCGA-DK-A2I2-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A2I2-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_3_rg.sorted	TCGA-DK-A2I2-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_3_rg.sorted.bam	49.35	NA	0.16	58cfa831e4b0c9d6adf6c912	TCGA-DK-A2I2-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2I2-01A	234086DD-5A74-4FF1-94AB-BAD43EE69D5C	Primary Tumor	Illumina HiSeq	99517da2-f39e-4005-8efc-4487b92c0dcc	Bladder	63	45F8E4B6-5D36-47D7-A77D-E5E4C15848B3	767D7AA5-093D-48AB-BCDA-92729F4B95B7	TCGA-DK-A2I2-01A-11D-A17R-02	HG19_Broad_variant	TCGA-DK-A2I2	TCGA-BLCA	237	s2708	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17R-02	TRUE
13722.58cfa831e4b0c9d6adf6c91b	58cfa831e4b0c9d6adf6c91b	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted.bam	37.09	NA	0.15	58cfa831e4b0c9d6adf6c91b	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2I1-01A	036B9681-AB58-4734-A8FD-E0D5D078BF5A	Primary Tumor	Illumina HiSeq	724308ea-3fa9-4762-9800-445a044e94f2	Bladder	73	F9BD70B2-6CDE-48E5-9F0D-55D86CCFEBA8	010259EE-2667-4B8E-BB20-0F75F53A64BA	TCGA-DK-A2I1-01A-11D-A17R-02	HG19_Broad_variant	TCGA-DK-A2I1	TCGA-BLCA	NA	s2704	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	TRUE
13722.58cfa831e4b0c9d6adf6c936	58cfa831e4b0c9d6adf6c936	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted.bam	37.7	1.95	0.15	58cfa831e4b0c9d6adf6c936	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16E-01A	E70465F6-1922-4EB7-B646-8B01AD3CE77B	Primary Tumor	Illumina HiSeq	d5fd8d77-e4f4-4b13-b244-0dbbc2f74021	Uterus	73	58FC1E66-39C4-44D1-BDD3-338E0D833792	0651FC75-DFFC-4271-8832-2DB47C642804	TCGA-D1-A16E-01A-22D-A12F-02	HG19_Broad_variant	TCGA-D1-A16E	TCGA-UCEC	NA	s4439	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6ca1b	58cfa831e4b0c9d6adf6ca1b	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted.bam	57.02	NA	0.16	58cfa831e4b0c9d6adf6ca1b	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2I6-01A	DE810AF0-4C18-4E8F-9836-F8ABC425E3EB	Primary Tumor	Illumina HiSeq	6567cd2d-a1e5-4226-9239-77c48c09c55e	Bladder	81	A536F8F9-3A68-4792-880D-387D78FD0C66	B791021D-173E-4B08-8769-A9F289818D11	TCGA-DK-A2I6-01A-12D-A18D-02	HG19_Broad_variant	TCGA-DK-A2I6	TCGA-BLCA	NA	s2703	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A18D-02	TRUE
13722.58cfa831e4b0c9d6adf6c92a	58cfa831e4b0c9d6adf6c92a	TCGA-CN-6017-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CN-6017-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_6_rg.sorted	TCGA-CN-6017-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_6_rg.sorted.bam	384.7	1.9	0.16	58cfa831e4b0c9d6adf6c92a	TCGA-CN-6017-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6017-10A	23C4E2EB-142B-4FCC-A974-9A248AEC3F37	Blood Derived Normal	Illumina HiSeq	553eeabf-a561-46bd-8f08-ad29986c1766	Head and Neck	55	EE520EE4-84F7-4CA2-B513-67C76368991E	088B8668-613A-4864-8C03-EA150C4E5AAE	TCGA-CN-6017-10A-01D-1681-02	HG19_Broad_variant	TCGA-CN-6017	TCGA-HNSC	NA	s16034	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6cae8	58cfa831e4b0c9d6adf6cae8	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted.bam	52.7	1.9	0.14	58cfa831e4b0c9d6adf6cae8	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6522-01A	8BB3FACB-1933-4350-9F78-74537559E000	Primary Tumor	Illumina HiSeq	ac3cc7c3-e03a-4218-b297-d6c525338753	Stomach	58	825AE87A-69C0-44AC-A1AF-D1FAD7746C05	030D9DF5-48AB-46F4-AC23-F299A069191C	TCGA-D7-6522-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6522	TCGA-STAD	NA	s15197	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c98b	58cfa831e4b0c9d6adf6c98b	TCGA-DJ-A1QL-10A-01D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DJ-A1QL-10A-01D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_3_rg.sorted	TCGA-DJ-A1QL-10A-01D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_3_rg.sorted.bam	21.22	1.98	0.16	58cfa831e4b0c9d6adf6c98b	TCGA-DJ-A1QL-10A-01D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QL-10A	E4B08E66-0772-4956-8670-E5C6553EECBE	Blood Derived Normal	Illumina HiSeq	72e4c07c-b432-4b1b-a6d3-b48c1c758af3	Thyroid	70	4A3FF681-4C8C-43DA-BFC7-9CF2598375B4	7160E4B1-ED02-4BB5-A8C9-6DE807D0B976	TCGA-DJ-A1QL-10A-01D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QL	TCGA-THCA	NA	s12242	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cac4	58cfa831e4b0c9d6adf6cac4	TCGA-E1-5303-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-E1-5303-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_4_rg.sorted	TCGA-E1-5303-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_4_rg.sorted.bam	24.4	1.9	0.17	58cfa831e4b0c9d6adf6cac4	TCGA-E1-5303-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-E1-5303-10A	44A5C3B4-62A7-407B-B492-7069E1A43A26	Blood Derived Normal	Illumina HiSeq	9d733e32-c2c8-481d-a4d1-ff87fd9a342f	Brain	38	3CE7EAD9-20C2-44B3-96F7-8425AE307CD6	4A280202-B193-4C9E-A33F-6272D77A2666	TCGA-E1-5303-10A-01D-1465-02	HG19_Broad_variant	TCGA-E1-5303	TCGA-LGG	2052	s8140	Harvard Medical School	Duke	United States	NO	Not available	Not available	Astrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6cb0a	58cfa831e4b0c9d6adf6cb0a	TCGA-DU-6408-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DU-6408-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_7_rg.sorted	TCGA-DU-6408-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_7_rg.sorted.bam	78	1.9	0.15	58cfa831e4b0c9d6adf6cb0a	TCGA-DU-6408-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6408-10A	14375753-A69F-41E0-B910-2BB8E84CC43A	Blood Derived Normal	Illumina HiSeq	8157eb3b-a140-425c-af13-e727b719c9ec	Brain	23	BD47E91E-1D28-4890-8596-6493EA7C8639	72A17A30-A2A6-4077-92FB-FBAEBA75E266	TCGA-DU-6408-10A-01D-1703-02	HG19_Broad_variant	TCGA-DU-6408	TCGA-LGG	3470	s8139	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6ca8a	58cfa831e4b0c9d6adf6ca8a	TCGA-DU-6399-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DU-6399-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_2_rg.sorted	TCGA-DU-6399-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_2_rg.sorted.bam	51	1.9	0.14	58cfa831e4b0c9d6adf6ca8a	TCGA-DU-6399-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6399-10A	4EF429BE-C345-4258-9B42-B56E215E1A2C	Blood Derived Normal	Illumina HiSeq	f4761372-b118-4406-97da-d7c39196df5e	Brain	54	A552CE70-38B2-4ED3-9DB8-B61EB91F537E	49C50948-0F65-4CDB-B8F1-A9E0987D775B	TCGA-DU-6399-10A-01D-1703-02	HG19_Broad_variant	TCGA-DU-6399	TCGA-LGG	2000	s8133	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6cb14	58cfa831e4b0c9d6adf6cb14	TCGA-DU-6405-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DU-6405-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_5_rg.sorted	TCGA-DU-6405-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_5_rg.sorted.bam	22	2.6	0.15	58cfa831e4b0c9d6adf6cb14	TCGA-DU-6405-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6405-10A	9239A22E-80B1-49A2-B0D5-CBAB7E415254	Blood Derived Normal	Illumina HiSeq	107b4f56-260b-41d1-85fc-a6746e87ca0e	Brain	51	D2389FBB-2FCA-4A1B-8992-3DB9B9BF6FBB	D0282997-6C05-4DF5-B79B-48E0788F2332	TCGA-DU-6405-10A-01D-1703-02	HG19_Broad_variant	TCGA-DU-6405	TCGA-LGG	605	s8138	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6cba2	58cfa831e4b0c9d6adf6cba2	TCGA-EJ-5519-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-5519-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_2_rg.sorted	TCGA-EJ-5519-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_2_rg.sorted.bam	763.4	1.9	0.17	58cfa831e4b0c9d6adf6cba2	TCGA-EJ-5519-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5519-10A	5313A055-C2D7-4CBD-A8C1-57AC85912D89	Blood Derived Normal	Illumina HiSeq	79a51d91-ec23-4cd1-be9c-59457bbad94a	Prostate	64	0ED92655-C273-4638-98F7-0BEE62811238	8FD697D8-1093-4960-99FD-9F803E59E92A	TCGA-EJ-5519-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5519	TCGA-PRAD	NA	s3951	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cbba	58cfa831e4b0c9d6adf6cbba	TCGA-EJ-5542-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-5542-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_6_rg.sorted	TCGA-EJ-5542-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_6_rg.sorted.bam	389.4	1.9	0.15	58cfa831e4b0c9d6adf6cbba	TCGA-EJ-5542-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5542-10A	5A92EC4C-36EE-4588-ACA2-E3303F29C7AD	Blood Derived Normal	Illumina HiSeq	1e52051f-16ba-40b2-bbf3-8cf3fd858f90	Prostate	60	5D13A5E3-AD75-40BA-A3B4-C7BCF53A1E1F	093883AA-B9C6-4416-9B8D-CF280DB8BEF5	TCGA-EJ-5542-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5542	TCGA-PRAD	NA	s3963	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cbab	58cfa831e4b0c9d6adf6cbab	TCGA-EK-A2PL-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EK-A2PL-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_5_rg.sorted	TCGA-EK-A2PL-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_5_rg.sorted.bam	17.04	NA	0.15	58cfa831e4b0c9d6adf6cbab	TCGA-EK-A2PL-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2PL-10A	45CADCF3-EA98-4063-9255-5C18D6A5CBAB	Blood Derived Normal	Illumina HiSeq	b844ef40-47ec-47f7-a517-bb3a171bfc7f	Cervix	36	62FEC159-331A-48EE-A6C4-19DE841FF7CE	EFD4F564-9625-4D10-87CC-F9B6079260EE	TCGA-EK-A2PL-10A-01D-A18I-02	HG19_Broad_variant	TCGA-EK-A2PL	TCGA-CESC	NA	s1369	Harvard Medical School	Gynecologic Oncology Group	United States	NO	Not available	Not available	Cervical Squamous Cell Carcinoma	Not available	A18I-02	TRUE
13722.58cfa831e4b0c9d6adf6cba0	58cfa831e4b0c9d6adf6cba0	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted.bam	233.7	1.9	0.15	58cfa831e4b0c9d6adf6cba0	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5519-01A	5313A055-C2D7-4CBD-A8C1-57AC85912D89	Primary Tumor	Illumina HiSeq	75f448c7-b10b-4c15-ae49-4eb217c65391	Prostate	64	EEE1828E-D25F-462B-9735-89CA2ECCC7E1	4C2E88A3-B668-40A8-B625-B6D7A48DEAF5	TCGA-EJ-5519-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5519	TCGA-PRAD	NA	s3949	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cc40	58cfa831e4b0c9d6adf6cc40	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted.bam	66.58	NA	0.17	58cfa831e4b0c9d6adf6cc40	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2R7-01A	D7A75BF5-5189-4978-99D9-FCEF91C9FBD2	Primary Tumor	Illumina HiSeq	b998e76d-dff1-4454-abce-bbe7b5a6c398	Cervix	45	EE9A22DF-8612-4B71-AF3A-6B16C73197EA	9C763A04-CC5B-41E1-A5AC-2CB06B9E80C3	TCGA-EK-A2R7-01A-11D-A18I-02	HG19_Broad_variant	TCGA-EK-A2R7	TCGA-CESC	NA	s1526	Harvard Medical School	Gynecologic Oncology Group	United States	NO	T1b1	N1	Cervical Squamous Cell Carcinoma	Not available	A18I-02	TRUE
13722.58cfa831e4b0c9d6adf6cb4f	58cfa831e4b0c9d6adf6cb4f	TCGA-EE-A20H-10A-01D-A190_120805_SN1222_0142_AD16TGACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EE-A20H-10A-01D-A190_120805_SN1222_0142_AD16TGACXX_s_2_rg.sorted	TCGA-EE-A20H-10A-01D-A190_120805_SN1222_0142_AD16TGACXX_s_2_rg.sorted.bam	41.34	NA	0.18	58cfa831e4b0c9d6adf6cb4f	TCGA-EE-A20H-10A-01D-A190_120805_SN1222_0142_AD16TGACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A20H-10A	267B98E7-708F-458A-82D1-5FAA415B9EE7	Blood Derived Normal	Illumina HiSeq	6bf8f988-3d85-4446-9a80-aae5d73a3ca1	Skin	56	FEED8018-70BD-461B-80CF-77AEA0C0D906	E202F603-4E1E-451B-AE65-78F232D7162D	TCGA-EE-A20H-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A20H	TCGA-SKCM	5118	s7338	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc5c	58cfa831e4b0c9d6adf6cc5c	TCGA-EJ-5502-01A-01D-1572_130329_SN590_0221_BD1WHDACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5502-01A-01D-1572_130329_SN590_0221_BD1WHDACXX_s_5_rg.sorted	TCGA-EJ-5502-01A-01D-1572_130329_SN590_0221_BD1WHDACXX_s_5_rg.sorted.bam	238.7	1.9	0.17	58cfa831e4b0c9d6adf6cc5c	TCGA-EJ-5502-01A-01D-1572_130329_SN590_0221_BD1WHDACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5502-01A	48E83A4C-C602-494A-80CD-E2F4B4DD701E	Primary Tumor	Illumina HiSeq	40f605db-50a6-4ed1-b652-61045959ba2e	Prostate	50	D36A0B54-6E09-4EE2-923B-C1516D78BB03	0432A271-DB73-434C-971A-B3B2C3FD2285	TCGA-EJ-5502-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5502	TCGA-PRAD	NA	s3785	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cba4	58cfa831e4b0c9d6adf6cba4	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted.bam	72.7	1.9	0.14	58cfa831e4b0c9d6adf6cba4	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5521-01A	D44D4BCB-BEB1-4464-ACD2-9972751F5018	Primary Tumor	Illumina HiSeq	c9a43591-8317-4ff5-a2e9-33c98c6a6012	Prostate	63	9EEBD2EC-AF9D-493C-A006-A436C28D4CD3	83248990-416D-48F0-B6F4-59C4C7CEEBD8	TCGA-EJ-5521-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5521	TCGA-PRAD	NA	s4134	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cc68	58cfa831e4b0c9d6adf6cc68	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted.bam	58.64	NA	0.17	58cfa831e4b0c9d6adf6cc68	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2R8-01A	D4510801-8CE4-4F10-8B31-25C0A39B5135	Primary Tumor	Illumina HiSeq	d050a7c3-8fe5-472e-bc71-4dff85991e92	Cervix	48	6B8E0AF3-1632-4FED-9A37-879EA013AE24	80B2C20E-8EFB-4105-8A96-A695FCFB73CB	TCGA-EK-A2R8-01A-21D-A18I-02	HG19_Broad_variant	TCGA-EK-A2R8	TCGA-CESC	NA	s1190	Harvard Medical School	Gynecologic Oncology Group	United States	NO	T1b2	N1	Cervical Squamous Cell Carcinoma	Not available	A18I-02	TRUE
13722.58cfa831e4b0c9d6adf6cb4b	58cfa831e4b0c9d6adf6cb4b	TCGA-EE-A2A6-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EE-A2A6-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_1_rg.sorted	TCGA-EE-A2A6-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_1_rg.sorted.bam	65.73	NA	0.16	58cfa831e4b0c9d6adf6cb4b	TCGA-EE-A2A6-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2A6-06A	CDCF4D91-98A1-4A65-98DD-C6FC80805A0C	Metastatic	Illumina HiSeq	6d7d5e8e-5581-42f1-9c7f-72f105da496d	Skin	43	5BB8D694-E4C5-4B02-91D6-B152DCDBA345	3C47A989-E13A-436B-8F57-783B8628D6C9	TCGA-EE-A2A6-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2A6	TCGA-SKCM	NA	s7680	Harvard Medical School	University of Sydney	Australia	NO	T1a	N0	Not available	Stage IA	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb3e	58cfa831e4b0c9d6adf6cb3e	TCGA-EE-A2GC-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EE-A2GC-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_7_rg.sorted	TCGA-EE-A2GC-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_7_rg.sorted.bam	24.03	NA	0.17	58cfa831e4b0c9d6adf6cb3e	TCGA-EE-A2GC-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GC-10A	0A4B780E-8143-4118-AD98-FD2A2A6678C3	Blood Derived Normal	Illumina HiSeq	5949ea6f-17c0-4445-98ef-38a1e483e726	Skin	82	50CBA159-A844-4EBE-B07B-AD9C5F0347EC	E79FDD40-B36B-4C39-B808-39FF4CCE3B6E	TCGA-EE-A2GC-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2GC	TCGA-SKCM	NA	s7684	Harvard Medical School	University of Sydney	Australia	NO	T3b	N0	Not available	Stage IIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ccca	58cfa831e4b0c9d6adf6ccca	TCGA-EJ-5497-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-5497-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_6_rg.sorted	TCGA-EJ-5497-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_6_rg.sorted.bam	1203.4	1.9	0.16	58cfa831e4b0c9d6adf6ccca	TCGA-EJ-5497-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5497-10A	DEE02265-D8DD-4379-AE08-72D72B03A570	Blood Derived Normal	Illumina HiSeq	e9e5af5e-fd0b-4048-9b62-94b0e5e932b8	Prostate	47	52A73803-24FD-4723-ADA2-73010373F825	395FCF15-E902-43EF-83CB-3F46C7CA0F19	TCGA-EJ-5497-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5497	TCGA-PRAD	NA	s3606	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cc74	58cfa831e4b0c9d6adf6cc74	TCGA-ER-A19K-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_5_rg.sorted.filtered.	WGS	TCGA-ER-A19K-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_5_rg.sorted	TCGA-ER-A19K-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_5_rg.sorted.bam	37.33	NA	0.16	58cfa831e4b0c9d6adf6cc74	TCGA-ER-A19K-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19K-10A	F9E36BC2-484F-48E8-82BA-99026957277A	Blood Derived Normal	Illumina HiSeq	8818c079-7f53-40c3-b16c-9e9f9fa6bb4e	Skin	79	5F73A302-CD64-4349-AC6D-A92145FBC5CE	A0D8A73C-3415-493E-8250-AA2EA9591590	TCGA-ER-A19K-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A19K	TCGA-SKCM	469	s7860	Harvard Medical School	University of Pittsburgh	United States	NO	T4b	N0	Not available	Stage IIC	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc82	58cfa831e4b0c9d6adf6cc82	TCGA-ER-A19A-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_8_rg.sorted.filtered.	WGS	TCGA-ER-A19A-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_8_rg.sorted	TCGA-ER-A19A-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_8_rg.sorted.bam	40.3	NA	0.16	58cfa831e4b0c9d6adf6cc82	TCGA-ER-A19A-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19A-10A	41FCB9D3-9FB0-4625-98F4-1F564095EBC2	Blood Derived Normal	Illumina HiSeq	9bcb5eb0-7146-42d1-bb51-a661b93142ac	Skin	79	24869B25-7ECF-4928-8E78-9B6ACA6A2197	9C635EFB-06D8-4379-B5CD-D93F3F64658A	TCGA-ER-A19A-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A19A	TCGA-SKCM	NA	s7360	Harvard Medical School	University of Pittsburgh	United States	NO	TX	N0	Not available	Stage IV	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cca9	58cfa831e4b0c9d6adf6cca9	TCGA-ER-A196-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-ER-A196-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_3_rg.sorted	TCGA-ER-A196-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_3_rg.sorted.bam	32.16	NA	0.17	58cfa831e4b0c9d6adf6cca9	TCGA-ER-A196-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A196-01A	A9EB1022-FFD3-42DE-A39D-2126FC7EC0CE	Primary Tumor	Illumina HiSeq	ef8b8b6f-6812-446b-b27c-03db8997900d	Skin	64	239F69F7-E78A-4B09-BF00-E521F63A3BB4	77937F29-C94F-4251-A0AB-9D07DED92796	TCGA-ER-A196-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A196	TCGA-SKCM	NA	s8021	Harvard Medical School	University of Pittsburgh	United States	NO	T4b	N0	Not available	Stage IIC	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6ca33	58cfa831e4b0c9d6adf6ca33	TCGA-DK-A2I2-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DK-A2I2-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_4_rg.sorted	TCGA-DK-A2I2-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_4_rg.sorted.bam	15.28	NA	0.16	58cfa831e4b0c9d6adf6ca33	TCGA-DK-A2I2-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2I2-10A	234086DD-5A74-4FF1-94AB-BAD43EE69D5C	Blood Derived Normal	Illumina HiSeq	e257ae8b-2d82-4b7d-b7a2-976b611b16b2	Bladder	63	A94F8AE7-CE64-4BB3-9A15-1E65E273A4DA	A709AC1F-F30A-4DEC-9990-F31841CBB3BD	TCGA-DK-A2I2-10A-01D-A17R-02	HG19_Broad_variant	TCGA-DK-A2I2	TCGA-BLCA	237	s3101	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17R-02	TRUE
13722.58cfa831e4b0c9d6adf6cd14	58cfa831e4b0c9d6adf6cd14	TCGA-EE-A2MP-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EE-A2MP-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_1_rg.sorted	TCGA-EE-A2MP-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_1_rg.sorted.bam	40.99	NA	0.16	58cfa831e4b0c9d6adf6cd14	TCGA-EE-A2MP-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MP-06A	54782BD7-79BE-4E3C-BF99-844E7BB0E5D7	Metastatic	Illumina HiSeq	1288fe80-f90b-46ac-a3fa-ac3529fd8e8c	Skin	34	BC9F8071-37F7-44BC-8A3C-F48860C7B5DC	E3BF7C48-9944-48C6-B1A0-26B69C28A49F	TCGA-EE-A2MP-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2MP	TCGA-SKCM	NA	s7853	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cd84	58cfa831e4b0c9d6adf6cd84	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted.bam	74.82	2	0.17	58cfa831e4b0c9d6adf6cd84	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A235-01A	C781B49E-D08F-49E6-B774-7CFE4100E92D	Primary Tumor	Illumina HiSeq	7eafbe04-60be-48a5-8e8a-937b1dde35e8	Thyroid	26	377A0CBF-6A82-43FA-BC95-DADECED8916D	F3F4F8FB-6FAD-46B7-85D0-C591EB926DD7	TCGA-FE-A235-01A-11D-A16N-02	HG19_Broad_variant	TCGA-FE-A235	TCGA-THCA	NA	s12528	Harvard Medical School	Ohio State University	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6ce02	58cfa832e4b0c9d6adf6ce02	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted.bam	248.7	1.9	0.14	58cfa832e4b0c9d6adf6ce02	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5524-01A	4048C139-1329-4E6A-8D2F-C0AA104A68EE	Primary Tumor	Illumina HiSeq	bc7b862d-c88b-41f2-9061-6c4895d6b5be	Prostate	57	C197A81D-2AA5-4285-88E3-761798E2C190	4B173FC3-DBE0-47AA-8ACC-D36466B5522D	TCGA-EJ-5524-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5524	TCGA-PRAD	NA	s3435	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cd7c	58cfa831e4b0c9d6adf6cd7c	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted.bam	42.39	NA	0.15	58cfa831e4b0c9d6adf6cd7c	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B3-01A	4B5D873B-BFDA-482E-92A0-BF84C0F9032A	Primary Tumor	Illumina HiSeq	6b702a7f-ff83-4ff2-96a8-9da2f015ebcc	Bladder	74	769EE027-5ED7-4EC2-86B5-FE40F9D6FB5A	57731F40-BBEF-4C7B-BFDC-CE75DA6EB1EB	TCGA-FD-A3B3-01A-12D-A204-02	HG19_Broad_variant	TCGA-FD-A3B3	TCGA-BLCA	NA	s2903	Harvard Medical School	BLN - University Of Chicago	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A204-02	TRUE
13722.58cfa831e4b0c9d6adf6cd34	58cfa831e4b0c9d6adf6cd34	TCGA-ER-A196-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ER-A196-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_7_rg.sorted	TCGA-ER-A196-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_7_rg.sorted.bam	53.46	NA	0.17	58cfa831e4b0c9d6adf6cd34	TCGA-ER-A196-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A196-10A	A9EB1022-FFD3-42DE-A39D-2126FC7EC0CE	Blood Derived Normal	Illumina HiSeq	b5f37fc3-4d8d-4df9-9af7-cb4b59f49dbf	Skin	64	CC5637D5-960B-46F9-BEDB-80773965D67E	46412D85-4008-45C9-A031-B8BF1A8D56CC	TCGA-ER-A196-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A196	TCGA-SKCM	NA	s8015	Harvard Medical School	University of Pittsburgh	United States	NO	T4b	N0	Not available	Stage IIC	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6ce06	58cfa832e4b0c9d6adf6ce06	TCGA-FD-A3B4-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FD-A3B4-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_4_rg.sorted	TCGA-FD-A3B4-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_4_rg.sorted.bam	14.43	NA	0.17	58cfa832e4b0c9d6adf6ce06	TCGA-FD-A3B4-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_4_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B4-10A	899F8D52-4C3A-4371-90EB-1F106001EDDC	Blood Derived Normal	Illumina HiSeq	c312905a-2708-40b3-9055-264aa217c722	Bladder	55	A6DE65C6-971C-4527-B5DE-2EA7EC56BBDA	EE8151F1-7D38-4804-ABE4-26DD9B220695	TCGA-FD-A3B4-10A-01D-A204-02	HG19_Broad_variant	TCGA-FD-A3B4	TCGA-BLCA	NA	s2908	Harvard Medical School	BLN - University Of Chicago	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A204-02	TRUE
13722.58cfa832e4b0c9d6adf6ceb7	58cfa832e4b0c9d6adf6ceb7	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted.bam	414.7	1.9	0.17	58cfa832e4b0c9d6adf6ceb7	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5522-01A	214884EF-A932-4FC3-B6FF-16CE5164DA3E	Primary Tumor	Illumina HiSeq	ee0fc9f9-f7ac-4f93-a066-2751ffaa3959	Prostate	51	8AC1E1E7-8266-48E0-8D4C-D78873111341	2312B3FC-1F68-43D5-8B19-D449089F153C	TCGA-EJ-5522-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5522	TCGA-PRAD	NA	s4133	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa832e4b0c9d6adf6cea8	58cfa832e4b0c9d6adf6cea8	TCGA-G2-A2EK-10A-01D-A18D_120913_SN208_0429_AC187FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-G2-A2EK-10A-01D-A18D_120913_SN208_0429_AC187FACXX_s_4_rg.sorted	TCGA-G2-A2EK-10A-01D-A18D_120913_SN208_0429_AC187FACXX_s_4_rg.sorted.bam	11.06	NA	0.17	58cfa832e4b0c9d6adf6cea8	TCGA-G2-A2EK-10A-01D-A18D_120913_SN208_0429_AC187FACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EK-10A	5DA1CB68-C438-4DDC-999F-90AED0C4BD7A	Blood Derived Normal	Illumina HiSeq	2d89e6fb-9416-4502-9329-ae8eaa2caa9c	Bladder	57	933F10B3-E2F5-472D-8AD1-2B9EC6F4157D	94CDAD33-E2F4-4CE7-B2FF-AF1F42E95155	TCGA-G2-A2EK-10A-01D-A18D-02	HG19_Broad_variant	TCGA-G2-A2EK	TCGA-BLCA	NA	s2916	Harvard Medical School	MD Anderson	United States	NO	Not available	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A18D-02	TRUE
13722.58cfa832e4b0c9d6adf6ced1	58cfa832e4b0c9d6adf6ced1	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted.bam	214.7	1.9	0.15	58cfa832e4b0c9d6adf6ced1	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5542-01A	5A92EC4C-36EE-4588-ACA2-E3303F29C7AD	Primary Tumor	Illumina HiSeq	45ba9a12-204e-4ab8-b544-61f2519b176f	Prostate	60	DFFC7994-E957-4451-A9DB-56D4560D6547	185234ED-0A19-490C-86D8-19762FB13C1A	TCGA-EJ-5542-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5542	TCGA-PRAD	NA	s3964	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa832e4b0c9d6adf6cec2	58cfa832e4b0c9d6adf6cec2	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted.bam	398.7	NA	0.13	58cfa832e4b0c9d6adf6cec2	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7080-01A	FD50FF41-EC9D-4DB1-A673-36BA0CA1EAC8	Primary Tumor	Illumina HiSeq	4012de79-f9d8-4ee6-ab04-538482e6a66c	Prostate	66	E30730B8-81F1-49A8-8446-547B5C3CC730	CEF3C431-0329-4619-834B-DC57B33399A5	TCGA-HC-7080-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7080	TCGA-PRAD	NA	s3807	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6ced3	58cfa832e4b0c9d6adf6ced3	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted.bam	188.7	1.9	0.15	58cfa832e4b0c9d6adf6ced3	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5527-01A	BA0C9096-5F35-4F0A-AE98-EE1A695B55F0	Primary Tumor	Illumina HiSeq	62c0aaa3-44c3-4b25-b1cb-8e6196d66189	Prostate	69	15A638FE-4DFD-4280-AD40-5E0D5FDE3812	AE85C536-0580-4A34-B686-161D337E7951	TCGA-EJ-5527-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5527	TCGA-PRAD	NA	s3443	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa832e4b0c9d6adf6cf07	58cfa832e4b0c9d6adf6cf07	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted.bam	133	NA	0.15	58cfa832e4b0c9d6adf6cf07	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7079-01A	10FBE481-F111-4F88-AE45-4D67CB265567	Primary Tumor	Illumina HiSeq	5debd428-e42f-459c-8945-f3e0a3053b9e	Prostate	51	190EF71A-5B5D-4009-B707-68F10147CB65	3935531A-0F99-4617-A5B6-6774E74CEE5E	TCGA-HC-7079-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7079	TCGA-PRAD	NA	s3624	Harvard Medical School	International Genomics Consortium	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cf74	58cfa832e4b0c9d6adf6cf74	TCGA-G9-6499-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6499-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_3_rg.sorted	TCGA-G9-6499-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_3_rg.sorted.bam	533	1.8	0.15	58cfa832e4b0c9d6adf6cf74	TCGA-G9-6499-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6499-10A	ACD5CEEF-C5CF-4E95-9394-C50FDBC70C8D	Blood Derived Normal	Illumina HiSeq	03cd9985-d047-464a-946a-1992ac4c8c1c	Prostate	66	F10976A2-68E6-4E06-8549-19EB0183E07C	AB941C2B-2FAB-45D6-99A8-551750EE30CA	TCGA-G9-6499-10A-01D-1957-02	HG19_Broad_variant	TCGA-G9-6499	TCGA-PRAD	NA	s3621	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cf34	58cfa832e4b0c9d6adf6cf34	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted.bam	313.4	1.8	0.13	58cfa832e4b0c9d6adf6cf34	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6363-01A	B5B3871C-078C-46A7-AC50-EF916D4A6781	Primary Tumor	Illumina HiSeq	a64da28b-c092-4dfb-9503-06c15e566ac3	Prostate	64	65D588FF-58E3-4932-A7F4-25EF23C433D5	DBF42C34-D2E5-4136-83F5-093453913D5B	TCGA-G9-6363-01A-21D-1784-02	HG19_Broad_variant	TCGA-G9-6363	TCGA-PRAD	NA	s3452	Harvard Medical School	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cfc6	58cfa832e4b0c9d6adf6cfc6	TCGA-G9-6353-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6353-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_5_rg.sorted	TCGA-G9-6353-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_5_rg.sorted.bam	16	1.8	0.15	58cfa832e4b0c9d6adf6cfc6	TCGA-G9-6353-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6353-10A	BCC94953-CE79-428E-99C1-632E42C1B9BC	Blood Derived Normal	Illumina HiSeq	e230f78f-00cc-4bd0-a15c-369e9ceb0adb	Prostate	58	3C7B873C-58A9-4B6B-9072-9951AD168D5E	41E46979-9567-422A-B925-4AA663DC0E76	TCGA-G9-6353-10A-01D-1957-02	HG19_Broad_variant	TCGA-G9-6353	TCGA-PRAD	NA	s3972	Harvard Medical School	Roswell Park	United States	NO	T3a	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cf39	58cfa832e4b0c9d6adf6cf39	TCGA-G9-6332-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_4_rg.sorted.filtered.	WGS	TCGA-G9-6332-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_4_rg.sorted	TCGA-G9-6332-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_4_rg.sorted.bam	24.7	1.8	0.14	58cfa832e4b0c9d6adf6cf39	TCGA-G9-6332-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6332-10A	C46022F8-B122-4367-836B-EC1AE641A87D	Blood Derived Normal	Illumina HiSeq	4e876235-3367-4541-8b5c-432145854a49	Prostate	55	008159C1-3E45-408D-A89C-DBBCDF585F41	6D2BAA7D-0488-4308-B53C-B6E1318EBA6D	TCGA-G9-6332-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6332	TCGA-PRAD	NA	s3969	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cfcc	58cfa832e4b0c9d6adf6cfcc	TCGA-G9-6343-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6343-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_1_rg.sorted	TCGA-G9-6343-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_1_rg.sorted.bam	38	1.8	0.15	58cfa832e4b0c9d6adf6cfcc	TCGA-G9-6343-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6343-10A	36B87D12-9F96-460F-A3B5-A4C08CBF5B07	Blood Derived Normal	Illumina HiSeq	f331491f-dba0-4053-b733-d52da4ca549c	Prostate	62	E1A1845B-E19F-4AB0-A286-3175BE9F50D9	06C3E81B-4F68-4FA4-A2F0-B4ED6E7A87FB	TCGA-G9-6343-10A-01D-1957-02	HG19_Broad_variant	TCGA-G9-6343	TCGA-PRAD	NA	s3975	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cfe4	58cfa832e4b0c9d6adf6cfe4	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted.bam	157.7	1.9	0.14	58cfa832e4b0c9d6adf6cfe4	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6333-01A	64BF32C9-9466-404A-A147-E7A0B9E91E34	Primary Tumor	Illumina HiSeq	0e4674b7-f8ed-422c-909a-b2bfdf58ecf1	Prostate	66	98013499-4FAC-4378-9D7E-B3686003A4FC	F6373E03-914F-44B2-954D-E63DE95F89E8	TCGA-G9-6333-01A-12D-1957-02	HG19_Broad_variant	TCGA-G9-6333	TCGA-PRAD	NA	s3611	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cffe	58cfa832e4b0c9d6adf6cffe	TCGA-G9-6377-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6377-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_1_rg.sorted	TCGA-G9-6377-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_1_rg.sorted.bam	27	1.9	0.17	58cfa832e4b0c9d6adf6cffe	TCGA-G9-6377-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6377-10A	007F9081-5093-4323-B4F8-CD510BF20705	Blood Derived Normal	Illumina HiSeq	82468f85-9845-4b13-b10d-4118b20e9e48	Prostate	61	509D8324-81CE-441E-BDC9-CEEECF00B936	C161B052-D60E-4782-878A-D5738B4D030A	TCGA-G9-6377-10A-01D-1957-02	HG19_Broad_variant	TCGA-G9-6377	TCGA-PRAD	NA	s3800	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cfc8	58cfa832e4b0c9d6adf6cfc8	TCGA-FS-A1ZN-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FS-A1ZN-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_6_rg.sorted	TCGA-FS-A1ZN-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_6_rg.sorted.bam	23.83	NA	0.16	58cfa832e4b0c9d6adf6cfc8	TCGA-FS-A1ZN-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZN-10A	9D86940D-50FB-4D2F-8B1E-539196885F46	Blood Derived Normal	Illumina HiSeq	27bdfcc3-454a-4619-a5db-13e91e2aff16	Skin	43	24D3D408-8417-4497-814E-31D407886EE0	A5E22F8F-A2D8-4968-B258-BC67282CB9C0	TCGA-FS-A1ZN-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZN	TCGA-SKCM	730	s7536	Harvard Medical School	Essen	Germany	NO	T4b	N1a	Not available	Stage IIIA	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d00c	58cfa832e4b0c9d6adf6d00c	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted.bam	142.3	NA	0.14	58cfa832e4b0c9d6adf6d00c	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7230-01A	03C66CF8-BC68-4EE1-A322-689A29B72262	Primary Tumor	Illumina HiSeq	40ad0094-93d2-45aa-a8b1-070359637c85	Prostate	50	B8BAC212-127D-4EEE-8647-3BDDC13C9415	CE9AA8B5-5CDB-42F1-A810-7F48FC241D20	TCGA-HC-7230-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7230	TCGA-PRAD	NA	s3804	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d014	58cfa832e4b0c9d6adf6d014	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted.bam	81.4	1.9	0.14	58cfa832e4b0c9d6adf6d014	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6336-01A	59207BCD-F127-481F-B576-8716DA7D7D97	Primary Tumor	Illumina HiSeq	35e1082b-0264-4bb6-93d6-1d0e1b133135	Prostate	57	34C8B195-ECAB-492B-AED2-43ACFEDEF708	DB1475AB-0C9E-4D4C-B7F4-88DD8BB2F9B9	TCGA-G9-6336-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6336	TCGA-PRAD	NA	s3799	Harvard Medical School	Roswell Park	United States	NO	Not available	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cffc	58cfa832e4b0c9d6adf6cffc	TCGA-G9-6329-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_2_rg.sorted.filtered.	WGS	TCGA-G9-6329-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_2_rg.sorted	TCGA-G9-6329-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_2_rg.sorted.bam	25	1.8	0.16	58cfa832e4b0c9d6adf6cffc	TCGA-G9-6329-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6329-10A	A08FD0A6-A89A-4ADB-B641-D4C1238ABB71	Blood Derived Normal	Illumina HiSeq	b3789c8a-7d5b-4bac-9ad7-4d8c002c629c	Prostate	67	07C6CFE4-E843-4E47-BB5F-AEC0EF337CEC	1EBB9324-2F1E-4AEA-9669-C29E1F251DF7	TCGA-G9-6329-10A-01D-1957-02	HG19_Broad_variant	TCGA-G9-6329	TCGA-PRAD	NA	s3448	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cfd6	58cfa832e4b0c9d6adf6cfd6	TCGA-FS-A1ZJ-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FS-A1ZJ-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_5_rg.sorted	TCGA-FS-A1ZJ-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_5_rg.sorted.bam	49.53	NA	0.16	58cfa832e4b0c9d6adf6cfd6	TCGA-FS-A1ZJ-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZJ-10A	2F0661E5-5006-481E-9B40-7B1EC96EAA3C	Blood Derived Normal	Illumina HiSeq	28dcf393-ff38-4302-be63-4a95793c09a0	Skin	75	88179E39-3DEA-471B-BE9B-F22773D67054	09F3648F-5FB8-4677-A458-DA2F6E77BC0E	TCGA-FS-A1ZJ-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZJ	TCGA-SKCM	1441	s7535	Harvard Medical School	Essen	Germany	NO	T2	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d07c	58cfa832e4b0c9d6adf6d07c	TCGA-HC-7213-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-HC-7213-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_7_rg.sorted	TCGA-HC-7213-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_7_rg.sorted.bam	187.6	NA	0.15	58cfa832e4b0c9d6adf6d07c	TCGA-HC-7213-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7213-10A	26EEFAA1-1666-4CE1-8CF4-F6FABFF81FD2	Blood Derived Normal	Illumina HiSeq	21be48c5-46c5-48a4-ad57-a4703154b4bf	Prostate	53	FA3DB8B0-1BD6-4C58-918C-8086C383AD5C	3579FC2E-0118-4CE3-A9C2-501C10AD2623	TCGA-HC-7213-10A-01D-2111-02	HG19_Broad_variant	TCGA-HC-7213	TCGA-PRAD	NA	s3627	Harvard Medical School	International Genomics Consortium	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d015	58cfa832e4b0c9d6adf6d015	TCGA-G9-6332-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6332-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_3_rg.sorted	TCGA-G9-6332-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_3_rg.sorted.bam	156.4	1.9	0.15	58cfa832e4b0c9d6adf6d015	TCGA-G9-6332-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6332-01A	C46022F8-B122-4367-836B-EC1AE641A87D	Primary Tumor	Illumina HiSeq	91b58182-30c5-4b45-bf21-ee32128e4ad0	Prostate	55	30558AEB-76B7-4D27-99C0-E3EE21A00BD1	B9FAA261-1FA4-4870-B98F-60153ED7AD8C	TCGA-G9-6332-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6332	TCGA-PRAD	NA	s3974	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6d06c	58cfa832e4b0c9d6adf6d06c	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted.bam	286.3	NA	0.14	58cfa832e4b0c9d6adf6d06c	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7211-01A	EC3870C9-4930-4AF7-B2EB-1E16C9EC9F14	Primary Tumor	Illumina HiSeq	c6d8e1f6-600a-4387-a51a-8812fee4f285	Prostate	62	79BF8C2C-470E-4BE8-8144-9C0B366ECADD	226F7F0E-AC30-4F20-87A2-EB8128402BE4	TCGA-HC-7211-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7211	TCGA-PRAD	NA	s3622	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d084	58cfa832e4b0c9d6adf6d084	TCGA-HC-7080-10A-01D-1957_130422_SN590_0225_BD23TLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-HC-7080-10A-01D-1957_130422_SN590_0225_BD23TLACXX_s_3_rg.sorted	TCGA-HC-7080-10A-01D-1957_130422_SN590_0225_BD23TLACXX_s_3_rg.sorted.bam	188	NA	0.16	58cfa832e4b0c9d6adf6d084	TCGA-HC-7080-10A-01D-1957_130422_SN590_0225_BD23TLACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7080-10A	FD50FF41-EC9D-4DB1-A673-36BA0CA1EAC8	Blood Derived Normal	Illumina HiSeq	eec2b211-fe5e-4169-883d-c614c804bdfd	Prostate	66	5E4C42B8-D17B-48D5-A8DE-C841E6313DE8	F31AA1B5-D26C-4178-A609-7A481B45F7AA	TCGA-HC-7080-10A-01D-1957-02	HG19_Broad_variant	TCGA-HC-7080	TCGA-PRAD	NA	s3626	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6d080	58cfa832e4b0c9d6adf6d080	TCGA-HC-7210-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-HC-7210-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_1_rg.sorted	TCGA-HC-7210-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_1_rg.sorted.bam	143.6	NA	0.14	58cfa832e4b0c9d6adf6d080	TCGA-HC-7210-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7210-10A	6A5AF80E-07AD-4CD3-AAAB-5DB1090835D9	Blood Derived Normal	Illumina HiSeq	51025f8f-6dc7-4e50-b60b-bbb7bc5cb367	Prostate	74	B119375C-2026-4B94-A619-92A0FBA24235	7FE62AF7-884E-450E-BFD8-AA56F3D3E889	TCGA-HC-7210-10A-01D-2111-02	HG19_Broad_variant	TCGA-HC-7210	TCGA-PRAD	NA	s3809	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d1a2	58cfa832e4b0c9d6adf6d1a2	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted.bam	116.3	NA	0.14	58cfa832e4b0c9d6adf6d1a2	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7168-01A	25D70934-01A5-45A2-9960-68D3058B6965	Primary Tumor	Illumina HiSeq	97c2b4ae-c671-4cf5-8b44-5c36e7e8fb57	Prostate	62	DD410832-95AA-4FA6-A2B9-3FECA6F70E1D	9FD5990D-22E1-4D64-996D-543BCD447500	TCGA-HI-7168-01A-11D-2111-02	HG19_Broad_variant	TCGA-HI-7168	TCGA-PRAD	NA	s3633	Harvard Medical School	Fox Chase	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d0ee	58cfa832e4b0c9d6adf6d0ee	TCGA-FS-A1ZG-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FS-A1ZG-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_7_rg.sorted	TCGA-FS-A1ZG-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_7_rg.sorted.bam	19.14	NA	0.18	58cfa832e4b0c9d6adf6d0ee	TCGA-FS-A1ZG-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZG-10A	F52AE9F4-8A61-4FF2-9C24-23F4048D3DA6	Blood Derived Normal	Illumina HiSeq	0121e582-d1b1-4c5c-a9be-8ef4511b3148	Skin	60	2905286F-8C55-48DC-8B52-D481514EDC09	CFCBC9B2-DD33-484D-829B-4606B4646D32	TCGA-FS-A1ZG-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZG	TCGA-SKCM	295	s7373	Harvard Medical School	Essen	Germany	NO	T4b	N2b	Not available	Stage IIIC	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d12c	58cfa832e4b0c9d6adf6d12c	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted.bam	16.85	NA	0.18	58cfa832e4b0c9d6adf6d12c	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EK-01A	5DA1CB68-C438-4DDC-999F-90AED0C4BD7A	Primary Tumor	Illumina HiSeq	f98c8702-90e5-4e7a-ad12-d11a9af57bf5	Bladder	57	FF1691F2-DF11-4068-8D8D-A778F384EC60	8A75CF19-7645-489D-AAEC-5D9AD293C4B1	TCGA-G2-A2EK-01A-22D-A18D-02	HG19_Broad_variant	TCGA-G2-A2EK	TCGA-BLCA	NA	s2725	Harvard Medical School	MD Anderson	United States	NO	Not available	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A18D-02	TRUE
13722.58cfa832e4b0c9d6adf6d210	58cfa832e4b0c9d6adf6d210	TCGA-H2-A26U-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_6_rg.sorted.filtered.	WGS	TCGA-H2-A26U-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_6_rg.sorted	TCGA-H2-A26U-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_6_rg.sorted.bam	169.94	1.69	0.15	58cfa832e4b0c9d6adf6d210	TCGA-H2-A26U-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-H2-A26U-10A	E61FB24B-613A-4B6D-BB2B-00CCEDBD3DBC	Blood Derived Normal	Illumina HiSeq	861454f1-5ad7-4baf-b14f-04dac8c86852	Thyroid	54	272D97A5-448E-4382-AEB3-3CD13A8433B6	83710020-E939-4AB3-A482-D51DCC937377	TCGA-H2-A26U-10A-01D-A16N-02	HG19_Broad_variant	TCGA-H2-A26U	TCGA-THCA	NA	s12533	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6d20c	58cfa832e4b0c9d6adf6d20c	TCGA-HC-7233-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-HC-7233-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_7_rg.sorted	TCGA-HC-7233-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_7_rg.sorted.bam	326.6	NA	0.15	58cfa832e4b0c9d6adf6d20c	TCGA-HC-7233-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	Not available	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7233-10A	E2B33861-2247-413F-B2E5-9BE3B604666C	Blood Derived Normal	Illumina HiSeq	5e685d94-c8fe-4fd0-945f-268e1a8d4d77	Prostate	73	E2E7CA1B-2EB0-4DCB-8887-CC9D4F1D9EC1	A1FA2146-4996-4D78-9BFC-B31F884ABD6D	TCGA-HC-7233-10A-01D-2111-02	HG19_Broad_variant	TCGA-HC-7233	TCGA-PRAD	NA	s3631	Harvard Medical School	International Genomics Consortium	Yemen	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d284	58cfa832e4b0c9d6adf6d284	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted.filtered.	WGS	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted.bam	22	NA	0.13	58cfa832e4b0c9d6adf6d284	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7481-01A	BFF37DE3-DC68-4E69-BDFC-8B524DD7774F	Primary Tumor	Illumina HiSeq	fbc2ca18-8dd6-41c3-9ec3-0189f96877ce	Brain	39	712405B3-14C4-4C26-9839-1749763D816B	AF69E75D-03C6-4EB0-A0B8-129BE37E30A2	TCGA-HT-7481-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7481	TCGA-LGG	NA	s8762	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d279	58cfa832e4b0c9d6adf6d279	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted.bam	79.7	NA	0.15	58cfa832e4b0c9d6adf6d279	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7475-01A	41456932-436E-4CDB-BFE8-97D089656786	Primary Tumor	Illumina HiSeq	13942ed5-f37e-4807-b133-369aab923f17	Brain	67	5E11FC94-CCDB-4E53-9A9D-5D7707157674	B59DECE1-1DE9-46D3-B5CD-0EFD8F453F8D	TCGA-HT-7475-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7475	TCGA-LGG	NA	s8372	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d2ce	58cfa832e4b0c9d6adf6d2ce	TCGA-HT-7475-10A-01D-2022_130913_SN1440_0167_AC2A6PACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HT-7475-10A-01D-2022_130913_SN1440_0167_AC2A6PACXX_s_8_rg.sorted	TCGA-HT-7475-10A-01D-2022_130913_SN1440_0167_AC2A6PACXX_s_8_rg.sorted.bam	125	NA	0.16	58cfa832e4b0c9d6adf6d2ce	TCGA-HT-7475-10A-01D-2022_130913_SN1440_0167_AC2A6PACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7475-10A	41456932-436E-4CDB-BFE8-97D089656786	Blood Derived Normal	Illumina HiSeq	688c23ec-5c4c-438c-9553-132c7c3da53b	Brain	67	ACF7770E-26CF-47C0-A0B5-B16E26FC4F13	CCEAE3AB-084B-4EE9-A98D-0DFB6A8C536F	TCGA-HT-7475-10A-01D-2022-02	HG19_Broad_variant	TCGA-HT-7475	TCGA-LGG	NA	s8760	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d226	58cfa832e4b0c9d6adf6d226	TCGA-FS-A1ZH-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FS-A1ZH-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_6_rg.sorted	TCGA-FS-A1ZH-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_6_rg.sorted.bam	51.84	NA	0.16	58cfa832e4b0c9d6adf6d226	TCGA-FS-A1ZH-10A-01D-A190_120605_SN1222_0113_BC0WUCACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZH-10A	9F5BD948-DC3D-4B17-A114-D2F5C46FE10C	Blood Derived Normal	Illumina HiSeq	b643b41e-59b2-4796-99cb-3c40e021942f	Skin	71	56B42C33-3400-40BA-903A-CC359E5689F0	5D27B80E-C27E-47B3-9689-63224B08C95B	TCGA-FS-A1ZH-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZH	TCGA-SKCM	996	s7371	Harvard Medical School	Essen	Germany	NO	T3b	N2c	Not available	Stage IV	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf00	58cfa832e4b0c9d6adf6cf00	TCGA-FS-A1Z7-06A-11D-A18Y_120712_SN1222_0124_AC11GPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FS-A1Z7-06A-11D-A18Y_120712_SN1222_0124_AC11GPACXX_s_3_rg.sorted	TCGA-FS-A1Z7-06A-11D-A18Y_120712_SN1222_0124_AC11GPACXX_s_3_rg.sorted.bam	25.78	NA	0.17	58cfa832e4b0c9d6adf6cf00	TCGA-FS-A1Z7-06A-11D-A18Y_120712_SN1222_0124_AC11GPACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1Z7-06A	F3BB6362-6801-4C95-A828-09C0002A8B87	Metastatic	Illumina HiSeq	3e98b38f-dcad-4b32-9291-c9cd6b59c84b	Skin	19	B50324D0-2C8B-42EE-8767-F9900D2068FD	01285377-C51D-46C6-9F23-2639D151AC28	TCGA-FS-A1Z7-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1Z7	TCGA-SKCM	237	s7867	Harvard Medical School	Essen	Germany	NO	T4b	N1b	Not available	Stage IIIC	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d175	58cfa832e4b0c9d6adf6d175	TCGA-FS-A1Z7-10A-01D-A190_120712_SN1222_0124_AC11GPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FS-A1Z7-10A-01D-A190_120712_SN1222_0124_AC11GPACXX_s_4_rg.sorted	TCGA-FS-A1Z7-10A-01D-A190_120712_SN1222_0124_AC11GPACXX_s_4_rg.sorted.bam	51.14	NA	0.18	58cfa832e4b0c9d6adf6d175	TCGA-FS-A1Z7-10A-01D-A190_120712_SN1222_0124_AC11GPACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1Z7-10A	F3BB6362-6801-4C95-A828-09C0002A8B87	Blood Derived Normal	Illumina HiSeq	affbe8f2-deb0-45e1-a584-9c4d3b4f981b	Skin	19	41F8841F-7164-4E6A-82B9-D2B52FEE61A4	B3CA6E8E-F372-4991-8AC4-989A36947C61	TCGA-FS-A1Z7-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1Z7	TCGA-SKCM	237	s7523	Harvard Medical School	Essen	Germany	NO	T4b	N1b	Not available	Stage IIIC	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d212	58cfa832e4b0c9d6adf6d212	TCGA-FS-A1ZA-10A-01D-A190_120712_SN1222_0124_AC11GPACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FS-A1ZA-10A-01D-A190_120712_SN1222_0124_AC11GPACXX_s_2_rg.sorted	TCGA-FS-A1ZA-10A-01D-A190_120712_SN1222_0124_AC11GPACXX_s_2_rg.sorted.bam	53.21	NA	0.17	58cfa832e4b0c9d6adf6d212	TCGA-FS-A1ZA-10A-01D-A190_120712_SN1222_0124_AC11GPACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZA-10A	177B515E-BCB9-4A08-9B38-3CCDEC0E293F	Blood Derived Normal	Illumina HiSeq	f44a5b70-d708-4509-a3f7-1bedc687a10a	Skin	45	02BF0806-A097-4024-A79C-16F7FD969CF7	F4D999FE-96FE-43F7-BC5D-C39F78938717	TCGA-FS-A1ZA-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZA	TCGA-SKCM	843	s8025	Harvard Medical School	Essen	Germany	NO	T4b	N2c	Not available	Stage IIIB	A190-02	TRUE
13722.58cfa82ee4b0c9d6adf6aee7	58cfa82ee4b0c9d6adf6aee7	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted.bam	182.7	1.9	0.16	58cfa82ee4b0c9d6adf6aee7	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4410-01A	D28E465C-E553-4C53-8BB7-3D8199B9A8A5	Primary Tumor	Illumina HiSeq	bdcc8e9a-8d27-4167-ae6f-3c41b38c6c51	Lung	62	F8961F5C-E28B-44A2-8E4E-B5759FE2D849	51E2038A-2D9D-481D-A3B6-D5D5D6B33E4F	TCGA-05-4410-01A-21D-1853-02	HG19_Broad_variant	TCGA-05-4410	TCGA-LUAD	NA	s10773	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae6c	58cfa82ee4b0c9d6adf6ae6c	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted.filtered.	WGS	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted.bam	175.7	1.9	0.17	58cfa82ee4b0c9d6adf6ae6c	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4405-01A	F587C9AB-2949-4410-80D6-A050865D48AA	Primary Tumor	Illumina HiSeq	47fe3db4-7a54-4703-b3a4-7ad7def2469c	Lung	74	9CE83CC4-7B9B-4CE7-98F5-5CE8A8D70902	8A9ADFB9-6266-490D-B1B6-F66F43F3F657	TCGA-05-4405-01A-21D-1853-02	HG19_Broad_variant	TCGA-05-4405	TCGA-LUAD	NA	s10768	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	TRUE
13722.58cfa82ee4b0c9d6adf6af98	58cfa82ee4b0c9d6adf6af98	TCGA-05-4410-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4410-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_4_rg.sorted	TCGA-05-4410-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_4_rg.sorted.bam	231	1.9	0.14	58cfa82ee4b0c9d6adf6af98	TCGA-05-4410-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4410-10A	D28E465C-E553-4C53-8BB7-3D8199B9A8A5	Blood Derived Normal	Illumina HiSeq	53af425f-3279-4968-bc2e-56cc1f8678b3	Lung	62	DBF225D7-8BDD-4C28-B0E9-55EBE7404A4C	ACB50D57-7B1B-416D-9D8A-B097168C04C5	TCGA-05-4410-10A-01D-1853-02	HG19_Broad_variant	TCGA-05-4410	TCGA-LUAD	NA	s11545	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5dc	58cfa82fe4b0c9d6adf6b5dc	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted.bam	111.7	1.9	0.15	58cfa82fe4b0c9d6adf6b5dc	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5939-01A	12B79B4F-C28C-418E-A1E7-E622F33FDCC2	Primary Tumor	Illumina HiSeq	7a3d6187-a909-4946-83bf-0d6fc6a753ee	Lung	85	6A27F5F8-F4EE-45C7-B953-DDD7D0291DBB	08D803D0-A294-4F70-9560-563357172BBB	TCGA-50-5939-01A-11D-1623-02	HG19_Broad_variant	TCGA-50-5939	TCGA-LUAD	460	s11007	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b69c	58cfa82fe4b0c9d6adf6b69c	TCGA-44-6777-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_3_rg.sorted.filtered.	WGS	TCGA-44-6777-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_3_rg.sorted	TCGA-44-6777-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_3_rg.sorted.bam	118.7	1.9	0.14	58cfa82fe4b0c9d6adf6b69c	TCGA-44-6777-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-44-6777-11A	349E6F38-2C67-4A69-A777-B9173A2A27CF	Solid Tissue Normal	Illumina HiSeq	e60ccd22-0cc2-4758-8098-0d5f331aceb1	Lung	85	5F42537F-8C2A-48B6-8D9C-1F409711D128	D3991B40-64D4-4B15-8CA9-E4F64F877210	TCGA-44-6777-11A-01D-1853-02	HG19_Broad_variant	TCGA-44-6777	TCGA-LUAD	987	s11452	Harvard Medical School	Christiana Healthcare	United States	NO	T2	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa82ee4b0c9d6adf6afae	58cfa82ee4b0c9d6adf6afae	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted.bam	357.4	1.9	0.15	58cfa82ee4b0c9d6adf6afae	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4425-01A	69B23036-ADD9-42C9-941F-02FB74D9B08C	Primary Tumor	Illumina HiSeq	bf137f71-691f-42f6-a29c-e37a457bad18	Lung	70	98BEE17E-0B07-40D8-A70F-3163DBFD9C79	C0DC5772-8A3E-43BE-9059-FC524A5183C9	TCGA-05-4425-01A-01D-1751-02	HG19_Broad_variant	TCGA-05-4425	TCGA-LUAD	NA	s10775	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IV	1751-02	TRUE
13722.58cfa82ee4b0c9d6adf6afa4	58cfa82ee4b0c9d6adf6afa4	TCGA-05-4425-10A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4425-10A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_4_rg.sorted	TCGA-05-4425-10A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_4_rg.sorted.bam	294.7	1.9	0.16	58cfa82ee4b0c9d6adf6afa4	TCGA-05-4425-10A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4425-10A	69B23036-ADD9-42C9-941F-02FB74D9B08C	Blood Derived Normal	Illumina HiSeq	bfe20429-49d0-4a72-a8e2-5254fa77bbc1	Lung	70	21FAC452-927C-4827-95B7-50F7026BBE81	5780D4D6-681B-440D-B7A6-31012DED5352	TCGA-05-4425-10A-01D-1751-02	HG19_Broad_variant	TCGA-05-4425	TCGA-LUAD	NA	s11444	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IV	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b720	58cfa82fe4b0c9d6adf6b720	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.bam	282.4	1.9	0.13	58cfa82fe4b0c9d6adf6b720	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6217-01A	108A71CF-B9DB-47CD-AA74-C03EC989B41B	Primary Tumor	Illumina HiSeq	cb2962fe-7f6e-4a68-871a-11d696bb5279	Lung	73	BC0FE45C-3249-46D7-8991-C6888F0B9579	565E717D-310B-4FB1-B79A-5F40FF12BBB8	TCGA-67-6217-01A-11D-1751-02	HG19_Broad_variant	TCGA-67-6217	TCGA-LUAD	NA	s11244	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6b3	58cfa82fe4b0c9d6adf6b6b3	TCGA-55-6642-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_2_rg.sorted.filtered.	WGS	TCGA-55-6642-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_2_rg.sorted	TCGA-55-6642-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_2_rg.sorted.bam	202.7	1.9	0.14	58cfa82fe4b0c9d6adf6b6b3	TCGA-55-6642-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-55-6642-11A	474B86D9-D897-467D-85D4-51DFA26EA107	Solid Tissue Normal	Illumina HiSeq	ae204af3-603b-4186-b84a-4634f70af495	Lung	63	16813145-731C-4C86-ADE2-3DF32A47D4B0	2F9F7057-AF60-41FA-AB40-0EB76A8455FD	TCGA-55-6642-11A-01D-1853-02	HG19_Broad_variant	TCGA-55-6642	TCGA-LUAD	NA	s10662	Harvard Medical School	International Genomics Consortium	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b81e	58cfa82fe4b0c9d6adf6b81e	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted.bam	82.92	2	0.17	58cfa82fe4b0c9d6adf6b81e	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GE-01A	A587E62E-430E-4F1B-82B7-6FBE856FDAF1	Primary Tumor	Illumina HiSeq	d3918efd-f063-4ea7-b839-9c0c143fd07c	Uterus	38	20C3F64D-ACF6-45B3-9ACE-2F93B3A951C8	3E23FB82-C875-460A-B19D-5EF9DCC58B9A	TCGA-A5-A0GE-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GE	TCGA-UCEC	NA	s4995	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b879	58cfa82fe4b0c9d6adf6b879	TCGA-A5-A0RA-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0RA-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_6_rg.sorted	TCGA-A5-A0RA-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_6_rg.sorted.bam	7.22	2.16	0.16	58cfa82fe4b0c9d6adf6b879	TCGA-A5-A0RA-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0RA-10A	AFD710B8-D172-4AC4-9973-E969DB1ED231	Blood Derived Normal	Illumina HiSeq	0299a5c4-cb18-4ec1-bbdc-6305aab55198	Uterus	68	55E3C47B-0A82-4347-98BD-F4F3B6D0C7C7	DCEB13CD-497F-4206-9055-3D034AD58997	TCGA-A5-A0RA-10A-01D-A101-02	HG19_Broad_variant	TCGA-A5-A0RA	TCGA-UCEC	NA	s5197	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae60	58cfa82ee4b0c9d6adf6ae60	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted.bam	827.4	1.9	0.14	58cfa82ee4b0c9d6adf6ae60	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4390-01A	B8475929-2D9D-4909-BD62-59684A140BD7	Primary Tumor	Illumina HiSeq	625e3715-ed9e-4946-8c92-f5a93e92e6d4	Lung	58	C7F76210-D0F2-4FB8-80F1-35098DBE03DE	4BC393B5-F924-4D66-BC93-58A3CB2EBBC5	TCGA-05-4390-01A-02D-1751-02	HG19_Broad_variant	TCGA-05-4390	TCGA-LUAD	NA	s11328	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b83a	58cfa82fe4b0c9d6adf6b83a	TCGA-A5-A0R8-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-A5-A0R8-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_4_rg.sorted	TCGA-A5-A0R8-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_4_rg.sorted.bam	16.35	1.97	0.15	58cfa82fe4b0c9d6adf6b83a	TCGA-A5-A0R8-10A-01D-A101_120406_SN1120_0131_BD0UK4ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R8-10A	06D16B6B-9CA6-4CEC-A785-F27AA4323CEC	Blood Derived Normal	Illumina HiSeq	aba38e39-8eb7-4475-b9d0-1d8868b47fbd	Uterus	81	2309BBE1-9809-4ABA-9A0E-6AF113447806	DE4B2450-F33C-448E-BC24-38A82B2232A2	TCGA-A5-A0R8-10A-01D-A101-02	HG19_Broad_variant	TCGA-A5-A0R8	TCGA-UCEC	NA	s4990	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82fe4b0c9d6adf6b674	58cfa82fe4b0c9d6adf6b674	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.bam	406.7	1.9	0.14	58cfa82fe4b0c9d6adf6b674	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-71-6725-01A	4B7CD595-E7F9-45A8-B736-A8C7C42D9539	Primary Tumor	Illumina HiSeq	9c1abbc4-5f6b-486c-a6a3-17a01c8783cb	Lung	48	83973755-FA6A-460A-A042-385B34698C39	1AD7566E-B9DD-43A3-94DC-96F525007EAA	TCGA-71-6725-01A-11D-1853-02	HG19_Broad_variant	TCGA-71-6725	TCGA-LUAD	NA	s11554	Harvard Medical School	ILSbio	Vietnam	NO	T2	N0	Lung Papillary Adenocarcinoma	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b646	58cfa82fe4b0c9d6adf6b646	TCGA-75-5126-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_6_rg.sorted.filtered.	WGS	TCGA-75-5126-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_6_rg.sorted	TCGA-75-5126-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_6_rg.sorted.bam	72.7	1.9	0.16	58cfa82fe4b0c9d6adf6b646	TCGA-75-5126-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-5126-10A	93766482-2F20-4C8F-BBD8-BDD203C37D5A	Blood Derived Normal	Illumina HiSeq	c15f5681-638a-4471-a349-56138d68fe62	Lung	NA	9D7D2BB6-7463-4695-AD94-E70C4CE0BAA8	43ACFB6F-D582-4016-BD27-24FA2B22B6E7	TCGA-75-5126-10A-01D-1751-02	HG19_Broad_variant	TCGA-75-5126	TCGA-LUAD	NA	s10801	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T3	N2	Lung Papillary Adenocarcinoma	Stage IIIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b724	58cfa82fe4b0c9d6adf6b724	TCGA-71-6725-10A-01D-1853_120305_SN1120_0119_BD0REAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-71-6725-10A-01D-1853_120305_SN1120_0119_BD0REAACXX_s_1_rg.sorted	TCGA-71-6725-10A-01D-1853_120305_SN1120_0119_BD0REAACXX_s_1_rg.sorted.bam	166	1.9	0.15	58cfa82fe4b0c9d6adf6b724	TCGA-71-6725-10A-01D-1853_120305_SN1120_0119_BD0REAACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-71-6725-10A	4B7CD595-E7F9-45A8-B736-A8C7C42D9539	Blood Derived Normal	Illumina HiSeq	6ab86bce-d92f-4638-a2d7-4761bcc675d7	Lung	48	9BE42F9A-4AC0-427F-A1BA-45FB541174B7	62E9B0D2-3A69-47EA-BE27-551213D303CC	TCGA-71-6725-10A-01D-1853-02	HG19_Broad_variant	TCGA-71-6725	TCGA-LUAD	NA	s10665	Harvard Medical School	ILSbio	Vietnam	NO	T2	N0	Lung Papillary Adenocarcinoma	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8a8	58cfa82fe4b0c9d6adf6b8a8	TCGA-A5-A0GD-10A-01D-A043_120504_SN208_0297_BC0VJEACXX_s_7_rg.sorted.filtered.	WGS	TCGA-A5-A0GD-10A-01D-A043_120504_SN208_0297_BC0VJEACXX_s_7_rg.sorted	TCGA-A5-A0GD-10A-01D-A043_120504_SN208_0297_BC0VJEACXX_s_7_rg.sorted.bam	14.89	1.93	0.16	58cfa82fe4b0c9d6adf6b8a8	TCGA-A5-A0GD-10A-01D-A043_120504_SN208_0297_BC0VJEACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GD-10A	1486A031-B74D-4976-8B0B-4569E6978F49	Blood Derived Normal	Illumina HiSeq	f57ef0e6-cdbc-412d-b41e-83ae999958b8	Uterus	75	FEA14411-8A57-4794-AD7F-D83C19104636	A43F9FE5-1CD2-44E6-9E11-42432A1702B8	TCGA-A5-A0GD-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0GD	TCGA-UCEC	NA	s4588	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b92a	58cfa82fe4b0c9d6adf6b92a	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.bam	349.7	1.9	0.14	58cfa82fe4b0c9d6adf6b92a	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6828-01A	9536E32D-2707-48D2-A36D-08C521665BB9	Primary Tumor	Illumina HiSeq	94e2b6af-1f25-4698-9414-f3d916d26aee	Lung	70	CFE0F0E4-D8BF-40CE-99F1-2BF99CECA18B	2C0D4A9F-857D-4C6F-B616-304AB5922A2F	TCGA-91-6828-01A-11D-1853-02	HG19_Broad_variant	TCGA-91-6828	TCGA-LUAD	NA	s10802	Harvard Medical School	ABS - IUPUI	United States	NO	T1a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5ce	58cfa82fe4b0c9d6adf6b5ce	TCGA-44-5643-10A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-44-5643-10A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_5_rg.sorted	TCGA-44-5643-10A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_5_rg.sorted.bam	330.4	1.9	0.15	58cfa82fe4b0c9d6adf6b5ce	TCGA-44-5643-10A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_5_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-5643-10A	27FCEEC1-3298-4CDD-A4E6-8F5CF34604F0	Blood Derived Normal	Illumina HiSeq	e4cbf4f2-ff4e-416e-bc31-0d67f0f9437a	Lung	53	E4463FF5-D83E-4C36-B700-EF17DDB195AB	F663AFD4-EA19-4E60-94D7-B4BC9AA54001	TCGA-44-5643-10A-01D-1623-02	HG19_Broad_variant	TCGA-44-5643	TCGA-LUAD	NA	s10990	Harvard Medical School	Christiana Healthcare	United States	NO	T2b	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9ab	58cfa82fe4b0c9d6adf6b9ab	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted.filtered.	WGS	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted.bam	36.7	1.9	0.15	58cfa82fe4b0c9d6adf6b9ab	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-44-6777-01A	349E6F38-2C67-4A69-A777-B9173A2A27CF	Primary Tumor	Illumina HiSeq	8f0fdfb5-6a7c-4e9a-9a4f-d32f9aca542d	Lung	85	174E4405-4848-4E5E-93CC-0CDF2795C91A	AAAAE42F-88A5-4E99-8057-A92D6759BE19	TCGA-44-6777-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6777	TCGA-LUAD	987	s11550	Harvard Medical School	Christiana Healthcare	United States	NO	T2	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b932	58cfa82fe4b0c9d6adf6b932	TCGA-91-6836-01A-21D-1853_120310_SN590_0144_AD0PNFACXX_s_7_rg.sorted.filtered.	WGS	TCGA-91-6836-01A-21D-1853_120310_SN590_0144_AD0PNFACXX_s_7_rg.sorted	TCGA-91-6836-01A-21D-1853_120310_SN590_0144_AD0PNFACXX_s_7_rg.sorted.bam	278.7	1.9	0.14	58cfa82fe4b0c9d6adf6b932	TCGA-91-6836-01A-21D-1853_120310_SN590_0144_AD0PNFACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6836-01A	0B31DBDF-0623-48E4-A0EC-017650DCEDA7	Primary Tumor	Illumina HiSeq	68fe0529-8b54-4c01-83f0-a5dc5097e2cb	Lung	52	49A0AB8A-F379-4394-ACCF-0B4B08D2DCC6	0D6B80DD-76A1-4174-9275-731B4A347213	TCGA-91-6836-01A-21D-1853-02	HG19_Broad_variant	TCGA-91-6836	TCGA-LUAD	NA	s10669	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8ee	58cfa82fe4b0c9d6adf6b8ee	TCGA-49-4512-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-4512-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_7_rg.sorted	TCGA-49-4512-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_7_rg.sorted.bam	151.7	1.9	0.15	58cfa82fe4b0c9d6adf6b8ee	TCGA-49-4512-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4512-11A	A1E65587-24C1-4B41-92A7-4E1F15FFFD78	Solid Tissue Normal	Illumina HiSeq	425e9966-6cdb-4456-8501-ac186279082f	Lung	69	67BF333D-F746-497F-B6B1-F241E93DC467	579F0180-CF2E-4BB4-9367-35131DC7524E	TCGA-49-4512-11A-01D-1853-02	HG19_Broad_variant	TCGA-49-4512	TCGA-LUAD	905	s11232	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	TRUE
13722.58cfa830e4b0c9d6adf6ba66	58cfa830e4b0c9d6adf6ba66	TCGA-91-6828-10A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_4_rg.sorted.filtered.	WGS	TCGA-91-6828-10A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_4_rg.sorted	TCGA-91-6828-10A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_4_rg.sorted.bam	442	1.9	0.16	58cfa830e4b0c9d6adf6ba66	TCGA-91-6828-10A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6828-10A	9536E32D-2707-48D2-A36D-08C521665BB9	Blood Derived Normal	Illumina HiSeq	a572c04b-c826-4837-94e8-72ccdc833516	Lung	70	4A3B397B-AD28-4817-A3EC-EF0B80996384	4AF2C139-3D39-4156-B258-841B9E085E98	TCGA-91-6828-10A-01D-1853-02	HG19_Broad_variant	TCGA-91-6828	TCGA-LUAD	NA	s11464	Harvard Medical School	ABS - IUPUI	United States	NO	T1a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	TRUE
13722.58cfa830e4b0c9d6adf6ba86	58cfa830e4b0c9d6adf6ba86	TCGA-91-6836-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_8_rg.sorted.filtered.	WGS	TCGA-91-6836-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_8_rg.sorted	TCGA-91-6836-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_8_rg.sorted.bam	279.7	1.9	0.13	58cfa830e4b0c9d6adf6ba86	TCGA-91-6836-11A-01D-1853_120310_SN590_0144_AD0PNFACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6836-11A	0B31DBDF-0623-48E4-A0EC-017650DCEDA7	Solid Tissue Normal	Illumina HiSeq	76fb7328-b5a3-43dd-b29f-412366ad711a	Lung	52	BAA41644-5248-4838-ACC4-56D35C7A88AE	706F3CC6-7D2F-4342-AB87-02FD79E3B8B4	TCGA-91-6836-11A-01D-1853-02	HG19_Broad_variant	TCGA-91-6836	TCGA-LUAD	NA	s11360	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa830e4b0c9d6adf6ba81	58cfa830e4b0c9d6adf6ba81	TCGA-91-6831-01A-11D-1853_120305_SN1120_0119_BD0REAACXX_s_4_rg.sorted.filtered.	WGS	TCGA-91-6831-01A-11D-1853_120305_SN1120_0119_BD0REAACXX_s_4_rg.sorted	TCGA-91-6831-01A-11D-1853_120305_SN1120_0119_BD0REAACXX_s_4_rg.sorted.bam	196.7	1.9	0.14	58cfa830e4b0c9d6adf6ba81	TCGA-91-6831-01A-11D-1853_120305_SN1120_0119_BD0REAACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6831-01A	DB0B9E63-4272-4F29-BF0E-1EC0FE79A9D7	Primary Tumor	Illumina HiSeq	319d6c8c-207c-477a-8254-30695b75f9e2	Lung	66	7B1D8B50-F3DF-4AAB-A654-C3810D8D576D	0D0D96AE-A83B-4C09-8ED9-4A568E816EFC	TCGA-91-6831-01A-11D-1853-02	HG19_Broad_variant	TCGA-91-6831	TCGA-LUAD	NA	s10670	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa830e4b0c9d6adf6be0d	58cfa830e4b0c9d6adf6be0d	TCGA-BG-A0M9-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0M9-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_6_rg.sorted	TCGA-BG-A0M9-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_6_rg.sorted.bam	7.78	2.03	0.16	58cfa830e4b0c9d6adf6be0d	TCGA-BG-A0M9-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M9-10A	4FD1CB59-6C50-4355-9D37-A341E1F4FAD9	Blood Derived Normal	Illumina HiSeq	2526461b-6bcd-4565-bb28-611a41d4286a	Uterus	73	C87CFE2D-33E1-43EE-9EF9-7DEA955DEBEE	5C73D70A-0685-4062-B760-6BBD60017C75	TCGA-BG-A0M9-10A-01D-A101-02	HG19_Broad_variant	TCGA-BG-A0M9	TCGA-UCEC	NA	s4250	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6be70	58cfa830e4b0c9d6adf6be70	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.bam	82.3	2.03	0.16	58cfa830e4b0c9d6adf6be70	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28R-01A	524A39EE-8FA3-418E-98A2-A6A90E9C8064	Primary Tumor	Illumina HiSeq	122e0c7e-da24-4121-907e-8b913b4e4147	Thyroid	38	F4906B86-3971-4ED3-AC3C-69635311FB45	A5170F7D-F298-4330-8272-8DACFF7775A1	TCGA-BJ-A28R-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28R	TCGA-THCA	NA	s11987	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6bc9f	58cfa830e4b0c9d6adf6bc9f	TCGA-AP-A0LO-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AP-A0LO-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_5_rg.sorted	TCGA-AP-A0LO-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_5_rg.sorted.bam	34.1	1.93	0.16	58cfa830e4b0c9d6adf6bc9f	TCGA-AP-A0LO-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LO-10A	A081DA6F-51F3-4555-A6B8-736F8C6CDA39	Blood Derived Normal	Illumina HiSeq	4486708d-e7b7-4dbc-868e-487277d40b95	Uterus	45	FBFCB809-4EE6-4402-9FB8-F435BA7B43A1	F389371A-6695-4E68-8167-F15CF57786EC	TCGA-AP-A0LO-10A-01D-A043-02	HG19_Broad_variant	TCGA-AP-A0LO	TCGA-UCEC	1016	s5201	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8c6	58cfa82fe4b0c9d6adf6b8c6	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.bam	89.76	2.06	0.14	58cfa82fe4b0c9d6adf6b8c6	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GX-01A	553F0CCD-4E6F-4AE2-9B39-97529EB3D826	Primary Tumor	Illumina HiSeq	cae767f1-aaee-4821-aa36-3ceb0b1756e8	Uterus	53	983A35A9-C825-4961-86C0-4C6133B5C9C1	FE0654FE-39AA-4993-8F36-768C7D829092	TCGA-A5-A0GX-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GX	TCGA-UCEC	NA	s4989	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bd88	58cfa830e4b0c9d6adf6bd88	TCGA-BG-A0LX-10A-01D-A043_120322_SN208_0278_BD0RB0ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0LX-10A-01D-A043_120322_SN208_0278_BD0RB0ACXX_s_6_rg.sorted	TCGA-BG-A0LX-10A-01D-A043_120322_SN208_0278_BD0RB0ACXX_s_6_rg.sorted.bam	21.13	2	0.15	58cfa830e4b0c9d6adf6bd88	TCGA-BG-A0LX-10A-01D-A043_120322_SN208_0278_BD0RB0ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0LX-10A	AC1D3946-FE6C-4BD8-B02C-638799CB0F67	Blood Derived Normal	Illumina HiSeq	5cefe5f6-99c7-421a-8cac-ecf860ae5139	Uterus	57	BB935FAB-8B12-4FDC-8A49-A03FD67CC014	6BD21A7A-30FC-4BD0-8ED7-F4ABE21ECBA8	TCGA-BG-A0LX-10A-01D-A043-02	HG19_Broad_variant	TCGA-BG-A0LX	TCGA-UCEC	NA	s4791	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bd92	58cfa830e4b0c9d6adf6bd92	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.bam	100.95	1.92	0.15	58cfa830e4b0c9d6adf6bd92	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0LW-01A	68181BC9-AA8B-44EC-8601-564B30EA0561	Primary Tumor	Illumina HiSeq	89430da6-f21d-4534-8b48-c645836813b5	Uterus	47	6527EC31-1D41-49C2-93FF-11615A6CBA8B	5D88ADF5-468B-4377-B3E3-DF986C613D24	TCGA-BG-A0LW-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0LW	TCGA-UCEC	NA	s5003	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bda2	58cfa830e4b0c9d6adf6bda2	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted.bam	42.01	NA	0.16	58cfa830e4b0c9d6adf6bda2	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PX-01A	197AC33E-D5DF-40DE-92F2-6EF7FE2AD6DD	Primary Tumor	Illumina HiSeq	4a62234d-e7fe-4cd1-a319-baafc27c9db8	Skin	56	EE2F9863-0DAE-4830-A780-E7745414BC3D	98B49A52-61EC-4A87-B2DD-EEFD6E0E028F	TCGA-BF-A1PX-01A-12D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PX	TCGA-SKCM	282	s7825	Harvard Medical School	Cureline	Russia	NO	T4b	N2a	Not available	Stage IIIB	A18Z-02	TRUE
13722.58cfa830e4b0c9d6adf6bee2	58cfa830e4b0c9d6adf6bee2	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted.bam	90.97	2.13	0.17	58cfa830e4b0c9d6adf6bee2	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LO-01A	A081DA6F-51F3-4555-A6B8-736F8C6CDA39	Primary Tumor	Illumina HiSeq	4726575a-1ad0-471a-8a8e-26eb668681f2	Uterus	45	9846D8F3-5B22-48E9-B972-A0FE9F509FB4	A91FCC79-7AE0-4BD1-BCAE-543E49E2D62E	TCGA-AP-A0LO-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LO	TCGA-UCEC	1016	s4243	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bf52	58cfa830e4b0c9d6adf6bf52	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted.bam	252.9	1.9	0.14	58cfa830e4b0c9d6adf6bf52	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4280-01A	E0916597-E489-45EF-A8F7-653A3C6591EF	Primary Tumor	Illumina HiSeq	418e722c-d444-43fe-87b1-6d8ce0ce5359	Stomach	78	797D2D3A-F01C-4985-B27C-4E4C2838D34D	7F073E1B-E936-44FF-B3C0-8F4C26ECC3A9	TCGA-BR-4280-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4280	TCGA-STAD	NA	s14880	Harvard Medical School	Asterand	Russia	NO	T2b	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage III	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bbf4	58cfa830e4b0c9d6adf6bbf4	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.bam	88.42	2.12	0.14	58cfa830e4b0c9d6adf6bbf4	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GW-01A	5B6B9D0F-787C-4AE9-AFD4-DE7CE6C57A42	Primary Tumor	Illumina HiSeq	84e2e6bd-f438-45e9-9d44-2af82246e341	Uterus	46	E84D0533-E892-4C1E-9415-99F92AA9A360	3DCC9DC1-990D-4053-967E-B8E4EE752C4E	TCGA-A5-A0GW-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GW	TCGA-UCEC	NA	s4421	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bf66	58cfa830e4b0c9d6adf6bf66	TCGA-BR-4294-11A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4294-11A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_5_rg.sorted	TCGA-BR-4294-11A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_5_rg.sorted.bam	219.9	1.9	0.15	58cfa830e4b0c9d6adf6bf66	TCGA-BR-4294-11A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4294-11A	ACAB1362-C8A0-448B-8533-0CD84D97959C	Solid Tissue Normal	Illumina HiSeq	77aba0c4-8048-441c-89af-698eee7d38aa	Stomach	65	301E4023-CCA5-42D9-B9F3-ECF06DCEED40	18B69220-5BDF-4B08-BE0D-1C99C2943DA5	TCGA-BR-4294-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4294	TCGA-STAD	NA	s15300	Harvard Medical School	Asterand	Russia	NO	T2a	NX	Stomach  Intestinal Adenocarcinoma  Tubular Type	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf8b	58cfa830e4b0c9d6adf6bf8b	TCGA-BR-6564-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-6564-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_2_rg.sorted	TCGA-BR-6564-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_2_rg.sorted.bam	76	1.9	0.17	58cfa830e4b0c9d6adf6bf8b	TCGA-BR-6564-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6564-10A	AF1086CC-B330-4AD6-AE1C-3B5C7259949A	Blood Derived Normal	Illumina HiSeq	471dc261-17ff-4b2a-9f63-5e47a77d7ae9	Stomach	46	1819FA3B-E55C-4B4D-98C2-F0C4D98C7327	B7B31E77-1472-42A3-903D-63C74F1A84DA	TCGA-BR-6564-10A-01D-1880-02	HG19_Broad_variant	TCGA-BR-6564	TCGA-STAD	NA	s15179	Harvard Medical School	Asterand	Russia	NO	T3	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6bfce	58cfa830e4b0c9d6adf6bfce	TCGA-BR-6710-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BR-6710-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_4_rg.sorted	TCGA-BR-6710-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_4_rg.sorted.bam	294	1.9	0.17	58cfa830e4b0c9d6adf6bfce	TCGA-BR-6710-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6710-10A	012E99FE-E3E8-4BB0-BB74-5B0C9992187C	Blood Derived Normal	Illumina HiSeq	a4f4bc0d-7d51-4c01-b0c7-98f206980452	Stomach	41	DDBC1E15-BF90-4A2A-BF72-A5E0F39149C3	2B49E069-0DB8-4574-ACFA-4B9B8A0F86F2	TCGA-BR-6710-10A-01D-1880-02	HG19_Broad_variant	TCGA-BR-6710	TCGA-STAD	NA	s15382	Harvard Medical School	Asterand	Ukraine	NO	T2	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6bf32	58cfa830e4b0c9d6adf6bf32	TCGA-BR-4188-01A-01D-1128_120805_SN1222_0143_BD172BACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4188-01A-01D-1128_120805_SN1222_0143_BD172BACXX_s_1_rg.sorted	TCGA-BR-4188-01A-01D-1128_120805_SN1222_0143_BD172BACXX_s_1_rg.sorted.bam	230.9	1.9	0.15	58cfa830e4b0c9d6adf6bf32	TCGA-BR-4188-01A-01D-1128_120805_SN1222_0143_BD172BACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4188-01A	151257D7-BA5B-49A0-94F5-50E28F9F46F1	Primary Tumor	Illumina HiSeq	3f570dc4-5d29-4f95-bcf8-281dd6d25981	Stomach	53	26398996-4EB5-4C24-BA78-3CA9A3B6EBC0	549B1391-8EBF-49D0-BF3A-6CAF92A8DC00	TCGA-BR-4188-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4188	TCGA-STAD	NA	s14811	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bfdf	58cfa830e4b0c9d6adf6bfdf	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.bam	172.7	1.9	0.15	58cfa830e4b0c9d6adf6bfdf	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6801-01A	24FED326-BDCF-4C20-A06E-7C1C3D6C9CC5	Primary Tumor	Illumina HiSeq	48843aff-35a1-472b-a298-6489ad1b7de7	Stomach	70	713F11EE-D285-4A3B-B421-1D416E5F8E52	FDD2EE8C-C74B-49B8-A530-8CC171C34804	TCGA-BR-6801-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6801	TCGA-STAD	NA	s15450	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6bee8	58cfa830e4b0c9d6adf6bee8	TCGA-AP-A0LL-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-AP-A0LL-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_4_rg.sorted	TCGA-AP-A0LL-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_4_rg.sorted.bam	30.29	2.07	0.13	58cfa830e4b0c9d6adf6bee8	TCGA-AP-A0LL-10A-01D-A101_120406_SN208_0281_AC0KDBACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LL-10A	D17668C4-5D66-4E16-8B70-B54616581AAE	Blood Derived Normal	Illumina HiSeq	e415e9ef-bee6-4c78-a8a2-07929e59fbfe	Uterus	56	ACC43C62-1C62-4BA1-ABFA-D8F4872E8D8B	D51C3BF5-BC45-4E48-9B34-6AC5AE6EFAED	TCGA-AP-A0LL-10A-01D-A101-02	HG19_Broad_variant	TCGA-AP-A0LL	TCGA-UCEC	NA	s5386	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bf08	58cfa830e4b0c9d6adf6bf08	TCGA-BR-4183-01A-02D-1128_120807_SN590_0174_BC11N6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4183-01A-02D-1128_120807_SN590_0174_BC11N6ACXX_s_7_rg.sorted	TCGA-BR-4183-01A-02D-1128_120807_SN590_0174_BC11N6ACXX_s_7_rg.sorted.bam	196.9	1.9	0.16	58cfa830e4b0c9d6adf6bf08	TCGA-BR-4183-01A-02D-1128_120807_SN590_0174_BC11N6ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4183-01A	33503349-BA7A-43F4-BCB2-AC8D16808432	Primary Tumor	Illumina HiSeq	d0ba8758-affb-40ae-84d2-6c4209a92090	Stomach	55	C17A8996-14C4-4A17-A55B-925172A45211	B5E3A2A5-71FD-4ED8-98DB-0CB725638C26	TCGA-BR-4183-01A-02D-1128-02	HG19_Broad_variant	TCGA-BR-4183	TCGA-STAD	NA	s14527	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6c002	58cfa830e4b0c9d6adf6c002	TCGA-BJ-A0Z2-10A-01D-A10R_120711_SN208_0414_BD13L5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z2-10A-01D-A10R_120711_SN208_0414_BD13L5ACXX_s_3_rg.sorted	TCGA-BJ-A0Z2-10A-01D-A10R_120711_SN208_0414_BD13L5ACXX_s_3_rg.sorted.bam	18.36	1.93	0.17	58cfa830e4b0c9d6adf6c002	TCGA-BJ-A0Z2-10A-01D-A10R_120711_SN208_0414_BD13L5ACXX_s_3_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z2-10A	F9CEFFC0-D544-418D-B4A9-BD3C84E37026	Blood Derived Normal	Illumina HiSeq	12bc46cb-9018-4c63-8a13-7e1d81aebc12	Thyroid	57	BB9C69C4-22D7-4462-BC55-71341EA4D000	3708A7B8-C70F-4452-9643-C580CB42304A	TCGA-BJ-A0Z2-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z2	TCGA-THCA	NA	s11986	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage IVC	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c0a2	58cfa830e4b0c9d6adf6c0a2	TCGA-BJ-A0ZG-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZG-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_7_rg.sorted	TCGA-BJ-A0ZG-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_7_rg.sorted.bam	6.76	1.71	0.13	58cfa830e4b0c9d6adf6c0a2	TCGA-BJ-A0ZG-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZG-10A	A3810F36-D2B4-4A45-AD08-A4DBFB9D27AA	Blood Derived Normal	Illumina HiSeq	ec575768-5714-4488-a113-a87ae6de34f0	Thyroid	80	CF6D9496-441B-4ED1-90D0-BDE9F2C8FD61	B66FBD46-CC3B-4881-ADA0-2998BAF442DA	TCGA-BJ-A0ZG-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZG	TCGA-THCA	NA	s12098	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c0fa	58cfa830e4b0c9d6adf6c0fa	TCGA-BS-A0TD-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BS-A0TD-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_2_rg.sorted	TCGA-BS-A0TD-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_2_rg.sorted.bam	18.7	1.95	0.15	58cfa830e4b0c9d6adf6c0fa	TCGA-BS-A0TD-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_2_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TD-10A	FFAA98A0-2B69-46DC-AEE5-C5C3F2ABBC38	Blood Derived Normal	Illumina HiSeq	74436d29-252b-4a2a-b3b1-42c41efd689f	Uterus	65	2729ED97-F971-4D98-8BAA-F99404DD2B9F	BF739F03-C24E-4FC8-81EE-1BC104FDE973	TCGA-BS-A0TD-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0TD	TCGA-UCEC	NA	s5011	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bff4	58cfa830e4b0c9d6adf6bff4	TCGA-B5-A0JR-10A-01D-A043_120403_SN1222_0094_BD0UKBACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B5-A0JR-10A-01D-A043_120403_SN1222_0094_BD0UKBACXX_s_7_rg.sorted	TCGA-B5-A0JR-10A-01D-A043_120403_SN1222_0094_BD0UKBACXX_s_7_rg.sorted.bam	8.16	1.98	0.17	58cfa830e4b0c9d6adf6bff4	TCGA-B5-A0JR-10A-01D-A043_120403_SN1222_0094_BD0UKBACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JR-10A	A766D113-BC3F-4448-A4E5-F391FB0C0E22	Blood Derived Normal	Illumina HiSeq	01608c11-9bd4-4e76-a8cd-b5fdf4fc19f9	Uterus	73	CA5FD93A-6951-451A-B41E-5B2A1C522B5E	311C1165-5FB7-4164-AF09-9C9ADB797544	TCGA-B5-A0JR-10A-01D-A043-02	HG19_Broad_variant	TCGA-B5-A0JR	TCGA-UCEC	NA	s5209	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c10a	58cfa830e4b0c9d6adf6c10a	TCGA-BS-A0TG-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BS-A0TG-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_4_rg.sorted	TCGA-BS-A0TG-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_4_rg.sorted.bam	15.46	1.82	0.14	58cfa830e4b0c9d6adf6c10a	TCGA-BS-A0TG-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TG-10A	13F31BCB-BEFD-4ED2-ADC0-DC9E9CE52B75	Blood Derived Normal	Illumina HiSeq	a1ae7935-6ba2-41ab-a964-95b087ce291a	Uterus	60	0762739C-25E9-48FB-BF71-4774FF5A6655	BAA329DB-9ED8-416D-BB51-75711DEF8057	TCGA-BS-A0TG-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0TG	TCGA-UCEC	NA	s4610	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c07c	58cfa830e4b0c9d6adf6c07c	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.bam	57.81	1.95	0.16	58cfa830e4b0c9d6adf6c07c	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZH-01A	866CA8AD-ADC9-45D4-AD92-9F8F1A161DDF	Primary Tumor	Illumina HiSeq	488591c3-7ba4-421a-9fc0-36d0604c8175	Thyroid	52	01EE736B-F907-465B-9142-C50BE0A3461B	8B8B2852-9D53-4654-A37C-2749C0F264ED	TCGA-BJ-A0ZH-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZH	TCGA-THCA	NA	s12096	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage IVA	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6bf54	58cfa830e4b0c9d6adf6bf54	TCGA-BR-4253-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-4253-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_6_rg.sorted	TCGA-BR-4253-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_6_rg.sorted.bam	166.9	1.9	0.13	58cfa830e4b0c9d6adf6bf54	TCGA-BR-4253-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4253-11A	411257A4-A148-4606-8C8B-F9F1240E40ED	Solid Tissue Normal	Illumina HiSeq	6237a524-9f83-4bf5-8956-06e3e60438b1	Stomach	80	9A8357DE-8FCE-4126-80FD-DFCEC05FF2F3	BD51E472-AB57-4A4C-B361-46D7A843BE18	TCGA-BR-4253-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4253	TCGA-STAD	NA	s15047	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6c126	58cfa830e4b0c9d6adf6c126	TCGA-BS-A0TJ-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BS-A0TJ-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_6_rg.sorted	TCGA-BS-A0TJ-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_6_rg.sorted.bam	11.22	1.88	0.16	58cfa830e4b0c9d6adf6c126	TCGA-BS-A0TJ-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_6_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TJ-10A	F74DA4C6-4291-46D2-ABD4-7D7F6EF03B00	Blood Derived Normal	Illumina HiSeq	5cdf9afa-86d9-4e53-a76a-8223c971f668	Uterus	59	B3FA5912-FFE9-4CC6-A973-FDF611415B50	E127BE60-BC96-4B16-AADA-98C546F2FE78	TCGA-BS-A0TJ-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0TJ	TCGA-UCEC	NA	s4609	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c0ba	58cfa830e4b0c9d6adf6c0ba	TCGA-BJ-A0ZF-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZF-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_3_rg.sorted	TCGA-BJ-A0ZF-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_3_rg.sorted.bam	11.62	1.93	0.17	58cfa830e4b0c9d6adf6c0ba	TCGA-BJ-A0ZF-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZF-10A	8BEEE000-ECAB-4A49-9C9D-BB8E677AE199	Blood Derived Normal	Illumina HiSeq	16e9c9be-3729-4e42-a182-b0de1f8a25be	Thyroid	54	2A0FC5CD-C936-44E4-852A-8C2797CB8729	E43257E9-B1AC-4DB6-8446-6661D5795ACE	TCGA-BJ-A0ZF-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZF	TCGA-THCA	NA	s12745	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Other  specify	Stage II	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c1de	58cfa830e4b0c9d6adf6c1de	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.bam	62.34	1.97	0.15	58cfa830e4b0c9d6adf6c1de	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A0YX-01A	22473AD4-DF39-4716-B558-3C1409D5FA0E	Primary Tumor	Illumina HiSeq	71886c7b-a73b-4c00-9555-5fd61b5e1347	Bladder	70	DA614214-F84C-43AB-983C-D9D76CF2D6AE	DC052DFC-26A8-4393-8849-FA954913C622	TCGA-BT-A0YX-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BT-A0YX	TCGA-BLCA	NA	s2867	Harvard Medical School	University of Pittsburgh	None	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c0e2	58cfa830e4b0c9d6adf6c0e2	TCGA-BJ-A0ZF-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZF-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_1_rg.sorted	TCGA-BJ-A0ZF-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_1_rg.sorted.bam	67.32	2.02	0.17	58cfa830e4b0c9d6adf6c0e2	TCGA-BJ-A0ZF-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZF-01A	8BEEE000-ECAB-4A49-9C9D-BB8E677AE199	Primary Tumor	Illumina HiSeq	9bd9796f-01f5-45d5-837b-b0bece0995f4	Thyroid	54	83A66A9D-916A-44E8-A7E6-A1385DB504DB	14EE09BE-144A-4461-8F5A-A738CC5D955E	TCGA-BJ-A0ZF-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZF	TCGA-THCA	NA	s12505	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Other  specify	Stage II	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c12a	58cfa830e4b0c9d6adf6c12a	TCGA-BS-A0U7-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BS-A0U7-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_7_rg.sorted	TCGA-BS-A0U7-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_7_rg.sorted.bam	18.15	1.88	0.15	58cfa830e4b0c9d6adf6c12a	TCGA-BS-A0U7-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0U7-10A	282DDC43-922D-4F1F-80C7-6BA2DE23B7BC	Blood Derived Normal	Illumina HiSeq	1d024fe0-273a-4aac-958d-5f2ece359b9b	Uterus	63	9D663867-F946-46AA-B126-959232A2E855	30687D43-CBDD-4557-A792-302873F3F75E	TCGA-BS-A0U7-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0U7	TCGA-UCEC	935	s5014	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c1e8	58cfa830e4b0c9d6adf6c1e8	TCGA-BT-A0YX-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BT-A0YX-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_7_rg.sorted	TCGA-BT-A0YX-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_7_rg.sorted.bam	20.99	1.95	0.16	58cfa830e4b0c9d6adf6c1e8	TCGA-BT-A0YX-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A0YX-10A	22473AD4-DF39-4716-B558-3C1409D5FA0E	Blood Derived Normal	Illumina HiSeq	a3d8075a-0e5e-4177-ba61-0f8cf6367170	Bladder	70	FA93053D-5905-4B53-B0E3-826150554E0B	F847285D-43DD-4EB6-8A97-E4224294318F	TCGA-BT-A0YX-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BT-A0YX	TCGA-BLCA	NA	s3266	Harvard Medical School	University of Pittsburgh	None	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c24e	58cfa830e4b0c9d6adf6c24e	TCGA-BT-A20J-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BT-A20J-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_2_rg.sorted	TCGA-BT-A20J-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_2_rg.sorted.bam	14.88	1.95	0.16	58cfa830e4b0c9d6adf6c24e	TCGA-BT-A20J-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20J-11A	74B1E72D-FDD0-4D84-8858-3BB32D58FF7E	Solid Tissue Normal	Illumina HiSeq	da071b6a-1e54-41d9-86c9-47599382a770	Bladder	75	C53A13EF-44CD-49AF-B69C-82C5C11A3AB4	61898C3F-4C48-4E04-9B67-BE546BC7C662	TCGA-BT-A20J-11A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20J	TCGA-BLCA	579	s3265	Harvard Medical School	University of Pittsburgh	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A14U-02	TRUE
13722.58cfa830e4b0c9d6adf6c22a	58cfa830e4b0c9d6adf6c22a	TCGA-BS-A0UJ-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BS-A0UJ-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_2_rg.sorted	TCGA-BS-A0UJ-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_2_rg.sorted.bam	15.86	1.93	0.15	58cfa830e4b0c9d6adf6c22a	TCGA-BS-A0UJ-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_2_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UJ-10A	FF82548A-F1BB-4DAA-A8F7-B3831B5843AD	Blood Derived Normal	Illumina HiSeq	d9b854a2-bbb4-46b4-af22-dc842d971d32	Uterus	68	A672454B-994C-4953-8B33-A77AE28C1BA0	C567555E-FD02-40F8-870C-254E066195AA	TCGA-BS-A0UJ-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0UJ	TCGA-UCEC	NA	s5008	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c206	58cfa830e4b0c9d6adf6c206	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted.bam	77.69	1.98	0.17	58cfa830e4b0c9d6adf6c206	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20W-01A	4DC5CFFE-ED8C-47AB-B5FC-F9615B5414F7	Primary Tumor	Illumina HiSeq	a817f2b5-a06a-422e-869a-694baf6bb127	Bladder	71	CA14F475-1BE4-450C-80C3-7094D23D0B3D	A32E59E0-242F-465D-8277-E0FE26124091	TCGA-BT-A20W-01A-21D-A14U-02	HG19_Broad_variant	TCGA-BT-A20W	TCGA-BLCA	254	s3085	Harvard Medical School	University of Pittsburgh	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A14U-02	TRUE
13722.58cfa830e4b0c9d6adf6c30e	58cfa830e4b0c9d6adf6c30e	TCGA-BR-6801-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-6801-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_6_rg.sorted	TCGA-BR-6801-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_6_rg.sorted.bam	187	1.9	0.15	58cfa830e4b0c9d6adf6c30e	TCGA-BR-6801-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6801-10A	24FED326-BDCF-4C20-A06E-7C1C3D6C9CC5	Blood Derived Normal	Illumina HiSeq	ad1f6971-d904-467d-a98d-2bc17299540c	Stomach	70	CC6EAF22-F6AB-413B-9495-BE715DA438E2	BC80C770-044A-41A1-8D11-171F99950B4C	TCGA-BR-6801-10A-01D-1880-02	HG19_Broad_variant	TCGA-BR-6801	TCGA-STAD	NA	s15449	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6c2af	58cfa830e4b0c9d6adf6c2af	TCGA-AX-A0J1-10A-01D-A043_120403_SN1222_0094_BD0UKBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AX-A0J1-10A-01D-A043_120403_SN1222_0094_BD0UKBACXX_s_5_rg.sorted	TCGA-AX-A0J1-10A-01D-A043_120403_SN1222_0094_BD0UKBACXX_s_5_rg.sorted.bam	7.14	1.93	0.17	58cfa830e4b0c9d6adf6c2af	TCGA-AX-A0J1-10A-01D-A043_120403_SN1222_0094_BD0UKBACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0J1-10A	EC7A9D74-8B3F-4747-8926-1739A016AB2B	Blood Derived Normal	Illumina HiSeq	a63b4482-6fb6-4554-a81b-a77003d1b12f	Uterus	80	7249199D-6E4A-4A4A-9F4C-996E9B7E2D20	89FA0B56-B5CD-49DA-8408-8A5ACA30813C	TCGA-AX-A0J1-10A-01D-A043-02	HG19_Broad_variant	TCGA-AX-A0J1	TCGA-UCEC	NA	s4592	Harvard Medical School	Gynecologic Oncology Group	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c319	58cfa830e4b0c9d6adf6c319	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.bam	27.7	1.9	0.15	58cfa830e4b0c9d6adf6c319	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6705-01A	B14F2FCB-E869-475E-BC7C-ADAF6E7E636F	Primary Tumor	Illumina HiSeq	cf5ffdf8-e424-4a51-862f-816cba0c92e0	Stomach	68	DB8D0AC1-23B7-49AB-8BB3-44782156F038	F55A158B-F7DB-4786-9553-65DEBCAE80BA	TCGA-BR-6705-01A-12D-1880-02	HG19_Broad_variant	TCGA-BR-6705	TCGA-STAD	NA	s15239	Harvard Medical School	Asterand	Ukraine	NO	T3	N3a	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIB	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6c310	58cfa830e4b0c9d6adf6c310	TCGA-BR-6710-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6710-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_3_rg.sorted	TCGA-BR-6710-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_3_rg.sorted.bam	391.7	1.9	0.14	58cfa830e4b0c9d6adf6c310	TCGA-BR-6710-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6710-01A	012E99FE-E3E8-4BB0-BB74-5B0C9992187C	Primary Tumor	Illumina HiSeq	e0e0146e-bf19-42c8-801b-c5a6ed564c5b	Stomach	41	25E9E880-4EA1-40CF-BBB6-0F961C735C97	999D0F8C-6A89-4753-AD18-F44304EA78F9	TCGA-BR-6710-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6710	TCGA-STAD	NA	s15383	Harvard Medical School	Asterand	Ukraine	NO	T2	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c338	58cfa831e4b0c9d6adf6c338	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted.bam	127.2	1.9	0.14	58cfa831e4b0c9d6adf6c338	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4476-01A	442D7415-D095-4962-8296-A14390BAD40A	Primary Tumor	Illumina HiSeq	87a698be-8fb0-4ced-842b-fdc852b98aa8	Stomach	69	37F5444F-A58D-4899-A11B-9C09ECD357FC	0C5818D8-5C20-4E4B-99CF-6F378CA6EBE7	TCGA-CG-4476-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4476	TCGA-STAD	NA	s14983	Harvard Medical School	Indivumed	Germany	NO	T4b	N3a	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIC	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6c2bc	58cfa830e4b0c9d6adf6c2bc	TCGA-BJ-A0ZH-10A-01D-A10R_120711_SN208_0414_BD13L5ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZH-10A-01D-A10R_120711_SN208_0414_BD13L5ACXX_s_4_rg.sorted	TCGA-BJ-A0ZH-10A-01D-A10R_120711_SN208_0414_BD13L5ACXX_s_4_rg.sorted.bam	10.76	1.39	0.16	58cfa830e4b0c9d6adf6c2bc	TCGA-BJ-A0ZH-10A-01D-A10R_120711_SN208_0414_BD13L5ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZH-10A	866CA8AD-ADC9-45D4-AD92-9F8F1A161DDF	Blood Derived Normal	Illumina HiSeq	765d1c43-26a7-45f8-9fd4-dff42c8b1d11	Thyroid	52	5B7A0DF5-39FE-4D79-8D47-0F1714872513	07B4F9EF-AF11-4B55-9FF0-1B947D7AC42A	TCGA-BJ-A0ZH-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZH	TCGA-THCA	NA	s12100	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage IVA	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c35a	58cfa831e4b0c9d6adf6c35a	TCGA-CG-4477-10A-01D-1154_121029_SN208_0438_AC18NJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-4477-10A-01D-1154_121029_SN208_0438_AC18NJACXX_s_4_rg.sorted	TCGA-CG-4477-10A-01D-1154_121029_SN208_0438_AC18NJACXX_s_4_rg.sorted.bam	67.9	1.9	0.16	58cfa831e4b0c9d6adf6c35a	TCGA-CG-4477-10A-01D-1154_121029_SN208_0438_AC18NJACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4477-10A	18D0AAE7-9694-4252-B8FE-16E62DADAB07	Blood Derived Normal	Illumina HiSeq	e9116b76-5b39-48ec-802b-70e4c7eec731	Stomach	58	02F3A2F6-914C-4201-AB90-A7F2830F5CBA	B851171C-FDED-4A21-8766-A0AFD1B147B2	TCGA-CG-4477-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4477	TCGA-STAD	NA	s14489	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c35e	58cfa831e4b0c9d6adf6c35e	TCGA-CG-4475-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_6_rg.sorted.filtered.	WGS	TCGA-CG-4475-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_6_rg.sorted	TCGA-CG-4475-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_6_rg.sorted.bam	45.9	1.9	0.15	58cfa831e4b0c9d6adf6c35e	TCGA-CG-4475-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4475-10A	CAD2ADC1-0F41-4651-9C80-AE9961E2DC8D	Blood Derived Normal	Illumina HiSeq	7b3804c3-ac4b-4a32-8dde-9ba52821064c	Stomach	76	5CEA6C63-C68C-41ED-B064-9941E60F64BD	0404F559-4DA5-4935-ACB5-D2F2F7730F30	TCGA-CG-4475-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4475	TCGA-STAD	NA	s14414	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Not available	Stage IIB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c340	58cfa831e4b0c9d6adf6c340	TCGA-CG-4474-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-4474-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_4_rg.sorted	TCGA-CG-4474-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_4_rg.sorted.bam	15.9	1.8	0.15	58cfa831e4b0c9d6adf6c340	TCGA-CG-4474-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4474-10A	39DD61A8-CD17-4DF3-AE17-61E239EB00BD	Blood Derived Normal	Illumina HiSeq	72d1cbea-ee5c-4c20-9e94-72684fb953df	Stomach	67	A546EC24-E8CE-4B04-B25F-A230A5EA1067	90FBAFC6-E6C2-40D3-A0A3-D1ACD2D19E64	TCGA-CG-4474-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4474	TCGA-STAD	NA	s14490	Harvard Medical School	Indivumed	Germany	NO	T4a	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c3e2	58cfa831e4b0c9d6adf6c3e2	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.bam	245.7	1.9	0.15	58cfa831e4b0c9d6adf6c3e2	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5743-01A	2DEE4BD8-B00E-4F8A-BFEA-5D8D1A068202	Primary Tumor	Illumina HiSeq	1c58f516-3239-499a-bbcd-f5a8d619d796	Prostate	66	6BD8573D-535F-4F6D-8EAF-60918B5DA578	EE5F51E6-F989-4380-A86F-29CBF50BA03A	TCGA-CH-5743-01A-21D-1572-02	HG19_Broad_variant	TCGA-CH-5743	TCGA-PRAD	NA	s3588	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c3b2	58cfa831e4b0c9d6adf6c3b2	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted.bam	127.2	1.9	0.14	58cfa831e4b0c9d6adf6c3b2	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4476-01A	442D7415-D095-4962-8296-A14390BAD40A	Primary Tumor	Illumina HiSeq	fa01457a-1a83-47ed-b744-7494b9756706	Stomach	69	37F5444F-A58D-4899-A11B-9C09ECD357FC	0C5818D8-5C20-4E4B-99CF-6F378CA6EBE7	TCGA-CG-4476-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4476	TCGA-STAD	NA	s14554	Harvard Medical School	Indivumed	Germany	NO	T4b	N3a	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIC	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c3e6	58cfa831e4b0c9d6adf6c3e6	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.bam	146.7	1.9	0.15	58cfa831e4b0c9d6adf6c3e6	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5745-01A	AC67D0DF-7DC0-4A1A-8B47-BEEC9B94DE86	Primary Tumor	Illumina HiSeq	c1d27dca-0355-41e5-a53b-0af94a125c6a	Prostate	68	BDA91E83-643B-4FAE-BFE9-B4660F3BDF02	780758FF-58EE-4B4B-AC71-DE15C89C4625	TCGA-CH-5745-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5745	TCGA-PRAD	NA	s3770	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c3e8	58cfa831e4b0c9d6adf6c3e8	TCGA-CD-5798-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CD-5798-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_3_rg.sorted	TCGA-CD-5798-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_3_rg.sorted.bam	214.7	1.9	0.15	58cfa831e4b0c9d6adf6c3e8	TCGA-CD-5798-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5798-10A	E42F45C6-FD00-44CF-A210-C8803DA326A1	Blood Derived Normal	Illumina HiSeq	89241089-c1c3-413f-8996-a3f43497f231	Stomach	82	FE945E1F-78EF-49E8-AFFE-40D7768BF07E	B612B3C3-A7C8-492D-934D-34E9BAF71C76	TCGA-CD-5798-10A-01D-1598-02	HG19_Broad_variant	TCGA-CD-5798	TCGA-STAD	NA	s14546	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3f2	58cfa831e4b0c9d6adf6c3f2	TCGA-CH-5748-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CH-5748-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_4_rg.sorted	TCGA-CH-5748-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_4_rg.sorted.bam	114.4	1.9	0.15	58cfa831e4b0c9d6adf6c3f2	TCGA-CH-5748-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5748-10A	0AF98331-9305-41E9-AF55-30390016D65E	Blood Derived Normal	Illumina HiSeq	c1f919a6-32b6-4134-a118-61ce369b31d2	Prostate	64	17C53B15-D6BF-4E3E-8BE2-7A14FABF33CA	178D7CC1-0C32-4D2F-8CF9-3E2789780A98	TCGA-CH-5748-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5748	TCGA-PRAD	NA	s3769	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c404	58cfa831e4b0c9d6adf6c404	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.bam	285.7	1.9	0.15	58cfa831e4b0c9d6adf6c404	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5790-01A	2B5EF82D-E137-43F6-BFEF-B202F20EE187	Primary Tumor	Illumina HiSeq	22e486a4-e20b-4211-b3fd-35f37d14e718	Prostate	64	5C8782C0-0B0D-4AFF-B996-423D214FF5FF	9BA30DBB-2730-48A1-94E5-10CCA134728F	TCGA-CH-5790-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5790	TCGA-PRAD	NA	s3936	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c400	58cfa831e4b0c9d6adf6c400	TCGA-CH-5789-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CH-5789-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_6_rg.sorted	TCGA-CH-5789-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_6_rg.sorted.bam	79.4	1.9	0.16	58cfa831e4b0c9d6adf6c400	TCGA-CH-5789-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5789-10A	BE5411DC-3CAA-4B25-9B94-CE463E8E52B4	Blood Derived Normal	Illumina HiSeq	df814918-8b73-4130-9bee-73bafbe5419b	Prostate	61	A5CDDC99-2677-4876-8070-F0260FC30BCD	C7A1BBF5-830E-47CC-BE4C-361109986056	TCGA-CH-5789-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5789	TCGA-PRAD	NA	s3429	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c3a2	58cfa831e4b0c9d6adf6c3a2	TCGA-BS-A0UV-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BS-A0UV-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_5_rg.sorted	TCGA-BS-A0UV-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_5_rg.sorted.bam	11.85	1.97	0.15	58cfa831e4b0c9d6adf6c3a2	TCGA-BS-A0UV-10A-01D-A101_120409_SN1222_0096_BD0VA2ACXX_s_5_rg.sorted.bam	Alive	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UV-10A	B19425AB-A82F-4C2A-BF58-D1BD30511D74	Blood Derived Normal	Illumina HiSeq	262ac8f5-08d6-47ea-9493-ded1af443ae2	Uterus	55	C1DB0188-CBB7-4202-B8CF-65D4DB60F512	B546C8AD-A075-4840-B01B-FE19371815D3	TCGA-BS-A0UV-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0UV	TCGA-UCEC	NA	s4611	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa831e4b0c9d6adf6c40a	58cfa831e4b0c9d6adf6c40a	TCGA-CH-5772-11A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CH-5772-11A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_2_rg.sorted	TCGA-CH-5772-11A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_2_rg.sorted.bam	52.7	2	0.15	58cfa831e4b0c9d6adf6c40a	TCGA-CH-5772-11A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5772-11A	ECF9F8BE-7830-4626-8617-694C68EF4074	Solid Tissue Normal	Illumina HiSeq	4101a708-70fa-42dd-8aae-c5e3d3b12dd5	Prostate	63	222A8CFC-3D32-48C2-BAAB-EBF25D7C8156	26283C5E-0BA5-4B9E-8771-401E1A31A437	TCGA-CH-5772-11A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5772	TCGA-PRAD	NA	s3776	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c40e	58cfa831e4b0c9d6adf6c40e	TCGA-CH-5790-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CH-5790-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_8_rg.sorted	TCGA-CH-5790-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_8_rg.sorted.bam	98.4	1.9	0.15	58cfa831e4b0c9d6adf6c40e	TCGA-CH-5790-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5790-10A	2B5EF82D-E137-43F6-BFEF-B202F20EE187	Blood Derived Normal	Illumina HiSeq	d44cf3be-e75c-45a3-a47b-d7571c521c1b	Prostate	64	3AF0A188-4B58-4FA5-A620-63B362741284	528D23A1-834C-4350-86C7-68D7EC56B73D	TCGA-CH-5790-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5790	TCGA-PRAD	NA	s3422	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c412	58cfa831e4b0c9d6adf6c412	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.bam	52.7	2	0.15	58cfa831e4b0c9d6adf6c412	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5794-01A	A80D3EE7-60DD-49BB-B049-9335AFC035F5	Primary Tumor	Illumina HiSeq	2cf518ee-af91-4cf0-a277-263170f71791	Prostate	65	D1A1CCFE-1215-4B34-94A9-C9765264F617	9D7EACBC-B476-4813-9215-AC0073382A25	TCGA-CH-5794-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5794	TCGA-PRAD	NA	s3775	Harvard Medical School	Indivumed	Germany	NO	T2b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c448	58cfa831e4b0c9d6adf6c448	TCGA-CH-5791-10A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CH-5791-10A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_2_rg.sorted	TCGA-CH-5791-10A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_2_rg.sorted.bam	161.4	1.9	0.15	58cfa831e4b0c9d6adf6c448	TCGA-CH-5791-10A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5791-10A	829BED0C-C40D-44FD-AEE8-6C7589DB60F9	Blood Derived Normal	Illumina HiSeq	747350b7-a5fa-4e6a-bf4b-72ea53989d5c	Prostate	72	B08C0243-25F7-4D67-AA5F-164D923EFC5C	14DD8BDC-9413-47FA-AB23-15EC575D06E5	TCGA-CH-5791-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5791	TCGA-PRAD	NA	s3932	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c438	58cfa831e4b0c9d6adf6c438	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.bam	85.7	1.9	0.16	58cfa831e4b0c9d6adf6c438	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5772-01A	ECF9F8BE-7830-4626-8617-694C68EF4074	Primary Tumor	Illumina HiSeq	97cf547a-bc4b-4b08-9f8e-c1986b18aa30	Prostate	63	068AC08D-1A9E-4C71-B436-4ED861A9DCF8	5C9AAB80-29D2-4D85-A9FE-99FA22222CA4	TCGA-CH-5772-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5772	TCGA-PRAD	NA	s4128	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c44a	58cfa831e4b0c9d6adf6c44a	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.bam	214.7	1.9	0.15	58cfa831e4b0c9d6adf6c44a	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5741-01A	B3BF57D4-E31A-4740-B438-FA826FB79550	Primary Tumor	Illumina HiSeq	ae88c859-e075-4e3a-ba86-e6018e71fa98	Prostate	56	B22CBB75-E6E5-443D-AB4E-1CFD0079C69A	6AC2CA6C-FC79-4E5D-B08F-029A4AC2577B	TCGA-CH-5741-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5741	TCGA-PRAD	NA	s3589	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c462	58cfa831e4b0c9d6adf6c462	TCGA-CH-5792-10A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CH-5792-10A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_4_rg.sorted	TCGA-CH-5792-10A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_4_rg.sorted.bam	195.4	1.9	0.15	58cfa831e4b0c9d6adf6c462	TCGA-CH-5792-10A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5792-10A	8A5F2D7F-835C-4726-B238-F82D6A7F25BD	Blood Derived Normal	Illumina HiSeq	a3ab0225-b534-4b3f-8356-d82c84c70db2	Prostate	57	C33B93D4-DAA9-43B9-AFD4-F3712F9ACCCF	2D818154-C3B0-4272-98F5-4EF38F1EAB41	TCGA-CH-5792-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5792	TCGA-PRAD	NA	s3934	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c47b	58cfa831e4b0c9d6adf6c47b	TCGA-CH-5751-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CH-5751-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_8_rg.sorted	TCGA-CH-5751-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_8_rg.sorted.bam	212.4	1.9	0.15	58cfa831e4b0c9d6adf6c47b	TCGA-CH-5751-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5751-10A	721E76D0-4B1D-4E78-ADB8-1344B8030062	Blood Derived Normal	Illumina HiSeq	31eb5a98-80e8-470f-9e31-765c00c7b655	Prostate	68	A701D962-E9E7-433A-9365-D02160134E04	2CE5E478-A5F2-4832-937F-3F41CDF81810	TCGA-CH-5751-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5751	TCGA-PRAD	NA	s3426	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c49a	58cfa831e4b0c9d6adf6c49a	TCGA-BR-4292-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4292-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_1_rg.sorted	TCGA-BR-4292-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_1_rg.sorted.bam	20.9	1.9	0.15	58cfa831e4b0c9d6adf6c49a	TCGA-BR-4292-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4292-01A	703D3E86-32F4-44AE-BD88-C02378FC2269	Primary Tumor	Illumina HiSeq	a7dacb77-1a29-40e8-a758-c37b5bc38631	Stomach	73	2E0E0776-6AD0-4118-B27E-C65D6076A3D4	CA45AA53-32C8-4412-B867-E242ED5B101C	TCGA-BR-4292-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4292	TCGA-STAD	NA	s14817	Harvard Medical School	Asterand	Russia	NO	T1	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa831e4b0c9d6adf6c432	58cfa831e4b0c9d6adf6c432	TCGA-C4-A0F6-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-C4-A0F6-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_3_rg.sorted	TCGA-C4-A0F6-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_3_rg.sorted.bam	14.74	2.11	0.15	58cfa831e4b0c9d6adf6c432	TCGA-C4-A0F6-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-C4-A0F6-10A	4FF9B4F2-6D04-4FED-8796-155902A8BF28	Blood Derived Normal	Illumina HiSeq	b54ac4b7-3c94-4496-bf96-61b3ca3db0c5	Bladder	82	5C24259B-6AFE-4FE2-A030-92659C071362	A44A6075-FCCC-4F8B-B11B-9ECD1B54D5AF	TCGA-C4-A0F6-10A-01D-A10R-02	HG19_Broad_variant	TCGA-C4-A0F6	TCGA-BLCA	NA	s2864	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c50e	58cfa831e4b0c9d6adf6c50e	TCGA-CH-5771-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CH-5771-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_8_rg.sorted	TCGA-CH-5771-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_8_rg.sorted.bam	129.7	2	0.13	58cfa831e4b0c9d6adf6c50e	TCGA-CH-5771-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5771-11A	3ACD8328-76F7-4F43-9660-394B95748C3D	Solid Tissue Normal	Illumina HiSeq	353ba45f-47db-42c5-bb67-3baf1e0a1733	Prostate	63	3BAC387D-1199-4842-863C-8BCC09EFBF3F	6C19FDB0-3E90-4740-8660-263965F296B2	TCGA-CH-5771-11A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5771	TCGA-PRAD	NA	s3773	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c530	58cfa831e4b0c9d6adf6c530	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted.bam	339.7	1.9	0.16	58cfa831e4b0c9d6adf6c530	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5753-01A	928C48A0-68EE-4E28-AE83-9832E52850CA	Primary Tumor	Illumina HiSeq	971890ca-4817-4b12-b817-51caf2239fa3	Prostate	70	2BEEEBA8-47FE-4857-8704-E4C63E38C926	302AE7E6-2ADD-4556-8173-21EA12412058	TCGA-CH-5753-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5753	TCGA-PRAD	NA	s3592	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c531	58cfa831e4b0c9d6adf6c531	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted.bam	131.7	1.9	0.15	58cfa831e4b0c9d6adf6c531	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5768-01A	F6C61A22-A711-416D-9E65-6A1B957E5B2E	Primary Tumor	Illumina HiSeq	98aa2eb7-52a4-424c-aa01-a574d0215ee6	Prostate	72	C4FF48C4-E953-4267-AB9C-3A09A97A88C4	9813DF8A-57D6-4D59-8534-3942B7FE672E	TCGA-CH-5768-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5768	TCGA-PRAD	NA	s3420	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa830e4b0c9d6adf6c278	58cfa830e4b0c9d6adf6c278	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.bam	82.72	2.05	0.16	58cfa830e4b0c9d6adf6c278	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K1-01A	40A3ED98-3892-449C-B07E-7B7612BD997E	Primary Tumor	Illumina HiSeq	fb29a0da-eb80-43a5-be71-85cf2d58268c	Uterus	69	B514F636-DEE3-45F3-BB31-197CA6A171F1	D4814366-AEF2-453B-8DC7-A731B5E53FE8	TCGA-B5-A0K1-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K1	TCGA-UCEC	NA	s5211	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa831e4b0c9d6adf6c544	58cfa831e4b0c9d6adf6c544	TCGA-CH-5788-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CH-5788-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_4_rg.sorted	TCGA-CH-5788-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_4_rg.sorted.bam	101.4	1.9	0.15	58cfa831e4b0c9d6adf6c544	TCGA-CH-5788-10A-01D-1572_130125_SN208_0450_AC1K3NACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5788-10A	C039014F-821C-43D6-9D3C-914F9C8D98FA	Blood Derived Normal	Illumina HiSeq	bd062ff6-6f65-449b-8441-b83018519258	Prostate	69	7B15C08B-3DB1-4505-A8A7-21FF56A7DCA6	E642F580-1F27-4773-AF08-2483009C4E7F	TCGA-CH-5788-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5788	TCGA-PRAD	NA	s3416	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c55c	58cfa831e4b0c9d6adf6c55c	TCGA-CH-5750-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CH-5750-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_6_rg.sorted	TCGA-CH-5750-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_6_rg.sorted.bam	289.4	1.9	0.16	58cfa831e4b0c9d6adf6c55c	TCGA-CH-5750-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5750-10A	DC40CF49-B208-4F59-B5F0-CFBDD02970B2	Blood Derived Normal	Illumina HiSeq	54cfd889-407a-47bf-97d6-e938fb0f0f0c	Prostate	72	3877B217-E1C2-4FFA-8956-DCD5EBF4FBBD	05EF9854-9858-4C11-9676-2C71A51F611C	TCGA-CH-5750-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5750	TCGA-PRAD	NA	s3774	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c546	58cfa831e4b0c9d6adf6c546	TCGA-CH-5768-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CH-5768-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_4_rg.sorted	TCGA-CH-5768-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_4_rg.sorted.bam	216.7	1.9	0.15	58cfa831e4b0c9d6adf6c546	TCGA-CH-5768-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5768-11A	F6C61A22-A711-416D-9E65-6A1B957E5B2E	Solid Tissue Normal	Illumina HiSeq	94474228-f50e-43be-ae1f-20104c2b61cc	Prostate	72	4B013862-E655-4A6F-AF4F-0B291C1242B5	8661FD53-3B4D-4AFF-A7BD-6B7654CE8740	TCGA-CH-5768-11A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5768	TCGA-PRAD	NA	s4130	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c59e	58cfa831e4b0c9d6adf6c59e	TCGA-CG-4465-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4465-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_1_rg.sorted	TCGA-CG-4465-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_1_rg.sorted.bam	122.2	1.9	0.13	58cfa831e4b0c9d6adf6c59e	TCGA-CG-4465-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_1_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4465-01A	C9AB5BF4-092A-420F-9B90-87DEEA58104C	Primary Tumor	Illumina HiSeq	543d167f-2418-4dea-b387-5baa5dc4309f	Stomach	69	89DAB798-0B26-470C-82AF-1B23C83FE4F5	2CCE681F-F5C6-496E-96C3-21046ECEAA56	TCGA-CG-4465-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4465	TCGA-STAD	274	s14411	Harvard Medical School	Indivumed	Germany	NO	T4	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c5a0	58cfa831e4b0c9d6adf6c5a0	TCGA-CG-4465-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4465-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_1_rg.sorted	TCGA-CG-4465-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_1_rg.sorted.bam	122.2	1.9	0.13	58cfa831e4b0c9d6adf6c5a0	TCGA-CG-4465-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_1_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4465-01A	C9AB5BF4-092A-420F-9B90-87DEEA58104C	Primary Tumor	Illumina HiSeq	cb9d270d-5328-46d7-b7ff-cb564fad9175	Stomach	69	89DAB798-0B26-470C-82AF-1B23C83FE4F5	2CCE681F-F5C6-496E-96C3-21046ECEAA56	TCGA-CG-4465-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4465	TCGA-STAD	274	s14826	Harvard Medical School	Indivumed	Germany	NO	T4	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c56b	58cfa831e4b0c9d6adf6c56b	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted.bam	299.7	1.9	0.15	58cfa831e4b0c9d6adf6c56b	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5746-01A	618272C0-C2ED-4BFB-BB4B-404F0987F822	Primary Tumor	Illumina HiSeq	c4373feb-ceca-4bb3-9db2-6f9e94d29605	Prostate	57	54AD063E-68D9-4104-856A-2BD3905FA971	ABAFDCA6-6109-4686-A058-BDBEB9ADD1E7	TCGA-CH-5746-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5746	TCGA-PRAD	NA	s3930	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c51a	58cfa831e4b0c9d6adf6c51a	TCGA-CN-4730-10A-01D-1431_120712_SN1222_0125_BD13TPACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-4730-10A-01D-1431_120712_SN1222_0125_BD13TPACXX_s_8_rg.sorted	TCGA-CN-4730-10A-01D-1431_120712_SN1222_0125_BD13TPACXX_s_8_rg.sorted.bam	928.4	1.9	0.16	58cfa831e4b0c9d6adf6c51a	TCGA-CN-4730-10A-01D-1431_120712_SN1222_0125_BD13TPACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4730-10A	35C1F2C6-771C-4533-82DF-F8E2EC7107D7	Blood Derived Normal	Illumina HiSeq	975d6473-5677-45fd-8930-d94f3addfc30	Head and Neck	62	3D7DC830-42C8-4746-AA06-C5A58E6AD510	D7DBCD9B-1AF6-41AE-8C6F-420E6041E346	TCGA-CN-4730-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4730	TCGA-HNSC	NA	s15623	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5ca	58cfa831e4b0c9d6adf6c5ca	TCGA-BR-6705-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BR-6705-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_4_rg.sorted	TCGA-BR-6705-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_4_rg.sorted.bam	187.3	1.9	0.15	58cfa831e4b0c9d6adf6c5ca	TCGA-BR-6705-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6705-10A	B14F2FCB-E869-475E-BC7C-ADAF6E7E636F	Blood Derived Normal	Illumina HiSeq	7fbe76eb-2522-4271-89b9-61797e2e206d	Stomach	68	EDB50087-0611-46DB-9BE5-C3DACE105CDB	693FA0BF-922B-44B2-827F-93FC366D8812	TCGA-BR-6705-10A-01D-1880-02	HG19_Broad_variant	TCGA-BR-6705	TCGA-STAD	NA	s14691	Harvard Medical School	Asterand	Ukraine	NO	T3	N3a	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIB	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c5ce	58cfa831e4b0c9d6adf6c5ce	TCGA-CG-5725-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-5725-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_1_rg.sorted	TCGA-CG-5725-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_1_rg.sorted.bam	333.7	1.9	0.14	58cfa831e4b0c9d6adf6c5ce	TCGA-CG-5725-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_1_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5725-01A	129D95CA-71EF-44AA-A93D-F87803C37C9A	Primary Tumor	Illumina HiSeq	61968fb0-fb5d-48fa-88eb-4cd76a6b4456	Stomach	72	E1DED05A-1BC0-42A7-A560-DD67EB804EB4	5254031E-CF64-4B0C-80D8-3EBB4A2DC70F	TCGA-CG-5725-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5725	TCGA-STAD	457	s15129	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c5cc	58cfa831e4b0c9d6adf6c5cc	TCGA-BR-4368-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-4368-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_6_rg.sorted	TCGA-BR-4368-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_6_rg.sorted.bam	192.3	1.9	0.15	58cfa831e4b0c9d6adf6c5cc	TCGA-BR-4368-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4368-11A	449BF2BE-B20E-4AD0-9FFB-910D83114018	Solid Tissue Normal	Illumina HiSeq	8d384344-e3de-49fd-b94d-7bf0f0c03920	Stomach	78	F294C5A3-6A15-4B8B-B8B6-BA0940EB2F00	AACEE07D-E09A-4EB7-B320-41F082A241E2	TCGA-BR-4368-11A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4368	TCGA-STAD	NA	s14616	Harvard Medical School	Asterand	Russia	NO	T4	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c60a	58cfa831e4b0c9d6adf6c60a	TCGA-CQ-6220-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CQ-6220-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_1_rg.sorted	TCGA-CQ-6220-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_1_rg.sorted.bam	342.7	1.9	0.15	58cfa831e4b0c9d6adf6c60a	TCGA-CQ-6220-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6220-01A	96D0CEFE-7949-4736-A7DC-1E4FA94765EC	Primary Tumor	Illumina HiSeq	d86390d3-24c6-4e56-9b8a-d6b3ec75c989	Head and Neck	69	E0E75203-3982-40B2-A057-FAA8433DFB7A	C7EABDCF-81F2-4C87-946A-B5BA42056B04	TCGA-CQ-6220-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6220	TCGA-HNSC	985	s16037	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c5bf	58cfa831e4b0c9d6adf6c5bf	TCGA-CN-5356-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-5356-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_8_rg.sorted	TCGA-CN-5356-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_8_rg.sorted.bam	231.4	1.9	0.16	58cfa831e4b0c9d6adf6c5bf	TCGA-CN-5356-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5356-10A	E1FED7AA-2BCE-45AE-B0C6-7F50EF97E425	Blood Derived Normal	Illumina HiSeq	057502ad-201c-4e2a-967a-1ed9dbf9245b	Head and Neck	56	CF684788-D8E6-49DA-8421-B2DBF040A529	9DCEEF82-8725-48B3-8728-4D48B3033796	TCGA-CN-5356-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5356	TCGA-HNSC	NA	s16183	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c602	58cfa831e4b0c9d6adf6c602	TCGA-CQ-6225-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CQ-6225-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_1_rg.sorted	TCGA-CQ-6225-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_1_rg.sorted.bam	191.7	1.9	0.15	58cfa831e4b0c9d6adf6c602	TCGA-CQ-6225-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6225-01A	90F44998-3C05-44B2-9501-BBD0F43C5147	Primary Tumor	Illumina HiSeq	a96392ab-a0d3-4c22-a2e2-08b58bb3e61b	Head and Neck	65	E907D8D4-C4C6-441F-9F19-FF3746E5D13E	40BFD664-E699-4F0D-9670-30D0F5CC8728	TCGA-CQ-6225-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6225	TCGA-HNSC	403	s16186	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c676	58cfa831e4b0c9d6adf6c676	TCGA-CS-5396-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CS-5396-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_6_rg.sorted	TCGA-CS-5396-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_6_rg.sorted.bam	18.7	1.9	0.13	58cfa831e4b0c9d6adf6c676	TCGA-CS-5396-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-5396-10A	B6C2C9BD-625B-4A98-830C-49C344F6CB5F	Blood Derived Normal	Illumina HiSeq	02bd97c1-a586-4f04-b6e2-16ca05a0ef21	Brain	53	8129E5AC-BE68-40AD-87ED-442DFFE9034A	E51ABE6B-7759-4B50-8919-51778F4BFA01	TCGA-CS-5396-10A-01D-1465-02	HG19_Broad_variant	TCGA-CS-5396	TCGA-LGG	NA	s8557	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c667	58cfa831e4b0c9d6adf6c667	TCGA-CG-4466-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4466-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_2_rg.sorted	TCGA-CG-4466-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_2_rg.sorted.bam	143.3	1.9	0.14	58cfa831e4b0c9d6adf6c667	TCGA-CG-4466-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4466-01A	2F1B96B2-7031-4F7D-9490-14728D320F3E	Primary Tumor	Illumina HiSeq	cea9fe91-10d4-464c-80a6-24b7ed98ba9c	Stomach	81	0BC4ABB4-047B-4C8D-9F79-5B9EB32969E9	623D5E6A-A5D3-4580-BEF7-04673D42A1D0	TCGA-CG-4466-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4466	TCGA-STAD	NA	s14757	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c68c	58cfa831e4b0c9d6adf6c68c	TCGA-CH-5746-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CH-5746-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_2_rg.sorted	TCGA-CH-5746-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_2_rg.sorted.bam	258.4	1.9	0.16	58cfa831e4b0c9d6adf6c68c	TCGA-CH-5746-10A-01D-1572_130103_SN1222_0165_AC1FBHACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5746-10A	618272C0-C2ED-4BFB-BB4B-404F0987F822	Blood Derived Normal	Illumina HiSeq	f96d7355-1ea6-48c4-8399-14a9bef45847	Prostate	57	317F224F-974F-4CD0-829C-EA777A96D726	2C125199-3BB0-4CF5-BA35-54DDF9EBF94D	TCGA-CH-5746-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5746	TCGA-PRAD	NA	s3590	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c673	58cfa831e4b0c9d6adf6c673	TCGA-CU-A0YR-11A-13D-A10R_120920_SN1222_0150_AC1927ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CU-A0YR-11A-13D-A10R_120920_SN1222_0150_AC1927ACXX_s_5_rg.sorted	TCGA-CU-A0YR-11A-13D-A10R_120920_SN1222_0150_AC1927ACXX_s_5_rg.sorted.bam	21.05	2.03	0.16	58cfa831e4b0c9d6adf6c673	TCGA-CU-A0YR-11A-13D-A10R_120920_SN1222_0150_AC1927ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A0YR-11A	811B3950-36E7-485F-BC48-ACA1EEE2DDEF	Solid Tissue Normal	Illumina HiSeq	1efc9ebb-a445-4460-9053-367c5b4daaf5	Bladder	83	C60912E4-2F70-4C1E-91BD-F2F5548E532B	4A3BA06D-AE96-4194-AC33-2133D7C5074A	TCGA-CU-A0YR-11A-13D-A10R-02	HG19_Broad_variant	TCGA-CU-A0YR	TCGA-BLCA	NA	s2880	Harvard Medical School	UNC	United States	NO	T2	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c69c	58cfa831e4b0c9d6adf6c69c	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted.bam	60.7	1.9	0.17	58cfa831e4b0c9d6adf6c69c	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6229-01A	A091822C-447A-49A5-8C20-E329DF79599C	Primary Tumor	Illumina HiSeq	c3f7b43b-25d2-4df3-a85c-231a6708bf8c	Head and Neck	61	F01165B0-911A-45B0-BA7D-7CD0E723A2E4	4AF0777A-6FE3-49AE-B3B9-4AB077DDB007	TCGA-CQ-6229-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6229	TCGA-HNSC	NA	s15631	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c70c	58cfa831e4b0c9d6adf6c70c	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted.bam	115	1.9	0.15	58cfa831e4b0c9d6adf6c70c	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5973-01A	8FC1F1BE-D2D5-4B3A-9973-F4D964018BEB	Primary Tumor	Illumina HiSeq	4965236e-7173-4701-bd61-0550f3451b03	Head and Neck	62	5078222F-B257-4286-A29A-BC1E395149BC	55E8AEAC-4C0E-49DF-8F57-605E7C820B89	TCGA-CV-5973-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5973	TCGA-HNSC	NA	s16193	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c6a0	58cfa831e4b0c9d6adf6c6a0	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted.bam	40.7	2	0.16	58cfa831e4b0c9d6adf6c6a0	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6224-01A	D86FD392-FA5C-4142-A647-440E6C32D478	Primary Tumor	Illumina HiSeq	e8b32a2c-944e-4b3e-a302-ffe9e9f8a3ea	Head and Neck	52	AD242EAC-A5AE-42B7-85CE-3E4D0DD308D6	3FAD44AE-89FC-4BB4-BA86-15A0EF7E2C3A	TCGA-CQ-6224-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6224	TCGA-HNSC	NA	s15633	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c6b8	58cfa831e4b0c9d6adf6c6b8	TCGA-CV-5431-11A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CV-5431-11A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_6_rg.sorted	TCGA-CV-5431-11A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_6_rg.sorted.bam	25.7	1.8	0.14	58cfa831e4b0c9d6adf6c6b8	TCGA-CV-5431-11A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5431-11A	64BB5550-2735-4401-A0DB-58EC1020A32D	Solid Tissue Normal	Illumina HiSeq	d7c39448-b5a1-49bb-8ff7-249509a8ffaf	Head and Neck	73	39E3FACF-6D13-4611-BCFA-90EF0350814D	2DD2EAD7-B8E3-4FEB-B03A-C799C73BEF17	TCGA-CV-5431-11A-01D-1509-02	HG19_Broad_variant	TCGA-CV-5431	TCGA-HNSC	522	s16044	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa831e4b0c9d6adf6c746	58cfa831e4b0c9d6adf6c746	TCGA-D7-6817-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D7-6817-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_3_rg.sorted	TCGA-D7-6817-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_3_rg.sorted.bam	435.7	1.9	0.17	58cfa831e4b0c9d6adf6c746	TCGA-D7-6817-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6817-01A	6FFEFB3F-3919-4FEF-AB15-5D32D8F51D57	Primary Tumor	Illumina HiSeq	9d6376df-5da8-4903-ac82-a2c69750107a	Stomach	63	9E01F1D4-7BA6-42B7-A43C-833195EF4B49	10358672-8D99-4098-8B0A-71D4960A45FA	TCGA-D7-6817-01A-11D-1880-02	HG19_Broad_variant	TCGA-D7-6817	TCGA-STAD	NA	s14422	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2b	N3	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c760	58cfa831e4b0c9d6adf6c760	TCGA-D7-6815-10A-01D-1880_130111_SN208_0447_AC1JP0ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D7-6815-10A-01D-1880_130111_SN208_0447_AC1JP0ACXX_s_2_rg.sorted	TCGA-D7-6815-10A-01D-1880_130111_SN208_0447_AC1JP0ACXX_s_2_rg.sorted.bam	185	1.9	0.15	58cfa831e4b0c9d6adf6c760	TCGA-D7-6815-10A-01D-1880_130111_SN208_0447_AC1JP0ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6815-10A	53086E20-A727-40D6-B42D-8030109B5130	Blood Derived Normal	Illumina HiSeq	f673f591-e023-4c88-9054-8433fa9d0e2f	Stomach	70	B051617A-8114-4EAF-A0E4-37D69CF65065	787C736A-143C-4BBF-B13F-146594B1C671	TCGA-D7-6815-10A-01D-1880-02	HG19_Broad_variant	TCGA-D7-6815	TCGA-STAD	NA	s14997	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIB	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c77f	58cfa831e4b0c9d6adf6c77f	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted.bam	457	1.9	0.15	58cfa831e4b0c9d6adf6c77f	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6815-01A	53086E20-A727-40D6-B42D-8030109B5130	Primary Tumor	Illumina HiSeq	aaa1a66d-814e-403e-bd88-38f4e3ea8c47	Stomach	70	B5F3D9A1-46B5-4A63-8F7D-9C993FE9340D	810C88A8-62F3-42C6-BBFD-A9D65E2A07A4	TCGA-D7-6815-01A-11D-1880-02	HG19_Broad_variant	TCGA-D7-6815	TCGA-STAD	NA	s14497	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIB	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c768	58cfa831e4b0c9d6adf6c768	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted.bam	86.58	1.84	0.16	58cfa831e4b0c9d6adf6c768	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A1O0-01A	A98BBE29-8817-4380-A738-3C1BF9F8E0CC	Primary Tumor	Illumina HiSeq	30d286e0-9e60-48a1-81f4-b35d81af6da1	Uterus	77	E113E0F0-3AE5-48A3-A226-AD920F41259E	8DF3928E-65CE-4578-96A4-BA3AE51E764C	TCGA-D1-A1O0-01A-11D-A17E-02	HG19_Broad_variant	TCGA-D1-A1O0	TCGA-UCEC	NA	s4619	Harvard Medical School	Mayo Clinic	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A17E-02	TRUE
13722.58cfa831e4b0c9d6adf6c74d	58cfa831e4b0c9d6adf6c74d	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted.bam	86.4	1.36	0.15	58cfa831e4b0c9d6adf6c74d	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A177-01A	E8C58D8B-51D7-4599-AF79-469EE6F269DB	Primary Tumor	Illumina HiSeq	cf08e174-408a-4212-8caf-72692bcb55af	Uterus	70	97587FD4-0F6F-4AF5-AC0A-7328ABB40E9C	2F6D7D10-84AA-48A6-9B8E-9CBB257C653D	TCGA-D1-A177-01A-21D-A12F-02	HG19_Broad_variant	TCGA-D1-A177	TCGA-UCEC	NA	s4800	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c7d8	58cfa831e4b0c9d6adf6c7d8	TCGA-D1-A169-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D1-A169-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_5_rg.sorted	TCGA-D1-A169-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_5_rg.sorted.bam	10.9	1.88	0.16	58cfa831e4b0c9d6adf6c7d8	TCGA-D1-A169-10A-01D-A12F_120522_SN208_0301_BC0VNWACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A169-10A	9A599F57-0E8D-4E1F-A181-791F5FDEADB7	Blood Derived Normal	Illumina HiSeq	8e7ebc74-1345-499c-82c8-6a3a7f866edc	Uterus	63	602219E4-F146-476B-BC3F-47B6CAEB16C8	67A2DCA1-02DD-4C46-88C6-19C592A96B0F	TCGA-D1-A169-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A169	TCGA-UCEC	NA	s4797	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c7a3	58cfa831e4b0c9d6adf6c7a3	TCGA-CV-6954-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-6954-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_3_rg.sorted	TCGA-CV-6954-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_3_rg.sorted.bam	62.7	1.9	0.15	58cfa831e4b0c9d6adf6c7a3	TCGA-CV-6954-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_3_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	Not available	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6954-01A	402FD96C-76D3-4AC2-9F64-77BD34BE0ADB	Primary Tumor	Illumina HiSeq	115469a6-3c3e-4a3b-adf9-ed831266829c	Head and Neck	59	F72D39EA-7DB5-47C6-9428-3E26454C9A9A	7FA6660F-0B18-4F4D-AEA1-17C22A9DBAA6	TCGA-CV-6954-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6954	TCGA-HNSC	2002	s16341	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	NX	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c7f3	58cfa831e4b0c9d6adf6c7f3	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted.bam	414	1.87	0.14	58cfa831e4b0c9d6adf6c7f3	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-5577-01A	2DC154AA-C478-404B-A92E-86ABCC8DBDB7	Primary Tumor	Illumina HiSeq	e417c8be-9c96-4e81-a2c9-ac3f23791347	Stomach	53	93BBD9FD-2385-46C3-AF21-E46C72A8A75D	8FCA6D2A-04D8-4A60-AEA3-298853E74752	TCGA-D7-5577-01A-01D-1598-02	HG19_Broad_variant	TCGA-D7-5577	TCGA-STAD	NA	s14908	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N3	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c7e7	58cfa831e4b0c9d6adf6c7e7	TCGA-CV-5977-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-5977-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_7_rg.sorted	TCGA-CV-5977-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_7_rg.sorted.bam	22	1.9	0.17	58cfa831e4b0c9d6adf6c7e7	TCGA-CV-5977-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5977-11A	50239D1D-B3A4-4240-AB83-B24BA67B1299	Solid Tissue Normal	Illumina HiSeq	e6770560-36ba-42ca-bdc1-8a715a864c51	Head and Neck	66	7DB4F0EF-5756-42F6-8D3B-68F68BCB7B8B	C4BE77A1-3AE3-4D82-B53B-7FAA22A796BD	TCGA-CV-5977-11A-01D-1681-02	HG19_Broad_variant	TCGA-CV-5977	TCGA-HNSC	NA	s16199	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c80f	58cfa831e4b0c9d6adf6c80f	TCGA-CV-6938-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-6938-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_4_rg.sorted	TCGA-CV-6938-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_4_rg.sorted.bam	62.7	2	0.16	58cfa831e4b0c9d6adf6c80f	TCGA-CV-6938-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6938-01A	FF9DB03D-F81C-4079-8B05-F5A8C05B8CFE	Primary Tumor	Illumina HiSeq	a328ffc7-c5cd-4726-a75a-e625d33859a8	Head and Neck	87	9EB292E6-AE4D-4613-98EE-0197FD97B633	87E1BCCB-5B03-40AF-A262-0B2B5E6A08D2	TCGA-CV-6938-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6938	TCGA-HNSC	144	s16050	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c858	58cfa831e4b0c9d6adf6c858	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted.bam	209.7	1.9	0.15	58cfa831e4b0c9d6adf6c858	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6517-01A	EBE99910-E9F2-43DC-AD57-AC2F610B60C8	Primary Tumor	Illumina HiSeq	e84f34a5-8df7-4824-92d7-4f53b4bace58	Head and Neck	59	8C099F45-3FD6-4966-8CDB-CA4B9288B1A2	97962F6C-B2FB-4618-A5A4-7B376714EC62	TCGA-D6-6517-01A-11D-1868-02	HG19_Broad_variant	TCGA-D6-6517	TCGA-HNSC	NA	s15655	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6c826	58cfa831e4b0c9d6adf6c826	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted.bam	73.35	1.96	0.17	58cfa831e4b0c9d6adf6c826	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17U-01A	6397C4A1-0A29-4C2C-B8CB-CE73AF93DD0B	Primary Tumor	Illumina HiSeq	8d00983f-b836-41a9-a4b9-51c75b4452a8	Uterus	53	1F1945EE-4CF3-43A3-9998-1C4528C7A511	1B9EB26F-48E0-4EBF-9094-5013E3DF2FBD	TCGA-D1-A17U-01A-21D-A12F-02	HG19_Broad_variant	TCGA-D1-A17U	TCGA-UCEC	NA	s4616	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c98e	58cfa831e4b0c9d6adf6c98e	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted.bam	94.4	1.9	0.14	58cfa831e4b0c9d6adf6c98e	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6520-01A	3C573AF6-6298-49DE-8DE0-6A7F9CE9B000	Primary Tumor	Illumina HiSeq	46b79d94-56c0-4b23-955d-2395a50ecaf9	Stomach	53	7C162352-903E-4723-AF91-6FDD8E8EAD3B	F1CB7996-BD0E-4123-84E9-D359E5DB7700	TCGA-D7-6520-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6520	TCGA-STAD	NA	s14494	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2b	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6c246	58cfa830e4b0c9d6adf6c246	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted.bam	747.33	1.9	0.16	58cfa830e4b0c9d6adf6c246	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4078-01A	C7353D6A-82A2-4A0D-8CD4-8C8957943EDB	Primary Tumor	Illumina HiSeq	cf3b040a-b4be-41ce-a172-1a295ebd79b2	Head and Neck	83	2027EDE3-13F5-40F6-BEF6-16704981D676	66A9CFF2-397E-415E-BF54-9A75CCC80BDE	TCGA-BA-4078-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4078	TCGA-HNSC	276	s15877	Harvard Medical School	UNC	None	NO	Not available	Not available	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c9d4	58cfa831e4b0c9d6adf6c9d4	TCGA-DB-5276-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DB-5276-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_5_rg.sorted	TCGA-DB-5276-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_5_rg.sorted.bam	52.7	1.9	0.15	58cfa831e4b0c9d6adf6c9d4	TCGA-DB-5276-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5276-01A	9D0C1552-00A7-4F0A-A04A-A82E721EE4E3	Primary Tumor	Illumina HiSeq	02206442-a052-4c44-a4b8-1467493df2eb	Brain	32	11CB167F-CD54-409F-BFEA-511E620C96FC	5396382E-9FBC-43DA-9C88-DF17FFDA1E2B	TCGA-DB-5276-01A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5276	TCGA-LGG	NA	s8131	Harvard Medical School	Mayo Clinic - Rochester	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c9d3	58cfa831e4b0c9d6adf6c9d3	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted.bam	16.46	1.91	0.17	58cfa831e4b0c9d6adf6c9d3	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A3-01A	C5B20CCC-523D-491C-8536-008E05C57212	Primary Tumor	Illumina HiSeq	0e78dec3-7b8b-425e-9cc5-489bf825e0ea	Bladder	60	954E46BA-514F-4708-AD3C-ECBF8CEF005A	DC0A234A-9177-4E2A-B218-212F1278B4A1	TCGA-DK-A1A3-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A3	TCGA-BLCA	NA	s3102	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c744	58cfa831e4b0c9d6adf6c744	TCGA-D3-A1Q7-06A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D3-A1Q7-06A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_1_rg.sorted	TCGA-D3-A1Q7-06A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_1_rg.sorted.bam	56.17	NA	0.17	58cfa831e4b0c9d6adf6c744	TCGA-D3-A1Q7-06A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A1Q7-06A	DF6303CD-FFB5-422F-9865-B09029A6D54F	Metastatic	Illumina HiSeq	f9cdbc4b-24de-4377-ac12-2d532ee5fa4f	Skin	42	E9879B40-CE83-49C6-A4D4-12B43CE2A55A	CF12EE87-5C0F-4450-8490-FECE5B88DF0B	TCGA-D3-A1Q7-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D3-A1Q7	TCGA-SKCM	NA	s7999	Harvard Medical School	MD Anderson	United States	NO	T1b	N0	Not available	Stage IB	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c9c7	58cfa831e4b0c9d6adf6c9c7	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted.bam	374.7	1.9	0.15	58cfa831e4b0c9d6adf6c9c7	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5630-01A	91A712B5-A724-48D0-BA06-4F6857683463	Primary Tumor	Illumina HiSeq	865b23ff-32b6-41bf-8316-cde4e80d7873	Head and Neck	73	A0CDB208-E66F-4AD7-86FA-5077145A4A68	4C2960DA-103B-4620-ABCD-0EE586F39E0D	TCGA-DQ-5630-01A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5630	TCGA-HNSC	NA	s16346	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6ca02	58cfa831e4b0c9d6adf6ca02	TCGA-DJ-A1QG-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DJ-A1QG-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_4_rg.sorted	TCGA-DJ-A1QG-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_4_rg.sorted.bam	39.36	1.91	0.16	58cfa831e4b0c9d6adf6ca02	TCGA-DJ-A1QG-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QG-10A	CB29E795-7618-4882-A7E0-69D39787B80C	Blood Derived Normal	Illumina HiSeq	c478083a-0e34-4cfb-83ef-b3038b04fce7	Thyroid	62	083FAC8E-F1CF-4870-AB32-1DC6ABE973AA	B5210C9F-CEC7-4109-9447-E7FA1B19FD09	TCGA-DJ-A1QG-10A-01D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QG	TCGA-THCA	NA	s12364	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6ca9c	58cfa831e4b0c9d6adf6ca9c	TCGA-D7-6817-10A-01D-1880_130111_SN208_0447_AC1JP0ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D7-6817-10A-01D-1880_130111_SN208_0447_AC1JP0ACXX_s_4_rg.sorted	TCGA-D7-6817-10A-01D-1880_130111_SN208_0447_AC1JP0ACXX_s_4_rg.sorted.bam	419	1.9	0.14	58cfa831e4b0c9d6adf6ca9c	TCGA-D7-6817-10A-01D-1880_130111_SN208_0447_AC1JP0ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6817-10A	6FFEFB3F-3919-4FEF-AB15-5D32D8F51D57	Blood Derived Normal	Illumina HiSeq	3b400a10-191c-44f7-af35-4b9ea1cb192e	Stomach	63	4F4A4499-0E06-4108-9F26-BF7D6A5DAF3F	0BDC98DD-3B4D-4737-8574-28E3F48366F7	TCGA-D7-6817-10A-01D-1880-02	HG19_Broad_variant	TCGA-D7-6817	TCGA-STAD	NA	s14995	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2b	N3	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6ca76	58cfa831e4b0c9d6adf6ca76	TCGA-DK-A2HX-10A-01D-A18D_120913_SN208_0429_AC187FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DK-A2HX-10A-01D-A18D_120913_SN208_0429_AC187FACXX_s_2_rg.sorted	TCGA-DK-A2HX-10A-01D-A18D_120913_SN208_0429_AC187FACXX_s_2_rg.sorted.bam	25.35	NA	0.15	58cfa831e4b0c9d6adf6ca76	TCGA-DK-A2HX-10A-01D-A18D_120913_SN208_0429_AC187FACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2HX-10A	C728FAC9-5452-4759-A4ED-A366E0F757CB	Blood Derived Normal	Illumina HiSeq	eb041cfc-02dc-491c-a584-db245f5d273a	Bladder	80	1E934A96-C1CE-4427-AFD3-5F311FCD795F	29357D01-F9BA-49B4-AD9F-5789986C092F	TCGA-DK-A2HX-10A-01D-A18D-02	HG19_Broad_variant	TCGA-DK-A2HX	TCGA-BLCA	NA	s2713	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A18D-02	TRUE
13722.58cfa831e4b0c9d6adf6ca86	58cfa831e4b0c9d6adf6ca86	TCGA-DJ-A1QI-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DJ-A1QI-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_7_rg.sorted	TCGA-DJ-A1QI-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_7_rg.sorted.bam	37.8	1.92	0.15	58cfa831e4b0c9d6adf6ca86	TCGA-DJ-A1QI-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QI-10A	3B1E2BD6-3D32-40F7-9B32-0DF32DFCBC72	Blood Derived Normal	Illumina HiSeq	67e8a52c-7619-457e-9e9b-96991cd41e73	Thyroid	63	FF0C61F9-7F90-48B4-BA4E-F9D7B61A8557	D921807B-9289-42D6-A27F-2D17056F12F4	TCGA-DJ-A1QI-10A-01D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QI	TCGA-THCA	NA	s12750	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cac2	58cfa831e4b0c9d6adf6cac2	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted.bam	78.88	1.95	0.16	58cfa831e4b0c9d6adf6cac2	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13R-01A	3E787A0E-B5D2-401E-B1E5-077376090B3A	Primary Tumor	Illumina HiSeq	84cf379b-0f45-44d0-b5e3-00a439bab300	Thyroid	50	27B0FF79-4213-4B57-B6E0-A393B8983D20	7B0104C8-1264-4580-94D1-C7C39D79C6E6	TCGA-DJ-A13R-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13R	TCGA-THCA	NA	s12368	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6ca92	58cfa831e4b0c9d6adf6ca92	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted.bam	98.7	1.9	0.15	58cfa831e4b0c9d6adf6ca92	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5624-01A	B4A41682-4ACA-4F1D-BACD-66F5E6EC7466	Primary Tumor	Illumina HiSeq	72ea153a-e312-4f8e-8fa6-bd705df2b106	Head and Neck	43	39A74037-6C20-4713-A6AA-E972218EFF90	45F819EB-F6B5-4B82-9E47-060B2E111851	TCGA-DQ-5624-01A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5624	TCGA-HNSC	NA	s15532	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1868-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7fa	58cfa82fe4b0c9d6adf6b7fa	TCGA-38-4629-01A-02D-1203_120305_SN1120_0119_BD0REAACXX_s_8_rg.sorted.filtered.	WGS	TCGA-38-4629-01A-02D-1203_120305_SN1120_0119_BD0REAACXX_s_8_rg.sorted	TCGA-38-4629-01A-02D-1203_120305_SN1120_0119_BD0REAACXX_s_8_rg.sorted.bam	155.9	1.9	0.14	58cfa82fe4b0c9d6adf6b7fa	TCGA-38-4629-01A-02D-1203_120305_SN1120_0119_BD0REAACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4629-01A	127BF818-F7E5-46B5-A9DE-39F6D96B8B83	Primary Tumor	Illumina HiSeq	ecb1f536-930a-4c20-a11a-c69c6740295f	Lung	68	EB822F95-8B15-4C86-B5E5-B0AFE9C32E0C	51FF3351-1A43-458F-9BD9-99BD39FDDAF3	TCGA-38-4629-01A-02D-1203-02	HG19_Broad_variant	TCGA-38-4629	TCGA-LUAD	864	s11450	Harvard Medical School	UNC	None	NO	T3	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	TRUE
13722.58cfa830e4b0c9d6adf6c250	58cfa830e4b0c9d6adf6c250	TCGA-BA-4078-10A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BA-4078-10A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_6_rg.sorted	TCGA-BA-4078-10A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_6_rg.sorted.bam	63.03	1.9	0.14	58cfa830e4b0c9d6adf6c250	TCGA-BA-4078-10A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4078-10A	C7353D6A-82A2-4A0D-8CD4-8C8957943EDB	Blood Derived Normal	Illumina HiSeq	406d17b0-5421-49f4-a66e-227f2076da6f	Head and Neck	83	25B0AE1D-2ADD-49B9-A5AE-99702A5C48F4	FA6F21FF-7667-491C-9A99-31B473C9D683	TCGA-BA-4078-10A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4078	TCGA-HNSC	276	s15489	Harvard Medical School	UNC	None	NO	Not available	Not available	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6ca8e	58cfa831e4b0c9d6adf6ca8e	TCGA-DK-A1A3-10A-01D-A13U_120921_SN208_0431_BD1D5FACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DK-A1A3-10A-01D-A13U_120921_SN208_0431_BD1D5FACXX_s_8_rg.sorted	TCGA-DK-A1A3-10A-01D-A13U_120921_SN208_0431_BD1D5FACXX_s_8_rg.sorted.bam	58.67	1.93	0.15	58cfa831e4b0c9d6adf6ca8e	TCGA-DK-A1A3-10A-01D-A13U_120921_SN208_0431_BD1D5FACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A3-10A	C5B20CCC-523D-491C-8536-008E05C57212	Blood Derived Normal	Illumina HiSeq	dea57f3e-8079-4c79-9961-51b68eba2dcc	Bladder	60	57DE21D1-0917-49B0-9813-7F4B7A94F6EB	CCBC402E-6FAB-4BB8-84CA-314649D26EF0	TCGA-DK-A1A3-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A3	TCGA-BLCA	NA	s2702	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6cb72	58cfa831e4b0c9d6adf6cb72	TCGA-EJ-5516-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-5516-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_4_rg.sorted	TCGA-EJ-5516-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_4_rg.sorted.bam	758.4	1.9	0.16	58cfa831e4b0c9d6adf6cb72	TCGA-EJ-5516-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5516-10A	1FD06207-54E0-4ABA-819C-C7F671871F39	Blood Derived Normal	Illumina HiSeq	62d826e0-8cb6-4568-9f74-02b23a1421df	Prostate	49	C0D9909A-4EED-44DE-AFBA-0D8C0A549DDD	121C2F4C-3B87-4094-8CD4-8ADB3E27859E	TCGA-EJ-5516-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5516	TCGA-PRAD	NA	s3783	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cb3c	58cfa831e4b0c9d6adf6cb3c	TCGA-EE-A2GP-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EE-A2GP-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_6_rg.sorted	TCGA-EE-A2GP-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_6_rg.sorted.bam	52.44	NA	0.16	58cfa831e4b0c9d6adf6cb3c	TCGA-EE-A2GP-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GP-10A	06F09D1C-BA44-4CF9-A518-762D241A30DB	Blood Derived Normal	Illumina HiSeq	202c00c0-a3f0-4582-a62c-9eea259bd599	Skin	80	AFD87E85-3310-41E5-8F66-9429CBD6DBCD	E4F81123-781A-407A-B922-C6CE48CFF9EC	TCGA-EE-A2GP-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2GP	TCGA-SKCM	423	s7510	Harvard Medical School	University of Sydney	Australia	NO	T4b	N1a	Not available	Stage IIIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb44	58cfa831e4b0c9d6adf6cb44	TCGA-EE-A17X-10A-01D-A190_120730_SN1222_0141_BC115GACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EE-A17X-10A-01D-A190_120730_SN1222_0141_BC115GACXX_s_7_rg.sorted	TCGA-EE-A17X-10A-01D-A190_120730_SN1222_0141_BC115GACXX_s_7_rg.sorted.bam	33.23	NA	0.17	58cfa831e4b0c9d6adf6cb44	TCGA-EE-A17X-10A-01D-A190_120730_SN1222_0141_BC115GACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	Not available	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A17X-10A	5F8CC8D6-8A1C-41D0-BAD6-FEDD2948F40A	Blood Derived Normal	Illumina HiSeq	f56ec114-dd45-40eb-aeb3-d10b94e3af35	Skin	54	4E9EF0D5-E5B0-4C8A-9C13-C8D088F205D6	3578D9CB-AB85-4041-9777-8A4C3EA3BDEE	TCGA-EE-A17X-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A17X	TCGA-SKCM	907	s7682	Harvard Medical School	University of Sydney	Australia	NO	T1a	N0	Not available	Stage IA	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb54	58cfa831e4b0c9d6adf6cb54	TCGA-EE-A2MC-06A-12D-A18Y_120724_SN208_0417_AC117BACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EE-A2MC-06A-12D-A18Y_120724_SN208_0417_AC117BACXX_s_3_rg.sorted	TCGA-EE-A2MC-06A-12D-A18Y_120724_SN208_0417_AC117BACXX_s_3_rg.sorted.bam	38.73	NA	0.18	58cfa831e4b0c9d6adf6cb54	TCGA-EE-A2MC-06A-12D-A18Y_120724_SN208_0417_AC117BACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MC-06A	3791BD88-C61E-46C3-AAA4-942C2169887C	Metastatic	Illumina HiSeq	f0ce1c44-2f33-40d9-842a-55269b546ed4	Skin	73	E51EADC7-1F85-464C-989B-9D464233618D	A536CA41-2718-41D6-9F86-9EA43F51A3A9	TCGA-EE-A2MC-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2MC	TCGA-SKCM	1871	s7689	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb4a	58cfa831e4b0c9d6adf6cb4a	TCGA-EE-A2M7-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EE-A2M7-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_4_rg.sorted	TCGA-EE-A2M7-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_4_rg.sorted.bam	53.73	NA	0.15	58cfa831e4b0c9d6adf6cb4a	TCGA-EE-A2M7-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2M7-06A	7B4BCF0E-EC55-489B-870F-A4360A6BEA2F	Metastatic	Illumina HiSeq	7212211c-0722-4a90-a452-49224f4e3e43	Skin	66	F2C3A0AD-8C29-45AA-BB06-C4A6641F136F	936FC6FD-3129-43C2-B102-2CBCD4E31DD2	TCGA-EE-A2M7-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2M7	TCGA-SKCM	877	s7850	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage II	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cbaa	58cfa831e4b0c9d6adf6cbaa	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted.bam	378.7	1.9	0.15	58cfa831e4b0c9d6adf6cbaa	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5526-01A	EEC48399-5660-4B25-8D34-191B54315C72	Primary Tumor	Illumina HiSeq	e57f50b5-06be-4be0-8b02-706bfb439f25	Prostate	56	4DBE4FA2-308F-4D5B-BF33-4C051F7DC537	4AC5F198-9558-42C9-8285-91D3F826E0E9	TCGA-EJ-5526-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5526	TCGA-PRAD	NA	s4143	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cbb8	58cfa831e4b0c9d6adf6cbb8	TCGA-EK-A2PM-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EK-A2PM-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_6_rg.sorted	TCGA-EK-A2PM-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_6_rg.sorted.bam	122.14	NA	0.17	58cfa831e4b0c9d6adf6cbb8	TCGA-EK-A2PM-10A-01D-A18I_140204_SN208_0508_BC2R1UACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2PM-10A	085FB6D8-6265-484E-9307-8292386714B7	Blood Derived Normal	Illumina HiSeq	c41a041f-a7af-40aa-b516-42ca0cca7082	Cervix	81	B62127DC-8526-4099-AFC3-BE2E295C7DEE	7A8CDBE5-834A-49F0-88D7-20F0D0E7127F	TCGA-EK-A2PM-10A-01D-A18I-02	HG19_Broad_variant	TCGA-EK-A2PM	TCGA-CESC	NA	s1189	Harvard Medical School	Gynecologic Oncology Group	United States	NO	Not available	Not available	Cervical Squamous Cell Carcinoma	Not available	A18I-02	TRUE
13722.58cfa831e4b0c9d6adf6cb9a	58cfa831e4b0c9d6adf6cb9a	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted.bam	61.4	NA	0.16	58cfa831e4b0c9d6adf6cb9a	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7317-01A	68FC3693-0910-4EE8-8997-99C6333B65F4	Primary Tumor	Illumina HiSeq	7c1cef2b-4606-4c6c-ad6d-b49ca86b9f74	Prostate	71	AEEA2F28-0766-42D7-9E6A-C14BEB03E692	B25F2F78-DB49-49DF-9150-DF43F23589A4	TCGA-EJ-7317-01A-31D-2111-02	HG19_Broad_variant	TCGA-EJ-7317	TCGA-PRAD	NA	s3959	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cb8a	58cfa831e4b0c9d6adf6cb8a	TCGA-EE-A29T-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EE-A29T-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_5_rg.sorted	TCGA-EE-A29T-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_5_rg.sorted.bam	45.93	NA	0.17	58cfa831e4b0c9d6adf6cb8a	TCGA-EE-A29T-06A-11D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29T-06A	9B99FFEE-FE9F-4BE5-A00A-EF86627282A4	Metastatic	Illumina HiSeq	b9efa6bb-7ce3-4b05-9ecb-6d56bedf6e7b	Skin	51	06072B6C-841F-493A-9DB0-6B555E692B2C	1B87EB2D-2F57-4CBD-8A00-57A0EB69AC7C	TCGA-EE-A29T-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29T	TCGA-SKCM	NA	s7847	Harvard Medical School	University of Sydney	Australia	NO	TX	NX	Not available	Not available	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cbbd	58cfa831e4b0c9d6adf6cbbd	TCGA-EJ-5522-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-5522-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_6_rg.sorted	TCGA-EJ-5522-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_6_rg.sorted.bam	467.4	1.9	0.17	58cfa831e4b0c9d6adf6cbbd	TCGA-EJ-5522-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5522-10A	214884EF-A932-4FC3-B6FF-16CE5164DA3E	Blood Derived Normal	Illumina HiSeq	63030ee9-29f8-4955-8347-16e12ab169ca	Prostate	51	DD1221A7-825F-4598-82EC-0A069639A36B	40816943-ECAF-4499-BD1A-07206D9328B9	TCGA-EJ-5522-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5522	TCGA-PRAD	NA	s3946	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cbca	58cfa831e4b0c9d6adf6cbca	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted.bam	52.7	1.9	0.15	58cfa831e4b0c9d6adf6cbca	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5517-01A	4B9AA301-D2E3-47F3-B724-A34F420B2B6B	Primary Tumor	Illumina HiSeq	add98c6f-07de-48db-b930-82504d0dd976	Prostate	55	B5FE6254-D1C6-4BA2-BD75-5CAF4FB2E2B7	62E5A068-01A5-40EC-8FF9-097D627127A0	TCGA-EJ-5517-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5517	TCGA-PRAD	NA	s3437	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cb92	58cfa831e4b0c9d6adf6cb92	TCGA-EE-A2GR-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EE-A2GR-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_5_rg.sorted	TCGA-EE-A2GR-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_5_rg.sorted.bam	16.7	NA	0.15	58cfa831e4b0c9d6adf6cb92	TCGA-EE-A2GR-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GR-10A	919DFC28-6B55-452E-884C-48CB86802AC2	Blood Derived Normal	Illumina HiSeq	48e07f50-8a21-4cbc-a141-7b4b16e333f5	Skin	78	733FB926-7791-46B4-BF47-848ED4B43177	6E77C52C-3C48-4AF0-9F0D-393CE3C268F2	TCGA-EE-A2GR-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2GR	TCGA-SKCM	NA	s7514	Harvard Medical School	University of Sydney	Australia	NO	T4	N0	Not available	Stage II	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cbcd	58cfa831e4b0c9d6adf6cbcd	TCGA-EJ-5526-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-5526-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_4_rg.sorted	TCGA-EJ-5526-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_4_rg.sorted.bam	713.4	1.9	0.16	58cfa831e4b0c9d6adf6cbcd	TCGA-EJ-5526-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5526-10A	EEC48399-5660-4B25-8D34-191B54315C72	Blood Derived Normal	Illumina HiSeq	7101d4c4-2636-40d7-85dd-c3036f889b7b	Prostate	56	B670084A-5C1B-4F10-9AAE-B0E80E5D0AE6	95D2B91D-833C-47CF-97FD-A4D2D7627D74	TCGA-EJ-5526-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5526	TCGA-PRAD	NA	s4144	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cbc7	58cfa831e4b0c9d6adf6cbc7	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted.bam	261.3	NA	0.14	58cfa831e4b0c9d6adf6cbc7	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7327-01A	E90AB72A-4BBB-4C37-B48A-8A1A85D79D04	Primary Tumor	Illumina HiSeq	fe462cbb-5d52-4a0e-8cb8-a7e6c0f39c7c	Prostate	61	992415EF-53DE-4C52-A538-07931E68182B	0FC53595-F61A-4171-B982-335AEE13CC85	TCGA-EJ-7327-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7327	TCGA-PRAD	NA	s4145	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cbd4	58cfa831e4b0c9d6adf6cbd4	TCGA-EJ-5527-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-5527-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_6_rg.sorted	TCGA-EJ-5527-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_6_rg.sorted.bam	329.4	1.9	0.16	58cfa831e4b0c9d6adf6cbd4	TCGA-EJ-5527-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5527-10A	BA0C9096-5F35-4F0A-AE98-EE1A695B55F0	Blood Derived Normal	Illumina HiSeq	38e4be78-cef4-4c22-9407-ba48b34614f5	Prostate	69	7373EF74-66D8-47AD-9267-AE41080B694F	68F24DF0-2CA8-4BA2-899C-1364400944CA	TCGA-EJ-5527-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5527	TCGA-PRAD	NA	s3607	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cbac	58cfa831e4b0c9d6adf6cbac	TCGA-EB-A24D-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EB-A24D-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_7_rg.sorted	TCGA-EB-A24D-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_7_rg.sorted.bam	48.4	NA	0.18	58cfa831e4b0c9d6adf6cbac	TCGA-EB-A24D-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EB-A24D-10A	D7EE2693-39A8-4E3A-B6F6-E4729800E34E	Blood Derived Normal	Illumina HiSeq	1418a25a-5829-4edd-a545-8bebb544a7e8	Skin	72	D9EE5E38-F7F7-4E9A-8C01-4CDED37DC2EC	9B6A527A-83F8-4B0A-95F4-AF1DD54B3404	TCGA-EB-A24D-10A-01D-A190-02	HG19_Broad_variant	TCGA-EB-A24D	TCGA-SKCM	NA	s7839	Harvard Medical School	Asterand	Ukraine	NO	T4a	N2b	Not available	Stage IIIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cbee	58cfa831e4b0c9d6adf6cbee	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted.bam	43.27	NA	0.16	58cfa831e4b0c9d6adf6cbee	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2PM-01A	085FB6D8-6265-484E-9307-8292386714B7	Primary Tumor	Illumina HiSeq	332b29bf-f948-4e2c-bf51-f768f819e9e9	Cervix	81	2E7F29FB-97DE-4EE0-BCA7-6A51C4C3E5CF	C32BE42D-CF78-4F46-B461-748796CEDA4A	TCGA-EK-A2PM-01A-11D-A18I-02	HG19_Broad_variant	TCGA-EK-A2PM	TCGA-CESC	NA	s1195	Harvard Medical School	Gynecologic Oncology Group	United States	NO	Not available	Not available	Cervical Squamous Cell Carcinoma	Not available	A18I-02	TRUE
13722.58cfa831e4b0c9d6adf6cbdd	58cfa831e4b0c9d6adf6cbdd	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted.bam	188.7	1.9	0.15	58cfa831e4b0c9d6adf6cbdd	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5532-01A	AE3A0C92-148D-4F1C-8563-06AC1050F53E	Primary Tumor	Illumina HiSeq	e7c833a1-c77a-4c65-b268-1db73a7028e3	Prostate	57	F32F7738-BAD4-40C9-B49F-084BB098A05A	E5F35020-2A9F-47B3-8271-FEF8E1883567	TCGA-EJ-5532-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5532	TCGA-PRAD	NA	s3956	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cc01	58cfa831e4b0c9d6adf6cc01	TCGA-E8-A242-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_4_rg.sorted.filtered.	WGS	TCGA-E8-A242-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_4_rg.sorted	TCGA-E8-A242-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_4_rg.sorted.bam	36.62	1.87	0.17	58cfa831e4b0c9d6adf6cc01	TCGA-E8-A242-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-E8-A242-10A	4D9DE9A1-7DF1-412E-9F16-15DD51B4C5F5	Blood Derived Normal	Illumina HiSeq	3fe95dc7-b12d-4021-b7f7-a5c31038f8ee	Thyroid	56	490FB30A-5455-48ED-95C9-86D044A364B7	ABA2F28E-DD7B-43B5-81F9-83C014DC2EF1	TCGA-E8-A242-10A-01D-A16N-02	HG19_Broad_variant	TCGA-E8-A242	TCGA-THCA	NA	s12517	Harvard Medical School	Asterand	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6cc50	58cfa831e4b0c9d6adf6cc50	TCGA-EJ-5503-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-5503-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_8_rg.sorted	TCGA-EJ-5503-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_8_rg.sorted.bam	248.4	1.9	0.15	58cfa831e4b0c9d6adf6cc50	TCGA-EJ-5503-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5503-10A	AA252F78-EBF3-42F9-86AF-BB6E57345706	Blood Derived Normal	Illumina HiSeq	6f2a0bc7-14c0-431b-ad1a-9ed9cdc21dc4	Prostate	50	84460943-D44C-4B47-9BF1-DEB1C5B5E0BD	165CBB8A-1D84-42E4-BAAA-31F4D0CFA3F1	TCGA-EJ-5503-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5503	TCGA-PRAD	NA	s3438	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cc46	58cfa831e4b0c9d6adf6cc46	TCGA-EJ-5521-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-5521-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_4_rg.sorted	TCGA-EJ-5521-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_4_rg.sorted.bam	212.4	1.9	0.15	58cfa831e4b0c9d6adf6cc46	TCGA-EJ-5521-10A-01D-1573_130218_SN208_0454_BD1TBTACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5521-10A	D44D4BCB-BEB1-4464-ACD2-9972751F5018	Blood Derived Normal	Illumina HiSeq	a00f8885-cc89-43c1-bf1a-d15ddf152756	Prostate	63	77E4A2C2-79F8-400E-8231-10D06E4CB32C	4A35BBF6-F6FA-4CD2-B673-8227EC846063	TCGA-EJ-5521-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5521	TCGA-PRAD	NA	s3601	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cb73	58cfa831e4b0c9d6adf6cb73	TCGA-EE-A2GC-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EE-A2GC-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_3_rg.sorted	TCGA-EE-A2GC-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_3_rg.sorted.bam	68.75	NA	0.15	58cfa831e4b0c9d6adf6cb73	TCGA-EE-A2GC-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GC-06A	0A4B780E-8143-4118-AD98-FD2A2A6678C3	Metastatic	Illumina HiSeq	0c42714c-45d4-4591-bb02-c4f3116a72ea	Skin	82	498B5692-1FF2-4D4E-B96A-9CE977A2F24F	BE14E43C-34E5-4F20-86BA-80226FE02DC8	TCGA-EE-A2GC-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2GC	TCGA-SKCM	NA	s8014	Harvard Medical School	University of Sydney	Australia	NO	T3b	N0	Not available	Stage IIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cca3	58cfa831e4b0c9d6adf6cca3	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted.bam	91.7	1.9	0.15	58cfa831e4b0c9d6adf6cca3	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5499-01A	FD1AA612-DF86-4D48-892D-2ACEBD76EA96	Primary Tumor	Illumina HiSeq	21f9da4c-83ce-44b4-b002-e18cd232ac6b	Prostate	61	22C4F5C2-1B1E-4212-8110-09DBD5CE10A9	0F4314C9-967C-4EF1-9CF2-A7B206E6129E	TCGA-EJ-5499-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5499	TCGA-PRAD	NA	s3789	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cca6	58cfa831e4b0c9d6adf6cca6	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted.bam	209.7	1.9	0.16	58cfa831e4b0c9d6adf6cca6	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5497-01A	DEE02265-D8DD-4379-AE08-72D72B03A570	Primary Tumor	Illumina HiSeq	453a9559-644e-46b9-8be3-7e4511448e7e	Prostate	47	317BE3B2-B7C1-4772-9E33-D55EB4B9FAA9	0B2246C7-CE2E-427D-BA10-4A2C942D0986	TCGA-EJ-5497-01A-02D-1572-02	HG19_Broad_variant	TCGA-EJ-5497	TCGA-PRAD	NA	s3944	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cc09	58cfa831e4b0c9d6adf6cc09	TCGA-EB-A299-10A-01D-A190_120805_SN1222_0142_AD16TGACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EB-A299-10A-01D-A190_120805_SN1222_0142_AD16TGACXX_s_1_rg.sorted	TCGA-EB-A299-10A-01D-A190_120805_SN1222_0142_AD16TGACXX_s_1_rg.sorted.bam	23.85	NA	0.16	58cfa831e4b0c9d6adf6cc09	TCGA-EB-A299-10A-01D-A190_120805_SN1222_0142_AD16TGACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EB-A299-10A	90402C32-9548-432E-85B8-A4F80E14401E	Blood Derived Normal	Illumina HiSeq	2b13cbc9-eda0-417f-b0a4-a227fa33aac1	Skin	63	7D5C395F-F4BA-49A7-8408-D4CE41A406EF	E2C9FDAC-FF37-421D-B802-38A3471EE9FB	TCGA-EB-A299-10A-01D-A190-02	HG19_Broad_variant	TCGA-EB-A299	TCGA-SKCM	NA	s8003	Harvard Medical School	Asterand	Russia	NO	T2b	N0	Not available	Stage IIA	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ccc2	58cfa831e4b0c9d6adf6ccc2	TCGA-EJ-5510-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-5510-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_6_rg.sorted	TCGA-EJ-5510-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_6_rg.sorted.bam	635.4	1.9	0.16	58cfa831e4b0c9d6adf6ccc2	TCGA-EJ-5510-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5510-10A	4A3D9EFE-F24E-4135-8A70-E202651E7A81	Blood Derived Normal	Illumina HiSeq	ded2ef5d-8342-4b98-be7e-ca384611f209	Prostate	48	20C35589-0E2B-4A88-80EC-B9E5E0CAEB7D	8F8E5DD8-A750-4DBC-A7EC-FC9AF143F0DD	TCGA-EJ-5510-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5510	TCGA-PRAD	NA	s3599	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cc2d	58cfa831e4b0c9d6adf6cc2d	TCGA-EE-A2A1-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EE-A2A1-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_6_rg.sorted	TCGA-EE-A2A1-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_6_rg.sorted.bam	28.75	NA	0.15	58cfa831e4b0c9d6adf6cc2d	TCGA-EE-A2A1-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2A1-10A	A92E70E1-C57D-45EF-A822-33B361C22291	Blood Derived Normal	Illumina HiSeq	d20d23e7-eda7-44ca-8c01-958309009ef8	Skin	46	0933084B-90BA-4105-8989-996F00776A8B	4E250771-0ED3-4FD5-A177-90276344D1FD	TCGA-EE-A2A1-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2A1	TCGA-SKCM	NA	s7678	Harvard Medical School	University of Sydney	Australia	NO	T2a	N0	Not available	Stage IB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc72	58cfa831e4b0c9d6adf6cc72	TCGA-ER-A199-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-ER-A199-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_5_rg.sorted	TCGA-ER-A199-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_5_rg.sorted.bam	39.1	NA	0.16	58cfa831e4b0c9d6adf6cc72	TCGA-ER-A199-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A199-10A	E218FC54-1139-4944-82E2-742839E5553A	Blood Derived Normal	Illumina HiSeq	5f956b1c-bc43-469e-8611-72b020b8830c	Skin	86	1BDFB4EA-F6E1-4C77-9FC6-421C246E4A9A	9EC20523-003B-4DE2-B573-82355C08EFEB	TCGA-ER-A199-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A199	TCGA-SKCM	279	s7519	Harvard Medical School	University of Pittsburgh	United States	NO	T4b	N3	Not available	Stage IIIC	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc6a	58cfa831e4b0c9d6adf6cc6a	TCGA-ER-A197-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-ER-A197-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_6_rg.sorted	TCGA-ER-A197-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_6_rg.sorted.bam	34.03	NA	0.16	58cfa831e4b0c9d6adf6cc6a	TCGA-ER-A197-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A197-10A	3EBB2374-4518-4E19-9B65-9C3E66252C4C	Blood Derived Normal	Illumina HiSeq	256ef618-0c68-4c1c-b754-2fb29870cf2c	Skin	83	3647C9F3-ADBF-47BD-98C5-DE52E323306B	564616DE-9FEF-436D-B3A0-5AFA65276D94	TCGA-ER-A197-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A197	TCGA-SKCM	424	s7354	Harvard Medical School	University of Pittsburgh	United States	NO	T4b	N1a	Not available	Stage IIIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cd10	58cfa831e4b0c9d6adf6cd10	TCGA-EJ-5494-10A-01D-1573_130125_SN208_0451_BD1RB1ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-5494-10A-01D-1573_130125_SN208_0451_BD1RB1ACXX_s_8_rg.sorted	TCGA-EJ-5494-10A-01D-1573_130125_SN208_0451_BD1RB1ACXX_s_8_rg.sorted.bam	1044.4	1.9	0.16	58cfa831e4b0c9d6adf6cd10	TCGA-EJ-5494-10A-01D-1573_130125_SN208_0451_BD1RB1ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5494-10A	E27C50E2-2A41-4F8C-9EF8-2BC51FB0C23E	Blood Derived Normal	Illumina HiSeq	7138c14a-2dab-4b19-b460-da77aa8d9819	Prostate	50	4AF92BBC-2716-4CBC-90F3-F0DB33FE4113	8C1C3F1B-CF15-44A3-9980-E614DE09A5A3	TCGA-EJ-5494-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5494	TCGA-PRAD	NA	s3942	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cccc	58cfa831e4b0c9d6adf6cccc	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted.bam	388.7	1.9	0.14	58cfa831e4b0c9d6adf6cccc	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5530-01A	E4A755E3-4938-4321-B5A9-27A445036791	Primary Tumor	Illumina HiSeq	83b4e2b0-670b-441b-9b17-fa5c1da740c5	Prostate	61	27D61473-39D6-478A-A576-427D1AEDA01F	CBA52846-FAD3-4D21-8949-0105BD2AE713	TCGA-EJ-5530-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5530	TCGA-PRAD	NA	s3961	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cd00	58cfa831e4b0c9d6adf6cd00	TCGA-EJ-5531-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-5531-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_2_rg.sorted	TCGA-EJ-5531-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_2_rg.sorted.bam	621.4	1.9	0.16	58cfa831e4b0c9d6adf6cd00	TCGA-EJ-5531-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5531-10A	ADF3C2F7-D5F9-41C3-BD8C-7F9F1F22FF73	Blood Derived Normal	Illumina HiSeq	4962332e-85c4-4f65-959e-90f2e6169742	Prostate	62	35177C7C-C669-4B3B-9B45-379A40255DF0	87D43596-60A3-42DD-91E1-0C20634B0467	TCGA-EJ-5531-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5531	TCGA-PRAD	NA	s3446	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cd60	58cfa831e4b0c9d6adf6cd60	TCGA-EJ-5498-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-5498-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_8_rg.sorted	TCGA-EJ-5498-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_8_rg.sorted.bam	265.4	1.9	0.16	58cfa831e4b0c9d6adf6cd60	TCGA-EJ-5498-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5498-10A	79EC7468-9AAF-4BB0-94C7-72BE4F497868	Blood Derived Normal	Illumina HiSeq	ed7ab548-eb8d-46b7-ae35-1b081b1ed787	Prostate	56	6C151588-2966-4624-BE3A-8657D36D51DE	67A226F5-7B7C-4A18-854C-EBB688E15FFF	TCGA-EJ-5498-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5498	TCGA-PRAD	NA	s3947	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cd62	58cfa831e4b0c9d6adf6cd62	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted.bam	52.7	1.9	0.17	58cfa831e4b0c9d6adf6cd62	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5498-01A	79EC7468-9AAF-4BB0-94C7-72BE4F497868	Primary Tumor	Illumina HiSeq	1ea5110e-6493-415f-ae21-019a8d1e2a17	Prostate	56	AAF0AF43-DAE0-4AA7-9D4C-6CAF1F039857	24F583BD-C378-4981-A661-97B8E39CE600	TCGA-EJ-5498-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5498	TCGA-PRAD	NA	s3948	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cd8a	58cfa831e4b0c9d6adf6cd8a	TCGA-FE-A235-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FE-A235-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_2_rg.sorted	TCGA-FE-A235-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_2_rg.sorted.bam	28.74	1.95	0.17	58cfa831e4b0c9d6adf6cd8a	TCGA-FE-A235-10A-01D-A16N_121204_SN208_0442_BC1F7YACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A235-10A	C781B49E-D08F-49E6-B774-7CFE4100E92D	Blood Derived Normal	Illumina HiSeq	008e77b4-0033-406b-9e24-84f55f7caf34	Thyroid	26	58E2000A-E322-43BF-B0DF-9C0757145F55	CB7CC52D-4E2A-4FDE-B45C-7AE89FB188C9	TCGA-FE-A235-10A-01D-A16N-02	HG19_Broad_variant	TCGA-FE-A235	TCGA-THCA	NA	s12649	Harvard Medical School	Ohio State University	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6ce6a	58cfa832e4b0c9d6adf6ce6a	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted.filtered.	WGS	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted.bam	65.58	1.91	0.17	58cfa832e4b0c9d6adf6ce6a	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-H2-A26U-01A	E61FB24B-613A-4B6D-BB2B-00CCEDBD3DBC	Primary Tumor	Illumina HiSeq	91b791c7-9ac1-4a55-bb8a-110046b81a61	Thyroid	54	A4240AB1-970E-4A99-989E-8968903E3A25	79850C4D-71D0-4905-946A-F309DCDDA59F	TCGA-H2-A26U-01A-11D-A16N-02	HG19_Broad_variant	TCGA-H2-A26U	TCGA-THCA	NA	s12762	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6cea9	58cfa832e4b0c9d6adf6cea9	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted.bam	197.7	1.9	0.16	58cfa832e4b0c9d6adf6cea9	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5516-01A	1FD06207-54E0-4ABA-819C-C7F671871F39	Primary Tumor	Illumina HiSeq	80ba9751-2e29-4949-a07f-6e3542df8770	Prostate	49	84D2D822-204E-4031-AF83-E188BB72F3AF	7DBAAFC9-A93D-4FFB-9FF0-85FACD567555	TCGA-EJ-5516-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5516	TCGA-PRAD	NA	s4136	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa832e4b0c9d6adf6cf48	58cfa832e4b0c9d6adf6cf48	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted.bam	242.7	NA	0.15	58cfa832e4b0c9d6adf6cf48	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7075-01A	5DD69C3E-9A3D-450C-9F10-10B4D6DAEEBA	Primary Tumor	Illumina HiSeq	7fee8465-32e2-4bef-bd48-102b2534003a	Prostate	63	1FA3E5C2-E415-42FA-AEA3-F6C84959522A	CFC425B3-7570-4FD2-8DB6-611EF4D627DF	TCGA-HC-7075-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7075	TCGA-PRAD	NA	s3811	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cefc	58cfa832e4b0c9d6adf6cefc	TCGA-H4-A2HQ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-H4-A2HQ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_5_rg.sorted	TCGA-H4-A2HQ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_5_rg.sorted.bam	54.46	NA	0.15	58cfa832e4b0c9d6adf6cefc	TCGA-H4-A2HQ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-H4-A2HQ-01A	CEDE5274-279D-4021-8ACA-5ECC4BF94D66	Primary Tumor	Illumina HiSeq	46adb3c9-ac82-4284-b0d1-f95b10435695	Bladder	64	CBEDC0DB-39FD-4661-9531-CC24D422FAC4	CD60EBC2-EF2A-4B47-8D42-C864AA095B8D	TCGA-H4-A2HQ-01A-11D-A17R-02	HG19_Broad_variant	TCGA-H4-A2HQ	TCGA-BLCA	NA	s2735	Harvard Medical School	Medical College of Georgia	United States	NO	Not available	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17R-02	TRUE
13722.58cfa832e4b0c9d6adf6cf86	58cfa832e4b0c9d6adf6cf86	TCGA-G9-6343-01A-21D-1957_130329_SN590_0221_BD1WHDACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G9-6343-01A-21D-1957_130329_SN590_0221_BD1WHDACXX_s_8_rg.sorted	TCGA-G9-6343-01A-21D-1957_130329_SN590_0221_BD1WHDACXX_s_8_rg.sorted.bam	108.7	1.9	0.14	58cfa832e4b0c9d6adf6cf86	TCGA-G9-6343-01A-21D-1957_130329_SN590_0221_BD1WHDACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6343-01A	36B87D12-9F96-460F-A3B5-A4C08CBF5B07	Primary Tumor	Illumina HiSeq	e413f861-4cba-4bf6-a805-aff9ecf4eb3b	Prostate	62	084C6D1F-047E-4B0E-9034-3B0FC18D510D	CB58EB3E-4769-4050-BB51-AE248D0FABAA	TCGA-G9-6343-01A-21D-1957-02	HG19_Broad_variant	TCGA-G9-6343	TCGA-PRAD	NA	s3453	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6ce92	58cfa832e4b0c9d6adf6ce92	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted.bam	36.89	NA	0.16	58cfa832e4b0c9d6adf6ce92	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EJ-01A	C6227D39-D9E8-4E28-9E70-D7F720AB25E4	Primary Tumor	Illumina HiSeq	18abb4d7-25d0-477e-bda6-011263e96364	Bladder	56	FBAD20BA-EE08-4D46-825B-870126AAD539	8D99E3A4-DECB-49D7-9727-C5D7606D60DF	TCGA-G2-A2EJ-01A-11D-A17R-02	HG19_Broad_variant	TCGA-G2-A2EJ	TCGA-BLCA	NA	s3304	Harvard Medical School	MD Anderson	United States	NO	Not available	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	TRUE
13722.58cfa832e4b0c9d6adf6ce9d	58cfa832e4b0c9d6adf6ce9d	TCGA-FE-A234-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FE-A234-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_4_rg.sorted	TCGA-FE-A234-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_4_rg.sorted.bam	16.68	1.89	0.17	58cfa832e4b0c9d6adf6ce9d	TCGA-FE-A234-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A234-10A	E4C85BDD-7B7C-414F-9503-647D9B825915	Blood Derived Normal	Illumina HiSeq	7a6f98a6-b049-415c-bce1-5294405f5eb7	Thyroid	26	2A2331F2-F5F1-42AA-BADE-1365E899CB78	580852B4-DE04-4646-B02E-F5EFAA3316BC	TCGA-FE-A234-10A-01D-A14U-02	HG19_Broad_variant	TCGA-FE-A234	TCGA-THCA	NA	s12387	Harvard Medical School	Ohio State University	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6d078	58cfa832e4b0c9d6adf6d078	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted.bam	130.7	NA	0.14	58cfa832e4b0c9d6adf6d078	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	Not available	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7081-01A	3DA2E90E-6450-4286-8C74-08DBECBFD788	Primary Tumor	Illumina HiSeq	f44b51c1-3e9f-49b0-817b-b31a58264c39	Prostate	62	D4EAA3C5-A0F0-4CD7-8B93-73DFB09B359A	AA4E666F-E577-4F00-82A7-EBC3B8739960	TCGA-HC-7081-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7081	TCGA-PRAD	NA	s3805	Harvard Medical School	International Genomics Consortium	United States	NO	T3b	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6d0a0	58cfa832e4b0c9d6adf6d0a0	TCGA-HW-7495-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_7_rg.sorted.filtered.	WGS	TCGA-HW-7495-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_7_rg.sorted	TCGA-HW-7495-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_7_rg.sorted.bam	366	NA	0.14	58cfa832e4b0c9d6adf6d0a0	TCGA-HW-7495-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HW-7495-10A	49967A57-7C12-46BB-8D71-CEBBB17C9935	Blood Derived Normal	Illumina HiSeq	938bedfd-8385-4a31-a739-3d8bb17c8a1d	Brain	45	3DA04A47-7161-4DC0-8F0D-0E439159BC74	48B8B9BE-BBE0-4CAF-B8DD-265BE265D256	TCGA-HW-7495-10A-01D-2022-02	HG19_Broad_variant	TCGA-HW-7495	TCGA-LGG	NA	s8375	Harvard Medical School	MSKCC	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6cff4	58cfa832e4b0c9d6adf6cff4	TCGA-G2-A2ES-11A-31D-A17R_120921_SN208_0430_AC18CWACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G2-A2ES-11A-31D-A17R_120921_SN208_0430_AC18CWACXX_s_8_rg.sorted	TCGA-G2-A2ES-11A-31D-A17R_120921_SN208_0430_AC18CWACXX_s_8_rg.sorted.bam	8.9	NA	0.16	58cfa832e4b0c9d6adf6cff4	TCGA-G2-A2ES-11A-31D-A17R_120921_SN208_0430_AC18CWACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2ES-11A	72D8EAE8-9EFB-45B2-ACBD-82C6B5732E38	Solid Tissue Normal	Illumina HiSeq	f8583339-ea56-43ba-af11-e7b5945ecfb4	Bladder	85	F7D5544F-E86D-410F-995C-86A717742036	F310E6C4-B237-4EA0-A8A1-679B5B49C50D	TCGA-G2-A2ES-11A-31D-A17R-02	HG19_Broad_variant	TCGA-G2-A2ES	TCGA-BLCA	NA	s3119	Harvard Medical School	MD Anderson	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	TRUE
13722.58cfa832e4b0c9d6adf6d038	58cfa832e4b0c9d6adf6d038	TCGA-FT-A3EE-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FT-A3EE-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_2_rg.sorted	TCGA-FT-A3EE-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_2_rg.sorted.bam	103.3	NA	0.16	58cfa832e4b0c9d6adf6d038	TCGA-FT-A3EE-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FT-A3EE-10A	CCE62116-3DCD-400D-ADA0-9839CA02466E	Blood Derived Normal	Illumina HiSeq	2398ce28-2b46-494f-a9fa-1bc987618a00	Bladder	80	6DFC7EAC-19ED-4BBB-936A-9D4591C7C2B3	AD854667-865A-4C6F-9AF6-1D09642EF5DC	TCGA-FT-A3EE-10A-01D-A204-02	HG19_Broad_variant	TCGA-FT-A3EE	TCGA-BLCA	99	s2724	Harvard Medical School	BLN - University of Miami	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A204-02	TRUE
13722.58cfa832e4b0c9d6adf6d0f0	58cfa832e4b0c9d6adf6d0f0	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted.bam	192.7	NA	0.15	58cfa832e4b0c9d6adf6d0f0	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7077-01A	92252560-5984-41F6-A4B5-A3AA8654C0C8	Primary Tumor	Illumina HiSeq	bea10bd4-1049-4162-bb70-0bf5073199c6	Prostate	64	F3E4CC00-D6FE-4291-BB07-8E501E772CE1	EFC4EC34-58ED-40DE-8E0D-BCBA6320BF4C	TCGA-HC-7077-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7077	TCGA-PRAD	NA	s4154	Harvard Medical School	International Genomics Consortium	United States	NO	T3a	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6d0f2	58cfa832e4b0c9d6adf6d0f2	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted.bam	408.3	NA	0.15	58cfa832e4b0c9d6adf6d0f2	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7213-01A	26EEFAA1-1666-4CE1-8CF4-F6FABFF81FD2	Primary Tumor	Illumina HiSeq	14482ee6-0af5-43ad-bc2b-c9574446f6b9	Prostate	53	0CB3DFFD-1521-4887-B19C-94DCD340D306	6D368C2B-4F13-4006-A487-7DB0ADA55C6A	TCGA-HC-7213-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7213	TCGA-PRAD	NA	s3812	Harvard Medical School	International Genomics Consortium	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d178	58cfa832e4b0c9d6adf6d178	TCGA-HC-7081-10A-01D-1958_130422_SN590_0225_BD23TLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HC-7081-10A-01D-1958_130422_SN590_0225_BD23TLACXX_s_5_rg.sorted	TCGA-HC-7081-10A-01D-1958_130422_SN590_0225_BD23TLACXX_s_5_rg.sorted.bam	193	NA	0.15	58cfa832e4b0c9d6adf6d178	TCGA-HC-7081-10A-01D-1958_130422_SN590_0225_BD23TLACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	Not available	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7081-10A	3DA2E90E-6450-4286-8C74-08DBECBFD788	Blood Derived Normal	Illumina HiSeq	8696b1a7-d544-4806-95c3-83dff3aa5508	Prostate	62	447E7951-2ECB-4646-8E3D-B3DE527F9838	14B57C36-7B01-449F-AB30-579156E08FA7	TCGA-HC-7081-10A-01D-1958-02	HG19_Broad_variant	TCGA-HC-7081	TCGA-PRAD	NA	s3461	Harvard Medical School	International Genomics Consortium	United States	NO	T3b	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1958-02	FALSE
13722.58cfa832e4b0c9d6adf6d174	58cfa832e4b0c9d6adf6d174	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted.bam	61.3	NA	0.17	58cfa832e4b0c9d6adf6d174	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	Not available	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7231-01A	B182BDA9-3D9F-4958-96EB-BD6CC441830C	Primary Tumor	Illumina HiSeq	4b0f4fcc-c7c6-44bc-95d3-e693b0fbc7c7	Prostate	66	6AC7857C-5446-4297-95A9-5F2C11C28220	9826D5D9-D6D3-4216-9CA1-FE010711E13E	TCGA-HC-7231-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7231	TCGA-PRAD	NA	s3806	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d17b	58cfa832e4b0c9d6adf6d17b	TCGA-HC-7209-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-HC-7209-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_7_rg.sorted	TCGA-HC-7209-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_7_rg.sorted.bam	132.6	NA	0.14	58cfa832e4b0c9d6adf6d17b	TCGA-HC-7209-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7209-10A	582D1177-73B0-4A9C-8505-70D6B402BD01	Blood Derived Normal	Illumina HiSeq	2c1969af-caf3-449f-9e39-f2387807413f	Prostate	60	AF82C7AB-99F0-408B-B64F-1CBE4BC57E57	569D456D-3A1F-4C57-A0C8-EBE4CE7B3A9D	TCGA-HC-7209-10A-01D-2111-02	HG19_Broad_variant	TCGA-HC-7209	TCGA-PRAD	NA	s3981	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d18a	58cfa832e4b0c9d6adf6d18a	TCGA-HC-7079-10A-01D-1957_130422_SN590_0225_BD23TLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-HC-7079-10A-01D-1957_130422_SN590_0225_BD23TLACXX_s_1_rg.sorted	TCGA-HC-7079-10A-01D-1957_130422_SN590_0225_BD23TLACXX_s_1_rg.sorted.bam	183.3	NA	0.15	58cfa832e4b0c9d6adf6d18a	TCGA-HC-7079-10A-01D-1957_130422_SN590_0225_BD23TLACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7079-10A	10FBE481-F111-4F88-AE45-4D67CB265567	Blood Derived Normal	Illumina HiSeq	105059d4-8eb5-4f7a-a63f-838e9c234d43	Prostate	51	53CD52BA-57F8-4924-9143-9CE98DDB607E	C5549F0E-C3F4-450A-A8DE-4D3AD0155C85	TCGA-HC-7079-10A-01D-1957-02	HG19_Broad_variant	TCGA-HC-7079	TCGA-PRAD	NA	s3460	Harvard Medical School	International Genomics Consortium	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6d1c2	58cfa832e4b0c9d6adf6d1c2	TCGA-HI-7171-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HI-7171-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_8_rg.sorted	TCGA-HI-7171-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_8_rg.sorted.bam	206.6	NA	0.16	58cfa832e4b0c9d6adf6d1c2	TCGA-HI-7171-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7171-10A	931FEB14-3F69-41C1-8435-5FD4FB775BDF	Blood Derived Normal	Illumina HiSeq	966d1a07-f599-4c0f-86a7-d4b4616c7bc1	Prostate	56	460D202A-7B89-4959-89F3-9A06A7A495C4	6F928FB8-3939-4628-A901-537528D56DC6	TCGA-HI-7171-10A-01D-2111-02	HG19_Broad_variant	TCGA-HI-7171	TCGA-PRAD	1329	s3984	Harvard Medical School	Fox Chase	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d14a	58cfa832e4b0c9d6adf6d14a	TCGA-FS-A1ZM-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FS-A1ZM-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_7_rg.sorted	TCGA-FS-A1ZM-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_7_rg.sorted.bam	46.64	NA	0.17	58cfa832e4b0c9d6adf6d14a	TCGA-FS-A1ZM-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZM-10A	9937259A-9D47-483C-8773-B3C60E02A653	Blood Derived Normal	Illumina HiSeq	802e023c-a4de-478e-8d5a-10bd9d163dec	Skin	74	D2AA13F1-D13B-43CC-95E1-1FA3A611F1CC	99346D7E-B398-4886-BCFB-29876B53964D	TCGA-FS-A1ZM-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZM	TCGA-SKCM	NA	s7539	Harvard Medical School	Essen	Germany	NO	T2	N2c	Not available	Stage III	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6c4ef	58cfa831e4b0c9d6adf6c4ef	TCGA-BK-A0CB-10A-05D-A101_120406_SN208_0281_AC0KDBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BK-A0CB-10A-05D-A101_120406_SN208_0281_AC0KDBACXX_s_1_rg.sorted	TCGA-BK-A0CB-10A-05D-A101_120406_SN208_0281_AC0KDBACXX_s_1_rg.sorted.bam	10.08	1.74	0.16	58cfa831e4b0c9d6adf6c4ef	TCGA-BK-A0CB-10A-05D-A101_120406_SN208_0281_AC0KDBACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BK-A0CB-10A	59E9029A-8DDD-4447-B35A-72BC39F82A30	Blood Derived Normal	Illumina HiSeq	9dd332ef-84c8-4b9d-b5d8-a0284caa04e8	Uterus	60	DBD6C648-E013-4249-9636-A0A2C6A8BFF0	88C92710-D589-4E52-811B-4D5B677C618E	TCGA-BK-A0CB-10A-05D-A101-02	HG19_Broad_variant	TCGA-BK-A0CB	TCGA-UCEC	NA	s4259	Harvard Medical School	Christiana Healthcare	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae64	58cfa82ee4b0c9d6adf6ae64	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted.bam	301.7	1.9	0.16	58cfa82ee4b0c9d6adf6ae64	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4396-01A	9F81C602-8AFA-4588-B0B6-6E5A1A128D5A	Primary Tumor	Illumina HiSeq	61bb72a1-5c87-411d-af04-3e058c2beab2	Lung	76	4D85772B-287E-4790-B1E8-CD1C0E88AD48	1F0C98A3-3EED-45E0-BF81-78632C02D375	TCGA-05-4396-01A-21D-1853-02	HG19_Broad_variant	TCGA-05-4396	TCGA-LUAD	303	s10640	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1853-02	TRUE
13722.58cfa82ee4b0c9d6adf6af9e	58cfa82ee4b0c9d6adf6af9e	TCGA-05-4427-01A-21D-1853_111207_SN590_0112_D09CDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4427-01A-21D-1853_111207_SN590_0112_D09CDACXX_s_3_rg.sorted	TCGA-05-4427-01A-21D-1853_111207_SN590_0112_D09CDACXX_s_3_rg.sorted.bam	290.7	1.8	0.17	58cfa82ee4b0c9d6adf6af9e	TCGA-05-4427-01A-21D-1853_111207_SN590_0112_D09CDACXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4427-01A	78A24C56-576C-4245-BB42-6603B3D19897	Primary Tumor	Illumina HiSeq	10c44e9b-d94b-4f27-b275-2dab46a863c6	Lung	65	785B0C56-BED5-4D19-B7B3-D1A0CEB5D648	6B6663FE-F439-4546-B256-0024F66F748D	TCGA-05-4427-01A-21D-1853-02	HG19_Broad_variant	TCGA-05-4427	TCGA-LUAD	NA	s11225	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1853-02	TRUE
13722.58cfa82ee4b0c9d6adf6afa8	58cfa82ee4b0c9d6adf6afa8	TCGA-05-4420-10A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4420-10A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_4_rg.sorted	TCGA-05-4420-10A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_4_rg.sorted.bam	98.23	1.9	0.14	58cfa82ee4b0c9d6adf6afa8	TCGA-05-4420-10A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4420-10A	3D2AA654-1B5F-4EB4-A1C2-AF31F5760069	Blood Derived Normal	Illumina HiSeq	13949a21-5d65-4769-8f90-de657bddf4e6	Lung	41	79586ED4-9D42-46D1-B318-70C5E1C471F2	0BAC6387-9717-41BF-B886-7D1636EACF43	TCGA-05-4420-10A-01D-1203-02	HG19_Broad_variant	TCGA-05-4420	TCGA-LUAD	NA	s11222	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b687	58cfa82fe4b0c9d6adf6b687	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.bam	164.4	1.9	0.16	58cfa82fe4b0c9d6adf6b687	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6148-01A	8994C8C4-9EA0-46CB-B4A5-0055D7DA5BFA	Primary Tumor	Illumina HiSeq	e3f95d46-09ce-43a0-a2c7-581cb9fe8da9	Lung	60	C0FE5FFE-C0A3-4E62-AA55-2BC18788E505	F8A1C395-E730-48F9-BF82-E8931E4AF154	TCGA-44-6148-01A-11D-1751-02	HG19_Broad_variant	TCGA-44-6148	TCGA-LUAD	NA	s10995	Harvard Medical School	Christiana Healthcare	United States	NO	T1b	N0	Lung Mucinous Adenocarcinoma	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6bb	58cfa82fe4b0c9d6adf6b6bb	TCGA-64-5774-10A-01D-1623_110826_SN590_0103_AC005WACXX_s_2_rg.sorted.filtered.	WGS	TCGA-64-5774-10A-01D-1623_110826_SN590_0103_AC005WACXX_s_2_rg.sorted	TCGA-64-5774-10A-01D-1623_110826_SN590_0103_AC005WACXX_s_2_rg.sorted.bam	147.4	1.9	0.14	58cfa82fe4b0c9d6adf6b6bb	TCGA-64-5774-10A-01D-1623_110826_SN590_0103_AC005WACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5774-10A	FD3FC273-C035-40EA-A459-FF4806F5D592	Blood Derived Normal	Illumina HiSeq	fee3375f-0641-4334-a876-7570f40bb0c0	Lung	60	C10D6419-C120-49BA-B2CD-BBB636B7A3F8	B40329F6-ABA0-4030-9F14-40CC2C20475A	TCGA-64-5774-10A-01D-1623-02	HG19_Broad_variant	TCGA-64-5774	TCGA-LUAD	NA	s11462	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae54	58cfa82ee4b0c9d6adf6ae54	TCGA-05-4250-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_2_rg.sorted.filtered.	WGS	TCGA-05-4250-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_2_rg.sorted	TCGA-05-4250-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_2_rg.sorted.bam	282.93	1.9	0.15	58cfa82ee4b0c9d6adf6ae54	TCGA-05-4250-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_2_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4250-01A	F98ECD8A-B878-4F53-B911-20CD8E17281C	Primary Tumor	Illumina HiSeq	b7bbb240-9e61-41e0-a669-1744d0bda12b	Lung	79	8F274178-7A8E-46B6-8D2C-900338BBB946	A444B1E8-9FE9-492B-A361-93CAAB3681BC	TCGA-05-4250-01A-01D-1103-02	HG19_Broad_variant	TCGA-05-4250	TCGA-LUAD	121	s11441	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1103-02	TRUE
13722.58cfa82ee4b0c9d6adf6b0a5	58cfa82ee4b0c9d6adf6b0a5	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted.bam	64.93	1.9	0.15	58cfa82ee4b0c9d6adf6b0a5	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4249-01A	4ADDF05F-3668-4B3F-A17F-C0227329CA52	Primary Tumor	Illumina HiSeq	94e6a5cd-7ba5-4f3e-bf83-7d07522963b4	Lung	67	80F196FE-1EAF-40CB-AB58-C84795ACC5C7	E3F50937-D6CF-423B-9DD3-31D715892FC7	TCGA-05-4249-01A-01D-1103-02	HG19_Broad_variant	TCGA-05-4249	TCGA-LUAD	NA	s10642	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7b8	58cfa82fe4b0c9d6adf6b7b8	TCGA-44-5645-11A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_8_rg.sorted.filtered.	WGS	TCGA-44-5645-11A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_8_rg.sorted	TCGA-44-5645-11A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_8_rg.sorted.bam	207.7	1.9	0.13	58cfa82fe4b0c9d6adf6b7b8	TCGA-44-5645-11A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_8_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-5645-11A	DDEACCCF-0953-4952-8A4E-C2617F2E7BCC	Solid Tissue Normal	Illumina HiSeq	046d2d90-c237-4a78-9661-79758711edfe	Lung	61	FEAF6024-F488-4636-BD99-7FD770CC3D15	27717C6D-D53D-490A-8065-620B7CFE302E	TCGA-44-5645-11A-01D-1623-02	HG19_Broad_variant	TCGA-44-5645	TCGA-LUAD	NA	s10991	Harvard Medical School	Christiana Healthcare	United States	NO	T1	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b80c	58cfa82fe4b0c9d6adf6b80c	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.bam	452.63	1.9	0.15	58cfa82fe4b0c9d6adf6b80c	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-4112-01A	68B86559-38B2-41F2-B66E-C3C2B628B14D	Primary Tumor	Illumina HiSeq	7c0e7b16-7643-4891-96de-63f2106bfb1a	Lung	60	6C206676-E511-4281-91F5-BFE91B3279A4	68185A4B-CC12-494D-99F5-84F5888A24F9	TCGA-44-4112-01A-01D-1103-02	HG19_Broad_variant	TCGA-44-4112	TCGA-LUAD	NA	s10651	Harvard Medical School	Christiana Healthcare	None	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b916	58cfa82fe4b0c9d6adf6b916	TCGA-A5-A0GE-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0GE-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_2_rg.sorted	TCGA-A5-A0GE-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_2_rg.sorted.bam	7.16	1.93	0.15	58cfa82fe4b0c9d6adf6b916	TCGA-A5-A0GE-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_2_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GE-10A	A587E62E-430E-4F1B-82B7-6FBE856FDAF1	Blood Derived Normal	Illumina HiSeq	e1f06289-6848-4ad1-835f-3f14509605cb	Uterus	38	FC6580A8-FFE8-4F16-A19D-DB65F2789369	C6F8AA30-A713-414E-9D09-B75367426478	TCGA-A5-A0GE-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0GE	TCGA-UCEC	NA	s4993	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b88f	58cfa82fe4b0c9d6adf6b88f	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.bam	216	1.9	0.15	58cfa82fe4b0c9d6adf6b88f	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4676-01A	195A5AFB-B79F-44D2-9D12-884487630C2B	Primary Tumor	Illumina HiSeq	a2b68d59-a4d4-4793-9e6c-72ccaf7c242b	Lung	45	22434A49-EB8A-43AC-8C08-AE6DCBE6FBB8	A79111BF-CB9D-4790-AE9F-6CB13C9334E2	TCGA-73-4676-01A-01D-1751-02	HG19_Broad_variant	TCGA-73-4676	TCGA-LUAD	NA	s11465	Harvard Medical School	Roswell Park	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b926	58cfa82fe4b0c9d6adf6b926	TCGA-49-6742-11A-01D-1853_111218_SN208_0258_C054RACXX_s_2_rg.sorted.filtered.	WGS	TCGA-49-6742-11A-01D-1853_111218_SN208_0258_C054RACXX_s_2_rg.sorted	TCGA-49-6742-11A-01D-1853_111218_SN208_0258_C054RACXX_s_2_rg.sorted.bam	62.7	1.9	0.13	58cfa82fe4b0c9d6adf6b926	TCGA-49-6742-11A-01D-1853_111218_SN208_0258_C054RACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-6742-11A	21FB46F9-4BBB-441C-AF19-A687E9138344	Solid Tissue Normal	Illumina HiSeq	b6826f9b-2630-48c0-a9e5-6046874af7d5	Lung	70	D9548FE4-5631-473A-82CD-1B089B638963	C87686FB-5CF8-4843-AD58-9DABFAA871AD	TCGA-49-6742-11A-01D-1853-02	HG19_Broad_variant	TCGA-49-6742	TCGA-LUAD	NA	s10782	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N1	Mucinous (Colloid) Carcinoma	Stage IIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b94e	58cfa82fe4b0c9d6adf6b94e	TCGA-A5-A0GB-10A-01D-A043_120530_SN1222_0110_AC0VLAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GB-10A-01D-A043_120530_SN1222_0110_AC0VLAACXX_s_3_rg.sorted	TCGA-A5-A0GB-10A-01D-A043_120530_SN1222_0110_AC0VLAACXX_s_3_rg.sorted.bam	20.06	2.26	0.17	58cfa82fe4b0c9d6adf6b94e	TCGA-A5-A0GB-10A-01D-A043_120530_SN1222_0110_AC0VLAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GB-10A	2F4458B6-3CAF-4E33-890E-A04722BADD1B	Blood Derived Normal	Illumina HiSeq	f8c18acc-2985-4620-aef4-9655b0d9e9c0	Uterus	65	BD040510-4425-4F67-836F-AD1523E2E035	4AD0F5C3-2433-4A60-A155-349039DB5C59	TCGA-A5-A0GB-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0GB	TCGA-UCEC	NA	s5383	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b950	58cfa82fe4b0c9d6adf6b950	TCGA-A5-A0GJ-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-A5-A0GJ-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_8_rg.sorted	TCGA-A5-A0GJ-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_8_rg.sorted.bam	35.22	2	0.15	58cfa82fe4b0c9d6adf6b950	TCGA-A5-A0GJ-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GJ-10A	94817E78-78F5-4556-9394-610DF65605E2	Blood Derived Normal	Illumina HiSeq	19ffb6c4-bc21-4995-b962-527122ff1061	Uterus	44	81C5B859-DB07-4FA5-90D8-B0C36E913743	51A30A94-7D94-47D0-AABE-F0600572255A	TCGA-A5-A0GJ-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0GJ	TCGA-UCEC	NA	s4774	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9b1	58cfa82fe4b0c9d6adf6b9b1	TCGA-50-6594-11A-01D-1751_120105_SN1120_0107_AC054PACXX_s_2_rg.sorted.filtered.	WGS	TCGA-50-6594-11A-01D-1751_120105_SN1120_0107_AC054PACXX_s_2_rg.sorted	TCGA-50-6594-11A-01D-1751_120105_SN1120_0107_AC054PACXX_s_2_rg.sorted.bam	76.4	1.9	0.15	58cfa82fe4b0c9d6adf6b9b1	TCGA-50-6594-11A-01D-1751_120105_SN1120_0107_AC054PACXX_s_2_rg.sorted.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6594-11A	8504FD86-A70A-4CBA-9EC8-25C9E60CA549	Solid Tissue Normal	Illumina HiSeq	29591d1b-39c4-4087-a852-643e35cc55b0	Lung	79	E4E03B13-95A6-4ED1-8DA2-66C517DD1516	78942C9E-D4AE-4D66-B756-AFD76F55ACDA	TCGA-50-6594-11A-01D-1751-02	HG19_Broad_variant	TCGA-50-6594	TCGA-LUAD	370	s11455	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b991	58cfa82fe4b0c9d6adf6b991	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted.bam	12.7	1.9	0.15	58cfa82fe4b0c9d6adf6b991	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6597-01A	0D66BF6C-EED0-4726-BD5B-3BF6D610B4E0	Primary Tumor	Illumina HiSeq	e7110ba5-6000-459a-8128-32b420e21194	Lung	79	C5363830-3DB9-4C0C-AA47-B32FDC888C60	84D15DBA-6689-4A93-B2CA-999BF7F97E96	TCGA-50-6597-01A-11D-1853-02	HG19_Broad_variant	TCGA-50-6597	TCGA-LUAD	NA	s11553	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b878	58cfa82fe4b0c9d6adf6b878	TCGA-75-6205-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_7_rg.sorted.filtered.	WGS	TCGA-75-6205-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_7_rg.sorted	TCGA-75-6205-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_7_rg.sorted.bam	202.7	1.9	0.15	58cfa82fe4b0c9d6adf6b878	TCGA-75-6205-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_7_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-6205-10A	9A63F744-4ED4-4B4D-AAC6-F9BDA66AA563	Blood Derived Normal	Illumina HiSeq	247f390f-cb78-4845-a99b-65b33f838887	Lung	NA	2E7C5E7E-EA36-42BE-A7E5-994D8B348789	67364D7F-58EB-4954-828A-5D31DC75AF20	TCGA-75-6205-10A-01D-1751-02	HG19_Broad_variant	TCGA-75-6205	TCGA-LUAD	NA	s11011	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9ad	58cfa82fe4b0c9d6adf6b9ad	TCGA-86-6562-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_8_rg.sorted.filtered.	WGS	TCGA-86-6562-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_8_rg.sorted	TCGA-86-6562-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_8_rg.sorted.bam	316.7	1.9	0.14	58cfa82fe4b0c9d6adf6b9ad	TCGA-86-6562-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-86-6562-10A	DCD066BA-5894-453E-B1DA-82092858C3DB	Blood Derived Normal	Illumina HiSeq	02776cc1-3edd-49d5-b77e-8a9ec2d68f5a	Lung	52	EB924A4A-EC5C-4E4A-856D-F5984B89687C	2DD29997-7D20-4F06-963B-C82274A2FD03	TCGA-86-6562-10A-01D-1751-02	HG19_Broad_variant	TCGA-86-6562	TCGA-LUAD	NA	s11254	Harvard Medical School	Asterand	Russia	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba42	58cfa82fe4b0c9d6adf6ba42	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted.filtered.	WGS	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted.bam	75.21	1.8	0.14	58cfa82fe4b0c9d6adf6ba42	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01R-01A	97F6C8D3-09A0-4128-8F10-41E736648A5F	Primary Tumor	Illumina HiSeq	dc5cfaa9-514c-4e4d-b882-21df489668aa	Colorectal	47	73EE34E8-422D-4AB1-B0F0-DA8A5A2DD9AB	F8021A03-B35B-4E6C-B196-2948789AFCF3	TCGA-AA-A01R-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A01R	TCGA-COAD	NA	s12876	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6ba54	58cfa830e4b0c9d6adf6ba54	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted.filtered.	WGS	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted.bam	237.45	1.73	0.15	58cfa830e4b0c9d6adf6ba54	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01Q-01A	4BE66108-E72A-406B-BB4B-F58FF2877336	Primary Tumor	Illumina HiSeq	f50b391c-a832-4938-86aa-0ae2e8261a9e	Colorectal	48	5D1D7C40-F636-46C6-9540-4DF11A466B15	D84E59D4-7777-4922-990F-622BD246A9F1	TCGA-AA-A01Q-01A-01D-A077-02	HG18_Broad_variant	TCGA-AA-A01Q	TCGA-COAD	NA	s13032	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6bb7e	58cfa830e4b0c9d6adf6bb7e	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.bam	52.54	2	0.16	58cfa830e4b0c9d6adf6bb7e	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GB-01A	2F4458B6-3CAF-4E33-890E-A04722BADD1B	Primary Tumor	Illumina HiSeq	c4dd9407-812c-41b2-9953-baec8808ddbd	Uterus	65	130744CA-A9A2-4C99-8ABB-20FE76E0A955	A025733C-E300-4C47-B2EF-D9C978B58BFD	TCGA-A5-A0GB-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GB	TCGA-UCEC	NA	s4585	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bad4	58cfa830e4b0c9d6adf6bad4	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted.filtered.	WGS	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted.bam	86.94	2	0.15	58cfa830e4b0c9d6adf6bad4	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01V-01A	0CB0DAC8-4CE2-444A-B1AE-1550E065B4D9	Primary Tumor	Illumina HiSeq	f9fde040-dea2-4d98-8a28-05cb13efa1c2	Colorectal	59	8816F14D-9FBB-4033-9CA4-6CA0DB66161A	D13F4522-90DC-41C8-A274-FBD9C0CD2E60	TCGA-AA-A01V-01A-23D-A079-02	HG18_Broad_variant	TCGA-AA-A01V	TCGA-COAD	NA	s13683	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bc4e	58cfa830e4b0c9d6adf6bc4e	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.bam	55.61	2.3	0.14	58cfa830e4b0c9d6adf6bc4e	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A05P-01A	3CB83517-78A4-47B8-8B1E-57E765DBDD2E	Primary Tumor	Illumina HiSeq	a12cb33f-6f29-4068-a6c8-3e20520bc2e0	Uterus	54	F51F7B0E-3EA6-4232-9DE4-A4DD63B23BB5	E08A6886-B019-4920-ACC3-73A4CAF18E3F	TCGA-AP-A05P-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A05P	TCGA-UCEC	NA	s5385	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bd8f	58cfa830e4b0c9d6adf6bd8f	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.bam	11.7	2	0.14	58cfa830e4b0c9d6adf6bd8f	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4223-01A	05F01280-BF77-4682-A7A8-20DD0EAC77BD	Primary Tumor	Illumina HiSeq	e8bc6546-004a-4702-9289-b5c90582298e	Head and Neck	48	82DB742D-885D-4788-B509-474715AE183B	007F0F41-C370-45F9-8053-2C774ADDED49	TCGA-BB-4223-01A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4223	TCGA-HNSC	NA	s15490	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6babc	58cfa830e4b0c9d6adf6babc	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted.filtered.	WGS	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted.bam	80.04	2.03	0.14	58cfa830e4b0c9d6adf6babc	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01T-01A	F87C6DCC-1A9E-4DF5-962C-1F946E2611F8	Primary Tumor	Illumina HiSeq	0dd44906-041d-4af2-8f42-a1bed185e1c6	Colorectal	63	BFC99C6D-7791-4037-9C74-A74BE68E616A	8F61B113-0E19-403E-9637-48E9D9733692	TCGA-AA-A01T-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A01T	TCGA-COAD	NA	s13839	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bd2e	58cfa830e4b0c9d6adf6bd2e	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	76.48	1.86	0.16	58cfa830e4b0c9d6adf6bd2e	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01P-01A	13AE9D83-A22F-451F-88BB-686051725CF3	Primary Tumor	Illumina HiSeq	bd44a9e2-a1a2-43a2-bfca-3a7d028fd86c	Colorectal	80	133C13DE-6C6B-45E2-A611-A5C5A4AEBAA6	7788130D-F341-4900-B7E0-95EAD3063A9F	TCGA-AA-A01P-01A-21D-A079-02	HG18	TCGA-AA-A01P	TCGA-COAD	1158	s13527	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bd90	58cfa830e4b0c9d6adf6bd90	TCGA-BF-A1PZ-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BF-A1PZ-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_6_rg.sorted	TCGA-BF-A1PZ-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_6_rg.sorted.bam	38.45	NA	0.17	58cfa830e4b0c9d6adf6bd90	TCGA-BF-A1PZ-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PZ-10A	455F982C-A067-46AC-BF89-3E535D0FFCA0	Blood Derived Normal	Illumina HiSeq	a56b528f-a7b0-4561-bfbd-279eb0517d9a	Skin	71	E4831A1B-FCF4-4249-AF6F-B851A021A4DE	D10573D8-10B1-4B7B-B4DE-E3946C95E9B0	TCGA-BF-A1PZ-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PZ	TCGA-SKCM	NA	s7827	Harvard Medical School	Cureline	Russia	NO	T4a	N0	Not available	Stage IIB	A18Z-02	TRUE
13722.58cfa830e4b0c9d6adf6bdab	58cfa830e4b0c9d6adf6bdab	TCGA-BG-A0MC-10A-01D-A043_120530_SN1222_0110_AC0VLAACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BG-A0MC-10A-01D-A043_120530_SN1222_0110_AC0VLAACXX_s_2_rg.sorted	TCGA-BG-A0MC-10A-01D-A043_120530_SN1222_0110_AC0VLAACXX_s_2_rg.sorted.bam	8.06	1.95	0.17	58cfa830e4b0c9d6adf6bdab	TCGA-BG-A0MC-10A-01D-A043_120530_SN1222_0110_AC0VLAACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MC-10A	884FD57D-BD8E-40E7-82F6-0BA1C71101A9	Blood Derived Normal	Illumina HiSeq	653d9980-8bbe-49a2-804c-6684090ddf62	Uterus	74	E9B69826-4669-4C37-BD74-1192C9660A22	41BAB218-A348-4E18-8E9C-6B345DDB22B9	TCGA-BG-A0MC-10A-01D-A043-02	HG19_Broad_variant	TCGA-BG-A0MC	TCGA-UCEC	NA	s4793	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bdc4	58cfa830e4b0c9d6adf6bdc4	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.bam	21.93	1.96	0.17	58cfa830e4b0c9d6adf6bdc4	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A18A-01A	FEB3E930-3638-44B4-AC0F-A5DCB01FED76	Primary Tumor	Illumina HiSeq	cf06b397-1811-4a38-93b4-05f1457e9882	Uterus	74	8FD0971D-40BA-46C2-B3C4-8E48A3E6C122	518AFA21-9E19-49DE-A2A6-387828A10837	TCGA-BG-A18A-01A-21D-A12F-02	HG19_Broad_variant	TCGA-BG-A18A	TCGA-UCEC	NA	s4789	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa830e4b0c9d6adf6bdc8	58cfa830e4b0c9d6adf6bdc8	TCGA-BH-A0BM-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BH-A0BM-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_4_rg.sorted	TCGA-BH-A0BM-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_4_rg.sorted.bam	10.8	1.92	0.15	58cfa830e4b0c9d6adf6bdc8	TCGA-BH-A0BM-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0BM-10A	C2AEEE6C-BA10-4CF9-B560-C739580F7BF3	Blood Derived Normal	Illumina HiSeq	dfd425ac-1f68-4ee1-b9cb-983f4bc32371	Breast	54	3F8B9139-A283-42B3-ACCB-AB8CF047B8AA	D770733C-EE28-4D36-845F-FD51C1F72666	TCGA-BH-A0BM-10A-01D-A060-02	HG19_Broad_variant	TCGA-BH-A0BM	TCGA-BRCA	NA	s5492	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6be01	58cfa830e4b0c9d6adf6be01	TCGA-BG-A0M8-01A-12D-A101_120330_SN1120_0129_BD0UCLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BG-A0M8-01A-12D-A101_120330_SN1120_0129_BD0UCLACXX_s_3_rg.sorted	TCGA-BG-A0M8-01A-12D-A101_120330_SN1120_0129_BD0UCLACXX_s_3_rg.sorted.bam	67.61	2	0.15	58cfa830e4b0c9d6adf6be01	TCGA-BG-A0M8-01A-12D-A101_120330_SN1120_0129_BD0UCLACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M8-01A	E055DB71-F3DA-43D3-A9B2-2F65DFB23D3E	Primary Tumor	Illumina HiSeq	f354958c-ea56-472d-b145-a7e2895af8e2	Uterus	50	9CFB7290-EF60-4FDA-ABD7-9552AE11E4E7	D45D62ED-7BC6-4682-BB4B-2CA6EBBCE717	TCGA-BG-A0M8-01A-12D-A101-02	HG19_Broad_variant	TCGA-BG-A0M8	TCGA-UCEC	NA	s4434	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6be06	58cfa830e4b0c9d6adf6be06	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.bam	87.16	2	0.14	58cfa830e4b0c9d6adf6be06	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MQ-01A	12D36A1D-9922-4311-BBDA-71F32AC2C03B	Primary Tumor	Illumina HiSeq	d1e9cdb8-f8a6-43da-9afb-28a6e6d72b6a	Uterus	71	3D1FA321-D2E8-4460-AE87-356AB1CA6281	08F01B17-0386-4C7E-B926-1736CEC043D2	TCGA-BG-A0MQ-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MQ	TCGA-UCEC	NA	s4253	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6be04	58cfa830e4b0c9d6adf6be04	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.bam	133.79	2	0.17	58cfa830e4b0c9d6adf6be04	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M9-01A	4FD1CB59-6C50-4355-9D37-A341E1F4FAD9	Primary Tumor	Illumina HiSeq	633f3cff-14c3-45f7-b568-caa86760d863	Uterus	73	DC487BBF-555B-423B-B7C0-3E92DEFA5A79	3D712314-6FDC-41C7-9CE1-5F9BB85929EE	TCGA-BG-A0M9-01A-21D-A101-02	HG19_Broad_variant	TCGA-BG-A0M9	TCGA-UCEC	NA	s4603	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6be2e	58cfa830e4b0c9d6adf6be2e	TCGA-BG-A0MS-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0MS-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_7_rg.sorted	TCGA-BG-A0MS-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_7_rg.sorted.bam	76.64	1.97	0.15	58cfa830e4b0c9d6adf6be2e	TCGA-BG-A0MS-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MS-01A	A798A8CC-4E72-4A8C-9E20-74A14DEAFD12	Primary Tumor	Illumina HiSeq	71c1fd79-298f-43fd-82ba-a1a2228aaa51	Uterus	53	EF7F78EB-314B-4CF2-B45B-810C84C6AA7B	463D0533-A168-4F50-8EA9-7812D01B5115	TCGA-BG-A0MS-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MS	TCGA-UCEC	NA	s5392	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6be6e	58cfa830e4b0c9d6adf6be6e	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.bam	53.09	1.95	0.16	58cfa830e4b0c9d6adf6be6e	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A190-01A	04FFF86A-B6F5-4900-9E37-C1F0B881B160	Primary Tumor	Illumina HiSeq	a9f1f6de-8f02-48c6-a9e2-6cef21cd8438	Thyroid	55	2EB89D79-861E-41C2-BDD5-6F16D2A84B25	42FE4D84-B54D-42B8-81F8-92191723D057	TCGA-BJ-A190-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A190	TCGA-THCA	NA	s12234	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6bed9	58cfa830e4b0c9d6adf6bed9	TCGA-BJ-A192-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BJ-A192-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_6_rg.sorted	TCGA-BJ-A192-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_6_rg.sorted.bam	18.86	1.82	0.16	58cfa830e4b0c9d6adf6bed9	TCGA-BJ-A192-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A192-10A	B55375C3-9EF2-4D2F-9C29-224E746931C4	Blood Derived Normal	Illumina HiSeq	eac8c42e-b403-4215-9111-4183ad1dbf57	Thyroid	54	4E667DBC-AED4-46CF-B7E9-5F380B5FF07F	5A78F9CD-834D-4561-AC79-836C2598C942	TCGA-BJ-A192-10A-01D-A13U-02	HG19_Broad_variant	TCGA-BJ-A192	TCGA-THCA	NA	s11988	Harvard Medical School	University of Pittsburgh	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6bed3	58cfa830e4b0c9d6adf6bed3	TCGA-AX-A0IW-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-AX-A0IW-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_4_rg.sorted	TCGA-AX-A0IW-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_4_rg.sorted.bam	11.25	1.88	0.15	58cfa830e4b0c9d6adf6bed3	TCGA-AX-A0IW-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0IW-10A	DB21FCCF-40CB-4235-A34D-336A03B8C8F4	Blood Derived Normal	Illumina HiSeq	a874be45-7770-40b7-b171-8acea42f3b9a	Uterus	67	750AC41E-C9D6-4425-82B0-E3609D42B194	E739607D-DEB1-41CA-9D33-B38168645123	TCGA-AX-A0IW-10A-01D-A043-02	HG19_Broad_variant	TCGA-AX-A0IW	TCGA-UCEC	NA	s4427	Harvard Medical School	Gynecologic Oncology Group	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bef6	58cfa830e4b0c9d6adf6bef6	TCGA-BJ-A28Z-10A-01D-A16N_120718_SN590_0169_AC0WL7ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A28Z-10A-01D-A16N_120718_SN590_0169_AC0WL7ACXX_s_4_rg.sorted	TCGA-BJ-A28Z-10A-01D-A16N_120718_SN590_0169_AC0WL7ACXX_s_4_rg.sorted.bam	68.68	1.83	0.15	58cfa830e4b0c9d6adf6bef6	TCGA-BJ-A28Z-10A-01D-A16N_120718_SN590_0169_AC0WL7ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28Z-10A	6BA76174-620E-4851-857A-D0ADBFD6F3E6	Blood Derived Normal	Illumina HiSeq	55bc34ed-0652-4e21-bc91-8a8301ae8813	Thyroid	46	D186595F-2F60-4DA1-9E19-EF9866667CBC	525DE278-22C8-4601-A667-19DF54F0ADAD	TCGA-BJ-A28Z-10A-01D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28Z	TCGA-THCA	NA	s12103	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6bf2a	58cfa830e4b0c9d6adf6bf2a	TCGA-AP-A0LD-10A-01D-A043_120330_SN1120_0128_AC0L52ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AP-A0LD-10A-01D-A043_120330_SN1120_0128_AC0L52ACXX_s_3_rg.sorted	TCGA-AP-A0LD-10A-01D-A043_120330_SN1120_0128_AC0L52ACXX_s_3_rg.sorted.bam	32.44	1.88	0.16	58cfa830e4b0c9d6adf6bf2a	TCGA-AP-A0LD-10A-01D-A043_120330_SN1120_0128_AC0L52ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LD-10A	1200C8B7-A058-4C01-BBE2-04EC09A65245	Blood Derived Normal	Illumina HiSeq	4fd3b516-8908-4161-8c02-d293169c11c0	Uterus	63	9D49BB1E-896D-4545-8CAC-E85405093B83	28DE6452-C37F-4B68-AFE5-2FA37E42198C	TCGA-AP-A0LD-10A-01D-A043-02	HG19_Broad_variant	TCGA-AP-A0LD	TCGA-UCEC	NA	s4782	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bfb2	58cfa830e4b0c9d6adf6bfb2	TCGA-BR-6455-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-6455-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_1_rg.sorted	TCGA-BR-6455-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_1_rg.sorted.bam	105.7	1.9	0.14	58cfa830e4b0c9d6adf6bfb2	TCGA-BR-6455-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6455-10A	75A29059-4705-4A55-BC3D-F5923B24B358	Blood Derived Normal	Illumina HiSeq	63bba89b-b557-47c5-9c7e-894a64d517e2	Stomach	59	322DD934-877A-4185-9ADF-B537C79CE640	A4E758A7-5BBF-46AF-A02C-CF9BEF16185B	TCGA-BR-6455-10A-01D-1798-02	HG19_Broad_variant	TCGA-BR-6455	TCGA-STAD	NA	s14610	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bfbc	58cfa830e4b0c9d6adf6bfbc	TCGA-BR-6565-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-6565-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_8_rg.sorted	TCGA-BR-6565-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_8_rg.sorted.bam	320.7	1.9	0.16	58cfa830e4b0c9d6adf6bfbc	TCGA-BR-6565-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6565-10A	DAECEA36-B379-46CE-8AE9-A38D22556CE2	Blood Derived Normal	Illumina HiSeq	99084bc3-84ee-4ccc-9c54-1b5a74af410b	Stomach	67	612F7812-9ED4-40AD-AD6C-4C80C1E19F35	E58458DC-B614-466B-863D-428B18FD3A64	TCGA-BR-6565-10A-01D-1798-02	HG19_Broad_variant	TCGA-BR-6565	TCGA-STAD	NA	s14531	Harvard Medical School	Asterand	Russia	NO	T4a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bf61	58cfa830e4b0c9d6adf6bf61	TCGA-BR-4366-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-4366-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_2_rg.sorted	TCGA-BR-4366-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_2_rg.sorted.bam	42.3	1.9	0.14	58cfa830e4b0c9d6adf6bf61	TCGA-BR-4366-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4366-11A	525A6978-2D7B-4F3A-AC68-13FE8CBBBDCC	Solid Tissue Normal	Illumina HiSeq	9179774b-7bf8-4aa0-886f-2917234201eb	Stomach	87	EFB4B208-B314-4B12-87DF-C8F776515842	009F6A4A-9D83-44DF-A83C-B707B74E37D1	TCGA-BR-4366-11A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4366	TCGA-STAD	NA	s15303	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6bfd3	58cfa830e4b0c9d6adf6bfd3	TCGA-BR-4357-11A-01D-1154_130815_VM001_0001_VMR0001CXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-4357-11A-01D-1154_130815_VM001_0001_VMR0001CXX_s_6_rg.sorted	TCGA-BR-4357-11A-01D-1154_130815_VM001_0001_VMR0001CXX_s_6_rg.sorted.bam	142.3	1.9	0.15	58cfa830e4b0c9d6adf6bfd3	TCGA-BR-4357-11A-01D-1154_130815_VM001_0001_VMR0001CXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4357-11A	BEC83DFF-2BBA-4467-92AA-5DC3DB9E0EAF	Solid Tissue Normal	Illumina HiSeq	9c4e7319-08e6-46e0-a33b-68d2dc8a6926	Stomach	58	0B8024D5-1268-49BC-B2F7-7B45701A17F1	5E69772F-6726-4D2A-9BA1-2C8636F3F1D5	TCGA-BR-4357-11A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4357	TCGA-STAD	NA	s15377	Harvard Medical School	Asterand	Russia	NO	T3	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6c0f8	58cfa830e4b0c9d6adf6c0f8	TCGA-B6-A0RI-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_4_rg.sorted.filtered.	WGS	TCGA-B6-A0RI-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_4_rg.sorted	TCGA-B6-A0RI-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_4_rg.sorted.bam	46.43	1.78	0.15	58cfa830e4b0c9d6adf6c0f8	TCGA-B6-A0RI-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RI-10A	BFD55808-DDDD-44C3-97D7-41600497B992	Blood Derived Normal	Illumina HiSeq	a498f419-7468-4a58-8a82-6692d63a46df	Breast	44	4E128A37-BE58-477A-A01F-448179360B7C	C9478F7D-BFE3-4E80-8161-39B3D440FA16	TCGA-B6-A0RI-10A-01D-A060-02	HG19_Broad_variant	TCGA-B6-A0RI	TCGA-BRCA	NA	s6463	Harvard Medical School	Duke	United States	NO	T4b	N1b	Infiltrating Ductal Carcinoma	Stage IIIB	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6c16a	58cfa830e4b0c9d6adf6c16a	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.bam	22.97	1.94	0.13	58cfa830e4b0c9d6adf6c16a	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HK-01A	24334AC1-28A3-4B61-B590-3F51E375B247	Primary Tumor	Illumina HiSeq	c4f3a9e0-4b45-4e06-9320-171c27d9e28d	Breast	81	8835B20E-9343-4266-A356-E0343C657130	B96AE5EC-0139-4B8D-8136-B5BFA7AF8987	TCGA-BH-A0HK-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0HK	TCGA-BRCA	NA	s5642	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6c146	58cfa830e4b0c9d6adf6c146	TCGA-BA-4074-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BA-4074-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_2_rg.sorted	TCGA-BA-4074-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_2_rg.sorted.bam	61.03	1.9	0.14	58cfa830e4b0c9d6adf6c146	TCGA-BA-4074-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4074-10A	A63CA97D-EF31-4118-9547-A6730967290F	Blood Derived Normal	Illumina HiSeq	669ebf5f-7222-410b-b76e-2551f11e014f	Head and Neck	69	BCB3B1E4-AD0E-44B7-9143-E6B642BC7F72	9DAE3CA2-1F5A-458E-98EF-7451D5F41EBC	TCGA-BA-4074-10A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4074	TCGA-HNSC	462	s15608	Harvard Medical School	UNC	None	NO	T2	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c05c	58cfa830e4b0c9d6adf6c05c	TCGA-BJ-A0ZB-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZB-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_7_rg.sorted	TCGA-BJ-A0ZB-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_7_rg.sorted.bam	16.66	2.02	0.17	58cfa830e4b0c9d6adf6c05c	TCGA-BJ-A0ZB-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZB-10A	DC4D8468-6F34-40CB-A826-8D582CD86FDE	Blood Derived Normal	Illumina HiSeq	ba7ddca6-c0da-4789-8a9c-7c30729af0a7	Thyroid	66	C2F1F7A8-2633-4166-95AB-501FB192AF39	65D9DF75-E244-4631-8065-BFB90CD80172	TCGA-BJ-A0ZB-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZB	TCGA-THCA	NA	s12627	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c160	58cfa830e4b0c9d6adf6c160	TCGA-BA-5149-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BA-5149-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_4_rg.sorted	TCGA-BA-5149-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_4_rg.sorted.bam	65.4	1.9	0.15	58cfa830e4b0c9d6adf6c160	TCGA-BA-5149-10A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5149-10A	CB99FB14-641C-4FB3-BF1D-17EFB8CD982A	Blood Derived Normal	Illumina HiSeq	4b0f007d-eb09-44cc-be19-114f76f43c09	Head and Neck	47	C991BC28-AB65-4D05-931A-676BE035B94C	9668CD24-0B23-4749-8C84-B12203236DA4	TCGA-BA-5149-10A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5149	TCGA-HNSC	NA	s16027	Harvard Medical School	UNC	None	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa830e4b0c9d6adf6c16c	58cfa830e4b0c9d6adf6c16c	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted.bam	52.7	1.9	0.16	58cfa830e4b0c9d6adf6c16c	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5557-01A	7E0575CE-670B-4035-8A90-4D35279707B2	Primary Tumor	Illumina HiSeq	bb531fb4-064f-47dd-8231-bd6131866968	Head and Neck	41	67D75889-E868-41F2-8255-5D5D1AA0A854	0DDC26B3-2D83-4539-A934-4B0FEF8D1F69	TCGA-BA-5557-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5557	TCGA-HNSC	NA	s15617	Harvard Medical School	UNC	None	NO	T1	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1509-02	TRUE
13722.58cfa830e4b0c9d6adf6bb3e	58cfa830e4b0c9d6adf6bb3e	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted.filtered.	WGS	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted.bam	89.57	1.8	0.13	58cfa830e4b0c9d6adf6bb3e	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01S-01A	84E34CF2-B3BB-4A1A-8FB7-6C2C604C4008	Primary Tumor	Illumina HiSeq	fe7c227a-1329-4956-b9bf-08bbb6fe161d	Colorectal	47	5743700C-CBD3-4F87-8109-6349A96EB605	DC9E606A-12D6-4AA6-9780-1D999EB72C5A	TCGA-AA-A01S-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A01S	TCGA-COAD	NA	s13206	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6c17e	58cfa830e4b0c9d6adf6c17e	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted.bam	598.33	1.9	0.16	58cfa830e4b0c9d6adf6c17e	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4074-01A	A63CA97D-EF31-4118-9547-A6730967290F	Primary Tumor	Illumina HiSeq	da78e5e3-ea94-4ac2-8b21-69809cabb0c7	Head and Neck	69	7BC6B159-19B4-4711-961D-830BC9E56493	4786A24C-D127-43FB-9D9C-FF59622B7B24	TCGA-BA-4074-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4074	TCGA-HNSC	462	s16168	Harvard Medical School	UNC	None	NO	T2	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c1ce	58cfa830e4b0c9d6adf6c1ce	TCGA-BB-4224-10A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BB-4224-10A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_2_rg.sorted	TCGA-BB-4224-10A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_2_rg.sorted.bam	100.4	1.9	0.13	58cfa830e4b0c9d6adf6c1ce	TCGA-BB-4224-10A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4224-10A	58574E35-8A30-4207-B127-59FFF7C87A43	Blood Derived Normal	Illumina HiSeq	5fadfb17-7c88-4357-a519-b6c61ea4dc49	Head and Neck	52	2C21CAA5-DD9B-43E1-807A-4A145D3AA192	A4ECE80F-3F1F-4930-817D-6F8F1606DE5B	TCGA-BB-4224-10A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4224	TCGA-HNSC	NA	s15613	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c1c9	58cfa830e4b0c9d6adf6c1c9	TCGA-BG-A0MQ-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0MQ-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_7_rg.sorted	TCGA-BG-A0MQ-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_7_rg.sorted.bam	6.94	1.79	0.14	58cfa830e4b0c9d6adf6c1c9	TCGA-BG-A0MQ-10A-02D-A101_120406_SN208_0281_AC0KDBACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MQ-10A	12D36A1D-9922-4311-BBDA-71F32AC2C03B	Blood Derived Normal	Illumina HiSeq	64f40fd7-7cbd-4f15-8f79-c145111f31bd	Uterus	71	0B751781-2FFF-44E0-B8C3-110EB62FCEE7	AB49DF17-7A69-4655-B35F-8B4FF56DFCF8	TCGA-BG-A0MQ-10A-02D-A101-02	HG19_Broad_variant	TCGA-BG-A0MQ	TCGA-UCEC	NA	s4432	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c263	58cfa830e4b0c9d6adf6c263	TCGA-BH-A0HX-10A-02D-A060_130807_SN590_0236_BC291KACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BH-A0HX-10A-02D-A060_130807_SN590_0236_BC291KACXX_s_8_rg.sorted	TCGA-BH-A0HX-10A-02D-A060_130807_SN590_0236_BC291KACXX_s_8_rg.sorted.bam	7.54	2.03	0.13	58cfa830e4b0c9d6adf6c263	TCGA-BH-A0HX-10A-02D-A060_130807_SN590_0236_BC291KACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HX-10A	3B01D064-8C00-4972-9F07-407EAC8E7534	Blood Derived Normal	Illumina HiSeq	f43d0ad4-4ad4-4388-833e-94faf1db1598	Breast	54	B17B1EEF-04FD-4D51-B4AE-6E071AFBED16	39C48C76-B9AC-4485-A7C3-4729A56F830C	TCGA-BH-A0HX-10A-02D-A060-02	HG19_Broad_variant	TCGA-BH-A0HX	TCGA-BRCA	NA	s6466	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6c1db	58cfa830e4b0c9d6adf6c1db	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.bam	16.7	1.9	0.13	58cfa830e4b0c9d6adf6c1db	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4224-01A	58574E35-8A30-4207-B127-59FFF7C87A43	Primary Tumor	Illumina HiSeq	44a7ef3f-57df-49e2-80b9-1f0dca51067f	Head and Neck	52	077ACD68-8C30-41A6-BB7E-5B014866B807	E2FF93EB-AE22-4C6B-B4D5-181B9393BC64	TCGA-BB-4224-01A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4224	TCGA-HNSC	NA	s15876	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa82ee4b0c9d6adf6affc	58cfa82ee4b0c9d6adf6affc	TCGA-05-4424-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_2_rg.sorted.filtered.	WGS	TCGA-05-4424-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_2_rg.sorted	TCGA-05-4424-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_2_rg.sorted.bam	129	1.9	0.14	58cfa82ee4b0c9d6adf6affc	TCGA-05-4424-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_2_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4424-10A	66763A0C-6CDA-4832-A0CC-E7B496D78EAA	Blood Derived Normal	Illumina HiSeq	d10fa246-b319-4797-ba50-e80f1686b364	Lung	70	83108C37-2C1C-4B3E-BAA1-E2DF6C56F32B	704B4714-B522-4AE3-AFFA-733FD095049C	TCGA-05-4424-10A-01D-1853-02	HG19_Broad_variant	TCGA-05-4424	TCGA-LUAD	NA	s10984	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1853-02	TRUE
13722.58cfa830e4b0c9d6adf6c2b4	58cfa830e4b0c9d6adf6c2b4	TCGA-BT-A2LB-11A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BT-A2LB-11A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_8_rg.sorted	TCGA-BT-A2LB-11A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_8_rg.sorted.bam	7.56	NA	0.18	58cfa830e4b0c9d6adf6c2b4	TCGA-BT-A2LB-11A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LB-11A	D17A5AB1-3789-4652-AFF5-D8F4F2291F9C	Solid Tissue Normal	Illumina HiSeq	c3d22884-08fb-4b8d-a589-f0ba4184d031	Bladder	73	085DA7A1-E01D-4273-B5F2-7AAB5D4D942A	00BA084F-E60A-41ED-BA1A-E1A07C85478E	TCGA-BT-A2LB-11A-11D-A18D-02	HG19_Broad_variant	TCGA-BT-A2LB	TCGA-BLCA	NA	s2868	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A18D-02	TRUE
13722.58cfa830e4b0c9d6adf6c2e0	58cfa830e4b0c9d6adf6c2e0	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted.bam	75.72	2.03	0.15	58cfa830e4b0c9d6adf6c2e0	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20P-01A	F48937ED-E294-41F0-8872-7010391167A9	Primary Tumor	Illumina HiSeq	814688fe-5071-40b6-bb89-643389543580	Bladder	81	6B43EEEC-4FEB-4062-827A-E63ED8CE3820	022AEFEC-CBAC-46C1-9F17-AC087BD7164E	TCGA-BT-A20P-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20P	TCGA-BLCA	544	s3272	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	TRUE
13722.58cfa830e4b0c9d6adf6c30a	58cfa830e4b0c9d6adf6c30a	TCGA-BR-6457-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BR-6457-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_4_rg.sorted	TCGA-BR-6457-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_4_rg.sorted.bam	147.7	1.9	0.15	58cfa830e4b0c9d6adf6c30a	TCGA-BR-6457-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6457-10A	05CE16D4-A999-491A-91AD-9449A57228FF	Blood Derived Normal	Illumina HiSeq	c937c321-5e90-4ec8-925e-e1cd02e6d5e5	Stomach	69	1D6C8FEB-3DD6-4B8F-8403-7B67B759E66B	A54F167D-F10B-4511-A956-AF502B5F3874	TCGA-BR-6457-10A-01D-1798-02	HG19_Broad_variant	TCGA-BR-6457	TCGA-STAD	NA	s14617	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6c242	58cfa830e4b0c9d6adf6c242	TCGA-BB-4223-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BB-4223-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_8_rg.sorted	TCGA-BB-4223-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_8_rg.sorted.bam	341.4	1.6	0.15	58cfa830e4b0c9d6adf6c242	TCGA-BB-4223-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4223-10A	05F01280-BF77-4682-A7A8-20DD0EAC77BD	Blood Derived Normal	Illumina HiSeq	a8c97047-ef56-4439-be7b-19e789bde2bf	Head and Neck	48	75430612-09BB-4D6F-9304-62A5B517D424	139A8577-EC63-4AAF-9796-200173B6DE91	TCGA-BB-4223-10A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4223	TCGA-HNSC	NA	s16172	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c308	58cfa830e4b0c9d6adf6c308	TCGA-BR-6458-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-6458-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_6_rg.sorted	TCGA-BR-6458-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_6_rg.sorted.bam	250.7	1.9	0.16	58cfa830e4b0c9d6adf6c308	TCGA-BR-6458-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6458-10A	E516880B-C4E5-43CD-A358-BE0DB88564D7	Blood Derived Normal	Illumina HiSeq	0fb3d589-66c9-49b8-9263-a04b09abcdd4	Stomach	57	ECBEC910-E4E1-4899-9547-0F649528E162	B787599F-7B73-4249-A813-19B87FFA98A2	TCGA-BR-6458-10A-01D-1798-02	HG19_Broad_variant	TCGA-BR-6458	TCGA-STAD	NA	s15380	Harvard Medical School	Asterand	Ukraine	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c375	58cfa831e4b0c9d6adf6c375	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted.bam	281.2	1.9	0.14	58cfa831e4b0c9d6adf6c375	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4477-01A	18D0AAE7-9694-4252-B8FE-16E62DADAB07	Primary Tumor	Illumina HiSeq	854ac518-e119-4ce6-97c4-b123e75a99ee	Stomach	58	6D7C7B4E-6913-487D-9DC3-DDA901434192	3AE56504-30EE-4C03-9F69-C5B415DE6738	TCGA-CG-4477-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4477	TCGA-STAD	NA	s14907	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c356	58cfa831e4b0c9d6adf6c356	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted.bam	281.2	1.9	0.14	58cfa831e4b0c9d6adf6c356	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4477-01A	18D0AAE7-9694-4252-B8FE-16E62DADAB07	Primary Tumor	Illumina HiSeq	6fb461b5-4d42-4cba-bc62-bb8f68c3deed	Stomach	58	6D7C7B4E-6913-487D-9DC3-DDA901434192	3AE56504-30EE-4C03-9F69-C5B415DE6738	TCGA-CG-4477-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4477	TCGA-STAD	NA	s14637	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6c174	58cfa830e4b0c9d6adf6c174	TCGA-BA-4076-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BA-4076-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_6_rg.sorted	TCGA-BA-4076-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_6_rg.sorted.bam	51.03	1.9	0.14	58cfa830e4b0c9d6adf6c174	TCGA-BA-4076-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4076-10A	7DE19081-D5FD-468C-AD0D-F6E3E8B2AD70	Blood Derived Normal	Illumina HiSeq	ebc1363c-072a-468d-abba-3a9ac03513bf	Head and Neck	39	D6F48BB2-379A-448D-B13D-2DFC5DA91D0C	01549853-3132-42A7-A2ED-5AD365EAA63F	TCGA-BA-4076-10A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4076	TCGA-HNSC	415	s15612	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c3d2	58cfa831e4b0c9d6adf6c3d2	TCGA-CG-5721-11A-01D-1598_121011_SN208_0434_AC18MYACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-5721-11A-01D-1598_121011_SN208_0434_AC18MYACXX_s_4_rg.sorted	TCGA-CG-5721-11A-01D-1598_121011_SN208_0434_AC18MYACXX_s_4_rg.sorted.bam	141	1.9	0.15	58cfa831e4b0c9d6adf6c3d2	TCGA-CG-5721-11A-01D-1598_121011_SN208_0434_AC18MYACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5721-11A	588ABAEA-AB16-42F4-9457-5901EE791B5F	Solid Tissue Normal	Illumina HiSeq	259d4033-0c05-4f3b-ab2a-b0c7018bad33	Stomach	58	700FCA23-4807-4ED5-9745-87C6BCD51FBF	87FDC6BA-3120-4F7F-94FC-B5E0E6B5306C	TCGA-CG-5721-11A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5721	TCGA-STAD	NA	s14989	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3c2	58cfa831e4b0c9d6adf6c3c2	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted.bam	56.34	2.11	0.15	58cfa831e4b0c9d6adf6c3c2	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20Q-01A	419DEAAC-EA45-4BDD-9FA0-B5CD8429B44F	Primary Tumor	Illumina HiSeq	9d2dc2d3-8995-42b8-9bee-010c8bce06e0	Bladder	73	F3906CD4-31C7-48A8-935B-5B7FAFEC1AE7	72AF980B-98A8-4572-8AF9-EFD4294700F9	TCGA-BT-A20Q-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20Q	TCGA-BLCA	593	s3083	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c3ce	58cfa831e4b0c9d6adf6c3ce	TCGA-CG-5722-11A-02D-1598_121011_SN208_0434_AC18MYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-5722-11A-02D-1598_121011_SN208_0434_AC18MYACXX_s_5_rg.sorted	TCGA-CG-5722-11A-02D-1598_121011_SN208_0434_AC18MYACXX_s_5_rg.sorted.bam	56	1.9	0.15	58cfa831e4b0c9d6adf6c3ce	TCGA-CG-5722-11A-02D-1598_121011_SN208_0434_AC18MYACXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5722-11A	F35E8FEF-F61D-4614-B73F-F7E1D0F21F52	Solid Tissue Normal	Illumina HiSeq	53d1fe8c-b529-4f7f-a9d7-672085ce2fab	Stomach	67	756AEB10-195E-409D-A8AC-8B3A048FC51A	8B4B06BF-79BA-47C9-BCFD-A5E54BEF972E	TCGA-CG-5722-11A-02D-1598-02	HG19_Broad_variant	TCGA-CG-5722	TCGA-STAD	NA	s15462	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c39c	58cfa831e4b0c9d6adf6c39c	TCGA-BG-A0MO-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BG-A0MO-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_2_rg.sorted	TCGA-BG-A0MO-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_2_rg.sorted.bam	7.1	1.95	0.15	58cfa831e4b0c9d6adf6c39c	TCGA-BG-A0MO-10A-01D-A043_120327_SN590_0148_BC0LM8ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MO-10A	734EF97F-807C-480E-8DF9-FEAF041032D2	Blood Derived Normal	Illumina HiSeq	1d255a62-a9f0-4075-b7cf-b09d3e044a24	Uterus	63	CA5DBD05-F91F-440B-B947-D0A060272E78	2B37CA7F-E0EF-4D91-ABD8-81E6468BF3AF	TCGA-BG-A0MO-10A-01D-A043-02	HG19_Broad_variant	TCGA-BG-A0MO	TCGA-UCEC	NA	s4252	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa831e4b0c9d6adf6c458	58cfa831e4b0c9d6adf6c458	TCGA-CG-5734-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-5734-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_8_rg.sorted	TCGA-CG-5734-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_8_rg.sorted.bam	46	1.9	0.16	58cfa831e4b0c9d6adf6c458	TCGA-CG-5734-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_8_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5734-11A	2A227292-C73D-45FC-AB68-CDFAF7AEF9E7	Solid Tissue Normal	Illumina HiSeq	a90934d5-13a4-4673-80b4-25d0755eb14c	Stomach	68	09D2C310-03CB-4AD8-8285-BB896EC1C1CC	91B72A4B-A301-46F5-8704-B4327804B307	TCGA-CG-5734-11A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5734	TCGA-STAD	243	s15195	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c47e	58cfa831e4b0c9d6adf6c47e	TCGA-CG-5727-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-5727-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_7_rg.sorted	TCGA-CG-5727-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_7_rg.sorted.bam	151	1.9	0.15	58cfa831e4b0c9d6adf6c47e	TCGA-CG-5727-11A-01D-1598_121011_SN208_0435_BD1E43ACXX_s_7_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5727-11A	B75EB694-8E9D-4DBB-B536-7D278C728CBB	Solid Tissue Normal	Illumina HiSeq	5ce3b760-487e-4111-9fdd-b0a32df72ed9	Stomach	66	B83A6E11-739B-4B4A-9B13-BB189E8FED70	A5D43809-AF5D-417E-94AD-EB03D681F951	TCGA-CG-5727-11A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5727	TCGA-STAD	NA	s14993	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c4a2	58cfa831e4b0c9d6adf6c4a2	TCGA-CG-5732-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-5732-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_2_rg.sorted	TCGA-CG-5732-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_2_rg.sorted.bam	180	1.9	0.16	58cfa831e4b0c9d6adf6c4a2	TCGA-CG-5732-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_2_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5732-01A	E62D5F3C-0A99-4932-A589-BFF4FA02B1D3	Primary Tumor	Illumina HiSeq	3bc07391-1ef5-4bbf-9614-e3f31b8448c9	Stomach	66	5295412B-3D28-4774-85D8-3D38C682C343	E09E88E6-7697-4A1F-BF79-6DE9BE6E0960	TCGA-CG-5732-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5732	TCGA-STAD	NA	s14491	Harvard Medical School	Indivumed	Germany	NO	T2	N3	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c4e7	58cfa831e4b0c9d6adf6c4e7	TCGA-BR-4367-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_4_rg.sorted.filtered.	WGS	TCGA-BR-4367-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_4_rg.sorted	TCGA-BR-4367-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_4_rg.sorted.bam	200	1.9	0.14	58cfa831e4b0c9d6adf6c4e7	TCGA-BR-4367-11A-01D-1154_130815_VM001_0002_VMR0002CXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4367-11A	D139BD0C-2EEB-44EC-856B-E77CB03D294E	Solid Tissue Normal	Illumina HiSeq	ea05becd-5829-4f1f-8dd3-56dedaa95846	Stomach	78	437E0DC0-CF92-43A0-B6AC-405A7B22B56D	3219D0B6-A19B-4359-A682-84B2E06B2201	TCGA-BR-4367-11A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4367	TCGA-STAD	NA	s15236	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c55a	58cfa831e4b0c9d6adf6c55a	TCGA-CG-5733-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CG-5733-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_6_rg.sorted	TCGA-CG-5733-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_6_rg.sorted.bam	129	1.9	0.16	58cfa831e4b0c9d6adf6c55a	TCGA-CG-5733-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_6_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5733-11A	8A9AFA5E-63CE-41EB-AAFB-B0B03653DA5A	Solid Tissue Normal	Illumina HiSeq	f72098d0-5e3e-49e7-a5e9-5bf9f620f2c0	Stomach	83	C7134D34-299D-440B-94C5-1A4D59978F01	6521DCC6-77A9-4DBC-A27A-6AF8194CB45A	TCGA-CG-5733-11A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5733	TCGA-STAD	641	s14992	Harvard Medical School	Indivumed	Germany	NO	T2	N2	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c522	58cfa831e4b0c9d6adf6c522	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted.bam	31.7	1.9	0.14	58cfa831e4b0c9d6adf6c522	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4731-01A	50E25A4B-2EB2-4770-9A2D-8922A1E0AB56	Primary Tumor	Illumina HiSeq	50e66965-d2d5-49dd-a113-8b1751d6f7b7	Head and Neck	63	CD4E9D8C-B1F9-486A-ADCD-BD4B77A50326	981D992B-B92F-4E42-AA43-FC48068648A8	TCGA-CN-4731-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4731	TCGA-HNSC	NA	s15753	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5b9	58cfa831e4b0c9d6adf6c5b9	TCGA-CG-4460-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-4460-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_4_rg.sorted	TCGA-CG-4460-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_4_rg.sorted.bam	1646.64	1.9	0.15	58cfa831e4b0c9d6adf6c5b9	TCGA-CG-4460-10A-01D-1154_121026_SN1120_0198_BC188JACXX_s_4_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4460-10A	3C3D4EF0-019A-423E-89B2-4AC5A7B567AB	Blood Derived Normal	Illumina HiSeq	88366088-e644-4828-abfa-01a45fdb23d3	Stomach	66	5567BCD4-E089-4E6E-9D4C-3B2696A0D696	3AF16C09-89EA-4CAE-9182-11A223BF6293	TCGA-CG-4460-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4460	TCGA-STAD	669	s14901	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c5d8	58cfa831e4b0c9d6adf6c5d8	TCGA-CN-5363-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-5363-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_3_rg.sorted	TCGA-CN-5363-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_3_rg.sorted.bam	197.7	1.9	0.15	58cfa831e4b0c9d6adf6c5d8	TCGA-CN-5363-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_3_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5363-01A	291B069C-9DDE-4E1E-8430-85146BC94338	Primary Tumor	Illumina HiSeq	624b1e50-b5bd-4a3f-98fd-4514bff3244d	Head and Neck	48	5E4E1E21-8016-4E27-8F72-2411714203E8	BEB17091-BD47-4666-8E3A-7A397977EA41	TCGA-CN-5363-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5363	TCGA-HNSC	253	s15891	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N3	Head and Neck Squamous Cell Carcinoma	Stage IVB	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5a4	58cfa831e4b0c9d6adf6c5a4	TCGA-CN-4739-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-4739-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_3_rg.sorted	TCGA-CN-4739-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_3_rg.sorted.bam	10.4	1.9	0.15	58cfa831e4b0c9d6adf6c5a4	TCGA-CN-4739-10A-01D-1509_120420_SN208_0286_BD0T87ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4739-10A	7E3B90C1-8772-4E12-8050-A156558BEB82	Blood Derived Normal	Illumina HiSeq	1f5e9479-345d-4dc7-a9c5-24dbf2e32405	Head and Neck	71	B916FA4A-1D15-4619-9D6C-1000E96B7E0D	86D66FCC-56C5-491A-95A9-B57E40F6C380	TCGA-CN-4739-10A-01D-1509-02	HG19_Broad_variant	TCGA-CN-4739	TCGA-HNSC	NA	s15628	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa831e4b0c9d6adf6c60c	58cfa831e4b0c9d6adf6c60c	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted.bam	449.7	1.9	0.15	58cfa831e4b0c9d6adf6c60c	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5360-01A	5793879B-F663-4A10-9BD9-1ACD2E189650	Primary Tumor	Illumina HiSeq	56414402-7420-42b7-a93d-3d1f88308155	Head and Neck	68	0C00768E-8B13-4B8E-80FC-B344740845F1	7EE362C2-86AD-462C-B478-21255D96ED90	TCGA-CN-5360-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5360	TCGA-HNSC	NA	s15883	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5fc	58cfa831e4b0c9d6adf6c5fc	TCGA-CN-5369-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-5369-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_3_rg.sorted	TCGA-CN-5369-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_3_rg.sorted.bam	345.7	1.9	0.15	58cfa831e4b0c9d6adf6c5fc	TCGA-CN-5369-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5369-01A	B98867D7-7D5A-4C58-8878-37BEE6F2F4FA	Primary Tumor	Illumina HiSeq	bd85b141-d240-412f-9b74-379c4e3797d2	Head and Neck	90	B4C02606-0F86-46E4-9DAF-DC7DBCD60D78	1A532CA9-E72F-4906-867B-272A18CFEC79	TCGA-CN-5369-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5369	TCGA-HNSC	380	s16323	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c60e	58cfa831e4b0c9d6adf6c60e	TCGA-CQ-6219-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CQ-6219-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_7_rg.sorted	TCGA-CQ-6219-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_7_rg.sorted.bam	187.7	1.9	0.16	58cfa831e4b0c9d6adf6c60e	TCGA-CQ-6219-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6219-01A	0CA3D25A-22E9-4E40-834B-65F402535005	Primary Tumor	Illumina HiSeq	e1a5a3ec-64d9-4348-8104-4f08021e914e	Head and Neck	50	2AAD293C-B3ED-4BD7-971D-EA8A5EFC66AD	215B7B8C-E4D0-4CD2-B2B8-9CDC222EBF25	TCGA-CQ-6219-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6219	TCGA-HNSC	479	s15632	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N2a	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c661	58cfa831e4b0c9d6adf6c661	TCGA-CG-4443-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4443-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_3_rg.sorted	TCGA-CG-4443-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_3_rg.sorted.bam	261.2	1.9	0.15	58cfa831e4b0c9d6adf6c661	TCGA-CG-4443-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4443-01A	8CB0144B-BE6B-40A1-86A2-708F96D9B615	Primary Tumor	Illumina HiSeq	d15f98aa-3849-4230-aea5-46a959ece810	Stomach	68	F4FB736A-42C9-4367-A327-D0D1C4CBA359	0FCF9057-D05B-480B-A17F-5FE35BFEB0CA	TCGA-CG-4443-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4443	TCGA-STAD	NA	s15245	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IA	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c5de	58cfa831e4b0c9d6adf6c5de	TCGA-CN-5364-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-5364-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_4_rg.sorted	TCGA-CN-5364-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_4_rg.sorted.bam	172.7	1.9	0.14	58cfa831e4b0c9d6adf6c5de	TCGA-CN-5364-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5364-01A	13F63218-0949-41E6-A661-C844414C45B5	Primary Tumor	Illumina HiSeq	c408c80c-a712-46f0-8945-22511233d2bf	Head and Neck	55	38A4AC42-BE08-4187-98C2-AF861218C3DB	6CE3D597-51F1-4807-A28F-271F25F95ED4	TCGA-CN-5364-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5364	TCGA-HNSC	493	s15767	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c62e	58cfa831e4b0c9d6adf6c62e	TCGA-CN-5361-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CN-5361-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_6_rg.sorted	TCGA-CN-5361-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_6_rg.sorted.bam	112.4	1.9	0.13	58cfa831e4b0c9d6adf6c62e	TCGA-CN-5361-10A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5361-10A	044579EF-16A6-4F00-B951-EDC423D8A14F	Blood Derived Normal	Illumina HiSeq	34ee605a-e704-413f-91ff-81dbaef22fb7	Head and Neck	80	5B2581D8-C087-4CAA-B9CE-BC0168FBFEFA	2B747573-FEA7-4404-937E-5D7D74772776	TCGA-CN-5361-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5361	TCGA-HNSC	NA	s15624	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2a	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c67d	58cfa831e4b0c9d6adf6c67d	TCGA-CG-4469-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4469-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_3_rg.sorted	TCGA-CG-4469-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_3_rg.sorted.bam	298.2	1.9	0.14	58cfa831e4b0c9d6adf6c67d	TCGA-CG-4469-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_3_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4469-01A	2AC986F6-CD6F-4CA5-90CC-7A105CFE85EA	Primary Tumor	Illumina HiSeq	dcd0352b-a451-4eaa-840e-14884d08bd89	Stomach	70	2A3D7538-D377-4D94-BB61-BF77BA56BE1B	9BAFEA4B-CCC4-4F5D-8BFE-BD13D56741F6	TCGA-CG-4469-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4469	TCGA-STAD	215	s14831	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c66d	58cfa831e4b0c9d6adf6c66d	TCGA-CU-A0YN-01A-21D-A10R_120926_SN590_0182_BD1EAGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CU-A0YN-01A-21D-A10R_120926_SN590_0182_BD1EAGACXX_s_3_rg.sorted	TCGA-CU-A0YN-01A-21D-A10R_120926_SN590_0182_BD1EAGACXX_s_3_rg.sorted.bam	82.02	2	0.16	58cfa831e4b0c9d6adf6c66d	TCGA-CU-A0YN-01A-21D-A10R_120926_SN590_0182_BD1EAGACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A0YN-01A	679A6869-2CE9-4472-8DB1-8869E2C1A440	Primary Tumor	Illumina HiSeq	89fcc222-6a37-406f-a641-b3d857104f9f	Bladder	60	DBCC2FCB-A103-46DA-9893-6EC689D2F98E	98E994A3-9823-472B-AED1-38876DEA7F24	TCGA-CU-A0YN-01A-21D-A10R-02	HG19_Broad_variant	TCGA-CU-A0YN	TCGA-BLCA	393	s3276	Harvard Medical School	UNC	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c698	58cfa831e4b0c9d6adf6c698	TCGA-CN-5366-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-5366-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_1_rg.sorted	TCGA-CN-5366-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_1_rg.sorted.bam	313.7	1.9	0.16	58cfa831e4b0c9d6adf6c698	TCGA-CN-5366-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5366-01A	30EB06A5-8E88-4C46-BEBB-FB93CA07F108	Primary Tumor	Illumina HiSeq	0a7fb0ab-3302-4187-a567-58bc19979dc5	Head and Neck	51	62FDF8F3-A028-453F-B27C-C2506BE68CBE	AE791AB1-78E2-4E8B-AB05-4435D9C67AA3	TCGA-CN-5366-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5366	TCGA-HNSC	360	s15497	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c718	58cfa831e4b0c9d6adf6c718	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted.bam	303.4	1.9	0.15	58cfa831e4b0c9d6adf6c718	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6528-01A	35496E4E-598F-4FFC-B11E-8EDAEB676079	Primary Tumor	Illumina HiSeq	478ea84f-df8f-4d1b-a7da-ab1ac7751e97	Stomach	70	DF817250-9A2C-42E8-AD90-0D9E13FE37B3	7DA37A25-E2DE-4193-AD71-2182B6DA5C26	TCGA-D7-6528-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6528	TCGA-STAD	NA	s14562	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IB	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c69a	58cfa831e4b0c9d6adf6c69a	TCGA-CQ-5329-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CQ-5329-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_7_rg.sorted	TCGA-CQ-5329-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_7_rg.sorted.bam	77.7	1.9	0.14	58cfa831e4b0c9d6adf6c69a	TCGA-CQ-5329-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5329-10A	02DCC11F-4F0E-4C9E-8D96-D22D47BEEF5D	Blood Derived Normal	Illumina HiSeq	9f0c3cb3-500d-46d1-8abc-1b4492354050	Head and Neck	46	03BF8F50-0D93-4656-A625-4D4BBF3A876F	E3943EA3-6B2E-402E-BB8D-B226FADF1038	TCGA-CQ-5329-10A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5329	TCGA-HNSC	NA	s16327	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c71e	58cfa831e4b0c9d6adf6c71e	TCGA-D7-6518-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D7-6518-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_3_rg.sorted	TCGA-D7-6518-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_3_rg.sorted.bam	59.4	1.8	0.16	58cfa831e4b0c9d6adf6c71e	TCGA-D7-6518-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6518-01A	40E507FB-E285-424B-A98B-362E47A53E4A	Primary Tumor	Illumina HiSeq	d4c1a136-c2f2-4cac-9b15-79669253b6e8	Stomach	75	B6B986E2-6770-4C59-9D0F-AEA3F3BA26E9	2BAFD8B4-962F-411F-89C6-BB5C7E2A1E78	TCGA-D7-6518-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6518	TCGA-STAD	NA	s14994	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c686	58cfa831e4b0c9d6adf6c686	TCGA-CN-4737-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-4737-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_4_rg.sorted	TCGA-CN-4737-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_4_rg.sorted.bam	702.7	1.9	0.16	58cfa831e4b0c9d6adf6c686	TCGA-CN-4737-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4737-10A	1F744ADA-6DE1-446D-B62C-76A7FC8B40AF	Blood Derived Normal	Illumina HiSeq	fdf0a7f2-3007-49fa-b8f8-88f75e9f9396	Head and Neck	19	E0D710B0-E301-4441-BF1C-44AE39CB3239	76742CF6-8394-4B19-A4A8-59C305F21DC4	TCGA-CN-4737-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4737	TCGA-HNSC	NA	s16031	Harvard Medical School	University of Pittsburgh	None	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c6c2	58cfa831e4b0c9d6adf6c6c2	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted.bam	78.7	1.9	0.14	58cfa831e4b0c9d6adf6c6c2	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4740-01A	E37C83DC-C2C4-4E5F-A57B-39FFCF9AA3CF	Primary Tumor	Illumina HiSeq	c1580763-a5d9-4753-b80c-f8d5498a7494	Head and Neck	79	2311DEEC-8DBC-4449-BE09-FCD4E3BAFD87	9DD678DF-BCE7-46C2-8454-3DE815FB85ED	TCGA-CN-4740-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4740	TCGA-HNSC	NA	s15884	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c75a	58cfa831e4b0c9d6adf6c75a	TCGA-D6-6515-01A-21D-1868_120530_SN1222_0110_AC0VLAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D6-6515-01A-21D-1868_120530_SN1222_0110_AC0VLAACXX_s_7_rg.sorted	TCGA-D6-6515-01A-21D-1868_120530_SN1222_0110_AC0VLAACXX_s_7_rg.sorted.bam	127.7	1.9	0.15	58cfa831e4b0c9d6adf6c75a	TCGA-D6-6515-01A-21D-1868_120530_SN1222_0110_AC0VLAACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6515-01A	8E0E456E-85EE-4DE5-8F0B-72393D6ACDE0	Primary Tumor	Illumina HiSeq	5a79073a-b6a0-41df-b26b-247649784d4d	Head and Neck	82	4453D224-F846-4CEE-972F-8438C964913B	D6E287D9-D7C4-496C-829F-F7D7980D77A2	TCGA-D6-6515-01A-21D-1868-02	HG19_Broad_variant	TCGA-D6-6515	TCGA-HNSC	403	s15914	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6c75e	58cfa831e4b0c9d6adf6c75e	TCGA-D1-A1O0-10A-01D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A1O0-10A-01D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_4_rg.sorted	TCGA-D1-A1O0-10A-01D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_4_rg.sorted.bam	19.49	1.98	0.17	58cfa831e4b0c9d6adf6c75e	TCGA-D1-A1O0-10A-01D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A1O0-10A	A98BBE29-8817-4380-A738-3C1BF9F8E0CC	Blood Derived Normal	Illumina HiSeq	28a1d78c-cec8-4067-8f4b-201ef9b7fe9d	Uterus	77	24C73392-0F24-418E-B89F-1C3D4613DDF3	BC47D6F0-E345-43D0-950B-89D6BFC019AE	TCGA-D1-A1O0-10A-01D-A17E-02	HG19_Broad_variant	TCGA-D1-A1O0	TCGA-UCEC	NA	s5025	Harvard Medical School	Mayo Clinic	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A17E-02	TRUE
13722.58cfa831e4b0c9d6adf6c774	58cfa831e4b0c9d6adf6c774	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted.bam	124.95	1.37	0.15	58cfa831e4b0c9d6adf6c774	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A174-01A	FC7315B0-9F48-4206-B197-2268C0518EB4	Primary Tumor	Illumina HiSeq	6ec3f35d-55a7-439a-b179-8a4aebcab751	Uterus	51	AD5A9CB6-B3F9-4651-B6D1-13C78010BD88	D661CFB9-248A-49E6-B0DB-865CA257E8DC	TCGA-D1-A174-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A174	TCGA-UCEC	NA	s4614	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c778	58cfa831e4b0c9d6adf6c778	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted.bam	99.41	2	0.15	58cfa831e4b0c9d6adf6c778	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17D-01A	7DDEDDD1-B2AD-425F-94A2-9C476B959F2A	Primary Tumor	Illumina HiSeq	9d6f1593-568e-447d-b4f7-10048102ce8f	Uterus	58	9EC5A25B-9CE1-4FDE-9341-13DA39BC74B0	0F6ECDCA-5659-426A-8DAC-3211183597BD	TCGA-D1-A17D-01A-12D-A12F-02	HG19_Broad_variant	TCGA-D1-A17D	TCGA-UCEC	NA	s4443	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c7eb	58cfa831e4b0c9d6adf6c7eb	TCGA-D1-A17Q-10A-01D-A12F_120418_SN1222_0097_AC0M28ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-D1-A17Q-10A-01D-A12F_120418_SN1222_0097_AC0M28ACXX_s_8_rg.sorted	TCGA-D1-A17Q-10A-01D-A12F_120418_SN1222_0097_AC0M28ACXX_s_8_rg.sorted.bam	26.66	1.96	0.17	58cfa831e4b0c9d6adf6c7eb	TCGA-D1-A17Q-10A-01D-A12F_120418_SN1222_0097_AC0M28ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17Q-10A	CA8DBBFD-8928-4E25-94C6-B875DE631BBD	Blood Derived Normal	Illumina HiSeq	8534d080-820f-47f9-bb58-a7bad05321ef	Uterus	54	884E1EE9-8CFD-46C6-8414-8316F41C986E	206EE62B-D698-44F5-A177-7950EAA0D849	TCGA-D1-A17Q-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A17Q	TCGA-UCEC	NA	s4446	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c7b8	58cfa831e4b0c9d6adf6c7b8	TCGA-D1-A16B-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A16B-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_2_rg.sorted	TCGA-D1-A16B-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_2_rg.sorted.bam	7.5	1.92	0.15	58cfa831e4b0c9d6adf6c7b8	TCGA-D1-A16B-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16B-10A	BCA1057A-1E96-404D-8A37-5A8DC1944EE7	Blood Derived Normal	Illumina HiSeq	ee24ca3f-bf5f-4dd3-8f41-15d8fcecf487	Uterus	64	AECBCF95-6D7A-401D-999E-D2169479D50B	CD46E08E-0A38-4B73-ACED-468468511434	TCGA-D1-A16B-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A16B	TCGA-UCEC	NA	s5223	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c89c	58cfa831e4b0c9d6adf6c89c	TCGA-DJ-A1QD-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DJ-A1QD-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_8_rg.sorted	TCGA-DJ-A1QD-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_8_rg.sorted.bam	30.45	1.91	0.18	58cfa831e4b0c9d6adf6c89c	TCGA-DJ-A1QD-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QD-10A	DA201150-748E-4B74-BB35-10C995E26079	Blood Derived Normal	Illumina HiSeq	9988a265-d995-48ca-b130-de90744c22b8	Thyroid	20	BE3A9226-DDA7-491F-910B-8BC614635DB5	F2A6B68F-6A10-4D99-AF4D-17309A015112	TCGA-DJ-A1QD-10A-01D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QD	TCGA-THCA	NA	s12238	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c8be	58cfa831e4b0c9d6adf6c8be	TCGA-DK-A1A5-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DK-A1A5-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_2_rg.sorted	TCGA-DK-A1A5-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_2_rg.sorted.bam	56.09	1.95	0.15	58cfa831e4b0c9d6adf6c8be	TCGA-DK-A1A5-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A5-10A	904A8757-E0C5-41EF-B583-C8F170CAAAC1	Blood Derived Normal	Illumina HiSeq	43d7b3d5-6a0c-49f1-a63c-d49c8fdb8c86	Bladder	79	608EEC1D-33BC-48DD-A928-49B09E87CCC8	BCB12F76-2D37-4B56-B1FC-62CA41B39703	TCGA-DK-A1A5-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A5	TCGA-BLCA	65	s2891	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c7e5	58cfa831e4b0c9d6adf6c7e5	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted.bam	68.97	1.95	0.15	58cfa831e4b0c9d6adf6c7e5	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A169-01A	9A599F57-0E8D-4E1F-A181-791F5FDEADB7	Primary Tumor	Illumina HiSeq	43a5a914-7913-4e5e-9d2f-42fcec7bab2f	Uterus	63	9B36F264-55C3-4E08-A151-4B356871520C	B3A7C237-92C3-448A-A87E-8C8B1061A79F	TCGA-D1-A169-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A169	TCGA-UCEC	NA	s4796	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c8fa	58cfa831e4b0c9d6adf6c8fa	TCGA-CU-A0YO-10A-01D-A10R_120926_SN590_0182_BD1EAGACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CU-A0YO-10A-01D-A10R_120926_SN590_0182_BD1EAGACXX_s_6_rg.sorted	TCGA-CU-A0YO-10A-01D-A10R_120926_SN590_0182_BD1EAGACXX_s_6_rg.sorted.bam	20.75	1.95	0.16	58cfa831e4b0c9d6adf6c8fa	TCGA-CU-A0YO-10A-01D-A10R_120926_SN590_0182_BD1EAGACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A0YO-10A	4A9EF220-922C-49CF-BBED-D173B214ED31	Blood Derived Normal	Illumina HiSeq	d9b681f1-ebb5-4f97-8585-796e6ae8fb6d	Bladder	84	ABD9CFE7-EF6B-4A64-8733-0637581A0FC4	16A7AF6E-660A-49F8-8291-BACDA29FB3E1	TCGA-CU-A0YO-10A-01D-A10R-02	HG19_Broad_variant	TCGA-CU-A0YO	TCGA-BLCA	149	s3275	Harvard Medical School	UNC	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c972	58cfa831e4b0c9d6adf6c972	TCGA-D7-6528-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D7-6528-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_6_rg.sorted	TCGA-D7-6528-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_6_rg.sorted.bam	291.7	1.9	0.15	58cfa831e4b0c9d6adf6c972	TCGA-D7-6528-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6528-10A	35496E4E-598F-4FFC-B11E-8EDAEB676079	Blood Derived Normal	Illumina HiSeq	d4ea96e7-6bf3-4ac4-88ad-e0199ddef1b7	Stomach	70	45FE00A2-0D61-4861-8F22-B0D306458CE4	E9E37E3D-03CA-41A1-B725-2768EDFB3017	TCGA-D7-6528-10A-01D-1798-02	HG19_Broad_variant	TCGA-D7-6528	TCGA-STAD	NA	s15407	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IB	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c967	58cfa831e4b0c9d6adf6c967	TCGA-DJ-A13V-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DJ-A13V-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_4_rg.sorted	TCGA-DJ-A13V-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_4_rg.sorted.bam	35.32	1.93	0.16	58cfa831e4b0c9d6adf6c967	TCGA-DJ-A13V-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13V-10A	99AC4F2E-2E63-4F1E-AF0F-8F23A2CAF999	Blood Derived Normal	Illumina HiSeq	e3b798f9-04a4-4365-a60b-37a5b6893d1a	Thyroid	21	727FF1F4-06E5-4B68-BCE4-EC16DCF4893F	EA9BCF86-E3C9-480C-AF3D-1C8C8A4D83A1	TCGA-DJ-A13V-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13V	TCGA-THCA	NA	s11994	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c988	58cfa831e4b0c9d6adf6c988	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted.bam	36.64	2.05	0.17	58cfa831e4b0c9d6adf6c988	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QE-01A	DCCBA97D-4E81-42FB-93B3-90BE68A034FB	Primary Tumor	Illumina HiSeq	b2380599-45dd-48d5-840c-f6e358db7169	Thyroid	62	E8BF40C4-8F4D-4032-B18B-D61A87A2DD1A	FB93D33F-510B-45BD-8E70-8FD3A0EA5DBE	TCGA-DJ-A1QE-01A-21D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QE	TCGA-THCA	NA	s12635	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c996	58cfa831e4b0c9d6adf6c996	TCGA-DK-A1AC-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DK-A1AC-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_6_rg.sorted	TCGA-DK-A1AC-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_6_rg.sorted.bam	64.42	1.91	0.16	58cfa831e4b0c9d6adf6c996	TCGA-DK-A1AC-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AC-10A	36C14E9D-1863-4C55-BBBB-F8C9DD418932	Blood Derived Normal	Illumina HiSeq	7b5dbb5a-bca2-4772-8f0f-af7cdca1713e	Bladder	72	00D99D48-F628-4533-8DDA-539ADD87CEDD	10182859-0BC3-434E-8773-007F65394926	TCGA-DK-A1AC-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AC	TCGA-BLCA	NA	s2706	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c998	58cfa831e4b0c9d6adf6c998	TCGA-DK-A1A7-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A1A7-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_1_rg.sorted	TCGA-DK-A1A7-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_1_rg.sorted.bam	35.04	2	0.15	58cfa831e4b0c9d6adf6c998	TCGA-DK-A1A7-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A7-01A	3ED614E7-F356-4D87-985B-D3BBBAE3BB40	Primary Tumor	Illumina HiSeq	4c14028a-f15d-42f9-ad5f-19f0dca3984e	Bladder	67	D68D16F7-6117-4D3D-8347-CF5CD3F23AE4	2DDD46A0-5304-4CA3-9AE3-AC3787D3C86A	TCGA-DK-A1A7-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A7	TCGA-BLCA	NA	s3280	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c973	58cfa831e4b0c9d6adf6c973	TCGA-DA-A1HW-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DA-A1HW-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_8_rg.sorted	TCGA-DA-A1HW-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_8_rg.sorted.bam	18.18	NA	0.16	58cfa831e4b0c9d6adf6c973	TCGA-DA-A1HW-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1HW-10A	800D3A17-269F-4D97-94FF-8585F20038D8	Blood Derived Normal	Illumina HiSeq	19d8b19f-ad7f-4a2e-8a4b-e1cac0212f82	Skin	37	8A27E6E0-A444-4701-B052-041F90267A69	8BD5C911-3AFB-4541-86E6-1330E7C9A5ED	TCGA-DA-A1HW-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-DA-A1HW	TCGA-SKCM	NA	s7838	Harvard Medical School	Yale	United States	NO	T1a	N1b	Not available	Stage IIIB	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c9a8	58cfa831e4b0c9d6adf6c9a8	TCGA-DK-A1AG-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A1AG-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_7_rg.sorted	TCGA-DK-A1AG-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_7_rg.sorted.bam	70.38	1.89	0.17	58cfa831e4b0c9d6adf6c9a8	TCGA-DK-A1AG-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AG-01A	F8C0A69C-DF53-4A0A-A30E-4424C0CE3DD5	Primary Tumor	Illumina HiSeq	4043eef2-fcc6-411c-a6a3-ddd71f3852d8	Bladder	65	64668AA0-DDE5-4534-8CD0-378881E4A4E4	69A3B1DB-3463-456C-B3D1-6BE1FD7EE1D9	TCGA-DK-A1AG-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AG	TCGA-BLCA	NA	s2885	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c95e	58cfa831e4b0c9d6adf6c95e	TCGA-DJ-A1QN-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DJ-A1QN-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_3_rg.sorted	TCGA-DJ-A1QN-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_3_rg.sorted.bam	18.72	2	0.16	58cfa831e4b0c9d6adf6c95e	TCGA-DJ-A1QN-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QN-10A	2012869D-C169-4CEA-AA09-C892FB79BBAA	Blood Derived Normal	Illumina HiSeq	d00042e4-f3b6-449e-be48-584604e5d67c	Thyroid	42	4D578AF6-98D7-4F4E-8379-63040529E147	4DE0299A-E33E-4ABF-863C-8656B5CF904C	TCGA-DJ-A1QN-10A-01D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QN	TCGA-THCA	NA	s12515	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c956	58cfa831e4b0c9d6adf6c956	TCGA-DJ-A1QQ-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DJ-A1QQ-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_7_rg.sorted	TCGA-DJ-A1QQ-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_7_rg.sorted.bam	25.11	0.18	0.16	58cfa831e4b0c9d6adf6c956	TCGA-DJ-A1QQ-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QQ-10A	99EF2FEC-5A3C-4E42-8F78-7EAF9877E26D	Blood Derived Normal	Illumina HiSeq	90c167bf-1373-46c1-bb08-0bdd5f44a2a4	Thyroid	43	3BBBC8D3-799A-4D4E-A43C-E7A8B449492A	C8A4F7A1-2E2F-4485-8201-9CB104D276E8	TCGA-DJ-A1QQ-10A-01D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QQ	TCGA-THCA	NA	s12516	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c9a0	58cfa831e4b0c9d6adf6c9a0	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted.bam	80.19	1.78	0.16	58cfa831e4b0c9d6adf6c9a0	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DO-A1K0-01A	B7A01148-5BAB-4268-986A-A9CF7BCA967F	Primary Tumor	Illumina HiSeq	52d6a725-e64a-4e5b-88cb-c4845dc97057	Thyroid	30	C25AED9B-A1B7-48A9-8587-8D218F6A9562	7BC99883-45C3-4ADF-8761-40B4836552F2	TCGA-DO-A1K0-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DO-A1K0	TCGA-THCA	NA	s12245	Harvard Medical School	Medical College of Georgia	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c9b4	58cfa831e4b0c9d6adf6c9b4	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted.bam	58.89	1.97	0.13	58cfa831e4b0c9d6adf6c9b4	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13S-01A	8AA99F35-C644-4F91-9EFF-A5D3FAE758B0	Primary Tumor	Illumina HiSeq	a19c2149-887d-4a36-992f-2a0ebb46072c	Thyroid	19	17952842-3447-4A38-90F4-D25B90C3233A	3C630C3D-343D-4F9F-8067-43B66466D382	TCGA-DJ-A13S-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13S	TCGA-THCA	NA	s12239	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6ca18	58cfa831e4b0c9d6adf6ca18	TCGA-DJ-A1QE-10A-01D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DJ-A1QE-10A-01D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_4_rg.sorted	TCGA-DJ-A1QE-10A-01D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_4_rg.sorted.bam	36.43	1.96	0.18	58cfa831e4b0c9d6adf6ca18	TCGA-DJ-A1QE-10A-01D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QE-10A	DCCBA97D-4E81-42FB-93B3-90BE68A034FB	Blood Derived Normal	Illumina HiSeq	fca4c4c6-e34c-4af8-a27e-debac8a5f0e3	Thyroid	62	144A8435-0F16-44A6-9651-71FB483AE5B7	6E01EA1F-B400-4FAC-A143-2DE218C224D9	TCGA-DJ-A1QE-10A-01D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QE	TCGA-THCA	NA	s12366	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6ca2d	58cfa831e4b0c9d6adf6ca2d	TCGA-DO-A1K0-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DO-A1K0-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_4_rg.sorted	TCGA-DO-A1K0-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_4_rg.sorted.bam	8.25	1.97	0.15	58cfa831e4b0c9d6adf6ca2d	TCGA-DO-A1K0-10A-01D-A13U_120706_SN1222_0123_BD1488ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DO-A1K0-10A	B7A01148-5BAB-4268-986A-A9CF7BCA967F	Blood Derived Normal	Illumina HiSeq	36a669c2-5641-40b8-9b53-d660e0636162	Thyroid	30	D654C724-9C1F-41F9-BE78-FD14A148CDCF	3C802666-0D28-49A9-8F6F-69ACEE0E7AEE	TCGA-DO-A1K0-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DO-A1K0	TCGA-THCA	NA	s12642	Harvard Medical School	Medical College of Georgia	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c9c6	58cfa831e4b0c9d6adf6c9c6	TCGA-DA-A1I7-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DA-A1I7-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_7_rg.sorted	TCGA-DA-A1I7-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_7_rg.sorted.bam	24.4	NA	0.15	58cfa831e4b0c9d6adf6c9c6	TCGA-DA-A1I7-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1I7-10A	DFE8BAA8-1C2C-4C36-92C9-61548CEBEC19	Blood Derived Normal	Illumina HiSeq	46644fd2-8d67-4fe0-bd0b-2a2d74d08596	Skin	62	3BB3E8C1-DF0C-4635-BF1B-7FFD3E58384C	9DB43937-2095-4F40-86BF-C86840D44150	TCGA-DA-A1I7-10A-01D-A190-02	HG19_Broad_variant	TCGA-DA-A1I7	TCGA-SKCM	NA	s7327	Harvard Medical School	Yale	United States	NO	T0	N2b	Not available	Stage IIIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ca26	58cfa831e4b0c9d6adf6ca26	TCGA-DJ-A13O-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DJ-A13O-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_8_rg.sorted	TCGA-DJ-A13O-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_8_rg.sorted.bam	34.01	1.9	0.15	58cfa831e4b0c9d6adf6ca26	TCGA-DJ-A13O-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13O-10A	77D5B246-33BA-4A96-9D73-06ACA797653E	Blood Derived Normal	Illumina HiSeq	811c4997-02a6-42c1-9075-e970fb42fbb5	Thyroid	56	A79EC95F-6285-4F6B-A9A1-4957F4F29172	C27C265E-8EB0-4808-A639-6F62C7E7BF4B	TCGA-DJ-A13O-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13O	TCGA-THCA	NA	s12638	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6ca43	58cfa831e4b0c9d6adf6ca43	TCGA-DJ-A1QL-01A-11D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A1QL-01A-11D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_1_rg.sorted	TCGA-DJ-A1QL-01A-11D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_1_rg.sorted.bam	77.76	1.96	0.18	58cfa831e4b0c9d6adf6ca43	TCGA-DJ-A1QL-01A-11D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_1_rg.sorted.bam	Alive	MALE	Not available	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QL-01A	E4B08E66-0772-4956-8670-E5C6553EECBE	Primary Tumor	Illumina HiSeq	115df95b-61fb-4fef-a23f-df0ade71c646	Thyroid	70	62B6D426-E1E4-48E8-BC8F-6B07C67CC0D0	C5B8FBAE-98B5-437B-A8BD-D695C5E8CB4F	TCGA-DJ-A1QL-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QL	TCGA-THCA	NA	s12373	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6ca6a	58cfa831e4b0c9d6adf6ca6a	TCGA-DJ-A13S-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DJ-A13S-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_8_rg.sorted	TCGA-DJ-A13S-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_8_rg.sorted.bam	37.77	1.92	0.14	58cfa831e4b0c9d6adf6ca6a	TCGA-DJ-A13S-10A-01D-A10R_120711_SN1120_0174_BD13R2ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13S-10A	8AA99F35-C644-4F91-9EFF-A5D3FAE758B0	Blood Derived Normal	Illumina HiSeq	bce12e97-f376-4f4e-b605-757fdaa9c477	Thyroid	19	932EB8E5-FEAF-4C8C-8037-2D4D3B56D677	CC298C32-42CE-4BDF-8363-2AC6A214B9AA	TCGA-DJ-A13S-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13S	TCGA-THCA	NA	s12370	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6ca88	58cfa831e4b0c9d6adf6ca88	TCGA-DU-5852-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DU-5852-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_8_rg.sorted	TCGA-DU-5852-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_8_rg.sorted.bam	93	1.8	0.14	58cfa831e4b0c9d6adf6ca88	TCGA-DU-5852-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5852-10A	9ED5AF0E-C87F-46FF-81E7-9D3041B4034E	Blood Derived Normal	Illumina HiSeq	6d9e6678-64e1-4fa4-b57d-338f163a62a1	Brain	61	5A82BD3E-7E2F-4D14-95F8-B85C684A3B7D	73074E40-BF47-4433-BA0E-FFEBFE1ED4C2	TCGA-DU-5852-10A-01D-1703-02	HG19_Broad_variant	TCGA-DU-5852	TCGA-LGG	205	s8560	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6ca74	58cfa831e4b0c9d6adf6ca74	TCGA-D3-A2J6-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D3-A2J6-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_7_rg.sorted	TCGA-D3-A2J6-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_7_rg.sorted.bam	16.83	NA	0.17	58cfa831e4b0c9d6adf6ca74	TCGA-D3-A2J6-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A2J6-10A	6F5157B8-D43A-4FBC-B7DA-23629F5B53DA	Blood Derived Normal	Illumina HiSeq	097403a5-4887-4f69-9102-7bad4016d96d	Skin	65	3EBFE354-A4CC-46EE-BD2A-ED7D84F3D76D	E5DB58D8-8AE1-47B3-AA3F-CDD7A8FFCF97	TCGA-D3-A2J6-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A2J6	TCGA-SKCM	1321	s7997	Harvard Medical School	MD Anderson	United States	NO	T3b	N0	Not available	Stage IIB	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6ca97	58cfa831e4b0c9d6adf6ca97	TCGA-D1-A17K-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D1-A17K-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_5_rg.sorted	TCGA-D1-A17K-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_5_rg.sorted.bam	29.91	1.96	0.17	58cfa831e4b0c9d6adf6ca97	TCGA-D1-A17K-10A-01D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17K-10A	5C22C8D6-5805-455C-8E1C-E6B8006738E4	Blood Derived Normal	Illumina HiSeq	3aa41447-e70b-41dc-9ca0-cac568fa8e39	Uterus	74	72719D9E-F802-4E2B-8979-0A080EE83E09	BE759333-002C-4763-8F1A-4A1CF5EDC33B	TCGA-D1-A17K-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A17K	TCGA-UCEC	NA	s4615	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6cae2	58cfa831e4b0c9d6adf6cae2	TCGA-DU-5854-10A-01D-1703_130806_SN1440_0159_BC29Y3ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DU-5854-10A-01D-1703_130806_SN1440_0159_BC29Y3ACXX_s_2_rg.sorted	TCGA-DU-5854-10A-01D-1703_130806_SN1440_0159_BC29Y3ACXX_s_2_rg.sorted.bam	85	1.8	0.15	58cfa831e4b0c9d6adf6cae2	TCGA-DU-5854-10A-01D-1703_130806_SN1440_0159_BC29Y3ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5854-10A	B95AFB1A-A1DF-4D85-AD34-191928E28A77	Blood Derived Normal	Illumina HiSeq	ef916508-4f9f-45d1-b65b-8d69a7895db8	Brain	57	8AC25071-2BC5-437A-AB26-1FEDBC3747CB	E7E00A72-A00D-4D50-A329-620A510A7B6C	TCGA-DU-5854-10A-01D-1703-02	HG19_Broad_variant	TCGA-DU-5854	TCGA-LGG	NA	s8344	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6cad8	58cfa831e4b0c9d6adf6cad8	TCGA-DU-6403-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DU-6403-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_4_rg.sorted	TCGA-DU-6403-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_4_rg.sorted.bam	78	1.9	0.15	58cfa831e4b0c9d6adf6cad8	TCGA-DU-6403-10A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6403-10A	8DAA29C0-F652-4130-A004-5183BBE30C63	Blood Derived Normal	Illumina HiSeq	5d588402-a79e-45a9-ba69-9bd3eba3aa6c	Brain	60	696EAE07-1FB0-4F51-B026-28B8684C2F30	56E72F88-2F97-483F-8AD2-359AAE10F380	TCGA-DU-6403-10A-01D-1703-02	HG19_Broad_variant	TCGA-DU-6403	TCGA-LGG	354	s8142	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6cab4	58cfa831e4b0c9d6adf6cab4	TCGA-DA-A1I8-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DA-A1I8-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_8_rg.sorted	TCGA-DA-A1I8-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_8_rg.sorted.bam	18.67	NA	0.15	58cfa831e4b0c9d6adf6cab4	TCGA-DA-A1I8-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1I8-10A	7B92FCD4-F9BE-4B97-94A2-B2E8348AEABA	Blood Derived Normal	Illumina HiSeq	2fd27dbc-9de2-4741-a087-0aee9dcda991	Skin	63	AAE8BDEA-4787-4144-8A1C-206F756ECDBC	2EA039F3-B715-4EA4-9D71-0509730885E2	TCGA-DA-A1I8-10A-01D-A190-02	HG19_Broad_variant	TCGA-DA-A1I8	TCGA-SKCM	NA	s7836	Harvard Medical School	Yale	United States	NO	T4b	N0	Not available	Stage IIC	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cad2	58cfa831e4b0c9d6adf6cad2	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted.bam	88.64	1.98	0.17	58cfa831e4b0c9d6adf6cad2	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-DI-A1BU-01A	53245616-E095-4616-89BB-6062669122DA	Primary Tumor	Illumina HiSeq	1a6e5cca-d65a-40c4-b8ce-b7b282493459	Uterus	55	241BFB1F-5CF8-458D-B335-18BABF507E85	085C72D3-C295-4D9B-A5CC-08F76CFF2284	TCGA-DI-A1BU-01A-11D-A133-02	HG19_Broad_variant	TCGA-DI-A1BU	TCGA-UCEC	NA	s4805	Harvard Medical School	MD Anderson	United States	NO	Not available	Not available	Mixed serous and endometrioid	Not available	A133-02	FALSE
13722.58cfa831e4b0c9d6adf6cb02	58cfa831e4b0c9d6adf6cb02	TCGA-EB-A24C-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EB-A24C-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_6_rg.sorted	TCGA-EB-A24C-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_6_rg.sorted.bam	51.27	NA	0.17	58cfa831e4b0c9d6adf6cb02	TCGA-EB-A24C-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EB-A24C-10A	2F1BBE96-49D9-417B-BC9C-A09992489340	Blood Derived Normal	Illumina HiSeq	cf91e71a-52c1-41bf-9864-33faccf6ec54	Skin	56	9B492DF2-8520-48E3-825A-F5519B511969	38A1ABF6-EF0C-43D2-AEA6-B00431957213	TCGA-EB-A24C-10A-01D-A190-02	HG19_Broad_variant	TCGA-EB-A24C	TCGA-SKCM	NA	s8006	Harvard Medical School	Asterand	Ukraine	NO	T4b	NX	Not available	Not available	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb40	58cfa831e4b0c9d6adf6cb40	TCGA-EE-A2GS-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EE-A2GS-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_3_rg.sorted	TCGA-EE-A2GS-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_3_rg.sorted.bam	46.23	NA	0.18	58cfa831e4b0c9d6adf6cb40	TCGA-EE-A2GS-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GS-06A	880BB701-F1D3-4BF2-BFC8-143AD8D07B6A	Metastatic	Illumina HiSeq	effe1a0a-bcd4-4a16-9d4b-62396920b6fb	Skin	28	B9D12203-7D72-4BE3-A1D2-53836EBBD599	D1786636-29E9-478A-A6CD-161FEDB453DA	TCGA-EE-A2GS-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2GS	TCGA-SKCM	NA	s8013	Harvard Medical School	University of Sydney	Australia	NO	T2a	N0	Not available	Stage IB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb4e	58cfa831e4b0c9d6adf6cb4e	TCGA-EE-A2M6-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EE-A2M6-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_8_rg.sorted	TCGA-EE-A2M6-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_8_rg.sorted.bam	28.18	NA	0.15	58cfa831e4b0c9d6adf6cb4e	TCGA-EE-A2M6-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2M6-10A	58F0AE89-E277-4DFF-BB73-777CDF602DC7	Blood Derived Normal	Illumina HiSeq	5d31b027-a845-46a7-94e8-1a9dcd01370a	Skin	61	CDE8691F-3F84-47CD-8565-824CCA801BEC	F8C1E946-924D-4EB3-A2B4-04756B782F2C	TCGA-EE-A2M6-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2M6	TCGA-SKCM	NA	s7511	Harvard Medical School	University of Sydney	Australia	NO	T1	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb8e	58cfa831e4b0c9d6adf6cb8e	TCGA-EE-A17X-06A-11D-A18Y_120730_SN1222_0141_BC115GACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EE-A17X-06A-11D-A18Y_120730_SN1222_0141_BC115GACXX_s_6_rg.sorted	TCGA-EE-A17X-06A-11D-A18Y_120730_SN1222_0141_BC115GACXX_s_6_rg.sorted.bam	48.71	NA	0.17	58cfa831e4b0c9d6adf6cb8e	TCGA-EE-A17X-06A-11D-A18Y_120730_SN1222_0141_BC115GACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	Not available	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A17X-06A	5F8CC8D6-8A1C-41D0-BAD6-FEDD2948F40A	Metastatic	Illumina HiSeq	6d053510-47ba-47ff-8349-8711be6a15c7	Skin	54	55AC45ED-8022-4386-8825-90A1A600D40E	F0FF8EF6-85B4-4241-BDF3-E5CA4549583A	TCGA-EE-A17X-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A17X	TCGA-SKCM	907	s8004	Harvard Medical School	University of Sydney	Australia	NO	T1a	N0	Not available	Stage IA	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb59	58cfa831e4b0c9d6adf6cb59	TCGA-EE-A2MG-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EE-A2MG-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_2_rg.sorted	TCGA-EE-A2MG-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_2_rg.sorted.bam	51.09	NA	0.15	58cfa831e4b0c9d6adf6cb59	TCGA-EE-A2MG-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MG-06A	E653F888-37CF-41D5-A1CF-45397C90B31D	Metastatic	Illumina HiSeq	e2184793-28bf-4bf1-b685-2958c8c0b8a3	Skin	23	F68D55B0-001D-460D-9EB8-81B2AA26A909	8EAACD8C-A326-45BF-97C3-E1F300E1A1AA	TCGA-EE-A2MG-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2MG	TCGA-SKCM	3139	s7348	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb6c	58cfa831e4b0c9d6adf6cb6c	TCGA-EE-A2MG-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EE-A2MG-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_6_rg.sorted	TCGA-EE-A2MG-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_6_rg.sorted.bam	32.01	NA	0.15	58cfa831e4b0c9d6adf6cb6c	TCGA-EE-A2MG-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MG-10A	E653F888-37CF-41D5-A1CF-45397C90B31D	Blood Derived Normal	Illumina HiSeq	0bf941ea-fb16-4935-9af6-a05d078fdf99	Skin	23	457F41A3-E268-4CF9-9585-FD2A87B9F683	20D8F05B-2BC0-4CB7-9476-0EA90E69C965	TCGA-EE-A2MG-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2MG	TCGA-SKCM	3139	s7515	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb68	58cfa831e4b0c9d6adf6cb68	TCGA-EE-A2M5-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EE-A2M5-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_1_rg.sorted	TCGA-EE-A2M5-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_1_rg.sorted.bam	77.34	NA	0.16	58cfa831e4b0c9d6adf6cb68	TCGA-EE-A2M5-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2M5-06A	B5E37B9B-6264-4CC8-9B44-1D8AC0692D6C	Metastatic	Illumina HiSeq	3ee9a207-ca0a-45f4-b364-4a70483214dd	Skin	49	B3189E4F-3B90-4A1E-8FF1-FA2FEDC46C4C	270E8D67-394C-49D7-971C-1C829302C9E9	TCGA-EE-A2M5-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2M5	TCGA-SKCM	659	s7857	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc16	58cfa831e4b0c9d6adf6cc16	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted.bam	62.7	NA	0.17	58cfa831e4b0c9d6adf6cc16	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7294-01A	3F6FFB08-32A9-4555-BFD1-243B7F526105	Primary Tumor	Illumina HiSeq	2df0ab9f-8d32-40e9-883d-f5afad653272	Brain	53	C2D0A3C8-2354-475C-9027-5DF9523391CE	E6552DAE-BDEA-4945-9BA9-9C88D34CEBBC	TCGA-DU-7294-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7294	TCGA-LGG	NA	s8362	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cbd0	58cfa831e4b0c9d6adf6cbd0	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted.bam	118.7	NA	0.15	58cfa831e4b0c9d6adf6cbd0	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7125-01A	ACA312AB-6DBD-4183-8B22-8F37834F3426	Primary Tumor	Illumina HiSeq	c476525e-5147-4afb-bed0-f9ad34226240	Prostate	44	08E17DE6-FE0D-4FF0-B588-1CF1AB03F594	4BAD4379-B8AB-4D28-968E-5729602757EB	TCGA-EJ-7125-01A-11D-1957-02	HG19_Broad_variant	TCGA-EJ-7125	TCGA-PRAD	NA	s3442	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa831e4b0c9d6adf6ccc4	58cfa831e4b0c9d6adf6ccc4	TCGA-EJ-7125-10A-01D-1957_130221_SN1120_0239_BD1V59ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-7125-10A-01D-1957_130221_SN1120_0239_BD1V59ACXX_s_8_rg.sorted	TCGA-EJ-7125-10A-01D-1957_130221_SN1120_0239_BD1V59ACXX_s_8_rg.sorted.bam	250	NA	0.14	58cfa831e4b0c9d6adf6ccc4	TCGA-EJ-7125-10A-01D-1957_130221_SN1120_0239_BD1V59ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7125-10A	ACA312AB-6DBD-4183-8B22-8F37834F3426	Blood Derived Normal	Illumina HiSeq	956fdfd4-adc9-438d-8935-bb8a0626167c	Prostate	44	CEE0CE25-5CB8-4C3F-AEAC-D67EA0BA9611	D088E931-4D7E-4A03-8B5F-7A5B6D081B25	TCGA-EJ-7125-10A-01D-1957-02	HG19_Broad_variant	TCGA-EJ-7125	TCGA-PRAD	NA	s3792	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa831e4b0c9d6adf6cc8b	58cfa831e4b0c9d6adf6cc8b	TCGA-ER-A19N-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ER-A19N-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_7_rg.sorted	TCGA-ER-A19N-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_7_rg.sorted.bam	45.46	NA	0.16	58cfa831e4b0c9d6adf6cc8b	TCGA-ER-A19N-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19N-10A	9EE83669-D7A4-476E-8857-304600B4917A	Blood Derived Normal	Illumina HiSeq	0b049bb6-7ac6-4ef2-b258-988bafaf88e0	Skin	47	7872967C-2ADD-4157-9CC0-FD87C2F32AEE	708F03DF-83EE-47F7-99F4-AD2E7E0DB63B	TCGA-ER-A19N-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A19N	TCGA-SKCM	NA	s7694	Harvard Medical School	University of Pittsburgh	United States	NO	Not available	Not available	Not available	Not available	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ccc6	58cfa831e4b0c9d6adf6ccc6	TCGA-EM-A1CS-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EM-A1CS-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_5_rg.sorted	TCGA-EM-A1CS-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_5_rg.sorted.bam	69.84	1.88	0.18	58cfa831e4b0c9d6adf6ccc6	TCGA-EM-A1CS-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CS-01A	E92BDB0D-969A-4D98-ADA8-5DFEC68119B5	Primary Tumor	Illumina HiSeq	b6cf1366-a645-4bd9-ac5f-0e8c5d18a4ca	Thyroid	55	C1DAF740-06E2-4509-86BE-5BFCC52B508A	67082C81-DE62-42A4-82B7-CB6BE2C961D3	TCGA-EM-A1CS-01A-11D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CS	TCGA-THCA	NA	s12251	Harvard Medical School	University Health Network	Canada	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c7a7	58cfa831e4b0c9d6adf6c7a7	TCGA-D1-A17C-10A-01D-A12F_120418_SN1222_0097_AC0M28ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D1-A17C-10A-01D-A12F_120418_SN1222_0097_AC0M28ACXX_s_7_rg.sorted	TCGA-D1-A17C-10A-01D-A12F_120418_SN1222_0097_AC0M28ACXX_s_7_rg.sorted.bam	25.1	1.94	0.18	58cfa831e4b0c9d6adf6c7a7	TCGA-D1-A17C-10A-01D-A12F_120418_SN1222_0097_AC0M28ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17C-10A	6F4F0CDD-8387-45D0-A9E8-EFCE6260159D	Blood Derived Normal	Illumina HiSeq	365415a3-ae32-4590-8f15-d95fc3622cb1	Uterus	78	1227DA0C-73A9-47A9-8BC2-C93D363B5AAD	B16483E2-968A-4BD5-B8AC-9B132DE1D050	TCGA-D1-A17C-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A17C	TCGA-UCEC	NA	s4444	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6cd0c	58cfa831e4b0c9d6adf6cd0c	TCGA-ET-A25L-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_2_rg.sorted.filtered.	WGS	TCGA-ET-A25L-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_2_rg.sorted	TCGA-ET-A25L-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_2_rg.sorted.bam	22.88	2.2	0.18	58cfa831e4b0c9d6adf6cd0c	TCGA-ET-A25L-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25L-10A	4481D84D-109E-44A0-BCB4-E6E61BDCE796	Blood Derived Normal	Illumina HiSeq	887ff57f-346c-4a44-a195-c4c113c48c23	Thyroid	52	517CF62F-A089-4BBE-B398-1913DEE1514F	14D6E945-1A5F-4EA7-B418-B8463BAAD0CF	TCGA-ET-A25L-10A-01D-A16N-02	HG19_Broad_variant	TCGA-ET-A25L	TCGA-THCA	NA	s12645	Harvard Medical School	Johns Hopkins	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage IVA	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6cd0d	58cfa831e4b0c9d6adf6cd0d	TCGA-ER-A19A-06A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_4_rg.sorted.filtered.	WGS	TCGA-ER-A19A-06A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_4_rg.sorted	TCGA-ER-A19A-06A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_4_rg.sorted.bam	37.44	NA	0.16	58cfa831e4b0c9d6adf6cd0d	TCGA-ER-A19A-06A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19A-06A	41FCB9D3-9FB0-4625-98F4-1F564095EBC2	Metastatic	Illumina HiSeq	d62acfb8-3c88-47ac-b523-665ad3712081	Skin	79	09EE780C-E3DE-4638-88A7-879DE8017CBA	CFD54992-FD66-4234-9468-90D1A1219520	TCGA-ER-A19A-06A-21D-A18Y-02	HG19_Broad_variant	TCGA-ER-A19A	TCGA-SKCM	NA	s7696	Harvard Medical School	University of Pittsburgh	United States	NO	TX	N0	Not available	Stage IV	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cd54	58cfa831e4b0c9d6adf6cd54	TCGA-ET-A25N-11A-01D-A16N_120718_SN590_0170_BD141RACXX_s_3_rg.sorted.filtered.	WGS	TCGA-ET-A25N-11A-01D-A16N_120718_SN590_0170_BD141RACXX_s_3_rg.sorted	TCGA-ET-A25N-11A-01D-A16N_120718_SN590_0170_BD141RACXX_s_3_rg.sorted.bam	21.32	1.91	0.16	58cfa831e4b0c9d6adf6cd54	TCGA-ET-A25N-11A-01D-A16N_120718_SN590_0170_BD141RACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25N-11A	EBCCFB5F-C0A8-4263-AAFF-B5DD83585191	Solid Tissue Normal	Illumina HiSeq	dd7d0489-9e8f-4905-887d-8946943c9729	Thyroid	28	57DB2F77-C805-4328-8B19-A1BF2C996C1D	2BAECDF9-667C-434C-8F8D-49232854778F	TCGA-ET-A25N-11A-01D-A16N-02	HG19_Broad_variant	TCGA-ET-A25N	TCGA-THCA	NA	s12386	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6cd39	58cfa831e4b0c9d6adf6cd39	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted.bam	63.41	1.93	0.17	58cfa831e4b0c9d6adf6cd39	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25L-01A	4481D84D-109E-44A0-BCB4-E6E61BDCE796	Primary Tumor	Illumina HiSeq	bd558097-490f-4ee3-af4a-093fd4aebaf1	Thyroid	52	7D90939F-BAB7-4A39-8D57-79540142BB63	3490DBDC-8BFC-476F-BC1F-2D142365D9A2	TCGA-ET-A25L-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25L	TCGA-THCA	NA	s12524	Harvard Medical School	Johns Hopkins	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage IVA	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6cd1c	58cfa831e4b0c9d6adf6cd1c	TCGA-EY-A1GC-10A-01D-A13M_120516_SN1222_0107_BD12HYACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EY-A1GC-10A-01D-A13M_120516_SN1222_0107_BD12HYACXX_s_6_rg.sorted	TCGA-EY-A1GC-10A-01D-A13M_120516_SN1222_0107_BD12HYACXX_s_6_rg.sorted.bam	20.75	1.73	0.16	58cfa831e4b0c9d6adf6cd1c	TCGA-EY-A1GC-10A-01D-A13M_120516_SN1222_0107_BD12HYACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-EY-A1GC-10A	EBC25A41-BECB-4395-AE33-483A304B07D8	Blood Derived Normal	Illumina HiSeq	09d75c63-a601-4014-87e9-b0ee743619ad	Uterus	62	4FB947E9-0D41-4002-850C-771D676AAA4F	62203496-84AA-4653-8578-EC9DCDD53F8F	TCGA-EY-A1GC-10A-01D-A13M-02	HG19_Broad_variant	TCGA-EY-A1GC	TCGA-UCEC	NA	s4266	Harvard Medical School	University of North Carolina	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A13M-02	FALSE
13722.58cfa831e4b0c9d6adf6cdda	58cfa831e4b0c9d6adf6cdda	TCGA-FG-6691-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FG-6691-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_6_rg.sorted	TCGA-FG-6691-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_6_rg.sorted.bam	41	1.9	0.14	58cfa831e4b0c9d6adf6cdda	TCGA-FG-6691-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6691-10A	E4D9B696-3311-44E7-9191-FDE56C080A00	Blood Derived Normal	Illumina HiSeq	87f5566b-671c-48b4-8170-bef9aa55eb6b	Brain	23	EB350E44-4AF0-46FA-B329-30F599B9A953	5261C079-4E84-44DB-8E0C-B097344AE1E7	TCGA-FG-6691-10A-01D-1891-02	HG19_Broad_variant	TCGA-FG-6691	TCGA-LGG	NA	s8572	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6cddc	58cfa831e4b0c9d6adf6cddc	TCGA-FS-A1YW-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FS-A1YW-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_2_rg.sorted	TCGA-FS-A1YW-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_2_rg.sorted.bam	56.24	NA	0.17	58cfa831e4b0c9d6adf6cddc	TCGA-FS-A1YW-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1YW-06A	57DD4D65-CFAD-4533-92B4-90742289603B	Metastatic	Illumina HiSeq	215f3593-6275-410b-b345-926e04f4c119	Skin	52	1070E0C9-F9D1-434A-ABB7-873756921138	26CD8807-D47B-4D9B-BB4A-4C40745B4C36	TCGA-FS-A1YW-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1YW	TCGA-SKCM	6598	s7522	Harvard Medical School	Essen	Germany	NO	T1b	N0	Not available	Stage IB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cda6	58cfa831e4b0c9d6adf6cda6	TCGA-FE-A231-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FE-A231-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_2_rg.sorted	TCGA-FE-A231-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_2_rg.sorted.bam	19.94	2	0.16	58cfa831e4b0c9d6adf6cda6	TCGA-FE-A231-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A231-10A	7044DEE0-FD6C-4E75-B731-DC60A386A1AB	Blood Derived Normal	Illumina HiSeq	d2802fde-7e81-4964-915a-9469258cc84a	Thyroid	70	2F9DB370-79E8-4656-82CE-1EF4D477B46A	C42AD034-4E5B-44A0-B4E8-977CDE011C8B	TCGA-FE-A231-10A-01D-A14U-02	HG19_Broad_variant	TCGA-FE-A231	TCGA-THCA	NA	s12759	Harvard Medical School	Ohio State University	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cd29	58cfa831e4b0c9d6adf6cd29	TCGA-ER-A2NF-06A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_2_rg.sorted.filtered.	WGS	TCGA-ER-A2NF-06A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_2_rg.sorted	TCGA-ER-A2NF-06A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_2_rg.sorted.bam	70.24	NA	0.15	58cfa831e4b0c9d6adf6cd29	TCGA-ER-A2NF-06A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A2NF-06A	D32A4219-4CCA-470F-B6B3-11447D9F5E0B	Metastatic	Illumina HiSeq	5edfca3e-18b8-45be-9168-c232a12a27eb	Skin	53	20ECF8D6-2CA9-4C8A-B6CE-8B2A3BA51AE3	B86BEFC7-9B14-40C8-82FB-8ED70C8B36C0	TCGA-ER-A2NF-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-ER-A2NF	TCGA-SKCM	NA	s7356	Harvard Medical School	University of Pittsburgh	None	NO	T4b	N3	Not available	Stage IIIC	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6cde6	58cfa831e4b0c9d6adf6cde6	TCGA-FS-A1YX-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FS-A1YX-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_1_rg.sorted	TCGA-FS-A1YX-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_1_rg.sorted.bam	36.84	NA	0.16	58cfa831e4b0c9d6adf6cde6	TCGA-FS-A1YX-06A-11D-A18Y_120724_SN208_0417_AC117BACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1YX-06A	4537C0E1-B2BD-425F-A6F4-27F4733DC25A	Metastatic	Illumina HiSeq	6126185a-3723-4e2e-8299-9b572802970a	Skin	39	15D812E2-2BB0-47F0-80D2-5F72697BA71B	F487FF4F-86E2-4F0B-A166-39A39670A9F9	TCGA-FS-A1YX-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1YX	TCGA-SKCM	1478	s7365	Harvard Medical School	Essen	Germany	NO	T2	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6ce1e	58cfa832e4b0c9d6adf6ce1e	TCGA-FG-5963-11A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FG-5963-11A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_8_rg.sorted	TCGA-FG-5963-11A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_8_rg.sorted.bam	157.3	1.9	0.13	58cfa832e4b0c9d6adf6ce1e	TCGA-FG-5963-11A-01D-1703_130813_SN1440_0161_BC29ENACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-5963-10A	68F550CA-3A33-45E4-B1C9-14F99E543263	Blood Derived Normal	Illumina HiSeq	58b865f4-5c4e-4736-b667-a649145bb764	Brain	23	41C11D33-7790-4033-99B4-087F0E87474A	6F920119-C9AD-4EBF-BBC8-7724FEAE7B7B	TCGA-FG-5963-10A-01D-1703-02	HG19_Broad_variant	TCGA-FG-5963	TCGA-LGG	NA	s8145	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa832e4b0c9d6adf6ce36	58cfa832e4b0c9d6adf6ce36	TCGA-EM-A1CV-11A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EM-A1CV-11A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_3_rg.sorted	TCGA-EM-A1CV-11A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_3_rg.sorted.bam	28.58	1.95	0.15	58cfa832e4b0c9d6adf6ce36	TCGA-EM-A1CV-11A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CV-11A	762EDDB5-1B47-4B79-B20A-1EDFB07C0705	Solid Tissue Normal	Illumina HiSeq	9f594300-3be6-48b9-8eaa-b71fd52d4222	Thyroid	32	B8989340-7811-4E27-A879-EC0D193715E7	ABDD39C6-E88D-4B87-BE62-CD8A39435EFE	TCGA-EM-A1CV-11A-11D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CV	TCGA-THCA	NA	s12753	Harvard Medical School	University Health Network	Canada	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa832e4b0c9d6adf6ceba	58cfa832e4b0c9d6adf6ceba	TCGA-FD-A3B4-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3B4-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_3_rg.sorted	TCGA-FD-A3B4-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_3_rg.sorted.bam	41.92	NA	0.16	58cfa832e4b0c9d6adf6ceba	TCGA-FD-A3B4-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B4-01A	899F8D52-4C3A-4371-90EB-1F106001EDDC	Primary Tumor	Illumina HiSeq	54b70ff2-6c53-438c-934a-97fe2837620e	Bladder	55	6895A68F-0EFD-4B0E-8CF2-9195833DBBA1	7E975842-6EB5-4D66-A2F1-7EA7E8E989FC	TCGA-FD-A3B4-01A-12D-A204-02	HG19_Broad_variant	TCGA-FD-A3B4	TCGA-BLCA	NA	s3111	Harvard Medical School	BLN - University Of Chicago	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A204-02	TRUE
13722.58cfa832e4b0c9d6adf6ce42	58cfa832e4b0c9d6adf6ce42	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted.bam	57.24	2	0.17	58cfa832e4b0c9d6adf6ce42	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25K-01A	2F9ED09D-2626-4C23-BA47-1850D36F812A	Primary Tumor	Illumina HiSeq	970a6dab-c1e4-4446-968a-4b37d1506eeb	Thyroid	36	343311B1-D586-4F92-9984-32AF1AFB1F62	663173D3-A9EE-4E73-8444-52F01727BE6D	TCGA-ET-A25K-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25K	TCGA-THCA	NA	s12757	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6cf02	58cfa832e4b0c9d6adf6cf02	TCGA-FS-A1YY-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FS-A1YY-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_6_rg.sorted	TCGA-FS-A1YY-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_6_rg.sorted.bam	36.8	NA	0.16	58cfa832e4b0c9d6adf6cf02	TCGA-FS-A1YY-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1YY-10A	C3A8881B-70F8-402C-AC75-1CC49FCA4E87	Blood Derived Normal	Illumina HiSeq	80ab908d-d526-4748-b549-a33d238a0ddd	Skin	55	33C8D0DE-B147-4027-A599-90ED0F46B095	64FBFA57-CFF3-4193-A826-415DE8F91396	TCGA-FS-A1YY-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1YY	TCGA-SKCM	6953	s7364	Harvard Medical School	Essen	Germany	NO	T3a	N0	Not available	Stage IIA	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf30	58cfa832e4b0c9d6adf6cf30	TCGA-HC-7075-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HC-7075-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_5_rg.sorted	TCGA-HC-7075-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_5_rg.sorted.bam	310	NA	0.16	58cfa832e4b0c9d6adf6cf30	TCGA-HC-7075-10A-01D-1957_130412_SN590_0224_BC1YMJACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7075-10A	5DD69C3E-9A3D-450C-9F10-10B4D6DAEEBA	Blood Derived Normal	Illumina HiSeq	a027a038-5142-4ed8-a1ab-1ae31a4dc271	Prostate	63	3EC216B1-4260-45E7-BF41-3F13676F3222	FF9017A8-BB23-47A4-A137-833BD5E6F753	TCGA-HC-7075-10A-01D-1957-02	HG19_Broad_variant	TCGA-HC-7075	TCGA-PRAD	NA	s3623	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cf38	58cfa832e4b0c9d6adf6cf38	TCGA-FS-A1ZS-06A-12D-A18Y_120602_SN1120_0147_BD13TBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FS-A1ZS-06A-12D-A18Y_120602_SN1120_0147_BD13TBACXX_s_5_rg.sorted	TCGA-FS-A1ZS-06A-12D-A18Y_120602_SN1120_0147_BD13TBACXX_s_5_rg.sorted.bam	43.28	NA	0.15	58cfa832e4b0c9d6adf6cf38	TCGA-FS-A1ZS-06A-12D-A18Y_120602_SN1120_0147_BD13TBACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZS-06A	31E94518-F6DD-4458-94D8-DDA3CC7A0831	Metastatic	Illumina HiSeq	38f5da25-1002-4a1a-b654-e111be27a91b	Skin	54	4B61F2EB-276C-4EC8-BCE0-E6E3AC0DD1F6	FA2EE471-5348-4ED3-A421-F188D6FA00C0	TCGA-FS-A1ZS-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZS	TCGA-SKCM	NA	s7872	Harvard Medical School	Essen	Germany	NO	T2	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cf44	58cfa832e4b0c9d6adf6cf44	TCGA-G9-6371-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G9-6371-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_8_rg.sorted	TCGA-G9-6371-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_8_rg.sorted.bam	1.7	1.9	0.15	58cfa832e4b0c9d6adf6cf44	TCGA-G9-6371-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6371-10A	D5C43A14-21AB-4178-AE33-2D8B7BAA256F	Blood Derived Normal	Illumina HiSeq	9e568f08-d30c-467b-a69d-7e89d377c1a7	Prostate	58	48B83AF3-9A1A-4C27-BBB3-DB6FA21F2886	29D36B2A-4434-4F5F-9405-82FF38A8A5D2	TCGA-G9-6371-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6371	TCGA-PRAD	NA	s3978	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf97	58cfa832e4b0c9d6adf6cf97	TCGA-G9-6362-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6362-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_3_rg.sorted	TCGA-G9-6362-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_3_rg.sorted.bam	385.4	1.8	0.13	58cfa832e4b0c9d6adf6cf97	TCGA-G9-6362-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6362-01A	F228EF91-ECFB-4D1E-8E6A-B43D2185270E	Primary Tumor	Illumina HiSeq	04834dec-1ae4-4a26-956a-f51c69d6c324	Prostate	57	1A626C6C-3DD9-4D87-BB93-CB2FEB82FBE8	A9B195C5-0441-4C98-8314-C50ECA082994	TCGA-G9-6362-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6362	TCGA-PRAD	NA	s4149	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf72	58cfa832e4b0c9d6adf6cf72	TCGA-G9-6370-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G9-6370-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_6_rg.sorted	TCGA-G9-6370-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_6_rg.sorted.bam	43.7	1.8	0.15	58cfa832e4b0c9d6adf6cf72	TCGA-G9-6370-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6370-10A	F947B0BC-BDAC-44E8-B5B9-FFAE4147740A	Blood Derived Normal	Illumina HiSeq	843714e6-d7a1-47d1-b3e1-9bc71c2e21ca	Prostate	52	8FF4EEBE-420C-442E-A41D-4C1F050B0EED	1BFB79D5-D5EE-47A3-AD7D-07F41AD4BA47	TCGA-G9-6370-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6370	TCGA-PRAD	NA	s4148	Harvard Medical School	Roswell Park	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cfec	58cfa832e4b0c9d6adf6cfec	TCGA-G9-6361-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6361-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_7_rg.sorted	TCGA-G9-6361-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_7_rg.sorted.bam	39	1.9	0.16	58cfa832e4b0c9d6adf6cfec	TCGA-G9-6361-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6361-10A	71D14304-CCB0-4A4C-B935-8C014CA75FD0	Blood Derived Normal	Illumina HiSeq	ae16cf88-3acd-4765-9960-e47c371159d7	Prostate	61	3AE1F56D-81A7-4201-8935-9A6D465043F5	F29AA876-D30B-4B4A-A279-B7590CE789A9	TCGA-G9-6361-10A-01D-1957-02	HG19_Broad_variant	TCGA-G9-6361	TCGA-PRAD	NA	s3615	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cf50	58cfa832e4b0c9d6adf6cf50	TCGA-FS-A1ZY-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FS-A1ZY-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_8_rg.sorted	TCGA-FS-A1ZY-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_8_rg.sorted.bam	51.2	NA	0.16	58cfa832e4b0c9d6adf6cf50	TCGA-FS-A1ZY-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZY-10A	A3DF4BA6-538E-4B53-A356-EB1EF743B2AB	Blood Derived Normal	Illumina HiSeq	38a9b4ea-ffdd-466d-a579-e92170d3b596	Skin	71	ED3DFADC-B57A-47F8-BC24-A4EDD2F19D2F	4839ACFD-CE38-47AF-AAFB-B423AAC76BF4	TCGA-FS-A1ZY-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZY	TCGA-SKCM	824	s7873	Harvard Medical School	Essen	Germany	NO	T3b	N0	Not available	Stage IIB	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cff5	58cfa832e4b0c9d6adf6cff5	TCGA-G9-6370-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6370-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_5_rg.sorted	TCGA-G9-6370-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_5_rg.sorted.bam	59.4	2	0.14	58cfa832e4b0c9d6adf6cff5	TCGA-G9-6370-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6370-01A	F947B0BC-BDAC-44E8-B5B9-FFAE4147740A	Primary Tumor	Illumina HiSeq	7b80e96d-c20b-4080-9382-26a778397c15	Prostate	52	644E1E7D-DFD1-4F83-82DC-AE0C7E010F6F	D97C0E4A-EB95-49BC-B430-EE0122726442	TCGA-G9-6370-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6370	TCGA-PRAD	NA	s3449	Harvard Medical School	Roswell Park	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cff8	58cfa832e4b0c9d6adf6cff8	TCGA-GD-A2C5-11A-11D-A17R_120927_SN208_0432_AC188LACXX_s_8_rg.sorted.filtered.	WGS	TCGA-GD-A2C5-11A-11D-A17R_120927_SN208_0432_AC188LACXX_s_8_rg.sorted	TCGA-GD-A2C5-11A-11D-A17R_120927_SN208_0432_AC188LACXX_s_8_rg.sorted.bam	18.62	NA	0.15	58cfa832e4b0c9d6adf6cff8	TCGA-GD-A2C5-11A-11D-A17R_120927_SN208_0432_AC188LACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A2C5-11A	5D54C742-5A8E-4C40-8D62-95E75E210AB8	Solid Tissue Normal	Illumina HiSeq	d56808f7-e6d9-4234-b65c-7ff6bad653f8	Bladder	53	892EB338-9C49-4378-A934-623F4EDACF7D	C0270E61-DE9A-4A93-941F-74A9E15BE419	TCGA-GD-A2C5-11A-11D-A17R-02	HG19_Broad_variant	TCGA-GD-A2C5	TCGA-BLCA	NA	s2926	Harvard Medical School	ABS - IUPUI	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17R-02	TRUE
13722.58cfa832e4b0c9d6adf6d009	58cfa832e4b0c9d6adf6d009	TCGA-G9-6338-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G9-6338-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_6_rg.sorted	TCGA-G9-6338-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_6_rg.sorted.bam	44	1.9	0.15	58cfa832e4b0c9d6adf6d009	TCGA-G9-6338-10A-01D-1957_130222_SN1222_0174_BC1RNEACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6338-10A	2C48B1BF-4E49-4869-874B-F08787FA04B5	Blood Derived Normal	Illumina HiSeq	618841c7-8398-44d8-bf70-1275e50d01cd	Prostate	61	4E890A54-84A6-4EFD-9F72-43759925B861	95600DE2-AE98-4D3A-9994-0E2ADB114036	TCGA-G9-6338-10A-01D-1957-02	HG19_Broad_variant	TCGA-G9-6338	TCGA-PRAD	NA	s3967	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6d004	58cfa832e4b0c9d6adf6d004	TCGA-HC-7230-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-HC-7230-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_1_rg.sorted	TCGA-HC-7230-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_1_rg.sorted.bam	208.7	NA	0.15	58cfa832e4b0c9d6adf6d004	TCGA-HC-7230-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7230-10A	03C66CF8-BC68-4EE1-A322-689A29B72262	Blood Derived Normal	Illumina HiSeq	0f575782-1639-413a-a7d0-e25ba87f997f	Prostate	50	E3D2EE1D-EDA1-4D28-AC3F-91F1579ABCF3	2AEFE035-4A89-4CF4-8F3D-5DF94AD636CC	TCGA-HC-7230-10A-01D-2111-02	HG19_Broad_variant	TCGA-HC-7230	TCGA-PRAD	NA	s3980	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d01a	58cfa832e4b0c9d6adf6d01a	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted.filtered.	WGS	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted.bam	144.7	1.9	0.15	58cfa832e4b0c9d6adf6d01a	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6353-01A	BCC94953-CE79-428E-99C1-632E42C1B9BC	Primary Tumor	Illumina HiSeq	86ec03a4-f08e-474e-b887-c5e06822b414	Prostate	58	4CBA0BA5-58C3-455C-9CD5-7D9428D27F8C	758712E3-95F1-4BB5-A83A-D01C4844122D	TCGA-G9-6353-01A-11D-1957-02	HG19_Broad_variant	TCGA-G9-6353	TCGA-PRAD	NA	s3970	Harvard Medical School	Roswell Park	United States	NO	T3a	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6d010	58cfa832e4b0c9d6adf6d010	TCGA-G9-6338-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6338-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_5_rg.sorted	TCGA-G9-6338-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_5_rg.sorted.bam	218.7	NA	0.16	58cfa832e4b0c9d6adf6d010	TCGA-G9-6338-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6338-01A	2C48B1BF-4E49-4869-874B-F08787FA04B5	Primary Tumor	Illumina HiSeq	3c22fc65-7067-4d13-a148-5e953f3a7097	Prostate	61	21FC7F0F-FCB3-422F-AA73-0E09FD06DA35	BF3CC12E-1835-40C8-B29F-C685B828AB18	TCGA-G9-6338-01A-12D-1957-02	HG19_Broad_variant	TCGA-G9-6338	TCGA-PRAD	NA	s3451	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6d031	58cfa832e4b0c9d6adf6d031	TCGA-G9-6364-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G9-6364-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_8_rg.sorted	TCGA-G9-6364-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_8_rg.sorted.bam	29.7	1.8	0.14	58cfa832e4b0c9d6adf6d031	TCGA-G9-6364-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6364-10A	F8D8B417-5945-42A5-850A-FBC04B4F0E61	Blood Derived Normal	Illumina HiSeq	fe1be0ad-62e6-4e97-b330-8f32afa551a0	Prostate	72	6D96E479-CB4A-4837-9580-AF1CE22EF0E5	EEA967FC-CB06-4F96-89EC-AAAA0B2C79A2	TCGA-G9-6364-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6364	TCGA-PRAD	NA	s4151	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6d086	58cfa832e4b0c9d6adf6d086	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted.bam	333.3	NA	0.15	58cfa832e4b0c9d6adf6d086	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7212-01A	907B64D6-A26A-4092-A247-AC9AF444D1C7	Primary Tumor	Illumina HiSeq	4ff229a3-6637-4fdc-a3b6-079e28773187	Prostate	56	92888479-B534-432D-8F70-CAE857E0074B	9BF25BFC-4E07-4979-9169-F6CDADDB3A90	TCGA-HC-7212-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7212	TCGA-PRAD	NA	s4153	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d0ea	58cfa832e4b0c9d6adf6d0ea	TCGA-HW-7489-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HW-7489-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_6_rg.sorted	TCGA-HW-7489-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_6_rg.sorted.bam	434.3	NA	0.14	58cfa832e4b0c9d6adf6d0ea	TCGA-HW-7489-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HW-7489-10A	6957D45E-7CCB-457D-800D-C2A2037F4F01	Blood Derived Normal	Illumina HiSeq	bcccd3c8-2eee-44ca-bb10-16e4dc8672d5	Brain	38	DC41823F-6A90-4D03-B8A2-2DF1DCE72687	706FE100-2E22-4CE8-8730-6515C2DB7ACE	TCGA-HW-7489-10A-01D-2022-02	HG19_Broad_variant	TCGA-HW-7489	TCGA-LGG	NA	s8374	Harvard Medical School	MSKCC	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d0e0	58cfa832e4b0c9d6adf6d0e0	TCGA-FS-A1ZD-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FS-A1ZD-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_2_rg.sorted	TCGA-FS-A1ZD-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_2_rg.sorted.bam	66.27	NA	0.17	58cfa832e4b0c9d6adf6d0e0	TCGA-FS-A1ZD-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZD-06A	C2948FE9-5798-43BC-A743-511E94E417F8	Metastatic	Illumina HiSeq	50f957e6-39df-4b6e-bd03-6b3ba6622543	Skin	63	3B63CB75-EC13-4CAB-B11D-EB6E7FAA8641	F550E879-225E-46BD-9A2C-8AD3ED801DF4	TCGA-FS-A1ZD-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZD	TCGA-SKCM	1628	s7530	Harvard Medical School	Essen	Germany	NO	T2b	N0	Not available	Stage IIA	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d155	58cfa832e4b0c9d6adf6d155	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted.bam	19.7	1.9	0.15	58cfa832e4b0c9d6adf6d155	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6361-01A	71D14304-CCB0-4A4C-B935-8C014CA75FD0	Primary Tumor	Illumina HiSeq	4fc66c05-8bf3-4a56-8bfe-6d20c3195258	Prostate	61	A369C190-964E-471C-878A-D8FADE7CF992	54B8E171-9BCC-469D-9315-114FE2C57DC1	TCGA-G9-6361-01A-21D-1957-02	HG19_Broad_variant	TCGA-G9-6361	TCGA-PRAD	NA	s3795	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6d184	58cfa832e4b0c9d6adf6d184	TCGA-HC-7212-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HC-7212-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_5_rg.sorted	TCGA-HC-7212-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_5_rg.sorted.bam	305.6	NA	0.14	58cfa832e4b0c9d6adf6d184	TCGA-HC-7212-10A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7212-10A	907B64D6-A26A-4092-A247-AC9AF444D1C7	Blood Derived Normal	Illumina HiSeq	e9912ef2-dbc1-4b69-8688-122162432c0a	Prostate	56	76008F3A-E2BF-47EF-A3C9-9C6EF4961CFA	79707D3F-B93A-48B5-9ECE-C70DE74A833F	TCGA-HC-7212-10A-01D-2111-02	HG19_Broad_variant	TCGA-HC-7212	TCGA-PRAD	NA	s3808	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d1cf	58cfa832e4b0c9d6adf6d1cf	TCGA-HR-A2OH-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_3_rg.sorted.filtered.	WGS	TCGA-HR-A2OH-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_3_rg.sorted	TCGA-HR-A2OH-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_3_rg.sorted.bam	81.58	NA	0.17	58cfa832e4b0c9d6adf6d1cf	TCGA-HR-A2OH-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_3_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Skin Cutaneous Melanoma	Aligned reads	TCGA-HR-A2OH-10A	6668ACFE-1594-42C0-B839-8A592702675F	Blood Derived Normal	Illumina HiSeq	2a69954c-008f-4a79-a1eb-0e0307cac08a	Skin	46	6F582EE2-246D-4985-9903-7CAFDDE5273C	1F0B2C4C-7A6E-462E-B67D-A81771F77FE0	TCGA-HR-A2OH-10A-01D-A190-02	HG19_Broad_variant	TCGA-HR-A2OH	TCGA-SKCM	2004	s7543	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T3b	N2a	Not available	Stage IIIB	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d2c1	58cfa832e4b0c9d6adf6d2c1	TCGA-HT-7476-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HT-7476-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_4_rg.sorted	TCGA-HT-7476-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_4_rg.sorted.bam	118	NA	0.13	58cfa832e4b0c9d6adf6d2c1	TCGA-HT-7476-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7476-10A	27D0D3CB-16C0-4BA8-9662-95917F665004	Blood Derived Normal	Illumina HiSeq	79fd9f03-72a7-4dca-8389-9855dd6660ae	Brain	26	0DDB502C-B171-4221-8D42-84C1F81574D8	C177E222-B7E4-464C-878B-31497E2794F6	TCGA-HT-7476-10A-01D-2022-02	HG19_Broad_variant	TCGA-HT-7476	TCGA-LGG	NA	s8761	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d298	58cfa832e4b0c9d6adf6d298	TCGA-HT-7481-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HT-7481-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_5_rg.sorted	TCGA-HT-7481-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_5_rg.sorted.bam	315	NA	0.13	58cfa832e4b0c9d6adf6d298	TCGA-HT-7481-10A-01D-2022_130913_SN1440_0168_BD2B0UACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7481-10A	BFF37DE3-DC68-4E69-BDFC-8B524DD7774F	Blood Derived Normal	Illumina HiSeq	7b00539d-b389-4e45-b200-b742550d68d3	Brain	39	F44899E6-7FA9-439E-8D5E-2AE0E6299CF0	5CA4D8F5-2CA5-44F2-8A2C-C4458B6C2B8D	TCGA-HT-7481-10A-01D-2022-02	HG19_Broad_variant	TCGA-HT-7481	TCGA-LGG	NA	s8373	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6cf25	58cfa832e4b0c9d6adf6cf25	TCGA-FS-A1Z3-10A-01D-A190_120711_SN208_0414_BD13L5ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FS-A1Z3-10A-01D-A190_120711_SN208_0414_BD13L5ACXX_s_8_rg.sorted	TCGA-FS-A1Z3-10A-01D-A190_120711_SN208_0414_BD13L5ACXX_s_8_rg.sorted.bam	53.95	NA	0.17	58cfa832e4b0c9d6adf6cf25	TCGA-FS-A1Z3-10A-01D-A190_120711_SN208_0414_BD13L5ACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1Z3-10A	29BCB876-5A91-4D56-AF47-7B4C856C151F	Blood Derived Normal	Illumina HiSeq	b12e8334-b794-42ce-97be-51daf06e6962	Skin	72	1AFC2065-A13D-4FD5-B9CA-DA874B15AF71	07583C97-A4DA-4856-AE27-44BF71C9A3D3	TCGA-FS-A1Z3-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1Z3	TCGA-SKCM	636	s7698	Harvard Medical School	Essen	Germany	NO	TX	N0	Not available	Stage IV	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ca96	58cfa831e4b0c9d6adf6ca96	TCGA-DI-A1BU-10A-01D-A133_120511_SN1120_0141_BC0VK9ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DI-A1BU-10A-01D-A133_120511_SN1120_0141_BC0VK9ACXX_s_8_rg.sorted	TCGA-DI-A1BU-10A-01D-A133_120511_SN1120_0141_BC0VK9ACXX_s_8_rg.sorted.bam	21.28	2.05	0.15	58cfa831e4b0c9d6adf6ca96	TCGA-DI-A1BU-10A-01D-A133_120511_SN1120_0141_BC0VK9ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-DI-A1BU-10A	53245616-E095-4616-89BB-6062669122DA	Blood Derived Normal	Illumina HiSeq	57bcc650-8415-4b37-b825-c09512d4993b	Uterus	55	565621D6-BB5C-42DE-85BF-3137AE9D22E2	7E5AB7AE-E070-44B2-A15C-63848C8002E9	TCGA-DI-A1BU-10A-01D-A133-02	HG19_Broad_variant	TCGA-DI-A1BU	TCGA-UCEC	NA	s4448	Harvard Medical School	MD Anderson	United States	NO	Not available	Not available	Mixed serous and endometrioid	Not available	A133-02	FALSE
13722.58cfa82ee4b0c9d6adf6b00e	58cfa82ee4b0c9d6adf6b00e	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted.bam	631.63	1.9	0.15	58cfa82ee4b0c9d6adf6b00e	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4422-01A	44DEC838-B653-42A7-A58B-A1FD232CD68C	Primary Tumor	Illumina HiSeq	9fcb53c6-7d0c-4468-8a77-40e6ea3d43d8	Lung	68	DACBC55D-25C6-4E86-BD1B-38345B4DF7A7	09DD9098-5702-44A6-B9EA-F148ECE1E264	TCGA-05-4422-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4422	TCGA-LUAD	NA	s11223	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5cc	58cfa82fe4b0c9d6adf6b5cc	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted.filtered.	WGS	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted.bam	32.52	1.9	0.13	58cfa82fe4b0c9d6adf6b5cc	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4628-01A	CC4BD56A-25C5-4C48-B583-AC3AEB778CA6	Primary Tumor	Illumina HiSeq	f215f323-8551-4bdc-bce7-17bc9bd45bf4	Lung	65	A74F6423-B5D3-4AE2-B61F-3EE04B1073BF	606E6830-C9FB-4107-8BD4-253C193D56B6	TCGA-38-4628-01A-01D-1203-02	HG19_Broad_variant	TCGA-38-4628	TCGA-LUAD	1492	s10652	Harvard Medical School	UNC	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5fa	58cfa82fe4b0c9d6adf6b5fa	TCGA-50-5933-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-50-5933-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_7_rg.sorted	TCGA-50-5933-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_7_rg.sorted.bam	200.4	1.9	0.14	58cfa82fe4b0c9d6adf6b5fa	TCGA-50-5933-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5933-11A	7A0EA814-F0DE-4BC4-A81A-DAA000559369	Solid Tissue Normal	Illumina HiSeq	0cb84810-ecf1-4b3a-99d2-525d6d78e81a	Lung	72	E535FB19-2411-4E71-A3CD-08AEC4F0FD4C	DCD4C5C5-650B-4125-89F5-5C3A123EC954	TCGA-50-5933-11A-01D-1751-02	HG19_Broad_variant	TCGA-50-5933	TCGA-LUAD	2393	s10792	Harvard Medical School	University of Pittsburgh	United States	NO	T4	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b684	58cfa82fe4b0c9d6adf6b684	TCGA-55-6712-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_6_rg.sorted.filtered.	WGS	TCGA-55-6712-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_6_rg.sorted	TCGA-55-6712-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_6_rg.sorted.bam	192	1.9	0.14	58cfa82fe4b0c9d6adf6b684	TCGA-55-6712-10A-01D-1853_120312_SN1120_0121_BD0RHPACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-55-6712-10A	F17D3463-AF6C-42C2-A8E9-FAE45F69286F	Blood Derived Normal	Illumina HiSeq	88cd05e2-cda3-4c5c-b350-f06a08f7be13	Lung	71	EB5FE1FB-E720-4E84-9F21-B2D6261EFA86	04630E6E-9636-47E2-B66D-D65844AFCF58	TCGA-55-6712-10A-01D-1853-02	HG19_Broad_variant	TCGA-55-6712	TCGA-LUAD	NA	s11351	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6d4	58cfa82fe4b0c9d6adf6b6d4	TCGA-75-6206-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_8_rg.sorted.filtered.	WGS	TCGA-75-6206-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_8_rg.sorted	TCGA-75-6206-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_8_rg.sorted.bam	687.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6d4	TCGA-75-6206-10A-01D-1751_120301_SN208_0270_AD0KLRACXX_s_8_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-6206-10A	C4C1469D-752F-42B6-8686-714AD4A8AC97	Blood Derived Normal	Illumina HiSeq	56ce7501-9487-4758-8a1c-0068f71b89b2	Lung	NA	27BF26D9-15F2-4A21-A62A-2C1AE8FA5CE4	E97EC9A4-9230-46B9-A0BC-06C14CE59235	TCGA-75-6206-10A-01D-1751-02	HG19_Broad_variant	TCGA-75-6206	TCGA-LUAD	NA	s10667	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7b4	58cfa82fe4b0c9d6adf6b7b4	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted.bam	181.4	2	0.16	58cfa82fe4b0c9d6adf6b7b4	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5930-01A	368E23F0-E573-4547-BF5A-14080BAF737B	Primary Tumor	Illumina HiSeq	09c8fefe-47f0-44eb-b4f4-160944e2991a	Lung	47	3E30DBD1-10BF-4450-8D19-6F44D3284E02	31047F3B-8F9D-47D9-87D3-BB2F8CF7E1EF	TCGA-50-5930-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5930	TCGA-LUAD	282	s11347	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1751-02	TRUE
13722.58cfa830e4b0c9d6adf6bc0a	58cfa830e4b0c9d6adf6bc0a	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.bam	42.49	2.13	0.16	58cfa830e4b0c9d6adf6bc0a	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GV-01A	5E3B981E-73FE-4CC9-8C89-B420E8E2F426	Primary Tumor	Illumina HiSeq	c99f6cb7-44cc-4045-a0f6-4fec580e964c	Uterus	67	339926E1-61E6-4256-A808-F931AA2C17D2	721D7961-15F0-4A52-8D2C-885278D3B579	TCGA-A5-A0GV-01A-31D-A043-02	HG19_Broad_variant	TCGA-A5-A0GV	TCGA-UCEC	NA	s4987	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bd32	58cfa830e4b0c9d6adf6bd32	TCGA-AA-A01P-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01P-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01P-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	53.07	1.95	0.15	58cfa830e4b0c9d6adf6bd32	TCGA-AA-A01P-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01P-11A	13AE9D83-A22F-451F-88BB-686051725CF3	Solid Tissue Normal	Illumina HiSeq	3608d4d3-d6e8-4b8d-a3bd-b921d4f9ae0e	Colorectal	80	16F6C3FC-3001-4FC4-81A5-9D24DFBCC087	C65B8095-F2F8-42AD-BDA6-6C4F2738BF54	TCGA-AA-A01P-11A-11D-A079-02	HG18	TCGA-AA-A01P	TCGA-COAD	1158	s13531	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae34	58cfa82ee4b0c9d6adf6ae34	TCGA-05-4382-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4382-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_4_rg.sorted	TCGA-05-4382-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_4_rg.sorted.bam	14.23	1.8	0.14	58cfa82ee4b0c9d6adf6ae34	TCGA-05-4382-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4382-10A	3434B91A-C05F-460F-A078-7B1BB6E7085D	Blood Derived Normal	Illumina HiSeq	12d07a36-94e0-4d6d-8625-86f383684a7d	Lung	68	ADF04F24-D50F-473D-AA66-AD4778ABAD3B	40ACF290-13FF-44D8-8CC7-9FE9DB183619	TCGA-05-4382-10A-01D-1203-02	HG19_Broad_variant	TCGA-05-4382	TCGA-LUAD	NA	s11436	Harvard Medical School	Indivumed	None	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b72a	58cfa82fe4b0c9d6adf6b72a	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.bam	291.7	1.9	0.14	58cfa82fe4b0c9d6adf6b72a	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-49-6767-01A	6BFFE800-EC2B-4638-9333-97FE85DCD91C	Primary Tumor	Illumina HiSeq	759c1dd3-0f7d-4ba7-8c8e-c276faf0255b	Lung	46	708A8742-F6D6-411D-9340-2C6C25885D22	FBCE84D6-2880-45F5-BD6F-B079C33C353E	TCGA-49-6767-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6767	TCGA-LUAD	NA	s11233	Harvard Medical School	Johns Hopkins	United States	NO	T3	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b754	58cfa82fe4b0c9d6adf6b754	TCGA-49-4505-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4505-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4505-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	307.53	1.9	0.16	58cfa82fe4b0c9d6adf6b754	TCGA-49-4505-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4505-11A	088EDF89-D2B5-40C7-B066-DF3BD383F7EA	Solid Tissue Normal	Illumina HiSeq	edd13c78-4a11-4932-8158-20f922466310	Lung	61	5812901F-A0CE-4772-862D-FF9AD12B0EE8	2FCDCB12-DC4B-4CCC-8E27-986DB65670A4	TCGA-49-4505-11A-01D-1203-02	GRCh37	TCGA-49-4505	TCGA-LUAD	428	s10779	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7f6	58cfa82fe4b0c9d6adf6b7f6	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	153	1.9	0.15	58cfa82fe4b0c9d6adf6b7f6	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4677-01A	03C3409A-9D16-41D0-9E26-F9FC2547A4C8	Primary Tumor	Illumina HiSeq	5dd207d7-c666-46ae-8154-cb0c0cd6467f	Lung	74	EF88B85A-61EE-44E1-BB63-1B4CE9154BFB	2E41BAD5-941E-4EE8-A1DC-5BBA14E89141	TCGA-73-4677-01A-01D-1203-02	GRCh37	TCGA-73-4677	TCGA-LUAD	38	s10914	Harvard Medical School	Roswell Park	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8bc	58cfa82fe4b0c9d6adf6b8bc	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	311.9	1.9	0.15	58cfa82fe4b0c9d6adf6b8bc	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	AMERICAN INDIAN OR ALASKA NATIVE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4668-01A	B2285924-9813-4F46-BB8F-91A0EFD8A9B6	Primary Tumor	Illumina HiSeq	c3c82aae-4b64-4f65-b4ed-048053aef739	Lung	66	FDBFDF52-C0CD-4FBB-A910-B747516DFEF4	DC227D17-FED3-489A-B5C6-3D4C910310FF	TCGA-73-4668-01A-01D-1203-02	GRCh37	TCGA-73-4668	TCGA-LUAD	NA	s10795	Harvard Medical School	Roswell Park	United States	NO	T2	N1	Lung Micropapillary Adenocarcinoma	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b714	58cfa82fe4b0c9d6adf6b714	TCGA-73-4666-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4666-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4666-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	160	1.9	0.15	58cfa82fe4b0c9d6adf6b714	TCGA-73-4666-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4666-11A	4C31127E-D095-4978-9DAC-35153C27F6ED	Solid Tissue Normal	Illumina HiSeq	eb82e62e-f7d1-4c52-8b12-2d7dba1bd1b8	Lung	52	D07AC871-EAE1-4892-9E0B-CEEA122D3A64	FC424E08-A5D0-4A6D-AC7A-0EF4826BC886	TCGA-73-4666-11A-01D-1203-02	GRCh37	TCGA-73-4666	TCGA-LUAD	NA	s11357	Harvard Medical School	Roswell Park	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6b034	58cfa82ee4b0c9d6adf6b034	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted.bam	666.2	1.9	0.14	58cfa82ee4b0c9d6adf6b034	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4426-01A	36BF02F8-C1C8-49F9-A417-ADF88A205C70	Primary Tumor	Illumina HiSeq	63037227-adb0-4505-bd71-2527743ec736	Lung	71	0C06CF85-61EB-4E6D-AE54-B8F5CBAB9B63	EA6C652F-4896-4D57-978D-7528578BB153	TCGA-05-4426-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4426	TCGA-LUAD	NA	s10645	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b980	58cfa82fe4b0c9d6adf6b980	TCGA-AA-3681-10A-01D-1638-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3681-10A-01D-1638-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3681-10A-01D-1638-02_IlluminaHiSeq-DNASeq_whole.bam	9.96	1.9	0.15	58cfa82fe4b0c9d6adf6b980	TCGA-AA-3681-10A-01D-1638-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3681-10A	ABB0D53F-F74E-45DC-8FBB-40863016F3C6	Blood Derived Normal	Illumina HiSeq	15b89ab0-b489-477c-8f9d-9ab768e31c22	Colorectal	77	330FD816-5184-41E7-9BAD-F271D7D1D295	F650F791-6E5F-46FC-BD54-1621F8A13514	TCGA-AA-3681-10A-01D-1638-02	HG18	TCGA-AA-3681	TCGA-COAD	NA	s13191	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	1638-02	FALSE
13722.58cfa82fe4b0c9d6adf6b964	58cfa82fe4b0c9d6adf6b964	TCGA-AA-3664-10A-01D-1167_101023_SN208_0166_A808PFABXX_s_6_rg.sorted.filtered.	WGS	TCGA-AA-3664-10A-01D-1167_101023_SN208_0166_A808PFABXX_s_6_rg.sorted	TCGA-AA-3664-10A-01D-1167_101023_SN208_0166_A808PFABXX_s_6_rg.sorted.bam	76.96	1.9	0.15	58cfa82fe4b0c9d6adf6b964	TCGA-AA-3664-10A-01D-1167_101023_SN208_0166_A808PFABXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3664-10A	A06C09A8-0951-49F4-A765-5147BBCAE109	Blood Derived Normal	Illumina HiSeq	803e167a-de07-4fb9-b8df-e555c5687f32	Colorectal	74	B4FFAC44-CCEF-458F-80CC-2D230D78012A	44FE059D-488A-4152-ABB9-A305EA066D2D	TCGA-AA-3664-10A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3664	TCGA-COAD	NA	s13360	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba00	58cfa82fe4b0c9d6adf6ba00	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	949.56	1.9	0.13	58cfa82fe4b0c9d6adf6ba00	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3555-01A	36EAF209-C332-4321-B6AA-51A3368ECD79	Primary Tumor	Illumina HiSeq	4abf3b47-09b2-46e1-8bca-eb46790b3930	Colorectal	81	9F9961F0-4EE2-4471-AE4A-A0122D630A28	099EA705-3D94-4746-AF72-E21B31D0425A	TCGA-AA-3555-01A-01D-1637-02	HG18	TCGA-AA-3555	TCGA-COAD	NA	s13513	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1637-02	FALSE
13722.58cfa82fe4b0c9d6adf6b9c8	58cfa82fe4b0c9d6adf6b9c8	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	212.1	1.72	0.15	58cfa82fe4b0c9d6adf6b9c8	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00Q-01A	62D39BE5-F029-4EB8-8B00-46470E06A755	Primary Tumor	Illumina HiSeq	5ccd68f8-a32c-47e2-805b-e3721dbb395d	Colorectal	66	89FC5DB9-EDFF-480F-8FC4-ADDD28C6D615	D458CE34-22B1-41F7-9CE7-659107AD6F77	TCGA-AA-A00Q-01A-01D-A077-02	HG18	TCGA-AA-A00Q	TCGA-COAD	NA	s13523	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Colon Adenocarcinoma	Stage IIIB	A077-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9cc	58cfa82fe4b0c9d6adf6b9cc	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	264.6	1.73	0.15	58cfa82fe4b0c9d6adf6b9cc	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00Z-01A	AF3A0634-4292-45BD-B948-6B6BD2D58090	Primary Tumor	Illumina HiSeq	9701e2c0-3702-4d55-9816-940f128d19e0	Colorectal	70	75A6A64E-11F0-41C8-9CBA-179AE3333621	DF16D4D9-DD5E-4614-AE58-465EC09F2992	TCGA-AA-A00Z-01A-01D-A077-02	HG18	TCGA-AA-A00Z	TCGA-COAD	NA	s13198	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6ba58	58cfa830e4b0c9d6adf6ba58	TCGA-AA-A01Q-10A-01D-A078_110409_SN590_0077_BB04EHABXX_s_3_rg.sorted.filtered.	WGS	TCGA-AA-A01Q-10A-01D-A078_110409_SN590_0077_BB04EHABXX_s_3_rg.sorted	TCGA-AA-A01Q-10A-01D-A078_110409_SN590_0077_BB04EHABXX_s_3_rg.sorted.bam	64.8	1.74	0.15	58cfa830e4b0c9d6adf6ba58	TCGA-AA-A01Q-10A-01D-A078_110409_SN590_0077_BB04EHABXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01Q-10A	4BE66108-E72A-406B-BB4B-F58FF2877336	Blood Derived Normal	Illumina HiSeq	d65a9979-1e3f-4a41-92ec-18be75411835	Colorectal	48	AA17437D-52F5-41D6-A4A8-5635B598242A	C641C01D-375D-4CBE-AF9C-1B861B489BCB	TCGA-AA-A01Q-10A-01D-A078-02	HG18_Broad_variant	TCGA-AA-A01Q	TCGA-COAD	NA	s13197	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	A078-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba16	58cfa82fe4b0c9d6adf6ba16	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	431.56	1.9	0.17	58cfa82fe4b0c9d6adf6ba16	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3549-01A	E6EC5A68-7555-4F26-BD7E-9CDB4C5F7004	Primary Tumor	Illumina HiSeq	cff80dc2-c080-4905-afce-cfd06a84f6c9	Colorectal	69	86158696-60A3-45B7-8351-D800F57EF23B	C5D50597-F0E1-4C34-AB95-3718566AF540	TCGA-AA-3549-01A-02D-1167-02	HG18	TCGA-AA-3549	TCGA-COAD	NA	s13358	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6baf8	58cfa830e4b0c9d6adf6baf8	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted.bam	263.29	1.9	0.15	58cfa830e4b0c9d6adf6baf8	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3514-01A	DDF69ED9-4C53-48B8-9F01-495BD60C3425	Primary Tumor	Illumina HiSeq	3737ce68-bbb0-4ecc-849f-0fd049fe4d85	Colorectal	81	A657AFDB-5322-454F-8DD7-8397291401C5	C0486DD0-5BE4-4B64-8A8F-3CF47BD5A330	TCGA-AA-3514-01A-02D-1547-02	HG18_Broad_variant	TCGA-AA-3514	TCGA-COAD	NA	s13361	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1547-02	FALSE
13722.58cfa830e4b0c9d6adf6baf9	58cfa830e4b0c9d6adf6baf9	TCGA-AA-3514-11A-01D-1547_110525_SN590_0091_AC02W2ABXX_s_2.rg.sorted.filtered.	WGS	TCGA-AA-3514-11A-01D-1547_110525_SN590_0091_AC02W2ABXX_s_2.rg.sorted	TCGA-AA-3514-11A-01D-1547_110525_SN590_0091_AC02W2ABXX_s_2.rg.sorted.bam	276.73	1.9	0.16	58cfa830e4b0c9d6adf6baf9	TCGA-AA-3514-11A-01D-1547_110525_SN590_0091_AC02W2ABXX_s_2.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3514-11A	DDF69ED9-4C53-48B8-9F01-495BD60C3425	Solid Tissue Normal	Illumina HiSeq	ae830bae-2a2d-412f-8150-07ddd6a7aef2	Colorectal	81	9681EB58-DE63-473B-85B8-91BDD07D5F45	E3814098-5BA3-4953-A4E3-B9BBB0BDC37C	TCGA-AA-3514-11A-01D-1547-02	HG18_Broad_variant	TCGA-AA-3514	TCGA-COAD	NA	s12866	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1547-02	FALSE
13722.58cfa830e4b0c9d6adf6ba75	58cfa830e4b0c9d6adf6ba75	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	270.96	1.9	0.15	58cfa830e4b0c9d6adf6ba75	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3812-01A	4563E4E0-A661-46DE-AD25-9C86A621E147	Primary Tumor	Illumina HiSeq	92316171-5ae2-4812-b824-183f14adf90a	Colorectal	82	98AD41D5-FD77-4F30-94B5-03BF7B9C69B9	B4AA0837-42E8-41B7-B44B-F84D48155C3E	TCGA-AA-3812-01A-01D-1167-02	HG18	TCGA-AA-3812	TCGA-COAD	NA	s13188	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bb07	58cfa830e4b0c9d6adf6bb07	TCGA-73-4677-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4677-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4677-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	63.9	1.9	0.15	58cfa830e4b0c9d6adf6bb07	TCGA-73-4677-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4677-11A	03C3409A-9D16-41D0-9E26-F9FC2547A4C8	Solid Tissue Normal	Illumina HiSeq	12b710fb-7df3-4422-baf3-33178cb5a9fc	Lung	74	4282FBEB-27B9-4BF9-BC76-44DF35D48126	E3737810-1E1A-411C-AB1F-79C490181DF1	TCGA-73-4677-11A-01D-1203-02	GRCh37	TCGA-73-4677	TCGA-LUAD	38	s10800	Harvard Medical School	Roswell Park	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	TRUE
13722.58cfa830e4b0c9d6adf6bb90	58cfa830e4b0c9d6adf6bb90	TCGA-AA-A02R-10A-01D-A078_110401_SN177_0152_A819RJABXX.sorted.filtered.	WGS	TCGA-AA-A02R-10A-01D-A078_110401_SN177_0152_A819RJABXX.sorted	TCGA-AA-A02R-10A-01D-A078_110401_SN177_0152_A819RJABXX.sorted.bam	22.97	1.74	0.15	58cfa830e4b0c9d6adf6bb90	TCGA-AA-A02R-10A-01D-A078_110401_SN177_0152_A819RJABXX.sorted.bam	Dead	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02R-10A	764C97C9-01D3-45CB-86BD-F8A52B5468DA	Blood Derived Normal	Illumina HiSeq	504339f4-40ca-46f4-9410-0e1d81df5210	Colorectal	84	B01A9BCF-A155-48B7-A3CC-5A6E3CB2E7AC	AEAF71B1-9EEB-4E7F-B4D8-D138B60D6CF3	TCGA-AA-A02R-10A-01D-A078-02	HG18_Broad_variant	TCGA-AA-A02R	TCGA-COAD	670	s13684	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6ba5a	58cfa830e4b0c9d6adf6ba5a	TCGA-AA-3947-10A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_2.rg.sorted.filtered.	WGS	TCGA-AA-3947-10A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_2.rg.sorted	TCGA-AA-3947-10A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_2.rg.sorted.bam	111.56	1.9	0.15	58cfa830e4b0c9d6adf6ba5a	TCGA-AA-3947-10A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_2.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3947-10A	654C6F5C-3E5C-49F0-B53F-87CD9797D7C9	Blood Derived Normal	Illumina HiSeq	fc7bc9a6-aec3-4170-bcb0-bea7670f93a4	Colorectal	60	9D9915E4-6918-4C69-B5DC-662EF545CA9E	8721FC52-DE61-486D-AFF2-921862F66212	TCGA-AA-3947-10A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3947	TCGA-COAD	NA	s13671	Harvard Medical School	Indivumed	Germany	NO	T4	N0	Colon Mucinous Adenocarcinoma	Stage IIB	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bba0	58cfa830e4b0c9d6adf6bba0	TCGA-AA-A01V-11A-11D-A079_110409_SN590_0077_BB04EHABXX_s_7_rg.sorted.filtered.	WGS	TCGA-AA-A01V-11A-11D-A079_110409_SN590_0077_BB04EHABXX_s_7_rg.sorted	TCGA-AA-A01V-11A-11D-A079_110409_SN590_0077_BB04EHABXX_s_7_rg.sorted.bam	40	1.86	0.13	58cfa830e4b0c9d6adf6bba0	TCGA-AA-A01V-11A-11D-A079_110409_SN590_0077_BB04EHABXX_s_7_rg.sorted.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01V-11A	0CB0DAC8-4CE2-444A-B1AE-1550E065B4D9	Solid Tissue Normal	Illumina HiSeq	a0120ca6-fc3e-4ff4-b926-6c38e3180674	Colorectal	59	398A605C-0A45-4757-BC28-996816990576	725B35D1-7AAA-4471-9539-6CC0EA98A6DE	TCGA-AA-A01V-11A-11D-A079-02	HG18_Broad_variant	TCGA-AA-A01V	TCGA-COAD	NA	s13528	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bbc8	58cfa830e4b0c9d6adf6bbc8	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	610.89	1.9	0.14	58cfa830e4b0c9d6adf6bbc8	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4015-01A	1388BBA1-02BA-40DF-93E5-C3D58B7BBAE0	Primary Tumor	Illumina HiSeq	70efc59a-8909-43e4-961b-76a7a3633927	Colorectal	85	3C910093-DF83-485B-86EF-26A0991D9A0B	2E183A8C-5755-4DC7-AEAB-6F7E9A9A5D1A	TCGA-AG-4015-01A-01D-1115-02	HG18	TCGA-AG-4015	TCGA-READ	NA	s1986	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bbe2	58cfa830e4b0c9d6adf6bbe2	TCGA-AG-A015-10A-01D-A078_110409_SN590_0076_AB04G5ABXX_s_6_rg.sorted.filtered.	WGS	TCGA-AG-A015-10A-01D-A078_110409_SN590_0076_AB04G5ABXX_s_6_rg.sorted	TCGA-AG-A015-10A-01D-A078_110409_SN590_0076_AB04G5ABXX_s_6_rg.sorted.bam	7.76	1.97	0.15	58cfa830e4b0c9d6adf6bbe2	TCGA-AG-A015-10A-01D-A078_110409_SN590_0076_AB04G5ABXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A015-10A	09DAFF79-6493-45C1-8CBA-9381259E2BEA	Blood Derived Normal	Illumina HiSeq	e61bfaa9-8fd2-4a31-8149-9812aa5a5406	Colorectal	64	BCF9BBF4-758D-4290-855E-5D913C3B53D8	B02FA52E-709A-4709-A4FD-629A7D7E4033	TCGA-AG-A015-10A-01D-A078-02	HG18_Broad_variant	TCGA-AG-A015	TCGA-READ	NA	s2173	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Rectal Adenocarcinoma	Stage I	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bc14	58cfa830e4b0c9d6adf6bc14	TCGA-AG-A014-10A-01D-A078_110504_SN590_0081_BB0BM5ABXX_s_7_rg.sorted.filtered.	WGS	TCGA-AG-A014-10A-01D-A078_110504_SN590_0081_BB0BM5ABXX_s_7_rg.sorted	TCGA-AG-A014-10A-01D-A078_110504_SN590_0081_BB0BM5ABXX_s_7_rg.sorted.bam	27.2	1.76	0.15	58cfa830e4b0c9d6adf6bc14	TCGA-AG-A014-10A-01D-A078_110504_SN590_0081_BB0BM5ABXX_s_7_rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A014-10A	51C37449-6A2E-4C3D-A7CC-06F901E1224F	Blood Derived Normal	Illumina HiSeq	a425b9fe-c528-4966-aee2-96c0be7b7839	Colorectal	86	0FA514AA-C0EB-4177-BA65-1B8616232054	36D22107-9741-44B7-9673-D26682C4280A	TCGA-AG-A014-10A-01D-A078-02	HG18_Broad_variant	TCGA-AG-A014	TCGA-READ	NA	s2174	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bbcc	58cfa830e4b0c9d6adf6bbcc	TCGA-AG-4007-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4007-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4007-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	3.59	1.9	0.16	58cfa830e4b0c9d6adf6bbcc	TCGA-AG-4007-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4007-10A	8E00E7E7-FFAF-44F0-91A7-172671F18E08	Blood Derived Normal	Illumina HiSeq	0497e43f-7588-413d-a72a-cf9badca95be	Colorectal	87	EB3A1A59-B2C5-4436-A971-FCFE5C643820	A7A0117E-4BA7-4AB2-B390-F77472D2F2B5	TCGA-AG-4007-10A-01D-1115-02	HG18	TCGA-AG-4007	TCGA-READ	NA	s1982	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Rectal Adenocarcinoma	Stage IV	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bbd2	58cfa830e4b0c9d6adf6bbd2	TCGA-AG-4015-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4015-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4015-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	44.59	1.9	0.15	58cfa830e4b0c9d6adf6bbd2	TCGA-AG-4015-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4015-10A	1388BBA1-02BA-40DF-93E5-C3D58B7BBAE0	Blood Derived Normal	Illumina HiSeq	0fb81d5a-c5b6-4a11-8255-4cd067ce53ea	Colorectal	85	3C5E0211-94A1-4760-AAF4-DE2B80A92DC3	F7C39024-56CA-4778-9225-6E2423426413	TCGA-AG-4015-10A-01D-1115-02	HG18	TCGA-AG-4015	TCGA-READ	NA	s1978	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bc18	58cfa830e4b0c9d6adf6bc18	TCGA-AG-4008-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4008-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4008-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	44.59	1.9	0.17	58cfa830e4b0c9d6adf6bc18	TCGA-AG-4008-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4008-10A	72802851-9340-4C5F-A90B-23B7AFD7577A	Blood Derived Normal	Illumina HiSeq	fc33b07e-7ad9-4cf9-be0a-b7abc28b8160	Colorectal	63	BA57F55A-1ADE-4C91-9B44-ED9DE039CF29	04D642B5-E53C-43E1-9B48-5A3C55F61950	TCGA-AG-4008-10A-01D-1115-02	HG18	TCGA-AG-4008	TCGA-READ	NA	s1993	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bc1c	58cfa830e4b0c9d6adf6bc1c	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted.bam	125.63	1.96	0.17	58cfa830e4b0c9d6adf6bc1c	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A020-01A	19E46A3D-18C5-4927-8501-2265E2D617B8	Primary Tumor	Illumina HiSeq	1aa43549-776a-4daf-b60e-f0b8c3287077	Colorectal	57	EEC9C9E3-6CB3-4589-B3A8-EA2337878599	140B186D-B7EC-4A31-8FE0-A490BBDAE19B	TCGA-AG-A020-01A-21D-A079-02	HG18_Broad_variant	TCGA-AG-A020	TCGA-READ	NA	s2003	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Mucinous Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bc44	58cfa830e4b0c9d6adf6bc44	TCGA-AO-A0JF-10A-01D-A060_130719_SN1120_0270_AC2CVRACXX_s_2_rg.sorted.filtered.	WGS	TCGA-AO-A0JF-10A-01D-A060_130719_SN1120_0270_AC2CVRACXX_s_2_rg.sorted	TCGA-AO-A0JF-10A-01D-A060_130719_SN1120_0270_AC2CVRACXX_s_2_rg.sorted.bam	33.53	1.83	0.13	58cfa830e4b0c9d6adf6bc44	TCGA-AO-A0JF-10A-01D-A060_130719_SN1120_0270_AC2CVRACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JF-10A	F357FE19-5359-4662-8CE9-AA996132283B	Blood Derived Normal	Illumina HiSeq	ecbc57df-ef58-47a5-9ae5-83e394d14191	Breast	68	DA127378-BDD7-4D9E-AD83-D2C223B4A40E	85F3A9D5-E0B8-47B2-B525-5C8177F22C46	TCGA-AO-A0JF-10A-01D-A060-02	HG19_Broad_variant	TCGA-AO-A0JF	TCGA-BRCA	NA	s6629	Harvard Medical School	MSKCC	None	NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bc46	58cfa830e4b0c9d6adf6bc46	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.bam	16.97	1.91	0.13	58cfa830e4b0c9d6adf6bc46	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JF-01A	F357FE19-5359-4662-8CE9-AA996132283B	Primary Tumor	Illumina HiSeq	031ab51d-07d0-4afe-a9dd-222889f5c32b	Breast	68	DDEE0B07-2771-40C7-BDDA-C1100958F0D8	BDAA1600-1B4F-4BBA-B4D6-A4D169B029D6	TCGA-AO-A0JF-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JF	TCGA-BRCA	NA	s5491	Harvard Medical School	MSKCC	None	NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bc6c	58cfa830e4b0c9d6adf6bc6c	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	915.89	1.9	0.16	58cfa830e4b0c9d6adf6bc6c	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4007-01A	8E00E7E7-FFAF-44F0-91A7-172671F18E08	Primary Tumor	Illumina HiSeq	5f015b15-7286-4700-88d4-e7c460f68336	Colorectal	87	E6FC3F28-1DE1-4587-9E0E-0861323E6772	E9D7A5C4-3E98-4C98-A953-B75EA555DD7D	TCGA-AG-4007-01A-01D-1115-02	HG18	TCGA-AG-4007	TCGA-READ	NA	s1985	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Rectal Adenocarcinoma	Stage IV	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bcb2	58cfa830e4b0c9d6adf6bcb2	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	275.02	1.9	0.15	58cfa830e4b0c9d6adf6bcb2	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4684-01A	CAC80259-3A26-4A99-B0D3-13454068E6ED	Primary Tumor	Illumina HiSeq	bab439b0-f1d3-41c2-98dd-a660818851fe	Colorectal	49	37AD61EA-96D1-40F1-B77A-56408E4243EA	6731F782-4435-497F-9626-C0199DAE8A8A	TCGA-AZ-4684-01A-01D-1405-02	HG18	TCGA-AZ-4684	TCGA-COAD	NA	s13391	Harvard Medical School	University of Pittsburgh	None	NO	T3	N2	Colon Adenocarcinoma	Stage IVA	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bd8e	58cfa830e4b0c9d6adf6bd8e	TCGA-BG-A0M3-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BG-A0M3-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_3_rg.sorted	TCGA-BG-A0M3-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_3_rg.sorted.bam	19.16	1.97	0.13	58cfa830e4b0c9d6adf6bd8e	TCGA-BG-A0M3-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M3-10A	8BDD4E0E-5BEC-43F2-B9FA-D6E94A72FE05	Blood Derived Normal	Illumina HiSeq	20d6cb0d-6d0f-4683-8837-180c95258795	Uterus	74	0EB45A88-73EA-4282-B0E1-2E2EA1E2D8F1	6A871B0F-421A-47E1-9B5D-150E4C3E0B99	TCGA-BG-A0M3-10A-01D-A101-02	HG19_Broad_variant	TCGA-BG-A0M3	TCGA-UCEC	NA	s4255	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bd98	58cfa830e4b0c9d6adf6bd98	TCGA-BF-A1PV-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BF-A1PV-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_2_rg.sorted	TCGA-BF-A1PV-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_2_rg.sorted.bam	39.59	NA	0.16	58cfa830e4b0c9d6adf6bd98	TCGA-BF-A1PV-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PV-10A	EFF78AF6-0F68-49B9-866B-0D511606F2B1	Blood Derived Normal	Illumina HiSeq	be8992e2-ef31-477b-a01b-e8a37a6e135b	Skin	74	0CC75509-DCDA-41FA-A4BB-2BFA77E7E9D4	298F1BB0-CC50-4805-9BDC-2635F16BC5D5	TCGA-BF-A1PV-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PV	TCGA-SKCM	NA	s7826	Harvard Medical School	Cureline	Russia	NO	T4b	N0	Not available	Stage IIC	A18Z-02	TRUE
13722.58cfa830e4b0c9d6adf6be13	58cfa830e4b0c9d6adf6be13	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.bam	55.92	1.91	0.16	58cfa830e4b0c9d6adf6be13	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0W5-01A	DA9C10EA-C13F-4D88-8B94-A0CBC106D036	Primary Tumor	Illumina HiSeq	eeccc516-2d3d-4f41-a324-c90f92a6f944	Breast	77	050E66BB-438A-49D5-A005-7967A006B3F0	6C8B3A70-CD58-4BFC-9418-54182588CFCB	TCGA-BH-A0W5-01A-11D-A106-02	HG19_Broad_variant	TCGA-BH-A0W5	TCGA-BRCA	NA	s5803	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A106-02	FALSE
13722.58cfa830e4b0c9d6adf6be28	58cfa830e4b0c9d6adf6be28	TCGA-BH-A0W5-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BH-A0W5-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_4_rg.sorted	TCGA-BH-A0W5-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_4_rg.sorted.bam	17.76	2.22	0.16	58cfa830e4b0c9d6adf6be28	TCGA-BH-A0W5-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0W5-10A	DA9C10EA-C13F-4D88-8B94-A0CBC106D036	Blood Derived Normal	Illumina HiSeq	b768a52b-e629-46df-b042-fa815cb7ce57	Breast	77	B49CDE05-00A3-4B24-A1B9-64E300CF63E0	154C09B7-C645-497A-9B14-655DB46CD990	TCGA-BH-A0W5-10A-01D-A106-02	HG19_Broad_variant	TCGA-BH-A0W5	TCGA-BRCA	NA	s5641	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A106-02	FALSE
13722.58cfa830e4b0c9d6adf6be2a	58cfa830e4b0c9d6adf6be2a	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted.bam	65.55	2.08	0.15	58cfa830e4b0c9d6adf6be2a	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0X4-01A	4E42FDC5-2A8B-49E9-87EF-6DB7A6692D08	Primary Tumor	Illumina HiSeq	1973be6c-c5a9-40d1-bdd2-a752dd33d6d1	Breast	62	45C3BD72-D260-4663-9091-5058E58F352D	062A41CC-4B23-49E2-AFF8-3CFE34DE9A36	TCGA-B6-A0X4-01A-11D-A106-02	HG19_Broad_variant	TCGA-B6-A0X4	TCGA-BRCA	860	s6462	Harvard Medical School	Duke	United States	NO	T2	N1b	Infiltrating Ductal Carcinoma	Stage IIB	A106-02	FALSE
13722.58cfa830e4b0c9d6adf6bd02	58cfa830e4b0c9d6adf6bd02	TCGA-AF-2691-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AF-2691-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AF-2691-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	372.21	1.9	0.14	58cfa830e4b0c9d6adf6bd02	TCGA-AF-2691-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2691-10A	830FD359-ABD4-4C99-89E4-2D6BB9CE5637	Blood Derived Normal	Illumina HiSeq	9b916a25-d6ee-4633-9d63-964fb2d45c38	Colorectal	48	2902CDFC-CF54-4459-B018-FE50678C284E	6E66F7DA-5AB7-4769-B367-1CFDFE3D058A	TCGA-AF-2691-10A-01D-1167-02	HG18	TCGA-AF-2691	TCGA-READ	NA	s1974	Harvard Medical School	Christiana Healthcare	None	NO	T1	N0	Rectal Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b96f	58cfa82fe4b0c9d6adf6b96f	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	554.96	1.9	0.17	58cfa82fe4b0c9d6adf6b96f	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3666-01A	A512701F-88BB-4B05-8C94-FD285B9DD13E	Primary Tumor	Illumina HiSeq	0bc29a5e-10c6-4c45-8cb6-2284ab7be445	Colorectal	68	F1064663-1462-4901-8BF7-9F50DA5EE7B1	CAD86B88-04E5-400F-B3EB-43D31A2D8358	TCGA-AA-3666-01A-02D-1167-02	HG18	TCGA-AA-3666	TCGA-COAD	61	s13363	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6be36	58cfa830e4b0c9d6adf6be36	TCGA-BJ-A18Z-10A-01D-A13U_120712_SN1222_0125_BD13TPACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A18Z-10A-01D-A13U_120712_SN1222_0125_BD13TPACXX_s_2_rg.sorted	TCGA-BJ-A18Z-10A-01D-A13U_120712_SN1222_0125_BD13TPACXX_s_2_rg.sorted.bam	32.23	1.72	0.17	58cfa830e4b0c9d6adf6be36	TCGA-BJ-A18Z-10A-01D-A13U_120712_SN1222_0125_BD13TPACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A18Z-10A	0D497FAF-2C1C-4173-A5FE-770CCA73323C	Blood Derived Normal	Illumina HiSeq	e2be58e6-cbfb-4ba0-acae-d10c09b96f62	Thyroid	58	FDF1E501-F34F-450C-9A5C-611157079A86	85A7922F-0327-437C-BDF5-1BB67A1E932F	TCGA-BJ-A18Z-10A-01D-A13U-02	HG19_Broad_variant	TCGA-BJ-A18Z	TCGA-THCA	NA	s12356	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6be52	58cfa830e4b0c9d6adf6be52	TCGA-BJ-A0ZJ-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZJ-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_5_rg.sorted	TCGA-BJ-A0ZJ-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_5_rg.sorted.bam	6.77	1.42	0.16	58cfa830e4b0c9d6adf6be52	TCGA-BJ-A0ZJ-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZJ-10A	8877B479-B62A-4794-B71E-418DE96DFF23	Blood Derived Normal	Illumina HiSeq	110bdb40-c410-4bef-a3c5-b142645edcd4	Thyroid	36	82C99A8E-9640-4F09-94C0-07FB8A7588B7	80EB5F2E-D4BA-41DE-B319-1723C12672F7	TCGA-BJ-A0ZJ-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZJ	TCGA-THCA	NA	s12102	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6bd44	58cfa830e4b0c9d6adf6bd44	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted.bam	117.13	2.03	0.16	58cfa830e4b0c9d6adf6bd44	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A054-01A	D77E4DBC-B239-4742-8CB7-EFD427010D13	Primary Tumor	Illumina HiSeq	a8fe0928-3d0c-4d16-be11-a5dd077bdb2c	Uterus	64	DDFFB9C7-185F-402F-99B8-8058B40086D9	F5A9F85D-4E8E-4400-A109-C227D6B4C0A4	TCGA-AP-A054-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A054	TCGA-UCEC	709	s4590	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bea9	58cfa830e4b0c9d6adf6bea9	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	208.89	1.9	0.14	58cfa830e4b0c9d6adf6bea9	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3909-01A	769880AE-34D9-405E-8EA7-33BA47CF2DD2	Primary Tumor	Illumina HiSeq	f11e5abe-82c7-4b53-bc65-7bde2dbc2bb1	Colorectal	69	12A43BEB-EDB6-4ABC-8322-CA8246D64B3F	F168205F-B2ED-4563-A211-DA59223830AB	TCGA-AG-3909-01A-01D-1115-02	HG18	TCGA-AG-3909	TCGA-READ	NA	s1987	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bebe	58cfa830e4b0c9d6adf6bebe	TCGA-AX-A0IU-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AX-A0IU-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_1_rg.sorted	TCGA-AX-A0IU-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_1_rg.sorted.bam	10.58	2.1	0.17	58cfa830e4b0c9d6adf6bebe	TCGA-AX-A0IU-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_1_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0IU-10A	7E64EA6C-A3DB-48EB-91BE-131361510A92	Blood Derived Normal	Illumina HiSeq	c794d801-58df-429e-af9f-4c21e2b0add2	Uterus	79	38271B9F-B5F8-4A0D-AE45-2E9E927F9FF7	23D83EA6-61EF-4BA3-AEB7-B12A5C58555B	TCGA-AX-A0IU-10A-01D-A101-02	HG19_Broad_variant	TCGA-AX-A0IU	TCGA-UCEC	NA	s4781	Harvard Medical School	Gynecologic Oncology Group	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bf16	58cfa830e4b0c9d6adf6bf16	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.bam	106.9	1.9	0.16	58cfa830e4b0c9d6adf6bf16	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4257-01A	DA112431-5579-4FD1-A230-9144B359B0E9	Primary Tumor	Illumina HiSeq	5e38d8b4-97fb-407a-ab06-2f002456472d	Stomach	79	97B44B05-97EB-486C-94DB-42838831DE0B	465E5E4D-A801-4BBC-9E1C-004C7718571F	TCGA-BR-4257-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4257	TCGA-STAD	NA	s15048	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf18	58cfa830e4b0c9d6adf6bf18	TCGA-BR-4257-11A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BR-4257-11A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_4_rg.sorted	TCGA-BR-4257-11A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_4_rg.sorted.bam	173.9	1.9	0.14	58cfa830e4b0c9d6adf6bf18	TCGA-BR-4257-11A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4257-11A	DA112431-5579-4FD1-A230-9144B359B0E9	Solid Tissue Normal	Illumina HiSeq	40fc7a6d-ebf3-490f-ab9d-19e641ea0dbb	Stomach	79	52D44B33-2D4C-4DE0-9777-5778536688EE	4822B1AA-E623-4C70-9958-A598E90D3467	TCGA-BR-4257-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4257	TCGA-STAD	NA	s15375	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bec2	58cfa830e4b0c9d6adf6bec2	TCGA-AR-A0TU-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_6_rg.sorted.filtered.	WGS	TCGA-AR-A0TU-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_6_rg.sorted	TCGA-AR-A0TU-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_6_rg.sorted.bam	28.88	1.95	0.15	58cfa830e4b0c9d6adf6bec2	TCGA-AR-A0TU-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-AR-A0TU-10A	DFE6DB17-CF45-488E-BD3C-B8433D7343CA	Blood Derived Normal	Illumina HiSeq	79a26532-d93b-48b3-8756-9508d69f56ad	Breast	35	D6BE9B14-E2D3-4CE1-BC6F-3BC967EC4D4C	C5244957-8900-4EAC-B127-01E2EA5663C5	TCGA-AR-A0TU-10A-01D-A106-02	HG19_Broad_variant	TCGA-AR-A0TU	TCGA-BRCA	NA	s6461	Harvard Medical School	Mayo	None	NO	T2	N0	Infiltrating Ductal Carcinoma	Stage IIA	A106-02	FALSE
13722.58cfa830e4b0c9d6adf6be86	58cfa830e4b0c9d6adf6be86	TCGA-AG-3892-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3892-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3892-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	8.59	1.9	0.16	58cfa830e4b0c9d6adf6be86	TCGA-AG-3892-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3892-10A	DED3FEB2-1079-4520-A7CA-F5B5FC73D7C5	Blood Derived Normal	Illumina HiSeq	359d1105-6b0b-4505-9c85-3e8b04d67dbb	Colorectal	57	00A6EA95-E9E2-41C5-9B0C-83F51B972B88	13881E1C-77C0-4063-A39D-98036ABA6FE8	TCGA-AG-3892-10A-01D-1115-02	HG18	TCGA-AG-3892	TCGA-READ	NA	s2155	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Rectal Adenocarcinoma	Stage I	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6be44	58cfa830e4b0c9d6adf6be44	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	406.94	1.9	0.15	58cfa830e4b0c9d6adf6be44	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2691-01A	830FD359-ABD4-4C99-89E4-2D6BB9CE5637	Primary Tumor	Illumina HiSeq	92f1a7a8-08ff-487e-bd7d-8146bc0109c6	Colorectal	48	CE252C3D-5CF3-46BC-A181-3714D1C65E4E	64EDFE90-619C-42A0-BBE1-EB78B4D5C26D	TCGA-AF-2691-01A-01D-1167-02	HG18	TCGA-AF-2691	TCGA-READ	NA	s2131	Harvard Medical School	Christiana Healthcare	None	NO	T1	N0	Rectal Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bf3c	58cfa830e4b0c9d6adf6bf3c	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.bam	67.9	1.9	0.15	58cfa830e4b0c9d6adf6bf3c	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4256-01A	7B0D69CA-13A6-46E0-839C-E433BBEDE3AD	Primary Tumor	Illumina HiSeq	6e990147-2463-4d38-a785-6c76ae1dbc25	Stomach	80	61C7AAB0-51D9-4706-A37C-D5058007DAF1	30AF7950-11F7-43BF-9A1D-98A57F416397	TCGA-BR-4256-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4256	TCGA-STAD	NA	s14396	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf6c	58cfa830e4b0c9d6adf6bf6c	TCGA-BR-6452-10A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6452-10A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_3_rg.sorted	TCGA-BR-6452-10A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_3_rg.sorted.bam	34.7	1.9	0.15	58cfa830e4b0c9d6adf6bf6c	TCGA-BR-6452-10A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6452-10A	27988B3E-CDE1-4F4B-82A1-6D8AD08DB8E9	Blood Derived Normal	Illumina HiSeq	b5d222fd-498a-40a1-880d-322d0a7a1323	Stomach	78	14F163DB-E740-48B9-8126-AC2A5A691288	617B4921-0897-4062-A233-BDA2F15A1E47	TCGA-BR-6452-10A-01D-1798-02	HG19_Broad_variant	TCGA-BR-6452	TCGA-STAD	NA	s14400	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bf72	58cfa830e4b0c9d6adf6bf72	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.bam	264.2	1.9	0.15	58cfa830e4b0c9d6adf6bf72	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4363-01A	66BCA2F8-F269-454D-ABE2-CE51A0704645	Primary Tumor	Illumina HiSeq	ab5af808-6239-48fa-ba17-b80aa3fc5e14	Stomach	60	06EC6231-EE0E-4C15-AF9F-5B9E5BF557B8	D62228AE-B0AB-4C31-9FD7-F9D48B140CDC	TCGA-BR-4363-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4363	TCGA-STAD	NA	s14528	Harvard Medical School	Asterand	Russia	NO	T3	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6bf6a	58cfa830e4b0c9d6adf6bf6a	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted.bam	409.4	1.9	0.16	58cfa830e4b0c9d6adf6bf6a	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6452-01A	27988B3E-CDE1-4F4B-82A1-6D8AD08DB8E9	Primary Tumor	Illumina HiSeq	cfd9aa7a-7f3d-4b70-9359-2c93f0238361	Stomach	78	76144F2F-2498-430D-B33C-F000394C427E	460DE564-5AAB-46B0-8174-36AF18D2DF4C	TCGA-BR-6452-01A-12D-1798-02	HG19_Broad_variant	TCGA-BR-6452	TCGA-STAD	NA	s14744	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bf80	58cfa830e4b0c9d6adf6bf80	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.bam	324.7	1.9	0.15	58cfa830e4b0c9d6adf6bf80	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6455-01A	75A29059-4705-4A55-BC3D-F5923B24B358	Primary Tumor	Illumina HiSeq	719ee3a5-cfe9-48cb-9e48-e11e49bd217c	Stomach	59	59BD0192-A50B-4672-A17F-4DF138F58988	6C038E7C-8B03-4AB6-A31A-00C3C6CE6204	TCGA-BR-6455-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6455	TCGA-STAD	NA	s14470	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bf7a	58cfa830e4b0c9d6adf6bf7a	TCGA-BR-6454-11A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6454-11A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_7_rg.sorted	TCGA-BR-6454-11A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_7_rg.sorted.bam	186.4	1.9	0.15	58cfa830e4b0c9d6adf6bf7a	TCGA-BR-6454-11A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6454-11A	AC2CBCE4-4BA8-42C9-AC61-70F42995588E	Solid Tissue Normal	Illumina HiSeq	e6845469-d068-4e77-bc48-b17e5ad0c4de	Stomach	58	71DFB0A1-8475-4990-82F3-51CD5CE7D230	5AEB6210-8FC6-45B4-8594-777F0A5D7CA7	TCGA-BR-6454-11A-01D-1798-02	HG19_Broad_variant	TCGA-BR-6454	TCGA-STAD	NA	s15180	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bec5	58cfa830e4b0c9d6adf6bec5	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	237.12	1.85	0.15	58cfa830e4b0c9d6adf6bec5	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A032-01A	0BB786EE-07CF-4853-9B49-EC95CD14E282	Primary Tumor	Illumina HiSeq	16a2716c-9563-4403-9a4b-8d4856022741	Colorectal	68	AE3C8931-C06F-466A-B6BF-440007E13387	AF7D94D6-C414-4812-A329-8856C086087E	TCGA-AG-A032-01A-01D-A077-02	HG18	TCGA-AG-A032	TCGA-READ	NA	s2175	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6bfa8	58cfa830e4b0c9d6adf6bfa8	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.bam	478.4	1.9	0.14	58cfa830e4b0c9d6adf6bfa8	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6454-01A	AC2CBCE4-4BA8-42C9-AC61-70F42995588E	Primary Tumor	Illumina HiSeq	e344c34d-da8c-4145-8a02-b9ae248ca3a3	Stomach	58	E7D94421-7A3B-4100-9CBF-1B1F2EC07737	6F5506E4-8375-4F62-8B85-64FD729C6136	TCGA-BR-6454-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6454	TCGA-STAD	NA	s14619	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bf9c	58cfa830e4b0c9d6adf6bf9c	TCGA-BR-6453-11A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-6453-11A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_5_rg.sorted	TCGA-BR-6453-11A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_5_rg.sorted.bam	263.4	1.9	0.14	58cfa830e4b0c9d6adf6bf9c	TCGA-BR-6453-11A-01D-1798_130115_SN1222_0169_BD1K2PACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6453-11A	AE633E83-303F-4A90-AC3B-34458FD9BEEF	Solid Tissue Normal	Illumina HiSeq	717f3dd6-5471-4f58-b218-01a2ca71eced	Stomach	54	B6DFCC18-F388-4486-8D3D-611C5E15FB29	C1402501-D8BA-4AF4-A88E-ABB79009DB18	TCGA-BR-6453-11A-01D-1798-02	HG19_Broad_variant	TCGA-BR-6453	TCGA-STAD	NA	s15306	Harvard Medical School	Asterand	Russia	NO	T2	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bf48	58cfa830e4b0c9d6adf6bf48	TCGA-BR-4184-11A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-4184-11A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_6_rg.sorted	TCGA-BR-4184-11A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_6_rg.sorted.bam	170.9	1.9	0.16	58cfa830e4b0c9d6adf6bf48	TCGA-BR-4184-11A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4184-11A	0D4D23BA-066B-4244-A3A5-922CDCAAA28F	Solid Tissue Normal	Illumina HiSeq	c3487483-8be4-437d-9ff4-0105653e0870	Stomach	70	67DCA15E-B2EC-4283-8602-3B39ADA18B3E	0B4713D1-6EAE-4D1C-8895-756154563BB3	TCGA-BR-4184-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4184	TCGA-STAD	NA	s14530	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf8d	58cfa830e4b0c9d6adf6bf8d	TCGA-B5-A0JV-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-B5-A0JV-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_4_rg.sorted	TCGA-B5-A0JV-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_4_rg.sorted.bam	4.9	2.08	0.16	58cfa830e4b0c9d6adf6bf8d	TCGA-B5-A0JV-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_4_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JV-10A	233E947A-D5E2-48E5-A8CE-5DA1ABB20681	Blood Derived Normal	Illumina HiSeq	2c067c19-fda2-4331-8fc7-1e59ff81b137	Uterus	63	9F2AD0C0-34CC-4100-9788-492988A0283B	1B4100CB-6FD4-4CF8-A6BB-773963BDA7C4	TCGA-B5-A0JV-10A-01D-A101-02	HG19_Broad_variant	TCGA-B5-A0JV	TCGA-UCEC	NA	s5206	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bfd6	58cfa830e4b0c9d6adf6bfd6	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	650.31	1.9	0.14	58cfa830e4b0c9d6adf6bfd6	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3728-01A	856A490C-C6DA-48FE-88B5-9FDE0F481365	Primary Tumor	Illumina HiSeq	d36f782a-483a-478d-a9a6-22f626b032bb	Colorectal	73	019EB82B-4A2D-4E67-99A6-FE10B0ABCB70	DF699DEA-C800-47D0-A526-A6C7A610041A	TCGA-AG-3728-01A-01D-1115-02	HG18	TCGA-AG-3728	TCGA-READ	NA	s2137	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6c010	58cfa830e4b0c9d6adf6c010	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.bam	106.93	1.95	0.16	58cfa830e4b0c9d6adf6c010	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K0-01A	29C8F468-5AC1-4D6C-8376-E36E6D246926	Primary Tumor	Illumina HiSeq	e5550bf6-3edf-480e-9dc5-6d590e837e5e	Uterus	48	11C43948-E7C9-4436-A654-82FA8033B625	3296C785-7C20-487D-BAEC-C66022E77E53	TCGA-B5-A0K0-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K0	TCGA-UCEC	NA	s4598	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c015	58cfa830e4b0c9d6adf6c015	TCGA-AG-3728-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3728-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3728-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	6.01	1.9	0.17	58cfa830e4b0c9d6adf6c015	TCGA-AG-3728-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3728-10A	856A490C-C6DA-48FE-88B5-9FDE0F481365	Blood Derived Normal	Illumina HiSeq	16067ed2-6dd1-4888-9db0-bcc0f3becf40	Colorectal	73	0BCFA029-86E5-47DE-A315-D9991F67E5CD	6A2A30EF-2FCF-485B-9FE3-D32C89393F50	TCGA-AG-3728-10A-01D-1115-02	HG18	TCGA-AG-3728	TCGA-READ	NA	s1962	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6c04c	58cfa830e4b0c9d6adf6c04c	TCGA-B5-A0K6-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-B5-A0K6-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_6_rg.sorted	TCGA-B5-A0K6-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_6_rg.sorted.bam	11.2	2	0.16	58cfa830e4b0c9d6adf6c04c	TCGA-B5-A0K6-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K6-10A	5CBA9441-6812-49C0-A0F6-7928ED4E5B81	Blood Derived Normal	Illumina HiSeq	d89fc39f-4622-4fd1-a54c-7ceeb21064d3	Uterus	58	8DCB31CF-3146-4698-A71B-BFEF58BE9FDC	EB3CFF8E-79EF-4922-85F9-354E49963B7C	TCGA-B5-A0K6-10A-01D-A043-02	HG19_Broad_variant	TCGA-B5-A0K6	TCGA-UCEC	NA	s4788	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c058	58cfa830e4b0c9d6adf6c058	TCGA-AZ-4308-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4308-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4308-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	123.72	1.9	0.16	58cfa830e4b0c9d6adf6c058	TCGA-AZ-4308-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4308-10A	3D8FD9B2-9AA2-4C81-8843-535AE66D6140	Blood Derived Normal	Illumina HiSeq	fc1a3245-0316-493f-b46a-f179c1f6a452	Colorectal	47	54F3DCE1-F69B-44BD-BAFB-17A6C937452E	4230CC2F-6B46-4130-A9E8-D7E834E13C4C	TCGA-AZ-4308-10A-01D-1405-02	HG18	TCGA-AZ-4308	TCGA-COAD	NA	s13686	Harvard Medical School	University of Pittsburgh	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6c024	58cfa830e4b0c9d6adf6c024	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted.bam	87.89	1.88	0.15	58cfa830e4b0c9d6adf6c024	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0J1-01A	EC7A9D74-8B3F-4747-8926-1739A016AB2B	Primary Tumor	Illumina HiSeq	7bce686e-1ac7-49b4-9b2f-c76eec80a77c	Uterus	80	AC14E378-2DE1-458A-B8CD-7C60131AA927	3612DB54-D93C-47FB-A5E7-3BA3CE404A3C	TCGA-AX-A0J1-01A-11D-A043-02	HG19_Broad_variant	TCGA-AX-A0J1	TCGA-UCEC	NA	s4594	Harvard Medical School	Gynecologic Oncology Group	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c072	58cfa830e4b0c9d6adf6c072	TCGA-B5-A0K7-10A-02D-A101_120406_SN208_0282_BC0L15ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B5-A0K7-10A-02D-A101_120406_SN208_0282_BC0L15ACXX_s_7_rg.sorted	TCGA-B5-A0K7-10A-02D-A101_120406_SN208_0282_BC0L15ACXX_s_7_rg.sorted.bam	10.79	1.95	0.13	58cfa830e4b0c9d6adf6c072	TCGA-B5-A0K7-10A-02D-A101_120406_SN208_0282_BC0L15ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K7-10A	2F0640BC-598C-4714-9E9B-7E0F2CA4567F	Blood Derived Normal	Illumina HiSeq	75f5b2c3-8f25-414e-ba05-28be0f8f09af	Uterus	64	7CC26CBE-ED1E-4AB4-A83A-C776DFCB4FFD	93CE4D46-6D02-4B2D-8D50-E9B82A41E0F6	TCGA-B5-A0K7-10A-02D-A101-02	HG19_Broad_variant	TCGA-B5-A0K7	TCGA-UCEC	NA	s4787	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c05e	58cfa830e4b0c9d6adf6c05e	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	651.89	1.9	0.14	58cfa830e4b0c9d6adf6c05e	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3999-01A	60778DA8-D99E-4E51-96A2-3E900B3978D9	Primary Tumor	Illumina HiSeq	3d30dbe4-9c61-402a-afcd-c869123af4c6	Colorectal	61	022BA0B0-F8CC-474C-9FB9-7928B45FD756	1C65913D-665D-455E-9F40-8464E5EA0D55	TCGA-AG-3999-01A-01D-1115-02	HG18	TCGA-AG-3999	TCGA-READ	NA	s2161	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Rectal Adenocarcinoma	Stage IIIC	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bc56	58cfa830e4b0c9d6adf6bc56	TCGA-AG-A011-10A-01D-A078-02_110409_SN590_0076_AB04G5ABXX_s_2.rg.sorted.filtered.	WGS	TCGA-AG-A011-10A-01D-A078-02_110409_SN590_0076_AB04G5ABXX_s_2.rg.sorted	TCGA-AG-A011-10A-01D-A078-02_110409_SN590_0076_AB04G5ABXX_s_2.rg.sorted.bam	33.9	1.72	0.15	58cfa830e4b0c9d6adf6bc56	TCGA-AG-A011-10A-01D-A078-02_110409_SN590_0076_AB04G5ABXX_s_2.rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A011-10A	3BE106BC-BA42-4C70-9B50-697D89DB617D	Blood Derived Normal	Illumina HiSeq	04332223-3071-4709-bd66-2081f4982c3c	Colorectal	80	3950AEDB-3B85-496C-9DED-BB55707362AF	81A99699-BB5D-4A80-B132-77EDDB57F984	TCGA-AG-A011-10A-01D-A078-02	HG18_Broad_variant	TCGA-AG-A011	TCGA-READ	NA	s2315	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6c106	58cfa830e4b0c9d6adf6c106	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.bam	96.9	1.86	0.16	58cfa830e4b0c9d6adf6c106	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TJ-01A	F74DA4C6-4291-46D2-ABD4-7D7F6EF03B00	Primary Tumor	Illumina HiSeq	d9625d1c-df48-4532-994d-9ab3a3c8f8b6	Uterus	59	AC35307B-AC7F-49FC-A237-5E03AB2E2276	C20AA17E-3866-4864-A4AE-44ACFD746221	TCGA-BS-A0TJ-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TJ	TCGA-UCEC	NA	s5012	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c11c	58cfa830e4b0c9d6adf6c11c	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted.bam	96.72	1.83	0.13	58cfa830e4b0c9d6adf6c11c	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TD-01A	FFAA98A0-2B69-46DC-AEE5-C5C3F2ABBC38	Primary Tumor	Illumina HiSeq	8f5ee5b5-1b1c-4af7-a179-4b71cc7c9f12	Uterus	65	8BB3A057-8958-4F62-AF81-976DA2E92DF7	3EF9C5ED-860A-4FF2-AA76-C53E9EB2453E	TCGA-BS-A0TD-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TD	TCGA-UCEC	NA	s5219	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c1ba	58cfa830e4b0c9d6adf6c1ba	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.bam	65.26	1.97	0.13	58cfa830e4b0c9d6adf6c1ba	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UT-01A	E2B1D0DE-5221-44A1-8FAD-9708A3CADA14	Primary Tumor	Illumina HiSeq	ca5a88b7-6801-435a-aeef-b9ca9d963c17	Uterus	62	824D0DBC-293F-4893-A68C-24DEDD437EA5	12674687-D555-40DB-ACC9-7638F85D0661	TCGA-BS-A0UT-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UT	TCGA-UCEC	NA	s4608	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c13a	58cfa830e4b0c9d6adf6c13a	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.bam	116.56	1.88	0.15	58cfa830e4b0c9d6adf6c13a	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0U8-01A	FB7475DF-30CC-4316-B9AC-37CBEEB6BA2B	Primary Tumor	Illumina HiSeq	44c78212-4860-4cf3-bd54-0e8e150cd0b1	Uterus	55	E3E23393-8597-4091-A343-CD544111C63B	89AB037F-B001-486F-A7EB-37AF8FBD0677	TCGA-BS-A0U8-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0U8	TCGA-UCEC	NA	s4261	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c1b2	58cfa830e4b0c9d6adf6c1b2	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.bam	37.97	2	0.16	58cfa830e4b0c9d6adf6c1b2	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MO-01A	734EF97F-807C-480E-8DF9-FEAF041032D2	Primary Tumor	Illumina HiSeq	e165d17d-a860-4111-9ae9-3fb19605cd21	Uterus	63	7582CBB9-42D3-496C-991D-D76BEA4C434C	9AD06738-F4A2-47A8-972E-BF8C817326A6	TCGA-BG-A0MO-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0MO	TCGA-UCEC	NA	s5215	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c167	58cfa830e4b0c9d6adf6c167	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.bam	75.83	2.17	0.13	58cfa830e4b0c9d6adf6c167	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z9-01A	86F9ECA0-D1EA-4375-A6BC-055E44B3198A	Primary Tumor	Illumina HiSeq	2fcaeaf0-3a03-4b60-975a-31ac8afe58aa	Thyroid	57	AA8578FE-EDB2-4137-B363-FEB2C27D475A	B761F912-BDF6-4F1F-8CD0-0AE9DFC57A59	TCGA-BJ-A0Z9-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z9	TCGA-THCA	NA	s12099	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c064	58cfa830e4b0c9d6adf6c064	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted.filtered.	WGS	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted.bam	618.89	1.9	0.15	58cfa830e4b0c9d6adf6c064	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4005-01A	866DE12B-E4DF-4F19-B62E-E3FD85D4EC08	Primary Tumor	Illumina HiSeq	06bb3e36-d2de-48c4-a23d-89eae00ec7e5	Colorectal	64	5B98C136-7BC3-411C-B07D-F0CF657F834D	284653D0-67A2-4ABF-9F75-1F045D0DAA70	TCGA-AG-4005-01A-01D-1115-02	HG18_Broad_variant	TCGA-AG-4005	TCGA-READ	NA	s1999	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Rectal Adenocarcinoma	Stage IV	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6c1c2	58cfa830e4b0c9d6adf6c1c2	TCGA-BG-A186-10A-01D-A12F_120413_SN1120_0132_AD0T6RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A186-10A-01D-A12F_120413_SN1120_0132_AD0T6RACXX_s_7_rg.sorted	TCGA-BG-A186-10A-01D-A12F_120413_SN1120_0132_AD0T6RACXX_s_7_rg.sorted.bam	23.56	1.97	0.15	58cfa830e4b0c9d6adf6c1c2	TCGA-BG-A186-10A-01D-A12F_120413_SN1120_0132_AD0T6RACXX_s_7_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A186-10A	FE4DB898-3A9F-4DFF-ADCB-7B8C30137350	Blood Derived Normal	Illumina HiSeq	8129312b-e94b-44d4-a281-81ed98ddc053	Uterus	61	E251DCCF-5BE4-49B3-987F-F12FA0F69A1D	F1D4B342-2032-4053-B725-F19B088FDB42	TCGA-BG-A186-10A-01D-A12F-02	HG19_Broad_variant	TCGA-BG-A186	TCGA-UCEC	NA	s4254	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa830e4b0c9d6adf6c1ec	58cfa830e4b0c9d6adf6c1ec	TCGA-BG-A0MT-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0MT-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_8_rg.sorted	TCGA-BG-A0MT-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_8_rg.sorted.bam	21.55	1.88	0.13	58cfa830e4b0c9d6adf6c1ec	TCGA-BG-A0MT-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MT-10A	082E32C5-7F82-466A-B52D-A3293A8F8E57	Blood Derived Normal	Illumina HiSeq	7782d010-e2ee-427f-8198-76914b5ce75c	Uterus	64	8D4F3C46-F13A-4CC8-B989-DE6DEE5F5F54	48BC2B88-56C8-442A-B864-39704586ED2C	TCGA-BG-A0MT-10A-01D-A101-02	HG19_Broad_variant	TCGA-BG-A0MT	TCGA-UCEC	NA	s5391	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c200	58cfa830e4b0c9d6adf6c200	TCGA-BG-A0M4-10A-02D-A101_120406_SN1120_0130_AD0UKGACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BG-A0M4-10A-02D-A101_120406_SN1120_0130_AD0UKGACXX_s_4_rg.sorted	TCGA-BG-A0M4-10A-02D-A101_120406_SN1120_0130_AD0UKGACXX_s_4_rg.sorted.bam	37.2	2.03	0.15	58cfa830e4b0c9d6adf6c200	TCGA-BG-A0M4-10A-02D-A101_120406_SN1120_0130_AD0UKGACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M4-10A	73E5310D-BA8C-4CBC-AA4F-E06206F898F4	Blood Derived Normal	Illumina HiSeq	948469de-ebaf-429d-b96b-b4d48cc57e3f	Uterus	60	D293C52A-3628-45E5-AFFE-F6839F6BB8B8	120F65B5-E0FD-4430-AEBD-78ABBB7832FF	TCGA-BG-A0M4-10A-02D-A101-02	HG19_Broad_variant	TCGA-BG-A0M4	TCGA-UCEC	NA	s5004	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c107	58cfa830e4b0c9d6adf6c107	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted.bam	95.02	2.03	0.15	58cfa830e4b0c9d6adf6c107	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted.bam	Alive	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TA-01A	AD3D8420-F562-4CBE-AC82-C968BD4F782D	Primary Tumor	Illumina HiSeq	ee69554a-eb4c-482a-b37e-a643758f27e5	Uterus	58	B6A042B6-F94A-4ACC-98CB-A1A2FE72B9AD	896590DE-B00E-40A3-912D-D625F3581AD8	TCGA-BS-A0TA-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TA	TCGA-UCEC	NA	s4437	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c20b	58cfa830e4b0c9d6adf6c20b	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted.bam	747.33	1.9	0.16	58cfa830e4b0c9d6adf6c20b	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4078-01A	C7353D6A-82A2-4A0D-8CD4-8C8957943EDB	Primary Tumor	Illumina HiSeq	aaa9123e-a827-4226-9b51-0b04709fadb2	Head and Neck	83	2027EDE3-13F5-40F6-BEF6-16704981D676	66A9CFF2-397E-415E-BF54-9A75CCC80BDE	TCGA-BA-4078-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4078	TCGA-HNSC	276	s15493	Harvard Medical School	UNC	None	NO	Not available	Not available	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c258	58cfa830e4b0c9d6adf6c258	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.bam	95.63	2.11	0.16	58cfa830e4b0c9d6adf6c258	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z5-01A	0FE3B19A-F5E4-497E-92DA-32FF6C77B066	Primary Tumor	Illumina HiSeq	84ec4e2b-c502-4348-b6ce-ae4a912e603c	Thyroid	58	D17746B4-EDEA-45DB-9AD1-5EE4973F007C	0AB5F114-C3CC-4DB4-87DF-1B339DDC54C2	TCGA-BJ-A0Z5-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z5	TCGA-THCA	NA	s12352	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c226	58cfa830e4b0c9d6adf6c226	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted.bam	96.07	1.92	0.15	58cfa830e4b0c9d6adf6c226	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted.bam	Alive	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UV-01A	B19425AB-A82F-4C2A-BF58-D1BD30511D74	Primary Tumor	Illumina HiSeq	91fbcf9b-f514-49ff-925b-08d6244293f7	Uterus	55	30945527-528A-448E-8DB4-2E0C31C9016D	A0F51177-4C00-4F97-8CD4-2E05B63B00DE	TCGA-BS-A0UV-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UV	TCGA-UCEC	NA	s5222	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c2a0	58cfa830e4b0c9d6adf6c2a0	TCGA-CE-A13K-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CE-A13K-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_3_rg.sorted	TCGA-CE-A13K-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_3_rg.sorted.bam	85.39	1.94	0.14	58cfa830e4b0c9d6adf6c2a0	TCGA-CE-A13K-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_3_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-CE-A13K-10A	A1227FFA-2733-4A43-BA82-834755453870	Blood Derived Normal	Illumina HiSeq	11f43f2a-bc3e-457f-aa02-8f62d0aa4650	Thyroid	30	E78C8BDF-CE47-4E6D-9839-C48C7A481A10	0FB298DB-426F-488E-A632-EE02CE231F09	TCGA-CE-A13K-10A-01D-A10R-02	HG19_Broad_variant	TCGA-CE-A13K	TCGA-THCA	NA	s12363	Harvard Medical School	ILSbio	Vietnam	NO	T3	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c392	58cfa831e4b0c9d6adf6c392	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted.bam	177.7	2	0.17	58cfa831e4b0c9d6adf6c392	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5799-01A	C991697F-77F9-412A-9BD1-0E47F7387CB2	Primary Tumor	Illumina HiSeq	a59236bd-649f-4f2d-a702-4fb190d7f92c	Stomach	45	A3180E0E-EB99-49DD-8252-5FEA05A9885F	74F06FDA-C4D0-4542-AC92-68677B595800	TCGA-CD-5799-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5799	TCGA-STAD	NA	s14633	Harvard Medical School	ILSbio	Vietnam	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c396	58cfa831e4b0c9d6adf6c396	TCGA-BG-A0MG-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0MG-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_7_rg.sorted	TCGA-BG-A0MG-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_7_rg.sorted.bam	8.16	2	0.17	58cfa831e4b0c9d6adf6c396	TCGA-BG-A0MG-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MG-10A	9CDE90C8-2BE0-4328-A032-FF1DC19E66FD	Blood Derived Normal	Illumina HiSeq	9079f7a8-53e7-4675-b3c6-f6c7b3f81eba	Uterus	73	8231519C-3DF2-4C72-A011-AE8DD15C4A93	7720E40E-CFCF-4514-A5B2-DD2643315F90	TCGA-BG-A0MG-10A-01D-A101-02	HG19_Broad_variant	TCGA-BG-A0MG	TCGA-UCEC	NA	s4433	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa831e4b0c9d6adf6c4c8	58cfa831e4b0c9d6adf6c4c8	TCGA-BR-4256-11A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-4256-11A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_2_rg.sorted	TCGA-BR-4256-11A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_2_rg.sorted.bam	7.9	1.9	0.13	58cfa831e4b0c9d6adf6c4c8	TCGA-BR-4256-11A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4256-11A	7B0D69CA-13A6-46E0-839C-E433BBEDE3AD	Solid Tissue Normal	Illumina HiSeq	9e52ce3a-8344-444b-b624-ae3604caa8be	Stomach	80	339C38E9-DA05-4C0C-AD3F-D6013815C00D	D94675A0-ACA4-4E03-8423-54E73EEA68A8	TCGA-BR-4256-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4256	TCGA-STAD	NA	s14686	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa831e4b0c9d6adf6c4f9	58cfa831e4b0c9d6adf6c4f9	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted.bam	161.2	1.9	0.14	58cfa831e4b0c9d6adf6c4f9	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4369-01A	FE9A5FCF-FF99-4DD1-8CC7-ED9F4B9D952B	Primary Tumor	Illumina HiSeq	cbba5183-9ada-4363-8f98-bf406b64f6d6	Stomach	75	39B440B3-F888-488A-A0CC-D7410DC73093	7220D8C0-DF8F-4A72-8338-795181BD8A47	TCGA-BR-4369-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4369	TCGA-STAD	NA	s14966	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c3a8	58cfa831e4b0c9d6adf6c3a8	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.bam	44	1.9	0.13	58cfa831e4b0c9d6adf6c3a8	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5798-01A	E42F45C6-FD00-44CF-A210-C8803DA326A1	Primary Tumor	Illumina HiSeq	5b2c6e2f-0b61-49e1-bef5-6d7408918d47	Stomach	82	72855D36-60BE-498F-96E9-0F10DC05B3A0	F9D13E07-70F4-48F3-B49E-06984C9E39EE	TCGA-CD-5798-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5798	TCGA-STAD	NA	s15455	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c4fd	58cfa831e4b0c9d6adf6c4fd	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted.bam	389	2	0.17	58cfa831e4b0c9d6adf6c4fd	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5800-01A	EEB114EA-ECEE-49EE-A162-B3B7BC0A60CD	Primary Tumor	Illumina HiSeq	e62fc018-7ddb-4d26-b187-0781aa2ba772	Stomach	51	B23E2D58-E61B-4B94-B4D8-407418351167	5EF4C8F7-B17A-48DA-AAF2-EF2FA32619A9	TCGA-CD-5800-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5800	TCGA-STAD	NA	s14753	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Papillary Type	Stage II	1598-02	TRUE
13722.58cfa830e4b0c9d6adf6c31b	58cfa830e4b0c9d6adf6c31b	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.bam	82.74	1.89	0.17	58cfa830e4b0c9d6adf6c31b	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TI-01A	DF857BC6-FD6A-4713-BEF9-6EE1301E5FB1	Primary Tumor	Illumina HiSeq	ea49ec05-391f-4ccc-8dbf-11ec80154839	Uterus	64	2F52C850-8E70-4EAB-88F3-D35DC55E385B	E1707EDD-FAC5-4213-BA50-2538F9F90EE5	TCGA-BS-A0TI-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TI	TCGA-UCEC	NA	s5010	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa831e4b0c9d6adf6c50a	58cfa831e4b0c9d6adf6c50a	TCGA-CM-4748-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4748-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4748-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	126.72	1.9	0.13	58cfa831e4b0c9d6adf6c50a	TCGA-CM-4748-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4748-10A	CD845618-4CC4-49C2-9055-C171D4C24EE1	Blood Derived Normal	Illumina HiSeq	d5afe3c7-77dc-415d-8178-1fff2cea011d	Colorectal	53	EB335F3B-6294-4C41-93E3-5731044A8DFD	2803D40C-88C2-40B7-85ED-DADDE3910DF5	TCGA-CM-4748-10A-01D-1405-02	HG18	TCGA-CM-4748	TCGA-COAD	NA	s13688	Harvard Medical School	MSKCC	None	NO	T4a	N1a	Colon Mucinous Adenocarcinoma	Stage IIIB	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6c27a	58cfa830e4b0c9d6adf6c27a	TCGA-AF-2689-01A-01D-1167_101023_SN208_0167_B80L4DABXX_s_3_rg.sorted.filtered.	WGS	TCGA-AF-2689-01A-01D-1167_101023_SN208_0167_B80L4DABXX_s_3_rg.sorted	TCGA-AF-2689-01A-01D-1167_101023_SN208_0167_B80L4DABXX_s_3_rg.sorted.bam	291.94	1.9	0.15	58cfa830e4b0c9d6adf6c27a	TCGA-AF-2689-01A-01D-1167_101023_SN208_0167_B80L4DABXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2689-01A	335D0351-3740-4847-9FF4-BE2F078C70F7	Primary Tumor	Illumina HiSeq	8f7ba742-44b6-41bd-8b8b-980ea208f9b8	Colorectal	41	8BEE44CB-3FE4-47A8-BD1B-90A59EA606BE	9AB254E9-6A35-46C6-BFB1-36247B20ABD6	TCGA-AF-2689-01A-01D-1167-02	HG18_Broad_variant	TCGA-AF-2689	TCGA-READ	NA	s1952	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Rectal Adenocarcinoma	Stage IV	1167-02	TRUE
13722.58cfa831e4b0c9d6adf6c510	58cfa831e4b0c9d6adf6c510	TCGA-CK-4951-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CK-4951-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CK-4951-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	543	1.9	0.16	58cfa831e4b0c9d6adf6c510	TCGA-CK-4951-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CK-4951-10A	2DB3C23D-C591-4EA0-B0A8-ED9C4343C80E	Blood Derived Normal	Illumina HiSeq	53f23902-49e3-4ebb-8694-fcf7b0c3ab7e	Colorectal	79	38BB4C4A-4414-411E-B94B-6A1044286106	0A96870C-4BC0-477C-B3F0-248D15A3D17E	TCGA-CK-4951-10A-01D-1405-02	HG18	TCGA-CK-4951	TCGA-COAD	NA	s13393	Harvard Medical School	Harvard	None	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c51c	58cfa831e4b0c9d6adf6c51c	TCGA-CM-4752-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4752-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4752-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	126.72	1.8	0.14	58cfa831e4b0c9d6adf6c51c	TCGA-CM-4752-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4752-10A	7EA546CE-F48A-4D9C-96B4-A0124C692870	Blood Derived Normal	Illumina HiSeq	8c9dcc5b-1f5c-4bf0-82e0-ce0697d2e59a	Colorectal	58	F9417E48-23D4-47D4-BF20-A8A4E64EFEA8	FEC9AC5A-D50A-44BD-BF54-0DF36D078227	TCGA-CM-4752-10A-01D-1405-02	HG18	TCGA-CM-4752	TCGA-COAD	NA	s13690	Harvard Medical School	MSKCC	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c548	58cfa831e4b0c9d6adf6c548	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	541	1.9	0.15	58cfa831e4b0c9d6adf6c548	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4747-01A	56EB96A4-D2C2-42FB-B26C-1A80012BCB8E	Primary Tumor	Illumina HiSeq	e66cdfc9-e0b0-4ca4-bbcc-9ae23d9d663f	Colorectal	47	D3DAA95A-19B5-4822-BCBE-35CEEC12FDF1	7E2021D4-E528-4EB1-A7A0-71D6BE77A71D	TCGA-CM-4747-01A-01D-1405-02	HG18	TCGA-CM-4747	TCGA-COAD	NA	s13217	Harvard Medical School	MSKCC	None	NO	T4a	N1b	Colon Adenocarcinoma	Stage IVA	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c588	58cfa831e4b0c9d6adf6c588	TCGA-CM-4748-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4748-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4748-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	227.02	1.9	0.13	58cfa831e4b0c9d6adf6c588	TCGA-CM-4748-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4748-01A	CD845618-4CC4-49C2-9055-C171D4C24EE1	Primary Tumor	Illumina HiSeq	f3119dfa-63bb-4098-9ea9-874f04789d12	Colorectal	53	1A465792-4DA7-4D37-9352-73E76ECFF4D2	3E7170B8-B0ED-4077-A65A-B6E399719A93	TCGA-CM-4748-01A-01D-1405-02	HG18	TCGA-CM-4748	TCGA-COAD	NA	s13392	Harvard Medical School	MSKCC	None	NO	T4a	N1a	Colon Mucinous Adenocarcinoma	Stage IIIB	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c605	58cfa831e4b0c9d6adf6c605	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted.bam	687	1.9	0.14	58cfa831e4b0c9d6adf6c605	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5329-01A	02DCC11F-4F0E-4C9E-8D96-D22D47BEEF5D	Primary Tumor	Illumina HiSeq	b54a3eac-9c58-453d-9db1-395601ae82ea	Head and Neck	46	D22E9B65-495B-4D42-926A-01BF2C436D76	63CE8A9C-2CC5-41D9-B24D-3FB88343B693	TCGA-CQ-5329-01A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5329	TCGA-HNSC	NA	s15772	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c61f	58cfa831e4b0c9d6adf6c61f	TCGA-CG-4436-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-4436-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_5_rg.sorted	TCGA-CG-4436-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_5_rg.sorted.bam	336.2	1.9	0.13	58cfa831e4b0c9d6adf6c61f	TCGA-CG-4436-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4436-01A	7938CA55-766E-4277-9E7E-603FFA02E570	Primary Tumor	Illumina HiSeq	0b869c68-28bb-4675-ba6c-6d20a89a1a49	Stomach	57	21F40CF9-D89F-4FEC-BE65-1740AB39DAE4	9215C180-AC30-4585-9AF3-4EF1D718E187	TCGA-CG-4436-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4436	TCGA-STAD	NA	s14980	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c598	58cfa831e4b0c9d6adf6c598	TCGA-CN-4735-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-4735-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_2_rg.sorted	TCGA-CN-4735-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_2_rg.sorted.bam	543.4	1.9	0.16	58cfa831e4b0c9d6adf6c598	TCGA-CN-4735-10A-01D-1431_120412_SN208_0284_BD0T51ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4735-10A	FE844945-3EA9-449E-993C-DF392FABCFD0	Blood Derived Normal	Illumina HiSeq	430a1e6e-314d-47f4-82fe-d5976cdc409d	Head and Neck	52	A2CAEAB5-55A4-412F-A647-0112F48BBBE7	9E74974B-EE15-4452-801B-770B4D7F9FD3	TCGA-CN-4735-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4735	TCGA-HNSC	NA	s16029	Harvard Medical School	University of Pittsburgh	None	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c6d2	58cfa831e4b0c9d6adf6c6d2	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted.bam	19.7	1.9	0.15	58cfa831e4b0c9d6adf6c6d2	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-4938-01B	334F715E-08DC-4A29-B8E4-B010B829C478	Primary Tumor	Illumina HiSeq	8b9dc3cd-2c99-405c-8306-3b388ad5bdf6	Brain	31	99104139-6CB5-44F7-8314-A4DDF02DE7D4	7FE72196-9DE8-4A43-87F2-D2E8F74B0007	TCGA-CS-4938-01B-11D-1891-02	HG19_Broad_variant	TCGA-CS-4938	TCGA-LGG	NA	s8553	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6c646	58cfa831e4b0c9d6adf6c646	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted.bam	234	1.9	0.15	58cfa831e4b0c9d6adf6c646	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5327-01A	5A03E2B6-4C8B-479A-9036-9859AF031DA4	Primary Tumor	Illumina HiSeq	3482a15d-acdc-4fcf-86a5-b015e57faefd	Head and Neck	61	93D283A7-E866-4F23-81F7-942DEE5009B8	55F0F300-E472-4254-9BDA-76AD94EA8C13	TCGA-CQ-5327-01A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5327	TCGA-HNSC	NA	s15638	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c764	58cfa831e4b0c9d6adf6c764	TCGA-D1-A17N-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A17N-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_4_rg.sorted	TCGA-D1-A17N-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_4_rg.sorted.bam	26.01	1.98	0.17	58cfa831e4b0c9d6adf6c764	TCGA-D1-A17N-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17N-10A	001E0309-9C50-42B0-9E38-347883EE2CD3	Blood Derived Normal	Illumina HiSeq	f78748fd-fd4c-4684-9f8e-ad983533175d	Uterus	46	24469145-571C-44CA-AACA-9ACAC7CCF417	0645ECD0-0B4B-4CAF-B5FE-B8BF4BFC74E1	TCGA-D1-A17N-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A17N	TCGA-UCEC	NA	s4798	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c77a	58cfa831e4b0c9d6adf6c77a	TCGA-D3-A3CC-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D3-A3CC-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_5_rg.sorted	TCGA-D3-A3CC-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_5_rg.sorted.bam	27.47	NA	0.16	58cfa831e4b0c9d6adf6c77a	TCGA-D3-A3CC-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A3CC-06A	2D36CEA4-73E9-493B-8433-0C2B911C0521	Metastatic	Illumina HiSeq	fd606b6a-a303-4b04-be1d-f12779b19969	Skin	69	2B274033-FA42-4A06-AEFE-7013E0E29318	D76073BC-61B7-4D7E-AF06-1C9CED11318B	TCGA-D3-A3CC-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D3-A3CC	TCGA-SKCM	NA	s7325	Harvard Medical School	MD Anderson	United States	NO	T4b	N0	Not available	Stage IIC	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c526	58cfa831e4b0c9d6adf6c526	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	516	1.9	0.15	58cfa831e4b0c9d6adf6c526	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4746-01A	C0B8C55C-B993-481D-AEEA-9EBFA64EE20E	Primary Tumor	Illumina HiSeq	cba07266-002c-406e-bfb3-5fc3483bb04b	Colorectal	61	85991716-6807-4F31-BE63-BF80CEC40CC2	32AAA8D7-1ABF-4AEF-8067-BE801C95D30B	TCGA-CM-4746-01A-01D-1405-02	HG18	TCGA-CM-4746	TCGA-COAD	NA	s12892	Harvard Medical School	MSKCC	None	NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c726	58cfa831e4b0c9d6adf6c726	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted.bam	288.7	1.9	0.14	58cfa831e4b0c9d6adf6c726	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6825-01A	42BC2336-2408-441A-83B9-AADC9700F750	Primary Tumor	Illumina HiSeq	e785062a-dcec-4a1d-aa67-6089980c9e35	Head and Neck	73	D9E2F5AA-A6E2-491A-9DBC-E5D10B4ABA58	8B36C904-50A1-4B17-94A2-F9331A5FED1E	TCGA-D6-6825-01A-21D-1911-02	HG19_Broad_variant	TCGA-D6-6825	TCGA-HNSC	NA	s15529	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c851	58cfa831e4b0c9d6adf6c851	TCGA-D3-A2J6-06A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D3-A2J6-06A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_4_rg.sorted	TCGA-D3-A2J6-06A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_4_rg.sorted.bam	31.51	NA	0.16	58cfa831e4b0c9d6adf6c851	TCGA-D3-A2J6-06A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A2J6-06A	6F5157B8-D43A-4FBC-B7DA-23629F5B53DA	Metastatic	Illumina HiSeq	27e93d3a-66fc-4038-8b4e-236c996851f2	Skin	65	60BDA95D-1E8B-4232-AFEE-DEB9FB3D5AFF	EF7E375F-A88C-4030-ACFC-D8BAB223820A	TCGA-D3-A2J6-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D3-A2J6	TCGA-SKCM	1321	s7998	Harvard Medical School	MD Anderson	United States	NO	T3b	N0	Not available	Stage IIB	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c882	58cfa831e4b0c9d6adf6c882	TCGA-CV-6939-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-6939-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_3_rg.sorted	TCGA-CV-6939-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_3_rg.sorted.bam	16.7	1.9	0.13	58cfa831e4b0c9d6adf6c882	TCGA-CV-6939-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	Not available	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6939-11A	E7D1F0DD-EEC0-4670-A2BA-00FFE38C6382	Solid Tissue Normal	Illumina HiSeq	c0371496-b9f6-4925-bbcf-e8a5de80d00d	Head and Neck	60	B7635DF8-644C-473D-8B07-F586693A1F3E	28B55601-835D-4281-828D-37363F5D7EAF	TCGA-CV-6939-11A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6939	TCGA-HNSC	666	s15781	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c8ac	58cfa831e4b0c9d6adf6c8ac	TCGA-D9-A1JX-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D9-A1JX-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_7_rg.sorted	TCGA-D9-A1JX-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_7_rg.sorted.bam	53.11	NA	0.17	58cfa831e4b0c9d6adf6c8ac	TCGA-D9-A1JX-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D9-A1JX-10A	F505058F-74F2-4476-887F-06590A605980	Blood Derived Normal	Illumina HiSeq	7a4a6e10-a6a2-4a78-be06-7e650df381ef	Skin	80	6D928F3A-A036-44CD-B714-15E0C19C30CD	6D4599CC-43B3-4AE5-805E-8D23DEF87FAA	TCGA-D9-A1JX-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D9-A1JX	TCGA-SKCM	NA	s7505	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	TX	NX	Not available	Not available	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c96e	58cfa831e4b0c9d6adf6c96e	TCGA-DJ-A1QO-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DJ-A1QO-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_8_rg.sorted	TCGA-DJ-A1QO-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_8_rg.sorted.bam	38.63	2.12	0.17	58cfa831e4b0c9d6adf6c96e	TCGA-DJ-A1QO-10A-01D-A14U_120629_SN1120_0168_BD1454ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QO-10A	F2AD720E-579F-4E2C-A3F0-17877CA91067	Blood Derived Normal	Illumina HiSeq	622981e6-e448-492c-bef1-f31bd0dea146	Thyroid	69	23A38BFD-4AF5-44A9-B3C4-737D07E4E4F1	2852AA8B-F5D8-423F-BE97-83053C855246	TCGA-DJ-A1QO-10A-01D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QO	TCGA-THCA	NA	s12374	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c95a	58cfa831e4b0c9d6adf6c95a	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted.bam	14.32	1.97	0.15	58cfa831e4b0c9d6adf6c95a	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QF-01A	FCA0C7D9-5E6F-4AA7-BA04-5DF2EB8BA398	Primary Tumor	Illumina HiSeq	267d7caa-22fc-41bc-8ea9-ee910a0ac510	Thyroid	61	E4B53CA1-D395-4FEA-A962-DFBD2B373A6B	FA0BE982-CE22-449F-9D2B-E688196BA8AE	TCGA-DJ-A1QF-01A-12D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QF	TCGA-THCA	NA	s11991	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c7ff	58cfa831e4b0c9d6adf6c7ff	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted.bam	91.84	2.11	0.16	58cfa831e4b0c9d6adf6c7ff	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16X-01A	22618073-4EF0-4C3A-97B9-90BA1CAA1D72	Primary Tumor	Illumina HiSeq	8f166eb0-a44e-4848-ae7a-4e174f470d5b	Uterus	54	6421D807-9BEC-4AD4-8B75-8F9DD594A977	E652FF84-B885-4245-86E5-70ADE972FD67	TCGA-D1-A16X-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16X	TCGA-UCEC	NA	s5023	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c97a	58cfa831e4b0c9d6adf6c97a	TCGA-DJ-A1QN-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A1QN-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_1_rg.sorted	TCGA-DJ-A1QN-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_1_rg.sorted.bam	94.75	1.91	0.17	58cfa831e4b0c9d6adf6c97a	TCGA-DJ-A1QN-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QN-01A	2012869D-C169-4CEA-AA09-C892FB79BBAA	Primary Tumor	Illumina HiSeq	5cfa9ea5-2e72-4f40-96be-d6accc8482a8	Thyroid	42	884C1978-00CF-4E48-BEF8-F03CA67D6C02	F5D0FC17-824D-42F7-931B-E23CD68B9E2F	TCGA-DJ-A1QN-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QN	TCGA-THCA	NA	s12640	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c94b	58cfa831e4b0c9d6adf6c94b	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted.bam	43.74	1.8	0.18	58cfa831e4b0c9d6adf6c94b	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QO-01A	F2AD720E-579F-4E2C-A3F0-17877CA91067	Primary Tumor	Illumina HiSeq	1ac10023-1615-4727-ac8d-23b842c19d3c	Thyroid	69	03811796-0ECE-4408-82F7-B449A631D2FB	9E0C97ED-7482-4400-B66A-72AB48BA11A2	TCGA-DJ-A1QO-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QO	TCGA-THCA	NA	s12372	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c97b	58cfa831e4b0c9d6adf6c97b	TCGA-D9-A1JW-06A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D9-A1JW-06A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_3_rg.sorted	TCGA-D9-A1JW-06A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_3_rg.sorted.bam	55.53	NA	0.16	58cfa831e4b0c9d6adf6c97b	TCGA-D9-A1JW-06A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D9-A1JW-06A	9A903FC2-57D7-4A02-94E7-9B9B7EE99276	Metastatic	Illumina HiSeq	dd38c2b9-2249-41f4-81df-ff133c8dc39d	Skin	82	65549283-35D4-4916-B990-BD714A63BB36	7B532980-AD10-4961-A39D-3B48A518DFD0	TCGA-D9-A1JW-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D9-A1JW	TCGA-SKCM	NA	s7672	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T1a	N2a	Not available	Not available	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c9c9	58cfa831e4b0c9d6adf6c9c9	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted.bam	51.98	1.61	0.16	58cfa831e4b0c9d6adf6c9c9	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QH-01A	F3C73DC9-6280-4619-A629-B575FDBDB0CA	Primary Tumor	Illumina HiSeq	0e84405e-6687-4f5d-89c9-c507d3c0bba0	Thyroid	58	B1775A45-D30D-42C3-91D8-53C662B4A974	31F3AA22-9E90-4FF7-872C-0EED3DB18545	TCGA-DJ-A1QH-01A-21D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QH	TCGA-THCA	NA	s12376	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6ca4b	58cfa831e4b0c9d6adf6ca4b	TCGA-D7-6820-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D7-6820-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_4_rg.sorted	TCGA-D7-6820-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_4_rg.sorted.bam	520	1.9	0.15	58cfa831e4b0c9d6adf6ca4b	TCGA-D7-6820-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6820-10A	1142251C-28EB-48BF-9C54-7126D4557605	Blood Derived Normal	Illumina HiSeq	99cd87aa-0deb-4ace-86d1-adfb8dbee226	Stomach	64	1FFC07AF-EDDD-461E-B600-D4DB171D48DC	E4430C45-E033-4BA6-B72A-999CE7624FE8	TCGA-D7-6820-10A-01D-1880-02	HG19_Broad_variant	TCGA-D7-6820	TCGA-STAD	NA	s14842	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIB	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6cac5	58cfa831e4b0c9d6adf6cac5	TCGA-DA-A1I8-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DA-A1I8-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_5_rg.sorted	TCGA-DA-A1I8-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_5_rg.sorted.bam	29.72	NA	0.16	58cfa831e4b0c9d6adf6cac5	TCGA-DA-A1I8-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1I8-06A	7B92FCD4-F9BE-4B97-94A2-B2E8348AEABA	Metastatic	Illumina HiSeq	0533c67c-0914-42e2-97d4-0f5e0bbacc84	Skin	63	53F3FC7C-3B45-4516-9749-776E039318AA	B33A4712-88D6-40C0-A09C-F837438461D3	TCGA-DA-A1I8-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-DA-A1I8	TCGA-SKCM	NA	s7502	Harvard Medical School	Yale	United States	NO	T4b	N0	Not available	Stage IIC	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cab0	58cfa831e4b0c9d6adf6cab0	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted.bam	76.6	1.95	0.16	58cfa831e4b0c9d6adf6cab0	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13U-01A	8C5AEF43-341E-4A37-84EB-FD730EB957C7	Primary Tumor	Illumina HiSeq	c717fac6-b3b3-4335-8ee8-5862d742ea16	Thyroid	60	CD19D6BB-21A4-409A-A7BA-A4521A03ABD3	B80A7146-1AB2-49BD-A3B2-7F6650840195	TCGA-DJ-A13U-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13U	TCGA-THCA	NA	s12104	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6bcf3	58cfa830e4b0c9d6adf6bcf3	TCGA-AG-3574-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3574-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3574-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	41.21	1.8	0.14	58cfa830e4b0c9d6adf6bcf3	TCGA-AG-3574-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3574-10A	0EDA7373-8335-455F-B90A-8C3540F28088	Blood Derived Normal	Illumina HiSeq	9211afac-c744-41bb-ac38-56805c35f544	Colorectal	89	FC65E77A-760D-49D6-81B3-CD55899C76AB	8BCF4B23-7007-4919-BC51-A71E98E295B4	TCGA-AG-3574-10A-01D-1167-02	HG18	TCGA-AG-3574	TCGA-READ	NA	s1967	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	1167-02	TRUE
13722.58cfa831e4b0c9d6adf6cabc	58cfa831e4b0c9d6adf6cabc	TCGA-DA-A1I7-06A-22D-A18Y_120730_SN208_0419_AC13W9ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DA-A1I7-06A-22D-A18Y_120730_SN208_0419_AC13W9ACXX_s_4_rg.sorted	TCGA-DA-A1I7-06A-22D-A18Y_120730_SN208_0419_AC13W9ACXX_s_4_rg.sorted.bam	26.08	NA	0.17	58cfa831e4b0c9d6adf6cabc	TCGA-DA-A1I7-06A-22D-A18Y_120730_SN208_0419_AC13W9ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1I7-06A	DFE8BAA8-1C2C-4C36-92C9-61548CEBEC19	Metastatic	Illumina HiSeq	85c1bc41-87de-4fc0-89c9-aa8f1e56755c	Skin	62	75633AC0-2F77-486E-BA9B-BCEA02CD7DC4	C48121FD-7F92-4206-BE49-41F103CB35C8	TCGA-DA-A1I7-06A-22D-A18Y-02	HG19_Broad_variant	TCGA-DA-A1I7	TCGA-SKCM	NA	s7329	Harvard Medical School	Yale	United States	NO	T0	N2b	Not available	Stage IIIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6c9ed	58cfa831e4b0c9d6adf6c9ed	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted.bam	104.83	1.95	0.16	58cfa831e4b0c9d6adf6c9ed	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13P-01A	CA95A11C-B54C-409E-B9A0-DA850945033D	Primary Tumor	Illumina HiSeq	5d993dc5-0dfb-4f12-bd8b-c21a2c64577d	Thyroid	52	EFAD8B07-B295-468F-A836-F94029AEC777	528EC19A-8218-4E8F-B1E7-8A149F54A6BE	TCGA-DJ-A13P-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13P	TCGA-THCA	NA	s11995	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6cada	58cfa831e4b0c9d6adf6cada	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted.bam	424.7	1.9	0.14	58cfa831e4b0c9d6adf6cada	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6542-01A	CD69D509-A652-4257-A8D3-767296BBB4EC	Primary Tumor	Illumina HiSeq	4b6cb752-5ed6-42e5-aed5-c8bdc6b95945	Brain	25	D00791AB-AA9D-406B-934C-E6946A430BB2	6EF0AE20-9197-4162-9A35-E235071A83B5	TCGA-DU-6542-01A-11D-1891-02	HG19_Broad_variant	TCGA-DU-6542	TCGA-LGG	NA	s8143	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6cab2	58cfa831e4b0c9d6adf6cab2	TCGA-D9-A1X3-01A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D9-A1X3-01A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_1_rg.sorted	TCGA-D9-A1X3-01A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_1_rg.sorted.bam	59.17	NA	0.16	58cfa831e4b0c9d6adf6cab2	TCGA-D9-A1X3-01A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D9-A1X3-06A	F0744FA2-DB4A-40DE-9FD2-F61863FD98D4	Metastatic	Illumina HiSeq	7f130a48-c6c4-40f7-b932-8ab8de632835	Skin	63	989C7C90-4017-4395-AD7B-4FB221370028	D9538A0C-8449-4969-8D94-3157029387E6	TCGA-D9-A1X3-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-D9-A1X3	TCGA-SKCM	NA	s7837	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T4b	N2b	Not available	Not available	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6caa0	58cfa831e4b0c9d6adf6caa0	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted.bam	41.49	1.86	0.16	58cfa831e4b0c9d6adf6caa0	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QM-01A	3597AF5E-65FF-40A7-95FC-DACC26CBCA14	Primary Tumor	Illumina HiSeq	e98815fd-cd95-4af1-af17-129186e4a00a	Thyroid	42	B4215B1F-3918-43D6-8862-380C35F891EC	A070BCA4-DDFA-4BE7-A635-69A2BA97FFE9	TCGA-DJ-A1QM-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QM	TCGA-THCA	NA	s12243	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1a	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cb32	58cfa831e4b0c9d6adf6cb32	TCGA-EE-A29C-06A-21D-A18Y_120807_SN590_0173_AC0VN5ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EE-A29C-06A-21D-A18Y_120807_SN590_0173_AC0VN5ACXX_s_2_rg.sorted	TCGA-EE-A29C-06A-21D-A18Y_120807_SN590_0173_AC0VN5ACXX_s_2_rg.sorted.bam	30.14	NA	0.17	58cfa831e4b0c9d6adf6cb32	TCGA-EE-A29C-06A-21D-A18Y_120807_SN590_0173_AC0VN5ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29C-06A	FC5B5D2F-0D03-45C2-B7A0-BA6EC108FE51	Metastatic	Illumina HiSeq	ad8de103-2a4c-4260-a774-90e01027128e	Skin	20	E6B3B5F4-1A6B-40BE-A1DE-1C680855F5D6	02881604-8976-48A4-947A-84391AEC2B24	TCGA-EE-A29C-06A-21D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29C	TCGA-SKCM	NA	s7331	Harvard Medical School	University of Sydney	Australia	NO	T2a	N0	Not available	Stage IB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb46	58cfa831e4b0c9d6adf6cb46	TCGA-EE-A29S-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EE-A29S-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_7_rg.sorted	TCGA-EE-A29S-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_7_rg.sorted.bam	45.66	NA	0.16	58cfa831e4b0c9d6adf6cb46	TCGA-EE-A29S-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29S-10A	5DEC1B6A-5D60-463C-9655-FC7ED79CA19D	Blood Derived Normal	Illumina HiSeq	acaa3027-4446-467e-bc84-eaf1b02d992c	Skin	79	FDFC609C-F6A9-4B25-82F5-D9FFFD07A8F8	DBD444A5-622C-4E3C-BFBD-15A7CD824EA8	TCGA-EE-A29S-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29S	TCGA-SKCM	NA	s7330	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage IIA	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc0c	58cfa831e4b0c9d6adf6cc0c	TCGA-EE-A29E-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EE-A29E-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_4_rg.sorted	TCGA-EE-A29E-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_4_rg.sorted.bam	41.77	NA	0.17	58cfa831e4b0c9d6adf6cc0c	TCGA-EE-A29E-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29E-06A	83D05B9A-F409-4169-BEF9-E772D2CFBFAF	Metastatic	Illumina HiSeq	93b49bcb-3ba4-4360-93e8-7c91eee744ee	Skin	54	ADDBE524-382B-48CA-B4A0-962FAB71E0D0	C1A44D60-23D2-46B9-93E7-7E9DC671902C	TCGA-EE-A29E-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29E	TCGA-SKCM	NA	s7335	Harvard Medical School	University of Sydney	Australia	NO	T3a	N1b	Not available	Stage IIIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cbe5	58cfa831e4b0c9d6adf6cbe5	TCGA-EE-A29P-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EE-A29P-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_4_rg.sorted	TCGA-EE-A29P-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_4_rg.sorted.bam	47.99	NA	0.16	58cfa831e4b0c9d6adf6cbe5	TCGA-EE-A29P-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29P-10A	FD1A49F2-FB3B-481D-888E-F4224D59F6D1	Blood Derived Normal	Illumina HiSeq	74fe7aee-fe79-4d9a-bb11-86f865d6a0b2	Skin	73	94437E00-B2E2-462C-AFC7-510FA17E5F3E	F86BBD71-66E1-4FA6-8F1E-A7C065DC3CFD	TCGA-EE-A29P-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29P	TCGA-SKCM	NA	s8009	Harvard Medical School	University of Sydney	Australia	NO	T4b	N0	Not available	Stage IIC	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc28	58cfa831e4b0c9d6adf6cc28	TCGA-EE-A29R-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EE-A29R-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_6_rg.sorted	TCGA-EE-A29R-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_6_rg.sorted.bam	45.53	NA	0.17	58cfa831e4b0c9d6adf6cc28	TCGA-EE-A29R-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29R-06A	D73D1B38-9AB4-409E-A360-E93F8C54715C	Metastatic	Illumina HiSeq	39cebd09-df59-45a2-bd13-b75055a7a352	Skin	48	9C98FCC2-FD1F-4F19-A550-B0FF0B78CF89	86C0AB31-7A14-40E7-AEA8-2CAD1F90CB27	TCGA-EE-A29R-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29R	TCGA-SKCM	NA	s7679	Harvard Medical School	University of Sydney	Australia	NO	T3b	N1b	Not available	Stage IIIC	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc54	58cfa831e4b0c9d6adf6cc54	TCGA-ER-A193-06A-12D-A18Y_120718_SN1222_0126_AC117AACXX_s_1_rg.sorted.filtered.	WGS	TCGA-ER-A193-06A-12D-A18Y_120718_SN1222_0126_AC117AACXX_s_1_rg.sorted	TCGA-ER-A193-06A-12D-A18Y_120718_SN1222_0126_AC117AACXX_s_1_rg.sorted.bam	48.72	NA	0.16	58cfa831e4b0c9d6adf6cc54	TCGA-ER-A193-06A-12D-A18Y_120718_SN1222_0126_AC117AACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A193-06A	8AB09143-DAF6-40A9-85D3-0FE9DE7B3E06	Metastatic	Illumina HiSeq	1095eea4-ccec-4aca-9afa-5f2c1ca24703	Skin	62	378B3D8A-ADBB-4912-A0BF-6B74A282113E	8A1BFE0E-C97A-41C4-815F-CF5BB5CFC69F	TCGA-ER-A193-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-ER-A193	TCGA-SKCM	955	s8017	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N0	Not available	Stage IIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc35	58cfa831e4b0c9d6adf6cc35	TCGA-EE-A29Q-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EE-A29Q-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_3_rg.sorted	TCGA-EE-A29Q-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_3_rg.sorted.bam	30.57	NA	0.18	58cfa831e4b0c9d6adf6cc35	TCGA-EE-A29Q-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29Q-10A	6A1818F9-9303-41B0-B3B7-07FAF5055C86	Blood Derived Normal	Illumina HiSeq	3a35cc5e-4313-46ab-857d-f22cddd7625f	Skin	70	CB5DCB2E-D966-42CA-8DFD-034FFEF5A40A	033506C2-A0D7-4E02-B9F5-F3ADE80F7094	TCGA-EE-A29Q-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29Q	TCGA-SKCM	NA	s7848	Harvard Medical School	University of Sydney	Australia	NO	T3b	N0	Not available	Stage IIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc21	58cfa831e4b0c9d6adf6cc21	TCGA-EE-A29Q-06A-11D-A18Y_120729_SN1120_0180_BC1176ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EE-A29Q-06A-11D-A18Y_120729_SN1120_0180_BC1176ACXX_s_1_rg.sorted	TCGA-EE-A29Q-06A-11D-A18Y_120729_SN1120_0180_BC1176ACXX_s_1_rg.sorted.bam	43.29	NA	0.16	58cfa831e4b0c9d6adf6cc21	TCGA-EE-A29Q-06A-11D-A18Y_120729_SN1120_0180_BC1176ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29Q-06A	6A1818F9-9303-41B0-B3B7-07FAF5055C86	Metastatic	Illumina HiSeq	ac015b9b-1772-42b1-a39c-c771b610492d	Skin	70	9B9F0B93-CF1E-4052-8938-2C56AD8A2FD2	E581778B-21C0-4DE9-9D03-B37046313700	TCGA-EE-A29Q-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29Q	TCGA-SKCM	NA	s7845	Harvard Medical School	University of Sydney	Australia	NO	T3b	N0	Not available	Stage IIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cca2	58cfa831e4b0c9d6adf6cca2	TCGA-EQ-5647-01A-01D-1598_130110_SN1222_0167_AC1JPDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EQ-5647-01A-01D-1598_130110_SN1222_0167_AC1JPDACXX_s_7_rg.sorted	TCGA-EQ-5647-01A-01D-1598_130110_SN1222_0167_AC1JPDACXX_s_7_rg.sorted.bam	255.7	1.87	0.15	58cfa831e4b0c9d6adf6cca2	TCGA-EQ-5647-01A-01D-1598_130110_SN1222_0167_AC1JPDACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-EQ-5647-01A	2D291FA3-F0FD-4BC1-91A6-783863714190	Primary Tumor	Illumina HiSeq	913ab9c5-864c-4652-a243-a0dc44a3b28e	Stomach	86	400FED84-FE61-4F7A-9DCC-6C32131106CD	ABD8CB7C-0FEC-4D00-950D-5A190A0D75F4	TCGA-EQ-5647-01A-01D-1598-02	HG19_Broad_variant	TCGA-EQ-5647	TCGA-STAD	19	s15252	Harvard Medical School	Christiana Healthcare	United States	NO	T4	N3	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6cd18	58cfa831e4b0c9d6adf6cd18	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted.bam	26.49	1.71	0.15	58cfa831e4b0c9d6adf6cd18	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25N-01A	EBCCFB5F-C0A8-4263-AAFF-B5DD83585191	Primary Tumor	Illumina HiSeq	2e9fb20e-cc3d-4aa3-a188-6695dc2532a3	Thyroid	28	0CD93B1F-1CBB-4C1E-A4F6-940F95C41683	1A00F009-28F5-406B-8F47-4BB9D55D25D6	TCGA-ET-A25N-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25N	TCGA-THCA	NA	s12525	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6cd32	58cfa831e4b0c9d6adf6cd32	TCGA-ER-A1A1-06A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_3_rg.sorted.filtered.	WGS	TCGA-ER-A1A1-06A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_3_rg.sorted	TCGA-ER-A1A1-06A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_3_rg.sorted.bam	80.44	NA	0.17	58cfa831e4b0c9d6adf6cd32	TCGA-ER-A1A1-06A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A1A1-06A	1251ACEE-CEB4-4530-BA5B-4D163FCAB8D2	Metastatic	Illumina HiSeq	a0dd4823-2335-43ba-8e32-a91e08f80afd	Skin	58	B813EC36-059B-4833-9D27-CC72D8FD3A20	8CE5648E-5D8C-4B99-B39D-5F0D47F98209	TCGA-ER-A1A1-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A1A1	TCGA-SKCM	NA	s7362	Harvard Medical School	University of Pittsburgh	United States	NO	TX	N3	Not available	Stage IIIC	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc6e	58cfa831e4b0c9d6adf6cc6e	TCGA-ER-A193-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_5_rg.sorted.filtered.	WGS	TCGA-ER-A193-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_5_rg.sorted	TCGA-ER-A193-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_5_rg.sorted.bam	37.78	NA	0.15	58cfa831e4b0c9d6adf6cc6e	TCGA-ER-A193-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A193-10A	8AB09143-DAF6-40A9-85D3-0FE9DE7B3E06	Blood Derived Normal	Illumina HiSeq	73c549f9-ad97-4f0c-9a29-143ee37774ba	Skin	62	7A384D44-8B05-4197-9921-7D020ADA2437	390B3574-BA23-4ECB-ACF8-F5AD8A958BD2	TCGA-ER-A193-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A193	TCGA-SKCM	955	s8023	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N0	Not available	Stage IIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cd5e	58cfa831e4b0c9d6adf6cd5e	TCGA-EE-A2MS-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EE-A2MS-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_3_rg.sorted	TCGA-EE-A2MS-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_3_rg.sorted.bam	64.33	NA	0.16	58cfa831e4b0c9d6adf6cd5e	TCGA-EE-A2MS-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MS-06A	4A4F5EE9-B588-4357-B058-EFFBFB53E2C3	Metastatic	Illumina HiSeq	4cc98a8c-1e89-4a0a-a8c5-4a23e7880ac4	Skin	72	CEFFDD2F-6C8E-43DB-BE2E-D111F892C683	10D894D7-3C7B-4DBB-AD20-8ED6A970572F	TCGA-EE-A2MS-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2MS	TCGA-SKCM	NA	s7346	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage II	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cd70	58cfa831e4b0c9d6adf6cd70	TCGA-ET-A25K-10A-01D-A16N_120717_SN1120_0176_BC1178ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-ET-A25K-10A-01D-A16N_120717_SN1120_0176_BC1178ACXX_s_8_rg.sorted	TCGA-ET-A25K-10A-01D-A16N_120717_SN1120_0176_BC1178ACXX_s_8_rg.sorted.bam	18.33	1.84	0.16	58cfa831e4b0c9d6adf6cd70	TCGA-ET-A25K-10A-01D-A16N_120717_SN1120_0176_BC1178ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25K-10A	2F9ED09D-2626-4C23-BA47-1850D36F812A	Blood Derived Normal	Illumina HiSeq	6f869861-b0d2-4022-a0ef-d1f46eea9f40	Thyroid	36	38379990-627C-4FAC-A13A-6AFD9D47A448	34182C38-B860-44A4-AA11-6D1DFD5BB267	TCGA-ET-A25K-10A-01D-A16N-02	HG19_Broad_variant	TCGA-ET-A25K	TCGA-THCA	NA	s12526	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6cd5a	58cfa831e4b0c9d6adf6cd5a	TCGA-EE-A2MS-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EE-A2MS-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_7_rg.sorted	TCGA-EE-A2MS-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_7_rg.sorted.bam	41.54	NA	0.16	58cfa831e4b0c9d6adf6cd5a	TCGA-EE-A2MS-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MS-10A	4A4F5EE9-B588-4357-B058-EFFBFB53E2C3	Blood Derived Normal	Illumina HiSeq	ff803ed6-50bf-4221-a401-0cc77d8299a6	Skin	72	6DC218EC-F0E8-4EEC-B905-0F1B24680088	C47237B8-13E6-4B9A-9A95-8CBA4C66327A	TCGA-EE-A2MS-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2MS	TCGA-SKCM	NA	s7690	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage II	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cd74	58cfa831e4b0c9d6adf6cd74	TCGA-ET-A25K-01A-11D-A16N_120717_SN1120_0176_BC1178ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ET-A25K-01A-11D-A16N_120717_SN1120_0176_BC1178ACXX_s_7_rg.sorted	TCGA-ET-A25K-01A-11D-A16N_120717_SN1120_0176_BC1178ACXX_s_7_rg.sorted.bam	57.24	2	0.17	58cfa831e4b0c9d6adf6cd74	TCGA-ET-A25K-01A-11D-A16N_120717_SN1120_0176_BC1178ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25K-01A	2F9ED09D-2626-4C23-BA47-1850D36F812A	Primary Tumor	Illumina HiSeq	81720382-db9a-41e3-814e-ee8ec59ce22d	Thyroid	36	343311B1-D586-4F92-9984-32AF1AFB1F62	663173D3-A9EE-4E73-8444-52F01727BE6D	TCGA-ET-A25K-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25K	TCGA-THCA	NA	s12115	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6cdb8	58cfa831e4b0c9d6adf6cdb8	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted.bam	105.7	1.9	0.16	58cfa831e4b0c9d6adf6cdb8	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6691-01A	E4D9B696-3311-44E7-9191-FDE56C080A00	Primary Tumor	Illumina HiSeq	b404ac67-1c7f-4b01-8038-7432d3d6e489	Brain	23	87800B98-1FD3-4A09-AC98-3125962BFA72	B4968770-4D21-4C51-9ECA-47E23D5C240E	TCGA-FG-6691-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6691	TCGA-LGG	NA	s8368	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6cc11	58cfa831e4b0c9d6adf6cc11	TCGA-EE-A29H-06A-12D-A18Y_120729_SN1120_0180_BC1176ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EE-A29H-06A-12D-A18Y_120729_SN1120_0180_BC1176ACXX_s_6_rg.sorted	TCGA-EE-A29H-06A-12D-A18Y_120729_SN1120_0180_BC1176ACXX_s_6_rg.sorted.bam	57.71	NA	0.17	58cfa831e4b0c9d6adf6cc11	TCGA-EE-A29H-06A-12D-A18Y_120729_SN1120_0180_BC1176ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29H-06A	C8BA1856-D055-4DC6-A184-72763C76AAE4	Metastatic	Illumina HiSeq	21070c2b-7503-4c5c-9a66-5e6564c37d01	Skin	59	92AE970D-75B4-4D9F-B84F-A2070F0CBE90	F32701EE-123A-4D6C-AE5A-06F52AAD063E	TCGA-EE-A29H-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29H	TCGA-SKCM	NA	s7840	Harvard Medical School	University of Sydney	Australia	NO	T1a	N0	Not available	Stage IA	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cda0	58cfa831e4b0c9d6adf6cda0	TCGA-FE-A233-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FE-A233-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_3_rg.sorted	TCGA-FE-A233-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_3_rg.sorted.bam	92.7	2.05	0.18	58cfa831e4b0c9d6adf6cda0	TCGA-FE-A233-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A233-01A	E70FEAFD-1390-4F4C-A635-DA65C1A7DAEB	Primary Tumor	Illumina HiSeq	3609a0f8-b027-4392-adea-96eab2e1d78f	Thyroid	18	76A6F76D-F33E-4B4A-B0EE-FB863345F194	4336BC49-7D28-4EB6-8B41-F43127ED8EC1	TCGA-FE-A233-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A233	TCGA-THCA	NA	s12758	Harvard Medical School	Ohio State University	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cd82	58cfa831e4b0c9d6adf6cd82	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted.bam	73.25	2.05	0.17	58cfa831e4b0c9d6adf6cd82	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A230-01A	B1D71782-2443-43F3-BD0E-8B7220515CB6	Primary Tumor	Illumina HiSeq	5aeaadf5-f228-4383-97ce-9048120f8b41	Thyroid	30	12FC3F30-08FB-47C6-92F1-009D961C1E94	001C6478-B20D-40D8-AF62-C45C64269129	TCGA-FE-A230-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A230	TCGA-THCA	NA	s12389	Harvard Medical School	Ohio State University	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cdcc	58cfa831e4b0c9d6adf6cdcc	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted.bam	86.7	1.9	0.16	58cfa831e4b0c9d6adf6cdcc	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6689-01A	8D07B1E8-5D1D-4A43-B616-D29DD58CE5FE	Primary Tumor	Illumina HiSeq	9e07a7ab-1033-43c4-a4f4-49ba35319fea	Brain	30	D81C3F19-BBCF-4071-8BA4-CB8C505307D7	2FD05E93-48E8-460E-80E0-C3262EAEE72B	TCGA-FG-6689-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6689	TCGA-LGG	NA	s8144	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6cdca	58cfa831e4b0c9d6adf6cdca	TCGA-FG-6692-10A-01D-1891_130923_SN1222_0220_BC2DUUACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FG-6692-10A-01D-1891_130923_SN1222_0220_BC2DUUACXX_s_2_rg.sorted	TCGA-FG-6692-10A-01D-1891_130923_SN1222_0220_BC2DUUACXX_s_2_rg.sorted.bam	278.3	1.9	0.14	58cfa831e4b0c9d6adf6cdca	TCGA-FG-6692-10A-01D-1891_130923_SN1222_0220_BC2DUUACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6692-10A	5F10CD91-1E03-4016-B35A-8629A1A8FCC9	Blood Derived Normal	Illumina HiSeq	08012a5a-0f7a-4f6e-92cf-b1878218e33c	Brain	63	D7EA0C8C-8642-4491-982E-6FC30D6D9237	C8066486-BC5A-4D91-B766-437C0A491304	TCGA-FG-6692-10A-01D-1891-02	HG19_Broad_variant	TCGA-FG-6692	TCGA-LGG	NA	s8369	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6cdf4	58cfa831e4b0c9d6adf6cdf4	TCGA-FS-A1YW-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FS-A1YW-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_8_rg.sorted	TCGA-FS-A1YW-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_8_rg.sorted.bam	46.15	NA	0.15	58cfa831e4b0c9d6adf6cdf4	TCGA-FS-A1YW-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1YW-10A	57DD4D65-CFAD-4533-92B4-90742289603B	Blood Derived Normal	Illumina HiSeq	fe104857-b150-4f94-8725-1ab7b8430b73	Skin	52	CFFED28D-93D2-4DCA-8B34-4F3B87858133	4577BE4B-3CA2-48A1-82B2-6CB50E1DABA3	TCGA-FS-A1YW-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1YW	TCGA-SKCM	6598	s7363	Harvard Medical School	Essen	Germany	NO	T1b	N0	Not available	Stage IB	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6ce20	58cfa832e4b0c9d6adf6ce20	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted.bam	62.7	2	0.17	58cfa832e4b0c9d6adf6ce20	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6688-01A	DADD7428-9E4D-4652-9469-AB521B88D529	Primary Tumor	Illumina HiSeq	3b45431a-1066-4467-bc8a-f1aa3342c5f0	Brain	59	8594744F-F317-4022-991B-21891DA7F80A	5977877C-7B55-4666-AC08-54FEF233FB2F	TCGA-FG-6688-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6688	TCGA-LGG	NA	s8570	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6cbe1	58cfa831e4b0c9d6adf6cbe1	TCGA-EE-A29P-06A-11D-A18Y_120729_SN1120_0180_BC1176ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EE-A29P-06A-11D-A18Y_120729_SN1120_0180_BC1176ACXX_s_2_rg.sorted	TCGA-EE-A29P-06A-11D-A18Y_120729_SN1120_0180_BC1176ACXX_s_2_rg.sorted.bam	56.49	NA	0.16	58cfa831e4b0c9d6adf6cbe1	TCGA-EE-A29P-06A-11D-A18Y_120729_SN1120_0180_BC1176ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29P-06A	FD1A49F2-FB3B-481D-888E-F4224D59F6D1	Metastatic	Illumina HiSeq	54534e99-c9b7-483e-aa8e-c9fd9fa41058	Skin	73	EC3CFAD3-2825-4BCC-B524-48282C546D80	27389E3E-4A1A-4628-9AA0-02B5B684DBF7	TCGA-EE-A29P-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29P	TCGA-SKCM	NA	s7846	Harvard Medical School	University of Sydney	Australia	NO	T4b	N0	Not available	Stage IIC	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6ceb5	58cfa832e4b0c9d6adf6ceb5	TCGA-EM-A1YA-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EM-A1YA-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_5_rg.sorted	TCGA-EM-A1YA-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_5_rg.sorted.bam	91.22	1.84	0.16	58cfa832e4b0c9d6adf6ceb5	TCGA-EM-A1YA-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YA-10A	567E4D90-5C5A-44F0-A462-90C831F3C096	Blood Derived Normal	Illumina HiSeq	d9bc79ac-a106-484a-88cf-2401b2a13b25	Thyroid	74	B823CFE2-8FC2-411E-BEED-92165341AC2F	1F7C16DC-32BA-4DBE-A864-AADCE33B9EC4	TCGA-EM-A1YA-10A-01D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YA	TCGA-THCA	NA	s12380	Harvard Medical School	University Health Network	Canada	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6ce97	58cfa832e4b0c9d6adf6ce97	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted.bam	40.86	NA	0.15	58cfa832e4b0c9d6adf6ce97	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EF-01A	2A142731-119C-495D-AD30-EB0B48BACB46	Primary Tumor	Illumina HiSeq	ac16538b-bd5d-496e-bccc-6f3374d226c6	Bladder	50	981F581E-32AF-486B-9B60-0C8F1047C879	CE2F4DE7-C8AE-4103-8084-5F783B1087A7	TCGA-G2-A2EF-01A-12D-A18D-02	HG19_Broad_variant	TCGA-G2-A2EF	TCGA-BLCA	NA	s3118	Harvard Medical School	MD Anderson	United States	NO	Not available	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A18D-02	TRUE
13722.58cfa832e4b0c9d6adf6cedf	58cfa832e4b0c9d6adf6cedf	TCGA-EM-A1YD-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EM-A1YD-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_5_rg.sorted	TCGA-EM-A1YD-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_5_rg.sorted.bam	41.17	1.98	0.17	58cfa832e4b0c9d6adf6cedf	TCGA-EM-A1YD-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YD-01A	8A3659A8-2A85-4BAB-8BF3-55795922474C	Primary Tumor	Illumina HiSeq	76d6fe1c-fb49-412c-bf6f-43229f7b7df6	Thyroid	53	AD5054BB-96D0-47CC-BB8C-F36E58784A31	CD27AF7E-F458-49BA-8C82-D18BDE252DB2	TCGA-EM-A1YD-01A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YD	TCGA-THCA	NA	s12381	Harvard Medical School	University Health Network	Canada	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6cec8	58cfa832e4b0c9d6adf6cec8	TCGA-EM-A1CW-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EM-A1CW-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_8_rg.sorted	TCGA-EM-A1CW-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_8_rg.sorted.bam	52.41	2	0.16	58cfa832e4b0c9d6adf6cec8	TCGA-EM-A1CW-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_8_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CW-10A	22EB9F00-6869-4D8F-B657-DFD64F81E9E9	Blood Derived Normal	Illumina HiSeq	b7ca46ef-71df-40f8-a10f-e27c97112b79	Thyroid	39	F4C14A19-949F-410C-9FC9-D81CBBA2D0B7	40DD4E1B-1BB2-47C1-A3AB-8F6D66FD12FF	TCGA-EM-A1CW-10A-01D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CW	TCGA-THCA	NA	s12756	Harvard Medical School	University Health Network	Canada	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A13U-02	TRUE
13722.58cfa832e4b0c9d6adf6cf68	58cfa832e4b0c9d6adf6cf68	TCGA-G9-6384-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G9-6384-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_6_rg.sorted	TCGA-G9-6384-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_6_rg.sorted.bam	43.7	1.9	0.13	58cfa832e4b0c9d6adf6cf68	TCGA-G9-6384-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6384-10A	A279D5AA-51F7-4E75-9E14-B206B97EC4BD	Blood Derived Normal	Illumina HiSeq	723bbf9b-83eb-429b-ae56-ab0fce6478b2	Prostate	53	FD710149-273E-455D-BFB6-C5EE4849D370	4A6911E9-EF41-4A88-B0C4-BD34DFB1CEB2	TCGA-G9-6384-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6384	TCGA-PRAD	NA	s3458	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf0c	58cfa832e4b0c9d6adf6cf0c	TCGA-FS-A1ZC-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FS-A1ZC-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_7_rg.sorted	TCGA-FS-A1ZC-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_7_rg.sorted.bam	30.03	NA	0.16	58cfa832e4b0c9d6adf6cf0c	TCGA-FS-A1ZC-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZC-10A	B1739CB5-09BC-414A-8F05-C66D2CB9868D	Blood Derived Normal	Illumina HiSeq	05f8afcc-0825-4cb1-b5fa-c947afc82409	Skin	51	A4CC2293-5B42-469C-960E-4BC3770C9E9C	45B62C9F-DD93-4A8C-BEED-384E3A6A5A58	TCGA-FS-A1ZC-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZC	TCGA-SKCM	10870	s7529	Harvard Medical School	Essen	Germany	NO	TX	N0	Not available	I or II NOS	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf91	58cfa832e4b0c9d6adf6cf91	TCGA-G9-6365-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6365-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_1_rg.sorted	TCGA-G9-6365-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_1_rg.sorted.bam	59.4	1.9	0.17	58cfa832e4b0c9d6adf6cf91	TCGA-G9-6365-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6365-01A	6845076E-E940-4437-8618-81DB4A447544	Primary Tumor	Illumina HiSeq	9d7979c6-8197-4347-806d-4bb667d5cb2b	Prostate	71	95D6E1D3-91C1-40E5-986D-1C5ABB33A03F	CD30C4FA-8BBF-4A8A-A1F7-4FA0D45CA380	TCGA-G9-6365-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6365	TCGA-PRAD	NA	s3973	Harvard Medical School	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf6e	58cfa832e4b0c9d6adf6cf6e	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted.bam	146.4	1.9	0.15	58cfa832e4b0c9d6adf6cf6e	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6384-01A	A279D5AA-51F7-4E75-9E14-B206B97EC4BD	Primary Tumor	Illumina HiSeq	75df59ac-7525-45fc-843a-5210bd036dca	Prostate	53	1ABCBE00-5A6F-4E0F-A61C-D158545C2293	1F750885-56C4-4953-8D22-BC7719F57F9F	TCGA-G9-6384-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6384	TCGA-PRAD	NA	s4152	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cfbc	58cfa832e4b0c9d6adf6cfbc	TCGA-G9-6496-10A-01D-1784_130131_SN1120_0234_AD1PVUACXX_s_4_rg.sorted.filtered.	WGS	TCGA-G9-6496-10A-01D-1784_130131_SN1120_0234_AD1PVUACXX_s_4_rg.sorted	TCGA-G9-6496-10A-01D-1784_130131_SN1120_0234_AD1PVUACXX_s_4_rg.sorted.bam	29.7	1.8	0.14	58cfa832e4b0c9d6adf6cfbc	TCGA-G9-6496-10A-01D-1784_130131_SN1120_0234_AD1PVUACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6496-10A	CE2B7E17-424E-4954-8A68-19D7F98D2E7E	Blood Derived Normal	Illumina HiSeq	6bf8c890-7563-4945-80e3-504f41b07661	Prostate	61	EA48E760-6854-4397-9FF3-39740419DEC7	46FECAD7-A6C0-49D5-B8CC-ED2F81C0C16E	TCGA-G9-6496-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6496	TCGA-PRAD	NA	s3457	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6d0a8	58cfa832e4b0c9d6adf6d0a8	TCGA-FS-A1Z0-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FS-A1Z0-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_5_rg.sorted	TCGA-FS-A1Z0-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_5_rg.sorted.bam	37.19	NA	0.16	58cfa832e4b0c9d6adf6d0a8	TCGA-FS-A1Z0-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1Z0-10A	6A1966C3-7F01-4304-B4A1-C4EF683B179A	Blood Derived Normal	Illumina HiSeq	3e0779ab-0f7e-470a-8d69-255e5d4fb90b	Skin	32	56E023E3-67FD-4361-8BA5-79B69EFA4EBC	28CD8467-DF08-4AE9-B50A-F7C7ED3F60F3	TCGA-FS-A1Z0-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1Z0	TCGA-SKCM	6164	s7526	Harvard Medical School	Essen	Germany	NO	T1a	N0	Not available	Stage IA	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d1f8	58cfa832e4b0c9d6adf6d1f8	TCGA-G9-6373-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_2_rg.sorted.filtered.	WGS	TCGA-G9-6373-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_2_rg.sorted	TCGA-G9-6373-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_2_rg.sorted.bam	37.7	1.8	0.13	58cfa832e4b0c9d6adf6d1f8	TCGA-G9-6373-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6373-10A	C3A509C6-35A6-4D17-A9FD-0AA8884B33A0	Blood Derived Normal	Illumina HiSeq	245d306c-0874-4b09-84db-125f16769148	Prostate	68	F4291A83-98AD-4FDD-91C3-AE2FB206015E	E41F9C47-07AA-4B54-AE7C-8B0F58EAB483	TCGA-G9-6373-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6373	TCGA-PRAD	NA	s3802	Harvard Medical School	Roswell Park	United States	NO	T3a	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6d008	58cfa832e4b0c9d6adf6d008	TCGA-FS-A1YY-06A-11D-A18Y_120718_SN1222_0127_BD147HACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FS-A1YY-06A-11D-A18Y_120718_SN1222_0127_BD147HACXX_s_2_rg.sorted	TCGA-FS-A1YY-06A-11D-A18Y_120718_SN1222_0127_BD147HACXX_s_2_rg.sorted.bam	37.95	NA	0.17	58cfa832e4b0c9d6adf6d008	TCGA-FS-A1YY-06A-11D-A18Y_120718_SN1222_0127_BD147HACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1YY-06A	C3A8881B-70F8-402C-AC75-1CC49FCA4E87	Metastatic	Illumina HiSeq	4c946768-7b87-4e7f-97eb-e35ca0ffdd80	Skin	55	877D00AD-E477-4EF6-9D32-9244EC62F0E5	26E8EBFA-B65D-4860-8B9A-B558ACE4F45B	TCGA-FS-A1YY-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1YY	TCGA-SKCM	6953	s8024	Harvard Medical School	Essen	Germany	NO	T3a	N0	Not available	Stage IIA	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cf41	58cfa832e4b0c9d6adf6cf41	TCGA-FS-A1ZR-06A-21D-A18Y_120602_SN208_0304_BC0WTWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FS-A1ZR-06A-21D-A18Y_120602_SN208_0304_BC0WTWACXX_s_7_rg.sorted	TCGA-FS-A1ZR-06A-21D-A18Y_120602_SN208_0304_BC0WTWACXX_s_7_rg.sorted.bam	45.28	NA	0.16	58cfa832e4b0c9d6adf6cf41	TCGA-FS-A1ZR-06A-21D-A18Y_120602_SN208_0304_BC0WTWACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZR-06A	9F4DDE50-FA0C-43BF-8D5D-70B76CC35793	Metastatic	Illumina HiSeq	3dc9427b-527d-465c-bfd9-7593de78af96	Skin	36	4EEC8951-5B1B-4881-BBC9-2B4C2C4FCD16	62E364ED-D71C-41D9-9C7C-04CC844CE8AE	TCGA-FS-A1ZR-06A-21D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZR	TCGA-SKCM	347	s8031	Harvard Medical School	Essen	Germany	NO	T2	N0	Not available	Stage II	A18Y-02	TRUE
13722.58cfa82ee4b0c9d6adf6af9a	58cfa82ee4b0c9d6adf6af9a	TCGA-05-4396-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_2_rg.sorted.filtered.	WGS	TCGA-05-4396-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_2_rg.sorted	TCGA-05-4396-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_2_rg.sorted.bam	73	1.9	0.14	58cfa82ee4b0c9d6adf6af9a	TCGA-05-4396-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_2_rg.sorted.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4396-10A	9F81C602-8AFA-4588-B0B6-6E5A1A128D5A	Blood Derived Normal	Illumina HiSeq	65a4aa5b-a7ca-4c50-a08f-ef176cfb2ff3	Lung	76	329954AA-6B53-4356-9429-09DD91CEA2C5	21900785-5668-4654-B046-19D1F2FA1674	TCGA-05-4396-10A-01D-1853-02	HG19_Broad_variant	TCGA-05-4396	TCGA-LUAD	303	s10772	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1853-02	TRUE
13722.58cfa82ee4b0c9d6adf6afea	58cfa82ee4b0c9d6adf6afea	TCGA-05-4430-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-05-4430-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_5_rg.sorted	TCGA-05-4430-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_5_rg.sorted.bam	81.9	1.9	0.14	58cfa82ee4b0c9d6adf6afea	TCGA-05-4430-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4430-10A	3A23CDB5-2327-45AC-B0B5-D4AFE038C757	Blood Derived Normal	Illumina HiSeq	794fbc75-e590-4df0-9b98-9e113eef5c46	Lung	59	39E4B10A-F05F-4EE7-85FE-700924C5507A	2EB474B5-5E99-4041-BFD3-7A50F1CA9136	TCGA-05-4430-10A-01D-1203-02	HG19_Broad_variant	TCGA-05-4430	TCGA-LUAD	NA	s10774	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6aff0	58cfa82ee4b0c9d6adf6aff0	TCGA-05-4434-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4434-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_1_rg.sorted	TCGA-05-4434-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_1_rg.sorted.bam	30	1.9	0.16	58cfa82ee4b0c9d6adf6aff0	TCGA-05-4434-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_1_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4434-10A	D94FE32F-BEDD-4F4C-9FEB-FCB60D40F4BB	Blood Derived Normal	Illumina HiSeq	9a0b4c83-372f-4226-889a-a732c74385ac	Lung	67	FE65992A-E982-44B2-BD53-D714C17A5E4A	8B98B536-3F48-4FA0-8FDB-EC787499CBD5	TCGA-05-4434-10A-01D-1203-02	HG19_Broad_variant	TCGA-05-4434	TCGA-LUAD	457	s11224	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Lung Adenocarcinoma Mixed Subtype	Stage IV	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6b001	58cfa82ee4b0c9d6adf6b001	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted.bam	342.2	1.9	0.15	58cfa82ee4b0c9d6adf6b001	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4430-01A	3A23CDB5-2327-45AC-B0B5-D4AFE038C757	Primary Tumor	Illumina HiSeq	e4ae6498-889f-4900-a73c-2e61a6e154d1	Lung	59	122AAA4F-8FD5-4C41-BFF8-8A45BDFB3F81	C14A77D1-DB59-434E-BD3C-DBBE647D790C	TCGA-05-4430-01A-02D-1203-02	HG19_Broad_variant	TCGA-05-4430	TCGA-LUAD	NA	s10646	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6b020	58cfa82ee4b0c9d6adf6b020	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted.bam	306.53	1.9	0.14	58cfa82ee4b0c9d6adf6b020	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4432-01A	E737F650-B72D-44E7-B750-558A56716803	Primary Tumor	Illumina HiSeq	6110bc85-6f14-48d5-b166-2b3f42776573	Lung	66	2A675528-1ABC-4220-A61A-25109850CE0D	A4E437A5-1603-4AE4-89C2-CD741FDE5015	TCGA-05-4432-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4432	TCGA-LUAD	NA	s11334	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b676	58cfa82fe4b0c9d6adf6b676	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	375.23	1.9	0.16	58cfa82fe4b0c9d6adf6b676	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4666-01A	4C31127E-D095-4978-9DAC-35153C27F6ED	Primary Tumor	Illumina HiSeq	7af89597-2a6c-4030-acf6-4bd33963a3f3	Lung	52	5BAE2E45-6DBC-458C-A66F-702EB1AF7357	AC0D75F8-B4C5-40A8-9044-0B74722424D8	TCGA-73-4666-01A-01D-1203-02	GRCh37	TCGA-73-4666	TCGA-LUAD	NA	s11461	Harvard Medical School	Roswell Park	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b678	58cfa82fe4b0c9d6adf6b678	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	343.9	1.9	0.16	58cfa82fe4b0c9d6adf6b678	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4670-01A	1B354837-4925-4480-AC32-6B44D0957314	Primary Tumor	Illumina HiSeq	8e4449ab-641c-44ea-af17-a681182f7299	Lung	69	646402AF-BA5F-438C-AE63-213EBD58B16D	D2FFA731-14A2-4A83-964E-C9969080263C	TCGA-73-4670-01A-01D-1203-02	GRCh37	TCGA-73-4670	TCGA-LUAD	NA	s11356	Harvard Medical School	Roswell Park	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b68e	58cfa82fe4b0c9d6adf6b68e	TCGA-38-4628-11A-01D-1203_120305_SN1120_0119_BD0REAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-38-4628-11A-01D-1203_120305_SN1120_0119_BD0REAACXX_s_7_rg.sorted	TCGA-38-4628-11A-01D-1203_120305_SN1120_0119_BD0REAACXX_s_7_rg.sorted.bam	97.53	1.9	0.15	58cfa82fe4b0c9d6adf6b68e	TCGA-38-4628-11A-01D-1203_120305_SN1120_0119_BD0REAACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4628-11A	CC4BD56A-25C5-4C48-B583-AC3AEB778CA6	Solid Tissue Normal	Illumina HiSeq	afa5b5e6-b6c7-42c3-9267-97e6d760c86c	Lung	65	CB638069-0750-4BA1-BB4E-A2EE25DCA5FF	F3E003F8-BD6F-4262-AE8E-BB45F1DABBE6	TCGA-38-4628-11A-01D-1203-02	HG19_Broad_variant	TCGA-38-4628	TCGA-LUAD	1492	s11118	Harvard Medical School	UNC	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6e2	58cfa82fe4b0c9d6adf6b6e2	TCGA-64-5775-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-64-5775-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_2_rg.sorted	TCGA-64-5775-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_2_rg.sorted.bam	85.4	1.9	0.13	58cfa82fe4b0c9d6adf6b6e2	TCGA-64-5775-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5775-10A	C8544FB3-B26E-4672-BB81-A271DB724B04	Blood Derived Normal	Illumina HiSeq	e35e2779-31f7-418f-8ed1-52c4af96d40c	Lung	71	EB99A1B7-D1A5-4C22-BC7C-C97CC57F664D	0141AC27-5124-4127-9B84-D3B01F37618B	TCGA-64-5775-10A-01D-1623-02	HG19_Broad_variant	TCGA-64-5775	TCGA-LUAD	62	s10797	Harvard Medical School	Fox Chase	United States	NO	T4	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6f6	58cfa82fe4b0c9d6adf6b6f6	TCGA-50-6591-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-50-6591-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_5_rg.sorted	TCGA-50-6591-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_5_rg.sorted.bam	351.4	1.8	0.14	58cfa82fe4b0c9d6adf6b6f6	TCGA-50-6591-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6591-01A	9B132E4F-7E35-4CC5-8711-43AD62B906D0	Primary Tumor	Illumina HiSeq	c1731efd-11ec-47b9-bb3c-32eab31d3552	Lung	63	0791E7AA-E97C-4DD0-9615-09EC7090F684	C57EF4F0-5BE8-4761-9763-5052EFDFD7D5	TCGA-50-6591-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-6591	TCGA-LUAD	119	s10784	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b764	58cfa82fe4b0c9d6adf6b764	TCGA-64-5778-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-64-5778-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_4_rg.sorted	TCGA-64-5778-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_4_rg.sorted.bam	181.4	1.9	0.14	58cfa82fe4b0c9d6adf6b764	TCGA-64-5778-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5778-10A	8FDBD88F-19AE-4AB8-BCD7-6BFA1BBDE742	Blood Derived Normal	Illumina HiSeq	daa71055-8f7e-4087-850f-1669fc21e1dd	Lung	60	71FC99BF-0BE2-44E2-B3DD-E000EF28734A	C48A8170-9BD1-4084-836C-933C79ABDDFC	TCGA-64-5778-10A-01D-1623-02	HG19_Broad_variant	TCGA-64-5778	TCGA-LUAD	NA	s11248	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Bronchioloalveolar Carcinoma Nonmucinous	Stage IB	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b834	58cfa82fe4b0c9d6adf6b834	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.bam	85.83	2.23	0.16	58cfa82fe4b0c9d6adf6b834	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0RA-01A	AFD710B8-D172-4AC4-9973-E969DB1ED231	Primary Tumor	Illumina HiSeq	d644ff0f-6dc7-4922-a46d-3223823e8118	Uterus	68	4ED231EE-0E54-4AC5-8278-1061AD3972A2	01EFCC42-CCFA-4D41-87BE-CA8F1C551823	TCGA-A5-A0RA-01A-21D-A101-02	HG19_Broad_variant	TCGA-A5-A0RA	TCGA-UCEC	NA	s5195	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82fe4b0c9d6adf6b84e	58cfa82fe4b0c9d6adf6b84e	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.filtered.	WGS	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.bam	80.74	2.11	0.16	58cfa82fe4b0c9d6adf6b84e	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R8-01A	06D16B6B-9CA6-4CEC-A785-F27AA4323CEC	Primary Tumor	Illumina HiSeq	ed11d53d-5cbb-44e2-b4d2-1603cef4ec13	Uterus	81	5B5CC2BA-6A10-4279-A0AA-8DDAE94D56EA	289CE7E4-AF92-4857-9D07-7CF334C40542	TCGA-A5-A0R8-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R8	TCGA-UCEC	NA	s4420	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82fe4b0c9d6adf6b86c	58cfa82fe4b0c9d6adf6b86c	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.bam	77.93	2.03	0.16	58cfa82fe4b0c9d6adf6b86c	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0VP-01A	2DB0FB62-64CE-457C-9E22-DD05EF59F684	Primary Tumor	Illumina HiSeq	26cc510d-e8a9-4782-9488-478373dbc1df	Uterus	74	F1FBE4AC-F3FD-4609-9A2B-507820ABE77E	E23FE404-0449-453D-971C-6E940B546119	TCGA-A5-A0VP-01A-21D-A101-02	HG19_Broad_variant	TCGA-A5-A0VP	TCGA-UCEC	NA	s4992	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82fe4b0c9d6adf6b876	58cfa82fe4b0c9d6adf6b876	TCGA-A6-2678-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2678-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2678-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	275.56	1.9	0.14	58cfa82fe4b0c9d6adf6b876	TCGA-A6-2678-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2678-10A	3A785E32-7960-4C72-84C4-FB42C4DD86F1	Blood Derived Normal	Illumina HiSeq	49b530ed-0c02-4603-9fe8-fcca89de8079	Colorectal	43	D010B8B9-6926-4ADB-A0F8-7613A5325C92	1CEE58FF-C097-408F-B6DF-EA79482C80F7	TCGA-A6-2678-10A-01D-1167-02	HG18	TCGA-A6-2678	TCGA-COAD	NA	s13658	Harvard Medical School	Christiana Healthcare	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b87d	58cfa82fe4b0c9d6adf6b87d	TCGA-A6-2680-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2680-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2680-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	161	1.9	0.15	58cfa82fe4b0c9d6adf6b87d	TCGA-A6-2680-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2680-10A	FF1407C6-9174-4BAE-A19B-D34CA71B898C	Blood Derived Normal	Illumina HiSeq	516bf47a-48a2-4f0d-af51-c876cfa2f44a	Colorectal	72	9A6C98F6-F3B0-4BB7-9825-ED33C33C33D0	4AB3A66F-319D-435E-84DA-2302950C6A04	TCGA-A6-2680-10A-01D-1405-02	HG18	TCGA-A6-2680	TCGA-COAD	NA	s12859	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b882	58cfa82fe4b0c9d6adf6b882	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	493.29	1.9	0.15	58cfa82fe4b0c9d6adf6b882	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2678-01A	3A785E32-7960-4C72-84C4-FB42C4DD86F1	Primary Tumor	Illumina HiSeq	31675676-aba0-4d34-a2dc-0356129ceaa2	Colorectal	43	20ECCD8A-DFAF-40E4-8128-D77AA41680C4	83E77250-E68B-4ECA-9592-4424151E0D79	TCGA-A6-2678-01A-01D-1167-02	HG18	TCGA-A6-2678	TCGA-COAD	NA	s12856	Harvard Medical School	Christiana Healthcare	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b892	58cfa82fe4b0c9d6adf6b892	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	308	1.9	0.15	58cfa82fe4b0c9d6adf6b892	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2681-01A	7D8EAB0A-E6C8-4449-9EBF-50C41DB94A06	Primary Tumor	Illumina HiSeq	eda754a1-3a13-47a5-8e0e-49ef1384646d	Colorectal	73	0537BAD8-0E85-4B05-91B3-FD965E96D0D7	BFF8CDA3-3C4B-416F-AF46-6811B139D670	TCGA-A6-2681-01A-01D-1405-02	HG18	TCGA-A6-2681	TCGA-COAD	NA	s12860	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8a1	58cfa82fe4b0c9d6adf6b8a1	TCGA-50-5051-10A-01D-1853_120322_SN208_0277_AD0PL1ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-50-5051-10A-01D-1853_120322_SN208_0277_AD0PL1ACXX_s_8_rg.sorted	TCGA-50-5051-10A-01D-1853_120322_SN208_0277_AD0PL1ACXX_s_8_rg.sorted.bam	125	1.9	0.15	58cfa82fe4b0c9d6adf6b8a1	TCGA-50-5051-10A-01D-1853_120322_SN208_0277_AD0PL1ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5051-10A	E1C55BAC-BB41-4964-ADD5-ECD6BA04B58D	Blood Derived Normal	Illumina HiSeq	8d384520-9763-4a0c-ba5d-b99274779d43	Lung	42	1895845D-5A35-42A4-A721-CDF7AF2DE35D	03DB87CD-5705-4F69-AE8A-D3DF5310B8DD	TCGA-50-5051-10A-01D-1853-02	HG19_Broad_variant	TCGA-50-5051	TCGA-LUAD	NA	s11239	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8cc	58cfa82fe4b0c9d6adf6b8cc	TCGA-49-4501-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4501-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4501-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	199.2	1.9	0.16	58cfa82fe4b0c9d6adf6b8cc	TCGA-49-4501-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4501-11A	0780EB43-D5B5-4C3D-9825-BEACBA5CC723	Solid Tissue Normal	Illumina HiSeq	2e94d307-de8c-4849-a870-8731a029c297	Lung	67	21AC5886-832B-4352-95D2-0147F90423CC	CE4FA727-5E58-4C07-921C-2C3B9BC509DB	TCGA-49-4501-11A-01D-1203-02	GRCh37	TCGA-49-4501	TCGA-LUAD	1421	s10905	Harvard Medical School	Johns Hopkins	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b900	58cfa82fe4b0c9d6adf6b900	TCGA-73-4675-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4675-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4675-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	90.2	1.9	0.15	58cfa82fe4b0c9d6adf6b900	TCGA-73-4675-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4675-11A	AE39E358-08D7-4367-AE68-82B469E791E4	Solid Tissue Normal	Illumina HiSeq	5c0c01fd-bde7-41d5-ab01-78909043c0fe	Lung	59	F422BC11-2BEC-4E61-AA7E-384B157A83F7	5BA6E146-2BE0-4F81-B023-7C53B8408113	TCGA-73-4675-11A-01D-1203-02	GRCh37	TCGA-73-4675	TCGA-LUAD	NA	s11012	Harvard Medical School	Roswell Park	United States	NO	T3	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b93e	58cfa82fe4b0c9d6adf6b93e	TCGA-AA-3861-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3861-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3861-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	101.56	1.9	0.15	58cfa82fe4b0c9d6adf6b93e	TCGA-AA-3861-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3861-10A	5DA56982-6DE7-4994-AA9E-3B01200B2959	Blood Derived Normal	Illumina HiSeq	51e1be67-574c-47ee-9d7f-9f7f081cdd0e	Colorectal	72	51992867-495A-41A3-B708-311F08B6981F	479CE743-8C57-4B91-98BA-A36F2B526CAE	TCGA-AA-3861-10A-01D-1167-02	HG18	TCGA-AA-3861	TCGA-COAD	NA	s13520	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b95c	58cfa82fe4b0c9d6adf6b95c	TCGA-AA-3549-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3549-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3549-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	54.56	1.9	0.14	58cfa82fe4b0c9d6adf6b95c	TCGA-AA-3549-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3549-10A	E6EC5A68-7555-4F26-BD7E-9CDB4C5F7004	Blood Derived Normal	Illumina HiSeq	6ae6ef34-eb3e-417d-8adc-ab3a6979baaa	Colorectal	69	5FCA30B8-1C68-4449-8070-CE5127CB0BFA	D1D611E2-C8EA-4FC5-9B12-6603CB932F3E	TCGA-AA-3549-10A-01D-1167-02	HG18	TCGA-AA-3549	TCGA-COAD	NA	s13184	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b95e	58cfa82fe4b0c9d6adf6b95e	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	628.56	1.9	0.16	58cfa82fe4b0c9d6adf6b95e	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3548-01A	2DCED66C-1F0D-4039-A5E5-54CCA77C16E9	Primary Tumor	Illumina HiSeq	362e7b19-891a-4eba-9cba-97d157a94152	Colorectal	71	633AFC4C-4A35-420E-9CE6-FF4670E28395	B5E87744-9963-4DBA-84C8-B61048169517	TCGA-AA-3548-01A-01D-1167-02	HG18	TCGA-AA-3548	TCGA-COAD	NA	s13669	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b965	58cfa82fe4b0c9d6adf6b965	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole.bam	109.29	1.9	0.13	58cfa82fe4b0c9d6adf6b965	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3529-01A	BFB07784-693B-4C25-874E-4AD6E04A5D46	Primary Tumor	Illumina HiSeq	8d96c289-9e08-45f8-a5dc-8c089ca7eb93	Colorectal	78	B083E3CB-0AF1-44EA-854D-85FD99B75AD5	B8C9B915-BD7E-41FA-B5E1-4A28478EDC6E	TCGA-AA-3529-01A-02D-1547-02	HG18	TCGA-AA-3529	TCGA-COAD	0	s13364	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1547-02	FALSE
13722.58cfa82fe4b0c9d6adf6b97e	58cfa82fe4b0c9d6adf6b97e	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	353.96	1.9	0.15	58cfa82fe4b0c9d6adf6b97e	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3681-01A	ABB0D53F-F74E-45DC-8FBB-40863016F3C6	Primary Tumor	Illumina HiSeq	4a7f8872-1280-4a05-8448-a62ee6de1108	Colorectal	77	190FECAB-1EF1-43FA-87A2-104014EB2CE2	85305E56-627C-4471-BD16-6818AD3751C2	TCGA-AA-3681-01A-01D-1637-02	HG18	TCGA-AA-3681	TCGA-COAD	NA	s13029	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	1637-02	FALSE
13722.58cfa82fe4b0c9d6adf6b982	58cfa82fe4b0c9d6adf6b982	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	294	1.9	0.15	58cfa82fe4b0c9d6adf6b982	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3861-01A	5DA56982-6DE7-4994-AA9E-3B01200B2959	Primary Tumor	Illumina HiSeq	041d683a-798a-4869-a98d-b7abfe977709	Colorectal	72	390070D8-EF9B-46FE-93EE-9CF01A642A92	3FF478FA-97AF-4122-AC93-1BF1DD21BCB3	TCGA-AA-3861-01A-01D-1167-02	HG18	TCGA-AA-3861	TCGA-COAD	NA	s13186	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba21	58cfa82fe4b0c9d6adf6ba21	TCGA-AA-3666-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3666-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3666-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	81.96	1.9	0.15	58cfa82fe4b0c9d6adf6ba21	TCGA-AA-3666-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3666-10A	A512701F-88BB-4B05-8C94-FD285B9DD13E	Blood Derived Normal	Illumina HiSeq	58cda208-4b02-4391-9361-09d9fb432ba9	Colorectal	68	F181B2C2-6FB2-4B7D-8C6B-A198EEE941FB	E48DCD11-E4C2-40AA-98C9-5CFE97E37E4F	TCGA-AA-3666-10A-01D-1167-02	HG18	TCGA-AA-3666	TCGA-COAD	61	s13026	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6ba6c	58cfa830e4b0c9d6adf6ba6c	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	113.85	1.65	0.15	58cfa830e4b0c9d6adf6ba6c	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A010-01A	0712566E-3371-4715-95F1-5B792E72D758	Primary Tumor	Illumina HiSeq	ea0e92bb-7617-4183-82be-773e8cc15dca	Colorectal	46	46FB1711-E385-49A4-BF15-7990123CBE6B	30FCD977-8C62-4925-BC84-5894A12BABDB	TCGA-AA-A010-01A-01D-A077-02	HG18	TCGA-AA-A010	TCGA-COAD	NA	s13200	Harvard Medical School	Indivumed	Germany	NO	T4	N0	Colon Adenocarcinoma	Stage IIB	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6bb80	58cfa830e4b0c9d6adf6bb80	TCGA-AA-3812-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3812-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3812-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	50.96	1.9	0.15	58cfa830e4b0c9d6adf6bb80	TCGA-AA-3812-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3812-10A	4563E4E0-A661-46DE-AD25-9C86A621E147	Blood Derived Normal	Illumina HiSeq	c10599a7-29dd-4112-9b47-0d65eac9945f	Colorectal	82	B8FE759F-F298-4AEB-AC2A-689D0586AF55	F85C5073-4043-4E77-A48D-CBA0EC45FE88	TCGA-AA-3812-10A-01D-1167-02	HG18	TCGA-AA-3812	TCGA-COAD	NA	s13378	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bbe4	58cfa830e4b0c9d6adf6bbe4	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted.bam	228.5	1.72	0.15	58cfa830e4b0c9d6adf6bbe4	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A002-01A	CB005C69-7301-41CE-B534-C9751F1436C5	Primary Tumor	Illumina HiSeq	90021059-77d3-4362-9cc9-f14fcfba46c9	Colorectal	35	B918B56C-5C78-4CEE-85A7-7C88501E88AD	901C5D59-CE0A-44AE-91AE-9C253E99B68E	TCGA-AG-A002-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A002	TCGA-READ	NA	s1991	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6c060	58cfa830e4b0c9d6adf6c060	TCGA-AG-4001-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4001-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4001-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	15.59	1.9	0.16	58cfa830e4b0c9d6adf6c060	TCGA-AG-4001-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4001-10A	D846228F-67AF-4B3B-9796-DBC263C2054C	Blood Derived Normal	Illumina HiSeq	0ada69d2-8f3d-4a5c-b254-7da0555e380f	Colorectal	74	1E7AC47A-A3DA-49BC-9871-6BE154A0014E	D5159D6F-6342-4D19-B7F2-35301995017A	TCGA-AG-4001-10A-01D-1115-02	HG18	TCGA-AG-4001	TCGA-READ	NA	s2162	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa831e4b0c9d6adf6c51f	58cfa831e4b0c9d6adf6c51f	TCGA-CM-4747-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4747-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4747-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	64.72	1.9	0.14	58cfa831e4b0c9d6adf6c51f	TCGA-CM-4747-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4747-10A	56EB96A4-D2C2-42FB-B26C-1A80012BCB8E	Blood Derived Normal	Illumina HiSeq	226c6a2b-0354-4f94-af55-1dc92b881c07	Colorectal	47	9B97D882-564D-4683-AAE3-4AA286113EC5	76C6378E-72C1-40AB-847B-C943D4B38105	TCGA-CM-4747-10A-01D-1405-02	HG18	TCGA-CM-4747	TCGA-COAD	NA	s13394	Harvard Medical School	MSKCC	None	NO	T4a	N1b	Colon Adenocarcinoma	Stage IVA	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c52c	58cfa831e4b0c9d6adf6c52c	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	36.02	1.9	0.17	58cfa831e4b0c9d6adf6c52c	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CK-4951-01A	2DB3C23D-C591-4EA0-B0A8-ED9C4343C80E	Primary Tumor	Illumina HiSeq	7dcee63f-adaa-46d6-a48c-750143760f41	Colorectal	79	EA9E7E8C-4151-4CFC-8631-5880C6F1A21F	C501681C-26B5-4385-AE24-BEC8FB230C51	TCGA-CK-4951-01A-01D-1405-02	HG18	TCGA-CK-4951	TCGA-COAD	NA	s13040	Harvard Medical School	Harvard	None	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa832e4b0c9d6adf6cef6	58cfa832e4b0c9d6adf6cef6	TCGA-EM-A1YC-11A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EM-A1YC-11A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_8_rg.sorted	TCGA-EM-A1YC-11A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_8_rg.sorted.bam	36.34	1.72	0.16	58cfa832e4b0c9d6adf6cef6	TCGA-EM-A1YC-11A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_8_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YC-11A	0AD2A2B3-C1BB-4597-B28E-A6385F93D09C	Solid Tissue Normal	Illumina HiSeq	48ec7cab-ce60-4ef3-af40-8674fd036459	Thyroid	71	1780D814-E472-4BD0-98DB-8DBCF68718D7	9B877E88-4F42-4688-9173-F650662BF50A	TCGA-EM-A1YC-11A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YC	TCGA-THCA	NA	s11997	Harvard Medical School	University Health Network	Canada	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A14U-02	TRUE
13722.58cfa82fe4b0c9d6adf6b657	58cfa82fe4b0c9d6adf6b657	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.bam	702.7	1.9	0.15	58cfa82fe4b0c9d6adf6b657	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5778-01A	8FDBD88F-19AE-4AB8-BCD7-6BFA1BBDE742	Primary Tumor	Illumina HiSeq	bd5570f2-ed45-408a-a615-0a6808c31d84	Lung	60	92514FD2-A178-42E8-8929-0910558E7F87	BC8FFDB4-AB99-44B7-95B0-7BC2F8110B76	TCGA-64-5778-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5778	TCGA-LUAD	NA	s10796	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Bronchioloalveolar Carcinoma Nonmucinous	Stage IB	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b664	58cfa82fe4b0c9d6adf6b664	TCGA-50-6594-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-6594-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_1_rg.sorted	TCGA-50-6594-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_1_rg.sorted.bam	193.4	1.8	0.13	58cfa82fe4b0c9d6adf6b664	TCGA-50-6594-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_1_rg.sorted.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6594-01A	8504FD86-A70A-4CBA-9EC8-25C9E60CA549	Primary Tumor	Illumina HiSeq	e9b1ca6e-b0f0-48d8-ba44-ebfcec8cd171	Lung	79	DAB00804-E92F-43F1-9348-16F3015B5DCE	9AED6934-5553-4BAC-AD76-BA2DDAE0DC72	TCGA-50-6594-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-6594	TCGA-LUAD	370	s11350	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1751-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae58	58cfa82ee4b0c9d6adf6ae58	TCGA-05-4398-10A-01D-1203_120322_SN208_0278_BD0RB0ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4398-10A-01D-1203_120322_SN208_0278_BD0RB0ACXX_s_4_rg.sorted	TCGA-05-4398-10A-01D-1203_120322_SN208_0278_BD0RB0ACXX_s_4_rg.sorted.bam	168.23	1.9	0.14	58cfa82ee4b0c9d6adf6ae58	TCGA-05-4398-10A-01D-1203_120322_SN208_0278_BD0RB0ACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4398-10A	31C96E35-5E2F-429C-B12A-7BC5A497A300	Blood Derived Normal	Illumina HiSeq	c5182685-5c5b-42dc-9a85-4c0076ee389a	Lung	47	A65C5573-B230-4CA0-8BE3-8BCCE6BE385E	900A4C89-CD98-4F90-AA26-CCC7B285A8CC	TCGA-05-4398-10A-01D-1203-02	HG19_Broad_variant	TCGA-05-4398	TCGA-LUAD	NA	s10770	Harvard Medical School	Indivumed	Germany	NO	T4	N3	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b730	58cfa82fe4b0c9d6adf6b730	TCGA-44-3919-11A-01D-1103_110707_SN590_0095_BD0D4KABXX_s_6_rg.sorted.filtered.	WGS	TCGA-44-3919-11A-01D-1103_110707_SN590_0095_BD0D4KABXX_s_6_rg.sorted	TCGA-44-3919-11A-01D-1103_110707_SN590_0095_BD0D4KABXX_s_6_rg.sorted.bam	569.93	1.9	0.14	58cfa82fe4b0c9d6adf6b730	TCGA-44-3919-11A-01D-1103_110707_SN590_0095_BD0D4KABXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3919-11A	66ED89F6-8BA2-49D0-AF0F-4B6EBF2381BF	Solid Tissue Normal	Illumina HiSeq	0b6ce057-abf2-4149-a103-a243ae3d9354	Lung	71	6C4744D1-7AAF-4A93-8C76-82B253C39EFC	7186DA3A-2D33-4087-9B1F-541223684945	TCGA-44-3919-11A-01D-1103-02	HG19_Broad_variant	TCGA-44-3919	TCGA-LUAD	NA	s11547	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b70e	58cfa82fe4b0c9d6adf6b70e	TCGA-73-4668-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4668-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4668-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	111.9	1.9	0.15	58cfa82fe4b0c9d6adf6b70e	TCGA-73-4668-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	AMERICAN INDIAN OR ALASKA NATIVE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4668-11A	B2285924-9813-4F46-BB8F-91A0EFD8A9B6	Solid Tissue Normal	Illumina HiSeq	c21a88c1-b349-46d8-8008-d9bc9b8cf337	Lung	66	8E273348-F4DA-41D4-8FEA-080222382FFA	79FEE508-0F2C-4825-BD6B-32CB6ACC6F83	TCGA-73-4668-11A-01D-1203-02	GRCh37	TCGA-73-4668	TCGA-LUAD	NA	s11353	Harvard Medical School	Roswell Park	United States	NO	T2	N1	Lung Micropapillary Adenocarcinoma	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7e4	58cfa82fe4b0c9d6adf6b7e4	TCGA-44-3396-10A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_5_rg.sorted.filtered.	WGS	TCGA-44-3396-10A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_5_rg.sorted	TCGA-44-3396-10A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_5_rg.sorted.bam	724.3	1.9	0.15	58cfa82fe4b0c9d6adf6b7e4	TCGA-44-3396-10A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3396-10A	3BD6BADB-27FF-4D8D-B206-4D28DC264862	Blood Derived Normal	Illumina HiSeq	03abf6dc-ed65-46a4-bca8-920d74f39139	Lung	74	C3FFB1CC-785E-49FE-AC62-1C99554C6001	0F4135A4-53D2-499B-9F1F-12A9317EDE14	TCGA-44-3396-10A-01D-1203-02	HG19_Broad_variant	TCGA-44-3396	TCGA-LUAD	NA	s11336	Harvard Medical School	Christiana Healthcare	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b806	58cfa82fe4b0c9d6adf6b806	TCGA-49-6744-11A-01D-1853_111218_SN208_0258_C054RACXX_s_6_rg.sorted.filtered.	WGS	TCGA-49-6744-11A-01D-1853_111218_SN208_0258_C054RACXX_s_6_rg.sorted	TCGA-49-6744-11A-01D-1853_111218_SN208_0258_C054RACXX_s_6_rg.sorted.bam	191.7	1.9	0.14	58cfa82fe4b0c9d6adf6b806	TCGA-49-6744-11A-01D-1853_111218_SN208_0258_C054RACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-49-6744-11A	15340DD3-84AE-49FB-989A-EB212F3E73DA	Solid Tissue Normal	Illumina HiSeq	f185e615-65c6-4c02-aa8a-77c17e89e5e5	Lung	64	E3962E0E-EAFA-4016-8FA4-1C4BA0D2A9AD	564E82B9-E3C8-4EDE-8E58-BE9D0BA157D5	TCGA-49-6744-11A-01D-1853-02	HG19_Broad_variant	TCGA-49-6744	TCGA-LUAD	NA	s10906	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIA	1853-02	TRUE
13722.58cfa82ee4b0c9d6adf6aeda	58cfa82ee4b0c9d6adf6aeda	TCGA-05-4397-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_8_rg.sorted.filtered.	WGS	TCGA-05-4397-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_8_rg.sorted	TCGA-05-4397-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_8_rg.sorted.bam	256.93	1.9	0.15	58cfa82ee4b0c9d6adf6aeda	TCGA-05-4397-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_8_rg.sorted.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4397-10A	6DFD47D2-831A-4386-9051-F78199A16BB5	Blood Derived Normal	Illumina HiSeq	6be1b088-22a4-428b-be61-923f6c558318	Lung	65	E9F8F56D-E3A6-4F92-807A-99BD857CAD8A	448DEB16-395E-480B-A492-374FFD9579FD	TCGA-05-4397-10A-01D-1203-02	HG19_Broad_variant	TCGA-05-4397	TCGA-LUAD	731	s11434	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6b7	58cfa82fe4b0c9d6adf6b6b7	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.bam	555.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6b7	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5781-01A	41C4C704-825E-49F5-9D54-DBD7D30725E0	Primary Tumor	Illumina HiSeq	901f4776-2659-4626-abec-5a9323e6f75e	Lung	55	B32F509D-91E5-4601-B8B3-4B0A5212C22B	69DEF564-A4D8-4820-9ED6-F17AF2CAB0A7	TCGA-64-5781-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5781	TCGA-LUAD	NA	s11352	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b852	58cfa82fe4b0c9d6adf6b852	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.bam	112.95	1.93	0.17	58cfa82fe4b0c9d6adf6b852	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R9-01A	284174FD-1320-4617-9E99-75BD75DF9BF3	Primary Tumor	Illumina HiSeq	4139f46d-ae94-47a2-a3ae-0b96262c6a89	Uterus	51	986AC6AC-087F-412B-BB0C-9BE10D104989	6BBEF031-7106-4D36-86A9-F8A2333448BB	TCGA-A5-A0R9-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R9	TCGA-UCEC	NA	s4419	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82fe4b0c9d6adf6b850	58cfa82fe4b0c9d6adf6b850	TCGA-A6-2671-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2671-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2671-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	5	1.9	0.15	58cfa82fe4b0c9d6adf6b850	TCGA-A6-2671-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2671-10A	565E2726-4942-4726-89D3-C5E3797F7204	Blood Derived Normal	Illumina HiSeq	6743db0e-7f17-4758-a3ff-6ca3e2297764	Colorectal	85	BC8A183F-C178-4F6B-AC3F-AEC164B9C0D9	DA65C9D3-62AC-4FB5-B452-1E9C551BA243	TCGA-A6-2671-10A-01D-1405-02	HG18	TCGA-A6-2671	TCGA-COAD	NA	s13501	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Adenocarcinoma	Stage IV	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b808	58cfa82fe4b0c9d6adf6b808	TCGA-44-5643-11A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_4_rg.sorted.filtered.	WGS	TCGA-44-5643-11A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_4_rg.sorted	TCGA-44-5643-11A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_4_rg.sorted.bam	105.7	1.9	0.14	58cfa82fe4b0c9d6adf6b808	TCGA-44-5643-11A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_4_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-5643-11A	27FCEEC1-3298-4CDD-A4E6-8F5CF34604F0	Solid Tissue Normal	Illumina HiSeq	7f469523-6155-4b35-86b7-4dd7791a1ea5	Lung	53	57F5E960-B2D3-41ED-A062-DC21ABA0E07B	320B802D-2F12-4C61-A021-E3B66486F1CE	TCGA-44-5643-11A-01D-1623-02	HG19_Broad_variant	TCGA-44-5643	TCGA-LUAD	NA	s11230	Harvard Medical School	Christiana Healthcare	United States	NO	T2b	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b85e	58cfa82fe4b0c9d6adf6b85e	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	38	1.9	0.16	58cfa82fe4b0c9d6adf6b85e	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2680-01A	FF1407C6-9174-4BAE-A19B-D34CA71B898C	Primary Tumor	Illumina HiSeq	b2bf326b-6022-44c8-87fd-c3777c1ab858	Colorectal	72	D664F620-CFEE-4700-B00E-68B65387883C	22A3FC8C-A661-4B3D-A4BA-B35DFDBE24BC	TCGA-A6-2680-01A-01D-1405-02	HG18	TCGA-A6-2680	TCGA-COAD	NA	s13356	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b86e	58cfa82fe4b0c9d6adf6b86e	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	243	1.9	0.15	58cfa82fe4b0c9d6adf6b86e	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2671-01A	565E2726-4942-4726-89D3-C5E3797F7204	Primary Tumor	Illumina HiSeq	866dc7b9-86cd-4842-ad2f-1d5e7c714ccb	Colorectal	85	81505915-6C01-4299-AE89-964DC20D93CB	82E23BAF-DA11-4175-BEE0-81C0C0137D72	TCGA-A6-2671-01A-01D-1405-02	HG18	TCGA-A6-2671	TCGA-COAD	NA	s13649	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Adenocarcinoma	Stage IV	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b866	58cfa82fe4b0c9d6adf6b866	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted.filtered.	WGS	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted.bam	618	1.9	0.16	58cfa82fe4b0c9d6adf6b866	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2682-01A	77A44132-AF22-4115-9FA2-78F2F74BF687	Primary Tumor	Illumina HiSeq	dd9a1c6d-4344-4fed-a29f-b60afcfaa5eb	Colorectal	70	F10F139D-1D7F-4923-8129-F103F5D3163B	F8B17713-D431-4418-A6F7-DC6DE3077212	TCGA-A6-2682-01A-01D-1405-02	HG18_Broad_variant	TCGA-A6-2682	TCGA-COAD	424	s13651	Harvard Medical School	Christiana Healthcare	United States	NO	T4b	N1	Colon Adenocarcinoma	Stage IV	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b874	58cfa82fe4b0c9d6adf6b874	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted.bam	105.24	2	0.15	58cfa82fe4b0c9d6adf6b874	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0VQ-01A	23489245-48D7-4F19-8A42-E23B1181412B	Primary Tumor	Illumina HiSeq	b4dd6449-2e78-432b-86c6-348339f37763	Uterus	62	952CB6A5-7527-470A-978E-EDD44E3A368F	97FE43D0-30DF-45A1-83F0-B4ED5EDF76AE	TCGA-A5-A0VQ-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0VQ	TCGA-UCEC	NA	s5381	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82fe4b0c9d6adf6b938	58cfa82fe4b0c9d6adf6b938	TCGA-64-5779-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-64-5779-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_5_rg.sorted	TCGA-64-5779-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_5_rg.sorted.bam	439.7	1.9	0.15	58cfa82fe4b0c9d6adf6b938	TCGA-64-5779-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5779-01A	1C58D9B8-17A2-4FC6-9898-FE6F47BD2C2A	Primary Tumor	Illumina HiSeq	40156a89-cb76-4ae2-b73d-ec06c1cbd7bb	Lung	61	4131DA8F-3C6C-43E1-A7EB-81CB8988F524	AE15BEF8-478B-432E-B429-643A75BD2EB8	TCGA-64-5779-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5779	TCGA-LUAD	NA	s11463	Harvard Medical School	Fox Chase	United States	NO	T2	N2	Lung Acinar Adenocarcinoma	Stage IIIA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b953	58cfa82fe4b0c9d6adf6b953	TCGA-AA-3529-11A-01D-1548-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3529-11A-01D-1548-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3529-11A-01D-1548-02_IlluminaHiSeq-DNASeq_whole.bam	446.7	1.9	0.16	58cfa82fe4b0c9d6adf6b953	TCGA-AA-3529-11A-01D-1548-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3529-11A	BFB07784-693B-4C25-874E-4AD6E04A5D46	Solid Tissue Normal	Illumina HiSeq	c3a90e62-0feb-4728-99f1-8b461bfa7760	Colorectal	78	B73F0D09-2505-4F94-9E8B-02B6E2B0FB92	43D26085-49A1-4247-B514-6349557FD2F8	TCGA-AA-3529-11A-01D-1548-02	HG18	TCGA-AA-3529	TCGA-COAD	0	s12865	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1548-02	FALSE
13722.58cfa82fe4b0c9d6adf6b8c4	58cfa82fe4b0c9d6adf6b8c4	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	177.53	1.9	0.14	58cfa82fe4b0c9d6adf6b8c4	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4510-01A	F77B6930-A1CE-446E-A15D-C018CBBECFEE	Primary Tumor	Illumina HiSeq	abe8920d-80b9-4fc8-a249-5bf0a4a06ac7	Lung	51	9A479D32-13A4-46C2-B26D-34CB6051A891	3324FA3E-B195-4974-A15B-0C8D8AC2EFA9	TCGA-49-4510-01A-01D-1203-02	GRCh37	TCGA-49-4510	TCGA-LUAD	896	s11338	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b994	58cfa82fe4b0c9d6adf6b994	TCGA-50-6591-11A-01D-1751_111111_SN208_0254_B0160ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-50-6591-11A-01D-1751_111111_SN208_0254_B0160ACXX_s_6_rg.sorted	TCGA-50-6591-11A-01D-1751_111111_SN208_0254_B0160ACXX_s_6_rg.sorted.bam	59.4	1.9	0.13	58cfa82fe4b0c9d6adf6b994	TCGA-50-6591-11A-01D-1751_111111_SN208_0254_B0160ACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6591-11A	9B132E4F-7E35-4CC5-8711-43AD62B906D0	Solid Tissue Normal	Illumina HiSeq	86f2ae5a-c2aa-41c4-869a-f8ffb3112aa9	Lung	63	76A1F269-62CE-4AE1-A08B-8AF43F853E5A	1BF4CDE2-93BB-4471-B7FD-EBCC768CD8F6	TCGA-50-6591-11A-01D-1751-02	HG19_Broad_variant	TCGA-50-6591	TCGA-LUAD	119	s10786	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9d4	58cfa82fe4b0c9d6adf6b9d4	TCGA-AA-A01I-10A-01D-A078_110326_SN590_0061_B702DPABXX_s_4_rg.sorted.filtered.	WGS	TCGA-AA-A01I-10A-01D-A078_110326_SN590_0061_B702DPABXX_s_4_rg.sorted	TCGA-AA-A01I-10A-01D-A078_110326_SN590_0061_B702DPABXX_s_4_rg.sorted.bam	25.35	1.75	0.15	58cfa82fe4b0c9d6adf6b9d4	TCGA-AA-A01I-10A-01D-A078_110326_SN590_0061_B702DPABXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01I-10A	86D18004-9478-4E46-83B4-4FBE445CCB70	Blood Derived Normal	Illumina HiSeq	4c584f48-2e93-4b94-91b6-ee509cff0531	Colorectal	76	65CF8358-D83A-4ED2-98B7-5E75A73D77B9	88062B48-3BB7-4FC4-852E-4E26715F74D3	TCGA-AA-A01I-10A-01D-A078-02	HG18_Broad_variant	TCGA-AA-A01I	TCGA-COAD	NA	s13202	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A078-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba02	58cfa82fe4b0c9d6adf6ba02	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	237.83	1.78	0.15	58cfa82fe4b0c9d6adf6ba02	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01I-01A	86D18004-9478-4E46-83B4-4FBE445CCB70	Primary Tumor	Illumina HiSeq	397e6c0b-1bf2-43ff-b659-15147ee8be30	Colorectal	76	FBA03796-B9C8-4042-9720-F21660CFEC28	DAED1A71-909A-42D8-87B4-6760B54D91AF	TCGA-AA-A01I-01A-02D-A077-02	HG18	TCGA-AA-A01I	TCGA-COAD	NA	s13201	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A077-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba44	58cfa82fe4b0c9d6adf6ba44	TCGA-AA-A01R-11A-12D-A079-02_110409_SN590_0077_BB04EHABXX_s_4.rg.sorted.filtered.	WGS	TCGA-AA-A01R-11A-12D-A079-02_110409_SN590_0077_BB04EHABXX_s_4.rg.sorted	TCGA-AA-A01R-11A-12D-A079-02_110409_SN590_0077_BB04EHABXX_s_4.rg.sorted.bam	76.75	1.9	0.16	58cfa82fe4b0c9d6adf6ba44	TCGA-AA-A01R-11A-12D-A079-02_110409_SN590_0077_BB04EHABXX_s_4.rg.sorted.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01R-11A	97F6C8D3-09A0-4128-8F10-41E736648A5F	Solid Tissue Normal	Illumina HiSeq	e3101288-fc25-4e13-b4de-7cf4122567d3	Colorectal	47	D19B4EE7-CBA4-491B-8764-99AC49304AD5	23D92BFE-081F-4563-AA86-D0E0786FFD2E	TCGA-AA-A01R-11A-12D-A079-02	HG18_Broad_variant	TCGA-AA-A01R	TCGA-COAD	NA	s12883	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6babe	58cfa830e4b0c9d6adf6babe	TCGA-AA-A01S-11A-21D-A079_110409_SN590_0077_BB04EHABXX_s_5_rg.sorted.filtered.	WGS	TCGA-AA-A01S-11A-21D-A079_110409_SN590_0077_BB04EHABXX_s_5_rg.sorted	TCGA-AA-A01S-11A-21D-A079_110409_SN590_0077_BB04EHABXX_s_5_rg.sorted.bam	16.83	1.81	0.16	58cfa830e4b0c9d6adf6babe	TCGA-AA-A01S-11A-21D-A079_110409_SN590_0077_BB04EHABXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01S-11A	84E34CF2-B3BB-4A1A-8FB7-6C2C604C4008	Solid Tissue Normal	Illumina HiSeq	272c148a-7ae2-411c-bdcf-153d522ba479	Colorectal	47	1F703295-7062-4692-87CB-1E5204837A60	56C81840-4216-4792-BA0F-8B0973F377E6	TCGA-AA-A01S-11A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A01S	TCGA-COAD	NA	s13382	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6baaa	58cfa830e4b0c9d6adf6baaa	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.bam	96.48	1.95	0.14	58cfa830e4b0c9d6adf6baaa	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GD-01A	1486A031-B74D-4976-8B0B-4569E6978F49	Primary Tumor	Illumina HiSeq	98b5ea92-9e57-4d1f-937d-8bb0dd2a3cf2	Uterus	75	F449F50A-7664-4DDC-87AA-6A061EE7190C	069406A8-56D7-4E93-8570-7880A99D6C2D	TCGA-A5-A0GD-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GD	TCGA-UCEC	NA	s4771	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82ee4b0c9d6adf6af63	58cfa82ee4b0c9d6adf6af63	TCGA-05-4433-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4433-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_4_rg.sorted	TCGA-05-4433-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_4_rg.sorted.bam	64	1.8	0.13	58cfa82ee4b0c9d6adf6af63	TCGA-05-4433-10A-01D-1853_120312_SN1120_0120_AD0PYGACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4433-10A	AEA68827-DC0F-484D-A00D-06DEEAA4B3CE	Blood Derived Normal	Illumina HiSeq	5d83cd06-942c-4ea6-827b-4d1fdb9c4cee	Lung	82	971AFEDB-FA6F-4B34-86F7-A8020E0A1448	45479C86-60A4-4BAC-9152-B9D4433841C2	TCGA-05-4433-10A-01D-1853-02	HG19_Broad_variant	TCGA-05-4433	TCGA-LUAD	NA	s10987	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	TRUE
13722.58cfa830e4b0c9d6adf6bb83	58cfa830e4b0c9d6adf6bb83	TCGA-AA-A01G-10A-01D-A078_110326_SN590_0061_B702DPABXX_s_2_rg.sorted.filtered.	WGS	TCGA-AA-A01G-10A-01D-A078_110326_SN590_0061_B702DPABXX_s_2_rg.sorted	TCGA-AA-A01G-10A-01D-A078_110326_SN590_0061_B702DPABXX_s_2_rg.sorted.bam	16.78	1.71	0.14	58cfa830e4b0c9d6adf6bb83	TCGA-AA-A01G-10A-01D-A078_110326_SN590_0061_B702DPABXX_s_2_rg.sorted.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01G-10A	6F2B5A14-569C-4084-8C67-B1A44D787897	Blood Derived Normal	Illumina HiSeq	032cb2e6-9cac-4851-bf1b-448209aceb57	Colorectal	63	38D09491-9FAE-4B43-BDFA-B262EBD93D02	4D746D14-DF9B-4B7B-87FD-7E6D9ECC76B3	TCGA-AA-A01G-10A-01D-A078-02	HG18_Broad_variant	TCGA-AA-A01G	TCGA-COAD	NA	s13381	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bbb8	58cfa830e4b0c9d6adf6bbb8	TCGA-AA-A01T-11A-11D-A079-02_110409_SN590_0077_BB04EHABXX_s_6.rg.sorted.filtered.	WGS	TCGA-AA-A01T-11A-11D-A079-02_110409_SN590_0077_BB04EHABXX_s_6.rg.sorted	TCGA-AA-A01T-11A-11D-A079-02_110409_SN590_0077_BB04EHABXX_s_6.rg.sorted.bam	40.17	1.97	0.14	58cfa830e4b0c9d6adf6bbb8	TCGA-AA-A01T-11A-11D-A079-02_110409_SN590_0077_BB04EHABXX_s_6.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01T-11A	F87C6DCC-1A9E-4DF5-962C-1F946E2611F8	Solid Tissue Normal	Illumina HiSeq	bb48e041-be2a-4f2c-83ff-39500c7790bb	Colorectal	63	4B1CA823-0752-4F67-AD05-70BDBCDC73B6	C5BE2240-6C97-4875-A26F-79B7F17D067F	TCGA-AA-A01T-11A-11D-A079-02	HG18_Broad_variant	TCGA-AA-A01T	TCGA-COAD	NA	s13031	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bc71	58cfa830e4b0c9d6adf6bc71	TCGA-AP-A0LQ-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-AP-A0LQ-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_8_rg.sorted	TCGA-AP-A0LQ-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_8_rg.sorted.bam	30.08	1.92	0.15	58cfa830e4b0c9d6adf6bc71	TCGA-AP-A0LQ-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LQ-10A	252500D2-86A3-4090-A57F-1E8C3D44C573	Blood Derived Normal	Illumina HiSeq	2883876d-43eb-49aa-8484-a338e112d898	Uterus	59	2B945126-5955-411F-97D5-0B5A956B6991	0ED05C05-F270-48D1-9526-2B5D45710385	TCGA-AP-A0LQ-10A-01D-A101-02	HG19_Broad_variant	TCGA-AP-A0LQ	TCGA-UCEC	NA	s5198	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bc0f	58cfa830e4b0c9d6adf6bc0f	TCGA-AG-A00Y-10A-01D-A078-02_110405_SN590_0074_AB04EUABXX_s_8.rg.sorted.filtered.	WGS	TCGA-AG-A00Y-10A-01D-A078-02_110405_SN590_0074_AB04EUABXX_s_8.rg.sorted	TCGA-AG-A00Y-10A-01D-A078-02_110405_SN590_0074_AB04EUABXX_s_8.rg.sorted.bam	21.77	1.74	0.15	58cfa830e4b0c9d6adf6bc0f	TCGA-AG-A00Y-10A-01D-A078-02_110405_SN590_0074_AB04EUABXX_s_8.rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A00Y-10A	C7E09161-60D6-4DFF-A840-7CEC3BB7A30A	Blood Derived Normal	Illumina HiSeq	6f10226b-f6f1-4624-8526-bff208e827a0	Colorectal	68	B67C3548-2135-4E0B-8687-624F330FD0AA	49EBF21C-8481-4D18-BF18-81A24A168FCA	TCGA-AG-A00Y-10A-01D-A078-02	HG18_Broad_variant	TCGA-AG-A00Y	TCGA-READ	NA	s1977	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bbc2	58cfa830e4b0c9d6adf6bbc2	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	624.89	1.9	0.14	58cfa830e4b0c9d6adf6bbc2	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4008-01A	72802851-9340-4C5F-A90B-23B7AFD7577A	Primary Tumor	Illumina HiSeq	95360a98-f3fd-40d4-b451-5973fe934b51	Colorectal	63	D803F092-3340-485D-9964-D6554D210E2E	CD36B70F-6819-4136-ADB5-8024E27B05A6	TCGA-AG-4008-01A-01D-1115-02	HG18	TCGA-AG-4008	TCGA-READ	NA	s2312	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bc80	58cfa830e4b0c9d6adf6bc80	TCGA-AP-A054-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_2_rg.sorted.filtered.	WGS	TCGA-AP-A054-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_2_rg.sorted	TCGA-AP-A054-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_2_rg.sorted.bam	29.88	1.72	0.15	58cfa830e4b0c9d6adf6bc80	TCGA-AP-A054-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A054-10A	D77E4DBC-B239-4742-8CB7-EFD427010D13	Blood Derived Normal	Illumina HiSeq	a6bc8f80-d89a-45e0-8e71-e6f13632dba6	Uterus	64	2A884E50-859A-4269-A604-210562E65E9C	3E58B079-B1CB-4356-842E-F08E2F1EBD65	TCGA-AP-A054-10A-01D-A043-02	HG19_Broad_variant	TCGA-AP-A054	TCGA-UCEC	709	s4591	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bc92	58cfa830e4b0c9d6adf6bc92	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	500.89	1.9	0.14	58cfa830e4b0c9d6adf6bc92	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3902-01A	BCFE4FE9-D090-49F9-85A7-2B472E0F7453	Primary Tumor	Illumina HiSeq	66b629b3-3801-4c84-966b-4b01243390f0	Colorectal	61	F52423C2-7780-4470-8E27-5982201CCB83	A8A88775-9775-4087-8C03-9B5BC771F983	TCGA-AG-3902-01A-01D-1115-02	HG18	TCGA-AG-3902	TCGA-READ	NA	s2159	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bd3c	58cfa830e4b0c9d6adf6bd3c	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	728.89	1.9	0.15	58cfa830e4b0c9d6adf6bd3c	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3892-01A	DED3FEB2-1079-4520-A7CA-F5B5FC73D7C5	Primary Tumor	Illumina HiSeq	adde3886-c16e-4d0c-8186-1a253ffca559	Colorectal	57	D5B6919D-5654-486F-95B0-D89CB1893614	8B81AA70-5B77-4BE9-8438-AE0928339E21	TCGA-AG-3892-01A-01D-1115-02	HG18	TCGA-AG-3892	TCGA-READ	NA	s1998	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Rectal Adenocarcinoma	Stage I	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bd7c	58cfa830e4b0c9d6adf6bd7c	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted.bam	78.67	NA	0.17	58cfa830e4b0c9d6adf6bd7c	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PV-01A	EFF78AF6-0F68-49B9-866B-0D511606F2B1	Primary Tumor	Illumina HiSeq	a219d21e-e657-407a-8e8f-aba8b0190425	Skin	74	090DEBB2-290D-49DD-B642-7F01C99A795C	BC0B690D-7C05-4B68-B2F2-5D38EA621A02	TCGA-BF-A1PV-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PV	TCGA-SKCM	NA	s7491	Harvard Medical School	Cureline	Russia	NO	T4b	N0	Not available	Stage IIC	A18Z-02	TRUE
13722.58cfa830e4b0c9d6adf6bcd2	58cfa830e4b0c9d6adf6bcd2	TCGA-AZ-4684-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4684-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4684-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	80.72	1.9	0.14	58cfa830e4b0c9d6adf6bcd2	TCGA-AZ-4684-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4684-10A	CAC80259-3A26-4A99-B0D3-13454068E6ED	Blood Derived Normal	Illumina HiSeq	058fc621-f56b-4373-bed9-e77a7ab13be4	Colorectal	49	8FBA5B6B-6883-4617-B1D9-B1063BCCDC12	B1BFE1F0-9C46-492D-8BA8-3B5451248B77	TCGA-AZ-4684-10A-01D-1405-02	HG18	TCGA-AZ-4684	TCGA-COAD	NA	s13036	Harvard Medical School	University of Pittsburgh	None	NO	T3	N2	Colon Adenocarcinoma	Stage IVA	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bd72	58cfa830e4b0c9d6adf6bd72	TCGA-AA-A01K-10A-01D-A078_110409_SN590_0076_AB04G5ABXX_s_8.rg.sorted.filtered.	WGS	TCGA-AA-A01K-10A-01D-A078_110409_SN590_0076_AB04G5ABXX_s_8.rg.sorted	TCGA-AA-A01K-10A-01D-A078_110409_SN590_0076_AB04G5ABXX_s_8.rg.sorted.bam	11.63	1.75	0.15	58cfa830e4b0c9d6adf6bd72	TCGA-AA-A01K-10A-01D-A078_110409_SN590_0076_AB04G5ABXX_s_8.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01K-10A	A72DD578-3A6F-4807-A843-4A942500944E	Blood Derived Normal	Illumina HiSeq	4d29a7d1-b004-42ad-a291-1eed2ad67b3c	Colorectal	74	A76B2563-5D11-4A5C-846B-6B5A1539FCA9	A99DF831-6313-455E-9180-77C0A9743248	TCGA-AA-A01K-10A-01D-A078-02	HG18_Broad_variant	TCGA-AA-A01K	TCGA-COAD	NA	s12882	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bd9e	58cfa830e4b0c9d6adf6bd9e	TCGA-BF-A1PX-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BF-A1PX-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_4_rg.sorted	TCGA-BF-A1PX-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_4_rg.sorted.bam	46.56	NA	0.16	58cfa830e4b0c9d6adf6bd9e	TCGA-BF-A1PX-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PX-10A	197AC33E-D5DF-40DE-92F2-6EF7FE2AD6DD	Blood Derived Normal	Illumina HiSeq	4b89e22d-ca8e-4b65-bc95-a9d403830b04	Skin	56	BC1A2679-829C-4E75-9BD4-26AAA3A9FB65	58BCC596-D401-44A7-85AE-AB47E3C939F9	TCGA-BF-A1PX-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PX	TCGA-SKCM	282	s7828	Harvard Medical School	Cureline	Russia	NO	T4b	N2a	Not available	Stage IIIB	A18Z-02	TRUE
13722.58cfa830e4b0c9d6adf6bda0	58cfa830e4b0c9d6adf6bda0	TCGA-BG-A0M0-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0M0-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_1_rg.sorted	TCGA-BG-A0M0-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_1_rg.sorted.bam	8.96	2.22	0.16	58cfa830e4b0c9d6adf6bda0	TCGA-BG-A0M0-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M0-10A	8BF0B156-6EB4-45E8-9CBB-0979EFBEA898	Blood Derived Normal	Illumina HiSeq	131e2c60-ce89-4bf3-8c00-24e790507005	Uterus	66	6C55929F-1C1E-48C9-873E-7FF6A1433ED3	6D3FBD58-8A84-4355-B4E6-D38E5D099E8A	TCGA-BG-A0M0-10A-01D-A101-02	HG19_Broad_variant	TCGA-BG-A0M0	TCGA-UCEC	NA	s4256	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6be10	58cfa830e4b0c9d6adf6be10	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.bam	19.84	1.95	0.16	58cfa830e4b0c9d6adf6be10	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HX-01A	3B01D064-8C00-4972-9F07-407EAC8E7534	Primary Tumor	Illumina HiSeq	06f7db86-540c-401d-bbd9-0b88698c5f36	Breast	54	989C2DF5-5183-4DAA-A8DA-FC9AB18A437C	11821020-0E93-4479-85F8-306976DE6722	TCGA-BH-A0HX-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0HX	TCGA-BRCA	NA	s6126	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6be3a	58cfa830e4b0c9d6adf6be3a	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.bam	45.3	1.98	0.17	58cfa830e4b0c9d6adf6be3a	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A18Z-01A	0D497FAF-2C1C-4173-A5FE-770CCA73323C	Primary Tumor	Illumina HiSeq	a740c90f-9cbc-4ff1-8cad-c78d4dbb92cf	Thyroid	58	19DEE039-9C98-4D4A-8BAF-EEA1B6DDA8EB	815C53C3-8ADD-4612-B93C-3ED4BFA530AA	TCGA-BJ-A18Z-01A-21D-A13U-02	HG19_Broad_variant	TCGA-BJ-A18Z	TCGA-THCA	NA	s12354	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6be3c	58cfa830e4b0c9d6adf6be3c	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.bam	77.56	2	0.18	58cfa830e4b0c9d6adf6be3c	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A18Y-01A	ACB3B9DB-16E9-40F5-87A9-9DF9D4CEEE54	Primary Tumor	Illumina HiSeq	0074a697-0800-4872-9a48-48945f46d18d	Thyroid	29	5D1D84D0-9A03-4381-9CF1-E460B3617AAA	56D2A069-7969-40F1-A237-E4FE7E62C84C	TCGA-BJ-A18Y-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A18Y	TCGA-THCA	NA	s12351	Harvard Medical School	University of Pittsburgh	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6bdf4	58cfa830e4b0c9d6adf6bdf4	TCGA-AG-A014-01A-02D-A077_110504_SN590_0081_BB0BM5ABXX_s_6_rg.sorted.filtered.	WGS	TCGA-AG-A014-01A-02D-A077_110504_SN590_0081_BB0BM5ABXX_s_6_rg.sorted	TCGA-AG-A014-01A-02D-A077_110504_SN590_0081_BB0BM5ABXX_s_6_rg.sorted.bam	223.31	1.73	0.15	58cfa830e4b0c9d6adf6bdf4	TCGA-AG-A014-01A-02D-A077_110504_SN590_0081_BB0BM5ABXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A014-01A	51C37449-6A2E-4C3D-A7CC-06F901E1224F	Primary Tumor	Illumina HiSeq	b165eaa6-faee-4f3f-967e-55f2b4b0bba2	Colorectal	86	FBFA61FE-4FB7-4B2A-9BF0-33140FD41873	7771CB7E-1405-4B8E-86B5-0E06A0EB7FD1	TCGA-AG-A014-01A-02D-A077-02	HG18_Broad_variant	TCGA-AG-A014	TCGA-READ	NA	s2000	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6bdc0	58cfa830e4b0c9d6adf6bdc0	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.bam	79.77	1.93	0.17	58cfa830e4b0c9d6adf6bdc0	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A186-01A	FE4DB898-3A9F-4DFF-ADCB-7B8C30137350	Primary Tumor	Illumina HiSeq	f65268ef-b937-4d49-922e-a5e3ebc0eab8	Uterus	61	B1645A83-57B7-4357-B977-63A5B6AEE39E	ECF410AD-B160-4F00-A165-38529FAE974B	TCGA-BG-A186-01A-11D-A12F-02	HG19_Broad_variant	TCGA-BG-A186	TCGA-UCEC	NA	s4792	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa830e4b0c9d6adf6be60	58cfa830e4b0c9d6adf6be60	TCGA-AP-A0L9-10A-01D-A043_120318_SN590_0147_BD0U3RACXX_s_4_rg.sorted.filtered.	WGS	TCGA-AP-A0L9-10A-01D-A043_120318_SN590_0147_BD0U3RACXX_s_4_rg.sorted	TCGA-AP-A0L9-10A-01D-A043_120318_SN590_0147_BD0U3RACXX_s_4_rg.sorted.bam	35.11	1.93	0.15	58cfa830e4b0c9d6adf6be60	TCGA-AP-A0L9-10A-01D-A043_120318_SN590_0147_BD0U3RACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0L9-10A	7B9947D5-E86B-4006-8890-EA5209584A88	Blood Derived Normal	Illumina HiSeq	da796750-9751-47a4-a977-f1ef14fbfbe5	Uterus	71	60EAC6D9-6404-4C11-A30C-3986D1CACAF2	9BEEC8F7-2E37-425F-8FE7-8E205CABF969	TCGA-AP-A0L9-10A-01D-A043-02	HG19_Broad_variant	TCGA-AP-A0L9	TCGA-UCEC	NA	s4424	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6be3e	58cfa830e4b0c9d6adf6be3e	TCGA-B5-A0JN-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-B5-A0JN-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_2_rg.sorted	TCGA-B5-A0JN-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_2_rg.sorted.bam	5.6	1.78	0.16	58cfa830e4b0c9d6adf6be3e	TCGA-B5-A0JN-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_2_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JN-10A	B60F22AC-A659-4F33-B01D-820E86A9A5C9	Blood Derived Normal	Illumina HiSeq	17e54440-953c-4773-a31f-d4aff974f24a	Uterus	84	00FD9A99-8E94-4AEF-94FC-4AABC6381BFC	0FF9F0E9-4672-42A2-BB98-102949DD8304	TCGA-B5-A0JN-10A-01D-A101-02	HG19_Broad_variant	TCGA-B5-A0JN	TCGA-UCEC	NA	s4785	Harvard Medical School	Duke	United States	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bbc4	58cfa830e4b0c9d6adf6bbc4	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted.filtered.	WGS	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted.bam	174.93	1.72	0.15	58cfa830e4b0c9d6adf6bbc4	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A008-01A	E7503A51-6647-4CC2-80DD-645D0DF4DB43	Primary Tumor	Illumina HiSeq	e31d4ba3-4d48-4e50-9932-05a2978a90df	Colorectal	50	AC02CD55-BC05-4329-8845-E09D088E3CB4	999D82E8-B92F-4397-A9F9-9AFBFD8A249C	TCGA-AG-A008-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A008	TCGA-READ	NA	s1995	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Mucinous Adenocarcinoma	Stage I	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6be8d	58cfa830e4b0c9d6adf6be8d	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.bam	79.7	1.9	0.16	58cfa830e4b0c9d6adf6be8d	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BK-A0CB-01A	59E9029A-8DDD-4447-B35A-72BC39F82A30	Primary Tumor	Illumina HiSeq	2c466122-c49e-4866-b9d4-faf31dde999c	Uterus	60	7678C70D-A298-4472-89A0-427AF1E93D28	F186159C-DCE6-467C-AAAF-BB08FBAE6827	TCGA-BK-A0CB-01A-32D-A101-02	HG19_Broad_variant	TCGA-BK-A0CB	TCGA-UCEC	NA	s5006	Harvard Medical School	Christiana Healthcare	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bee6	58cfa830e4b0c9d6adf6bee6	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.bam	117.75	2.28	0.16	58cfa830e4b0c9d6adf6bee6	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0IU-01A	7E64EA6C-A3DB-48EB-91BE-131361510A92	Primary Tumor	Illumina HiSeq	927c6e80-e2e3-4198-98a4-77a79159fb8a	Uterus	79	DC4B3695-CE62-48D5-9F1D-7DD70D049C97	24746F36-88BC-44B0-955A-55A2CC98E17C	TCGA-AX-A0IU-01A-11D-A101-02	HG19_Broad_variant	TCGA-AX-A0IU	TCGA-UCEC	NA	s4999	Harvard Medical School	Gynecologic Oncology Group	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bec0	58cfa830e4b0c9d6adf6bec0	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted.bam	73.2	1.9	0.15	58cfa830e4b0c9d6adf6bec0	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-AR-A0TU-01A	DFE6DB17-CF45-488E-BD3C-B8433D7343CA	Primary Tumor	Illumina HiSeq	fb34c291-904a-4613-80cd-9788ff446157	Breast	35	1E629A73-68CD-449D-A1C0-B856BE4143E6	E00819A1-4A65-4289-9DDE-0800FC6C69F6	TCGA-AR-A0TU-01A-31D-A106-02	HG19_Broad_variant	TCGA-AR-A0TU	TCGA-BRCA	NA	s6630	Harvard Medical School	Mayo	None	NO	T2	N0	Infiltrating Ductal Carcinoma	Stage IIA	A106-02	FALSE
13722.58cfa830e4b0c9d6adf6be98	58cfa830e4b0c9d6adf6be98	TCGA-AG-3896-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3896-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3896-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	44.59	1.9	0.14	58cfa830e4b0c9d6adf6be98	TCGA-AG-3896-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3896-10A	9AF35239-FFB9-4D4F-889E-F743DA271EEF	Blood Derived Normal	Illumina HiSeq	5936dd60-e257-4b23-9cd8-a67a0afcbb78	Colorectal	85	C8B8CE61-200B-4FD8-B315-CA68823CFBCC	08DEACDA-23DF-416A-8235-E5342322D44F	TCGA-AG-3896-10A-01D-1115-02	HG18	TCGA-AG-3896	TCGA-READ	NA	s2168	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bf2e	58cfa830e4b0c9d6adf6bf2e	TCGA-BR-4255-01A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4255-01A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_7_rg.sorted	TCGA-BR-4255-01A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_7_rg.sorted.bam	0	1.9	0.13	58cfa830e4b0c9d6adf6bf2e	TCGA-BR-4255-01A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4255-01A	956017BA-5E4B-42C7-B93D-42316874BA93	Primary Tumor	Illumina HiSeq	17f1cd5b-fb98-46b4-bfb0-906c39341a06	Stomach	76	A64A7CB8-BA30-45A3-B1DC-2A62D6B1919F	11EA17E5-60EF-4695-866B-B328A51D15A9	TCGA-BR-4255-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4255	TCGA-STAD	NA	s14741	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf0e	58cfa830e4b0c9d6adf6bf0e	TCGA-BR-4183-11A-01D-1128_120807_SN590_0174_BC11N6ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-4183-11A-01D-1128_120807_SN590_0174_BC11N6ACXX_s_8_rg.sorted	TCGA-BR-4183-11A-01D-1128_120807_SN590_0174_BC11N6ACXX_s_8_rg.sorted.bam	174.9	1.9	0.16	58cfa830e4b0c9d6adf6bf0e	TCGA-BR-4183-11A-01D-1128_120807_SN590_0174_BC11N6ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4183-11A	33503349-BA7A-43F4-BCB2-AC8D16808432	Solid Tissue Normal	Illumina HiSeq	29ec7ccd-2408-49f4-a189-cc1afd540e0c	Stomach	55	2846005F-B9E8-432F-91F6-2D9DE5D80943	612DD500-0EBB-4FA1-B929-F4B2ABC28B06	TCGA-BR-4183-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4183	TCGA-STAD	NA	s14879	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf83	58cfa830e4b0c9d6adf6bf83	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.bam	93.7	1.9	0.15	58cfa830e4b0c9d6adf6bf83	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6453-01A	AE633E83-303F-4A90-AC3B-34458FD9BEEF	Primary Tumor	Illumina HiSeq	e92977c9-6880-4f84-842a-9152e558d0b1	Stomach	54	A8F3B148-5929-4025-81A1-6595D49F2279	EE3446DC-7278-47AF-8F65-F63A1D423644	TCGA-BR-6453-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6453	TCGA-STAD	NA	s15305	Harvard Medical School	Asterand	Russia	NO	T2	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bf30	58cfa830e4b0c9d6adf6bf30	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.bam	266.9	1.9	0.15	58cfa830e4b0c9d6adf6bf30	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4191-01A	74F859CF-6DF5-4E96-AE6B-CFAAB691D5FD	Primary Tumor	Illumina HiSeq	d71fa3ea-a7fb-40af-a7b9-64ceca39e135	Stomach	72	E5A1A598-5896-46F9-8DCA-BA19AC138D14	125C563B-A1CE-4FFC-8D8D-19C7CA2E1049	TCGA-BR-4191-01A-02D-1128-02	HG19_Broad_variant	TCGA-BR-4191	TCGA-STAD	NA	s14608	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6be96	58cfa830e4b0c9d6adf6be96	TCGA-AZ-4681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	495.02	1.9	0.14	58cfa830e4b0c9d6adf6be96	TCGA-AZ-4681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4681-01A	6FBC2B46-6762-4778-AA7E-782162C5397C	Primary Tumor	Illumina HiSeq	6ba6ed18-e876-4135-beef-7355f9bafa79	Colorectal	79	6171DB74-FE5A-4495-8B6A-724BE0CBA79E	37179766-A54A-4FA0-9E6E-5A33ABF3AC45	TCGA-AZ-4681-01A-01D-1405-02	HG18	TCGA-AZ-4681	TCGA-COAD	NA	s13543	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bfa4	58cfa830e4b0c9d6adf6bfa4	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.bam	77.4	1.9	0.15	58cfa830e4b0c9d6adf6bfa4	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6457-01A	05CE16D4-A999-491A-91AD-9449A57228FF	Primary Tumor	Illumina HiSeq	695f7145-7735-48f7-98e8-99b86bb936f4	Stomach	69	BADB9AE0-9C44-41D4-848B-EE03B6FCA503	85EEEBBE-BDBB-4FE7-8CCD-401E818EEB29	TCGA-BR-6457-01A-21D-1798-02	HG19_Broad_variant	TCGA-BR-6457	TCGA-STAD	NA	s14618	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bfa9	58cfa830e4b0c9d6adf6bfa9	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted.bam	282.7	1.9	0.15	58cfa830e4b0c9d6adf6bfa9	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6456-01A	1CA3C5E0-32B0-4467-8EC0-CA212E35D2B3	Primary Tumor	Illumina HiSeq	a772744a-8f77-4f03-adaf-cbd5db4ba399	Stomach	74	53369A25-3BC4-48CB-9004-DA3507C4D478	B2D5157F-5D0A-451C-8E78-AFFFC67B2F68	TCGA-BR-6456-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6456	TCGA-STAD	NA	s14399	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bf74	58cfa830e4b0c9d6adf6bf74	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted.bam	84.77	1.86	0.16	58cfa830e4b0c9d6adf6bf74	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LD-01A	1200C8B7-A058-4C01-BBE2-04EC09A65245	Primary Tumor	Illumina HiSeq	aa90984a-1483-43a2-8b20-f1654e3f601e	Uterus	63	649DADDA-5823-4B0D-B5A2-49F501ADC029	3D587F43-D9C5-4E3B-B245-60BB0AE92808	TCGA-AP-A0LD-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LD	TCGA-UCEC	NA	s5199	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b700	58cfa82fe4b0c9d6adf6b700	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted.bam	360.7	1.9	0.14	58cfa82fe4b0c9d6adf6b700	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5775-01A	C8544FB3-B26E-4672-BB81-A271DB724B04	Primary Tumor	Illumina HiSeq	af9f3482-e78b-4fe4-ac01-64f69b84d78d	Lung	71	5449BCED-1356-4DE5-9352-349725656C5C	11AEF70D-D22B-4936-BD8C-863BDBD4940E	TCGA-64-5775-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5775	TCGA-LUAD	62	s10664	Harvard Medical School	Fox Chase	United States	NO	T4	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1623-02	TRUE
13722.58cfa830e4b0c9d6adf6bfb4	58cfa830e4b0c9d6adf6bfb4	TCGA-B5-A0JS-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B5-A0JS-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_3_rg.sorted	TCGA-B5-A0JS-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_3_rg.sorted.bam	8.12	1.94	0.14	58cfa830e4b0c9d6adf6bfb4	TCGA-B5-A0JS-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JS-10A	0DA7BBD4-ED8D-474B-B494-CB93C5FA811E	Blood Derived Normal	Illumina HiSeq	c0a0da0a-9cca-4ed6-915b-59f87d57f0b6	Uterus	54	DEAC81F9-E5C9-402A-9B45-121E2C7DCF7A	38161F2E-8148-4B49-A822-CA9F0D0A5CF2	TCGA-B5-A0JS-10A-01D-A101-02	HG19_Broad_variant	TCGA-B5-A0JS	TCGA-UCEC	NA	s5205	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bfc0	58cfa830e4b0c9d6adf6bfc0	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.bam	61.49	1.87	0.17	58cfa830e4b0c9d6adf6bfc0	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JS-01A	0DA7BBD4-ED8D-474B-B494-CB93C5FA811E	Primary Tumor	Illumina HiSeq	06607d3e-b9f0-4332-aee8-7001d26e7d12	Uterus	54	D0B88B1C-150D-4ABC-9F9E-8C51CB208EFA	D2DD7ED4-03F6-463E-94BD-6CF98D80E8FD	TCGA-B5-A0JS-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JS	TCGA-UCEC	NA	s5208	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bff6	58cfa830e4b0c9d6adf6bff6	TCGA-AG-3887-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3887-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3887-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	12.59	1.9	0.17	58cfa830e4b0c9d6adf6bff6	TCGA-AG-3887-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3887-10A	8C7CCDB0-7653-4A8D-86B6-DE39AFC40765	Blood Derived Normal	Illumina HiSeq	aa0d32fd-4a31-43c5-9b23-6a623a285c80	Colorectal	68	52C98B93-E4D6-43AF-A56A-542D7DE940B6	79732BB4-4ACB-47D0-95C0-38D934C99F0D	TCGA-AG-3887-10A-01D-1115-02	HG18	TCGA-AG-3887	TCGA-READ	NA	s1959	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Mucinous Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bffc	58cfa830e4b0c9d6adf6bffc	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	614.89	1.9	0.15	58cfa830e4b0c9d6adf6bffc	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3890-01A	E2D395F8-BF13-4FE4-8031-683B0EEDD875	Primary Tumor	Illumina HiSeq	b4bf7544-0816-4940-aa9f-d770f09f35f3	Colorectal	62	DB70A6DD-DE09-4ED7-916C-708B21734500	12064771-AE96-441D-BE8B-EE49B63F1E4E	TCGA-AG-3890-01A-01D-1115-02	HG18	TCGA-AG-3890	TCGA-READ	NA	s2145	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6c022	58cfa830e4b0c9d6adf6c022	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.bam	36.9	2.03	0.15	58cfa830e4b0c9d6adf6c022	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZE-01A	AB8C9101-ADEB-4C43-A8BB-B089EBD711F6	Primary Tumor	Illumina HiSeq	b215d9c2-6a64-45cf-8e4b-0e2b87207119	Thyroid	63	695C5627-F442-4A86-9702-EF35DEFD8C8C	ED0B1C86-A516-422F-92C4-7C535E709989	TCGA-BJ-A0ZE-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZE	TCGA-THCA	NA	s12231	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c073	58cfa830e4b0c9d6adf6c073	TCGA-BJ-A0ZE-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZE-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_7_rg.sorted	TCGA-BJ-A0ZE-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_7_rg.sorted.bam	15.88	1.98	0.16	58cfa830e4b0c9d6adf6c073	TCGA-BJ-A0ZE-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZE-10A	AB8C9101-ADEB-4C43-A8BB-B089EBD711F6	Blood Derived Normal	Illumina HiSeq	4568433f-6965-4efc-8d70-3369d6a70e72	Thyroid	63	ABE80C37-F3CB-4A56-9C18-9080057AA81D	9A3C6D5A-4AD4-40BC-A4B0-69544AA5A5D0	TCGA-BJ-A0ZE-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZE	TCGA-THCA	NA	s12229	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c1c6	58cfa830e4b0c9d6adf6c1c6	TCGA-BG-A0M2-10A-02D-A101_120406_SN1120_0130_AD0UKGACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BG-A0M2-10A-02D-A101_120406_SN1120_0130_AD0UKGACXX_s_2_rg.sorted	TCGA-BG-A0M2-10A-02D-A101_120406_SN1120_0130_AD0UKGACXX_s_2_rg.sorted.bam	8.71	1.91	0.13	58cfa830e4b0c9d6adf6c1c6	TCGA-BG-A0M2-10A-02D-A101_120406_SN1120_0130_AD0UKGACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M2-10A	9731E0B3-C62D-43CB-8AE7-8F973D69AB19	Blood Derived Normal	Illumina HiSeq	b02fc796-b592-46f5-8222-5a702393c7cb	Uterus	62	56931C60-F82B-4F1F-8C4F-547B7EFCFF0B	115C6BD3-1D4D-481F-A939-2B5D0F89BD7F	TCGA-BG-A0M2-10A-02D-A101-02	HG19_Broad_variant	TCGA-BG-A0M2	TCGA-UCEC	NA	s5214	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c12f	58cfa830e4b0c9d6adf6c12f	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.bam	74.26	2.08	0.16	58cfa830e4b0c9d6adf6c12f	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MU-01A	A7329910-B1C7-4A18-B28E-8FAD79121339	Primary Tumor	Illumina HiSeq	c676fa46-db3a-402d-804d-9717141fdae6	Uterus	78	F0AF3F30-3D64-4BD8-9A8F-7FF7AB9BB7B0	0BB10C9F-C337-4E2E-A661-9CE12C8BEB35	TCGA-BG-A0MU-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MU	TCGA-UCEC	NA	s5393	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bff8	58cfa830e4b0c9d6adf6bff8	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	745.89	1.9	0.15	58cfa830e4b0c9d6adf6bff8	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3887-01A	8C7CCDB0-7653-4A8D-86B6-DE39AFC40765	Primary Tumor	Illumina HiSeq	0041b462-7ad7-4a4d-8fea-1942532341ed	Colorectal	68	7F10DD13-E2C3-4F27-8673-FF5CD1632B2B	5986038D-2696-4F89-A5F5-C8173BA7D70F	TCGA-AG-3887-01A-01D-1115-02	HG18	TCGA-AG-3887	TCGA-READ	NA	s2136	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Mucinous Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6c164	58cfa830e4b0c9d6adf6c164	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.bam	227.7	1.9	0.15	58cfa830e4b0c9d6adf6c164	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5151-01A	A55FB87D-F606-48A5-82F5-09EACBACF41B	Primary Tumor	Illumina HiSeq	d1067ce4-863a-49f4-9061-d2e677695382	Head and Neck	72	63384A6A-9686-44EE-8C8F-22923968C9DE	5B29B8E2-23E6-4E6E-815C-B8D0EF534B14	TCGA-BA-5151-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-5151	TCGA-HNSC	NA	s15488	Harvard Medical School	UNC	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9f6	58cfa82fe4b0c9d6adf6b9f6	TCGA-AA-3555-10A-01D-1638-02_110525_SN590_0091_AC02W2ABXX_s_6.rg.sorted.filtered.	WGS	TCGA-AA-3555-10A-01D-1638-02_110525_SN590_0091_AC02W2ABXX_s_6.rg.sorted	TCGA-AA-3555-10A-01D-1638-02_110525_SN590_0091_AC02W2ABXX_s_6.rg.sorted.bam	0	1.9	0.14	58cfa82fe4b0c9d6adf6b9f6	TCGA-AA-3555-10A-01D-1638-02_110525_SN590_0091_AC02W2ABXX_s_6.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3555-10A	36EAF209-C332-4321-B6AA-51A3368ECD79	Blood Derived Normal	Illumina HiSeq	4ca4d097-aba8-4b2e-80ef-1c1b06463366	Colorectal	81	A08213B9-B852-4C99-9469-8C9DF8A34AD0	631554D6-FDA1-4D51-8FA8-2225A0A0F285	TCGA-AA-3555-10A-01D-1638-02	HG18_Broad_variant	TCGA-AA-3555	TCGA-COAD	NA	s13508	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1638-02	FALSE
13722.58cfa830e4b0c9d6adf6c1cc	58cfa830e4b0c9d6adf6c1cc	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted.bam	55.01	NA	0.18	58cfa830e4b0c9d6adf6c1cc	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PU-01A	3DD5A206-D7F3-42F1-B9CC-4B31C76D495D	Primary Tumor	Illumina HiSeq	26c2ab51-9411-4718-8733-1c3c5ba19602	Skin	46	D9C8128A-5990-43C8-AC08-CBDF035213D6	AAC0230D-759F-4B2E-9904-3F7822E6B13C	TCGA-BF-A1PU-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PU	TCGA-SKCM	NA	s7667	Harvard Medical School	Cureline	Russia	NO	T4b	N0	Not available	Stage IIC	A18Z-02	TRUE
13722.58cfa830e4b0c9d6adf6c21a	58cfa830e4b0c9d6adf6c21a	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted.bam	422.7	1.9	0.15	58cfa830e4b0c9d6adf6c21a	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5153-01A	B3631718-9E0A-454C-BEE1-8F36EBC509D8	Primary Tumor	Illumina HiSeq	3bd56918-8f2b-4486-86ea-e479c2cab413	Head and Neck	51	2DC7070A-9C70-4BB1-9634-8C934BB9C8D1	F14D0AA8-E7BB-4E0E-B887-DA7B6FA0BC86	TCGA-BA-5153-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-5153	TCGA-HNSC	1762	s16316	Harvard Medical School	UNC	None	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c360	58cfa831e4b0c9d6adf6c360	TCGA-CG-5719-10A-01D-1598_121029_SN208_0439_BD1KHKACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-5719-10A-01D-1598_121029_SN208_0439_BD1KHKACXX_s_3_rg.sorted	TCGA-CG-5719-10A-01D-1598_121029_SN208_0439_BD1KHKACXX_s_3_rg.sorted.bam	94.7	1.8	0.15	58cfa831e4b0c9d6adf6c360	TCGA-CG-5719-10A-01D-1598_121029_SN208_0439_BD1KHKACXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5719-10A	263F67E0-0A28-42E6-B3F3-1DDD0D397220	Blood Derived Normal	Illumina HiSeq	74d5e460-86bd-441b-9409-00b8f0248eb9	Stomach	54	6CF9DAA3-1ED5-45C2-9A6F-3340D256C9D7	B0A51CDD-A3AC-4497-B9CB-3B766E4A549F	TCGA-CG-5719-10A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5719	TCGA-STAD	NA	s14902	Harvard Medical School	Indivumed	Germany	NO	T4	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c36c	58cfa831e4b0c9d6adf6c36c	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.bam	193.3	1.9	0.14	58cfa831e4b0c9d6adf6c36c	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5803-01A	33901C6F-9180-4A19-866C-F4AC6BEC76DA	Primary Tumor	Illumina HiSeq	1002025d-03b9-46ab-988a-576f59957cac	Stomach	78	EB71264D-C896-4910-BF46-D6F129B83941	EABD49CE-0F0C-443D-9BF4-0ADD2C2532B2	TCGA-CD-5803-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5803	TCGA-STAD	NA	s15118	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c346	58cfa831e4b0c9d6adf6c346	TCGA-CG-5717-10A-01D-1598_121029_SN208_0438_AC18NJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-5717-10A-01D-1598_121029_SN208_0438_AC18NJACXX_s_7_rg.sorted	TCGA-CG-5717-10A-01D-1598_121029_SN208_0438_AC18NJACXX_s_7_rg.sorted.bam	27.7	1.9	0.16	58cfa831e4b0c9d6adf6c346	TCGA-CG-5717-10A-01D-1598_121029_SN208_0438_AC18NJACXX_s_7_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5717-10A	BDC3899E-15AE-421F-829B-0E07FBD27C60	Blood Derived Normal	Illumina HiSeq	6aa2ef88-18e7-4056-b37a-72a9acd0fed9	Stomach	58	AB9865D3-94CD-404B-B7A0-3703038C2E32	54637B38-876F-4F77-918F-8AD88539274B	TCGA-CG-5717-10A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5717	TCGA-STAD	212	s14830	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa830e4b0c9d6adf6c038	58cfa830e4b0c9d6adf6c038	TCGA-AG-3909-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3909-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3909-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	11.59	1.8	0.16	58cfa830e4b0c9d6adf6c038	TCGA-AG-3909-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3909-10A	769880AE-34D9-405E-8EA7-33BA47CF2DD2	Blood Derived Normal	Illumina HiSeq	897a4144-0e3c-4ce6-9031-d32b8f3f18a7	Colorectal	69	1176543D-336D-451F-8A8E-3AC97C76EBEB	FD9134ED-57B7-4220-9F8E-C9AFC2AF6A9E	TCGA-AG-3909-10A-01D-1115-02	HG18	TCGA-AG-3909	TCGA-READ	NA	s2167	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6c2ca	58cfa830e4b0c9d6adf6c2ca	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.bam	73.32	1.95	0.16	58cfa830e4b0c9d6adf6c2ca	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0RY-01A	F299AD43-BB16-46CE-9617-48CC6C6F29E7	Primary Tumor	Illumina HiSeq	5464e1b6-9efc-49a0-bd5b-4fcd152a7718	Uterus	68	260692E1-9B2C-4F8B-952D-1B95C042E659	8DB9ED84-C708-4075-B93D-CC58E84E6D99	TCGA-BG-A0RY-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0RY	TCGA-UCEC	NA	s4258	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c03c	58cfa830e4b0c9d6adf6c03c	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	420.89	1.9	0.15	58cfa830e4b0c9d6adf6c03c	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4001-01A	D846228F-67AF-4B3B-9796-DBC263C2054C	Primary Tumor	Illumina HiSeq	53c6af7e-4876-4559-b1b1-d7dc58c2b702	Colorectal	74	6160C363-B050-4B3B-9909-4EBC33ED3A1A	05B6BA78-DDE8-4E68-9622-7B618A083CC8	TCGA-AG-4001-01A-02D-1115-02	HG18	TCGA-AG-4001	TCGA-READ	NA	s2164	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa831e4b0c9d6adf6c36d	58cfa831e4b0c9d6adf6c36d	TCGA-CD-5802-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CD-5802-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_7_rg.sorted	TCGA-CD-5802-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_7_rg.sorted.bam	199	2	0.17	58cfa831e4b0c9d6adf6c36d	TCGA-CD-5802-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5802-01A	0AECAC64-5982-4D76-8F31-958F6A00951D	Primary Tumor	Illumina HiSeq	43a17980-59c7-4b7c-a3a6-9ed51fb03889	Stomach	58	93C38FFB-27AC-4C91-939D-7102EE72F404	B0BEA59D-9484-4FF9-BC14-0DD1882EF6BE	TCGA-CD-5802-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5802	TCGA-STAD	NA	s14477	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c394	58cfa831e4b0c9d6adf6c394	TCGA-BJ-A0Z5-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z5-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_4_rg.sorted	TCGA-BJ-A0Z5-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_4_rg.sorted.bam	16.85	2.05	0.16	58cfa831e4b0c9d6adf6c394	TCGA-BJ-A0Z5-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z5-10A	0FE3B19A-F5E4-497E-92DA-32FF6C77B066	Blood Derived Normal	Illumina HiSeq	db8a561b-7268-464c-851c-223c161825ed	Thyroid	58	8C067558-66E7-43F3-8332-6CB96F657B4C	0707D604-60AA-4399-9703-E9758C0BA08A	TCGA-BJ-A0Z5-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z5	TCGA-THCA	NA	s12230	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c560	58cfa831e4b0c9d6adf6c560	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted.bam	200.4	1.9	0.16	58cfa831e4b0c9d6adf6c560	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5767-01A	8DC53431-44AB-485E-B4E6-C3D06509506D	Primary Tumor	Illumina HiSeq	4ec6dbff-5194-4938-949c-d5ae0ec6a882	Prostate	66	A87E6352-C469-484D-87FC-FABDBA237D01	02D28407-4AE4-4DA6-ABB5-6D6A4BB3D8D3	TCGA-CH-5767-01A-11D-1784-02	HG19_Broad_variant	TCGA-CH-5767	TCGA-PRAD	NA	s4129	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa831e4b0c9d6adf6c4b4	58cfa831e4b0c9d6adf6c4b4	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted.bam	88.59	2.02	0.17	58cfa831e4b0c9d6adf6c4b4	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-CE-A13K-01A	A1227FFA-2733-4A43-BA82-834755453870	Primary Tumor	Illumina HiSeq	7f979498-38e3-4b28-b84a-c3eede43fa06	Thyroid	30	DAF2A444-AB89-48D4-9DA7-888AC3099AB7	7CEF35A1-E530-47C9-9A86-3EA2C970FCD3	TCGA-CE-A13K-01A-11D-A10R-02	HG19_Broad_variant	TCGA-CE-A13K	TCGA-THCA	NA	s12632	Harvard Medical School	ILSbio	Vietnam	NO	T3	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c4e9	58cfa831e4b0c9d6adf6c4e9	TCGA-AZ-4682-01B-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4682-01B-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4682-01B-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	752.02	1.9	0.15	58cfa831e4b0c9d6adf6c4e9	TCGA-AZ-4682-01B-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4682-01B	E588714A-7753-4C3C-ABB6-EAF1AAB53AB3	Primary Tumor	Illumina HiSeq	fb93cdea-2ff1-454c-9fac-523a4bb11d62	Colorectal	61	A2412F6F-324E-4EF2-BD46-0D33596A033B	2007180A-F4AC-4300-A560-903ACEAC4F71	TCGA-AZ-4682-01B-01D-1405-02	HG18	TCGA-AZ-4682	TCGA-COAD	680	s13390	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Colon Adenocarcinoma	Stage IVA	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c5e4	58cfa831e4b0c9d6adf6c5e4	TCGA-CG-4437-01A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-4437-01A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_4_rg.sorted	TCGA-CG-4437-01A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_4_rg.sorted.bam	215.4	1.9	0.14	58cfa831e4b0c9d6adf6c5e4	TCGA-CG-4437-01A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4437-01A	6244E506-D163-4D34-8FEC-6158191679CB	Primary Tumor	Illumina HiSeq	ff02c427-3a7b-4e29-9ddc-0b8034807ad6	Stomach	83	A882F6C0-D12D-4D49-9A2A-3850EA736C37	B6D1C576-6AB8-4759-B1B0-6E18DC162962	TCGA-CG-4437-01A-01D-1798-02	HG19_Broad_variant	TCGA-CG-4437	TCGA-STAD	NA	s14553	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c624	58cfa831e4b0c9d6adf6c624	TCGA-CG-4301-10A-01D-1154_130218_SN208_0453_AC1T26ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-4301-10A-01D-1154_130218_SN208_0453_AC1T26ACXX_s_8_rg.sorted	TCGA-CG-4301-10A-01D-1154_130218_SN208_0453_AC1T26ACXX_s_8_rg.sorted.bam	80.6	1.9	0.15	58cfa831e4b0c9d6adf6c624	TCGA-CG-4301-10A-01D-1154_130218_SN208_0453_AC1T26ACXX_s_8_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4301-10A	7E13FE2A-3D6E-487F-900D-F5891D986AA2	Blood Derived Normal	Illumina HiSeq	6015c990-2a38-459d-9d91-64c1561fac75	Stomach	75	7189941F-88C7-4E4A-94E9-D9E9EBEE1CDE	D9A32B4F-0323-45B8-97B8-C88E75E95431	TCGA-CG-4301-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4301	TCGA-STAD	NA	s15190	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c604	58cfa831e4b0c9d6adf6c604	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted.bam	258	1.9	0.14	58cfa831e4b0c9d6adf6c604	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5330-01A	9FFA79FA-D2D8-48E1-8FD6-4B020ECF357C	Primary Tumor	Illumina HiSeq	a37f15ec-e0df-4bcd-8275-88312d0a1566	Head and Neck	69	A70301B0-F66D-49B7-B420-C1F56B90002D	AB6DC814-ECE0-497C-BC58-5FECE5D3DCE6	TCGA-CQ-5330-01A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5330	TCGA-HNSC	NA	s15640	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c68a	58cfa831e4b0c9d6adf6c68a	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted.bam	36.74	1.82	0.16	58cfa831e4b0c9d6adf6c68a	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A0YR-01A	811B3950-36E7-485F-BC48-ACA1EEE2DDEF	Primary Tumor	Illumina HiSeq	197d19a7-07c1-4cd3-b41d-a8233c9d8a42	Bladder	83	B362FCFA-4E31-4321-9E17-11A8BAE839C3	0CB51232-CFEA-4F4F-A26A-173B1094A64B	TCGA-CU-A0YR-01A-12D-A10R-02	HG19_Broad_variant	TCGA-CU-A0YR	TCGA-BLCA	NA	s3096	Harvard Medical School	UNC	United States	NO	T2	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c678	58cfa831e4b0c9d6adf6c678	TCGA-CQ-5325-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CQ-5325-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_1_rg.sorted	TCGA-CQ-5325-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_1_rg.sorted.bam	166	1.9	0.14	58cfa831e4b0c9d6adf6c678	TCGA-CQ-5325-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5325-01A	408C5D54-7888-4955-8386-BF8819B48A6C	Primary Tumor	Illumina HiSeq	a7440672-d797-4ad6-979a-c0835f0c2768	Head and Neck	65	8394A7F6-1BF6-473E-A155-3DA1A3DE244F	FFB4F8E1-B683-4A35-A5E7-15DBF610AE47	TCGA-CQ-5325-01A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5325	TCGA-HNSC	654	s16331	Harvard Medical School	University Health Network, Toronto	Canada	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c662	58cfa831e4b0c9d6adf6c662	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	450.02	1.9	0.14	58cfa831e4b0c9d6adf6c662	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4750-01A	C777A777-373A-4773-9566-6C373261F00A	Primary Tumor	Illumina HiSeq	eae74e76-b630-469d-9ad7-549fbfe64297	Colorectal	34	463D4B1E-2068-45DD-9631-FB9C7268FE6C	EE814BA4-311A-4ABC-B7A6-F32C68C50F2A	TCGA-CM-4750-01A-01D-1405-02	HG18	TCGA-CM-4750	TCGA-COAD	NA	s12891	Harvard Medical School	MSKCC	United States	NO	T1	N1b	Colon Adenocarcinoma	Stage IIIA	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c6da	58cfa831e4b0c9d6adf6c6da	TCGA-CS-6186-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CS-6186-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_4_rg.sorted	TCGA-CS-6186-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_4_rg.sorted.bam	250	1.9	0.16	58cfa831e4b0c9d6adf6c6da	TCGA-CS-6186-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-6186-10A	9EE6E821-3AF2-42D7-9D14-F0CA455F338C	Blood Derived Normal	Illumina HiSeq	e995755c-602f-4204-8174-82c097701e8a	Brain	58	8443AA4F-9650-45F4-921B-927C1F00A31C	1B2818EA-5C5F-4464-9DBF-0FFEDD77A707	TCGA-CS-6186-10A-01D-2022-02	HG19_Broad_variant	TCGA-CS-6186	TCGA-LGG	538	s8128	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6c6d4	58cfa831e4b0c9d6adf6c6d4	TCGA-CQ-5327-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CQ-5327-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_6_rg.sorted	TCGA-CQ-5327-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_6_rg.sorted.bam	87.7	1.9	0.14	58cfa831e4b0c9d6adf6c6d4	TCGA-CQ-5327-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_6_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5327-10A	5A03E2B6-4C8B-479A-9036-9859AF031DA4	Blood Derived Normal	Illumina HiSeq	f13990a7-88ec-44b6-b54c-82cd223ab0e2	Head and Neck	61	1C3A8D45-573F-49F3-AF6C-F5686B6F21C5	B39DC256-152A-4592-B7BC-6859E46D1F8E	TCGA-CQ-5327-10A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5327	TCGA-HNSC	NA	s16330	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c75b	58cfa831e4b0c9d6adf6c75b	TCGA-D1-A16D-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A16D-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_4_rg.sorted	TCGA-D1-A16D-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_4_rg.sorted.bam	7.4	1.95	0.15	58cfa831e4b0c9d6adf6c75b	TCGA-D1-A16D-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16D-10A	5693302A-4548-4C0B-8725-0CB7C67BC4F8	Blood Derived Normal	Illumina HiSeq	1632a50b-463d-4306-a663-2af6737ce5c8	Uterus	49	9341A9C7-C7D3-4695-A721-2EE86F5F188D	FD5F8332-92E6-4A62-95A5-2A377BFAD623	TCGA-D1-A16D-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A16D	TCGA-UCEC	NA	s5019	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c794	58cfa831e4b0c9d6adf6c794	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted.bam	69	1.9	0.15	58cfa831e4b0c9d6adf6c794	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6017-01A	23C4E2EB-142B-4FCC-A974-9A248AEC3F37	Primary Tumor	Illumina HiSeq	e0dae8a5-f74f-4e25-98c2-238e28c54863	Head and Neck	55	6C07CD48-2269-4D42-9879-309EA4CD3A74	48A22F9A-2A18-4FCA-8271-44B3F7C3A628	TCGA-CN-6017-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6017	TCGA-HNSC	NA	s16181	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c7ac	58cfa831e4b0c9d6adf6c7ac	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted.bam	262.7	1.9	0.14	58cfa831e4b0c9d6adf6c7ac	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6827-01A	3C5BC678-41E9-46B3-9686-5CD95659AB71	Primary Tumor	Illumina HiSeq	849f41d7-0557-40ce-bca0-8a54c496fef2	Head and Neck	55	C53D6135-C614-45F4-8F41-49B20ED4A549	E2CDC496-8A62-4501-98C0-2AF2CCF48988	TCGA-D6-6827-01A-11D-1911-02	HG19_Broad_variant	TCGA-D6-6827	TCGA-HNSC	NA	s16057	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c804	58cfa831e4b0c9d6adf6c804	TCGA-D1-A2G6-01A-11D-A17E_120511_SN208_0299_BD12J9ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D1-A2G6-01A-11D-A17E_120511_SN208_0299_BD12J9ACXX_s_7_rg.sorted	TCGA-D1-A2G6-01A-11D-A17E_120511_SN208_0299_BD12J9ACXX_s_7_rg.sorted.bam	60.54	NA	0.18	58cfa831e4b0c9d6adf6c804	TCGA-D1-A2G6-01A-11D-A17E_120511_SN208_0299_BD12J9ACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A2G6-01A	46CD8DED-F8A1-4F8C-A4C2-2D5B51C04F18	Primary Tumor	Illumina HiSeq	4ac2b259-f781-4a71-b271-2d326472c965	Uterus	53	2127E58B-BD7B-490E-B34B-4F626B2A4053	079C1D47-95AC-456B-8DD5-C89B4076E578	TCGA-D1-A2G6-01A-11D-A17E-02	HG19_Broad_variant	TCGA-D1-A2G6	TCGA-UCEC	258	s5230	Harvard Medical School	Mayo Clinic	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A17E-02	TRUE
13722.58cfa831e4b0c9d6adf6c820	58cfa831e4b0c9d6adf6c820	TCGA-D1-A16Q-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D1-A16Q-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_6_rg.sorted	TCGA-D1-A16Q-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_6_rg.sorted.bam	8.1	1.88	0.16	58cfa831e4b0c9d6adf6c820	TCGA-D1-A16Q-10A-01D-A12F_120511_SN208_0299_BD12J9ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16Q-10A	7F4F3AED-69AF-421E-817B-B258DCC0BAC5	Blood Derived Normal	Illumina HiSeq	5a60f363-a607-4fc0-9cac-d1c33bcacd05	Uterus	54	083F8BFB-D189-4E99-A597-89DD3A7769EB	A0CD8E6F-AEDE-4B7D-A9E1-E38034C51638	TCGA-D1-A16Q-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A16Q	TCGA-UCEC	NA	s5021	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c876	58cfa831e4b0c9d6adf6c876	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted.bam	275.7	1.9	0.14	58cfa831e4b0c9d6adf6c876	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6826-01A	31243867-8E9F-46E9-A213-B83544EB8028	Primary Tumor	Illumina HiSeq	377f848a-3e59-4eee-bd9d-87fdc1a898bb	Head and Neck	64	1737989D-8463-4761-B111-53E4FD396375	07759CEA-B923-4D20-96DB-7952D50314C7	TCGA-D6-6826-01A-11D-1911-02	HG19_Broad_variant	TCGA-D6-6826	TCGA-HNSC	NA	s15912	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c7bc	58cfa831e4b0c9d6adf6c7bc	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted.bam	172	1.9	0.15	58cfa831e4b0c9d6adf6c7bc	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6019-01A	EE3061EC-273C-4BEF-A325-35E9C469BF01	Primary Tumor	Illumina HiSeq	e7b9cb7d-0a1a-4461-ab89-108d02821762	Head and Neck	61	AC349695-2219-4A67-ADD5-A94FF85794E1	2C509E96-12D7-4DBB-A02F-DCDCC6F76952	TCGA-CN-6019-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6019	TCGA-HNSC	NA	s16178	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c866	58cfa831e4b0c9d6adf6c866	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted.bam	384.7	1.9	0.14	58cfa831e4b0c9d6adf6c866	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6823-01A	FBDAB01C-191C-4AEF-9451-CA3AFEC55FA1	Primary Tumor	Illumina HiSeq	250e5855-f3af-4c16-9efe-918be02bf754	Head and Neck	50	2DA83450-04C2-44D0-AB8A-9CC876242D5A	FE15C318-C3B1-4541-A0DA-4E41D7E99FBB	TCGA-D6-6823-01A-11D-1911-02	HG19_Broad_variant	TCGA-D6-6823	TCGA-HNSC	NA	s15531	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c8cc	58cfa831e4b0c9d6adf6c8cc	TCGA-D7-5579-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D7-5579-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_3_rg.sorted	TCGA-D7-5579-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_3_rg.sorted.bam	84.7	1.89	0.15	58cfa831e4b0c9d6adf6c8cc	TCGA-D7-5579-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-5579-01A	8B5746F9-DBEE-40BD-9141-1081960CF286	Primary Tumor	Illumina HiSeq	269741db-5bad-48aa-af11-42d222310df9	Stomach	74	633DCE5B-7A88-46DC-AD06-8897A609675B	CFF33A88-0211-46EE-AB5B-78F56C63E2A6	TCGA-D7-5579-01A-01D-1598-02	HG19_Broad_variant	TCGA-D7-5579	TCGA-STAD	NA	s15198	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N2	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c896	58cfa831e4b0c9d6adf6c896	TCGA-DJ-A13V-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DJ-A13V-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_2_rg.sorted	TCGA-DJ-A13V-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_2_rg.sorted.bam	80.38	1.94	0.14	58cfa831e4b0c9d6adf6c896	TCGA-DJ-A13V-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13V-01A	99AC4F2E-2E63-4F1E-AF0F-8F23A2CAF999	Primary Tumor	Illumina HiSeq	a3620988-3968-488b-88e7-9ae555459dc7	Thyroid	21	A870F5CA-F049-48C1-AFAC-B788A3111086	DB0AC00C-ABED-4D02-B05B-A3CD87DCA75F	TCGA-DJ-A13V-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13V	TCGA-THCA	NA	s12634	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c8da	58cfa831e4b0c9d6adf6c8da	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted.bam	60.13	1.98	0.15	58cfa831e4b0c9d6adf6c8da	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A168-01A	41893E97-7E90-4B03-B738-260F288ADE4C	Primary Tumor	Illumina HiSeq	f7d0c63d-0a01-4ff3-b721-3c10692581ca	Uterus	67	B44C673E-9560-4B59-9FF3-34CE230CAD1C	4593D11C-3A35-4269-80EC-D282497CF71C	TCGA-D1-A168-01A-31D-A12F-02	HG19_Broad_variant	TCGA-D1-A168	TCGA-UCEC	NA	s4438	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c982	58cfa831e4b0c9d6adf6c982	TCGA-D7-6520-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_8_rg.sorted.filtered.	WGS	TCGA-D7-6520-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_8_rg.sorted	TCGA-D7-6520-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_8_rg.sorted.bam	377.7	1.9	0.15	58cfa831e4b0c9d6adf6c982	TCGA-D7-6520-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6520-10A	3C573AF6-6298-49DE-8DE0-6A7F9CE9B000	Blood Derived Normal	Illumina HiSeq	c35f64e9-94a7-4b34-aba4-01aea848176d	Stomach	53	08B577B2-7497-4C99-8963-D8E70CFFA135	24639C02-25A3-48D6-B248-C46DFF509941	TCGA-D7-6520-10A-01D-1798-02	HG19_Broad_variant	TCGA-D7-6520	TCGA-STAD	NA	s14643	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2b	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c949	58cfa831e4b0c9d6adf6c949	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted.bam	21.24	1.93	0.16	58cfa831e4b0c9d6adf6c949	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13O-01A	77D5B246-33BA-4A96-9D73-06ACA797653E	Primary Tumor	Illumina HiSeq	ae4a78d9-4c9a-40f7-9612-17d11799ea67	Thyroid	56	457B11C0-3C36-4907-8C76-60E3861EBABB	EC713290-9998-489B-9D1E-CC9D33CF5428	TCGA-DJ-A13O-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13O	TCGA-THCA	NA	s12241	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c993	58cfa831e4b0c9d6adf6c993	TCGA-D9-A1JW-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D9-A1JW-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_6_rg.sorted	TCGA-D9-A1JW-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_6_rg.sorted.bam	44.09	NA	0.18	58cfa831e4b0c9d6adf6c993	TCGA-D9-A1JW-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D9-A1JW-10A	9A903FC2-57D7-4A02-94E7-9B9B7EE99276	Blood Derived Normal	Illumina HiSeq	81b083e1-deb3-4935-b274-bded2a4d47fb	Skin	82	7402F1FA-E9DF-45A3-9DD7-B5F82F427F52	790E7D9B-A1E6-40EF-B46D-22E35DAB4E5D	TCGA-D9-A1JW-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D9-A1JW	TCGA-SKCM	NA	s7673	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T1a	N2a	Not available	Not available	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c9b0	58cfa831e4b0c9d6adf6c9b0	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted.bam	24.89	1.93	0.14	58cfa831e4b0c9d6adf6c9b0	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13M-01A	BA9DEC81-FFC0-453A-9621-94BEBA45FAB1	Primary Tumor	Illumina HiSeq	6d7b5f3b-5fba-469e-a651-31a4569d7877	Thyroid	28	28913C64-8637-4537-AF8C-7315097A5AD1	8C708D3B-B312-4C27-898B-A0FE87110474	TCGA-DJ-A13M-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13M	TCGA-THCA	NA	s12369	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c730	58cfa831e4b0c9d6adf6c730	TCGA-D1-A17N-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D1-A17N-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_6_rg.sorted	TCGA-D1-A17N-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_6_rg.sorted.bam	98.78	1.87	0.17	58cfa831e4b0c9d6adf6c730	TCGA-D1-A17N-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17N-01A	001E0309-9C50-42B0-9E38-347883EE2CD3	Primary Tumor	Illumina HiSeq	610d595a-df00-4af9-9644-d750501c1737	Uterus	46	F93931BA-8333-4E22-A430-CA02D9DA3FFC	DB0F8EE9-33A0-46CC-8218-59E18B2F824F	TCGA-D1-A17N-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17N	TCGA-UCEC	NA	s5226	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c9e7	58cfa831e4b0c9d6adf6c9e7	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted.bam	48.48	1.91	0.16	58cfa831e4b0c9d6adf6c9e7	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QQ-01A	99EF2FEC-5A3C-4E42-8F78-7EAF9877E26D	Primary Tumor	Illumina HiSeq	091bb28f-4fe0-41e6-b7c5-b952dc370506	Thyroid	43	64D1F58A-986F-4D4B-962E-DA59A48C988B	DDE34A05-A208-4F86-9803-0FB1EB858947	TCGA-DJ-A1QQ-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QQ	TCGA-THCA	NA	s12639	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6ca25	58cfa831e4b0c9d6adf6ca25	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted.bam	63	2.03	0.14	58cfa831e4b0c9d6adf6ca25	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DE-A0Y2-01A	6AD260AD-769A-4F3C-BD07-927ADF6B2338	Primary Tumor	Illumina HiSeq	eaf940db-08d0-4dc4-b390-0576523fb2f5	Thyroid	30	EB4FEEBB-293E-43E3-A2ED-344B17D180B3	E86091EB-6DCC-479B-BAFD-3DABA65787EC	TCGA-DE-A0Y2-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DE-A0Y2	TCGA-THCA	NA	s12514	Harvard Medical School	University of North Carolina	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6ca9e	58cfa831e4b0c9d6adf6ca9e	TCGA-D3-A1QB-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D3-A1QB-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_3_rg.sorted	TCGA-D3-A1QB-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_3_rg.sorted.bam	67.14	NA	0.18	58cfa831e4b0c9d6adf6ca9e	TCGA-D3-A1QB-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A1QB-06A	C59A5615-2DD1-4902-A62B-0E312EAB5484	Metastatic	Illumina HiSeq	6f1f7dfb-3aa1-435f-a587-d289d5b4872a	Skin	75	52F51508-F3A2-4752-A0E5-8CF0160D5CE1	7D4C74D8-F98C-43B4-AB7F-28E9DCB0D961	TCGA-D3-A1QB-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D3-A1QB	TCGA-SKCM	NA	s7831	Harvard Medical School	MD Anderson	United States	NO	T0	N2c	Not available	Stage III	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6caa8	58cfa831e4b0c9d6adf6caa8	TCGA-D1-A16X-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A16X-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_2_rg.sorted	TCGA-D1-A16X-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_2_rg.sorted.bam	51.17	2	0.17	58cfa831e4b0c9d6adf6caa8	TCGA-D1-A16X-10A-01D-A12F_120413_SN1120_0133_BC0J8UACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16X-10A	22618073-4EF0-4C3A-97B9-90BA1CAA1D72	Blood Derived Normal	Illumina HiSeq	39003c18-13a0-4376-81fa-0efb483df6bb	Uterus	54	6E19DB42-C247-4736-9204-E279B2C50B37	A5170FF0-1D2C-48BD-B254-4978E17794EE	TCGA-D1-A16X-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A16X	TCGA-UCEC	NA	s5020	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6ca5e	58cfa831e4b0c9d6adf6ca5e	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted.bam	73.27	1.98	0.17	58cfa831e4b0c9d6adf6ca5e	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QG-01A	CB29E795-7618-4882-A7E0-69D39787B80C	Primary Tumor	Illumina HiSeq	cd7d52cc-20ac-4fa7-a821-231d15f926fc	Thyroid	62	D0A669AF-1A0A-451D-9D6F-9EEE15F7264C	EF88FE61-36C4-43CF-BD57-D15F7E264DF0	TCGA-DJ-A1QG-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QG	TCGA-THCA	NA	s12240	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cadc	58cfa831e4b0c9d6adf6cadc	TCGA-DE-A0Y3-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DE-A0Y3-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_6_rg.sorted	TCGA-DE-A0Y3-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_6_rg.sorted.bam	23.61	1.93	0.15	58cfa831e4b0c9d6adf6cadc	TCGA-DE-A0Y3-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_6_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DE-A0Y3-10A	C31B3ADF-3FC6-4A72-83B0-BBC0F295B5E7	Blood Derived Normal	Illumina HiSeq	645c3982-4de8-4fca-b798-0fad3d0c28af	Thyroid	60	2B40DE55-0CBB-44D8-A26F-B48448B32354	7FFF3470-5023-47AE-B166-496D0AB4DE13	TCGA-DE-A0Y3-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DE-A0Y3	TCGA-THCA	NA	s12365	Harvard Medical School	University of North Carolina	United States	NO	T4a	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVC	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6ca60	58cfa831e4b0c9d6adf6ca60	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted.bam	354	1.9	0.15	58cfa831e4b0c9d6adf6ca60	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6013-01A	714496C5-D221-4397-9C5A-CD2D22603E6F	Primary Tumor	Illumina HiSeq	2ca5ef3f-76f6-4db9-85e7-d32249cd642f	Head and Neck	56	D018CD44-6B01-44F2-9181-81153225AAB8	2DE7DBC6-2A3E-4E67-BB96-552E27137618	TCGA-CN-6013-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6013	TCGA-HNSC	NA	s15629	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6cb42	58cfa831e4b0c9d6adf6cb42	TCGA-EE-A29B-06A-11D-A18Y_120807_SN590_0173_AC0VN5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EE-A29B-06A-11D-A18Y_120807_SN590_0173_AC0VN5ACXX_s_1_rg.sorted	TCGA-EE-A29B-06A-11D-A18Y_120807_SN590_0173_AC0VN5ACXX_s_1_rg.sorted.bam	66.45	NA	0.17	58cfa831e4b0c9d6adf6cb42	TCGA-EE-A29B-06A-11D-A18Y_120807_SN590_0173_AC0VN5ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29B-06A	905EA29F-588A-497B-9F06-2EEF3BDC9442	Metastatic	Illumina HiSeq	0d511b2e-752b-43a4-b27f-81a205cac15e	Skin	67	73ED3AA7-1AAD-42B6-AC8A-1CA284A75A48	4A8251BE-6505-4681-AB78-55086FC7D877	TCGA-EE-A29B-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29B	TCGA-SKCM	NA	s7677	Harvard Medical School	University of Sydney	Australia	NO	T3b	N0	Not available	Stage IIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb48	58cfa831e4b0c9d6adf6cb48	TCGA-EE-A29S-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EE-A29S-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_5_rg.sorted	TCGA-EE-A29S-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_5_rg.sorted.bam	34.67	NA	0.17	58cfa831e4b0c9d6adf6cb48	TCGA-EE-A29S-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29S-06A	5DEC1B6A-5D60-463C-9655-FC7ED79CA19D	Metastatic	Illumina HiSeq	b6eef3eb-6a3c-4010-a637-48540f303a1c	Skin	79	4EA37293-D9B4-4231-A283-6839810566D9	512F2D57-71FC-4050-AD4F-FBCC6EA2E687	TCGA-EE-A29S-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29S	TCGA-SKCM	NA	s7675	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage IIA	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb5e	58cfa831e4b0c9d6adf6cb5e	TCGA-DU-7018-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DU-7018-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_5_rg.sorted	TCGA-DU-7018-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_5_rg.sorted.bam	193.7	NA	0.15	58cfa831e4b0c9d6adf6cb5e	TCGA-DU-7018-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7018-01A	F18DAB99-26B0-4727-89A9-7F16BD382356	Primary Tumor	Illumina HiSeq	2736e751-ccc3-4721-b516-238f987ad26f	Brain	57	FE98F78B-2C80-4999-B430-E1D95A53F356	02FCFCBB-05D7-4671-BDDF-DED65316FCC6	TCGA-DU-7018-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7018	TCGA-LGG	933	s8567	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cb78	58cfa831e4b0c9d6adf6cb78	TCGA-DU-7292-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DU-7292-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_2_rg.sorted	TCGA-DU-7292-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_2_rg.sorted.bam	49	NA	0.14	58cfa831e4b0c9d6adf6cb78	TCGA-DU-7292-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7292-10A	145F87A3-5E86-4A87-8E49-B166A2271D02	Blood Derived Normal	Illumina HiSeq	0ac4dae2-d60a-4869-a3a6-c2ecd1c7640f	Brain	69	568D1C55-344D-4294-85C5-1CA8356F23EB	20E6FABE-8B03-4E27-B98A-0501685E1A90	TCGA-DU-7292-10A-01D-2022-02	HG19_Broad_variant	TCGA-DU-7292	TCGA-LGG	242	s8358	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cb52	58cfa831e4b0c9d6adf6cb52	TCGA-EE-A29B-10A-01D-A190_120807_SN590_0173_AC0VN5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EE-A29B-10A-01D-A190_120807_SN590_0173_AC0VN5ACXX_s_3_rg.sorted	TCGA-EE-A29B-10A-01D-A190_120807_SN590_0173_AC0VN5ACXX_s_3_rg.sorted.bam	23.54	NA	0.15	58cfa831e4b0c9d6adf6cb52	TCGA-EE-A29B-10A-01D-A190_120807_SN590_0173_AC0VN5ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29B-10A	905EA29F-588A-497B-9F06-2EEF3BDC9442	Blood Derived Normal	Illumina HiSeq	628ddf51-45ee-4b67-891e-132909689e76	Skin	67	CDBC7250-CFDB-485B-BD1F-B3D82DCD168D	352C1BF5-2EA6-4E78-833D-8F16B117A2A8	TCGA-EE-A29B-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29B	TCGA-SKCM	NA	s7336	Harvard Medical School	University of Sydney	Australia	NO	T3b	N0	Not available	Stage IIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb86	58cfa831e4b0c9d6adf6cb86	TCGA-DU-7010-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DU-7010-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_4_rg.sorted	TCGA-DU-7010-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_4_rg.sorted.bam	74	NA	0.14	58cfa831e4b0c9d6adf6cb86	TCGA-DU-7010-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7010-10A	834E560A-A506-456D-BAF2-A206CA058153	Blood Derived Normal	Illumina HiSeq	550d6316-2067-4f67-ba64-a8687f3320b1	Brain	58	7820F440-CDBA-4F4C-8B1D-A2E089055BE7	8F524DED-7AE8-44CD-8E62-5DB87178452C	TCGA-DU-7010-10A-01D-2022-02	HG19_Broad_variant	TCGA-DU-7010	TCGA-LGG	456	s8565	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cae6	58cfa831e4b0c9d6adf6cae6	TCGA-D9-A1JX-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D9-A1JX-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_5_rg.sorted	TCGA-D9-A1JX-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_5_rg.sorted.bam	50.25	NA	0.14	58cfa831e4b0c9d6adf6cae6	TCGA-D9-A1JX-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D9-A1JX-06A	F505058F-74F2-4476-887F-06590A605980	Metastatic	Illumina HiSeq	88b1dbb7-2897-4de5-a042-e5a7d53d6389	Skin	80	24A6A89E-4FA9-4245-BB7F-C28C9385AE0F	1A90853A-2BEE-415D-854B-456C8CDABC0C	TCGA-D9-A1JX-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D9-A1JX	TCGA-SKCM	NA	s8002	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	TX	NX	Not available	Not available	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6cb6e	58cfa831e4b0c9d6adf6cb6e	TCGA-EE-A29N-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EE-A29N-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_7_rg.sorted	TCGA-EE-A29N-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_7_rg.sorted.bam	20.7	NA	0.17	58cfa831e4b0c9d6adf6cb6e	TCGA-EE-A29N-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29N-10A	8AAD9690-D1AD-424B-9A80-D7980760D093	Blood Derived Normal	Illumina HiSeq	a5f48fa3-7af5-4273-be19-0d3562ccb440	Skin	78	5EFDE57D-D614-4DD4-9506-6B2A9BC6ADA3	B9CB409B-AC7F-4C8D-AE93-906AFBF3EC93	TCGA-EE-A29N-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29N	TCGA-SKCM	566	s7842	Harvard Medical School	University of Sydney	Australia	NO	TX	N0	Not available	I or II NOS	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb58	58cfa831e4b0c9d6adf6cb58	TCGA-EB-A299-01A-21D-A18Y_120730_SN208_0420_BC12YJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EB-A299-01A-21D-A18Y_120730_SN208_0420_BC12YJACXX_s_5_rg.sorted	TCGA-EB-A299-01A-21D-A18Y_120730_SN208_0420_BC12YJACXX_s_5_rg.sorted.bam	56.25	NA	0.15	58cfa831e4b0c9d6adf6cb58	TCGA-EB-A299-01A-21D-A18Y_120730_SN208_0420_BC12YJACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EB-A299-01A	90402C32-9548-432E-85B8-A4F80E14401E	Primary Tumor	Illumina HiSeq	8780c547-110c-4e3a-88fa-1feeb9a57ad0	Skin	63	5678AE8F-382C-4167-839E-A160CE6710C7	C164DE0A-E762-48BE-B940-9E5EA31AD026	TCGA-EB-A299-01A-21D-A18Y-02	HG19_Broad_variant	TCGA-EB-A299	TCGA-SKCM	NA	s7844	Harvard Medical School	Asterand	Russia	NO	T2b	N0	Not available	Stage IIA	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb62	58cfa831e4b0c9d6adf6cb62	TCGA-EE-A2ME-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EE-A2ME-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_3_rg.sorted	TCGA-EE-A2ME-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_3_rg.sorted.bam	55.34	NA	0.16	58cfa831e4b0c9d6adf6cb62	TCGA-EE-A2ME-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2ME-06A	D70E0D27-7F27-4807-A36E-9FB7B00F0A70	Metastatic	Illumina HiSeq	81c3a18a-d39b-4ddf-a120-483e380a99ad	Skin	51	1ED77DED-07C5-4428-9393-56A8585E832E	B4C34C6E-B437-4AE6-B1E1-344C6A9C660A	TCGA-EE-A2ME-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2ME	TCGA-SKCM	3141	s7686	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc48	58cfa831e4b0c9d6adf6cc48	TCGA-E1-5307-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-E1-5307-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_2_rg.sorted	TCGA-E1-5307-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_2_rg.sorted.bam	20	1.9	0.15	58cfa831e4b0c9d6adf6cc48	TCGA-E1-5307-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-E1-5307-10A	A6EE311C-0A7B-4F47-86F1-F2164B128F9C	Blood Derived Normal	Illumina HiSeq	39a2e360-0a4c-4285-ace9-946e589970f4	Brain	62	011BB79A-079B-4EDF-A004-B699AB42F04F	B1BA990A-9299-42AB-BA66-CA60073B02F5	TCGA-E1-5307-10A-01D-1891-02	HG19_Broad_variant	TCGA-E1-5307	TCGA-LGG	1762	s8351	Harvard Medical School	Duke	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6cc18	58cfa831e4b0c9d6adf6cc18	TCGA-DU-7290-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DU-7290-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_8_rg.sorted	TCGA-DU-7290-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_8_rg.sorted.bam	74	NA	0.13	58cfa831e4b0c9d6adf6cc18	TCGA-DU-7290-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7290-10A	E00A9855-C15E-46EF-988F-25CA64EC4717	Blood Derived Normal	Illumina HiSeq	3a7ec773-52e2-4eed-bd70-2dc1f059a2ec	Brain	45	BC285F76-F7AE-4E4A-8D30-3AD400926D14	74D15A12-81B2-407D-A75E-C8C6297FFAB2	TCGA-DU-7290-10A-01D-2022-02	HG19_Broad_variant	TCGA-DU-7290	TCGA-LGG	315	s8356	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cb9c	58cfa831e4b0c9d6adf6cb9c	TCGA-EE-A29H-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EE-A29H-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_8_rg.sorted	TCGA-EE-A29H-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_8_rg.sorted.bam	28.94	NA	0.15	58cfa831e4b0c9d6adf6cb9c	TCGA-EE-A29H-10A-01D-A190_120729_SN1120_0180_BC1176ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29H-10A	C8BA1856-D055-4DC6-A184-72763C76AAE4	Blood Derived Normal	Illumina HiSeq	66ec2170-64e3-497d-aa60-e0f40b3875a6	Skin	59	D9FB008D-2BD2-4F50-99D3-C4E0863A5AE0	63B79CED-2594-4C16-9788-95BBF1F99D37	TCGA-EE-A29H-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29H	TCGA-SKCM	NA	s7849	Harvard Medical School	University of Sydney	Australia	NO	T1a	N0	Not available	Stage IA	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc4a	58cfa831e4b0c9d6adf6cc4a	TCGA-EB-A24C-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EB-A24C-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_3_rg.sorted	TCGA-EB-A24C-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_3_rg.sorted.bam	54.37	NA	0.17	58cfa831e4b0c9d6adf6cc4a	TCGA-EB-A24C-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EB-A24C-01A	2F1BBE96-49D9-417B-BC9C-A09992489340	Primary Tumor	Illumina HiSeq	536296fc-5bec-4776-8ce4-7eee8581fbc3	Skin	56	67D59A46-5944-4B23-AA7B-9561C6F7B956	B48D03D1-E323-4119-B62E-1952163AAB2A	TCGA-EB-A24C-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-EB-A24C	TCGA-SKCM	NA	s7333	Harvard Medical School	Asterand	Ukraine	NO	T4b	NX	Not available	Not available	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc4e	58cfa831e4b0c9d6adf6cc4e	TCGA-DU-7007-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DU-7007-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_7_rg.sorted	TCGA-DU-7007-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_7_rg.sorted.bam	200.7	NA	0.17	58cfa831e4b0c9d6adf6cc4e	TCGA-DU-7007-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7007-01A	8E2DCC00-9F7E-4DEE-B24D-43C8B30294C5	Primary Tumor	Illumina HiSeq	84edb90d-0a24-46dd-bed3-126c5fdcda42	Brain	33	E8E363D0-D9EA-478F-880C-7ADED5846237	A15321DD-20AE-4D64-9D89-C64A92468ECA	TCGA-DU-7007-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7007	TCGA-LGG	1915	s8352	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cc05	58cfa831e4b0c9d6adf6cc05	TCGA-EE-A29D-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EE-A29D-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_1_rg.sorted	TCGA-EE-A29D-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_1_rg.sorted.bam	72.15	NA	0.18	58cfa831e4b0c9d6adf6cc05	TCGA-EE-A29D-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29D-06A	EF608754-3F87-458E-9BCF-4434C54C8C9E	Metastatic	Illumina HiSeq	a8d2aa91-891f-4915-ab15-e620b21c436c	Skin	87	C129BD85-B320-4B3C-9316-CE00F58BA3D0	332D373A-A849-4B7E-854A-38DC56DC627D	TCGA-EE-A29D-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29D	TCGA-SKCM	425	s7841	Harvard Medical School	University of Sydney	Australia	NO	T3b	N1b	Not available	Stage IIIC	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc7e	58cfa831e4b0c9d6adf6cc7e	TCGA-ER-A19L-06A-12D-A18Y_120718_SN208_0416_BD140PACXX_s_4_rg.sorted.filtered.	WGS	TCGA-ER-A19L-06A-12D-A18Y_120718_SN208_0416_BD140PACXX_s_4_rg.sorted	TCGA-ER-A19L-06A-12D-A18Y_120718_SN208_0416_BD140PACXX_s_4_rg.sorted.bam	49.69	NA	0.17	58cfa831e4b0c9d6adf6cc7e	TCGA-ER-A19L-06A-12D-A18Y_120718_SN208_0416_BD140PACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19L-06A	5F6DF69C-4EBF-4811-8B28-AD393DFBE1A3	Metastatic	Illumina HiSeq	1db4cf92-091c-4a30-996d-ce04e7c3f2e2	Skin	35	83679B9D-34F4-487B-93E3-08F1B8060120	E77400BE-0BAE-4D18-BA27-3C208A7565EA	TCGA-ER-A19L-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-ER-A19L	TCGA-SKCM	4000	s7521	Harvard Medical School	University of Pittsburgh	United States	NO	Not available	Not available	Not available	Not available	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc66	58cfa831e4b0c9d6adf6cc66	TCGA-EB-A24D-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EB-A24D-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_4_rg.sorted	TCGA-EB-A24D-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_4_rg.sorted.bam	62.95	NA	0.16	58cfa831e4b0c9d6adf6cc66	TCGA-EB-A24D-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EB-A24D-01A	D7EE2693-39A8-4E3A-B6F6-E4729800E34E	Primary Tumor	Illumina HiSeq	44c42419-04e6-439f-aceb-e330fd514f35	Skin	72	A74E2FEC-291C-4967-AFE3-101955578225	0FD8F30A-936E-4A72-AA69-4DAC1E4BCE49	TCGA-EB-A24D-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-EB-A24D	TCGA-SKCM	NA	s7508	Harvard Medical School	Asterand	Ukraine	NO	T4a	N2b	Not available	Stage IIIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc83	58cfa831e4b0c9d6adf6cc83	TCGA-ER-A19O-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_2_rg.sorted.filtered.	WGS	TCGA-ER-A19O-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_2_rg.sorted	TCGA-ER-A19O-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_2_rg.sorted.bam	47.63	NA	0.16	58cfa831e4b0c9d6adf6cc83	TCGA-ER-A19O-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19O-06A	69C0EF46-3117-46F3-B36E-581EB03EB829	Metastatic	Illumina HiSeq	906d1045-517c-43da-94cc-b05bd82e61a5	Skin	56	24DDB156-D896-44BB-B0B1-A5191ABCDC3F	40A9B358-E49D-42B6-AEF0-CF04F33F2E14	TCGA-ER-A19O-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A19O	TCGA-SKCM	NA	s8016	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1b	Not available	Stage IIIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cdb1	58cfa831e4b0c9d6adf6cdb1	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted.bam	270.7	1.9	0.15	58cfa831e4b0c9d6adf6cdb1	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6692-01A	5F10CD91-1E03-4016-B35A-8629A1A8FCC9	Primary Tumor	Illumina HiSeq	66eb8fac-6ead-47b2-be40-effbb245f499	Brain	63	FDDB3709-5F1C-40C8-A39A-48329DFE9C97	5BB5BFCC-DB34-474C-95E6-3A84C3A7DBAA	TCGA-FG-6692-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6692	TCGA-LGG	NA	s8367	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1891-02	TRUE
13722.58cfa830e4b0c9d6adf6beaa	58cfa830e4b0c9d6adf6beaa	TCGA-AG-3902-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3902-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3902-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	72.59	1.9	0.16	58cfa830e4b0c9d6adf6beaa	TCGA-AG-3902-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3902-10A	BCFE4FE9-D090-49F9-85A7-2B472E0F7453	Blood Derived Normal	Illumina HiSeq	95d95b49-faee-4d63-9800-12a04600f01c	Colorectal	61	52980AB7-69C5-4FA3-83ED-EB21E703C60D	D70EBF7E-FBCE-48D0-A2DC-BAD5CD28928D	TCGA-AG-3902-10A-01D-1115-02	HG18	TCGA-AG-3902	TCGA-READ	NA	s2156	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa831e4b0c9d6adf6ccdc	58cfa831e4b0c9d6adf6ccdc	TCGA-EM-A1YC-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EM-A1YC-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_7_rg.sorted	TCGA-EM-A1YC-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_7_rg.sorted.bam	43.33	1.93	0.17	58cfa831e4b0c9d6adf6ccdc	TCGA-EM-A1YC-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_7_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YC-01A	0AD2A2B3-C1BB-4597-B28E-A6385F93D09C	Primary Tumor	Illumina HiSeq	256cee86-6dd3-4d12-bb0b-e3ab680044aa	Thyroid	71	17610B7B-F2EC-4B55-808C-1C2219A0D1BA	3D02FB7F-EB7D-49F9-BD40-20E9BDA1FBAB	TCGA-EM-A1YC-01A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YC	TCGA-THCA	NA	s12752	Harvard Medical School	University Health Network	Canada	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cc9e	58cfa831e4b0c9d6adf6cc9e	TCGA-EE-A2MH-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EE-A2MH-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_5_rg.sorted	TCGA-EE-A2MH-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_5_rg.sorted.bam	35.5	NA	0.18	58cfa831e4b0c9d6adf6cc9e	TCGA-EE-A2MH-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MH-10A	BD2345ED-33B8-4010-8479-4D6C67E29561	Blood Derived Normal	Illumina HiSeq	7ea403bb-8745-4d11-b0a5-e6b28b5c7114	Skin	66	BA0B86CE-0A55-4698-A73D-966F4D2C88B3	595733A4-7B2B-4052-8A2E-66E910D9A28F	TCGA-EE-A2MH-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2MH	TCGA-SKCM	516	s7687	Harvard Medical School	University of Sydney	Australia	NO	T4a	N0	Not available	Stage III	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cde0	58cfa831e4b0c9d6adf6cde0	TCGA-EQ-5647-10A-01D-1598_130110_SN1222_0167_AC1JPDACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EQ-5647-10A-01D-1598_130110_SN1222_0167_AC1JPDACXX_s_8_rg.sorted	TCGA-EQ-5647-10A-01D-1598_130110_SN1222_0167_AC1JPDACXX_s_8_rg.sorted.bam	716.4	1.9	0.15	58cfa831e4b0c9d6adf6cde0	TCGA-EQ-5647-10A-01D-1598_130110_SN1222_0167_AC1JPDACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-EQ-5647-10A	2D291FA3-F0FD-4BC1-91A6-783863714190	Blood Derived Normal	Illumina HiSeq	20f56565-871a-4820-bb70-9b7b7e4745e5	Stomach	86	7E8AA1C7-AA0E-4205-914C-A2A48DC11844	D88ABB94-74D3-45D6-BAFB-8158DB1AEA94	TCGA-EQ-5647-10A-01D-1598-02	HG19_Broad_variant	TCGA-EQ-5647	TCGA-STAD	19	s14843	Harvard Medical School	Christiana Healthcare	United States	NO	T4	N3	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6ccf6	58cfa831e4b0c9d6adf6ccf6	TCGA-EM-A1CU-11A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EM-A1CU-11A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_8_rg.sorted	TCGA-EM-A1CU-11A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_8_rg.sorted.bam	35.57	1.9	0.16	58cfa831e4b0c9d6adf6ccf6	TCGA-EM-A1CU-11A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_8_rg.sorted.bam	Alive	MALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CU-11A	4E80F403-0E10-4725-854D-F023C12EE1E2	Solid Tissue Normal	Illumina HiSeq	6237f724-77de-47ae-bd28-0e479ae2def9	Thyroid	31	9EBED2E5-A61B-4F2A-9B9F-1693B660EA5F	BEC01D9D-E7EA-48F7-9272-7C71AA578CB8	TCGA-EM-A1CU-11A-11D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CU	TCGA-THCA	NA	s12250	Harvard Medical School	University Health Network	Canada	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6cd9e	58cfa831e4b0c9d6adf6cd9e	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted.bam	71.81	1.88	0.16	58cfa831e4b0c9d6adf6cd9e	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A238-01A	DFFC4F7A-C67A-4AC5-A338-717DFFDE686D	Primary Tumor	Illumina HiSeq	004a2d8a-2dac-4e95-b287-dde59c5f0561	Thyroid	36	D68C3B99-CB82-48BD-A1F8-BEE0A9A9E8C3	BA986EBD-8E2D-4BAF-AC16-FCEB1286F590	TCGA-FE-A238-01A-11D-A16N-02	HG19_Broad_variant	TCGA-FE-A238	TCGA-THCA	NA	s12004	Harvard Medical School	Ohio State University	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6cdc4	58cfa831e4b0c9d6adf6cdc4	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted.bam	113.7	1.9	0.16	58cfa831e4b0c9d6adf6cdc4	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6690-01A	AD202887-88B3-4E0F-A4C3-7E135D4CB258	Primary Tumor	Illumina HiSeq	e33fa79f-3d33-4f0b-81d9-705ab9c8a19c	Brain	70	F6C7B8C5-02DF-4B89-B527-F647762A98B7	BA96EFD0-90DE-4458-89DE-8B16639760B8	TCGA-FG-6690-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6690	TCGA-LGG	NA	s8146	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6cdf8	58cfa831e4b0c9d6adf6cdf8	TCGA-FS-A1YX-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FS-A1YX-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_7_rg.sorted	TCGA-FS-A1YX-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_7_rg.sorted.bam	39	NA	0.17	58cfa831e4b0c9d6adf6cdf8	TCGA-FS-A1YX-10A-01D-A190_120718_SN1222_0127_BD147HACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1YX-10A	4537C0E1-B2BD-425F-A6F4-27F4733DC25A	Blood Derived Normal	Illumina HiSeq	a2b998a3-6ed9-4244-b31a-5c256868a3d8	Skin	39	7FD6C9CC-CA57-4F01-AE4F-7F097B7017D1	3248BAFD-512C-4096-956F-B4FEFC4C4394	TCGA-FS-A1YX-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1YX	TCGA-SKCM	1478	s7525	Harvard Medical School	Essen	Germany	NO	T2	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cdb4	58cfa831e4b0c9d6adf6cdb4	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted.bam	101.76	2.16	0.16	58cfa831e4b0c9d6adf6cdb4	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A231-01A	7044DEE0-FD6C-4E75-B731-DC60A386A1AB	Primary Tumor	Illumina HiSeq	2983a837-7d6a-4e9d-a68a-a3aa674fbb8b	Thyroid	70	96C298EB-0699-42AE-B2EA-63A192353D69	056B3922-279A-4869-A933-0C53C1137450	TCGA-FE-A231-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A231	TCGA-THCA	NA	s12256	Harvard Medical School	Ohio State University	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6ce11	58cfa832e4b0c9d6adf6ce11	TCGA-EM-A1YE-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EM-A1YE-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_3_rg.sorted	TCGA-EM-A1YE-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_3_rg.sorted.bam	72.49	1.98	0.17	58cfa832e4b0c9d6adf6ce11	TCGA-EM-A1YE-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YE-01A	E632B443-CF6A-4592-96C6-C3493EC86FEA	Primary Tumor	Illumina HiSeq	a16ef214-00f5-4385-81e9-e66da356395c	Thyroid	47	A5DE766B-9CCC-4B56-8D9B-25704C1C91D0	4AE46D2E-BA86-426F-A127-4C1AAF92AB5B	TCGA-EM-A1YE-01A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YE	TCGA-THCA	NA	s12519	Harvard Medical School	University Health Network	Canada	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6ce34	58cfa832e4b0c9d6adf6ce34	TCGA-ER-A19T-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_8_rg.sorted.filtered.	WGS	TCGA-ER-A19T-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_8_rg.sorted	TCGA-ER-A19T-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_8_rg.sorted.bam	76.29	NA	0.18	58cfa832e4b0c9d6adf6ce34	TCGA-ER-A19T-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19T-01A	B85B14D7-3B5A-4800-AF12-622EC03B9FE5	Primary Tumor	Illumina HiSeq	f16ac608-e77d-4717-aeea-b71439dc385a	Skin	51	11E2F891-251A-4813-AA90-E944F350C54D	9C1427B0-B112-4BB7-89B3-27934F92E077	TCGA-ER-A19T-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-ER-A19T	TCGA-SKCM	270	s8022	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N3	Not available	Stage IV	A18Z-02	TRUE
13722.58cfa832e4b0c9d6adf6ced7	58cfa832e4b0c9d6adf6ced7	TCGA-EM-A1YE-11A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EM-A1YE-11A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_6_rg.sorted	TCGA-EM-A1YE-11A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_6_rg.sorted.bam	43.93	1.89	0.17	58cfa832e4b0c9d6adf6ced7	TCGA-EM-A1YE-11A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YE-11A	E632B443-CF6A-4592-96C6-C3493EC86FEA	Solid Tissue Normal	Illumina HiSeq	48d31326-3565-4dff-ae01-be3fd0b5ca6c	Thyroid	47	B3126B21-FD84-4E3D-BB16-B7834044D5BE	57CCBCC4-DF14-48CB-9F31-BF776D712E32	TCGA-EM-A1YE-11A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YE	TCGA-THCA	NA	s12520	Harvard Medical School	University Health Network	Canada	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6ce24	58cfa832e4b0c9d6adf6ce24	TCGA-FI-A2D0-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FI-A2D0-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_4_rg.sorted	TCGA-FI-A2D0-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_4_rg.sorted.bam	151.56	NA	0.16	58cfa832e4b0c9d6adf6ce24	TCGA-FI-A2D0-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-FI-A2D0-10A	1B35D083-F7C9-47D2-9A9E-718788F9E39A	Blood Derived Normal	Illumina HiSeq	452078a9-1e91-4915-9a31-397391041482	Uterus	55	96923E73-5E5F-4234-BF2E-E34EAE4C0AB5	FB0BFE72-D375-41D6-90F6-DF04FA514215	TCGA-FI-A2D0-10A-01D-A17E-02	HG19_Broad_variant	TCGA-FI-A2D0	TCGA-UCEC	NA	s4806	Harvard Medical School	Washington University	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A17E-02	TRUE
13722.58cfa832e4b0c9d6adf6ce40	58cfa832e4b0c9d6adf6ce40	TCGA-ER-A1A1-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ER-A1A1-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_7_rg.sorted	TCGA-ER-A1A1-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_7_rg.sorted.bam	26.11	NA	0.18	58cfa832e4b0c9d6adf6ce40	TCGA-ER-A1A1-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A1A1-10A	1251ACEE-CEB4-4530-BA5B-4D163FCAB8D2	Blood Derived Normal	Illumina HiSeq	a929309c-6fce-4ba9-ab55-aca676e8c78d	Skin	58	38829905-3718-4085-B50E-ACB5FF37D546	5DC16C47-0D73-491B-B153-7F80E8453720	TCGA-ER-A1A1-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A1A1	TCGA-SKCM	NA	s7353	Harvard Medical School	University of Pittsburgh	United States	NO	TX	N3	Not available	Stage IIIC	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf04	58cfa832e4b0c9d6adf6cf04	TCGA-FS-A1ZB-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FS-A1ZB-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_8_rg.sorted	TCGA-FS-A1ZB-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_8_rg.sorted.bam	30.5	NA	0.18	58cfa832e4b0c9d6adf6cf04	TCGA-FS-A1ZB-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZB-10A	6F2EF983-0A22-4A65-9E53-8742AC89A1C4	Blood Derived Normal	Illumina HiSeq	047bc4fc-13cd-4dc5-b9d5-8f46a3cfe2a8	Skin	57	0E2E739B-B421-44B9-8524-1ED5CAA6F13A	D583AB9A-A74E-416E-967D-97AEDEE476AA	TCGA-FS-A1ZB-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZB	TCGA-SKCM	1486	s7531	Harvard Medical School	Essen	Germany	NO	T3a	N0	Not available	Stage II	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf3c	58cfa832e4b0c9d6adf6cf3c	TCGA-G9-6373-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6373-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_1_rg.sorted	TCGA-G9-6373-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_1_rg.sorted.bam	59.4	2	0.15	58cfa832e4b0c9d6adf6cf3c	TCGA-G9-6373-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6373-01A	C3A509C6-35A6-4D17-A9FD-0AA8884B33A0	Primary Tumor	Illumina HiSeq	b8d1f15f-e927-4a6e-8154-620ccb08e6f5	Prostate	68	18365C1F-9BC0-4865-B40D-DEF3EE73331C	A0563516-591D-4FC2-AF37-8BA62A071C58	TCGA-G9-6373-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6373	TCGA-PRAD	NA	s3976	Harvard Medical School	Roswell Park	United States	NO	T3a	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cee6	58cfa832e4b0c9d6adf6cee6	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted.bam	65.38	NA	0.17	58cfa832e4b0c9d6adf6cee6	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-FI-A2D0-01A	1B35D083-F7C9-47D2-9A9E-718788F9E39A	Primary Tumor	Illumina HiSeq	5d8357bd-6f87-41b8-af0f-a2bdcb483e07	Uterus	55	A2D2A29A-5ABC-48C3-AC17-76B8B9EE1717	9406B9B9-CC2D-470D-BFB6-2118C0B84982	TCGA-FI-A2D0-01A-11D-A17E-02	HG19_Broad_variant	TCGA-FI-A2D0	TCGA-UCEC	NA	s5399	Harvard Medical School	Washington University	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A17E-02	TRUE
13722.58cfa832e4b0c9d6adf6ce54	58cfa832e4b0c9d6adf6ce54	TCGA-GN-A265-06A-21D-A18Y_120602_SN208_0304_BC0WTWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-GN-A265-06A-21D-A18Y_120602_SN208_0304_BC0WTWACXX_s_2_rg.sorted	TCGA-GN-A265-06A-21D-A18Y_120602_SN208_0304_BC0WTWACXX_s_2_rg.sorted.bam	56.4	NA	0.18	58cfa832e4b0c9d6adf6ce54	TCGA-GN-A265-06A-21D-A18Y_120602_SN208_0304_BC0WTWACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-GN-A265-06A	61B777F6-A59A-4500-AD33-107E2C9254C1	Metastatic	Illumina HiSeq	95729723-84b0-4360-acd5-b7f42668ae18	Skin	53	06B6BF3E-9158-4829-91E7-4A79EC5EFADD	2DA18FF0-EB58-450F-8179-B903BC9C03E6	TCGA-GN-A265-06A-21D-A18Y-02	HG19_Broad_variant	TCGA-GN-A265	TCGA-SKCM	NA	s7875	Harvard Medical School	Roswell	United States	NO	Not available	Not available	Not available	Not available	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cf24	58cfa832e4b0c9d6adf6cf24	TCGA-G9-6351-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6351-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_3_rg.sorted	TCGA-G9-6351-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_3_rg.sorted.bam	30	1.8	0.15	58cfa832e4b0c9d6adf6cf24	TCGA-G9-6351-10A-01D-1957_130405_SN590_0222_BD21LGACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6351-10A	F59B9C65-46E8-4CC3-AA71-8844F6C2273C	Blood Derived Normal	Illumina HiSeq	8cd65f12-8354-414b-a45b-9cc78613df38	Prostate	51	69DD99BE-72DD-46BC-96FB-97531992367D	F73E670B-2D6D-4E55-AA8E-D99FF270E536	TCGA-G9-6351-10A-01D-1957-02	HG19_Broad_variant	TCGA-G9-6351	TCGA-PRAD	NA	s3616	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cf4e	58cfa832e4b0c9d6adf6cf4e	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted.bam	144.4	1.9	0.15	58cfa832e4b0c9d6adf6cf4e	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6356-01A	1D7FFBE7-6139-412B-8739-8082A63A2B33	Primary Tumor	Illumina HiSeq	4c78b0a9-d4e9-4656-95bf-0306c7bb406e	Prostate	60	C6E0F83F-ABA3-4705-ABAC-C81C885B53BA	E43C07B2-F48D-4780-9766-15CC08CE6FE2	TCGA-G9-6356-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6356	TCGA-PRAD	NA	s4146	Harvard Medical School	Roswell Park	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf59	58cfa832e4b0c9d6adf6cf59	TCGA-GN-A266-06A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GN-A266-06A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_1_rg.sorted	TCGA-GN-A266-06A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_1_rg.sorted.bam	47.6	NA	0.15	58cfa832e4b0c9d6adf6cf59	TCGA-GN-A266-06A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-GN-A266-06A	3429967F-4F77-4894-BF27-C4A22698CA92	Metastatic	Illumina HiSeq	faac710c-c974-41c3-ba2d-102952992342	Skin	45	EA59B74A-7456-43DD-B79C-74040176F0CD	E13423F1-89D5-41CC-9E1F-B2E8B1F42F25	TCGA-GN-A266-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-GN-A266	TCGA-SKCM	308	s7376	Harvard Medical School	Roswell	United States	NO	Not available	Not available	Not available	Not available	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cf6c	58cfa832e4b0c9d6adf6cf6c	TCGA-G9-6496-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6496-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_3_rg.sorted	TCGA-G9-6496-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_3_rg.sorted.bam	223.4	1.9	0.14	58cfa832e4b0c9d6adf6cf6c	TCGA-G9-6496-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6496-01A	CE2B7E17-424E-4954-8A68-19D7F98D2E7E	Primary Tumor	Illumina HiSeq	9bf9f3ef-b79e-4a93-8df6-ab2b9a3f24aa	Prostate	61	ECE85143-957D-4AD1-BFCC-B71307EFB911	10BB38BE-9E75-4793-89B5-7BB19D7AA4F8	TCGA-G9-6496-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6496	TCGA-PRAD	NA	s3619	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cfda	58cfa832e4b0c9d6adf6cfda	TCGA-FS-A1ZJ-06A-12D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FS-A1ZJ-06A-12D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_1_rg.sorted	TCGA-FS-A1ZJ-06A-12D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_1_rg.sorted.bam	67.75	NA	0.16	58cfa832e4b0c9d6adf6cfda	TCGA-FS-A1ZJ-06A-12D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZJ-06A	2F0661E5-5006-481E-9B40-7B1EC96EAA3C	Metastatic	Illumina HiSeq	54b65a8a-8a6e-4bb3-96ce-4ae0b250e615	Skin	75	73FDF583-1BDB-41AA-98B9-1E433023A144	16D2CC2B-3D7C-4180-8AE2-B8A977064CE6	TCGA-FS-A1ZJ-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZJ	TCGA-SKCM	1441	s7370	Harvard Medical School	Essen	Germany	NO	T2	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d00d	58cfa832e4b0c9d6adf6d00d	TCGA-GF-A2C7-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_6_rg.sorted.filtered.	WGS	TCGA-GF-A2C7-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_6_rg.sorted	TCGA-GF-A2C7-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_6_rg.sorted.bam	37.69	NA	0.15	58cfa832e4b0c9d6adf6d00d	TCGA-GF-A2C7-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-GF-A2C7-10A	285D8E2C-F183-49D5-BC1C-FD47C6670ACC	Blood Derived Normal	Illumina HiSeq	eb7c9c39-ce72-4d12-ad47-16a2553d134f	Skin	48	D8D62D62-BF65-4F7D-A2E2-D97A1A0B7F6B	89BB0409-1D64-4FEE-A5CE-39B9AAB6408C	TCGA-GF-A2C7-10A-01D-A190-02	HG19_Broad_variant	TCGA-GF-A2C7	TCGA-SKCM	NA	s7704	Harvard Medical School	ABS - IUPUI	United States	NO	T4b	N0	Not available	Stage IIC	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d02e	58cfa832e4b0c9d6adf6d02e	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted.bam	59.4	1.9	0.14	58cfa832e4b0c9d6adf6d02e	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6367-01A	9F751C9D-AD41-4F02-B7F8-12423857D418	Primary Tumor	Illumina HiSeq	d4203e0e-c16e-4638-a239-378ffed98124	Prostate	60	5BC98578-E4C7-4BE8-89DF-F26AA5D545A9	9667EB66-775F-4C37-9309-FF73E55D553B	TCGA-G9-6367-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6367	TCGA-PRAD	NA	s3612	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf88	58cfa832e4b0c9d6adf6cf88	TCGA-G9-6494-10A-01D-1784_130131_SN1120_0234_AD1PVUACXX_s_2_rg.sorted.filtered.	WGS	TCGA-G9-6494-10A-01D-1784_130131_SN1120_0234_AD1PVUACXX_s_2_rg.sorted	TCGA-G9-6494-10A-01D-1784_130131_SN1120_0234_AD1PVUACXX_s_2_rg.sorted.bam	227.7	1.9	0.17	58cfa832e4b0c9d6adf6cf88	TCGA-G9-6494-10A-01D-1784_130131_SN1120_0234_AD1PVUACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6494-10A	0C459149-0DFE-4206-B50B-DB79180EBB57	Blood Derived Normal	Illumina HiSeq	b30a02c0-4047-4759-bcc8-ae1a36aec49d	Prostate	66	E9D501EB-D41B-4419-80C8-4941CF3EF3E9	EDDF0801-9067-45FA-AD22-F8B6B5F71945	TCGA-G9-6494-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6494	TCGA-PRAD	NA	s3979	Harvard Medical School	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6d0c8	58cfa832e4b0c9d6adf6d0c8	TCGA-FS-A1ZN-01A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FS-A1ZN-01A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_2_rg.sorted	TCGA-FS-A1ZN-01A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_2_rg.sorted.bam	65.89	NA	0.15	58cfa832e4b0c9d6adf6d0c8	TCGA-FS-A1ZN-01A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZN-01A	9D86940D-50FB-4D2F-8B1E-539196885F46	Primary Tumor	Illumina HiSeq	497c930e-47cd-4669-a434-af770d331308	Skin	43	C6C66FAF-676B-4302-B825-143E1E72D04D	507A59F5-70A6-464C-ADA3-3E686414045A	TCGA-FS-A1ZN-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZN	TCGA-SKCM	730	s7372	Harvard Medical School	Essen	Germany	NO	T4b	N1a	Not available	Stage IIIA	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d139	58cfa832e4b0c9d6adf6d139	TCGA-FS-A1ZE-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FS-A1ZE-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_5_rg.sorted	TCGA-FS-A1ZE-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_5_rg.sorted.bam	51.96	NA	0.16	58cfa832e4b0c9d6adf6d139	TCGA-FS-A1ZE-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZE-10A	2C79ADD1-8093-4E81-8F80-069AF7B7C2FA	Blood Derived Normal	Illumina HiSeq	c24d750d-c28d-461b-b1b0-31a50556c535	Skin	40	B3D6F0EE-2E71-4139-A421-044034679F48	D2393DD6-8CE3-42D4-BD36-27FEF8F4F170	TCGA-FS-A1ZE-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZE	TCGA-SKCM	NA	s8030	Harvard Medical School	Essen	Germany	NO	T4b	N0	Not available	Stage IIC	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d1a8	58cfa832e4b0c9d6adf6d1a8	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted.bam	62.7	NA	0.17	58cfa832e4b0c9d6adf6d1a8	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7472-01A	482D4078-7576-48CF-BF7C-29014935FD47	Primary Tumor	Illumina HiSeq	518f9b23-97da-447f-90e5-a03c5ae09642	Brain	38	F05081A2-2465-4EA4-9EC3-319810FE2D45	A68374D7-4782-4FF5-B921-35D45468A4D1	TCGA-HT-7472-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7472	TCGA-LGG	NA	s8574	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d1e4	58cfa832e4b0c9d6adf6d1e4	TCGA-FG-6688-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FG-6688-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_3_rg.sorted	TCGA-FG-6688-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_3_rg.sorted.bam	107	1.9	0.15	58cfa832e4b0c9d6adf6d1e4	TCGA-FG-6688-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6688-10A	DADD7428-9E4D-4652-9469-AB521B88D529	Blood Derived Normal	Illumina HiSeq	ed5c4e17-1960-4f9e-9152-02db5a6f6ec9	Brain	59	845A2B47-F2B9-431C-8E95-B2DDCB1F6DF0	898DE9F3-554F-4445-B365-D8C2F9B85780	TCGA-FG-6688-10A-01D-1891-02	HG19_Broad_variant	TCGA-FG-6688	TCGA-LGG	NA	s8571	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa832e4b0c9d6adf6d1ec	58cfa832e4b0c9d6adf6d1ec	TCGA-HT-7604-10A-01D-2088_130910_SN208_0494_AC2A1DACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HT-7604-10A-01D-2088_130910_SN208_0494_AC2A1DACXX_s_2_rg.sorted	TCGA-HT-7604-10A-01D-2088_130910_SN208_0494_AC2A1DACXX_s_2_rg.sorted.bam	135	NA	0.13	58cfa832e4b0c9d6adf6d1ec	TCGA-HT-7604-10A-01D-2088_130910_SN208_0494_AC2A1DACXX_s_2_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7604-10A	019C5DE9-74FD-48B7-95A3-227532E16C5A	Blood Derived Normal	Illumina HiSeq	b43b5074-d9bd-4d06-b367-bebab284ebfe	Brain	50	2D4653B8-97BC-4074-8BCB-670897CEB16A	17624312-479E-4C9B-9C97-65D8C13B0217	TCGA-HT-7604-10A-01D-2088-02	HG19_Broad_variant	TCGA-HT-7604	TCGA-LGG	NA	s8576	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Astrocytoma	Not available	2088-02	FALSE
13722.58cfa832e4b0c9d6adf6d138	58cfa832e4b0c9d6adf6d138	TCGA-FS-A1ZG-06A-11D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FS-A1ZG-06A-11D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_3_rg.sorted	TCGA-FS-A1ZG-06A-11D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_3_rg.sorted.bam	69.36	NA	0.17	58cfa832e4b0c9d6adf6d138	TCGA-FS-A1ZG-06A-11D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZG-06A	F52AE9F4-8A61-4FF2-9C24-23F4048D3DA6	Metastatic	Illumina HiSeq	0cac5d8a-2184-4f80-9dc3-2ad5a8d9f0de	Skin	60	C283D7F9-CC6A-43AE-B5BE-6043FAD85111	60D3B4B4-5B8E-4423-9834-25AE8223B2AB	TCGA-FS-A1ZG-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZG	TCGA-SKCM	295	s7537	Harvard Medical School	Essen	Germany	NO	T4b	N2b	Not available	Stage IIIC	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d182	58cfa832e4b0c9d6adf6d182	TCGA-FI-A2D4-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FI-A2D4-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_8_rg.sorted	TCGA-FI-A2D4-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_8_rg.sorted.bam	114.51	NA	0.17	58cfa832e4b0c9d6adf6d182	TCGA-FI-A2D4-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-FI-A2D4-10A	490AE247-EE67-48D4-94ED-93DF5B9BBEFE	Blood Derived Normal	Illumina HiSeq	5e4179ce-75a2-4122-b1a8-62dda9ba7956	Uterus	44	3BBCA20D-49CD-43EC-A564-7CB92F0B21A0	A5A21FE6-266C-4A55-A57D-CE21AEB1C50A	TCGA-FI-A2D4-10A-01D-A17E-02	HG19_Broad_variant	TCGA-FI-A2D4	TCGA-UCEC	243	s4449	Harvard Medical School	Washington University	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A17E-02	TRUE
13722.58cfa832e4b0c9d6adf6d220	58cfa832e4b0c9d6adf6d220	TCGA-HR-A2OG-01A-21D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HR-A2OG-01A-21D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_2_rg.sorted	TCGA-HR-A2OG-01A-21D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_2_rg.sorted.bam	45	NA	0.15	58cfa832e4b0c9d6adf6d220	TCGA-HR-A2OG-01A-21D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Skin Cutaneous Melanoma	Aligned reads	TCGA-HR-A2OG-06A	021D32B0-A94A-4DAD-95F4-8EB0ABD894BF	Metastatic	Illumina HiSeq	714a155f-a1c4-4187-87f5-bcfe1d63b0dc	Skin	50	4DEB7C12-15A2-456D-B46B-B70B29AE3EEC	7ED57F3A-334B-465C-A179-632F84FCD10E	TCGA-HR-A2OG-06A-21D-A18Y-02	HG19_Broad_variant	TCGA-HR-A2OG	TCGA-SKCM	NA	s8033	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	Not available	Not available	Not available	Not available	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d266	58cfa832e4b0c9d6adf6d266	TCGA-HT-7472-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HT-7472-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_8_rg.sorted	TCGA-HT-7472-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_8_rg.sorted.bam	312	NA	0.15	58cfa832e4b0c9d6adf6d266	TCGA-HT-7472-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7472-10A	482D4078-7576-48CF-BF7C-29014935FD47	Blood Derived Normal	Illumina HiSeq	480868bd-a33a-4c42-855e-c6bfafe22ecb	Brain	38	7F8D24AB-5E9D-4AFF-9B0B-EB2BFAD0509E	0FF070CF-955D-40C8-8BD0-1475E3AA49F8	TCGA-HT-7472-10A-01D-2022-02	HG19_Broad_variant	TCGA-HT-7472	TCGA-LGG	NA	s8151	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6cfc1	58cfa832e4b0c9d6adf6cfc1	TCGA-FS-A1ZQ-06A-11D-A18Y_120602_SN1120_0147_BD13TBACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FS-A1ZQ-06A-11D-A18Y_120602_SN1120_0147_BD13TBACXX_s_6_rg.sorted	TCGA-FS-A1ZQ-06A-11D-A18Y_120602_SN1120_0147_BD13TBACXX_s_6_rg.sorted.bam	50.02	NA	0.16	58cfa832e4b0c9d6adf6cfc1	TCGA-FS-A1ZQ-06A-11D-A18Y_120602_SN1120_0147_BD13TBACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZQ-06A	B91AF125-A024-4BA3-A5E8-99955FF9EFC5	Metastatic	Illumina HiSeq	62f92046-b8e5-402d-9e66-c3285a06b50f	Skin	31	32C0747F-0DBF-4047-B6D0-AD274724EB93	FA4F4875-8DB0-4CA3-9A4F-72074AE2A7C5	TCGA-FS-A1ZQ-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZQ	TCGA-SKCM	4062	s8026	Harvard Medical School	Essen	Germany	NO	TX	N0	Not available	I or II NOS	A18Y-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6a8	58cfa82fe4b0c9d6adf6b6a8	TCGA-50-5944-10A-01D-1751_111221_SN1120_0106_BD0M7HACXX_s_2_rg.sorted.filtered.	WGS	TCGA-50-5944-10A-01D-1751_111221_SN1120_0106_BD0M7HACXX_s_2_rg.sorted	TCGA-50-5944-10A-01D-1751_111221_SN1120_0106_BD0M7HACXX_s_2_rg.sorted.bam	216.7	1.9	0.16	58cfa82fe4b0c9d6adf6b6a8	TCGA-50-5944-10A-01D-1751_111221_SN1120_0106_BD0M7HACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-50-5944-10A	1C339545-C08A-4A77-B8E9-A7E49E53853F	Blood Derived Normal	Illumina HiSeq	8879c93f-169f-4772-9556-86a9ed97e824	Lung	69	8586678E-D6D9-4B29-BB21-BF7BD0244322	1CB5A4D2-AF01-4F13-921E-068C63417920	TCGA-50-5944-10A-01D-1751-02	HG19_Broad_variant	TCGA-50-5944	TCGA-LUAD	NA	s11241	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Acinar Adenocarcinoma	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b721	58cfa82fe4b0c9d6adf6b721	TCGA-73-4659-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4659-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4659-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	274.3	1.9	0.16	58cfa82fe4b0c9d6adf6b721	TCGA-73-4659-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4659-11A	CD0DC947-B708-464E-BEB7-954C9D4583E7	Solid Tissue Normal	Illumina HiSeq	b8f31350-d0a7-4223-90f8-280be07f9351	Lung	66	C3A0A2B9-B84B-48DF-BE21-1B2D9EBC7955	F44A21FC-E317-42C7-BAB8-F0E1AC8331EB	TCGA-73-4659-11A-01D-1203-02	GRCh37	TCGA-73-4659	TCGA-LUAD	711	s11354	Harvard Medical School	Roswell Park	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	TRUE
13722.58cfa831e4b0c9d6adf6c485	58cfa831e4b0c9d6adf6c485	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	846.02	1.9	0.15	58cfa831e4b0c9d6adf6c485	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4752-01A	7EA546CE-F48A-4D9C-96B4-A0124C692870	Primary Tumor	Illumina HiSeq	ad469933-d84b-4305-85e2-a7d919298b71	Colorectal	58	5703F0D8-DB96-40CE-8009-51D2EC188ABF	43756C1F-6ED2-468B-B0AD-D44A447C7709	TCGA-CM-4752-01A-01D-1405-02	HG18	TCGA-CM-4752	TCGA-COAD	NA	s13219	Harvard Medical School	MSKCC	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6ca05	58cfa831e4b0c9d6adf6ca05	TCGA-DE-A0Y3-01B-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DE-A0Y3-01B-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_3_rg.sorted	TCGA-DE-A0Y3-01B-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_3_rg.sorted.bam	60.48	2.03	0.14	58cfa831e4b0c9d6adf6ca05	TCGA-DE-A0Y3-01B-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_3_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DE-A0Y3-01B	C31B3ADF-3FC6-4A72-83B0-BBC0F295B5E7	Primary Tumor	Illumina HiSeq	e17f6c8d-d069-4561-8371-8138731e3dd2	Thyroid	60	3AE03B86-1473-409C-8118-A91A73A36F60	F3099D9B-DBBE-46CB-BA22-DAD7F9428C4F	TCGA-DE-A0Y3-01B-11D-A10R-02	HG19_Broad_variant	TCGA-DE-A0Y3	TCGA-THCA	NA	s12848	Harvard Medical School	University of North Carolina	United States	NO	T4a	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVC	A10R-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae6a	58cfa82ee4b0c9d6adf6ae6a	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted.bam	403.53	1.9	0.15	58cfa82ee4b0c9d6adf6ae6a	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4398-01A	31C96E35-5E2F-429C-B12A-7BC5A497A300	Primary Tumor	Illumina HiSeq	af507e03-fa73-4b22-88ae-8d5d9cee85dc	Lung	47	DA010683-C537-478F-8F95-E606B05DBC5C	CC8C5E2D-1878-49EC-9D63-D65EB4FE8256	TCGA-05-4398-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4398	TCGA-LUAD	NA	s10981	Harvard Medical School	Indivumed	Germany	NO	T4	N3	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae50	58cfa82ee4b0c9d6adf6ae50	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted.bam	445.53	1.9	0.14	58cfa82ee4b0c9d6adf6ae50	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4382-01A	3434B91A-C05F-460F-A078-7B1BB6E7085D	Primary Tumor	Illumina HiSeq	42d76c95-55a7-4160-b22f-4338315e6146	Lung	68	CCE6D71F-369E-467F-BD7E-03D20E97B7F3	EE1D241A-B371-433A-9AF7-F1C9074C155F	TCGA-05-4382-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4382	TCGA-LUAD	NA	s11435	Harvard Medical School	Indivumed	None	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6b02c	58cfa82ee4b0c9d6adf6b02c	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted.bam	651.3	1.9	0.16	58cfa82ee4b0c9d6adf6b02c	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4420-01A	3D2AA654-1B5F-4EB4-A1C2-AF31F5760069	Primary Tumor	Illumina HiSeq	067a9600-61b8-4de1-ac32-914605c3033e	Lung	41	4B202550-9744-4C6C-AD17-97F764EA3F18	A50583F2-BB90-4848-9A5F-EAF4656A1866	TCGA-05-4420-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4420	TCGA-LUAD	NA	s11332	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b631	58cfa82fe4b0c9d6adf6b631	TCGA-44-6148-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_8_rg.sorted.filtered.	WGS	TCGA-44-6148-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_8_rg.sorted	TCGA-44-6148-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_8_rg.sorted.bam	27.4	1.9	0.15	58cfa82fe4b0c9d6adf6b631	TCGA-44-6148-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6148-11A	8994C8C4-9EA0-46CB-B4A5-0055D7DA5BFA	Solid Tissue Normal	Illumina HiSeq	453af1ae-a7ef-4716-8eff-3295325729cd	Lung	60	ACE83CB7-28BC-44BA-A600-8A6155E08A42	967F0F6A-855F-4544-BD9B-E49909EB6ACB	TCGA-44-6148-11A-01D-1751-02	HG19_Broad_variant	TCGA-44-6148	TCGA-LUAD	NA	s10904	Harvard Medical School	Christiana Healthcare	United States	NO	T1b	N0	Lung Mucinous Adenocarcinoma	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b64a	58cfa82fe4b0c9d6adf6b64a	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.filtered.	WGS	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.bam	337.2	1.9	0.15	58cfa82fe4b0c9d6adf6b64a	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4662-01A	294FF941-AEA1-4588-9A0E-E9F5393E2BB6	Primary Tumor	Illumina HiSeq	bb68d6e1-efca-4ccb-bbd6-45c4da207bb7	Lung	65	C7D727B6-47C6-4339-B9DD-5BAF41527BD4	DCC0A32E-EF17-4AA8-8321-A03137A61D72	TCGA-73-4662-01A-01D-1203-02	HG19_Broad_variant	TCGA-73-4662	TCGA-LUAD	NA	s10663	Harvard Medical School	Roswell Park	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b635	58cfa82fe4b0c9d6adf6b635	TCGA-44-2661-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_6_rg.sorted.filtered.	WGS	TCGA-44-2661-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_6_rg.sorted	TCGA-44-2661-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_6_rg.sorted.bam	454.63	1.9	0.14	58cfa82fe4b0c9d6adf6b635	TCGA-44-2661-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-2661-10A	F3501466-CF32-4866-B5FB-E94DD32341BC	Blood Derived Normal	Illumina HiSeq	d921a1d0-fc6b-4140-adea-0274147e2026	Lung	69	5464840F-763F-45AC-892C-C7A11E7969EB	7EC94B2F-ECF5-407A-9D70-6C158288F30A	TCGA-44-2661-10A-01D-1103-02	HG19_Broad_variant	TCGA-44-2661	TCGA-LUAD	NA	s11117	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b659	58cfa82fe4b0c9d6adf6b659	TCGA-50-6592-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-50-6592-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_7_rg.sorted	TCGA-50-6592-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_7_rg.sorted.bam	254.4	1.9	0.13	58cfa82fe4b0c9d6adf6b659	TCGA-50-6592-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6592-01A	09918B81-4696-4CBA-A45A-5FE7407C2337	Primary Tumor	Illumina HiSeq	207da806-7a0b-406f-aaa6-b5bb17f7f28a	Lung	71	01F94091-EB70-40D3-9D56-70C4F847CB4C	F61D3411-6EED-4EDE-8BBA-A40AF0C9DA84	TCGA-50-6592-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-6592	TCGA-LUAD	777	s10793	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b653	58cfa82fe4b0c9d6adf6b653	TCGA-50-6592-11A-01D-1751_111111_SN208_0254_B0160ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-50-6592-11A-01D-1751_111111_SN208_0254_B0160ACXX_s_8_rg.sorted	TCGA-50-6592-11A-01D-1751_111111_SN208_0254_B0160ACXX_s_8_rg.sorted.bam	45.4	1.9	0.14	58cfa82fe4b0c9d6adf6b653	TCGA-50-6592-11A-01D-1751_111111_SN208_0254_B0160ACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6592-11A	09918B81-4696-4CBA-A45A-5FE7407C2337	Solid Tissue Normal	Illumina HiSeq	e1284c11-5577-48dd-b880-07c391fb1cc6	Lung	71	6C1516A2-6916-4D9B-949D-4F5ABB97B94C	85C013AC-B0E7-4ACD-9031-E8E31E92C5CC	TCGA-50-6592-11A-01D-1751-02	HG19_Broad_variant	TCGA-50-6592	TCGA-LUAD	777	s11459	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b666	58cfa82fe4b0c9d6adf6b666	TCGA-50-5946-10A-01D-1751_111111_SN208_0254_B0160ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-50-5946-10A-01D-1751_111111_SN208_0254_B0160ACXX_s_4_rg.sorted	TCGA-50-5946-10A-01D-1751_111111_SN208_0254_B0160ACXX_s_4_rg.sorted.bam	375.7	1.9	0.16	58cfa82fe4b0c9d6adf6b666	TCGA-50-5946-10A-01D-1751_111111_SN208_0254_B0160ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-50-5946-10A	C95957A7-1A1A-4C8D-BB61-7C99B500F224	Blood Derived Normal	Illumina HiSeq	e8b95c33-23ff-4672-86df-5200e75ba0fc	Lung	62	085A5EEE-EB20-4B3D-BBFF-D477971DFD89	59E74FEE-E0A0-4392-A42E-9CB3EAE8E931	TCGA-50-5946-10A-01D-1751-02	HG19_Broad_variant	TCGA-50-5946	TCGA-LUAD	NA	s11010	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma Mixed Subtype	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b66c	58cfa82fe4b0c9d6adf6b66c	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.bam	242.4	1.9	0.14	58cfa82fe4b0c9d6adf6b66c	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-50-5946-01A	C95957A7-1A1A-4C8D-BB61-7C99B500F224	Primary Tumor	Illumina HiSeq	b7f024ff-9569-4d31-b652-ffc2ceaa2789	Lung	62	AD9A794F-52DD-4572-BF29-CD3D11BA6C24	F9F38A15-2964-4AE0-90AA-E5F3F7461AB3	TCGA-50-5946-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5946	TCGA-LUAD	NA	s10790	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma Mixed Subtype	Stage IA	1751-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae52	58cfa82ee4b0c9d6adf6ae52	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted.bam	372.53	1.9	0.14	58cfa82ee4b0c9d6adf6ae52	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4389-01A	A3DE401D-91FE-49A2-BB07-81C1A06506E6	Primary Tumor	Illumina HiSeq	63a06f9b-e1c2-495a-8f7e-88e19c550049	Lung	70	ED61AC6A-F21F-4B88-928A-029340D4AEBD	575D4BEF-5610-41F4-B219-C9BBBA72F047	TCGA-05-4389-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4389	TCGA-LUAD	NA	s10769	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Lung Adenocarcinoma Mixed Subtype	Stage IA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6ba	58cfa82fe4b0c9d6adf6b6ba	TCGA-44-6778-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-44-6778-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_5_rg.sorted	TCGA-44-6778-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_5_rg.sorted.bam	227.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6ba	TCGA-44-6778-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_5_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-44-6778-01A	5D5CC436-6E57-4D23-A164-7F5153C2E666	Primary Tumor	Illumina HiSeq	8d0de456-4a8c-48ad-bfc5-fa6e66ba6e0d	Lung	59	15321297-7110-4E79-8D6F-94C95BC83C94	737A7A30-1F60-4D88-B94D-B5FCD996FED2	TCGA-44-6778-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6778	TCGA-LUAD	NA	s11126	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b704	58cfa82fe4b0c9d6adf6b704	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	665.52	1.9	0.15	58cfa82fe4b0c9d6adf6b704	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4659-01A	CD0DC947-B708-464E-BEB7-954C9D4583E7	Primary Tumor	Illumina HiSeq	37276b21-3a00-4b58-b1df-cc2199584cb0	Lung	66	C35A5ED1-1821-4077-BA1E-B972DFA3233B	277D2F7F-1A7F-4D39-BD15-0334CC02840E	TCGA-73-4659-01A-01D-1203-02	GRCh37	TCGA-73-4659	TCGA-LUAD	711	s11246	Harvard Medical School	Roswell Park	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6aa	58cfa82fe4b0c9d6adf6b6aa	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.bam	62.7	1.9	0.17	58cfa82fe4b0c9d6adf6b6aa	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6774-01A	33C71EAD-4C2A-476D-85EF-885DBBFC2CBD	Primary Tumor	Illumina HiSeq	5ff8e7e5-3b91-49af-b384-9d870bd9e425	Lung	56	79CF84B5-84FF-42E5-B438-697B35D272FC	6B977266-994D-4440-BC09-59FD8737F2D0	TCGA-44-6774-01A-21D-1853-02	HG19_Broad_variant	TCGA-44-6774	TCGA-LUAD	NA	s10996	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6de	58cfa82fe4b0c9d6adf6b6de	TCGA-44-6147-11A-01D-1751_111207_SN590_0112_D09CDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-44-6147-11A-01D-1751_111207_SN590_0112_D09CDACXX_s_2_rg.sorted	TCGA-44-6147-11A-01D-1751_111207_SN590_0112_D09CDACXX_s_2_rg.sorted.bam	59.4	1.9	0.16	58cfa82fe4b0c9d6adf6b6de	TCGA-44-6147-11A-01D-1751_111207_SN590_0112_D09CDACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6147-11A	889AEC8E-14BA-48D9-8FE1-F2416E82B333	Solid Tissue Normal	Illumina HiSeq	ea7b7b64-8b4e-46fd-91d3-0a22729856f0	Lung	67	D990632B-B55A-4893-9C3D-5AC0FB6BB6F8	503A3086-3453-4AAE-987B-019FBCB13272	TCGA-44-6147-11A-01D-1751-02	HG19_Broad_variant	TCGA-44-6147	TCGA-LUAD	NA	s11342	Harvard Medical School	Christiana Healthcare	United States	NO	T1b	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b64b	58cfa82fe4b0c9d6adf6b64b	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted.bam	392.4	1.9	0.15	58cfa82fe4b0c9d6adf6b64b	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-5126-01A	93766482-2F20-4C8F-BBD8-BDD203C37D5A	Primary Tumor	Illumina HiSeq	8c670948-9cf1-4db3-82d5-39ed824c61ff	Lung	NA	39509EA1-E728-4350-B444-798C72ADE33A	7BCB1D5A-871F-472E-A964-9B68259D9716	TCGA-75-5126-01A-01D-1751-02	HG19_Broad_variant	TCGA-75-5126	TCGA-LUAD	NA	s11251	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T3	N2	Lung Papillary Adenocarcinoma	Stage IIIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b716	58cfa82fe4b0c9d6adf6b716	TCGA-73-4662-11A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_6_rg.sorted.filtered.	WGS	TCGA-73-4662-11A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_6_rg.sorted	TCGA-73-4662-11A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_6_rg.sorted.bam	648.3	1.9	0.15	58cfa82fe4b0c9d6adf6b716	TCGA-73-4662-11A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4662-11A	294FF941-AEA1-4588-9A0E-E9F5393E2BB6	Solid Tissue Normal	Illumina HiSeq	2018de7f-d9e8-4e7f-8459-9794814494b5	Lung	65	D4E6A949-F60C-4B76-8810-A778180F9139	998F30CD-957A-4E93-87A8-BED043774480	TCGA-73-4662-11A-01D-1203-02	HG19_Broad_variant	TCGA-73-4662	TCGA-LUAD	NA	s11245	Harvard Medical School	Roswell Park	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b790	58cfa82fe4b0c9d6adf6b790	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.filtered.	WGS	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.bam	72	1.9	0.16	58cfa82fe4b0c9d6adf6b790	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6146-01A	0C0B610E-FE4C-406D-A5ED-5CC3B11DABF5	Primary Tumor	Illumina HiSeq	99148000-be38-4da1-aeaa-4b0271725662	Lung	64	AD66185F-983D-4416-B705-25D3D4D8B5A5	2D5C6425-E3F4-4389-9DDF-FDE694B4227E	TCGA-44-6146-01A-11D-1751-02	HG19_Broad_variant	TCGA-44-6146	TCGA-LUAD	NA	s11337	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Lung Mucinous Adenocarcinoma	Stage IIB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b738	58cfa82fe4b0c9d6adf6b738	TCGA-49-4488-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_2_rg.sorted.filtered.	WGS	TCGA-49-4488-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_2_rg.sorted	TCGA-49-4488-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_2_rg.sorted.bam	59.4	1.9	0.13	58cfa82fe4b0c9d6adf6b738	TCGA-49-4488-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4488-11A	D721BFE0-90E3-415E-B9F3-1A270EFA5FBB	Solid Tissue Normal	Illumina HiSeq	1a64c497-725c-488a-a6a9-c32abe246dea	Lung	74	B5A8C70C-9BE7-4923-945C-32807605402A	104B5C75-71A5-4757-A244-E393AB14FC0E	TCGA-49-4488-11A-01D-1751-02	HG19_Broad_variant	TCGA-49-4488	TCGA-LUAD	869	s11340	Harvard Medical School	Johns Hopkins	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7b6	58cfa82fe4b0c9d6adf6b7b6	TCGA-44-3918-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_6_rg.sorted.filtered.	WGS	TCGA-44-3918-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_6_rg.sorted	TCGA-44-3918-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_6_rg.sorted.bam	467.53	1.9	0.16	58cfa82fe4b0c9d6adf6b7b6	TCGA-44-3918-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3918-01A	6E3B6B72-142D-4B8D-A462-28A205796E41	Primary Tumor	Illumina HiSeq	96ae9138-6a97-4b93-9d28-35ec09a8d772	Lung	60	2FF8BAFD-2AC5-4BFD-8C60-81519CD44166	81D8D7E2-65FA-4E92-B064-0D7D41C54E7F	TCGA-44-3918-01A-01D-1103-02	HG19_Broad_variant	TCGA-44-3918	TCGA-LUAD	NA	s11122	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7d8	58cfa82fe4b0c9d6adf6b7d8	TCGA-50-5932-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-50-5932-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_5_rg.sorted	TCGA-50-5932-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_5_rg.sorted.bam	147.4	1.9	0.15	58cfa82fe4b0c9d6adf6b7d8	TCGA-50-5932-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5932-11A	EBCBA7F2-CE13-4BAE-97CD-91A6B1DCD465	Solid Tissue Normal	Illumina HiSeq	f7b98f6e-b7a7-4ed0-91bd-7e0749dbf7a0	Lung	75	0E7847D9-D1D0-4980-8F44-C428F36B83F0	6BF1CE92-0865-4D8B-AB4D-EFC68871FED1	TCGA-50-5932-11A-01D-1751-02	HG19_Broad_variant	TCGA-50-5932	TCGA-LUAD	1235	s11127	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b868	58cfa82fe4b0c9d6adf6b868	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.bam	88.28	1.87	0.17	58cfa82fe4b0c9d6adf6b868	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R7-01A	02B25675-094D-4098-96DA-51D121380FEC	Primary Tumor	Illumina HiSeq	daa92f08-7339-46a6-8a74-e6756c170ed5	Uterus	55	550C6341-260A-4156-B00C-0AE9031D647F	4C9B54D0-A58E-44CF-8937-913A34F0788C	TCGA-A5-A0R7-01A-31D-A101-02	HG19_Broad_variant	TCGA-A5-A0R7	TCGA-UCEC	NA	s4777	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7c6	58cfa82fe4b0c9d6adf6b7c6	TCGA-49-4507-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4507-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4507-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	258.2	1.9	0.16	58cfa82fe4b0c9d6adf6b7c6	TCGA-49-4507-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4507-11A	50B2C647-AECD-4C81-AF22-0D8116593552	Solid Tissue Normal	Illumina HiSeq	85ba42cf-c97b-4bd6-910f-d3e06fb69a79	Lung	73	8A603532-91DB-487A-A4E2-A8C1F848FA19	6C9A73D4-8E10-4957-9739-603EAF942BBD	TCGA-49-4507-11A-01D-1203-02	GRCh37	TCGA-49-4507	TCGA-LUAD	268	s10781	Harvard Medical School	Johns Hopkins	United States	NO	T3	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8fe	58cfa82fe4b0c9d6adf6b8fe	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.filtered.	WGS	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.bam	62.7	1.9	0.15	58cfa82fe4b0c9d6adf6b8fe	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-49-6744-01A	15340DD3-84AE-49FB-989A-EB212F3E73DA	Primary Tumor	Illumina HiSeq	8290093a-0193-41fa-8e87-71960e0e640e	Lung	64	A9D69D7E-298C-4AB6-B64F-1EDC58832CCD	7455D0A5-45DB-461F-9026-5A0FE3D55A6A	TCGA-49-6744-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6744	TCGA-LUAD	NA	s10656	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b88d	58cfa82fe4b0c9d6adf6b88d	TCGA-49-4510-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4510-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4510-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	247.53	1.9	0.15	58cfa82fe4b0c9d6adf6b88d	TCGA-49-4510-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4510-11A	F77B6930-A1CE-446E-A15D-C018CBBECFEE	Solid Tissue Normal	Illumina HiSeq	b8bf16ce-9774-4ef9-a278-487ae6ec947e	Lung	51	DB4E6EFA-79AA-44D7-AB88-4866B4E94B0D	DA919955-6B7A-4A94-B62F-4A31555A4AA9	TCGA-49-4510-11A-01D-1203-02	GRCh37	TCGA-49-4510	TCGA-LUAD	896	s11002	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8b3	58cfa82fe4b0c9d6adf6b8b3	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.bam	416.7	1.9	0.15	58cfa82fe4b0c9d6adf6b8b3	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5051-01A	E1C55BAC-BB41-4964-ADD5-ECD6BA04B58D	Primary Tumor	Illumina HiSeq	fd2a1c20-3ed6-4057-8fb5-4027ce0eec74	Lung	42	180EB213-0DDC-4F10-AB0E-B3AF92CDE3C3	80170E98-4886-4A34-BC88-F2B2F84743B2	TCGA-50-5051-01A-21D-1853-02	HG19_Broad_variant	TCGA-50-5051	TCGA-LUAD	NA	s10789	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b903	58cfa82fe4b0c9d6adf6b903	TCGA-49-4506-11A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_8_rg.sorted.filtered.	WGS	TCGA-49-4506-11A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_8_rg.sorted	TCGA-49-4506-11A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_8_rg.sorted.bam	147.2	1.9	0.15	58cfa82fe4b0c9d6adf6b903	TCGA-49-4506-11A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4506-11A	B61ABDFD-B7A0-4E1A-B570-D1EAECAD3A9E	Solid Tissue Normal	Illumina HiSeq	30c3d956-3fe6-4cf5-9829-00573c3a5813	Lung	68	5185FAF2-69D2-40D6-8554-97D5D71AB112	8641683B-986D-4A4F-878E-CE0E3754727F	TCGA-49-4506-11A-01D-1203-02	HG19_Broad_variant	TCGA-49-4506	TCGA-LUAD	999	s11005	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b955	58cfa82fe4b0c9d6adf6b955	TCGA-A5-A0GN-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-A5-A0GN-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_4_rg.sorted	TCGA-A5-A0GN-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_4_rg.sorted.bam	19.14	1.86	0.16	58cfa82fe4b0c9d6adf6b955	TCGA-A5-A0GN-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GN-10A	A2A2DBDA-D10C-49C4-86A8-61BAF6160CDA	Blood Derived Normal	Illumina HiSeq	1c07f20d-3b72-45ca-8708-cd4d625736d2	Uterus	65	31CA1860-C5E6-43CB-AB4D-E9A0F5A6D605	97FEC691-A406-45EC-BC0F-61D1F1439D74	TCGA-A5-A0GN-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0GN	TCGA-UCEC	NA	s4772	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b90e	58cfa82fe4b0c9d6adf6b90e	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	289.2	1.9	0.14	58cfa82fe4b0c9d6adf6b90e	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4507-01A	50B2C647-AECD-4C81-AF22-0D8116593552	Primary Tumor	Illumina HiSeq	557606c6-d245-45ba-b9f0-adc05c6a5f4f	Lung	73	962F85FF-1F27-49E4-8C3D-798FACEA122F	EF299B98-6A9F-4022-8683-A9C830E7263C	TCGA-49-4507-01A-01D-1203-02	GRCh37	TCGA-49-4507	TCGA-LUAD	268	s11453	Harvard Medical School	Johns Hopkins	United States	NO	T3	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b912	58cfa82fe4b0c9d6adf6b912	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted.bam	258.2	1.9	0.13	58cfa82fe4b0c9d6adf6b912	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4506-01A	B61ABDFD-B7A0-4E1A-B570-D1EAECAD3A9E	Primary Tumor	Illumina HiSeq	b07f7ea8-c74b-4559-97d3-987f1985f2e9	Lung	68	9EDEA53D-AD06-4B5D-BFF0-48E834C3684F	2270ABD6-565B-46B6-8154-505C5659A7C3	TCGA-49-4506-01A-01D-1203-02	HG19_Broad_variant	TCGA-49-4506	TCGA-LUAD	999	s11234	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9f8	58cfa82fe4b0c9d6adf6b9f8	TCGA-64-5781-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-64-5781-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_8_rg.sorted	TCGA-64-5781-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_8_rg.sorted.bam	142.4	1.9	0.15	58cfa82fe4b0c9d6adf6b9f8	TCGA-64-5781-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5781-10A	41C4C704-825E-49F5-9D54-DBD7D30725E0	Blood Derived Normal	Illumina HiSeq	ef6d1a20-4c6f-43f4-96c3-26a38a678e60	Lung	55	68DD1C45-4DBE-4B8D-B6B6-034EB1AE9DC0	F5139F81-3CCA-4253-BBCD-8C210DEEE920	TCGA-64-5781-10A-01D-1623-02	HG19_Broad_variant	TCGA-64-5781	TCGA-LUAD	NA	s11355	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba10	58cfa82fe4b0c9d6adf6ba10	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	233.25	1.69	0.15	58cfa82fe4b0c9d6adf6ba10	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01G-01A	6F2B5A14-569C-4084-8C67-B1A44D787897	Primary Tumor	Illumina HiSeq	efd511ca-ff06-4cbe-afe2-2c025120233e	Colorectal	63	A09ABC20-4F93-4130-A23A-8413E6C32FE5	D7D83B15-9EE5-4206-805D-AC3E5914BCC6	TCGA-AA-A01G-01A-01D-A077-02	HG18	TCGA-AA-A01G	TCGA-COAD	NA	s13205	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6ba84	58cfa830e4b0c9d6adf6ba84	TCGA-AA-A03J-11A-11D-A079_110405_SN590_0074_AB04EUABXX_s_2_rg.sorted.filtered.	WGS	TCGA-AA-A03J-11A-11D-A079_110405_SN590_0074_AB04EUABXX_s_2_rg.sorted	TCGA-AA-A03J-11A-11D-A079_110405_SN590_0074_AB04EUABXX_s_2_rg.sorted.bam	66.74	2.13	0.16	58cfa830e4b0c9d6adf6ba84	TCGA-AA-A03J-11A-11D-A079_110405_SN590_0074_AB04EUABXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A03J-11A	E6C8C5FC-158A-4DE4-B3F6-3B645584BBC7	Solid Tissue Normal	Illumina HiSeq	39ecbe8b-f969-4295-91c5-0a82dff4041a	Colorectal	65	F7D192AA-1D64-404A-BC35-A8603E1567E1	E4A72EFE-8456-45A1-A935-1769A2298CEE	TCGA-AA-A03J-11A-11D-A079-02	HG18_Broad_variant	TCGA-AA-A03J	TCGA-COAD	NA	s12885	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bbd8	58cfa830e4b0c9d6adf6bbd8	TCGA-AG-A00H-10A-01D-A078_110405_SN590_0074_AB04EUABXX_s_6_rg.sorted.filtered.	WGS	TCGA-AG-A00H-10A-01D-A078_110405_SN590_0074_AB04EUABXX_s_6_rg.sorted	TCGA-AG-A00H-10A-01D-A078_110405_SN590_0074_AB04EUABXX_s_6_rg.sorted.bam	31.86	1.75	0.15	58cfa830e4b0c9d6adf6bbd8	TCGA-AG-A00H-10A-01D-A078_110405_SN590_0074_AB04EUABXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A00H-10A	9F4574EC-A58A-4410-8735-C5E5BC4CA7E0	Blood Derived Normal	Illumina HiSeq	b60fa920-96ee-45f5-945a-5efb41023fac	Colorectal	75	A94D44D3-470F-4CA2-B93C-5D5A06340345	59D8A039-76E5-4E7E-B461-6DBDC5BE4398	TCGA-AG-A00H-10A-01D-A078-02	HG18_Broad_variant	TCGA-AG-A00H	TCGA-READ	NA	s2150	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6ba91	58cfa830e4b0c9d6adf6ba91	TCGA-AA-3510-11A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3510-11A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3510-11A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	507.02	1.9	0.14	58cfa830e4b0c9d6adf6ba91	TCGA-AA-3510-11A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3510-11A	35C295C2-37D1-44B2-87A3-1039645E5BAE	Solid Tissue Normal	Illumina HiSeq	0032406a-20bf-4092-832e-d73a3da4c00d	Colorectal	70	3EA9A3FD-16A0-4ED0-A9C8-45CB3972FE2B	EEC8BD6A-B080-43D6-971B-3E2E56DCA0AF	TCGA-AA-3510-11A-01D-1405-02	HG18	TCGA-AA-3510	TCGA-COAD	NA	s13510	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bc52	58cfa830e4b0c9d6adf6bc52	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted.bam	217.29	1.72	0.15	58cfa830e4b0c9d6adf6bc52	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A011-01A	3BE106BC-BA42-4C70-9B50-697D89DB617D	Primary Tumor	Illumina HiSeq	af371ab1-77bf-4408-860e-ccc4386c99aa	Colorectal	80	B5DD8F49-26FC-48D9-A964-D8EBDCCA9E19	8C282A6C-3D47-4F9E-96C4-2C0852E7785B	TCGA-AG-A011-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A011	TCGA-READ	NA	s2001	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6bc62	58cfa830e4b0c9d6adf6bc62	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted.filtered.	WGS	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted.bam	150.39	1.72	0.15	58cfa830e4b0c9d6adf6bc62	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A00Y-01A	C7E09161-60D6-4DFF-A840-7CEC3BB7A30A	Primary Tumor	Illumina HiSeq	2c284389-2d4d-4e3b-9b5b-a37212874f6e	Colorectal	68	8EC6ADED-026E-47F5-91F1-2A75F07BD8D0	27B036A3-5277-4C0F-93EE-593FDA1441DC	TCGA-AG-A00Y-01A-02D-A077-02	HG18_Broad_variant	TCGA-AG-A00Y	TCGA-READ	NA	s1983	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6bc88	58cfa830e4b0c9d6adf6bc88	TCGA-AG-3901-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3901-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3901-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	44.59	1.9	0.16	58cfa830e4b0c9d6adf6bc88	TCGA-AG-3901-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3901-10A	1586CB0A-081A-4364-9470-46F9D0F0167D	Blood Derived Normal	Illumina HiSeq	89a4a4fc-6853-4e6e-ae7c-a413dcd1b0bf	Colorectal	67	339F4C4C-C973-40F0-85EC-C244987AA9C1	D6A98EC3-E843-482D-88AB-484235F648B0	TCGA-AG-3901-10A-01D-1115-02	HG18	TCGA-AG-3901	TCGA-READ	NA	s1994	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Mucinous Adenocarcinoma	Stage IIIB	1115-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7c4	58cfa82fe4b0c9d6adf6b7c4	TCGA-44-4112-11A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_2_rg.sorted.filtered.	WGS	TCGA-44-4112-11A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_2_rg.sorted	TCGA-44-4112-11A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_2_rg.sorted.bam	555.93	1.9	0.17	58cfa82fe4b0c9d6adf6b7c4	TCGA-44-4112-11A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-4112-11A	68B86559-38B2-41F2-B66E-C3C2B628B14D	Solid Tissue Normal	Illumina HiSeq	e885be2d-89c8-413a-bae1-1458a975bd33	Lung	60	6D41EF8F-9599-40F3-8A7D-32DE1ED0ACC0	161AB88F-51DF-41DF-B38C-C1DC9764DC82	TCGA-44-4112-11A-01D-1103-02	HG19_Broad_variant	TCGA-44-4112	TCGA-LUAD	NA	s10902	Harvard Medical School	Christiana Healthcare	None	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1103-02	TRUE
13722.58cfa830e4b0c9d6adf6bc8c	58cfa830e4b0c9d6adf6bc8c	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	913.89	1.9	0.15	58cfa830e4b0c9d6adf6bc8c	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3896-01A	9AF35239-FFB9-4D4F-889E-F743DA271EEF	Primary Tumor	Illumina HiSeq	5666993b-483e-4cb2-ac08-c5f26b31b9cd	Colorectal	85	03B40342-3CCE-4A45-B2EC-8855AEB85100	D33D46C5-F3FD-4FD5-9CE2-06839BF33A37	TCGA-AG-3896-01A-01D-1115-02	HG18	TCGA-AG-3896	TCGA-READ	NA	s1988	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bc90	58cfa830e4b0c9d6adf6bc90	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	414.02	1.9	0.15	58cfa830e4b0c9d6adf6bc90	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4308-01A	3D8FD9B2-9AA2-4C81-8843-535AE66D6140	Primary Tumor	Illumina HiSeq	562ea734-bcd1-499a-8054-f710f2de3e41	Colorectal	47	6F0E65B2-7CA0-4F10-8952-B64900009001	1C7E82B6-A8EB-4593-B329-5299BC05140E	TCGA-AZ-4308-01A-01D-1405-02	HG18	TCGA-AZ-4308	TCGA-COAD	NA	s13540	Harvard Medical School	University of Pittsburgh	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bd64	58cfa830e4b0c9d6adf6bd64	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	205.35	1.73	0.15	58cfa830e4b0c9d6adf6bd64	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00R-01A	CA22EDD4-EB7C-4677-84AA-6F0354459A19	Primary Tumor	Illumina HiSeq	f8afa471-fd74-43ef-8cc5-58a4f3788e31	Colorectal	64	F72EEAE9-F7F5-4576-A072-5021119117D6	AC9F45EC-C004-475F-8537-8977F20B0DE8	TCGA-AA-A00R-01A-01D-A077-02	HG18	TCGA-AA-A00R	TCGA-COAD	NA	s13517	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A077-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae66	58cfa82ee4b0c9d6adf6ae66	TCGA-05-4389-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_6_rg.sorted.filtered.	WGS	TCGA-05-4389-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_6_rg.sorted	TCGA-05-4389-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_6_rg.sorted.bam	61.23	1.8	0.15	58cfa82ee4b0c9d6adf6ae66	TCGA-05-4389-10A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4389-10A	A3DE401D-91FE-49A2-BB07-81C1A06506E6	Blood Derived Normal	Illumina HiSeq	2952e37a-d8f8-4392-9a0e-7bde008209b0	Lung	70	BDCAC214-BA95-4DDD-8C84-9B60C14109BB	575A85DF-E14B-46E3-ACA2-60F32FABC941	TCGA-05-4389-10A-01D-1203-02	HG19_Broad_variant	TCGA-05-4389	TCGA-LUAD	NA	s11546	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Lung Adenocarcinoma Mixed Subtype	Stage IA	1203-02	TRUE
13722.58cfa830e4b0c9d6adf6bd8c	58cfa830e4b0c9d6adf6bd8c	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.bam	94.25	2.11	0.15	58cfa830e4b0c9d6adf6bd8c	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M0-01A	8BF0B156-6EB4-45E8-9CBB-0979EFBEA898	Primary Tumor	Illumina HiSeq	bedca351-a4f7-4fbd-af8e-d49f3d9b2c37	Uterus	66	E3F599DB-19CF-4086-8E5D-D3527119120F	78D21C64-205B-4C9C-A862-8A70348D2602	TCGA-BG-A0M0-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M0	TCGA-UCEC	NA	s5216	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa82fe4b0c9d6adf6b98a	58cfa82fe4b0c9d6adf6b98a	TCGA-A5-A0GW-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0GW-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_6_rg.sorted	TCGA-A5-A0GW-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_6_rg.sorted.bam	18.14	2.16	0.13	58cfa82fe4b0c9d6adf6b98a	TCGA-A5-A0GW-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_6_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GW-10A	5B6B9D0F-787C-4AE9-AFD4-DE7CE6C57A42	Blood Derived Normal	Illumina HiSeq	3077e8e1-511d-46c3-8240-c6c80f64d770	Uterus	46	7AE1717D-A559-42CB-8197-47F279B612F1	843EA109-EF2F-48C5-A955-2420D9B7F00E	TCGA-A5-A0GW-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0GW	TCGA-UCEC	NA	s4775	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bc9e	58cfa830e4b0c9d6adf6bc9e	TCGA-AZ-4315-10A-01D-1405_110225_SN177_0142_B81JPFABXX_s_4.rg.sorted.filtered.	WGS	TCGA-AZ-4315-10A-01D-1405_110225_SN177_0142_B81JPFABXX_s_4.rg.sorted	TCGA-AZ-4315-10A-01D-1405_110225_SN177_0142_B81JPFABXX_s_4.rg.sorted.bam	287.72	1.9	0.15	58cfa830e4b0c9d6adf6bc9e	TCGA-AZ-4315-10A-01D-1405_110225_SN177_0142_B81JPFABXX_s_4.rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4315-10A	DE287A25-981D-49F8-81AF-FE0300E4CD31	Blood Derived Normal	Illumina HiSeq	9a6322eb-3fac-4d37-bbec-89355ddc9dbb	Colorectal	61	8D10297B-DEF9-4F00-B231-B1448967FA7A	59F67AA1-B650-40DD-A6F8-D2BC53380B6C	TCGA-AZ-4315-10A-01D-1405-02	HG18_Broad_variant	TCGA-AZ-4315	TCGA-COAD	NA	s13541	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bda8	58cfa830e4b0c9d6adf6bda8	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted.bam	66.95	NA	0.16	58cfa830e4b0c9d6adf6bda8	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1Q0-01A	633DDC04-C424-42C8-8E54-673968B130A7	Primary Tumor	Illumina HiSeq	44801af7-d042-441d-afc9-4c0d7b493b01	Skin	80	B68CFB6B-4249-4855-8278-B18C0F561EFD	C94F7E24-8073-4786-BFC0-C45A37D85B2F	TCGA-BF-A1Q0-01A-21D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1Q0	TCGA-SKCM	NA	s7320	Harvard Medical School	Cureline	Russia	NO	T4b	N0	Not available	Stage IIC	A18Z-02	TRUE
13722.58cfa830e4b0c9d6adf6bded	58cfa830e4b0c9d6adf6bded	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.bam	43.73	2.05	0.16	58cfa830e4b0c9d6adf6bded	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0DK-01A	F2BBFA9D-9A9D-4F46-9FDE-378E4C44E2AD	Primary Tumor	Illumina HiSeq	71acb20b-f186-44d4-a92e-a2751f845fe3	Breast	49	1ACAE6E0-3100-4DE8-A436-E15CDBE1322B	92245807-8B1B-4E96-8567-6CFE5E70ADE4	TCGA-BH-A0DK-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0DK	TCGA-BRCA	NA	s5493	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bd9b	58cfa830e4b0c9d6adf6bd9b	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.bam	101.93	1.88	0.15	58cfa830e4b0c9d6adf6bd9b	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M3-01A	8BDD4E0E-5BEC-43F2-B9FA-D6E94A72FE05	Primary Tumor	Illumina HiSeq	d3fa774f-c50e-499c-ad6e-1a5f67dd2be3	Uterus	74	1802CD6B-4D4A-45FA-B839-7450071E41EE	04E49830-378E-4EB2-B77C-70D6955627F7	TCGA-BG-A0M3-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M3	TCGA-UCEC	NA	s5394	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6be6a	58cfa830e4b0c9d6adf6be6a	TCGA-BL-A0C8-10A-01D-A10R_120926_SN590_0181_AC19HCACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BL-A0C8-10A-01D-A10R_120926_SN590_0181_AC19HCACXX_s_2_rg.sorted	TCGA-BL-A0C8-10A-01D-A10R_120926_SN590_0181_AC19HCACXX_s_2_rg.sorted.bam	19.58	1.95	0.14	58cfa830e4b0c9d6adf6be6a	TCGA-BL-A0C8-10A-01D-A10R_120926_SN590_0181_AC19HCACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A0C8-10A	A6003B1C-56A9-430A-A5E2-B70AF3F81BDB	Blood Derived Normal	Illumina HiSeq	ccc5396b-d9e0-4f96-85ec-4a894585996f	Bladder	73	4BD51539-3638-4721-B7CA-C9AFC50611B7	61A64D7A-438E-47DE-9521-B5FD28DFBA20	TCGA-BL-A0C8-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BL-A0C8	TCGA-BLCA	NA	s2856	Harvard Medical School	Christiana Healthcare	United States	NO	T1	NX	Not available	Stage I	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6bdc2	58cfa830e4b0c9d6adf6bdc2	TCGA-BG-A0RY-10A-02D-A101_120409_SN1222_0096_BD0VA2ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0RY-10A-02D-A101_120409_SN1222_0096_BD0VA2ACXX_s_8_rg.sorted	TCGA-BG-A0RY-10A-02D-A101_120409_SN1222_0096_BD0VA2ACXX_s_8_rg.sorted.bam	8.16	2.15	0.17	58cfa830e4b0c9d6adf6bdc2	TCGA-BG-A0RY-10A-02D-A101_120409_SN1222_0096_BD0VA2ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0RY-10A	F299AD43-BB16-46CE-9617-48CC6C6F29E7	Blood Derived Normal	Illumina HiSeq	b0821143-56d7-444a-af2f-dafc2980c4d6	Uterus	68	6F9655B3-797D-4CD0-9E22-99C1D20C7938	BBD003F7-A80A-4F04-AC85-B023C527922C	TCGA-BG-A0RY-10A-02D-A101-02	HG19_Broad_variant	TCGA-BG-A0RY	TCGA-UCEC	NA	s5212	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6be74	58cfa830e4b0c9d6adf6be74	TCGA-BJ-A191-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A191-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_2_rg.sorted	TCGA-BJ-A191-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_2_rg.sorted.bam	61.82	1.95	0.17	58cfa830e4b0c9d6adf6be74	TCGA-BJ-A191-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A191-10A	2501EE46-8D38-448B-8765-E9C9706CBBE8	Blood Derived Normal	Illumina HiSeq	71641a64-f2ef-4736-9e22-5982cfc1280f	Thyroid	49	88A3A560-FB2D-4E5E-B7B5-831CF7F9671C	C49240A9-A6FB-4612-A5F9-F855585E12EA	TCGA-BJ-A191-10A-01D-A13U-02	HG19_Broad_variant	TCGA-BJ-A191	TCGA-THCA	NA	s12509	Harvard Medical School	University of Pittsburgh	United States	NO	T1b	N0	Other  specify	Stage I	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6be7e	58cfa830e4b0c9d6adf6be7e	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.bam	32.81	2.02	0.17	58cfa830e4b0c9d6adf6be7e	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A192-01A	B55375C3-9EF2-4D2F-9C29-224E746931C4	Primary Tumor	Illumina HiSeq	9218178e-761c-40ac-b3ca-044bf37f8686	Thyroid	54	582C3030-1F23-4535-9C8B-6B594E656AF4	6D770754-E14D-4E47-AE33-BE0FC9B40CE9	TCGA-BJ-A192-01A-31D-A13U-02	HG19_Broad_variant	TCGA-BJ-A192	TCGA-THCA	NA	s12235	Harvard Medical School	University of Pittsburgh	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6be84	58cfa830e4b0c9d6adf6be84	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted.bam	110.16	1.93	0.17	58cfa830e4b0c9d6adf6be84	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A191-01A	2501EE46-8D38-448B-8765-E9C9706CBBE8	Primary Tumor	Illumina HiSeq	fb73296b-b8ef-4ff9-a954-fab7d29ab101	Thyroid	49	C92FC4E3-7A96-4000-A969-AA894CA58A33	B3EDF2BC-5E8F-435A-ADA1-F292722EDD9C	TCGA-BJ-A191-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A191	TCGA-THCA	NA	s12237	Harvard Medical School	University of Pittsburgh	United States	NO	T1b	N0	Other  specify	Stage I	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6bec9	58cfa830e4b0c9d6adf6bec9	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.bam	109.58	1.91	0.16	58cfa830e4b0c9d6adf6bec9	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LP-01A	EFAE3940-D3CC-4988-BDB4-FA05D977AFF5	Primary Tumor	Illumina HiSeq	369f32c0-ebb9-490e-baa4-0735e0efa092	Uterus	76	D67450C1-8848-4B28-9C16-83AA7132E8C8	C7A70C11-A05E-473D-929E-59A260FFBD97	TCGA-AP-A0LP-01A-12D-A101-02	HG19_Broad_variant	TCGA-AP-A0LP	TCGA-UCEC	NA	s5202	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bf21	58cfa830e4b0c9d6adf6bf21	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.bam	7.9	1.9	0.16	58cfa830e4b0c9d6adf6bf21	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4279-01A	117EB38B-0C62-4336-A866-FA5BD013256A	Primary Tumor	Illumina HiSeq	0fa8a7d6-6636-4135-82f6-21c9df279b16	Stomach	43	84AD647D-76B8-4EDA-8603-40220089BE34	01DC88B7-45FC-464C-A613-9793CD0C068B	TCGA-BR-4279-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4279	TCGA-STAD	NA	s14814	Harvard Medical School	Asterand	Russia	NO	T2a	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf77	58cfa830e4b0c9d6adf6bf77	TCGA-BR-4280-11A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4280-11A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_3_rg.sorted	TCGA-BR-4280-11A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_3_rg.sorted.bam	0	1.9	0.14	58cfa830e4b0c9d6adf6bf77	TCGA-BR-4280-11A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4280-11A	E0916597-E489-45EF-A8F7-653A3C6591EF	Solid Tissue Normal	Illumina HiSeq	c1175b78-f7af-45d0-ba00-7b437cfbda5e	Stomach	78	4DC8B427-EBDF-40E0-922C-FCB5020C94FC	04EFD145-592B-499E-931B-4BF17F9C447D	TCGA-BR-4280-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4280	TCGA-STAD	NA	s14813	Harvard Medical School	Asterand	Russia	NO	T2b	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage III	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf1f	58cfa830e4b0c9d6adf6bf1f	TCGA-BR-4191-11A-01D-1128_120805_SN1222_0143_BD172BACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-4191-11A-01D-1128_120805_SN1222_0143_BD172BACXX_s_6_rg.sorted	TCGA-BR-4191-11A-01D-1128_120805_SN1222_0143_BD172BACXX_s_6_rg.sorted.bam	193.3	1.9	0.14	58cfa830e4b0c9d6adf6bf1f	TCGA-BR-4191-11A-01D-1128_120805_SN1222_0143_BD172BACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4191-11A	74F859CF-6DF5-4E96-AE6B-CFAAB691D5FD	Solid Tissue Normal	Illumina HiSeq	78b2b7ff-d302-4923-bfa4-f8d169667d90	Stomach	72	B69926B2-1C04-4F98-935E-2F9F9849504B	6E50ABE2-9B55-471A-A75E-62B119882476	TCGA-BR-4191-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4191	TCGA-STAD	NA	s14687	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf85	58cfa830e4b0c9d6adf6bf85	TCGA-BR-6456-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-6456-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_2_rg.sorted	TCGA-BR-6456-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_2_rg.sorted.bam	66	1.9	0.14	58cfa830e4b0c9d6adf6bf85	TCGA-BR-6456-10A-01D-1798_130116_SN208_0448_AC1J58ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6456-10A	1CA3C5E0-32B0-4467-8EC0-CA212E35D2B3	Blood Derived Normal	Illumina HiSeq	4fcd3184-8cb8-4097-8550-b9905d13adb4	Stomach	74	3A8917B9-B3FC-4221-AB95-84927E1DEC28	602267D7-4BCC-4F1A-9F65-6102235DAEB0	TCGA-BR-6456-10A-01D-1798-02	HG19_Broad_variant	TCGA-BR-6456	TCGA-STAD	NA	s15379	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6befc	58cfa830e4b0c9d6adf6befc	TCGA-BK-A0CB-11A-33D-A101_120504_SN590_0156_BC0H68ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BK-A0CB-11A-33D-A101_120504_SN590_0156_BC0H68ACXX_s_6_rg.sorted	TCGA-BK-A0CB-11A-33D-A101_120504_SN590_0156_BC0H68ACXX_s_6_rg.sorted.bam	56.21	1.83	0.15	58cfa830e4b0c9d6adf6befc	TCGA-BK-A0CB-11A-33D-A101_120504_SN590_0156_BC0H68ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BK-A0CB-11A	59E9029A-8DDD-4447-B35A-72BC39F82A30	Solid Tissue Normal	Illumina HiSeq	1f202d50-0049-42ea-9454-b7a7487a247c	Uterus	60	F1D2D79C-CE6A-4160-9DE2-C169F0DAB321	827E9BF6-71A0-4329-8CDB-DC588E496AFB	TCGA-BK-A0CB-11A-33D-A101-02	HG19_Broad_variant	TCGA-BK-A0CB	TCGA-UCEC	NA	s5395	Harvard Medical School	Christiana Healthcare	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bead	58cfa830e4b0c9d6adf6bead	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	510.89	1.9	0.15	58cfa830e4b0c9d6adf6bead	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3901-01A	1586CB0A-081A-4364-9470-46F9D0F0167D	Primary Tumor	Illumina HiSeq	c8ff4c94-25ea-4468-8ae0-06cb92ffa025	Colorectal	67	93B755E6-5D6E-4542-8BAE-2121F44F590C	F5D4395A-5E00-4616-A402-CDCAD8702E1B	TCGA-AG-3901-01A-01D-1115-02	HG18	TCGA-AG-3901	TCGA-READ	NA	s2148	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Mucinous Adenocarcinoma	Stage IIIB	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bf9f	58cfa830e4b0c9d6adf6bf9f	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.bam	306.4	1.9	0.15	58cfa830e4b0c9d6adf6bf9f	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6458-01A	E516880B-C4E5-43CD-A358-BE0DB88564D7	Primary Tumor	Illumina HiSeq	545acf44-8e16-46b9-b35a-c860c08b416b	Stomach	57	A30B45F5-C6E4-4975-A912-8313D93DFD27	2DD3E59B-4DBB-49B4-9DC4-A949FE48AA17	TCGA-BR-6458-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6458	TCGA-STAD	NA	s14613	Harvard Medical School	Asterand	Ukraine	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6bf91	58cfa830e4b0c9d6adf6bf91	TCGA-BJ-A291-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A291-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_4_rg.sorted	TCGA-BJ-A291-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_4_rg.sorted.bam	64.65	1.83	0.15	58cfa830e4b0c9d6adf6bf91	TCGA-BJ-A291-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A291-10A	D4C68C1C-A3F3-4E0C-B555-D457378A1D24	Blood Derived Normal	Illumina HiSeq	5f3310c7-9ee7-4637-b188-b3dad474042f	Thyroid	56	8051F3C6-7C36-45D1-B403-032983DA863F	4DEB3BDB-15F0-42E8-BBD6-EC9657F55AD1	TCGA-BJ-A291-10A-01D-A16N-02	HG19_Broad_variant	TCGA-BJ-A291	TCGA-THCA	NA	s12360	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6bfe8	58cfa830e4b0c9d6adf6bfe8	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.bam	338.7	1.9	0.14	58cfa830e4b0c9d6adf6bfe8	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6565-01A	DAECEA36-B379-46CE-8AE9-A38D22556CE2	Primary Tumor	Illumina HiSeq	8cfafa49-f561-4e59-98c5-b9a816534417	Stomach	67	1D7AAE07-2453-4DC3-A26D-D67161172648	E5F188AD-28C2-4AD0-89DD-C13493CE4B03	TCGA-BR-6565-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6565	TCGA-STAD	NA	s14881	Harvard Medical School	Asterand	Russia	NO	T4a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	TRUE
13722.58cfa830e4b0c9d6adf6c01e	58cfa830e4b0c9d6adf6c01e	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted.bam	89.84	1.92	0.14	58cfa830e4b0c9d6adf6c01e	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z2-01A	F9CEFFC0-D544-418D-B4A9-BD3C84E37026	Primary Tumor	Illumina HiSeq	9493c81d-440a-4066-975b-c6265b7641a6	Thyroid	57	B06B7493-F38A-493F-8B47-61E0FA4D111F	D8B6F131-76CA-45D3-8934-A6CDEA8153AD	TCGA-BJ-A0Z2-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z2	TCGA-THCA	NA	s12353	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage IVC	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c01c	58cfa830e4b0c9d6adf6c01c	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.bam	106.4	2	0.15	58cfa830e4b0c9d6adf6c01c	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K7-01A	2F0640BC-598C-4714-9E9B-7E0F2CA4567F	Primary Tumor	Illumina HiSeq	b1ac8e27-775c-4d91-8a4d-9d096cde589d	Uterus	64	51E8577D-6849-422E-8F37-2EA8C400BBE5	ED30E619-1EBE-4CCE-B7FD-93B552953B65	TCGA-B5-A0K7-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0K7	TCGA-UCEC	NA	s5390	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c026	58cfa830e4b0c9d6adf6c026	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted.bam	79.63	2	0.16	58cfa830e4b0c9d6adf6c026	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZB-01A	DC4D8468-6F34-40CB-A826-8D582CD86FDE	Primary Tumor	Illumina HiSeq	72ce31c8-5889-450a-ac21-159c97d9b125	Thyroid	66	145A474E-D262-468A-8DB7-EE9F1B7CE0A7	EBAA6AE4-66C0-49A7-938C-620E24564846	TCGA-BJ-A0ZB-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZB	TCGA-THCA	NA	s12097	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6bcac	58cfa830e4b0c9d6adf6bcac	TCGA-AG-3894-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3894-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3894-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	7.59	1.9	0.16	58cfa830e4b0c9d6adf6bcac	TCGA-AG-3894-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3894-10A	065B26FC-6827-44D5-83D8-1100C63FCDA6	Blood Derived Normal	Illumina HiSeq	6a9c36f1-b845-4ba6-abf3-648188c51636	Colorectal	65	5D172F3A-8B5B-4CEB-A5C7-314571E3EB30	6B64DF2F-F727-46E7-BD39-518D8D68F796	TCGA-AG-3894-10A-01D-1115-02	HG18	TCGA-AG-3894	TCGA-READ	NA	s2165	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6c050	58cfa830e4b0c9d6adf6c050	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.bam	110.74	2.06	0.14	58cfa830e4b0c9d6adf6c050	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K6-01A	5CBA9441-6812-49C0-A0F6-7928ED4E5B81	Primary Tumor	Illumina HiSeq	06cd1c7f-2531-4a07-bf4f-c086f7a954a0	Uterus	58	69BF0D3A-B7AE-4EE1-B7D1-18A32FCFA67C	A4364F57-81A8-4B96-BA31-1D8B1CC78C5D	TCGA-B5-A0K6-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K6	TCGA-UCEC	NA	s4247	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c15c	58cfa830e4b0c9d6adf6c15c	TCGA-BA-4075-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BA-4075-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_4_rg.sorted	TCGA-BA-4075-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_4_rg.sorted.bam	80.03	1.9	0.14	58cfa830e4b0c9d6adf6c15c	TCGA-BA-4075-10A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_4_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4075-10A	6FA62461-E721-415A-8B0F-363B84292B82	Blood Derived Normal	Illumina HiSeq	5481b0b3-1652-4735-9746-fbf7bfb454a9	Head and Neck	49	4A5BA6E2-C47A-4CF4-A657-5FD0E962E49C	515D017E-D7A6-4CFF-AC82-F58E5A47005D	TCGA-BA-4075-10A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4075	TCGA-HNSC	283	s15487	Harvard Medical School	UNC	None	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c041	58cfa830e4b0c9d6adf6c041	TCGA-AG-3893-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3893-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3893-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	44.59	1.9	0.15	58cfa830e4b0c9d6adf6c041	TCGA-AG-3893-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3893-10A	ADD567B7-29EF-4122-8A54-57D36F735E78	Blood Derived Normal	Illumina HiSeq	089d5f62-916b-4ea2-b8cf-7e0e2540e174	Colorectal	74	E2428535-1739-45BC-8466-FF8BAEB59F57	E815B25F-95E5-4AC6-96D0-CB4BB686E712	TCGA-AG-3893-10A-01D-1115-02	HG18	TCGA-AG-3893	TCGA-READ	NA	s2153	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6c066	58cfa830e4b0c9d6adf6c066	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	710.89	1.9	0.15	58cfa830e4b0c9d6adf6c066	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3894-01A	065B26FC-6827-44D5-83D8-1100C63FCDA6	Primary Tumor	Illumina HiSeq	8db01c5c-36a6-4060-ada7-3d57682daaf6	Colorectal	65	D6B7E2F3-01AD-4E77-87BB-9CBAEF03A5FB	339E9078-1166-45F6-A6BD-A2818B8918A1	TCGA-AG-3894-01A-01D-1115-02	HG18	TCGA-AG-3894	TCGA-READ	NA	s2163	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6c044	58cfa830e4b0c9d6adf6c044	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	551.89	1.9	0.15	58cfa830e4b0c9d6adf6c044	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3893-01A	ADD567B7-29EF-4122-8A54-57D36F735E78	Primary Tumor	Illumina HiSeq	d98305fc-80c0-4336-b35c-0c47d8c297b8	Colorectal	74	7E16AFE9-DA05-451B-BD8C-86D75C8E475C	5815181B-A53B-4AAF-9817-168AC41DAD2A	TCGA-AG-3893-01A-01D-1115-02	HG18	TCGA-AG-3893	TCGA-READ	NA	s2152	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6c1a7	58cfa830e4b0c9d6adf6c1a7	TCGA-BA-5153-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BA-5153-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_6_rg.sorted	TCGA-BA-5153-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_6_rg.sorted.bam	61.4	1.9	0.14	58cfa830e4b0c9d6adf6c1a7	TCGA-BA-5153-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5153-10A	B3631718-9E0A-454C-BEE1-8F36EBC509D8	Blood Derived Normal	Illumina HiSeq	246bc4c7-cd66-439e-b78e-15222d1efba7	Head and Neck	51	F079E825-160A-40D5-97CC-1931F11C4E2E	88631234-EDDF-4B86-BAAD-6450C21ED2CC	TCGA-BA-5153-10A-01D-1431-02	HG19_Broad_variant	TCGA-BA-5153	TCGA-HNSC	1762	s16170	Harvard Medical School	UNC	None	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c1e0	58cfa830e4b0c9d6adf6c1e0	TCGA-BA-5151-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BA-5151-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_4_rg.sorted	TCGA-BA-5151-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_4_rg.sorted.bam	73.4	1.9	0.14	58cfa830e4b0c9d6adf6c1e0	TCGA-BA-5151-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5151-10A	A55FB87D-F606-48A5-82F5-09EACBACF41B	Blood Derived Normal	Illumina HiSeq	fe120e7f-b67b-43e6-9502-3878c982d056	Head and Neck	72	18B31768-284F-4B52-9BED-D0ACE9B8D4FE	5B6DC28D-F368-4A15-8CAE-781081317AB9	TCGA-BA-5151-10A-01D-1431-02	HG19_Broad_variant	TCGA-BA-5151	TCGA-HNSC	NA	s15750	Harvard Medical School	UNC	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c1b8	58cfa830e4b0c9d6adf6c1b8	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted.bam	64.32	NA	0.18	58cfa830e4b0c9d6adf6c1b8	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PZ-01A	455F982C-A067-46AC-BF89-3E535D0FFCA0	Primary Tumor	Illumina HiSeq	61217185-aa8a-467c-ba89-48231f6a81cc	Skin	71	2A5EE782-122E-432B-98E0-0849B6F9A3D9	25D65D8B-ED75-47D6-B7F6-95CF26CCBE06	TCGA-BF-A1PZ-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PZ	TCGA-SKCM	NA	s7319	Harvard Medical School	Cureline	Russia	NO	T4a	N0	Not available	Stage IIB	A18Z-02	TRUE
13722.58cfa830e4b0c9d6adf6c1fc	58cfa830e4b0c9d6adf6c1fc	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.bam	63.57	1.97	0.15	58cfa830e4b0c9d6adf6c1fc	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M2-01A	9731E0B3-C62D-43CB-8AE7-8F973D69AB19	Primary Tumor	Illumina HiSeq	9dcd7360-a8dc-49cb-bf13-8fb36c436e30	Uterus	62	2AF18345-2A71-4574-AC8E-83DDEED3AD57	E59EB8B5-DA68-44B3-BB18-8C42F583B2BA	TCGA-BG-A0M2-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M2	TCGA-UCEC	NA	s4604	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c222	58cfa830e4b0c9d6adf6c222	TCGA-BA-4078-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BA-4078-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_2_rg.sorted	TCGA-BA-4078-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_2_rg.sorted.bam	63.03	1.9	0.14	58cfa830e4b0c9d6adf6c222	TCGA-BA-4078-10A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4078-10A	C7353D6A-82A2-4A0D-8CD4-8C8957943EDB	Blood Derived Normal	Illumina HiSeq	9f383e84-52bd-4beb-b916-e1c652c45e27	Head and Neck	83	25B0AE1D-2ADD-49B9-A5AE-99702A5C48F4	FA6F21FF-7667-491C-9A99-31B473C9D683	TCGA-BA-4078-10A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4078	TCGA-HNSC	276	s15618	Harvard Medical School	UNC	None	NO	Not available	Not available	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c23c	58cfa830e4b0c9d6adf6c23c	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.bam	51.24	NA	0.18	58cfa830e4b0c9d6adf6c23c	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LB-01A	D17A5AB1-3789-4652-AFF5-D8F4F2291F9C	Primary Tumor	Illumina HiSeq	de67212f-594e-409c-bd19-3d40f013b89a	Bladder	73	7C6178A6-6D4C-4DEF-B4AC-A064AB4A6C8A	FAD087E0-3752-4144-960B-659B59312C92	TCGA-BT-A2LB-01A-11D-A18D-02	HG19_Broad_variant	TCGA-BT-A2LB	TCGA-BLCA	NA	s3087	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A18D-02	TRUE
13722.58cfa830e4b0c9d6adf6c29e	58cfa830e4b0c9d6adf6c29e	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.bam	194.2	1.9	0.15	58cfa830e4b0c9d6adf6c29e	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4366-01A	525A6978-2D7B-4F3A-AC68-13FE8CBBBDCC	Primary Tumor	Illumina HiSeq	c4b9424f-d0da-48ae-8723-69cbccfdefc6	Stomach	87	8C2D2CCE-E071-42E8-89B2-77C56B4F3472	5AF4101A-F7F6-4014-BC9C-02446DA9CBDC	TCGA-BR-4366-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4366	TCGA-STAD	NA	s15235	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6c272	58cfa830e4b0c9d6adf6c272	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.bam	34.66	1.95	0.15	58cfa830e4b0c9d6adf6c272	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZA-01A	4C513413-263E-4C7B-B997-7B688C47B698	Primary Tumor	Illumina HiSeq	787aed3e-08d4-4fa8-93e1-c04216a9875f	Thyroid	67	A61A9EC7-B893-44A5-AB6F-A390C168BE88	F3A353BB-07C3-49D1-BED2-2F8F5A328E1C	TCGA-BJ-A0ZA-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZA	TCGA-THCA	NA	s12744	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c248	58cfa830e4b0c9d6adf6c248	TCGA-BT-A2LA-11A-11D-A18D_120912_SN1222_0148_AC188PACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BT-A2LA-11A-11D-A18D_120912_SN1222_0148_AC188PACXX_s_4_rg.sorted	TCGA-BT-A2LA-11A-11D-A18D_120912_SN1222_0148_AC188PACXX_s_4_rg.sorted.bam	9.14	NA	0.16	58cfa830e4b0c9d6adf6c248	TCGA-BT-A2LA-11A-11D-A18D_120912_SN1222_0148_AC188PACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LA-11A	797A71EE-372D-41E5-AEEE-5AB3C4661110	Solid Tissue Normal	Illumina HiSeq	ee7f989e-a375-4956-a120-aab1394e350f	Bladder	54	F12723EF-51A8-4071-B612-B47A14C2B459	BA6BC788-FE48-412B-B303-B45370501109	TCGA-BT-A2LA-11A-11D-A18D-02	HG19_Broad_variant	TCGA-BT-A2LA	TCGA-BLCA	NA	s2866	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A18D-02	TRUE
13722.58cfa830e4b0c9d6adf6c2b2	58cfa830e4b0c9d6adf6c2b2	TCGA-CF-A1HR-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CF-A1HR-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_4_rg.sorted	TCGA-CF-A1HR-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_4_rg.sorted.bam	57.84	1.95	0.16	58cfa830e4b0c9d6adf6c2b2	TCGA-CF-A1HR-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A1HR-10A	39EA19E1-4959-4F1B-9934-54BDAF766842	Blood Derived Normal	Illumina HiSeq	8f5d258a-5720-4244-a4e2-2288d64a7ef9	Bladder	62	0AE65E89-1DB2-4E20-96D7-D337AACBB040	A854E387-FD99-4C95-9F75-0B359B1592FD	TCGA-CF-A1HR-10A-01D-A13U-02	HG19_Broad_variant	TCGA-CF-A1HR	TCGA-BLCA	NA	s2701	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6c2da	58cfa830e4b0c9d6adf6c2da	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.bam	179.2	1.9	0.15	58cfa830e4b0c9d6adf6c2da	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4370-01A	A2A71CB0-9DBD-45CC-8867-DA84500515E7	Primary Tumor	Illumina HiSeq	a1feb789-c851-4608-a5c1-382bb432c4c7	Stomach	74	CFB7901B-E4E1-42FE-802D-DCD34F8C4912	B27FAC46-97C3-4262-B8CB-6E15AA75483A	TCGA-BR-4370-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4370	TCGA-STAD	NA	s14883	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c34e	58cfa831e4b0c9d6adf6c34e	TCGA-CG-5718-10A-01D-1598_121029_SN208_0438_AC18NJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-5718-10A-01D-1598_121029_SN208_0438_AC18NJACXX_s_8_rg.sorted	TCGA-CG-5718-10A-01D-1598_121029_SN208_0438_AC18NJACXX_s_8_rg.sorted.bam	305.7	1.9	0.15	58cfa831e4b0c9d6adf6c34e	TCGA-CG-5718-10A-01D-1598_121029_SN208_0438_AC18NJACXX_s_8_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5718-10A	D5C58161-05ED-4472-81ED-176216F49929	Blood Derived Normal	Illumina HiSeq	30044c1d-1cc7-49e5-9bed-dbb5168be8f4	Stomach	78	D44D5BD5-5034-4D33-8554-CD1A8179A711	C1D35FF6-7260-49C2-A7C1-2E22CBB10ED7	TCGA-CG-5718-10A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5718	TCGA-STAD	NA	s15324	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa830e4b0c9d6adf6c2cc	58cfa830e4b0c9d6adf6c2cc	TCGA-CF-A1HS-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CF-A1HS-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_6_rg.sorted	TCGA-CF-A1HS-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_6_rg.sorted.bam	49.47	1.98	0.17	58cfa830e4b0c9d6adf6c2cc	TCGA-CF-A1HS-10A-01D-A13U_121011_SN590_0184_BC192GACXX_s_6_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A1HS-10A	A73C0842-39C5-4C2C-AA6A-F31341A4F36E	Blood Derived Normal	Illumina HiSeq	6774ba08-2ee0-4555-946b-3fcf2996801b	Bladder	75	0157F04D-8289-4163-88AB-1D1AAACFCB7B	CEC780F5-CAB3-4786-8E82-26BB356E4801	TCGA-CF-A1HS-10A-01D-A13U-02	HG19_Broad_variant	TCGA-CF-A1HS	TCGA-BLCA	NA	s2877	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6c2ec	58cfa830e4b0c9d6adf6c2ec	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.bam	118.7	1.9	0.15	58cfa830e4b0c9d6adf6c2ec	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6566-01A	43F0421C-6578-4D77-9314-EF0305C7EFBD	Primary Tumor	Illumina HiSeq	ae711b74-3be9-4959-addd-03427c07f35b	Stomach	64	EEB8703E-5F0A-429D-9A5C-7C5227EB7A01	7BAAEED3-AA68-4825-84F1-0516B543C762	TCGA-BR-6566-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6566	TCGA-STAD	NA	s14884	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c384	58cfa831e4b0c9d6adf6c384	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.bam	374	2	0.17	58cfa831e4b0c9d6adf6c384	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5801-01A	DF822EA3-E0E6-4AD3-A228-E20E3A737DAC	Primary Tumor	Illumina HiSeq	5196b0dd-1d41-47f4-84a8-999f211443f4	Stomach	69	9D0DF8D7-8D59-4983-9BBF-C6C106BDEFEC	F32CB4AA-D842-427A-8B7E-371764308512	TCGA-CD-5801-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5801	TCGA-STAD	NA	s15317	Harvard Medical School	ILSbio	Vietnam	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c498	58cfa831e4b0c9d6adf6c498	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted.bam	52.7	1.9	0.16	58cfa831e4b0c9d6adf6c498	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4722-01A	B64BFCA1-033C-4501-A900-103AC105C084	Primary Tumor	Illumina HiSeq	3723e20c-1e27-4158-8bc5-1768c49ee5e5	Head and Neck	61	6E767FC9-0F5A-49EC-999A-CDA2DAEBA6FF	0CA196A7-5A71-4E70-8FA6-9506E1883032	TCGA-CN-4722-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4722	TCGA-HNSC	NA	s15758	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c424	58cfa831e4b0c9d6adf6c424	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.bam	52.7	1.9	0.17	58cfa831e4b0c9d6adf6c424	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4725-01A	3BE2ACE5-1C2A-49E9-8DA9-CEED6119530B	Primary Tumor	Illumina HiSeq	7ddc2537-f164-4a40-befe-6e0a3deed186	Head and Neck	60	DD42AB2F-E936-4ACE-93D8-60375E03F2FE	C8B71532-685F-47AC-B019-B898A8D1670D	TCGA-CN-4725-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4725	TCGA-HNSC	NA	s15755	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c4ce	58cfa831e4b0c9d6adf6c4ce	TCGA-BR-4363-11A-01D-1154_130815_VM001_0001_VMR0001CXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-4363-11A-01D-1154_130815_VM001_0001_VMR0001CXX_s_8_rg.sorted	TCGA-BR-4363-11A-01D-1154_130815_VM001_0001_VMR0001CXX_s_8_rg.sorted.bam	193.3	1.9	0.14	58cfa831e4b0c9d6adf6c4ce	TCGA-BR-4363-11A-01D-1154_130815_VM001_0001_VMR0001CXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4363-11A	66BCA2F8-F269-454D-ABE2-CE51A0704645	Solid Tissue Normal	Illumina HiSeq	06da121c-66ee-44be-8a1c-58e736f82e55	Stomach	60	12B616D2-B101-4B61-9285-121AA7D6C11F	3A3723C2-50D2-4F01-95C8-6298E1FD303E	TCGA-BR-4363-11A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4363	TCGA-STAD	NA	s14815	Harvard Medical School	Asterand	Russia	NO	T3	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c4a4	58cfa831e4b0c9d6adf6c4a4	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted.bam	37.6	2	0.16	58cfa831e4b0c9d6adf6c4a4	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A1HR-01A	39EA19E1-4959-4F1B-9934-54BDAF766842	Primary Tumor	Illumina HiSeq	65dee943-f41b-4f59-a5bb-2477053d1079	Bladder	62	6E77AB45-9C53-4A74-9581-043005C3E685	B048E28D-38FC-4E37-9C54-9C56526AD0E3	TCGA-CF-A1HR-01A-11D-A13U-02	HG19_Broad_variant	TCGA-CF-A1HR	TCGA-BLCA	NA	s2872	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c514	58cfa831e4b0c9d6adf6c514	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted.bam	52.7	1.9	0.13	58cfa831e4b0c9d6adf6c514	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4735-01A	FE844945-3EA9-449E-993C-DF392FABCFD0	Primary Tumor	Illumina HiSeq	b8913a67-9dd4-41f9-8888-c998df0a0a23	Head and Neck	52	FBB300FA-8793-42DA-A68E-4570AE2E5186	F759672A-62CA-49DC-BC4F-643E8A885787	TCGA-CN-4735-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4735	TCGA-HNSC	NA	s16032	Harvard Medical School	University of Pittsburgh	None	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c57e	58cfa831e4b0c9d6adf6c57e	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted.bam	99.7	1.9	0.15	58cfa831e4b0c9d6adf6c57e	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4729-01A	2FC960BD-01B0-422D-AD33-34520FA3DF0E	Primary Tumor	Illumina HiSeq	8b48a937-18eb-4e54-95d1-680ce9284b60	Head and Neck	73	1DA8FE25-AEE2-45FD-A1F3-3239A42E54B2	A49670C2-95A6-4DEB-BFC5-59B0FF37389E	TCGA-CN-4729-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4729	TCGA-HNSC	NA	s15620	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c102	58cfa830e4b0c9d6adf6c102	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.bam	97.15	2.16	0.13	58cfa830e4b0c9d6adf6c102	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K9-01A	4485CC98-5D58-4EB4-8325-7D1A617B6461	Primary Tumor	Illumina HiSeq	71c016d1-ab89-4d8f-acb9-92767959d603	Uterus	88	52A96216-708F-43F2-A923-130A1C35922D	30D94271-91F3-4CF5-83C0-4708662115D0	TCGA-B5-A0K9-01A-21D-A101-02	HG19_Broad_variant	TCGA-B5-A0K9	TCGA-UCEC	NA	s5210	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa831e4b0c9d6adf6c5ea	58cfa831e4b0c9d6adf6c5ea	TCGA-CG-4437-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-4437-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_5_rg.sorted	TCGA-CG-4437-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_5_rg.sorted.bam	9	1.9	0.14	58cfa831e4b0c9d6adf6c5ea	TCGA-CG-4437-10A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4437-10A	6244E506-D163-4D34-8FEC-6158191679CB	Blood Derived Normal	Illumina HiSeq	a6985d3e-05da-443e-9b5e-7098618981c5	Stomach	83	A03A5DAB-F43F-4A95-8560-FA1D2A613D92	C49F85DE-B830-44D8-A89A-8857899F0CD3	TCGA-CG-4437-10A-01D-1798-02	HG19_Broad_variant	TCGA-CG-4437	TCGA-STAD	NA	s14410	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c5fe	58cfa831e4b0c9d6adf6c5fe	TCGA-CQ-5330-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CQ-5330-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_8_rg.sorted	TCGA-CQ-5330-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_8_rg.sorted.bam	55.7	1.9	0.14	58cfa831e4b0c9d6adf6c5fe	TCGA-CQ-5330-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5330-10A	9FFA79FA-D2D8-48E1-8FD6-4B020ECF357C	Blood Derived Normal	Illumina HiSeq	583ffff7-e647-470a-ac1d-3d6bab206e8a	Head and Neck	69	B3D8B1A6-DCC5-434F-B17A-BCC2D1D9CA2D	3BF2FBFA-2B1F-423B-9FB5-84C16EF882DE	TCGA-CQ-5330-10A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5330	TCGA-HNSC	NA	s15773	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c651	58cfa831e4b0c9d6adf6c651	TCGA-CN-4736-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-4736-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_3_rg.sorted	TCGA-CN-4736-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_3_rg.sorted.bam	52.7	1.9	0.15	58cfa831e4b0c9d6adf6c651	TCGA-CN-4736-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4736-01A	0FB3E5FF-54F0-43C5-9322-541BB7825E7F	Primary Tumor	Illumina HiSeq	45c5cea2-56a4-43af-9c53-19302867f2d9	Head and Neck	70	6DB0B6EE-23B3-43BF-8AA9-FDF641AFC673	8141905F-DE66-4DB2-A9F9-5819C953A465	TCGA-CN-4736-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4736	TCGA-HNSC	395	s15881	Harvard Medical School	University of Pittsburgh	None	NO	T1	NX	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c696	58cfa831e4b0c9d6adf6c696	TCGA-CS-6186-01A-12D-2022_130910_SN208_0494_AC2A1DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CS-6186-01A-12D-2022_130910_SN208_0494_AC2A1DACXX_s_3_rg.sorted	TCGA-CS-6186-01A-12D-2022_130910_SN208_0494_AC2A1DACXX_s_3_rg.sorted.bam	324.7	NA	0.15	58cfa831e4b0c9d6adf6c696	TCGA-CS-6186-01A-12D-2022_130910_SN208_0494_AC2A1DACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-6186-01A	9EE6E821-3AF2-42D7-9D14-F0CA455F338C	Primary Tumor	Illumina HiSeq	5660aee8-60eb-40d1-9083-d4fc781e8ddc	Brain	58	5F73FA4E-FC7D-4FC0-8436-2241E57B9B69	4143FB11-BA46-4129-8543-F72C015AE5C4	TCGA-CS-6186-01A-12D-2022-02	HG19_Broad_variant	TCGA-CS-6186	TCGA-LGG	538	s8556	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6c528	58cfa831e4b0c9d6adf6c528	TCGA-CM-4750-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4750-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4750-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	166.72	1.9	0.13	58cfa831e4b0c9d6adf6c528	TCGA-CM-4750-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4750-10A	C777A777-373A-4773-9566-6C373261F00A	Blood Derived Normal	Illumina HiSeq	ec4b40d2-142c-4754-8825-4cdae52c5b9b	Colorectal	34	0D218B20-9C44-4C04-8BD5-3490D4E67333	5F8BF9A0-0680-44A1-809D-A2CAA776B977	TCGA-CM-4750-10A-01D-1405-02	HG18	TCGA-CM-4750	TCGA-COAD	NA	s13218	Harvard Medical School	MSKCC	United States	NO	T1	N1b	Colon Adenocarcinoma	Stage IIIA	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c750	58cfa831e4b0c9d6adf6c750	TCGA-D3-A3CE-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D3-A3CE-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_7_rg.sorted	TCGA-D3-A3CE-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_7_rg.sorted.bam	57.35	NA	0.17	58cfa831e4b0c9d6adf6c750	TCGA-D3-A3CE-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A3CE-06A	730F7400-E94A-4F41-B081-5227FA1A9C18	Metastatic	Illumina HiSeq	32fb9058-a555-47ba-8e2e-29360b53085b	Skin	74	8A1C62F5-4F3B-43C8-879D-370EE764B01F	75C4A565-3E22-46BA-B9FE-0A43B9556EBB	TCGA-D3-A3CE-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D3-A3CE	TCGA-SKCM	1832	s7499	Harvard Medical School	MD Anderson	United States	NO	T0	N1b	Not available	Stage III	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c73e	58cfa831e4b0c9d6adf6c73e	TCGA-D3-A2JP-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D3-A2JP-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_4_rg.sorted	TCGA-D3-A2JP-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_4_rg.sorted.bam	18.1	NA	0.17	58cfa831e4b0c9d6adf6c73e	TCGA-D3-A2JP-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A2JP-10A	E9A42A85-9513-41B2-A71D-6D62F70B00E4	Blood Derived Normal	Illumina HiSeq	4b9843ae-869e-4a07-ba84-7e300b9c03cc	Skin	37	071D73D9-5C08-4BE9-8C14-DF3D6EC9BF56	BBB42C52-862D-4BF6-A09F-B65BAEAF3841	TCGA-D3-A2JP-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A2JP	TCGA-SKCM	NA	s7323	Harvard Medical School	MD Anderson	United States	NO	T0	N3	Not available	Stage IIIC	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c753	58cfa831e4b0c9d6adf6c753	TCGA-D3-A2JC-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-D3-A2JC-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_8_rg.sorted	TCGA-D3-A2JC-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_8_rg.sorted.bam	25.03	NA	0.15	58cfa831e4b0c9d6adf6c753	TCGA-D3-A2JC-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A2JC-10A	DB239624-3DBA-48BB-9889-F479DC2BA046	Blood Derived Normal	Illumina HiSeq	cfb3a5aa-61a3-4974-b482-8860495c3f56	Skin	53	02B48BFC-E122-4E01-8DB6-B979C5A21AB6	E21E67AD-2A45-4833-8DA8-C2D467D5412A	TCGA-D3-A2JC-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A2JC	TCGA-SKCM	NA	s7495	Harvard Medical School	MD Anderson	United States	NO	T0	N2b	Not available	Stage III	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c76a	58cfa831e4b0c9d6adf6c76a	TCGA-D3-A2JC-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D3-A2JC-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_6_rg.sorted	TCGA-D3-A2JC-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_6_rg.sorted.bam	52.51	NA	0.15	58cfa831e4b0c9d6adf6c76a	TCGA-D3-A2JC-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A2JC-06A	DB239624-3DBA-48BB-9889-F479DC2BA046	Metastatic	Illumina HiSeq	a7d7b7f7-01dd-4c3f-9406-513601821293	Skin	53	350D1C39-1CE1-4140-ACE9-3FB908D0FF5B	61155BF2-23AB-49CC-BEE7-FE6901B7D1D7	TCGA-D3-A2JC-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D3-A2JC	TCGA-SKCM	NA	s7493	Harvard Medical School	MD Anderson	United States	NO	T0	N2b	Not available	Stage III	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c810	58cfa831e4b0c9d6adf6c810	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted.bam	59.69	NA	0.17	58cfa831e4b0c9d6adf6c810	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A2G0-01A	6F661F0D-F08B-486E-8BD7-4306E1593EB9	Primary Tumor	Illumina HiSeq	675cc0ce-f2e1-4e4c-a337-4bc31fcb46c5	Uterus	70	134CD317-CBEB-4633-B540-B639454615F7	DF417E78-8258-40C2-8305-2FE14DCC8035	TCGA-D1-A2G0-01A-11D-A17E-02	HG19_Broad_variant	TCGA-D1-A2G0	TCGA-UCEC	NA	s4803	Harvard Medical School	Mayo Clinic	United States	NO	Not available	Not available	Mixed serous and endometrioid	Not available	A17E-02	TRUE
13722.58cfa831e4b0c9d6adf6c770	58cfa831e4b0c9d6adf6c770	TCGA-D3-A3C3-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D3-A3C3-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_4_rg.sorted	TCGA-D3-A3C3-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_4_rg.sorted.bam	24.92	NA	0.16	58cfa831e4b0c9d6adf6c770	TCGA-D3-A3C3-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A3C3-10A	FC59CC57-CA7A-4DE3-BD13-2E283716A243	Blood Derived Normal	Illumina HiSeq	c29f3065-3e54-48d6-bbed-7aac0fbd2f92	Skin	30	4396781F-3443-4AB0-82DA-0151CEE7085F	B3AF114B-4AF4-46EB-8545-916D55C38FC1	TCGA-D3-A3C3-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A3C3	TCGA-SKCM	NA	s7671	Harvard Medical School	MD Anderson	United States	NO	TX	N0	Not available	I or II NOS	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c77e	58cfa831e4b0c9d6adf6c77e	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted.bam	152.7	1.9	0.15	58cfa831e4b0c9d6adf6c77e	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-5396-01A	B6C2C9BD-625B-4A98-830C-49C344F6CB5F	Primary Tumor	Illumina HiSeq	3d26b7bb-4cc9-4d9b-8c42-6fbd2ea9b590	Brain	53	CE1ED4B3-AF89-4BBD-B9A6-EEFA007E4368	F2F5E5EE-B807-4CAF-99B3-68270C1F305E	TCGA-CS-5396-01A-02D-1465-02	HG19_Broad_variant	TCGA-CS-5396	TCGA-LGG	NA	s8342	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c83a	58cfa831e4b0c9d6adf6c83a	TCGA-D3-A3C8-06A-12D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D3-A3C8-06A-12D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_5_rg.sorted	TCGA-D3-A3C8-06A-12D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_5_rg.sorted.bam	72.53	NA	0.15	58cfa831e4b0c9d6adf6c83a	TCGA-D3-A3C8-06A-12D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A3C8-06A	16182443-12A1-4B0F-A6AB-33C2942E2991	Metastatic	Illumina HiSeq	21d12df1-c29f-4e93-86da-c2c511ada473	Skin	58	D0ECA475-4A80-42EB-BC91-4159699CDFBA	F088E04C-D72E-43E4-ACBF-BBF455866244	TCGA-D3-A3C8-06A-12D-A18Z-02	HG19_Broad_variant	TCGA-D3-A3C8	TCGA-SKCM	NA	s7498	Harvard Medical School	MD Anderson	United States	NO	TX	N3	Not available	Stage IIIC	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c854	58cfa831e4b0c9d6adf6c854	TCGA-D3-A2JD-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D3-A2JD-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_1_rg.sorted	TCGA-D3-A2JD-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_1_rg.sorted.bam	57.77	NA	0.15	58cfa831e4b0c9d6adf6c854	TCGA-D3-A2JD-06A-11D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A2JD-06A	A5F95C6C-E25A-4AD8-BD5D-FCFD8A31933C	Metastatic	Illumina HiSeq	65653c49-be73-44c2-b13c-3aa7f55d5748	Skin	58	5A484E4E-D555-4AC6-9269-6E36FCC955B9	512AF874-0BA3-4BD2-A1FE-361C73F3EADF	TCGA-D3-A2JD-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D3-A2JD	TCGA-SKCM	361	s7669	Harvard Medical School	MD Anderson	United States	NO	T4b	N1b	Not available	Stage IIIC	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c879	58cfa831e4b0c9d6adf6c879	TCGA-D3-A3CC-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D3-A3CC-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_6_rg.sorted	TCGA-D3-A3CC-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_6_rg.sorted.bam	17.68	NA	0.15	58cfa831e4b0c9d6adf6c879	TCGA-D3-A3CC-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A3CC-10A	2D36CEA4-73E9-493B-8433-0C2B911C0521	Blood Derived Normal	Illumina HiSeq	59c97e2f-e76c-4017-a55f-31efc29ca6c1	Skin	69	1F41A22B-7415-4DEB-8EF0-78D6FE7E5576	3EFAE3EC-F99E-40C8-8265-0FBA134E19EB	TCGA-D3-A3CC-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A3CC	TCGA-SKCM	NA	s7324	Harvard Medical School	MD Anderson	United States	NO	T4b	N0	Not available	Stage IIC	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c8d6	58cfa831e4b0c9d6adf6c8d6	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted.bam	93.6	1.92	0.15	58cfa831e4b0c9d6adf6c8d6	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16B-01A	BCA1057A-1E96-404D-8A37-5A8DC1944EE7	Primary Tumor	Illumina HiSeq	fee88e21-5479-4b67-8933-80c22e6fa222	Uterus	64	6A59FF6E-7CC6-4D46-8983-7D9E6A48CC19	D581BCAA-4EA7-4364-840B-E2D24F1916E4	TCGA-D1-A16B-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16B	TCGA-UCEC	NA	s5017	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c872	58cfa831e4b0c9d6adf6c872	TCGA-D3-A3C3-06A-12D-A18Z_120520_SN590_0158_AC0J99ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D3-A3C3-06A-12D-A18Z_120520_SN590_0158_AC0J99ACXX_s_3_rg.sorted	TCGA-D3-A3C3-06A-12D-A18Z_120520_SN590_0158_AC0J99ACXX_s_3_rg.sorted.bam	63.5	NA	0.16	58cfa831e4b0c9d6adf6c872	TCGA-D3-A3C3-06A-12D-A18Z_120520_SN590_0158_AC0J99ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A3C3-06A	FC59CC57-CA7A-4DE3-BD13-2E283716A243	Metastatic	Illumina HiSeq	fcc6bf30-9ef1-43ac-84e6-68661b4266d8	Skin	30	56E5EA92-2D58-494F-8350-B31E95060314	2FD34FBF-5B0C-4171-BAC1-38FD03A62295	TCGA-D3-A3C3-06A-12D-A18Z-02	HG19_Broad_variant	TCGA-D3-A3C3	TCGA-SKCM	NA	s7833	Harvard Medical School	MD Anderson	United States	NO	TX	N0	Not available	I or II NOS	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c8ce	58cfa831e4b0c9d6adf6c8ce	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted.bam	74.24	1.92	0.14	58cfa831e4b0c9d6adf6c8ce	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16Q-01A	7F4F3AED-69AF-421E-817B-B258DCC0BAC5	Primary Tumor	Illumina HiSeq	c23e5f4d-d7be-44b1-a19e-c949819d58c9	Uterus	54	BFE3DA05-506E-4837-AC72-A285FE079C58	23DF790A-0AB3-4EFB-AD9D-62AF1B79D941	TCGA-D1-A16Q-01A-12D-A12F-02	HG19_Broad_variant	TCGA-D1-A16Q	TCGA-UCEC	NA	s5024	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c9da	58cfa831e4b0c9d6adf6c9da	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted.bam	48.83	2	0.16	58cfa831e4b0c9d6adf6c9da	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13T-01A	0B170ED4-D919-466B-B765-47878B865AED	Primary Tumor	Illumina HiSeq	f42aa2a6-4acd-4650-aea7-c83fbddf27d2	Thyroid	37	6883BA87-9184-40D7-840B-603B15D73F7A	76DCBA6C-0992-44BB-9492-3023A2430CC4	TCGA-DJ-A13T-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13T	TCGA-THCA	NA	s12513	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c999	58cfa831e4b0c9d6adf6c999	TCGA-DJ-A13T-10A-01D-A10R_120629_SN1120_0167_AC0WMBACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DJ-A13T-10A-01D-A10R_120629_SN1120_0167_AC0WMBACXX_s_2_rg.sorted	TCGA-DJ-A13T-10A-01D-A10R_120629_SN1120_0167_AC0WMBACXX_s_2_rg.sorted.bam	30.25	1.92	0.14	58cfa831e4b0c9d6adf6c999	TCGA-DJ-A13T-10A-01D-A10R_120629_SN1120_0167_AC0WMBACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13T-10A	0B170ED4-D919-466B-B765-47878B865AED	Blood Derived Normal	Illumina HiSeq	b76e1212-5c0d-4aa2-8571-b51b3b490d27	Thyroid	37	ABFEC4E3-79D8-4263-B6F7-F98FDFEB1877	70AE0C44-BF61-4871-88A2-C7F5EE11296C	TCGA-DJ-A13T-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13T	TCGA-THCA	NA	s11993	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c962	58cfa831e4b0c9d6adf6c962	TCGA-DE-A0Y2-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DE-A0Y2-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_6_rg.sorted	TCGA-DE-A0Y2-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_6_rg.sorted.bam	21.64	2	0.14	58cfa831e4b0c9d6adf6c962	TCGA-DE-A0Y2-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DE-A0Y2-10A	6AD260AD-769A-4F3C-BD07-927ADF6B2338	Blood Derived Normal	Illumina HiSeq	49e7891f-4770-48d9-819b-603aec748234	Thyroid	30	8E3AF0FC-266C-47E7-8FD0-25C2DBBFB372	9279B921-3B76-4AD0-88C2-03BB66D1C235	TCGA-DE-A0Y2-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DE-A0Y2	TCGA-THCA	NA	s12633	Harvard Medical School	University of North Carolina	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6ca04	58cfa831e4b0c9d6adf6ca04	TCGA-DB-5273-10A-01D-1465_130808_SN208_0488_BC294YACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DB-5273-10A-01D-1465_130808_SN208_0488_BC294YACXX_s_2_rg.sorted	TCGA-DB-5273-10A-01D-1465_130808_SN208_0488_BC294YACXX_s_2_rg.sorted.bam	51.7	1.9	0.14	58cfa831e4b0c9d6adf6ca04	TCGA-DB-5273-10A-01D-1465_130808_SN208_0488_BC294YACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5273-10A	AE2DB022-EB4F-4B65-89B6-9FD4439DDEEF	Blood Derived Normal	Illumina HiSeq	fe0c497b-caa5-4108-8564-a1507ba99ed4	Brain	33	3C8435A1-E37C-417E-B3D7-27F4E15014ED	A10E85BD-5A8B-4697-87C3-B2F060C02436	TCGA-DB-5273-10A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5273	TCGA-LGG	NA	s8343	Harvard Medical School	Mayo Clinic - Rochester	United States	NO	Not available	Not available	Astrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c96a	58cfa831e4b0c9d6adf6c96a	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted.bam	97.61	1.98	0.17	58cfa831e4b0c9d6adf6c96a	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QI-01A	3B1E2BD6-3D32-40F7-9B32-0DF32DFCBC72	Primary Tumor	Illumina HiSeq	e0052e53-2d8c-45ba-8d2c-db4eab61a141	Thyroid	63	C58506A1-8C6B-4CE8-99E0-F2D1234F95F5	3C049586-BD3C-490D-93DB-E344BD6A1AE8	TCGA-DJ-A1QI-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QI	TCGA-THCA	NA	s12641	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6ca37	58cfa831e4b0c9d6adf6ca37	TCGA-DB-5279-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DB-5279-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_7_rg.sorted	TCGA-DB-5279-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_7_rg.sorted.bam	81	1.9	0.14	58cfa831e4b0c9d6adf6ca37	TCGA-DB-5279-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_7_rg.sorted.bam	Alive	MALE	Not available	Not available	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5279-01A	85F77526-791E-47CD-904D-D1DBB49EAEAB	Primary Tumor	Illumina HiSeq	1c15ff7e-3cbc-41b1-b814-1cf03f1f5a27	Brain	59	0096C7FB-34E3-4D0F-BA81-3559CC00080A	109052DB-CACF-4E14-8258-500E90B6B476	TCGA-DB-5279-01A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5279	TCGA-LGG	NA	s8559	Harvard Medical School	Mayo Clinic - Rochester	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6ca1d	58cfa831e4b0c9d6adf6ca1d	TCGA-D1-A2G6-10A-01D-A17E_120511_SN208_0299_BD12J9ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-D1-A2G6-10A-01D-A17E_120511_SN208_0299_BD12J9ACXX_s_8_rg.sorted	TCGA-D1-A2G6-10A-01D-A17E_120511_SN208_0299_BD12J9ACXX_s_8_rg.sorted.bam	12.4	NA	0.16	58cfa831e4b0c9d6adf6ca1d	TCGA-D1-A2G6-10A-01D-A17E_120511_SN208_0299_BD12J9ACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A2G6-10A	46CD8DED-F8A1-4F8C-A4C2-2D5B51C04F18	Blood Derived Normal	Illumina HiSeq	88a27a1c-460f-45a8-8579-5e7a02138395	Uterus	53	397A60A8-E8A7-4FAE-B4AD-27ED69507657	22A38614-AE6F-4E56-8B54-7C09F02695E0	TCGA-D1-A2G6-10A-01D-A17E-02	HG19_Broad_variant	TCGA-D1-A2G6	TCGA-UCEC	258	s5022	Harvard Medical School	Mayo Clinic	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A17E-02	TRUE
13722.58cfa831e4b0c9d6adf6ca2e	58cfa831e4b0c9d6adf6ca2e	TCGA-DA-A1IC-06A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DA-A1IC-06A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_1_rg.sorted	TCGA-DA-A1IC-06A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_1_rg.sorted.bam	43.33	NA	0.16	58cfa831e4b0c9d6adf6ca2e	TCGA-DA-A1IC-06A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1IC-06A	6625CE3F-3A1F-45F9-AA42-AB1931D6DAF4	Metastatic	Illumina HiSeq	805d3497-3d9a-4634-b16a-2e69b7424813	Skin	81	B9FDDA29-EBD4-4B0B-A8DA-555BA05D3567	3D33A1E2-8AC8-4EE2-8659-2B15EB1C3949	TCGA-DA-A1IC-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-DA-A1IC	TCGA-SKCM	NA	s7506	Harvard Medical School	Yale	United States	NO	T3a	N2c	Not available	Stage IIIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6ca39	58cfa831e4b0c9d6adf6ca39	TCGA-DJ-A13M-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DJ-A13M-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_8_rg.sorted	TCGA-DJ-A13M-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_8_rg.sorted.bam	44.61	1.89	0.14	58cfa831e4b0c9d6adf6ca39	TCGA-DJ-A13M-10A-01D-A10R_120616_SN1120_0154_BD142VACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13M-10A	BA9DEC81-FFC0-453A-9621-94BEBA45FAB1	Blood Derived Normal	Illumina HiSeq	88b57bac-8053-4bda-992c-1bcbae291251	Thyroid	28	CA0A1B87-487B-4214-9EFA-E9C6AC46EA9A	A684E286-8E67-4A5A-B295-AAEAA0E8F5CD	TCGA-DJ-A13M-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13M	TCGA-THCA	NA	s12637	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6ca54	58cfa831e4b0c9d6adf6ca54	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted.bam	325.7	1.9	0.15	58cfa831e4b0c9d6adf6ca54	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5280-01A	4797C600-F024-42FE-B287-D919B24DCB79	Primary Tumor	Illumina HiSeq	47363648-94bb-4221-a905-4832396ef90e	Brain	43	D9B929FD-335C-46B1-B60D-B846C372AA6A	677B8F71-325E-49F9-B3D7-B6ADB6831ED5	TCGA-DB-5280-01A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5280	TCGA-LGG	NA	s8130	Harvard Medical School	Mayo Clinic - Rochester	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6ca7c	58cfa831e4b0c9d6adf6ca7c	TCGA-DJ-A13X-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A13X-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_1_rg.sorted	TCGA-DJ-A13X-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_1_rg.sorted.bam	52.8	1.95	0.16	58cfa831e4b0c9d6adf6ca7c	TCGA-DJ-A13X-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13X-01A	3B3C99AB-5336-4433-B682-E1A590221611	Primary Tumor	Illumina HiSeq	a3b0754a-92ca-4ef2-b612-4e5bf2f74048	Thyroid	51	AC52BED3-FDD6-4281-89DE-D2F125BA038E	3E92A45C-FFFB-4C07-BD81-DB3EBF41841F	TCGA-DJ-A13X-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13X	TCGA-THCA	NA	s12748	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6ca67	58cfa831e4b0c9d6adf6ca67	TCGA-D9-A148-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D9-A148-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_2_rg.sorted	TCGA-D9-A148-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_2_rg.sorted.bam	18.06	NA	0.17	58cfa831e4b0c9d6adf6ca67	TCGA-D9-A148-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D9-A148-10A	FED23055-1600-4128-8D73-E1AA902A9D1D	Blood Derived Normal	Illumina HiSeq	a0f07bb7-ce52-49fe-83aa-97c4fe2af227	Skin	40	93BEBC8E-9072-407B-AE4F-E763B7193F5C	F7E5B9A6-E556-4DA7-AC55-B0312C05DF0F	TCGA-D9-A148-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D9-A148	TCGA-SKCM	NA	s7326	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	TX	N3	Not available	Not available	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6caa6	58cfa831e4b0c9d6adf6caa6	TCGA-D3-A1Q9-06A-11D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D3-A1Q9-06A-11D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_3_rg.sorted	TCGA-D3-A1Q9-06A-11D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_3_rg.sorted.bam	41.58	NA	0.17	58cfa831e4b0c9d6adf6caa6	TCGA-D3-A1Q9-06A-11D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A1Q9-06A	798074D3-0B84-4DD5-AA88-91FEDA9AC8C6	Metastatic	Illumina HiSeq	08f6a8cd-257b-49ce-8dcb-a0c8de2d345c	Skin	72	F5AA07C1-3302-4B54-A791-007714139901	7EF9AAEF-51C2-424E-A14C-C2C35942EE22	TCGA-D3-A1Q9-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D3-A1Q9	TCGA-SKCM	961	s7322	Harvard Medical School	MD Anderson	United States	NO	T4b	N2a	Not available	Stage IIIB	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6ca08	58cfa831e4b0c9d6adf6ca08	TCGA-DJ-A13X-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DJ-A13X-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_2_rg.sorted	TCGA-DJ-A13X-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_2_rg.sorted.bam	38.18	1.95	0.15	58cfa831e4b0c9d6adf6ca08	TCGA-DJ-A13X-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13X-10A	3B3C99AB-5336-4433-B682-E1A590221611	Blood Derived Normal	Illumina HiSeq	e05a7c3c-afd8-40a3-a5c3-93f13f5a77e6	Thyroid	51	F42843AA-6AD0-4FBB-BA27-1D821E9C9D17	F4474674-D623-4B24-BF83-420FA71317DC	TCGA-DJ-A13X-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13X	TCGA-THCA	NA	s12512	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6caa2	58cfa831e4b0c9d6adf6caa2	TCGA-D3-A3CE-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_8_rg.sorted.filtered.	WGS	TCGA-D3-A3CE-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_8_rg.sorted	TCGA-D3-A3CE-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_8_rg.sorted.bam	15.52	NA	0.17	58cfa831e4b0c9d6adf6caa2	TCGA-D3-A3CE-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A3CE-10A	730F7400-E94A-4F41-B081-5227FA1A9C18	Blood Derived Normal	Illumina HiSeq	2562aa30-08b4-450f-b475-0acd4a83cc07	Skin	74	AC3EE2A0-FF6D-47F5-BC29-865DF8B9DEFC	07C8BA8D-7364-44D6-A546-5BFFF1C795BA	TCGA-D3-A3CE-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A3CE	TCGA-SKCM	1832	s7832	Harvard Medical School	MD Anderson	United States	NO	T0	N1b	Not available	Stage III	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6caaa	58cfa831e4b0c9d6adf6caaa	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted.bam	64.8	1.88	0.16	58cfa831e4b0c9d6adf6caaa	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16D-01A	5693302A-4548-4C0B-8725-0CB7C67BC4F8	Primary Tumor	Illumina HiSeq	c72febd1-cbf3-4ba1-9e3e-35d65e99aa5e	Uterus	49	007BDFD3-81B6-42C3-A4A6-C4DDAF1BE0AE	DCA0D1DE-E9A0-45CF-B709-A492D513C1C4	TCGA-D1-A16D-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16D	TCGA-UCEC	NA	s4613	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6caac	58cfa831e4b0c9d6adf6caac	TCGA-DJ-A13P-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DJ-A13P-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_8_rg.sorted	TCGA-DJ-A13P-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_8_rg.sorted.bam	40.13	1.88	0.16	58cfa831e4b0c9d6adf6caac	TCGA-DJ-A13P-10A-01D-A10R_120617_SN1222_0117_BD1414ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13P-10A	CA95A11C-B54C-409E-B9A0-DA850945033D	Blood Derived Normal	Illumina HiSeq	3ad8b774-daba-42c2-8cab-709a65bf8803	Thyroid	52	74FE8C42-926C-43EB-81D0-CF4E56C9DC12	7AC0BF88-1435-4589-9A2A-318E32C9344B	TCGA-DJ-A13P-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13P	TCGA-THCA	NA	s12636	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6caca	58cfa831e4b0c9d6adf6caca	TCGA-DA-A1I5-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DA-A1I5-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_3_rg.sorted	TCGA-DA-A1I5-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_3_rg.sorted.bam	27.32	NA	0.16	58cfa831e4b0c9d6adf6caca	TCGA-DA-A1I5-06A-11D-A18Y_120730_SN208_0419_AC13W9ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1I5-06A	E2271488-1A7D-4733-A1EA-38BBAEB97B4C	Metastatic	Illumina HiSeq	8a4bbbcb-4e6d-4d92-b983-e45ad42d97f1	Skin	27	378ABE14-B9FB-4D03-9287-7ECA9C0B8368	F8FA24D5-DB63-4545-BCDD-55B50E01BC3E	TCGA-DA-A1I5-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-DA-A1I5	TCGA-SKCM	NA	s7501	Harvard Medical School	Yale	United States	NO	T1a	N0	Not available	Stage IV	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6c9dc	58cfa831e4b0c9d6adf6c9dc	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted.bam	16	2	0.13	58cfa831e4b0c9d6adf6c9dc	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6392-01A	FCD9E1C4-BDDB-4856-844C-03DF48FBA499	Primary Tumor	Illumina HiSeq	8f4eff17-77e1-4e7d-9fc7-83ae4db50b3a	Brain	35	14780BB2-67A9-4ACA-BCE4-12793FB1808E	E7B36F2D-9AB1-4A46-B669-65367B841752	TCGA-DU-6392-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-6392	TCGA-LGG	NA	s8561	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6caf0	58cfa831e4b0c9d6adf6caf0	TCGA-DU-7006-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DU-7006-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_5_rg.sorted	TCGA-DU-7006-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_5_rg.sorted.bam	301.7	NA	0.16	58cfa831e4b0c9d6adf6caf0	TCGA-DU-7006-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7006-01A	215E117C-4D76-463C-8F8A-FD6A28D23929	Primary Tumor	Illumina HiSeq	a423d9b3-2389-45d5-b834-d5cf57e5e647	Brain	60	21E471E0-6B87-4D98-A7E0-DE0F34598460	FDA752F3-371F-460B-8D81-216E0AC53B0E	TCGA-DU-7006-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7006	TCGA-LGG	349	s8357	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cb1b	58cfa831e4b0c9d6adf6cb1b	TCGA-DU-7006-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DU-7006-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_6_rg.sorted	TCGA-DU-7006-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_6_rg.sorted.bam	73	NA	0.16	58cfa831e4b0c9d6adf6cb1b	TCGA-DU-7006-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7006-10A	215E117C-4D76-463C-8F8A-FD6A28D23929	Blood Derived Normal	Illumina HiSeq	7d7ca01f-5584-4e12-a544-5ffb6d2cdc3f	Brain	60	24717D65-D851-4101-A942-18C112C35A7A	E4871FA8-7D51-4AEF-8027-B0F212931DFA	TCGA-DU-7006-10A-01D-2022-02	HG19_Broad_variant	TCGA-DU-7006	TCGA-LGG	349	s8756	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cad6	58cfa831e4b0c9d6adf6cad6	TCGA-DU-6408-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DU-6408-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_8_rg.sorted	TCGA-DU-6408-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_8_rg.sorted.bam	157.3	1.9	0.15	58cfa831e4b0c9d6adf6cad6	TCGA-DU-6408-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6408-01A	14375753-A69F-41E0-B910-2BB8E84CC43A	Primary Tumor	Illumina HiSeq	f441e949-5e27-4235-a0db-39c77aacdb5c	Brain	23	F68159AD-A0E9-4F9F-AD68-A29D53772982	57952871-E6FE-4C1F-87FE-404FADFC67C1	TCGA-DU-6408-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-6408	TCGA-LGG	3470	s8757	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6cab6	58cfa831e4b0c9d6adf6cab6	TCGA-D9-A148-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D9-A148-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_1_rg.sorted	TCGA-D9-A148-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_1_rg.sorted.bam	54.12	NA	0.15	58cfa831e4b0c9d6adf6cab6	TCGA-D9-A148-06A-11D-A18Z_120626_SN590_0164_BC0VMVACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D9-A148-06A	FED23055-1600-4128-8D73-E1AA902A9D1D	Metastatic	Illumina HiSeq	5581a0f7-47cd-4369-995b-8c74d2e3d62e	Skin	40	8F476CE5-CCCE-4CF6-8374-69F447F17008	63C72F1C-4A39-4E59-B615-1809B196A2C8	TCGA-D9-A148-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D9-A148	TCGA-SKCM	NA	s7834	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	TX	N3	Not available	Not available	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6cc15	58cfa831e4b0c9d6adf6cc15	TCGA-DU-7290-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DU-7290-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_7_rg.sorted	TCGA-DU-7290-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_7_rg.sorted.bam	157.7	NA	0.14	58cfa831e4b0c9d6adf6cc15	TCGA-DU-7290-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7290-01A	E00A9855-C15E-46EF-988F-25CA64EC4717	Primary Tumor	Illumina HiSeq	827baf09-e242-460a-8d97-75059c6c3a98	Brain	45	942B676C-CCFD-4005-A564-C48F558D5D3B	9A452E24-A4D1-4229-9256-6A30800A5DDF	TCGA-DU-7290-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7290	TCGA-LGG	315	s8353	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cbe8	58cfa831e4b0c9d6adf6cbe8	TCGA-DU-7018-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DU-7018-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_6_rg.sorted	TCGA-DU-7018-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_6_rg.sorted.bam	88.3	NA	0.14	58cfa831e4b0c9d6adf6cbe8	TCGA-DU-7018-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7018-10A	F18DAB99-26B0-4727-89A9-7F16BD382356	Blood Derived Normal	Illumina HiSeq	7ee7f69e-1fcd-495d-bbfa-f262e711b4a6	Brain	57	DE3EF329-B9B1-4CE3-BC89-9D0CA332B620	AD54AA45-1111-4E52-8971-C86ED709F3FB	TCGA-DU-7018-10A-01D-2022-02	HG19_Broad_variant	TCGA-DU-7018	TCGA-LGG	933	s8564	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cb69	58cfa831e4b0c9d6adf6cb69	TCGA-EE-A2MD-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EE-A2MD-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_8_rg.sorted	TCGA-EE-A2MD-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_8_rg.sorted.bam	33.67	NA	0.18	58cfa831e4b0c9d6adf6cb69	TCGA-EE-A2MD-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MD-10A	D28B2D64-2399-4CE1-9C9A-7538DABAB862	Blood Derived Normal	Illumina HiSeq	036982a1-44c4-415d-bccb-fc3d2738a8f4	Skin	52	ECE5B357-8523-4EB7-B583-80A639DC4C72	48E9ED1E-9771-494E-89AC-A8C2BDC0522B	TCGA-EE-A2MD-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2MD	TCGA-SKCM	1438	s7513	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage II	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb34	58cfa831e4b0c9d6adf6cb34	TCGA-EE-A29D-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EE-A29D-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_2_rg.sorted	TCGA-EE-A29D-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_2_rg.sorted.bam	48.84	NA	0.18	58cfa831e4b0c9d6adf6cb34	TCGA-EE-A29D-10A-01D-A190_120730_SN208_0419_AC13W9ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29D-10A	EF608754-3F87-458E-9BCF-4434C54C8C9E	Blood Derived Normal	Illumina HiSeq	1b436706-8b80-4fb0-bf1c-1375bfc4d0f1	Skin	87	66039C7A-457B-4BB7-96BB-36B094817E77	CCB9460E-97C4-481F-AD9F-103BDF67F2AF	TCGA-EE-A29D-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29D	TCGA-SKCM	425	s7334	Harvard Medical School	University of Sydney	Australia	NO	T3b	N1b	Not available	Stage IIIC	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb38	58cfa831e4b0c9d6adf6cb38	TCGA-EE-A2GT-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EE-A2GT-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_2_rg.sorted	TCGA-EE-A2GT-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_2_rg.sorted.bam	81.94	NA	0.16	58cfa831e4b0c9d6adf6cb38	TCGA-EE-A2GT-06A-12D-A18Y_120724_SN208_0418_BD13N7ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GT-06A	97D9DFC9-C937-48B4-B453-DF081950419F	Metastatic	Illumina HiSeq	c72f6347-e501-475f-a0b1-44e625169c38	Skin	77	549F66DB-E789-4BBA-897A-297DD6A0EE8E	A3857F08-F577-41B4-A573-71D084FC9CE4	TCGA-EE-A2GT-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2GT	TCGA-SKCM	NA	s7856	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage IIA	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc31	58cfa831e4b0c9d6adf6cc31	TCGA-DU-7008-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DU-7008-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_2_rg.sorted	TCGA-DU-7008-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_2_rg.sorted.bam	61	NA	0.15	58cfa831e4b0c9d6adf6cc31	TCGA-DU-7008-10A-01D-2022_130910_SN208_0495_BD2FGNACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7008-10A	427C40F6-D1BD-49F2-B303-A975793B937E	Blood Derived Normal	Illumina HiSeq	259728ba-b3fd-4001-a0d5-cef1d22b2ff2	Brain	41	64EA52EB-A005-4D05-BBA1-536F0D76A890	580B19BF-F779-4B08-A79B-21367B9E0F4B	TCGA-DU-7008-10A-01D-2022-02	HG19_Broad_variant	TCGA-DU-7008	TCGA-LGG	NA	s8364	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cc70	58cfa831e4b0c9d6adf6cc70	TCGA-DU-7294-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DU-7294-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_4_rg.sorted	TCGA-DU-7294-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_4_rg.sorted.bam	41	NA	0.15	58cfa831e4b0c9d6adf6cc70	TCGA-DU-7294-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7294-10A	3F6FFB08-32A9-4555-BFD1-243B7F526105	Blood Derived Normal	Illumina HiSeq	fb816713-22f8-4650-a51e-d1dc31150849	Brain	53	8B4922DC-8990-4A9A-892F-CA57EBD6D987	E6951FEB-A4F1-42ED-BC55-E6BC8DFBC1AD	TCGA-DU-7294-10A-01D-2022-02	HG19_Broad_variant	TCGA-DU-7294	TCGA-LGG	NA	s8568	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cc1f	58cfa831e4b0c9d6adf6cc1f	TCGA-EE-A29R-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EE-A29R-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_8_rg.sorted	TCGA-EE-A29R-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_8_rg.sorted.bam	37	NA	0.17	58cfa831e4b0c9d6adf6cc1f	TCGA-EE-A29R-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29R-10A	D73D1B38-9AB4-409E-A360-E93F8C54715C	Blood Derived Normal	Illumina HiSeq	a15d7730-71dc-45c5-b2e1-e431da6b8f38	Skin	48	A16B0EA8-3F15-4F42-A709-06B6BAC4AF91	E54FFA2C-E4BB-4048-AF1A-63CE7BA1F45E	TCGA-EE-A29R-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29R	TCGA-SKCM	NA	s8010	Harvard Medical School	University of Sydney	Australia	NO	T3b	N1b	Not available	Stage IIIC	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc7c	58cfa831e4b0c9d6adf6cc7c	TCGA-EM-A1CU-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EM-A1CU-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_3_rg.sorted	TCGA-EM-A1CU-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_3_rg.sorted.bam	50.69	1.91	0.18	58cfa831e4b0c9d6adf6cc7c	TCGA-EM-A1CU-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CU-01A	4E80F403-0E10-4725-854D-F023C12EE1E2	Primary Tumor	Illumina HiSeq	a03be55f-c2fb-41d6-88ae-f1063ed587f6	Thyroid	31	C285C3AC-26D7-4481-BAAF-769F49AED55A	A9886789-6859-4FC9-812A-D9813FD1C20D	TCGA-EM-A1CU-01A-11D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CU	TCGA-THCA	NA	s12379	Harvard Medical School	University Health Network	Canada	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6cc9f	58cfa831e4b0c9d6adf6cc9f	TCGA-EE-A2MN-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EE-A2MN-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_2_rg.sorted	TCGA-EE-A2MN-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_2_rg.sorted.bam	76.45	NA	0.16	58cfa831e4b0c9d6adf6cc9f	TCGA-EE-A2MN-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MN-06A	0797CAAF-18AD-41C6-820A-E96554D14B31	Metastatic	Illumina HiSeq	73490ea3-b79d-4ba3-a8ef-250ff13e4c21	Skin	58	6AE1DCF7-E35C-419F-B132-7E5F7BEDE538	7CF2B294-2EE5-4AAC-98CF-30E9FA1C374B	TCGA-EE-A2MN-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2MN	TCGA-SKCM	1446	s7854	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc98	58cfa831e4b0c9d6adf6cc98	TCGA-EE-A2MI-06A-11D-A18Y_120724_SN208_0418_BD13N7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EE-A2MI-06A-11D-A18Y_120724_SN208_0418_BD13N7ACXX_s_7_rg.sorted	TCGA-EE-A2MI-06A-11D-A18Y_120724_SN208_0418_BD13N7ACXX_s_7_rg.sorted.bam	23.06	NA	0.17	58cfa831e4b0c9d6adf6cc98	TCGA-EE-A2MI-06A-11D-A18Y_120724_SN208_0418_BD13N7ACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MI-06A	C061AE6C-7A02-47C3-AECD-A56487C01603	Metastatic	Illumina HiSeq	535ded66-253b-4519-b2d3-4e45793d2ee6	Skin	43	3C7442C7-5655-4D38-AE50-41D4E531CE12	779F841E-DB02-429D-A5A8-39CEFC074719	TCGA-EE-A2MI-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2MI	TCGA-SKCM	6225	s7685	Harvard Medical School	University of Sydney	Australia	NO	T4	N0	Not available	Stage IIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6ccd0	58cfa831e4b0c9d6adf6ccd0	TCGA-EM-A1YA-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EM-A1YA-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_2_rg.sorted	TCGA-EM-A1YA-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_2_rg.sorted.bam	45.94	1.87	0.18	58cfa831e4b0c9d6adf6ccd0	TCGA-EM-A1YA-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YA-01A	567E4D90-5C5A-44F0-A462-90C831F3C096	Primary Tumor	Illumina HiSeq	69cba75e-7be6-4707-b524-255288547622	Thyroid	74	D0880877-36CF-4DED-87B2-898C3446F90D	D1BD818E-62BF-4375-A171-ED388341014F	TCGA-EM-A1YA-01A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YA	TCGA-THCA	NA	s12754	Harvard Medical School	University Health Network	Canada	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cc86	58cfa831e4b0c9d6adf6cc86	TCGA-ER-A19L-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_8_rg.sorted.filtered.	WGS	TCGA-ER-A19L-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_8_rg.sorted	TCGA-ER-A19L-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_8_rg.sorted.bam	12.67	NA	0.15	58cfa831e4b0c9d6adf6cc86	TCGA-ER-A19L-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19L-10A	5F6DF69C-4EBF-4811-8B28-AD393DFBE1A3	Blood Derived Normal	Illumina HiSeq	656f4bf4-fed8-4e7c-b480-6387636bd29b	Skin	35	A2CADDC2-B60F-42C0-B863-09AE4FC38249	CC6B0115-4DD4-4B35-9AAA-E31125A8D890	TCGA-ER-A19L-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A19L	TCGA-SKCM	4000	s7865	Harvard Medical School	University of Pittsburgh	United States	NO	Not available	Not available	Not available	Not available	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ccd8	58cfa831e4b0c9d6adf6ccd8	TCGA-EM-A1CU-10A-02D-A13U_120706_SN1120_0170_BD1422ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EM-A1CU-10A-02D-A13U_120706_SN1120_0170_BD1422ACXX_s_5_rg.sorted	TCGA-EM-A1CU-10A-02D-A13U_120706_SN1120_0170_BD1422ACXX_s_5_rg.sorted.bam	7.14	1.98	0.17	58cfa831e4b0c9d6adf6ccd8	TCGA-EM-A1CU-10A-02D-A13U_120706_SN1120_0170_BD1422ACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CU-10A	4E80F403-0E10-4725-854D-F023C12EE1E2	Blood Derived Normal	Illumina HiSeq	e983d945-1e86-4d1a-ba00-131dea102879	Thyroid	31	457E4448-24E8-412C-A7DA-77CA0582A32A	918729C5-0155-4161-8C98-2F473CF87907	TCGA-EM-A1CU-10A-02D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CU	TCGA-THCA	NA	s11996	Harvard Medical School	University Health Network	Canada	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6ccf4	58cfa831e4b0c9d6adf6ccf4	TCGA-EE-A2MJ-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EE-A2MJ-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_4_rg.sorted	TCGA-EE-A2MJ-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_4_rg.sorted.bam	59.56	NA	0.16	58cfa831e4b0c9d6adf6ccf4	TCGA-EE-A2MJ-06A-11D-A18Y_120724_SN1222_0138_AC1168ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MJ-06A	8509F10A-C454-45A5-9C22-853FDA423B9F	Metastatic	Illumina HiSeq	b16f81f2-a92c-4e0d-8f13-16041c8c6cf5	Skin	60	369D076F-430B-4E9A-8835-07A02B736CBF	1C803F97-8436-4E2A-82CE-58DE4B49DEA3	TCGA-EE-A2MJ-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2MJ	TCGA-SKCM	2927	s7349	Harvard Medical School	University of Sydney	Australia	NO	T4b	N0	Not available	Stage III	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cd3c	58cfa831e4b0c9d6adf6cd3c	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted.filtered.	WGS	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted.bam	54.33	1.96	0.17	58cfa831e4b0c9d6adf6cd3c	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25M-01A	8023D4C9-B56D-417A-9A52-D45B59C756ED	Primary Tumor	Illumina HiSeq	893b646b-2fc5-4163-905e-37bfeb036280	Thyroid	33	0C601625-ED21-47E5-BC3D-A0057D6A148F	7DE80DCB-BBFD-4D87-AD80-EE29258EFFD1	TCGA-ET-A25M-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25M	TCGA-THCA	NA	s12002	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6cd04	58cfa831e4b0c9d6adf6cd04	TCGA-EE-A2MN-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EE-A2MN-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_6_rg.sorted	TCGA-EE-A2MN-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_6_rg.sorted.bam	18.48	NA	0.16	58cfa831e4b0c9d6adf6cd04	TCGA-EE-A2MN-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MN-10A	0797CAAF-18AD-41C6-820A-E96554D14B31	Blood Derived Normal	Illumina HiSeq	4dd5f91c-db26-4412-82e2-69e29de55207	Skin	58	32AF5A86-4721-4842-B88A-821506D7DDFB	8A8CC4E3-C877-43A1-BD00-9FAA04CA6E66	TCGA-EE-A2MN-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2MN	TCGA-SKCM	1446	s7692	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cdc0	58cfa831e4b0c9d6adf6cdc0	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted.bam	72.14	NA	0.16	58cfa831e4b0c9d6adf6cdc0	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-FI-A2CY-01A	B9AB4AB9-BA9C-4A01-9F61-55C82B924936	Primary Tumor	Illumina HiSeq	d1004865-f030-4d10-90a0-3d6d105408a0	Uterus	60	047B688C-AA29-4A63-B555-9275AF4B0CEE	4BCC9DA0-4F58-4BB8-B660-D8591AD1CE18	TCGA-FI-A2CY-01A-11D-A17E-02	HG19_Broad_variant	TCGA-FI-A2CY	TCGA-UCEC	NA	s5398	Harvard Medical School	Washington University	United States	NO	Not available	Not available	Mixed serous and endometrioid	Not available	A17E-02	TRUE
13722.58cfa831e4b0c9d6adf6cdab	58cfa831e4b0c9d6adf6cdab	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted.bam	101.34	2.14	0.18	58cfa831e4b0c9d6adf6cdab	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A234-01A	E4C85BDD-7B7C-414F-9503-647D9B825915	Primary Tumor	Illumina HiSeq	f1eeb2ea-cc97-40b1-ac5b-fa027012fff2	Thyroid	26	8765B072-83E1-40B2-B1C9-15F38D799FC3	D4A41A96-02D5-455E-BB12-7225EBEA15A5	TCGA-FE-A234-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A234	TCGA-THCA	NA	s12388	Harvard Medical School	Ohio State University	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6ce2c	58cfa832e4b0c9d6adf6ce2c	TCGA-ER-A19T-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-ER-A19T-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_8_rg.sorted	TCGA-ER-A19T-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_8_rg.sorted.bam	23.88	NA	0.18	58cfa832e4b0c9d6adf6ce2c	TCGA-ER-A19T-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19T-10A	B85B14D7-3B5A-4800-AF12-622EC03B9FE5	Blood Derived Normal	Illumina HiSeq	40fd8b7e-4227-45f0-8438-9eeb0c2ba2b2	Skin	51	C070D019-1F19-43D0-8B34-A46DC4C8790E	69B15A85-AF40-4FDA-AF0A-E71FBBDFA7B6	TCGA-ER-A19T-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-ER-A19T	TCGA-SKCM	270	s7359	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N3	Not available	Stage IV	A18Z-02	TRUE
13722.58cfa832e4b0c9d6adf6ce30	58cfa832e4b0c9d6adf6ce30	TCGA-ER-A19N-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_3_rg.sorted.filtered.	WGS	TCGA-ER-A19N-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_3_rg.sorted	TCGA-ER-A19N-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_3_rg.sorted.bam	58.25	NA	0.16	58cfa832e4b0c9d6adf6ce30	TCGA-ER-A19N-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19N-06A	9EE83669-D7A4-476E-8857-304600B4917A	Metastatic	Illumina HiSeq	82cbbead-49f8-4968-aece-ebb693a35c8f	Skin	47	69508F90-DC5F-4B36-AC71-566B29496868	6EE8D916-F53C-4604-8801-029DA7809D11	TCGA-ER-A19N-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A19N	TCGA-SKCM	NA	s7863	Harvard Medical School	University of Pittsburgh	United States	NO	Not available	Not available	Not available	Not available	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cd72	58cfa831e4b0c9d6adf6cd72	TCGA-ET-A25M-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_8_rg.sorted.filtered.	WGS	TCGA-ET-A25M-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_8_rg.sorted	TCGA-ET-A25M-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_8_rg.sorted.bam	26.1	1.88	0.18	58cfa831e4b0c9d6adf6cd72	TCGA-ET-A25M-10A-01D-A16N_120718_SN590_0170_BD141RACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25M-10A	8023D4C9-B56D-417A-9A52-D45B59C756ED	Blood Derived Normal	Illumina HiSeq	7f27862b-c742-46ca-b311-8c6eb5df24f3	Thyroid	33	5972C59C-3CD2-41D9-AE04-42DEC3ECC565	0B4371FA-86D7-4C34-8E65-3D53CE130BE2	TCGA-ET-A25M-10A-01D-A16N-02	HG19_Broad_variant	TCGA-ET-A25M	TCGA-THCA	NA	s12385	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6cea0	58cfa832e4b0c9d6adf6cea0	TCGA-ER-A2NF-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ER-A2NF-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_7_rg.sorted	TCGA-ER-A2NF-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_7_rg.sorted.bam	52.36	NA	0.16	58cfa832e4b0c9d6adf6cea0	TCGA-ER-A2NF-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A2NF-01A	D32A4219-4CCA-470F-B6B3-11447D9F5E0B	Primary Tumor	Illumina HiSeq	cf624be8-7ec3-4fce-9ab0-1d9ac2fb1edb	Skin	53	52EDD1DB-F1C3-4B87-B959-B5B095E52463	DB2D94A9-5B22-4163-AE7A-1DA11F7037A6	TCGA-ER-A2NF-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-ER-A2NF	TCGA-SKCM	NA	s7861	Harvard Medical School	University of Pittsburgh	None	NO	T4b	N3	Not available	Stage IIIC	A18Z-02	TRUE
13722.58cfa832e4b0c9d6adf6ceec	58cfa832e4b0c9d6adf6ceec	TCGA-FS-A1ZD-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FS-A1ZD-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_6_rg.sorted	TCGA-FS-A1ZD-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_6_rg.sorted.bam	45.56	NA	0.16	58cfa832e4b0c9d6adf6ceec	TCGA-FS-A1ZD-10A-01D-A190_120609_SN208_0343_BC0WVWACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZD-10A	C2948FE9-5798-43BC-A743-511E94E417F8	Blood Derived Normal	Illumina HiSeq	701956ba-1fb7-423e-a1b1-a5d7bf040bdf	Skin	63	D502A3A3-2BD2-49FE-92B7-5DF2826B53E9	6D0B52E3-2420-42A8-A655-B60579DB056D	TCGA-FS-A1ZD-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZD	TCGA-SKCM	1628	s8027	Harvard Medical School	Essen	Germany	NO	T2b	N0	Not available	Stage IIA	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf10	58cfa832e4b0c9d6adf6cf10	TCGA-FS-A1ZF-06A-12D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FS-A1ZF-06A-12D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_4_rg.sorted	TCGA-FS-A1ZF-06A-12D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_4_rg.sorted.bam	57.08	NA	0.16	58cfa832e4b0c9d6adf6cf10	TCGA-FS-A1ZF-06A-12D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZF-06A	E0D36CC0-652C-4224-BB10-09D15C7BD8F1	Metastatic	Illumina HiSeq	fc766dcd-902b-4505-bf3f-e747d286eec1	Skin	78	FE7D6D24-E8DA-4703-BC74-2720363B4C01	876B574E-6381-47ED-A60B-0E7216F3D665	TCGA-FS-A1ZF-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZF	TCGA-SKCM	470	s7874	Harvard Medical School	Essen	Germany	NO	T4b	N0	Not available	Stage IIC	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cf3d	58cfa832e4b0c9d6adf6cf3d	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted.bam	245.4	1.9	0.13	58cfa832e4b0c9d6adf6cf3d	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6378-01A	12F225D0-CBFF-44EB-9183-BACC7F33B090	Primary Tumor	Illumina HiSeq	cc75d8b4-ea9f-4b89-9c12-d370ba7a227f	Prostate	54	940BBB5C-7280-41ED-9332-47C2072AE072	CA3B6408-29B5-4DB1-A56D-7B47F966177D	TCGA-G9-6378-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6378	TCGA-PRAD	NA	s3801	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf18	58cfa832e4b0c9d6adf6cf18	TCGA-FS-A1ZB-06A-12D-A18Y_120609_SN208_0343_BC0WVWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FS-A1ZB-06A-12D-A18Y_120609_SN208_0343_BC0WVWACXX_s_4_rg.sorted	TCGA-FS-A1ZB-06A-12D-A18Y_120609_SN208_0343_BC0WVWACXX_s_4_rg.sorted.bam	40.46	NA	0.16	58cfa832e4b0c9d6adf6cf18	TCGA-FS-A1ZB-06A-12D-A18Y_120609_SN208_0343_BC0WVWACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZB-06A	6F2EF983-0A22-4A65-9E53-8742AC89A1C4	Metastatic	Illumina HiSeq	61e179ee-80dc-4bdc-bc49-9e53a7bf0600	Skin	57	323FF6EE-1901-4D6B-8FE5-0C9BB4B246D1	4DB084C7-2C0F-4DFF-995A-A069E011D42C	TCGA-FS-A1ZB-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZB	TCGA-SKCM	1486	s7527	Harvard Medical School	Essen	Germany	NO	T3a	N0	Not available	Stage II	A18Y-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5f9	58cfa82fe4b0c9d6adf6b5f9	TCGA-75-5125-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_4_rg.sorted.filtered.	WGS	TCGA-75-5125-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_4_rg.sorted	TCGA-75-5125-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_4_rg.sorted.bam	314.7	1.9	0.17	58cfa82fe4b0c9d6adf6b5f9	TCGA-75-5125-10A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-5125-10A	205759A6-6391-491B-9857-0080C3A5871E	Blood Derived Normal	Illumina HiSeq	44fab539-38d3-48de-af3c-307ac13fbe93	Lung	NA	1822469A-D526-4A61-B1B3-7F167407448B	66BFF328-E44D-4A86-AE1A-311B5CA4B44C	TCGA-75-5125-10A-01D-1751-02	HG19_Broad_variant	TCGA-75-5125	TCGA-LUAD	NA	s11253	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1751-02	TRUE
13722.58cfa832e4b0c9d6adf6cf61	58cfa832e4b0c9d6adf6cf61	TCGA-G9-6378-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_4_rg.sorted.filtered.	WGS	TCGA-G9-6378-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_4_rg.sorted	TCGA-G9-6378-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_4_rg.sorted.bam	16.7	1.9	0.13	58cfa832e4b0c9d6adf6cf61	TCGA-G9-6378-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_4_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6378-10A	12F225D0-CBFF-44EB-9183-BACC7F33B090	Blood Derived Normal	Illumina HiSeq	0d86bec5-370a-4a3d-a9e9-120faf1ed159	Prostate	54	71A35F86-610E-433B-80CF-0B496F3A604C	39E1FE96-A986-4FCE-B017-B5FC5B49068E	TCGA-G9-6378-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6378	TCGA-PRAD	NA	s3455	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf57	58cfa832e4b0c9d6adf6cf57	TCGA-FS-A1ZP-06A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FS-A1ZP-06A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_1_rg.sorted	TCGA-FS-A1ZP-06A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_1_rg.sorted.bam	66.69	NA	0.15	58cfa832e4b0c9d6adf6cf57	TCGA-FS-A1ZP-06A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZP-06A	4CDB18F5-47BF-475F-B34C-FA4912515268	Metastatic	Illumina HiSeq	f5d63bd9-91dc-447c-a780-e7203db239c7	Skin	52	3FC2F92E-E55E-4484-B306-4303A9A0CBF5	B5D10C46-EDAB-475F-830A-D3DE0D187046	TCGA-FS-A1ZP-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZP	TCGA-SKCM	2273	s7701	Harvard Medical School	Essen	Germany	NO	T3	N0	Not available	Stage II	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cf5b	58cfa832e4b0c9d6adf6cf5b	TCGA-GN-A265-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GN-A265-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_5_rg.sorted	TCGA-GN-A265-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_5_rg.sorted.bam	16.67	NA	0.18	58cfa832e4b0c9d6adf6cf5b	TCGA-GN-A265-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-GN-A265-10A	61B777F6-A59A-4500-AD33-107E2C9254C1	Blood Derived Normal	Illumina HiSeq	8ad44bb1-82fb-42de-8306-68b2e86c747f	Skin	53	5045BC39-C8BA-4AC5-A6F4-F175E41DB27C	7457238B-0093-49A0-8B19-F71894346253	TCGA-GN-A265-10A-01D-A190-02	HG19_Broad_variant	TCGA-GN-A265	TCGA-SKCM	NA	s7541	Harvard Medical School	Roswell	United States	NO	Not available	Not available	Not available	Not available	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf8e	58cfa832e4b0c9d6adf6cf8e	TCGA-G9-6367-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-G9-6367-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_4_rg.sorted	TCGA-G9-6367-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_4_rg.sorted.bam	11.7	1.8	0.17	58cfa832e4b0c9d6adf6cf8e	TCGA-G9-6367-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6367-10A	9F751C9D-AD41-4F02-B7F8-12423857D418	Blood Derived Normal	Illumina HiSeq	0c245fbb-c69b-4134-9b5f-883401c73269	Prostate	60	233F06E4-3E3D-4FC5-BED3-8B543E1ED896	DEEB5EEC-2375-4911-8B02-4E9928860E4D	TCGA-G9-6367-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6367	TCGA-PRAD	NA	s3968	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf90	58cfa832e4b0c9d6adf6cf90	TCGA-G9-6348-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G9-6348-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_8_rg.sorted	TCGA-G9-6348-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_8_rg.sorted.bam	33.7	1.8	0.13	58cfa832e4b0c9d6adf6cf90	TCGA-G9-6348-10A-01D-1784_130115_SN590_0208_BD1TAGACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6348-10A	8AD78C4F-C84C-4F9E-88C9-42A05EB65498	Blood Derived Normal	Illumina HiSeq	4c26631b-a745-412f-890f-793dd4b04e14	Prostate	68	0E5F2922-DEE4-4048-ADFA-E9BAEB9120E4	B79A7DF4-6CB9-4885-8CA8-7341500BDC76	TCGA-G9-6348-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6348	TCGA-PRAD	NA	s3610	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf52	58cfa832e4b0c9d6adf6cf52	TCGA-FS-A1ZC-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FS-A1ZC-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_3_rg.sorted	TCGA-FS-A1ZC-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_3_rg.sorted.bam	65.24	NA	0.17	58cfa832e4b0c9d6adf6cf52	TCGA-FS-A1ZC-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZC-06A	B1739CB5-09BC-414A-8F05-C66D2CB9868D	Metastatic	Illumina HiSeq	446e73e5-004b-4ac5-9413-27d76ce8fad0	Skin	51	1C388CA4-2E3E-429D-844E-52D6DF03F240	30CED7B6-9CD7-4F9B-96CC-3264EF036734	TCGA-FS-A1ZC-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZC	TCGA-SKCM	10870	s7366	Harvard Medical School	Essen	Germany	NO	TX	N0	Not available	I or II NOS	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cfb6	58cfa832e4b0c9d6adf6cfb6	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted.bam	201.7	1.9	0.14	58cfa832e4b0c9d6adf6cfb6	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6342-01A	00E41E6A-9FE7-44F9-978B-7B05B179506A	Primary Tumor	Illumina HiSeq	2e8198a3-6874-4ea2-9d85-405122d87da4	Prostate	61	2C85548B-D1FD-4FC8-9908-60205A42E080	0C765D21-A6AE-4FE8-9B80-7DEBA8459E76	TCGA-G9-6342-01A-11D-1957-02	HG19_Broad_variant	TCGA-G9-6342	TCGA-PRAD	NA	s3797	Harvard Medical School	Roswell Park	United States	NO	T3a	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cfb2	58cfa832e4b0c9d6adf6cfb2	TCGA-FS-A1ZW-06A-12D-A18Y_120602_SN1120_0147_BD13TBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FS-A1ZW-06A-12D-A18Y_120602_SN1120_0147_BD13TBACXX_s_1_rg.sorted	TCGA-FS-A1ZW-06A-12D-A18Y_120602_SN1120_0147_BD13TBACXX_s_1_rg.sorted.bam	58.48	NA	0.16	58cfa832e4b0c9d6adf6cfb2	TCGA-FS-A1ZW-06A-12D-A18Y_120602_SN1120_0147_BD13TBACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZW-06A	49A6F6A6-BF6F-45CF-93DC-B006B4A0637D	Metastatic	Illumina HiSeq	5e95e70e-4afd-41fb-87d9-eaf4198223e9	Skin	65	7E7CA145-7979-4105-AEAC-0417C6052AAF	F96DD387-37CA-4EDE-9851-4EB769271D76	TCGA-FS-A1ZW-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZW	TCGA-SKCM	NA	s8029	Harvard Medical School	Essen	Germany	NO	T2b	N1a	Not available	Stage IIIB	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cfea	58cfa832e4b0c9d6adf6cfea	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted.bam	129.4	1.9	0.13	58cfa832e4b0c9d6adf6cfea	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6494-01A	0C459149-0DFE-4206-B50B-DB79180EBB57	Primary Tumor	Illumina HiSeq	d55338b0-a49a-4c6e-ba7d-757df0a55dfe	Prostate	66	45DB5303-BBAB-4F8C-A2A2-9A9A9BFA2FD1	5BCBE988-68F6-48D0-8F2A-B34369A5FBB9	TCGA-G9-6494-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6494	TCGA-PRAD	NA	s3620	Harvard Medical School	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cfc0	58cfa832e4b0c9d6adf6cfc0	TCGA-GF-A2C7-01A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-GF-A2C7-01A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_3_rg.sorted	TCGA-GF-A2C7-01A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_3_rg.sorted.bam	42.41	NA	0.16	58cfa832e4b0c9d6adf6cfc0	TCGA-GF-A2C7-01A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-GF-A2C7-01A	285D8E2C-F183-49D5-BC1C-FD47C6670ACC	Primary Tumor	Illumina HiSeq	9e0dd24f-4e97-44c0-916f-03fc02fc29ac	Skin	48	053CAF96-E851-401D-A5CC-214DBA82FE05	12E86E5E-AA64-4E6F-B5BC-846DDCBF4A64	TCGA-GF-A2C7-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-GF-A2C7	TCGA-SKCM	NA	s7374	Harvard Medical School	ABS - IUPUI	United States	NO	T4b	N0	Not available	Stage IIC	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d103	58cfa832e4b0c9d6adf6d103	TCGA-FS-A1ZH-06A-11D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FS-A1ZH-06A-11D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_2_rg.sorted	TCGA-FS-A1ZH-06A-11D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_2_rg.sorted.bam	60.02	NA	0.17	58cfa832e4b0c9d6adf6d103	TCGA-FS-A1ZH-06A-11D-A18Y_120605_SN1222_0113_BC0WUCACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZH-06A	9F5BD948-DC3D-4B17-A114-D2F5C46FE10C	Metastatic	Illumina HiSeq	a2479881-3488-41b7-be08-204b2027d50f	Skin	71	A3A4EFCC-DFA8-4A69-AEE4-D2A93CD98F30	A6A5CEBF-FBB3-4228-B776-B3B792D0574B	TCGA-FS-A1ZH-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZH	TCGA-SKCM	996	s7700	Harvard Medical School	Essen	Germany	NO	T3b	N2c	Not available	Stage IV	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d136	58cfa832e4b0c9d6adf6d136	TCGA-FS-A1ZK-06A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FS-A1ZK-06A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_4_rg.sorted	TCGA-FS-A1ZK-06A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_4_rg.sorted.bam	33.04	NA	0.16	58cfa832e4b0c9d6adf6d136	TCGA-FS-A1ZK-06A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZK-06A	1404791B-86BF-4DFD-85B4-C8FF356F109C	Metastatic	Illumina HiSeq	e43f4ad5-e270-438e-b3c0-0449ebdb43b1	Skin	68	07E2FEA3-4BA5-49B3-AE9B-61FF8492026C	25F7EF72-9CE1-4BFB-BEBE-3815E34FFCB8	TCGA-FS-A1ZK-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZK	TCGA-SKCM	728	s7368	Harvard Medical School	Essen	Germany	NO	T4	N0	Not available	Stage II	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cfce	58cfa832e4b0c9d6adf6cfce	TCGA-FS-A1ZR-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FS-A1ZR-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_8_rg.sorted	TCGA-FS-A1ZR-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_8_rg.sorted.bam	58	NA	0.17	58cfa832e4b0c9d6adf6cfce	TCGA-FS-A1ZR-10A-01D-A190_120602_SN208_0304_BC0WTWACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZR-10A	9F4DDE50-FA0C-43BF-8D5D-70B76CC35793	Blood Derived Normal	Illumina HiSeq	474ef1b0-6baa-490c-a7db-37e3d083bc3b	Skin	36	77933881-ACDD-4EB4-BB5C-5E0C3FA29794	03A94509-FF21-40B8-83BE-B24887F8A1A3	TCGA-FS-A1ZR-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZR	TCGA-SKCM	347	s8028	Harvard Medical School	Essen	Germany	NO	T2	N0	Not available	Stage II	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d14c	58cfa832e4b0c9d6adf6d14c	TCGA-G9-6385-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G9-6385-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_8_rg.sorted	TCGA-G9-6385-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_8_rg.sorted.bam	22.7	1.9	0.14	58cfa832e4b0c9d6adf6d14c	TCGA-G9-6385-10A-01D-1784_130301_SN590_0217_BC1UHMACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6385-10A	E82A04CF-E81E-43C6-9CD9-0E29FA0F00AE	Blood Derived Normal	Illumina HiSeq	40e5463c-dc65-437e-a884-d99c34009f5a	Prostate	66	79E5CAE9-6334-4E3E-9524-5DD7D0A4FFB9	BCC5E846-D84A-469B-ACB6-68EC1BE537D3	TCGA-G9-6385-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6385	TCGA-PRAD	NA	s3803	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6d1b0	58cfa832e4b0c9d6adf6d1b0	TCGA-FG-6689-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FG-6689-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_4_rg.sorted	TCGA-FG-6689-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_4_rg.sorted.bam	111	1.9	0.15	58cfa832e4b0c9d6adf6d1b0	TCGA-FG-6689-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6689-10A	8D07B1E8-5D1D-4A43-B616-D29DD58CE5FE	Blood Derived Normal	Illumina HiSeq	08b74256-79b2-4fe1-81c5-28cc122988ca	Brain	30	BAD0094C-DE01-4419-9ADB-5E8EF0A4D397	983E8501-88CE-42E5-8C99-752182F14D81	TCGA-FG-6689-10A-01D-1891-02	HG19_Broad_variant	TCGA-FG-6689	TCGA-LGG	NA	s8147	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa832e4b0c9d6adf6d20e	58cfa832e4b0c9d6adf6d20e	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted.bam	188	NA	0.13	58cfa832e4b0c9d6adf6d20e	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7468-01A	E6C55BA6-4C8A-4EA4-8DDE-74D01915DB02	Primary Tumor	Illumina HiSeq	e1855a2f-1904-41ee-ba33-a27e1c202d99	Brain	30	D2775F99-CC96-4C72-94FF-E3BA985DC151	143CEFE3-F477-4CDE-AEA6-CE0610835570	TCGA-HT-7468-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7468	TCGA-LGG	NA	s8759	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d281	58cfa832e4b0c9d6adf6d281	TCGA-HT-7601-10A-01D-2088_130910_SN208_0494_AC2A1DACXX_s_1_rg.sorted.filtered.	WGS	TCGA-HT-7601-10A-01D-2088_130910_SN208_0494_AC2A1DACXX_s_1_rg.sorted	TCGA-HT-7601-10A-01D-2088_130910_SN208_0494_AC2A1DACXX_s_1_rg.sorted.bam	67.3	NA	0.14	58cfa832e4b0c9d6adf6d281	TCGA-HT-7601-10A-01D-2088_130910_SN208_0494_AC2A1DACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7601-10A	E7FDF164-A85D-4FF5-9676-D2215CA35403	Blood Derived Normal	Illumina HiSeq	94873a5a-9d98-4c3a-8ea2-528afa271e07	Brain	30	6D717D58-096B-4E45-B0B0-A0069B72028D	7E20EB67-B215-4519-96A6-6233B9E5AE9F	TCGA-HT-7601-10A-01D-2088-02	HG19_Broad_variant	TCGA-HT-7601	TCGA-LGG	NA	s8371	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Astrocytoma	Not available	2088-02	FALSE
13722.58cfa832e4b0c9d6adf6d1de	58cfa832e4b0c9d6adf6d1de	TCGA-HR-A2OG-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HR-A2OG-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_4_rg.sorted	TCGA-HR-A2OG-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_4_rg.sorted.bam	52.33	NA	0.18	58cfa832e4b0c9d6adf6d1de	TCGA-HR-A2OG-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Skin Cutaneous Melanoma	Aligned reads	TCGA-HR-A2OG-10A	021D32B0-A94A-4DAD-95F4-8EB0ABD894BF	Blood Derived Normal	Illumina HiSeq	e5c8850f-c39d-4383-8ab4-a1c8872882da	Skin	50	A06A0BBF-D4D2-4705-828D-100ED335E812	65C5FDD8-86E3-4ACA-9DFB-46CDF39E49BC	TCGA-HR-A2OG-10A-01D-A190-02	HG19_Broad_variant	TCGA-HR-A2OG	TCGA-SKCM	NA	s7542	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	Not available	Not available	Not available	Not available	A190-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5f4	58cfa82fe4b0c9d6adf6b5f4	TCGA-44-6146-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_5_rg.sorted.filtered.	WGS	TCGA-44-6146-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_5_rg.sorted	TCGA-44-6146-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_5_rg.sorted.bam	59.4	1.9	0.16	58cfa82fe4b0c9d6adf6b5f4	TCGA-44-6146-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6146-11A	0C0B610E-FE4C-406D-A5ED-5CC3B11DABF5	Solid Tissue Normal	Illumina HiSeq	f7ee8faa-879c-4d5c-ac00-24452fb7fe3f	Lung	64	DED52BAC-FEDF-43E0-BE97-E261A84383AD	03A2138C-B699-47D1-A5EB-161399020946	TCGA-44-6146-11A-01D-1751-02	HG19_Broad_variant	TCGA-44-6146	TCGA-LUAD	NA	s11228	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Lung Mucinous Adenocarcinoma	Stage IIB	1751-02	TRUE
13722.58cfa82ee4b0c9d6adf6af8c	58cfa82ee4b0c9d6adf6af8c	TCGA-05-4249-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4249-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_1_rg.sorted	TCGA-05-4249-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_1_rg.sorted.bam	36.63	1.9	0.16	58cfa82ee4b0c9d6adf6af8c	TCGA-05-4249-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_1_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4249-10A	4ADDF05F-3668-4B3F-A17F-C0227329CA52	Blood Derived Normal	Illumina HiSeq	61a4cbac-f493-484b-bbd9-4a2745d89f22	Lung	67	6E8AF3CE-3987-44F1-BF4C-E52F68039567	E6DEFCC8-1E9D-46ED-B8BA-B8C62B21A5B5	TCGA-05-4249-10A-01D-1103-02	HG19_Broad_variant	TCGA-05-4249	TCGA-LUAD	NA	s11439	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1103-02	TRUE
13722.58cfa831e4b0c9d6adf6c7d2	58cfa831e4b0c9d6adf6c7d2	TCGA-CV-6951-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-6951-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_4_rg.sorted	TCGA-CV-6951-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_4_rg.sorted.bam	99.7	1.9	0.14	58cfa831e4b0c9d6adf6c7d2	TCGA-CV-6951-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6951-11A	91728CD6-ED91-49DC-9279-FAEDBE211A9D	Solid Tissue Normal	Illumina HiSeq	a087903d-fb41-4d87-9500-6b62de815139	Head and Neck	57	E5D22220-4951-42F5-80E5-4510AC3E99C2	73E856AD-F850-4433-AF90-1D7EF628FBB8	TCGA-CV-6951-11A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6951	TCGA-HNSC	915	s15907	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6cd68	58cfa831e4b0c9d6adf6cd68	TCGA-FE-A232-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FE-A232-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_8_rg.sorted	TCGA-FE-A232-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_8_rg.sorted.bam	19.22	1.85	0.18	58cfa831e4b0c9d6adf6cd68	TCGA-FE-A232-10A-01D-A14U_120629_SN1222_0120_AC0WKWACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A232-10A	5EB0D577-223B-4409-89D1-5C5D196AFFC3	Blood Derived Normal	Illumina HiSeq	b0870db2-3e35-4d95-926d-744f50c9ad56	Thyroid	44	305278F6-641B-45C8-A758-5148346161C8	8DC86F0D-2853-49B9-89D3-046871A44F42	TCGA-FE-A232-10A-01D-A14U-02	HG19_Broad_variant	TCGA-FE-A232	TCGA-THCA	NA	s12005	Harvard Medical School	Ohio State University	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6ce3d	58cfa832e4b0c9d6adf6ce3d	TCGA-ER-A19Q-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_1_rg.sorted.filtered.	WGS	TCGA-ER-A19Q-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_1_rg.sorted	TCGA-ER-A19Q-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_1_rg.sorted.bam	51.18	NA	0.17	58cfa832e4b0c9d6adf6ce3d	TCGA-ER-A19Q-06A-11D-A18Y_120718_SN208_0416_BD140PACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19Q-06A	391EAB51-B140-4BC2-BC8C-99400FBA9066	Metastatic	Illumina HiSeq	d8a90220-2acb-4d71-9feb-6febee1f8745	Skin	37	1BBEF533-EB97-492C-A674-AC5C8B8AC7F2	4CDA923B-2193-4654-9525-468CDDD89E62	TCGA-ER-A19Q-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A19Q	TCGA-SKCM	1548	s7361	Harvard Medical School	University of Pittsburgh	United States	NO	Not available	N0	Not available	Not available	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cf2e	58cfa832e4b0c9d6adf6cf2e	TCGA-G9-6362-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-G9-6362-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_4_rg.sorted	TCGA-G9-6362-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_4_rg.sorted.bam	23.7	1.8	0.14	58cfa832e4b0c9d6adf6cf2e	TCGA-G9-6362-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6362-10A	F228EF91-ECFB-4D1E-8E6A-B43D2185270E	Blood Derived Normal	Illumina HiSeq	a86b9f92-8f31-484f-9706-b320c5f42cfd	Prostate	57	1A7B59F4-CD3A-4FAD-BACA-A948676498CC	4F214276-0F7B-4ED4-B0EB-FC69C1A89514	TCGA-G9-6362-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6362	TCGA-PRAD	NA	s3617	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cf8a	58cfa832e4b0c9d6adf6cf8a	TCGA-FS-A1ZY-06A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FS-A1ZY-06A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_6_rg.sorted	TCGA-FS-A1ZY-06A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_6_rg.sorted.bam	53.49	NA	0.15	58cfa832e4b0c9d6adf6cf8a	TCGA-FS-A1ZY-06A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZY-06A	A3DF4BA6-538E-4B53-A356-EB1EF743B2AB	Metastatic	Illumina HiSeq	aa1f701f-1d30-46f6-a60c-0d519147d690	Skin	71	483D87A4-7427-4BE0-83C2-32807C2D3A59	AB390594-05F0-4B2F-AD4D-CD680F6CB7FB	TCGA-FS-A1ZY-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZY	TCGA-SKCM	824	s7702	Harvard Medical School	Essen	Germany	NO	T3b	N0	Not available	Stage IIB	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d18e	58cfa832e4b0c9d6adf6d18e	TCGA-FI-A2D4-01A-12D-A17E_120511_SN1120_0140_AD12J0ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FI-A2D4-01A-12D-A17E_120511_SN1120_0140_AD12J0ACXX_s_7_rg.sorted	TCGA-FI-A2D4-01A-12D-A17E_120511_SN1120_0140_AD12J0ACXX_s_7_rg.sorted.bam	28.14	NA	0.16	58cfa832e4b0c9d6adf6d18e	TCGA-FI-A2D4-01A-12D-A17E_120511_SN1120_0140_AD12J0ACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-FI-A2D4-01A	490AE247-EE67-48D4-94ED-93DF5B9BBEFE	Primary Tumor	Illumina HiSeq	8f265179-0deb-4bbd-bd06-f6a211fae179	Uterus	44	A8393121-29DF-4525-BF4F-FCE0DEAF25F5	6DA2AADF-7B34-4F4F-93E4-0963248B3DEB	TCGA-FI-A2D4-01A-12D-A17E-02	HG19_Broad_variant	TCGA-FI-A2D4	TCGA-UCEC	243	s5232	Harvard Medical School	Washington University	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A17E-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae62	58cfa82ee4b0c9d6adf6ae62	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted.filtered.	WGS	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted.bam	385.2	1.9	0.14	58cfa82ee4b0c9d6adf6ae62	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4395-01A	762DEA8A-5B41-4058-979A-B7876ED13D7E	Primary Tumor	Illumina HiSeq	dcb07672-8bde-427e-9d94-ac644e457e91	Lung	76	9DED6605-39A3-4C0F-AD2E-7F6863960DBE	5E9E0A0C-75C0-48AA-BD85-A2E102787EF9	TCGA-05-4395-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4395	TCGA-LUAD	0	s11115	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae74	58cfa82ee4b0c9d6adf6ae74	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	176.2	1.9	0.14	58cfa82ee4b0c9d6adf6ae74	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4402-01A	722D6818-F1CB-49F4-B68A-FD0A31304681	Primary Tumor	Illumina HiSeq	603e16bf-9b05-49c9-a925-f409626c969a	Lung	57	07C1FCE4-EC48-47A4-8391-E553936B67F2	5E791B10-E5FD-412D-9F42-72CAC197F253	TCGA-05-4402-01A-01D-1203-02	GRCh37	TCGA-05-4402	TCGA-LUAD	244	s10900	Harvard Medical School	Indivumed	Germany	NO	T2	NX	Lung Adenocarcinoma Mixed Subtype	Stage IV	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6aeb4	58cfa82ee4b0c9d6adf6aeb4	TCGA-05-4403-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4403-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4403-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	126.9	1.9	0.14	58cfa82ee4b0c9d6adf6aeb4	TCGA-05-4403-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4403-10A	CE15F31F-2BAD-4485-96FA-495BFA262E66	Blood Derived Normal	Illumina HiSeq	09d1673e-6daf-469e-ae53-19559464d5ed	Lung	76	0C58725D-22C6-4621-B1EA-D8E3E212D366	5E511CAA-31C9-48F7-BCF5-DD3838BD9B30	TCGA-05-4403-10A-01D-1203-02	GRCh37	TCGA-05-4403	TCGA-LUAD	NA	s11219	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae68	58cfa82ee4b0c9d6adf6ae68	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	211.2	1.9	0.15	58cfa82ee4b0c9d6adf6ae68	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4403-01A	CE15F31F-2BAD-4485-96FA-495BFA262E66	Primary Tumor	Illumina HiSeq	80e2118c-7ebf-42fc-8600-573afcbb3fe6	Lung	76	44B1D21C-0794-428C-BA01-82812D74DA2F	48F1FF7F-84F4-4420-96F9-DA1917577B6D	TCGA-05-4403-01A-01D-1203-02	GRCh37	TCGA-05-4403	TCGA-LUAD	NA	s10980	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae71	58cfa82ee4b0c9d6adf6ae71	TCGA-05-4402-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4402-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4402-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	65.9	1.8	0.14	58cfa82ee4b0c9d6adf6ae71	TCGA-05-4402-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4402-10A	722D6818-F1CB-49F4-B68A-FD0A31304681	Blood Derived Normal	Illumina HiSeq	30d6ff50-187c-495a-8364-d0ae343f89c2	Lung	57	02C4F8D1-061F-4897-AF1F-755345D7D91B	A9423B91-152F-4BD3-97FC-8B715A63136A	TCGA-05-4402-10A-01D-1203-02	GRCh37	TCGA-05-4402	TCGA-LUAD	244	s10983	Harvard Medical School	Indivumed	Germany	NO	T2	NX	Lung Adenocarcinoma Mixed Subtype	Stage IV	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6afe6	58cfa82ee4b0c9d6adf6afe6	TCGA-05-4434-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-05-4434-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_2_rg.sorted	TCGA-05-4434-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_2_rg.sorted.bam	724.9	1.9	0.15	58cfa82ee4b0c9d6adf6afe6	TCGA-05-4434-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_2_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4434-01A	D94FE32F-BEDD-4F4C-9FEB-FCB60D40F4BB	Primary Tumor	Illumina HiSeq	f43f1ef0-b383-4a17-a3cc-25c353416799	Lung	67	7A03048B-58B6-4CAE-B143-81C0A4977AC6	8A64C790-988A-4B51-8E5F-B4F746F2D9EB	TCGA-05-4434-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4434	TCGA-LUAD	457	s10644	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Lung Adenocarcinoma Mixed Subtype	Stage IV	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6af57	58cfa82ee4b0c9d6adf6af57	TCGA-05-5429-10A-01D-1623_110714_SN590_0097_BD0CMJABXX_s_2_rg.sorted.filtered.	WGS	TCGA-05-5429-10A-01D-1623_110714_SN590_0097_BD0CMJABXX_s_2_rg.sorted	TCGA-05-5429-10A-01D-1623_110714_SN590_0097_BD0CMJABXX_s_2_rg.sorted.bam	136.4	1.9	0.16	58cfa82ee4b0c9d6adf6af57	TCGA-05-5429-10A-01D-1623_110714_SN590_0097_BD0CMJABXX_s_2_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-5429-10A	63BD2175-4B7C-44C9-AEF3-9EFC8F79837B	Blood Derived Normal	Illumina HiSeq	bcdedbe7-cbd5-46a7-b0e3-3586421a59ec	Lung	60	CBFF89AF-5FC7-4C9C-B081-5774657967C2	8637A9F5-39CB-4E47-9029-FB9B2F2BA2C4	TCGA-05-5429-10A-01D-1623-02	HG19_Broad_variant	TCGA-05-5429	TCGA-LUAD	NA	s11442	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1623-02	TRUE
13722.58cfa82ee4b0c9d6adf6b030	58cfa82ee4b0c9d6adf6b030	TCGA-05-4432-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4432-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_3_rg.sorted	TCGA-05-4432-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_3_rg.sorted.bam	97.23	1.9	0.14	58cfa82ee4b0c9d6adf6b030	TCGA-05-4432-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4432-10A	E737F650-B72D-44E7-B750-558A56716803	Blood Derived Normal	Illumina HiSeq	10b90006-c305-434b-a1e6-0d2d780fe84f	Lung	66	DF254D50-B666-4512-99E9-F65D94454FDE	92BC38C1-04F3-419F-877A-0D020898851A	TCGA-05-4432-10A-01D-1203-02	HG19_Broad_variant	TCGA-05-4432	TCGA-LUAD	NA	s10647	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b624	58cfa82fe4b0c9d6adf6b624	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted.filtered.	WGS	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted.bam	692.7	1.9	0.15	58cfa82fe4b0c9d6adf6b624	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-5146-01A	1D276B62-5E64-48FB-B2CE-5192B511FE37	Primary Tumor	Illumina HiSeq	926ac8ca-ff8f-4822-bf62-819bf5525a5d	Lung	NA	373C5231-B6AE-49DB-AC0D-D674A0C9C100	2578C781-0BDF-4CA2-A8FA-8B624489818B	TCGA-75-5146-01A-01D-1623-02	HG19_Broad_variant	TCGA-75-5146	TCGA-LUAD	NA	s10668	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	TRUE
13722.58cfa82ee4b0c9d6adf6b146	58cfa82ee4b0c9d6adf6b146	TCGA-05-4426-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-05-4426-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_7_rg.sorted	TCGA-05-4426-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_7_rg.sorted.bam	65.9	1.9	0.15	58cfa82ee4b0c9d6adf6b146	TCGA-05-4426-10A-01D-1203_111013_SN208_0253_B00PJACXX_s_7_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4426-10A	36BF02F8-C1C8-49F9-A417-ADF88A205C70	Blood Derived Normal	Illumina HiSeq	7e65d1f5-4103-44eb-a39a-9944b9f86be9	Lung	71	7DBB3F0E-B957-4AE1-A1B2-2672DC10FE87	4071BFD9-5804-4F10-899F-5C5DFC27D93B	TCGA-05-4426-10A-01D-1203-02	HG19_Broad_variant	TCGA-05-4426	TCGA-LUAD	NA	s11333	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5da	58cfa82fe4b0c9d6adf6b5da	TCGA-35-4123-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_6_rg.sorted.filtered.	WGS	TCGA-35-4123-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_6_rg.sorted	TCGA-35-4123-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_6_rg.sorted.bam	766.93	1.9	0.16	58cfa82fe4b0c9d6adf6b5da	TCGA-35-4123-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-35-4123-01A	6CF49CF0-DE4C-4C90-8358-EAE19C6206B0	Primary Tumor	Illumina HiSeq	c620a587-dd69-4a1c-81c9-5ae742181fbc	Lung	38	3AF63E86-157B-408C-9527-58A45107DDD2	D1765CB9-4A13-425F-8B2D-E632B656058B	TCGA-35-4123-01A-01D-1103-02	HG19_Broad_variant	TCGA-35-4123	TCGA-LUAD	NA	s11335	Harvard Medical School	Cureline	Russia	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5e4	58cfa82fe4b0c9d6adf6b5e4	TCGA-44-2661-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-2661-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_7_rg.sorted	TCGA-44-2661-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_7_rg.sorted.bam	735.66	1.9	0.15	58cfa82fe4b0c9d6adf6b5e4	TCGA-44-2661-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-2661-01A	F3501466-CF32-4866-B5FB-E94DD32341BC	Primary Tumor	Illumina HiSeq	fbe0b7e0-45f4-4c61-9965-be52ae790251	Lung	69	48DD9724-8848-48C3-8628-7E78A24E3F2C	5F5307B5-02FF-4262-BB72-A215897B2EA7	TCGA-44-2661-01A-01D-1103-02	HG19_Broad_variant	TCGA-44-2661	TCGA-LUAD	NA	s10650	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b617	58cfa82fe4b0c9d6adf6b617	TCGA-35-4122-01A-01D-1103_110804_SN208_0217_BC03EKABXX_s_3_rg.sorted.filtered.	WGS	TCGA-35-4122-01A-01D-1103_110804_SN208_0217_BC03EKABXX_s_3_rg.sorted	TCGA-35-4122-01A-01D-1103_110804_SN208_0217_BC03EKABXX_s_3_rg.sorted.bam	244.93	1.9	0.15	58cfa82fe4b0c9d6adf6b617	TCGA-35-4122-01A-01D-1103_110804_SN208_0217_BC03EKABXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-35-4122-01A	44ADF4CB-2829-4153-80FD-A8B7EE0E654A	Primary Tumor	Illumina HiSeq	3887aeb9-e6df-492e-ad08-f4037acba9aa	Lung	69	587F8383-3A48-49AF-8AC4-D86E6009C96B	DD8A0F54-0311-49FB-B270-ABF1AE9B56A5	TCGA-35-4122-01A-01D-1103-02	HG19_Broad_variant	TCGA-35-4122	TCGA-LUAD	NA	s11445	Harvard Medical School	Cureline	Russia	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b71c	58cfa82fe4b0c9d6adf6b71c	TCGA-64-5779-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-64-5779-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_6_rg.sorted	TCGA-64-5779-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_6_rg.sorted.bam	134.4	1.9	0.14	58cfa82fe4b0c9d6adf6b71c	TCGA-64-5779-10A-01D-1623_110824_SN208_0222_BB0164ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5779-10A	1C58D9B8-17A2-4FC6-9898-FE6F47BD2C2A	Blood Derived Normal	Illumina HiSeq	c02b55b5-b815-4d90-9374-32d338c3a9c3	Lung	61	EF7E3BD2-56CE-478D-BBF8-3A9BFA941F40	8D610E60-A626-458E-B768-D3058F421662	TCGA-64-5779-10A-01D-1623-02	HG19_Broad_variant	TCGA-64-5779	TCGA-LUAD	NA	s11358	Harvard Medical School	Fox Chase	United States	NO	T2	N2	Lung Acinar Adenocarcinoma	Stage IIIA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b682	58cfa82fe4b0c9d6adf6b682	TCGA-44-5645-10A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_6_rg.sorted.filtered.	WGS	TCGA-44-5645-10A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_6_rg.sorted	TCGA-44-5645-10A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_6_rg.sorted.bam	312.7	2	0.16	58cfa82fe4b0c9d6adf6b682	TCGA-44-5645-10A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_6_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-5645-10A	DDEACCCF-0953-4952-8A4E-C2617F2E7BCC	Blood Derived Normal	Illumina HiSeq	9eac595e-5daf-4448-bb4f-5c16b028bddb	Lung	61	0F56A5D5-274E-4599-9566-3EABA30AF2F9	78734754-0680-489A-886B-2F5FCE472560	TCGA-44-5645-10A-01D-1623-02	HG19_Broad_variant	TCGA-44-5645	TCGA-LUAD	NA	s11549	Harvard Medical School	Christiana Healthcare	United States	NO	T1	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b694	58cfa82fe4b0c9d6adf6b694	TCGA-49-4486-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4486-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4486-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	176.53	1.9	0.16	58cfa82fe4b0c9d6adf6b694	TCGA-49-4486-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4486-11A	61C655EC-52B5-453F-A6CC-B2ABA445B027	Solid Tissue Normal	Illumina HiSeq	20f65a1e-78a9-454e-a05c-5c944d95f215	Lung	72	5AF4A67E-13EF-41DD-945C-18669C7D2701	C0F67DA7-7FC7-4C97-9D1D-EA984206252B	TCGA-49-4486-11A-01D-1203-02	GRCh37	TCGA-49-4486	TCGA-LUAD	2318	s10654	Harvard Medical School	Johns Hopkins	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b72e	58cfa82fe4b0c9d6adf6b72e	TCGA-50-5045-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_2_rg.sorted.filtered.	WGS	TCGA-50-5045-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_2_rg.sorted	TCGA-50-5045-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_2_rg.sorted.bam	120.4	1.9	0.14	58cfa82fe4b0c9d6adf6b72e	TCGA-50-5045-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_2_rg.sorted.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5045-10A	9EE20C0D-A1C3-47F3-ABDA-131B3F190F52	Blood Derived Normal	Illumina HiSeq	425edc83-a2c5-4ada-be24-0e87cc319fbe	Lung	57	33B96FAD-DAF0-4E90-834C-4BBE9F2FD129	0C850234-0109-4AB4-B0B5-7E7E976BAFFC	TCGA-50-5045-10A-01D-1623-02	HG19_Broad_variant	TCGA-50-5045	TCGA-LUAD	2174	s11123	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b67d	58cfa82fe4b0c9d6adf6b67d	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	142.53	1.9	0.14	58cfa82fe4b0c9d6adf6b67d	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4486-01A	61C655EC-52B5-453F-A6CC-B2ABA445B027	Primary Tumor	Illumina HiSeq	cb4d8cf1-9903-481c-8ba1-df0586b69916	Lung	72	5AE9B10F-347C-48C3-90CD-9290055CFE4B	EC0EE49C-D1D4-490D-BA82-CFAE6D451B8D	TCGA-49-4486-01A-01D-1203-02	GRCh37	TCGA-49-4486	TCGA-LUAD	2318	s10907	Harvard Medical School	Johns Hopkins	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b726	58cfa82fe4b0c9d6adf6b726	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted.filtered.	WGS	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted.bam	817.7	1.9	0.15	58cfa82fe4b0c9d6adf6b726	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-5147-01A	D2824E6D-3784-45C2-9B0F-52B17356B5DA	Primary Tumor	Illumina HiSeq	ca549b28-f771-489d-93fe-90211aa22391	Lung	NA	F9F9C1DD-8462-4560-82B8-AEA4309854C9	1291FD50-F1A9-4A2A-A2FD-2320ED01FB4E	TCGA-75-5147-01A-01D-1623-02	HG19_Broad_variant	TCGA-75-5147	TCGA-LUAD	NA	s11466	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7b0	58cfa82fe4b0c9d6adf6b7b0	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	245.2	1.9	0.16	58cfa82fe4b0c9d6adf6b7b0	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4494-01A	C6D78E27-E510-4F57-ABAE-19EFA6105A8D	Primary Tumor	Illumina HiSeq	3cb48d09-95ac-452f-9c92-19d7f966aec0	Lung	77	7CA68089-C61F-4D31-8CC8-FB11AE70910A	8DF0AEB4-1455-4760-A230-54FE1551D08C	TCGA-49-4494-01A-01D-1203-02	GRCh37	TCGA-49-4494	TCGA-LUAD	1081	s10783	Harvard Medical School	Johns Hopkins	United States	NO	T3	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b797	58cfa82fe4b0c9d6adf6b797	TCGA-49-4494-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4494-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4494-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	228.2	1.9	0.14	58cfa82fe4b0c9d6adf6b797	TCGA-49-4494-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4494-11A	C6D78E27-E510-4F57-ABAE-19EFA6105A8D	Solid Tissue Normal	Illumina HiSeq	56ee8c8c-9b38-4430-97b6-3272b9f84d68	Lung	77	DFD80010-DE16-4E33-B408-71B37AFE3FDF	D3182B5C-BA8F-49F0-967E-A209011B552B	TCGA-49-4494-11A-01D-1203-02	GRCh37	TCGA-49-4494	TCGA-LUAD	1081	s10659	Harvard Medical School	Johns Hopkins	United States	NO	T3	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b70c	58cfa82fe4b0c9d6adf6b70c	TCGA-73-4670-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4670-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4670-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	149.9	1.9	0.13	58cfa82fe4b0c9d6adf6b70c	TCGA-73-4670-11A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4670-11A	1B354837-4925-4480-AC32-6B44D0957314	Solid Tissue Normal	Illumina HiSeq	fb70791d-abaa-4c78-8e45-77605f89d966	Lung	69	D46B3B2F-00FD-4F1F-97A5-BDBE14F5F119	6353F7CF-C3E0-4059-8C7E-92A313474444	TCGA-73-4670-11A-01D-1203-02	GRCh37	TCGA-73-4670	TCGA-LUAD	NA	s11556	Harvard Medical School	Roswell Park	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b77c	58cfa82fe4b0c9d6adf6b77c	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.filtered.	WGS	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.bam	466.6	1.9	0.16	58cfa82fe4b0c9d6adf6b77c	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-5645-01A	DDEACCCF-0953-4952-8A4E-C2617F2E7BCC	Primary Tumor	Illumina HiSeq	e1f13e42-abbc-4a28-91d2-65b2a95b0018	Lung	61	37A8D3A5-BAA0-427C-AB43-48AE4B93633B	A35054A5-9324-47AD-841E-E2ADCD97126D	TCGA-44-5645-01A-01D-1623-02	HG19_Broad_variant	TCGA-44-5645	TCGA-LUAD	NA	s10993	Harvard Medical School	Christiana Healthcare	United States	NO	T1	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7da	58cfa82fe4b0c9d6adf6b7da	TCGA-44-3918-11A-01D-1103_110712_SN590_0096_A80WMCABXX_s_8_rg.sorted.filtered.	WGS	TCGA-44-3918-11A-01D-1103_110712_SN590_0096_A80WMCABXX_s_8_rg.sorted	TCGA-44-3918-11A-01D-1103_110712_SN590_0096_A80WMCABXX_s_8_rg.sorted.bam	480.93	1.9	0.17	58cfa82fe4b0c9d6adf6b7da	TCGA-44-3918-11A-01D-1103_110712_SN590_0096_A80WMCABXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3918-11A	6E3B6B72-142D-4B8D-A462-28A205796E41	Solid Tissue Normal	Illumina HiSeq	297c5d46-e808-423b-9a00-4da7e03a6cc5	Lung	60	E1A3BB46-6508-4DC0-9A81-361C8E1B5A66	46149026-2FAD-4FCD-A4E5-B02224FED763	TCGA-44-3918-11A-01D-1103-02	HG19_Broad_variant	TCGA-44-3918	TCGA-LUAD	NA	s10989	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7d4	58cfa82fe4b0c9d6adf6b7d4	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.bam	427.33	1.9	0.15	58cfa82fe4b0c9d6adf6b7d4	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3919-01A	66ED89F6-8BA2-49D0-AF0F-4B6EBF2381BF	Primary Tumor	Illumina HiSeq	14d2cfc2-f4ac-4ab1-93d3-0e178305e26f	Lung	71	9DE8D353-3442-41D8-8BFE-A08C4975EACA	9C982400-B6C3-4D00-9981-BA06775FEF4F	TCGA-44-3919-01A-02D-1103-02	HG19_Broad_variant	TCGA-44-3919	TCGA-LUAD	NA	s10994	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b840	58cfa82fe4b0c9d6adf6b840	TCGA-A6-2679-01A-02D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2679-01A-02D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2679-01A-02D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	556	1.9	0.17	58cfa82fe4b0c9d6adf6b840	TCGA-A6-2679-01A-02D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2679-01A	0F74D992-00DA-4728-9564-086CA1B95921	Primary Tumor	Illumina HiSeq	6ba315a4-973a-47a1-b157-8f6ab62fdaef	Colorectal	73	1FCB9C83-18CB-42A4-8769-FDDB3541C95D	118D83B1-3464-40E3-8A77-270650CFED42	TCGA-A6-2679-01A-02D-1405-02	HG18	TCGA-A6-2679	TCGA-COAD	NA	s13014	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIB	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b842	58cfa82fe4b0c9d6adf6b842	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	260.29	1.9	0.14	58cfa82fe4b0c9d6adf6b842	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2674-01A	57CDAA1C-4E94-4A28-AB3B-300C0457555F	Primary Tumor	Illumina HiSeq	92b3a16b-1a9e-47a3-9146-1a297c51c5a3	Colorectal	71	8ACA008C-F55A-420A-82C7-ACD2CCA77D85	9FDFC199-B878-4049-994E-B5CA384678FB	TCGA-A6-2674-01A-02D-1167-02	HG18	TCGA-A6-2674	TCGA-COAD	NA	s13013	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IV	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7ec	58cfa82fe4b0c9d6adf6b7ec	TCGA-35-4122-10A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_4_rg.sorted.filtered.	WGS	TCGA-35-4122-10A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_4_rg.sorted	TCGA-35-4122-10A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_4_rg.sorted.bam	168.63	1.9	0.15	58cfa82fe4b0c9d6adf6b7ec	TCGA-35-4122-10A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-35-4122-10A	44ADF4CB-2829-4153-80FD-A8B7EE0E654A	Blood Derived Normal	Illumina HiSeq	7b36ec07-4c97-4a6e-a53d-7325e0d04974	Lung	69	CA26FD6D-CF60-4EB0-8D86-BCD9067356C7	F68CAE7E-7619-4D5A-81DA-71EA6F05CFEA	TCGA-35-4122-10A-01D-1103-02	HG19_Broad_variant	TCGA-35-4122	TCGA-LUAD	NA	s10988	Harvard Medical School	Cureline	Russia	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b88c	58cfa82fe4b0c9d6adf6b88c	TCGA-A6-2681-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2681-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2681-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	466	1.9	0.15	58cfa82fe4b0c9d6adf6b88c	TCGA-A6-2681-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2681-10A	7D8EAB0A-E6C8-4449-9EBF-50C41DB94A06	Blood Derived Normal	Illumina HiSeq	39e367a8-940b-4e1b-aa38-cdb0fdfe9d26	Colorectal	73	EA27374C-3F62-4128-A14A-8418966AFDB3	CCF319C5-BF63-4423-8D31-10013BB84BAA	TCGA-A6-2681-10A-01D-1405-02	HG18	TCGA-A6-2681	TCGA-COAD	NA	s13171	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b889	58cfa82fe4b0c9d6adf6b889	TCGA-A6-2674-10A-01D-1167_101023_SN208_0166_A808PFABXX_s_4_rg.sorted.filtered.	WGS	TCGA-A6-2674-10A-01D-1167_101023_SN208_0166_A808PFABXX_s_4_rg.sorted	TCGA-A6-2674-10A-01D-1167_101023_SN208_0166_A808PFABXX_s_4_rg.sorted.bam	342.56	1.9	0.15	58cfa82fe4b0c9d6adf6b889	TCGA-A6-2674-10A-01D-1167_101023_SN208_0166_A808PFABXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2674-10A	57CDAA1C-4E94-4A28-AB3B-300C0457555F	Blood Derived Normal	Illumina HiSeq	1aeeda77-810f-4e12-bd35-f5a7cf7a31b2	Colorectal	71	CED59EE0-9A95-4E2D-AC39-22EF6F80EBF7	DD75656D-6DF6-4C53-972D-439791C908AC	TCGA-A6-2674-10A-01D-1167-02	HG18_Broad_variant	TCGA-A6-2674	TCGA-COAD	NA	s13021	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IV	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8d5	58cfa82fe4b0c9d6adf6b8d5	TCGA-A6-2682-10A-01D-1405_110503_SN177_0159_AB02MCABXX_s_8_rg.sorted.filtered.	WGS	TCGA-A6-2682-10A-01D-1405_110503_SN177_0159_AB02MCABXX_s_8_rg.sorted	TCGA-A6-2682-10A-01D-1405_110503_SN177_0159_AB02MCABXX_s_8_rg.sorted.bam	611	1.9	0.15	58cfa82fe4b0c9d6adf6b8d5	TCGA-A6-2682-10A-01D-1405_110503_SN177_0159_AB02MCABXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2682-10A	77A44132-AF22-4115-9FA2-78F2F74BF687	Blood Derived Normal	Illumina HiSeq	d4197dea-75a2-40e6-9698-efb40827723a	Colorectal	70	CA3662D9-88B8-4E80-8C54-9DC7DF374DE5	0CBA805A-F14E-42A5-B4C7-AA7EE434EED8	TCGA-A6-2682-10A-01D-1405-02	HG18_Broad_variant	TCGA-A6-2682	TCGA-COAD	424	s13020	Harvard Medical School	Christiana Healthcare	United States	NO	T4b	N1	Colon Adenocarcinoma	Stage IV	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8e8	58cfa82fe4b0c9d6adf6b8e8	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	346	1.9	0.13	58cfa82fe4b0c9d6adf6b8e8	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3510-01A	35C295C2-37D1-44B2-87A3-1039645E5BAE	Primary Tumor	Illumina HiSeq	0bb810fb-0134-4ea2-a821-41bbbdbd9155	Colorectal	70	C71C031C-3089-44E5-A49F-5284D7D300CE	DA2A173C-BBD3-4A90-8D1D-CD35CBE750F3	TCGA-AA-3510-01A-01D-1405-02	HG18	TCGA-AA-3510	TCGA-COAD	NA	s13666	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8b8	58cfa82fe4b0c9d6adf6b8b8	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	482.2	1.9	0.16	58cfa82fe4b0c9d6adf6b8b8	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4675-01A	AE39E358-08D7-4367-AE68-82B469E791E4	Primary Tumor	Illumina HiSeq	14b3ad66-64c9-4b39-a34e-5cb29788735a	Lung	59	1F5FA8FD-1DE8-4456-8935-71B5A8B54BD2	356D01E0-DF80-40C6-BA06-8CD4EDFBD1EC	TCGA-73-4675-01A-01D-1203-02	GRCh37	TCGA-73-4675	TCGA-LUAD	NA	s11013	Harvard Medical School	Roswell Park	United States	NO	T3	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8f8	58cfa82fe4b0c9d6adf6b8f8	TCGA-A6-2683-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2683-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2683-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	790.56	1.9	0.16	58cfa82fe4b0c9d6adf6b8f8	TCGA-A6-2683-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2683-10A	FAFD4576-0709-49E1-926F-AD1EE09907EC	Blood Derived Normal	Illumina HiSeq	98608f88-13ef-4b96-91d0-d6f053a8a8a3	Colorectal	57	D62CA19B-102E-4018-A957-ACFB23055369	98056E22-3F16-4920-94E1-39E334B37D18	TCGA-A6-2683-10A-01D-1167-02	HG18	TCGA-A6-2683	TCGA-COAD	NA	s13504	Harvard Medical School	Christiana Healthcare	None	NO	T4	N0	Colon Adenocarcinoma	Stage IV	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b83f	58cfa82fe4b0c9d6adf6b83f	TCGA-A6-2676-10A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_2.rg.sorted.filtered.	WGS	TCGA-A6-2676-10A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_2.rg.sorted	TCGA-A6-2676-10A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_2.rg.sorted.bam	362.56	1.9	0.14	58cfa82fe4b0c9d6adf6b83f	TCGA-A6-2676-10A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_2.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2676-10A	89A6384E-1CEA-440B-9F17-D57CB0805174	Blood Derived Normal	Illumina HiSeq	d6eb31c8-71e8-41a3-9cb0-1dcd5bb091d4	Colorectal	75	74BBC0AF-904E-4F03-B750-7A0585D15215	5A85D32F-EC89-43D1-9B06-2D3EDD680F6D	TCGA-A6-2676-10A-01D-1167-02	HG18_Broad_variant	TCGA-A6-2676	TCGA-COAD	NA	s13655	Harvard Medical School	Christiana Healthcare	None	NO	T4	N0	Colon Adenocarcinoma	Stage IIB	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b91e	58cfa82fe4b0c9d6adf6b91e	TCGA-A6-2674-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2674-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2674-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	342.56	1.9	0.15	58cfa82fe4b0c9d6adf6b91e	TCGA-A6-2674-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2674-10A	57CDAA1C-4E94-4A28-AB3B-300C0457555F	Blood Derived Normal	Illumina HiSeq	6c0170f4-886c-4c9e-b831-9e7ddbe64526	Colorectal	71	CED59EE0-9A95-4E2D-AC39-22EF6F80EBF7	DD75656D-6DF6-4C53-972D-439791C908AC	TCGA-A6-2674-10A-01D-1167-02	HG18	TCGA-A6-2674	TCGA-COAD	NA	s13350	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IV	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b898	58cfa82fe4b0c9d6adf6b898	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.filtered.	WGS	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.bam	296.29	1.9	0.17	58cfa82fe4b0c9d6adf6b898	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2676-01A	89A6384E-1CEA-440B-9F17-D57CB0805174	Primary Tumor	Illumina HiSeq	c175a01b-eba5-4c4d-b786-fc9f54a2fa60	Colorectal	75	CBBD1187-E8F7-4E63-A8E2-3C19863E89F5	D02407DB-AECE-475A-AA3F-00653B1E7BEE	TCGA-A6-2676-01A-01D-1167-02	HG18_Broad_variant	TCGA-A6-2676	TCGA-COAD	NA	s13022	Harvard Medical School	Christiana Healthcare	None	NO	T4	N0	Colon Adenocarcinoma	Stage IIB	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b914	58cfa82fe4b0c9d6adf6b914	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	129.53	1.9	0.14	58cfa82fe4b0c9d6adf6b914	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4505-01A	088EDF89-D2B5-40C7-B066-DF3BD383F7EA	Primary Tumor	Illumina HiSeq	af550be6-0986-458b-8206-9c7cf928c215	Lung	61	D1FB0862-8D9C-4BC4-AAC6-81DC4EED66C9	30B77A0C-3439-44E2-A586-5DF68C0D0002	TCGA-49-4505-01A-01D-1203-02	GRCh37	TCGA-49-4505	TCGA-LUAD	428	s11125	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b89a	58cfa82fe4b0c9d6adf6b89a	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	467.29	1.9	0.16	58cfa82fe4b0c9d6adf6b89a	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2683-01A	FAFD4576-0709-49E1-926F-AD1EE09907EC	Primary Tumor	Illumina HiSeq	06c41745-bee7-471d-9c51-8886c6c8dd9c	Colorectal	57	C24759F8-566B-42DA-A26D-BB0BF51EE15F	B22E3766-3FC6-4E77-86D0-0A10A810D313	TCGA-A6-2683-01A-01D-1167-02	HG18	TCGA-A6-2683	TCGA-COAD	NA	s12852	Harvard Medical School	Christiana Healthcare	None	NO	T4	N0	Colon Adenocarcinoma	Stage IV	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b960	58cfa82fe4b0c9d6adf6b960	TCGA-AA-3558-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3558-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3558-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	969.56	1.9	0.14	58cfa82fe4b0c9d6adf6b960	TCGA-AA-3558-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3558-01A	A56D528B-238A-4556-92C8-7645304A2DA0	Primary Tumor	Illumina HiSeq	803b71f6-51cd-4b3d-86d6-0f321432fe8f	Colorectal	70	B0ACDAFA-A75C-48B9-812D-3FB449157F8B	B1AEDAAD-A964-4D7E-A641-F05AC4F174F2	TCGA-AA-3558-01A-01D-1167-02	HG18	TCGA-AA-3558	TCGA-COAD	NA	s13511	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b928	58cfa82fe4b0c9d6adf6b928	TCGA-A6-2679-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2679-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2679-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	236	1.9	0.15	58cfa82fe4b0c9d6adf6b928	TCGA-A6-2679-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2679-10A	0F74D992-00DA-4728-9564-086CA1B95921	Blood Derived Normal	Illumina HiSeq	ad1b1f81-bc17-4bdc-8bb9-06993af79462	Colorectal	73	2863DE87-C342-45EB-8448-F4ACDEC30A3E	822A50C3-E1D1-4CE4-93C6-E563328852D1	TCGA-A6-2679-10A-01D-1405-02	HG18	TCGA-A6-2679	TCGA-COAD	NA	s13507	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIB	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b96b	58cfa82fe4b0c9d6adf6b96b	TCGA-AA-3558-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3558-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3558-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	42.56	1.9	0.14	58cfa82fe4b0c9d6adf6b96b	TCGA-AA-3558-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3558-10A	A56D528B-238A-4556-92C8-7645304A2DA0	Blood Derived Normal	Illumina HiSeq	42785715-e63b-4e12-a1e2-9623cb000df0	Colorectal	70	AAA77FAE-A493-42B5-B03D-6488422FA0FA	6A7C5A1E-2A2A-49A9-A113-3DDEEFD16456	TCGA-AA-3558-10A-01D-1167-02	HG18	TCGA-AA-3558	TCGA-COAD	NA	s13178	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b974	58cfa82fe4b0c9d6adf6b974	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	570.96	1.9	0.14	58cfa82fe4b0c9d6adf6b974	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3675-01A	41658CF8-0DE1-4A97-BB60-0F0107C84E00	Primary Tumor	Illumina HiSeq	f57af06a-9d5a-4a69-888a-8d611982b88e	Colorectal	84	A4CE3727-4506-493B-95F4-2F11CEB09CEB	D611373E-EF0A-46E4-8D3E-0722F221E828	TCGA-AA-3675-01A-02D-1109-02	HG18	TCGA-AA-3675	TCGA-COAD	NA	s13672	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1109-02	TRUE
13722.58cfa82fe4b0c9d6adf6b940	58cfa82fe4b0c9d6adf6b940	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	236	1.9	0.14	58cfa82fe4b0c9d6adf6b940	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3808-01A	4F9775F2-B663-4DAF-AA9E-50915CAE9407	Primary Tumor	Illumina HiSeq	58504a37-4eb0-44ec-bb5d-83e955521de2	Colorectal	73	037BA047-2228-43DE-8DF8-32920A689ECA	2B2625B5-FBDD-41C3-9BB3-71566C5FBBA4	TCGA-A6-3808-01A-01D-1167-02	HG18	TCGA-A6-3808	TCGA-COAD	NA	s13173	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b98e	58cfa82fe4b0c9d6adf6b98e	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.bam	115.4	1.9	0.14	58cfa82fe4b0c9d6adf6b98e	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-50-5944-01A	1C339545-C08A-4A77-B8E9-A7E49E53853F	Primary Tumor	Illumina HiSeq	c76f3861-5117-4ed7-9ca6-eecc10e949f3	Lung	69	BF8FDF82-62B4-4B5D-93E7-CE153576FE49	71CD46A8-30B0-4452-860D-3ED173C461A7	TCGA-50-5944-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5944	TCGA-LUAD	NA	s11348	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Acinar Adenocarcinoma	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9a3	58cfa82fe4b0c9d6adf6b9a3	TCGA-AA-3675-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3675-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3675-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	56.66	1.9	0.15	58cfa82fe4b0c9d6adf6b9a3	TCGA-AA-3675-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3675-10A	41658CF8-0DE1-4A97-BB60-0F0107C84E00	Blood Derived Normal	Illumina HiSeq	a1895003-f469-49f2-a729-93d8405faf2c	Colorectal	84	9C0C79F7-1500-452C-904C-35CC9D3C4634	215719E3-587A-4CCC-8A65-B659BD0FA78A	TCGA-AA-3675-10A-01D-1109-02	HG18	TCGA-AA-3675	TCGA-COAD	NA	s13521	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1109-02	TRUE
13722.58cfa82fe4b0c9d6adf6b96c	58cfa82fe4b0c9d6adf6b96c	TCGA-AA-3675-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3675-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3675-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	56.66	1.9	0.15	58cfa82fe4b0c9d6adf6b96c	TCGA-AA-3675-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3675-10A	41658CF8-0DE1-4A97-BB60-0F0107C84E00	Blood Derived Normal	Illumina HiSeq	b96e4a5b-ccba-4670-96a2-87b4bde329ea	Colorectal	84	9C0C79F7-1500-452C-904C-35CC9D3C4634	07C43104-A2D5-4F74-B22F-166D8364562E	TCGA-AA-3675-10A-01D-1167-02	HG18	TCGA-AA-3675	TCGA-COAD	NA	s12869	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9ca	58cfa82fe4b0c9d6adf6b9ca	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	232.95	1.72	0.15	58cfa82fe4b0c9d6adf6b9ca	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00U-01A	091E3084-04EE-4497-893C-D46226DEC78F	Primary Tumor	Illumina HiSeq	95f8b5f7-db6e-4a69-959f-dde28a98d4ed	Colorectal	50	2FC854D7-4F80-4C39-BD92-397E94FEE4A0	6765593B-17DC-4B0F-A20B-7F0FF67DFF64	TCGA-AA-A00U-01A-01D-A077-02	HG18	TCGA-AA-A00U	TCGA-COAD	NA	s13682	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	A077-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9c2	58cfa82fe4b0c9d6adf6b9c2	TCGA-AA-3970-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3970-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3970-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	24.22	1.9	0.15	58cfa82fe4b0c9d6adf6b9c2	TCGA-AA-3970-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3970-10A	733D8B6A-CA9D-4A69-8C9C-1F88733E8B68	Blood Derived Normal	Illumina HiSeq	4026ba28-eed0-4ab6-b27f-69b6f55197e1	Colorectal	65	46E88E56-D24F-4E70-B2DD-E87DF153A137	67C863D0-F45C-40F0-9668-B0A92339D290	TCGA-AA-3970-10A-01D-1109-02	HG18	TCGA-AA-3970	TCGA-COAD	NA	s13187	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1109-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9dc	58cfa82fe4b0c9d6adf6b9dc	TCGA-AA-3994-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3994-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3994-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	9.59	1.9	0.13	58cfa82fe4b0c9d6adf6b9dc	TCGA-AA-3994-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3994-10A	750770DB-53CF-4021-A8C2-5E0DDB97FEF5	Blood Derived Normal	Illumina HiSeq	0bea6476-1972-414f-be09-4c4197784248	Colorectal	69	775698AF-8ABC-408B-A47A-C00430B1224B	A6F4E88E-40A5-4CE3-827D-A4A2C9DC02A8	TCGA-AA-3994-10A-01D-1109-02	HG18	TCGA-AA-3994	TCGA-COAD	NA	s13376	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Mucinous Adenocarcinoma	Stage IIIB	1109-02	TRUE
13722.58cfa82fe4b0c9d6adf6b978	58cfa82fe4b0c9d6adf6b978	TCGA-AA-3664-10A-01D-1167_110111_SN208_0178_B818TTABXX_s_6.rg.sorted.filtered.	WGS	TCGA-AA-3664-10A-01D-1167_110111_SN208_0178_B818TTABXX_s_6.rg.sorted	TCGA-AA-3664-10A-01D-1167_110111_SN208_0178_B818TTABXX_s_6.rg.sorted.bam	76.96	1.9	0.15	58cfa82fe4b0c9d6adf6b978	TCGA-AA-3664-10A-01D-1167_110111_SN208_0178_B818TTABXX_s_6.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3664-10A	A06C09A8-0951-49F4-A765-5147BBCAE109	Blood Derived Normal	Illumina HiSeq	bb549fb1-8744-496c-bf19-13b063fd8edd	Colorectal	74	B4FFAC44-CCEF-458F-80CC-2D230D78012A	44FE059D-488A-4152-ABB9-A305EA066D2D	TCGA-AA-3664-10A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3664	TCGA-COAD	NA	s13175	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b95a	58cfa82fe4b0c9d6adf6b95a	TCGA-AA-3548-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3548-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3548-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	45.56	1.9	0.14	58cfa82fe4b0c9d6adf6b95a	TCGA-AA-3548-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3548-10A	2DCED66C-1F0D-4039-A5E5-54CCA77C16E9	Blood Derived Normal	Illumina HiSeq	16ab76f5-0b3e-4aad-b31c-125bf8ae94d1	Colorectal	71	F43CBCA2-40EF-493A-8D28-2D58A65C7898	4F954A4C-1E74-445C-A681-9C3B3AF8AC81	TCGA-AA-3548-10A-01D-1167-02	HG18	TCGA-AA-3548	TCGA-COAD	NA	s13357	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9ec	58cfa82fe4b0c9d6adf6b9ec	TCGA-A5-A0G9-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-A5-A0G9-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_4_rg.sorted	TCGA-A5-A0G9-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_4_rg.sorted.bam	15.75	1.83	0.15	58cfa82fe4b0c9d6adf6b9ec	TCGA-A5-A0G9-10A-01D-A043_120318_SN590_0146_AC0KH7ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G9-10A	45D58088-D3F4-4EB0-B75C-BCB98C0981DC	Blood Derived Normal	Illumina HiSeq	f3c31c9e-b618-476e-a3aa-2ca4fc7347b1	Uterus	79	824F35BF-457F-4E24-90FB-4F2934263C69	07E576F1-2D19-4850-A0F1-52CE65696BD7	TCGA-A5-A0G9-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0G9	TCGA-UCEC	NA	s4417	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba0c	58cfa82fe4b0c9d6adf6ba0c	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	686.66	1.9	0.15	58cfa82fe4b0c9d6adf6ba0c	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3970-01A	733D8B6A-CA9D-4A69-8C9C-1F88733E8B68	Primary Tumor	Illumina HiSeq	9a7a59e0-b435-4e8b-b503-c49ce6f819e4	Colorectal	65	767A5260-34F4-4BED-9CDA-305BC431A402	0F57E6B4-FE51-4ACF-B65B-1FDB2CF9C6CB	TCGA-AA-3970-01A-01D-1109-02	HG18	TCGA-AA-3970	TCGA-COAD	NA	s13190	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1109-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba0e	58cfa82fe4b0c9d6adf6ba0e	TCGA-AA-3966-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3966-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3966-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	44.59	1.9	0.14	58cfa82fe4b0c9d6adf6ba0e	TCGA-AA-3966-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3966-10A	BC42FE2D-1A33-428D-A601-B1871F4C8D9B	Blood Derived Normal	Illumina HiSeq	58f3078c-baa2-4a9f-a588-8c6f8a3811e2	Colorectal	89	70893CD9-CCF1-423B-B39F-884974A30EA4	E7FEF3FA-293D-49F6-A3E2-C079E1ABF260	TCGA-AA-3966-10A-01D-1109-02	HG18	TCGA-AA-3966	TCGA-COAD	NA	s13522	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1109-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba39	58cfa82fe4b0c9d6adf6ba39	TCGA-A6-2684-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2684-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2684-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	93.3	1.9	0.14	58cfa82fe4b0c9d6adf6ba39	TCGA-A6-2684-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2684-10A	49929108-023E-4D35-B26D-50AB4D3AE581	Blood Derived Normal	Illumina HiSeq	86cc24c1-f3f5-4564-9c97-63a25b07290c	Colorectal	75	955A8753-B2CC-4378-BBC0-4100F76E3609	A77948EC-84FD-4A3E-9452-29434410D95F	TCGA-A6-2684-10A-01D-1405-02	HG18	TCGA-A6-2684	TCGA-COAD	NA	s13506	Harvard Medical School	Christiana Healthcare	None	NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9d8	58cfa82fe4b0c9d6adf6b9d8	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted.bam	880.86	1.9	0.14	58cfa82fe4b0c9d6adf6b9d8	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3947-01A	654C6F5C-3E5C-49F0-B53F-87CD9797D7C9	Primary Tumor	Illumina HiSeq	2d1ad0b4-c460-4a5b-ae6d-2926bfe40052	Colorectal	60	5241539D-65AC-434D-8EAA-AE57F702C8CE	EE2FCBCE-108F-46EC-8C7A-12D34142820A	TCGA-AA-3947-01A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3947	TCGA-COAD	NA	s13679	Harvard Medical School	Indivumed	Germany	NO	T4	N0	Colon Mucinous Adenocarcinoma	Stage IIB	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9fe	58cfa82fe4b0c9d6adf6b9fe	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	756	1.9	0.15	58cfa82fe4b0c9d6adf6b9fe	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3968-01A	CAB7BDBC-0A11-4901-97C3-26B884F79CB5	Primary Tumor	Illumina HiSeq	7c5f1648-b5c0-4e96-a5ca-38b2630f40ee	Colorectal	55	E950BC59-116F-4366-8524-F0731B1C9A3D	193F15A1-6BE4-4992-AC6E-EF34CBB3B57A	TCGA-AA-3968-01A-01D-1167-02	HG18	TCGA-AA-3968	TCGA-COAD	NA	s13030	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba3e	58cfa82fe4b0c9d6adf6ba3e	TCGA-A5-A0GU-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0GU-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_6_rg.sorted	TCGA-A5-A0GU-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_6_rg.sorted.bam	17.29	2.1	0.13	58cfa82fe4b0c9d6adf6ba3e	TCGA-A5-A0GU-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GU-10A	ADC22472-E31D-419F-AEAE-CB01B9423343	Blood Derived Normal	Illumina HiSeq	91b25823-6457-4f3a-a469-d6a89777c2ec	Uterus	58	14A66466-7AC3-48D7-B39F-5353E27D370F	1D6A08A4-CB4C-499F-A0D2-874DDC00D825	TCGA-A5-A0GU-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0GU	TCGA-UCEC	NA	s4416	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba1e	58cfa82fe4b0c9d6adf6ba1e	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted.filtered.	WGS	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted.bam	338.96	1.9	0.16	58cfa82fe4b0c9d6adf6ba1e	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3664-01A	A06C09A8-0951-49F4-A765-5147BBCAE109	Primary Tumor	Illumina HiSeq	1eb3d869-c9bd-4087-80cd-7fb426eb7997	Colorectal	74	D448668C-90F3-40FA-9961-88407090DA31	4B4C0EDF-1012-4A6A-B01E-CDEB130FF2E6	TCGA-AA-3664-01A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3664	TCGA-COAD	NA	s12864	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6ba52	58cfa830e4b0c9d6adf6ba52	TCGA-AA-A02K-10A-01D-A079_110401_SN177_0152_A819RJABXX_s_3.rg.sorted.filtered.	WGS	TCGA-AA-A02K-10A-01D-A079_110401_SN177_0152_A819RJABXX_s_3.rg.sorted	TCGA-AA-A02K-10A-01D-A079_110401_SN177_0152_A819RJABXX_s_3.rg.sorted.bam	9.16	1.85	0.08	58cfa830e4b0c9d6adf6ba52	TCGA-AA-A02K-10A-01D-A079_110401_SN177_0152_A819RJABXX_s_3.rg.sorted.bam	Dead	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02K-10A	10881458-55B2-41D1-8358-4EE6CCB8EC85	Blood Derived Normal	Illumina HiSeq	02957b7f-f470-4222-8764-6e333e997592	Colorectal	50	413A3C76-E914-435C-8311-A874004A7B34	44235651-438D-4E5D-90F3-E42E5ED3F236	TCGA-AA-A02K-10A-01D-A079-02	HG18_Broad_variant	TCGA-AA-A02K	TCGA-COAD	426	s13203	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Colon Adenocarcinoma	Stage IV	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6ba62	58cfa830e4b0c9d6adf6ba62	TCGA-AA-A01D-10A-01D-A078_110329_SN208_0198_B702NLABXX_s_8_rg.sorted.filtered.	WGS	TCGA-AA-A01D-10A-01D-A078_110329_SN208_0198_B702NLABXX_s_8_rg.sorted	TCGA-AA-A01D-10A-01D-A078_110329_SN208_0198_B702NLABXX_s_8_rg.sorted.bam	23.49	1.74	0.15	58cfa830e4b0c9d6adf6ba62	TCGA-AA-A01D-10A-01D-A078_110329_SN208_0198_B702NLABXX_s_8_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01D-10A	E2EDBF3F-25D8-49AA-B656-2A59C3B99AEB	Blood Derived Normal	Illumina HiSeq	f2fab628-0348-4344-8274-3e741299a65f	Colorectal	47	A962D396-8357-4093-BCC5-854E59FE7F98	8EFAC126-7B81-4E97-9F8A-C6D3F921E7E6	TCGA-AA-A01D-10A-01D-A078-02	HG18_Broad_variant	TCGA-AA-A01D	TCGA-COAD	NA	s13530	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IIIC	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6ba6e	58cfa830e4b0c9d6adf6ba6e	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	119.82	1.79	0.15	58cfa830e4b0c9d6adf6ba6e	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01D-01A	E2EDBF3F-25D8-49AA-B656-2A59C3B99AEB	Primary Tumor	Illumina HiSeq	dc156fb1-9b36-4d02-a6f0-54027775ed04	Colorectal	47	082DEF2F-4D99-4270-83E7-5A9A5C049C23	5BF3D0AB-D301-4EE7-84A1-83F596C29E6E	TCGA-AA-A01D-01A-01D-A077-02	HG18	TCGA-AA-A01D	TCGA-COAD	NA	s13525	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IIIC	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6ba56	58cfa830e4b0c9d6adf6ba56	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	526.89	1.9	0.15	58cfa830e4b0c9d6adf6ba56	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3966-01A	BC42FE2D-1A33-428D-A601-B1871F4C8D9B	Primary Tumor	Illumina HiSeq	3a88f23b-5740-4937-be5d-a5aed2c4e962	Colorectal	89	8C5799BF-DB65-40F6-9A67-ABD4DA4025F2	F1E05BF6-0B98-45F8-9F97-10ABE5957C99	TCGA-AA-3966-01A-01D-1109-02	HG18	TCGA-AA-3966	TCGA-COAD	NA	s13674	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1109-02	TRUE
13722.58cfa830e4b0c9d6adf6ba50	58cfa830e4b0c9d6adf6ba50	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted.filtered.	WGS	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted.bam	28.83	1.9	0.15	58cfa830e4b0c9d6adf6ba50	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted.bam	Dead	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02K-01A	10881458-55B2-41D1-8358-4EE6CCB8EC85	Primary Tumor	Illumina HiSeq	7942eab9-d80a-496e-b3cb-50b42bd23334	Colorectal	50	685DF015-1B7B-4993-BF05-E3206619DFBA	7CC17F3D-27F5-484A-8E22-C9D0B5B27836	TCGA-AA-A02K-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A02K	TCGA-COAD	426	s13842	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Colon Adenocarcinoma	Stage IV	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6ba70	58cfa830e4b0c9d6adf6ba70	TCGA-AA-A00Z-10A-01D-A078-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00Z-10A-01D-A078-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00Z-10A-01D-A078-02_IlluminaHiSeq-DNASeq_whole.bam	10.8	1.73	0.15	58cfa830e4b0c9d6adf6ba70	TCGA-AA-A00Z-10A-01D-A078-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00Z-10A	AF3A0634-4292-45BD-B948-6B6BD2D58090	Blood Derived Normal	Illumina HiSeq	be8d500d-5a28-4752-bb94-e477bd22168e	Colorectal	70	C58C91E2-443F-49D4-A568-9F087F4153F7	2D40907C-B742-4853-9863-70F92CB5D712	TCGA-AA-A00Z-10A-01D-A078-02	HG18	TCGA-AA-A00Z	TCGA-COAD	NA	s12878	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6ba68	58cfa830e4b0c9d6adf6ba68	TCGA-AA-A02W-10A-01D-A078_110406_SN177_0153_A818P3ABXX_s_2_rg.sorted.filtered.	WGS	TCGA-AA-A02W-10A-01D-A078_110406_SN177_0153_A818P3ABXX_s_2_rg.sorted	TCGA-AA-A02W-10A-01D-A078_110406_SN177_0153_A818P3ABXX_s_2_rg.sorted.bam	15.84	1.72	0.13	58cfa830e4b0c9d6adf6ba68	TCGA-AA-A02W-10A-01D-A078_110406_SN177_0153_A818P3ABXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02W-10A	73448B56-A6C6-4C98-A153-AB704261E073	Blood Derived Normal	Illumina HiSeq	d8ea3ea4-455e-45dd-829f-b2ba608c4a27	Colorectal	73	0ABE6B1F-88DA-4739-9F30-02D4C28159FD	98C33AB6-987A-4DDA-A0FA-BB6CD04D2B9E	TCGA-AA-A02W-10A-01D-A078-02	HG18_Broad_variant	TCGA-AA-A02W	TCGA-COAD	NA	s12879	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6baa6	58cfa830e4b0c9d6adf6baa6	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	124.44	1.85	0.17	58cfa830e4b0c9d6adf6baa6	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A03F-01A	2A971E32-B0E7-4A3F-8C40-62D69C0307D8	Primary Tumor	Illumina HiSeq	93e089c5-c259-445d-9ffa-10073ad2d336	Colorectal	90	8ABA8350-B5EE-4CA2-BC99-5C7922A886C4	F445E8E6-6A82-4400-8307-1DE92AC03539	TCGA-AA-A03F-01A-11D-A079-02	HG18	TCGA-AA-A03F	TCGA-COAD	549	s13207	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6ba7a	58cfa830e4b0c9d6adf6ba7a	TCGA-AA-A02Y-10A-01D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A02Y-10A-01D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A02Y-10A-01D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	42.84	1.95	0.15	58cfa830e4b0c9d6adf6ba7a	TCGA-AA-A02Y-10A-01D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02Y-10A	A435FDF4-A89A-499E-9006-CBB5693EAB26	Blood Derived Normal	Illumina HiSeq	2769747d-4ce8-4519-b01e-2cb2d9afd496	Colorectal	73	DDA1BA9D-36A4-45EA-A100-8B9B8204A3EF	129EA15A-A5D4-4971-BDA2-22700248990B	TCGA-AA-A02Y-10A-01D-A079-02	HG18	TCGA-AA-A02Y	TCGA-COAD	NA	s13535	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6ba83	58cfa830e4b0c9d6adf6ba83	TCGA-AA-3509-11A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3509-11A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3509-11A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	106.02	1.9	0.14	58cfa830e4b0c9d6adf6ba83	TCGA-AA-3509-11A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3509-11A	80E677B1-5EBE-4069-A1A5-1538FFEE6642	Solid Tissue Normal	Illumina HiSeq	4b1f49df-c379-4fdf-8cca-aa65f0a35643	Colorectal	54	2B81FC5F-9198-4D3A-A969-30AFFFF7CF87	E6370F83-5CBA-409A-8EF1-4A5AC69D95BF	TCGA-AA-3509-11A-01D-1405-02	HG18	TCGA-AA-3509	TCGA-COAD	NA	s13661	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bb0a	58cfa830e4b0c9d6adf6bb0a	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.bam	55.64	2.08	0.15	58cfa830e4b0c9d6adf6bb0a	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R6-01A	39609D3C-F5D3-4BC4-B356-1403C6DD1CB5	Primary Tumor	Illumina HiSeq	7485f99f-a7fe-456f-873d-eb1be9fa04b1	Uterus	64	836BD487-091B-4728-BCD7-8065E5B76465	FBE6A365-A19A-42F1-9198-63549F77CD9B	TCGA-A5-A0R6-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R6	TCGA-UCEC	NA	s4991	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6baf6	58cfa830e4b0c9d6adf6baf6	TCGA-49-6767-11A-01D-1853_120205_SN590_0136_BD0LRYACXX_s_8_rg.sorted.filtered.	WGS	TCGA-49-6767-11A-01D-1853_120205_SN590_0136_BD0LRYACXX_s_8_rg.sorted	TCGA-49-6767-11A-01D-1853_120205_SN590_0136_BD0LRYACXX_s_8_rg.sorted.bam	32.7	1.9	0.13	58cfa830e4b0c9d6adf6baf6	TCGA-49-6767-11A-01D-1853_120205_SN590_0136_BD0LRYACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-49-6767-11A	6BFFE800-EC2B-4638-9333-97FE85DCD91C	Solid Tissue Normal	Illumina HiSeq	a55991e3-e5fc-4ba4-b7e8-a98bfc625775	Lung	46	3C1E2C11-A721-4AF0-BA91-FD0D77A75E0C	A7E94D11-09B7-41BF-A21E-BC5C7DA0A972	TCGA-49-6767-11A-01D-1853-02	HG19_Broad_variant	TCGA-49-6767	TCGA-LUAD	NA	s11001	Harvard Medical School	Johns Hopkins	United States	NO	T3	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1853-02	TRUE
13722.58cfa830e4b0c9d6adf6ba7c	58cfa830e4b0c9d6adf6ba7c	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	496	1.9	0.14	58cfa830e4b0c9d6adf6ba7c	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3509-01A	80E677B1-5EBE-4069-A1A5-1538FFEE6642	Primary Tumor	Illumina HiSeq	41b8f6a5-58f8-4e97-bbd3-a2587a70e30d	Colorectal	54	BA6E3333-3651-450E-A6EA-4E47CF0D18BF	ACCC21A8-D026-40E4-AA2C-C0F998A1D370	TCGA-AA-3509-01A-01D-1405-02	HG18	TCGA-AA-3509	TCGA-COAD	NA	s13183	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bac2	58cfa830e4b0c9d6adf6bac2	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	133.2	1.9	0.14	58cfa830e4b0c9d6adf6bac2	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4501-01A	0780EB43-D5B5-4C3D-9825-BEACBA5CC723	Primary Tumor	Illumina HiSeq	2df919ad-215d-40a5-8e9d-e22862898cd7	Lung	67	FC511A67-5383-4877-AEEF-36C0B7934B77	FA521F2B-4BB1-4A15-9101-422B2B65489A	TCGA-49-4501-01A-01D-1203-02	GRCh37	TCGA-49-4501	TCGA-LUAD	1421	s11003	Harvard Medical School	Johns Hopkins	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1203-02	TRUE
13722.58cfa830e4b0c9d6adf6bb40	58cfa830e4b0c9d6adf6bb40	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	146.73	1.77	0.15	58cfa830e4b0c9d6adf6bb40	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02R-01A	764C97C9-01D3-45CB-86BD-F8A52B5468DA	Primary Tumor	Illumina HiSeq	5affe933-9b26-4971-81d9-e380618fbfa0	Colorectal	84	197245F6-A310-4AF4-9231-0AFEFC547ECD	A803F2CD-F90D-4E51-8D90-1E6AF6897413	TCGA-AA-A02R-01A-01D-A077-02	HG18	TCGA-AA-A02R	TCGA-COAD	670	s13204	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6bb48	58cfa830e4b0c9d6adf6bb48	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	84.8	1.91	0.16	58cfa830e4b0c9d6adf6bb48	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02Y-01A	A435FDF4-A89A-499E-9006-CBB5693EAB26	Primary Tumor	Illumina HiSeq	faa460a7-9c39-4da6-93c1-22d5d99742f0	Colorectal	73	8537633B-6426-4B66-A2A3-FA942EEDF01B	CD188DB1-ED81-42A6-B550-07D4008143EE	TCGA-AA-A02Y-01A-43D-A079-02	HG18	TCGA-AA-A02Y	TCGA-COAD	NA	s13195	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bb5a	58cfa830e4b0c9d6adf6bb5a	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	1010.56	1.9	0.17	58cfa830e4b0c9d6adf6bb5a	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3553-01A	D181C72B-843C-4B2D-B014-2A6DD1C3C1EC	Primary Tumor	Illumina HiSeq	b8e8f766-3a6f-4c2c-aeb0-ba7b926a3b99	Colorectal	61	B1DCD03C-3CDD-4C23-9391-C5ADEEBFF489	2159EE82-6427-4E1F-9C6F-28B48562DF0C	TCGA-AA-3553-01A-01D-1167-02	HG18	TCGA-AA-3553	TCGA-COAD	NA	s13362	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bb6e	58cfa830e4b0c9d6adf6bb6e	TCGA-AA-A02O-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A02O-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A02O-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	47.17	1.97	0.13	58cfa830e4b0c9d6adf6bb6e	TCGA-AA-A02O-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02O-11A	6FA41234-9077-4D05-A295-6820F3BEDF5B	Solid Tissue Normal	Illumina HiSeq	8fc33742-2fc4-4f40-8319-f7aa7d19f507	Colorectal	82	DD519F88-2D62-425B-9553-8BB374CD054B	7C1C19E2-1B4A-4D59-88CA-E111AA111165	TCGA-AA-A02O-11A-11D-A079-02	HG18	TCGA-AA-A02O	TCGA-COAD	NA	s13841	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bb78	58cfa830e4b0c9d6adf6bb78	TCGA-AA-A00U-10A-01D-A078_110429_SN590_0080_AC02UTABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AA-A00U-10A-01D-A078_110429_SN590_0080_AC02UTABXX_s_1.rg.sorted	TCGA-AA-A00U-10A-01D-A078_110429_SN590_0080_AC02UTABXX_s_1.rg.sorted.bam	49.5	1.73	0.15	58cfa830e4b0c9d6adf6bb78	TCGA-AA-A00U-10A-01D-A078_110429_SN590_0080_AC02UTABXX_s_1.rg.sorted.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00U-10A	091E3084-04EE-4497-893C-D46226DEC78F	Blood Derived Normal	Illumina HiSeq	40302890-3ffe-40e0-870d-debebe9c5015	Colorectal	50	4F0B6C3E-065D-4C16-93ED-26BFFFB2A79A	E063BC1B-1347-4301-A09D-0FCCC244DB7A	TCGA-AA-A00U-10A-01D-A078-02	HG18_Broad_variant	TCGA-AA-A00U	TCGA-COAD	NA	s13196	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bba5	58cfa830e4b0c9d6adf6bba5	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted.filtered.	WGS	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted.bam	226.38	1.78	0.15	58cfa830e4b0c9d6adf6bba5	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02W-01A	73448B56-A6C6-4C98-A153-AB704261E073	Primary Tumor	Illumina HiSeq	faf93a8d-56fb-4e28-97fa-1fcee234250c	Colorectal	73	B0F0EA02-B1DA-4613-A9B0-D18A07910010	4D2B2573-105C-4770-B8CF-9243B6D709EC	TCGA-AA-A02W-01A-01D-A077-02	HG18_Broad_variant	TCGA-AA-A02W	TCGA-COAD	NA	s13532	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6bb5c	58cfa830e4b0c9d6adf6bb5c	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	570.96	1.9	0.14	58cfa830e4b0c9d6adf6bb5c	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3675-01A	41658CF8-0DE1-4A97-BB60-0F0107C84E00	Primary Tumor	Illumina HiSeq	971987d4-bd49-45d8-949e-4c2108a7cbc7	Colorectal	84	A4CE3727-4506-493B-95F4-2F11CEB09CEB	42AD4E5A-8E58-47EC-9D1F-F65D5C22DA49	TCGA-AA-3675-01A-02D-1167-02	HG18	TCGA-AA-3675	TCGA-COAD	NA	s13372	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bb70	58cfa830e4b0c9d6adf6bb70	TCGA-AA-3956-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3956-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3956-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	75.56	1.8	0.15	58cfa830e4b0c9d6adf6bb70	TCGA-AA-3956-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3956-10A	7B47489F-C3CC-4388-B5D7-C7C02790A5F6	Blood Derived Normal	Illumina HiSeq	10d20517-4670-47bf-b211-1c3989c3a7e0	Colorectal	65	5C8C7A7D-1677-43B6-9526-52EF9B17D11A	2182EAC8-282F-460D-821B-EAB404F6B01A	TCGA-AA-3956-10A-01D-1167-02	HG18	TCGA-AA-3956	TCGA-COAD	NA	s13676	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bbac	58cfa830e4b0c9d6adf6bbac	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	107.64	2.11	0.16	58cfa830e4b0c9d6adf6bbac	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02O-01A	6FA41234-9077-4D05-A295-6820F3BEDF5B	Primary Tumor	Illumina HiSeq	e53db54a-bb1b-4c60-8214-aaa269abd153	Colorectal	82	2151DC9E-F76A-4CFF-8A20-B7C107D59C27	519A6BBF-68D8-4275-854A-5216FC4DFD15	TCGA-AA-A02O-01A-21D-A079-02	HG18	TCGA-AA-A02O	TCGA-COAD	NA	s12873	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bbda	58cfa830e4b0c9d6adf6bbda	TCGA-AG-4005-10A-01D-1115_101122_SN177_0123_B20APUABXX_s_4_rg.sorted.filtered.	WGS	TCGA-AG-4005-10A-01D-1115_101122_SN177_0123_B20APUABXX_s_4_rg.sorted	TCGA-AG-4005-10A-01D-1115_101122_SN177_0123_B20APUABXX_s_4_rg.sorted.bam	44.59	1.9	0.13	58cfa830e4b0c9d6adf6bbda	TCGA-AG-4005-10A-01D-1115_101122_SN177_0123_B20APUABXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4005-10A	866DE12B-E4DF-4F19-B62E-E3FD85D4EC08	Blood Derived Normal	Illumina HiSeq	bdef1f23-55e4-48bd-ad1b-4463e64ebaea	Colorectal	64	0A308492-A312-4FE2-9C7A-BFA189C009A4	703F6CA3-4393-4199-86EE-B3FBFE1FD121	TCGA-AG-4005-10A-01D-1115-02	HG18_Broad_variant	TCGA-AG-4005	TCGA-READ	NA	s1996	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Rectal Adenocarcinoma	Stage IV	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bbc6	58cfa830e4b0c9d6adf6bbc6	TCGA-AG-A002-10A-01D-A078-02_110217_SN208_0190_B81CLKABXX_s_2.rg.sorted.filtered.	WGS	TCGA-AG-A002-10A-01D-A078-02_110217_SN208_0190_B81CLKABXX_s_2.rg.sorted	TCGA-AG-A002-10A-01D-A078-02_110217_SN208_0190_B81CLKABXX_s_2.rg.sorted.bam	17.06	1.74	0.14	58cfa830e4b0c9d6adf6bbc6	TCGA-AG-A002-10A-01D-A078-02_110217_SN208_0190_B81CLKABXX_s_2.rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A002-10A	CB005C69-7301-41CE-B534-C9751F1436C5	Blood Derived Normal	Illumina HiSeq	ab767da1-ed1c-4246-8d29-4d8f720c4f46	Colorectal	35	E2660CFD-8FEC-437F-8A0E-4869030DE46E	26E7A890-3DE3-486F-91AB-C76F14908F1C	TCGA-AG-A002-10A-01D-A078-02	HG18_Broad_variant	TCGA-AG-A002	TCGA-READ	NA	s1979	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bb88	58cfa830e4b0c9d6adf6bb88	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	282.86	1.9	0.14	58cfa830e4b0c9d6adf6bb88	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3956-01A	7B47489F-C3CC-4388-B5D7-C7C02790A5F6	Primary Tumor	Illumina HiSeq	edcd6fc2-ca83-409b-957a-ff0199cedf0d	Colorectal	65	DC1FFDA5-5B8F-4227-BE04-321643F73731	63EEF7A5-A1CC-4BB6-BA02-464D2DE89E2A	TCGA-AA-3956-01A-02D-1167-02	HG18	TCGA-AA-3956	TCGA-COAD	NA	s13519	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bbea	58cfa830e4b0c9d6adf6bbea	TCGA-AG-A008-10A-01D-A078-02_110217_SN208_0190_B81CLKABXX_s_8.rg.sorted.filtered.	WGS	TCGA-AG-A008-10A-01D-A078-02_110217_SN208_0190_B81CLKABXX_s_8.rg.sorted	TCGA-AG-A008-10A-01D-A078-02_110217_SN208_0190_B81CLKABXX_s_8.rg.sorted.bam	47.46	1.73	0.15	58cfa830e4b0c9d6adf6bbea	TCGA-AG-A008-10A-01D-A078-02_110217_SN208_0190_B81CLKABXX_s_8.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A008-10A	E7503A51-6647-4CC2-80DD-645D0DF4DB43	Blood Derived Normal	Illumina HiSeq	6a8b3387-94d5-401f-ba50-c00e0b2d1c7f	Colorectal	50	5CD9C79F-D0C1-48B0-85AA-5270C0E866B5	2CEB5DAF-1FA5-4163-82EF-8304514D8D9A	TCGA-AG-A008-10A-01D-A078-02	HG18_Broad_variant	TCGA-AG-A008	TCGA-READ	NA	s2311	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Mucinous Adenocarcinoma	Stage I	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bbf0	58cfa830e4b0c9d6adf6bbf0	TCGA-A6-3807-11A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3807-11A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3807-11A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	203.86	1.9	0.16	58cfa830e4b0c9d6adf6bbf0	TCGA-A6-3807-11A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3807-11A	5116E3B4-2BAC-40F5-8046-B9C1783FAAA5	Solid Tissue Normal	Illumina HiSeq	e14fd460-b6c8-44b8-81ad-b9ce224af5cb	Colorectal	53	6CC29D0A-19C3-4C7F-AD8D-BF10E1392E09	BADA9982-36A5-48B3-BE62-DFD0D8AC7FC8	TCGA-A6-3807-11A-01D-1167-02	HG18	TCGA-A6-3807	TCGA-COAD	NA	s13352	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bbfe	58cfa830e4b0c9d6adf6bbfe	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	463.6	1.9	0.15	58cfa830e4b0c9d6adf6bbfe	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2684-01A	49929108-023E-4D35-B26D-50AB4D3AE581	Primary Tumor	Illumina HiSeq	1d127721-dd08-4127-af3b-0dfd623ea7bf	Colorectal	75	73B6994E-C9BF-41A8-A455-17D7BE309A9F	5A35E547-72DB-4B4E-8459-1264D0845506	TCGA-A6-2684-01A-01D-1405-02	HG18	TCGA-A6-2684	TCGA-COAD	NA	s13174	Harvard Medical School	Christiana Healthcare	None	NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bbf6	58cfa830e4b0c9d6adf6bbf6	TCGA-AA-A01C-10A-01D-A078_110329_SN208_0198_B702NLABXX_s_6_rg.sorted.filtered.	WGS	TCGA-AA-A01C-10A-01D-A078_110329_SN208_0198_B702NLABXX_s_6_rg.sorted	TCGA-AA-A01C-10A-01D-A078_110329_SN208_0198_B702NLABXX_s_6_rg.sorted.bam	34.25	1.75	0.15	58cfa830e4b0c9d6adf6bbf6	TCGA-AA-A01C-10A-01D-A078_110329_SN208_0198_B702NLABXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01C-10A	80809D79-92E1-4D6C-BA2E-0A9589997792	Blood Derived Normal	Illumina HiSeq	5008c942-2f6d-42fb-bac0-f992c3f5f122	Colorectal	75	0D2F53A8-9261-4E57-A0CD-5CD5E6376743	8683DA63-3130-447E-89E9-3137D78E8475	TCGA-AA-A01C-10A-01D-A078-02	HG18_Broad_variant	TCGA-AA-A01C	TCGA-COAD	NA	s13533	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Colon Adenocarcinoma	Stage IIIA	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bc1a	58cfa830e4b0c9d6adf6bc1a	TCGA-AG-A01W-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A01W-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A01W-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	55.89	1.98	0.16	58cfa830e4b0c9d6adf6bc1a	TCGA-AG-A01W-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01W-11A	74543FA4-CE73-46E4-9C59-224E8242B4A2	Solid Tissue Normal	Illumina HiSeq	8e0654a7-ab7a-42c0-ba12-438dee1fd119	Colorectal	67	C913E113-9731-488A-AC17-652F5A52F771	7897A8D4-72BE-4C87-BADE-523FCDBBEFBD	TCGA-AG-A01W-11A-11D-A079-02	HG18	TCGA-AG-A01W	TCGA-READ	NA	s2004	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bc1e	58cfa830e4b0c9d6adf6bc1e	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	100.13	2.07	0.17	58cfa830e4b0c9d6adf6bc1e	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01Y-01A	A91F7A8C-E0FE-403A-9EF0-F7679B2761CC	Primary Tumor	Illumina HiSeq	9b6deb45-fcab-4b6f-8c5d-225444c42154	Colorectal	49	28B76ABF-6A5F-4D3B-87FE-18EA7139DEDF	D295156A-3A31-4540-B295-0B620340E4DB	TCGA-AG-A01Y-01A-41D-A079-02	HG18	TCGA-AG-A01Y	TCGA-READ	NA	s2172	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bc16	58cfa830e4b0c9d6adf6bc16	TCGA-AA-3516-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3516-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3516-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	88.56	1.9	0.15	58cfa830e4b0c9d6adf6bc16	TCGA-AA-3516-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3516-10A	D9D7F0D4-FA64-48F2-8037-52CBF0B34AD8	Blood Derived Normal	Illumina HiSeq	7b47a89f-cadb-4126-be00-ec268b11a135	Colorectal	74	E0942099-D2A8-4110-99C4-9B968B88C09D	28C399FE-B886-4FBA-976F-F0B03A795CA7	TCGA-AA-3516-10A-01D-1167-02	HG18	TCGA-AA-3516	TCGA-COAD	NA	s13660	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bc2a	58cfa830e4b0c9d6adf6bc2a	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	631.89	1.9	0.16	58cfa830e4b0c9d6adf6bc2a	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3994-01A	750770DB-53CF-4021-A8C2-5E0DDB97FEF5	Primary Tumor	Illumina HiSeq	dadc0f63-410b-4eb6-b287-c05bbc274608	Colorectal	69	41933A62-1325-4089-80B5-06E3EBB238DA	FED1DBB6-D332-4239-A878-8587A7CE4D05	TCGA-AA-3994-01A-01D-1109-02	HG18	TCGA-AA-3994	TCGA-COAD	NA	s13518	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Mucinous Adenocarcinoma	Stage IIIB	1109-02	TRUE
13722.58cfa830e4b0c9d6adf6bb52	58cfa830e4b0c9d6adf6bb52	TCGA-AA-3685-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3685-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3685-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	110.96	1.9	0.15	58cfa830e4b0c9d6adf6bb52	TCGA-AA-3685-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3685-10A	DCA004BF-9C14-45A1-B186-AB3759F6C7FE	Blood Derived Normal	Illumina HiSeq	559d0dc8-235b-43f5-8ee5-0af39884be50	Colorectal	69	EAB2CE78-F983-46D1-BCA1-643049B73934	4AE07847-2759-47E7-B5FE-687C851365EA	TCGA-AA-3685-10A-01D-1167-02	HG18	TCGA-AA-3685	TCGA-COAD	NA	s13675	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bc38	58cfa830e4b0c9d6adf6bc38	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	91.92	1.64	0.15	58cfa830e4b0c9d6adf6bc38	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01C-01A	80809D79-92E1-4D6C-BA2E-0A9589997792	Primary Tumor	Illumina HiSeq	a7b8c819-1f82-43d2-93aa-5c85e2710e7e	Colorectal	75	1E191EED-2238-450E-A384-26DF9C569FD0	77F9EF43-7202-4C9B-9556-F00F0A66D2D4	TCGA-AA-A01C-01A-01D-A077-02	HG18	TCGA-AA-A01C	TCGA-COAD	NA	s13199	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Colon Adenocarcinoma	Stage IIIA	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6bc3c	58cfa830e4b0c9d6adf6bc3c	TCGA-AG-A01Y-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A01Y-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A01Y-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	78.77	2.06	0.14	58cfa830e4b0c9d6adf6bc3c	TCGA-AG-A01Y-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01Y-11A	A91F7A8C-E0FE-403A-9EF0-F7679B2761CC	Solid Tissue Normal	Illumina HiSeq	10fb3294-ad7e-403d-a856-0932f5e15052	Colorectal	49	9E602612-9215-46E5-8058-6FA8FCE6B739	B70F17F6-457E-4FF0-8E50-2A1573BC5EB9	TCGA-AG-A01Y-11A-11D-A079-02	HG18	TCGA-AG-A01Y	TCGA-READ	NA	s2008	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bc42	58cfa830e4b0c9d6adf6bc42	TCGA-AA-3553-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3553-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3553-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	20.56	1.9	0.14	58cfa830e4b0c9d6adf6bc42	TCGA-AA-3553-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3553-10A	D181C72B-843C-4B2D-B014-2A6DD1C3C1EC	Blood Derived Normal	Illumina HiSeq	6795b83b-1ca7-4060-a078-6649fa9004bb	Colorectal	61	FE42F5D3-CFBB-478F-BB34-6518206A8718	B7B44E75-51E9-4F51-9523-B54C92828A01	TCGA-AA-3553-10A-01D-1167-02	HG18	TCGA-AA-3553	TCGA-COAD	NA	s13023	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bc26	58cfa830e4b0c9d6adf6bc26	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	420.6	1.9	0.16	58cfa830e4b0c9d6adf6bc26	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3810-01A	B728E6E8-A0E4-496B-904C-6F07C12E901F	Primary Tumor	Illumina HiSeq	54687a8d-c693-4ae5-8451-4f4c80adca53	Colorectal	62	F2BD44D3-A53C-4A10-9AE1-A93E762F174C	AD4275F1-789D-471C-88DD-B6E76069D856	TCGA-A6-3810-01A-01D-1167-02	HG18	TCGA-A6-3810	TCGA-COAD	NA	s13016	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bc54	58cfa830e4b0c9d6adf6bc54	TCGA-AG-3582-10A-01D-1167_101105_SN208_0168_A80A3BABXX_s_2_rg.sorted.filtered.	WGS	TCGA-AG-3582-10A-01D-1167_101105_SN208_0168_A80A3BABXX_s_2_rg.sorted	TCGA-AG-3582-10A-01D-1167_101105_SN208_0168_A80A3BABXX_s_2_rg.sorted.bam	20	1.9	0.17	58cfa830e4b0c9d6adf6bc54	TCGA-AG-3582-10A-01D-1167_101105_SN208_0168_A80A3BABXX_s_2_rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3582-10A	DB1E3104-8BFD-4353-854A-C478BA1F7D07	Blood Derived Normal	Illumina HiSeq	f5b3fbbc-73ee-4343-9f0d-d1ed07587650	Colorectal	75	E948F2D0-E1BF-46FA-A0E0-A733036D3DA3	1D663F25-1724-47FF-9D68-6842EF17F51A	TCGA-AG-3582-10A-01D-1167-02	HG18_Broad_variant	TCGA-AG-3582	TCGA-READ	NA	s1961	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IV	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bc68	58cfa830e4b0c9d6adf6bc68	TCGA-AG-A01L-10A-01D-A078_110406_SN177_0154_B818URABXX_s_2_rg.sorted.filtered.	WGS	TCGA-AG-A01L-10A-01D-A078_110406_SN177_0154_B818URABXX_s_2_rg.sorted	TCGA-AG-A01L-10A-01D-A078_110406_SN177_0154_B818URABXX_s_2_rg.sorted.bam	22.13	1.73	0.15	58cfa830e4b0c9d6adf6bc68	TCGA-AG-A01L-10A-01D-A078_110406_SN177_0154_B818URABXX_s_2_rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01L-10A	848A5838-8A06-45A9-A3D6-E4ED47B824AB	Blood Derived Normal	Illumina HiSeq	8d5db315-7d34-49ae-915e-152128dc9162	Colorectal	58	7F43C713-73CA-4971-A247-E7E2022C2A6B	B4B64FC1-C309-48D2-8B1D-E0F7AA1ED9A4	TCGA-AG-A01L-10A-01D-A078-02	HG18_Broad_variant	TCGA-AG-A01L	TCGA-READ	NA	s2006	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bc7e	58cfa830e4b0c9d6adf6bc7e	TCGA-AG-A020-11A-11D-A079-02_110409_SN590_0077_BB04EHABXX_s_2.rg.sorted.filtered.	WGS	TCGA-AG-A020-11A-11D-A079-02_110409_SN590_0077_BB04EHABXX_s_2.rg.sorted	TCGA-AG-A020-11A-11D-A079-02_110409_SN590_0077_BB04EHABXX_s_2.rg.sorted.bam	58.34	2.2	0.13	58cfa830e4b0c9d6adf6bc7e	TCGA-AG-A020-11A-11D-A079-02_110409_SN590_0077_BB04EHABXX_s_2.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A020-11A	19E46A3D-18C5-4927-8501-2265E2D617B8	Solid Tissue Normal	Illumina HiSeq	48f20c48-bd37-4231-9bac-8b276e4a31ea	Colorectal	57	1268F79E-4F75-4363-AFD9-342DD40BACA8	18047D41-47EA-4CC0-9918-19D33D182298	TCGA-AG-A020-11A-11D-A079-02	HG18_Broad_variant	TCGA-AG-A020	TCGA-READ	NA	s2176	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Mucinous Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bc6e	58cfa830e4b0c9d6adf6bc6e	TCGA-AF-3913-11A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AF-3913-11A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AF-3913-11A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	448.89	1.9	0.15	58cfa830e4b0c9d6adf6bc6e	TCGA-AF-3913-11A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-3913-11A	03A9DD9D-62AE-4ACD-9272-389274858F3D	Solid Tissue Normal	Illumina HiSeq	af7c14b7-a3d9-4dba-99b0-753ad2c7d90d	Colorectal	60	4A702DED-02FC-40BA-A4F8-A9C4FE7007F9	A5CC1277-D1B0-4662-97FC-84A21AD24CFF	TCGA-AF-3913-11A-01D-1115-02	HG18	TCGA-AF-3913	TCGA-READ	316	s2310	Harvard Medical School	Christiana Healthcare	None	NO	T3	N1	Rectal Adenocarcinoma	Stage IV	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bcae	58cfa830e4b0c9d6adf6bcae	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	449.02	1.9	0.16	58cfa830e4b0c9d6adf6bcae	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4614-01A	3334201D-A3C0-45EC-A9ED-CF48CC8C38E8	Primary Tumor	Illumina HiSeq	50679ea1-6443-43b4-ab23-0f7542f4cb98	Colorectal	71	0C4DAF52-CC9F-4099-8825-33C484CED5B1	29DA0D99-6FD9-4CC0-84BE-E1670FC253E7	TCGA-AZ-4614-01A-01D-1405-02	HG18	TCGA-AZ-4614	TCGA-COAD	172	s12888	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N1	Colon Adenocarcinoma	Stage IVA	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bc22	58cfa830e4b0c9d6adf6bc22	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted.filtered.	WGS	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted.bam	489.31	1.9	0.15	58cfa830e4b0c9d6adf6bc22	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3727-01A	E6827400-0D95-46B0-8874-6CE9E9D5011B	Primary Tumor	Illumina HiSeq	c29d4836-8104-479e-98ce-a8c435a242d7	Colorectal	78	DA1CA84F-6C55-4536-9449-3C87E51EF85A	D8361FC2-8AB1-4D36-9009-237D905CF899	TCGA-AG-3727-01A-01D-1167-02	HG18_Broad_variant	TCGA-AG-3727	TCGA-READ	NA	s2141	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage III	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bcc4	58cfa830e4b0c9d6adf6bcc4	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	397.02	1.9	0.15	58cfa830e4b0c9d6adf6bcc4	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4313-01A	1FD75C4D-E74C-410C-A150-814722C6C1CC	Primary Tumor	Illumina HiSeq	b8e9093c-1570-45c6-8278-f686c276ee91	Colorectal	51	475F161C-2F7F-43A2-B187-DE6038752F39	F64D4985-D460-435C-8EC0-477D313A895A	TCGA-AZ-4313-01A-01D-1405-02	HG18	TCGA-AZ-4313	TCGA-COAD	NA	s13212	Harvard Medical School	University of Pittsburgh	None	NO	T1	N0	Colon Adenocarcinoma	Stage I	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bcb0	58cfa830e4b0c9d6adf6bcb0	TCGA-AZ-4614-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4614-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4614-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	494.72	1.9	0.14	58cfa830e4b0c9d6adf6bcb0	TCGA-AZ-4614-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4614-10A	3334201D-A3C0-45EC-A9ED-CF48CC8C38E8	Blood Derived Normal	Illumina HiSeq	d265532f-fb66-4ede-9987-db7efa4fb8bb	Colorectal	71	202EF751-89B7-4F0A-B67A-75E08342335D	44D70E0C-69C3-405A-946D-5A48D45D5429	TCGA-AZ-4614-10A-01D-1405-02	HG18	TCGA-AZ-4614	TCGA-COAD	172	s13213	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N1	Colon Adenocarcinoma	Stage IVA	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bd5d	58cfa830e4b0c9d6adf6bd5d	TCGA-AA-3516-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3516-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3516-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	47.29	1.9	0.13	58cfa830e4b0c9d6adf6bd5d	TCGA-AA-3516-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3516-01A	D9D7F0D4-FA64-48F2-8037-52CBF0B34AD8	Primary Tumor	Illumina HiSeq	99b382c5-00ca-4acd-81bc-0c46b9c7ccea	Colorectal	74	4E4F7BEC-56AF-4888-B40B-A33218B010E8	3F9A934E-C9BE-4A5F-A1F5-EB51BED8DCDD	TCGA-AA-3516-01A-02D-1167-02	HG18	TCGA-AA-3516	TCGA-COAD	NA	s13181	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bcda	58cfa830e4b0c9d6adf6bcda	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	750.21	1.9	0.14	58cfa830e4b0c9d6adf6bcda	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3574-01A	0EDA7373-8335-455F-B90A-8C3540F28088	Primary Tumor	Illumina HiSeq	44e4b931-5188-44b9-aea5-fdff70c4c058	Colorectal	89	DA897A5D-B2CC-419F-ACD7-473B4928C5D5	5DAA6B90-B302-4B0E-A44B-0A6D3159DACE	TCGA-AG-3574-01A-01D-1167-02	HG18	TCGA-AG-3574	TCGA-READ	NA	s1955	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bdde	58cfa830e4b0c9d6adf6bdde	TCGA-AG-A01N-10A-01D-A078_110406_SN177_0154_B818URABXX_s_4.rg.sorted.filtered.	WGS	TCGA-AG-A01N-10A-01D-A078_110406_SN177_0154_B818URABXX_s_4.rg.sorted	TCGA-AG-A01N-10A-01D-A078_110406_SN177_0154_B818URABXX_s_4.rg.sorted.bam	20.24	1.77	0.15	58cfa830e4b0c9d6adf6bdde	TCGA-AG-A01N-10A-01D-A078_110406_SN177_0154_B818URABXX_s_4.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01N-10A	1118490D-75AA-43CC-B2A2-C2AF61829FFC	Blood Derived Normal	Illumina HiSeq	3aceb122-1e5e-4a17-b935-f21972323dbe	Colorectal	68	64D63876-3188-4D41-877F-BBA0E771AB03	D585FD9D-B88A-44F3-9672-2E0C067C78BF	TCGA-AG-A01N-10A-01D-A078-02	HG18_Broad_variant	TCGA-AG-A01N	TCGA-READ	NA	s2005	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage IV	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bde2	58cfa830e4b0c9d6adf6bde2	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted.filtered.	WGS	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted.bam	237.59	1.78	0.15	58cfa830e4b0c9d6adf6bde2	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01N-01A	1118490D-75AA-43CC-B2A2-C2AF61829FFC	Primary Tumor	Illumina HiSeq	1e5467f7-e974-4244-b9fb-2afff5ed40b4	Colorectal	68	0350E0DE-7B86-485A-A057-50E77D899ED9	49977602-A81B-4DDD-9354-8949BC3208CF	TCGA-AG-A01N-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A01N	TCGA-READ	NA	s2007	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage IV	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6bcc8	58cfa830e4b0c9d6adf6bcc8	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted.filtered.	WGS	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted.bam	747.21	1.9	0.15	58cfa830e4b0c9d6adf6bcc8	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3582-01A	DB1E3104-8BFD-4353-854A-C478BA1F7D07	Primary Tumor	Illumina HiSeq	85a5fdbc-5a9a-4ddf-aac9-84a213ee17fd	Colorectal	75	1B1EF856-EA45-4857-8B4B-C4330FA930D8	CA0DD61C-D4F2-4ED9-91EF-11F7B1BE15AF	TCGA-AG-3582-01A-01D-1167-02	HG18_Broad_variant	TCGA-AG-3582	TCGA-READ	NA	s1973	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IV	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bdf5	58cfa830e4b0c9d6adf6bdf5	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	140.75	2	0.15	58cfa830e4b0c9d6adf6bdf5	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01W-01A	74543FA4-CE73-46E4-9C59-224E8242B4A2	Primary Tumor	Illumina HiSeq	66ffc729-68c6-4bd6-b4d2-e68e3989e252	Colorectal	67	C481ABBB-21EB-4393-AB8D-C27E3DA1B8F7	BC3C3340-5E36-4754-AF22-F08EF550BD07	TCGA-AG-A01W-01A-21D-A079-02	HG18	TCGA-AG-A01W	TCGA-READ	NA	s2171	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6be18	58cfa830e4b0c9d6adf6be18	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	361.02	1.9	0.15	58cfa830e4b0c9d6adf6be18	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4615-01A	BF69A4CE-EC7E-4752-A86D-DCC80E3C9A57	Primary Tumor	Illumina HiSeq	82dc215a-4234-4f8b-a4c0-50c8103dda6e	Colorectal	84	89811300-8202-4A82-8353-5B2B2B2ECFD4	90D11094-F492-4B05-81AB-E637AEC8F953	TCGA-AZ-4615-01A-01D-1405-02	HG18	TCGA-AZ-4615	TCGA-COAD	NA	s13216	Harvard Medical School	University of Pittsburgh	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bd00	58cfa830e4b0c9d6adf6bd00	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	2	1.9	0.15	58cfa830e4b0c9d6adf6bd00	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2692-01A	71A32FCA-D48F-4EA3-8DF7-69F9DDA8FA91	Primary Tumor	Illumina HiSeq	f19d4bca-a876-4c65-a830-4d5f12eb5803	Colorectal	54	3CA7589A-E887-4DA2-8D59-19FE5963AC21	CC1B3C2A-43B7-43CB-85F8-383A3C255D4B	TCGA-AF-2692-01A-01D-1167-02	HG18	TCGA-AF-2692	TCGA-READ	NA	s1972	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Not available	Stage IIA	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6be8e	58cfa830e4b0c9d6adf6be8e	TCGA-AZ-4681-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4681-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4681-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	483.72	1.9	0.15	58cfa830e4b0c9d6adf6be8e	TCGA-AZ-4681-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4681-10A	6FBC2B46-6762-4778-AA7E-782162C5397C	Blood Derived Normal	Illumina HiSeq	dc4796f6-2368-48bd-b430-d1c8295cbd5e	Colorectal	79	CCCCF1C4-7B2D-465A-BF22-9EA9DC2B8545	E84FBE12-AD2B-469B-8883-65CBB46B7A0D	TCGA-AZ-4681-10A-01D-1405-02	HG18	TCGA-AZ-4681	TCGA-COAD	NA	s12889	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bde4	58cfa830e4b0c9d6adf6bde4	TCGA-AG-A032-10A-01D-A078-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A032-10A-01D-A078-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A032-10A-01D-A078-02_IlluminaHiSeq-DNASeq_whole.bam	17.49	1.84	0.15	58cfa830e4b0c9d6adf6bde4	TCGA-AG-A032-10A-01D-A078-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A032-10A	0BB786EE-07CF-4853-9B49-EC95CD14E282	Blood Derived Normal	Illumina HiSeq	8eaed029-ac09-41bb-bb2c-3ac4e7f86390	Colorectal	68	02E756EF-31BD-4E2F-AC81-2476368DBD96	549B9DFE-21E5-4A0B-BEE5-F8C71ADEACA2	TCGA-AG-A032-10A-01D-A078-02	HG18	TCGA-AG-A032	TCGA-READ	NA	s2177	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bea6	58cfa830e4b0c9d6adf6bea6	TCGA-AZ-4615-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4615-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4615-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	170.72	1.9	0.14	58cfa830e4b0c9d6adf6bea6	TCGA-AZ-4615-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4615-10A	BF69A4CE-EC7E-4752-A86D-DCC80E3C9A57	Blood Derived Normal	Illumina HiSeq	90608783-775c-48d4-a0e7-3b07c961c2e6	Colorectal	84	ADA35D85-5095-452A-B796-8684F1688500	7FE7E146-7FD2-4C9E-A64B-644543E97DE3	TCGA-AZ-4615-10A-01D-1405-02	HG18	TCGA-AZ-4615	TCGA-COAD	NA	s13035	Harvard Medical School	University of Pittsburgh	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6bed1	58cfa830e4b0c9d6adf6bed1	TCGA-AP-A0LT-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-AP-A0LT-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_2_rg.sorted	TCGA-AP-A0LT-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_2_rg.sorted.bam	31.35	1.97	0.15	58cfa830e4b0c9d6adf6bed1	TCGA-AP-A0LT-10A-01D-A043_120327_SN590_0149_AD0U12ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LT-10A	43714E9A-E9C4-4206-AF92-1D00D2A8AE35	Blood Derived Normal	Illumina HiSeq	9984e9fd-d5fa-4d3d-928b-43d15de26280	Uterus	57	52D5B5E2-55AA-4622-B266-0DC88D470B5C	C8CC7D82-73D0-4640-938E-773CDE42FF4E	TCGA-AP-A0LT-10A-01D-A043-02	HG19_Broad_variant	TCGA-AP-A0LT	TCGA-UCEC	NA	s4997	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bede	58cfa830e4b0c9d6adf6bede	TCGA-AA-A03F-11A-12D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A03F-11A-12D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A03F-11A-12D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	80.18	1.92	0.14	58cfa830e4b0c9d6adf6bede	TCGA-AA-A03F-11A-12D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A03F-11A	2A971E32-B0E7-4A3F-8C40-62D69C0307D8	Solid Tissue Normal	Illumina HiSeq	8bc5ee97-80b0-460b-a611-d26490800e55	Colorectal	90	3CED81F6-87AB-49F3-9C9C-0E2A7DA86182	C3ACEE2B-AA06-4400-A29E-9C244DD6EDA8	TCGA-AA-A03F-11A-12D-A079-02	HG18	TCGA-AA-A03F	TCGA-COAD	549	s13385	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bea4	58cfa830e4b0c9d6adf6bea4	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	722.89	1.9	0.15	58cfa830e4b0c9d6adf6bea4	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3898-01A	5A7D19F9-6BE2-45AC-9FFC-11E28594EEEE	Primary Tumor	Illumina HiSeq	846bcf47-2650-4479-be12-96589e587f3a	Colorectal	61	C782D6BF-AA57-4184-8276-E08D6B64E6B2	AA49029D-0F51-4836-BD7B-74CC0C2F9576	TCGA-AG-3898-01A-01D-1115-02	HG18	TCGA-AG-3898	TCGA-READ	NA	s2314	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6beb1	58cfa830e4b0c9d6adf6beb1	TCGA-AG-3890-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3890-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3890-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	8.59	1.9	0.17	58cfa830e4b0c9d6adf6beb1	TCGA-AG-3890-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3890-10A	E2D395F8-BF13-4FE4-8031-683B0EEDD875	Blood Derived Normal	Illumina HiSeq	4dc195af-fda9-4230-ab6a-998f1e36540b	Colorectal	62	C5DC7F19-74F0-4053-A405-42EF3E6049B4	B0DA3675-FA73-4BC9-9E24-63A31968FDCB	TCGA-AG-3890-10A-01D-1115-02	HG18	TCGA-AG-3890	TCGA-READ	NA	s1971	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bf36	58cfa830e4b0c9d6adf6bf36	TCGA-AY-4070-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AY-4070-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AY-4070-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	18.29	1.9	0.16	58cfa830e4b0c9d6adf6bf36	TCGA-AY-4070-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AY-4070-10A	6BAF61B6-AE5B-42F0-ADC9-0D26FDA231F7	Blood Derived Normal	Illumina HiSeq	b2605015-9592-44b0-b1e7-23aa852eff26	Colorectal	50	0D65E88C-0275-4A7D-A116-470897A07F13	46D73EBC-5D30-4452-9EE2-CD16E22B4140	TCGA-AY-4070-10A-01D-1109-02	HG18	TCGA-AY-4070	TCGA-COAD	496	s13844	Harvard Medical School	UNC	None	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1109-02	TRUE
13722.58cfa830e4b0c9d6adf6bf42	58cfa830e4b0c9d6adf6bf42	TCGA-AY-4071-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AY-4071-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AY-4071-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	79.29	1.9	0.14	58cfa830e4b0c9d6adf6bf42	TCGA-AY-4071-10A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AY-4071-10A	315EF7F6-CA21-4D87-8F19-40BD455885EC	Blood Derived Normal	Illumina HiSeq	31d451c9-cf15-4db5-beb0-ed60aa728435	Colorectal	63	FADCFBCB-EB8C-464A-ABDE-C349EFDC2583	B208E815-84DF-439C-8187-CC8994DB7FBF	TCGA-AY-4071-10A-01D-1109-02	HG18	TCGA-AY-4071	TCGA-COAD	29	s13210	Harvard Medical School	UNC	None	NO	T1	N0	Not available	Stage I	1109-02	TRUE
13722.58cfa830e4b0c9d6adf6bf97	58cfa830e4b0c9d6adf6bf97	TCGA-B5-A0JY-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-B5-A0JY-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_5_rg.sorted	TCGA-B5-A0JY-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_5_rg.sorted.bam	7.92	1.89	0.13	58cfa830e4b0c9d6adf6bf97	TCGA-B5-A0JY-10A-01D-A101_120406_SN208_0282_BC0L15ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JY-10A	61935424-44D0-4211-81C1-C925E436EAC5	Blood Derived Normal	Illumina HiSeq	f9b617a6-9bb1-4794-9174-1ee1aa7d653a	Uterus	50	F3FF3E83-7B73-4243-BDAC-837D6AB60BF7	F8D2C20A-39DF-448D-8532-5299988AEB97	TCGA-B5-A0JY-10A-01D-A101-02	HG19_Broad_variant	TCGA-B5-A0JY	TCGA-UCEC	NA	s5207	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bcf5	58cfa830e4b0c9d6adf6bcf5	TCGA-AF-2692-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AF-2692-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AF-2692-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	254.21	1.9	0.14	58cfa830e4b0c9d6adf6bcf5	TCGA-AF-2692-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2692-10A	71A32FCA-D48F-4EA3-8DF7-69F9DDA8FA91	Blood Derived Normal	Illumina HiSeq	41bfa67f-dcaa-4ae8-8c1d-99652cd97c9a	Colorectal	54	C80E7FB0-4536-404A-BE8B-21A2DAA61D47	D5B76166-4D9A-48AB-93C4-47E3524CD423	TCGA-AF-2692-10A-01D-1167-02	HG18	TCGA-AF-2692	TCGA-READ	NA	s1963	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Not available	Stage IIA	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6c05a	58cfa830e4b0c9d6adf6c05a	TCGA-AZ-4313-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4313-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4313-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	91.72	1.9	0.15	58cfa830e4b0c9d6adf6c05a	TCGA-AZ-4313-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4313-10A	1FD75C4D-E74C-410C-A150-814722C6C1CC	Blood Derived Normal	Illumina HiSeq	4ffaabe7-0883-46bc-82c8-dc80170cd61a	Colorectal	51	0C7A7506-169C-471D-8148-F81D48BA20A7	260C8250-6170-4932-9AD1-6DFFFD711ED0	TCGA-AZ-4313-10A-01D-1405-02	HG18	TCGA-AZ-4313	TCGA-COAD	NA	s13539	Harvard Medical School	University of Pittsburgh	None	NO	T1	N0	Colon Adenocarcinoma	Stage I	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6c02a	58cfa830e4b0c9d6adf6c02a	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.bam	112.67	1.79	0.14	58cfa830e4b0c9d6adf6c02a	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0IW-01A	DB21FCCF-40CB-4235-A34D-336A03B8C8F4	Primary Tumor	Illumina HiSeq	26dfa889-ba7c-4cc0-8adc-59d5eb4e4026	Uterus	67	874A1C5C-229B-4BCE-B612-55EFF238D533	CFB35E8C-470B-4F9E-B7C1-63FCAA162F3C	TCGA-AX-A0IW-01A-11D-A043-02	HG19_Broad_variant	TCGA-AX-A0IW	TCGA-UCEC	NA	s4422	Harvard Medical School	Gynecologic Oncology Group	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c11a	58cfa830e4b0c9d6adf6c11a	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted.bam	53.44	1.91	0.17	58cfa830e4b0c9d6adf6c11a	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted.bam	Dead	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TE-01A	09066FBF-6A1D-46C9-A4C5-C53340C3D1BA	Primary Tumor	Illumina HiSeq	a687b0ac-0eda-43c1-ab2f-cf8b3d6ffb94	Uterus	35	2D1226A1-1C88-422B-9A8D-316BEBEB65FD	250BF272-4CCD-41DB-ABD1-4FE2E304AB21	TCGA-BS-A0TE-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TE	TCGA-UCEC	146	s4607	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c147	58cfa830e4b0c9d6adf6c147	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted.bam	411	1.9	0.14	58cfa830e4b0c9d6adf6c147	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-B7-5818-01A	6E03B415-84A1-4B91-8717-1A41EDD4A255	Primary Tumor	Illumina HiSeq	e2875187-aeca-43f4-85d8-13ecd0452ec3	Stomach	62	FD97CDF5-0F7F-48A2-B5DA-5C5F56A89166	0EBF1A63-C6E4-49FE-B21B-AE46FF14261D	TCGA-B7-5818-01A-11D-1598-02	HG19_Broad_variant	TCGA-B7-5818	TCGA-STAD	NA	s15372	Harvard Medical School	Cureline	Russia	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1598-02	TRUE
13722.58cfa830e4b0c9d6adf6c124	58cfa830e4b0c9d6adf6c124	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted.bam	60.12	1.87	0.14	58cfa830e4b0c9d6adf6c124	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TC-01A	7B7D2D2B-ABE6-4F32-ADD0-3715096995D1	Primary Tumor	Illumina HiSeq	402004c3-b5d0-41ad-990c-203cbf02ec5d	Uterus	69	C4C99327-B778-4E29-A111-75569AD38696	99E19D8C-EC6E-45D7-89E5-091D101BF466	TCGA-BS-A0TC-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TC	TCGA-UCEC	NA	s5015	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c170	58cfa830e4b0c9d6adf6c170	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted.bam	31.82	1.93	0.16	58cfa830e4b0c9d6adf6c170	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TG-01A	13F31BCB-BEFD-4ED2-ADC0-DC9E9CE52B75	Primary Tumor	Illumina HiSeq	bbb0de46-a395-47cf-938b-3a6a6c59b9ec	Uterus	60	36E44603-A1EE-4A5B-9506-49A9358BF8D0	FABEC5F4-2EF2-41CB-A728-E21D6C49F3F7	TCGA-BS-A0TG-01A-32D-A101-02	HG19_Broad_variant	TCGA-BS-A0TG	TCGA-UCEC	NA	s4795	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c070	58cfa830e4b0c9d6adf6c070	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	458.59	1.9	0.13	58cfa830e4b0c9d6adf6c070	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AY-4070-01A	6BAF61B6-AE5B-42F0-ADC9-0D26FDA231F7	Primary Tumor	Illumina HiSeq	c0679a4e-afc6-4b64-80a5-35bf5e446cb1	Colorectal	50	C35CB7B2-7A85-4320-89AC-3A395EF8C1BE	B9EFEB1A-FA1D-4917-8FC5-149ECAF26989	TCGA-AY-4070-01A-01D-1109-02	HG18	TCGA-AY-4070	TCGA-COAD	496	s13388	Harvard Medical School	UNC	None	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1109-02	TRUE
13722.58cfa830e4b0c9d6adf6c172	58cfa830e4b0c9d6adf6c172	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted.bam	86.95	1.93	0.17	58cfa830e4b0c9d6adf6c172	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0U7-01A	282DDC43-922D-4F1F-80C7-6BA2DE23B7BC	Primary Tumor	Illumina HiSeq	1d76b3a6-ff5e-4092-b273-cc2380e0810c	Uterus	63	803C6D51-0EBA-475A-9C3C-7B3401787907	652088F1-AB84-40C7-8B24-FD92A32DFA44	TCGA-BS-A0U7-01A-21D-A101-02	HG19_Broad_variant	TCGA-BS-A0U7	TCGA-UCEC	935	s4436	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c1a1	58cfa830e4b0c9d6adf6c1a1	TCGA-B7-5816-01A-21D-1598_121025_SN590_0187_BC191FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-B7-5816-01A-21D-1598_121025_SN590_0187_BC191FACXX_s_1_rg.sorted	TCGA-B7-5816-01A-21D-1598_121025_SN590_0187_BC191FACXX_s_1_rg.sorted.bam	114	1.9	0.15	58cfa830e4b0c9d6adf6c1a1	TCGA-B7-5816-01A-21D-1598_121025_SN590_0187_BC191FACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-B7-5816-01A	F07070C0-FD0A-4C19-BA1E-5F06B933CD7C	Primary Tumor	Illumina HiSeq	b9711ffa-01b8-4434-ac32-445717298e6c	Stomach	51	1B4B19C1-75A6-4434-831E-ADCE44C54EB5	52F84358-E1B4-4837-8C3D-9B4E8DDB4FAB	TCGA-B7-5816-01A-21D-1598-02	HG19_Broad_variant	TCGA-B7-5816	TCGA-STAD	NA	s14607	Harvard Medical School	Cureline	Russia	NO	T4a	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IIB	1598-02	TRUE
13722.58cfa830e4b0c9d6adf6c1bc	58cfa830e4b0c9d6adf6c1bc	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted.filtered.	WGS	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted.bam	251.75	1.72	0.15	58cfa830e4b0c9d6adf6c1bc	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01L-01A	848A5838-8A06-45A9-A3D6-E4ED47B824AB	Primary Tumor	Illumina HiSeq	f1b7cb66-3e14-4411-b17a-0ad856d8c686	Colorectal	58	B034C90B-D0BD-466A-88BA-B61EFD36C6E4	337F94D6-ECFB-4653-A63C-49F0D1893BF0	TCGA-AG-A01L-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A01L	TCGA-READ	NA	s2002	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	A077-02	TRUE
13722.58cfa830e4b0c9d6adf6c204	58cfa830e4b0c9d6adf6c204	TCGA-BG-A0M8-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0M8-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_6_rg.sorted	TCGA-BG-A0M8-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_6_rg.sorted.bam	11.34	2	0.14	58cfa830e4b0c9d6adf6c204	TCGA-BG-A0M8-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M8-10A	E055DB71-F3DA-43D3-A9B2-2F65DFB23D3E	Blood Derived Normal	Illumina HiSeq	59c03a66-dea6-47f6-a91b-d3d200938b26	Uterus	50	575EA3DD-0638-4CFE-9FC6-80D1C566D266	4B474E3A-F2D2-40E5-956C-316AD96A9840	TCGA-BG-A0M8-10A-01D-A101-02	HG19_Broad_variant	TCGA-BG-A0M8	TCGA-UCEC	NA	s4430	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c280	58cfa830e4b0c9d6adf6c280	TCGA-AZ-4682-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4682-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4682-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	332.72	1.9	0.14	58cfa830e4b0c9d6adf6c280	TCGA-AZ-4682-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4682-10A	E588714A-7753-4C3C-ABB6-EAF1AAB53AB3	Blood Derived Normal	Illumina HiSeq	06999186-ddf0-40ae-b4fb-80e9ffdac6d6	Colorectal	61	03CDE413-3796-4E16-8EF7-6FF0B8629F30	18D2197B-A289-4CD8-B545-FA3F29137DF4	TCGA-AZ-4682-10A-01D-1405-02	HG18	TCGA-AZ-4682	TCGA-COAD	680	s13214	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Colon Adenocarcinoma	Stage IVA	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6c1fe	58cfa830e4b0c9d6adf6c1fe	TCGA-AF-2689-10A-01D-1167_101023_SN208_0167_B80L4DABXX_s_4_rg.sorted.filtered.	WGS	TCGA-AF-2689-10A-01D-1167_101023_SN208_0167_B80L4DABXX_s_4_rg.sorted	TCGA-AF-2689-10A-01D-1167_101023_SN208_0167_B80L4DABXX_s_4_rg.sorted.bam	3.21	1.9	0.14	58cfa830e4b0c9d6adf6c1fe	TCGA-AF-2689-10A-01D-1167_101023_SN208_0167_B80L4DABXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2689-10A	335D0351-3740-4847-9FF4-BE2F078C70F7	Blood Derived Normal	Illumina HiSeq	86649ab3-345e-430f-9b1e-e734f487554a	Colorectal	41	DC4852E8-3E77-4D45-8E7E-F9B6EFFF01E4	6EFA7CE1-E770-4DD6-9E61-E52E87134298	TCGA-AF-2689-10A-01D-1167-02	HG18_Broad_variant	TCGA-AF-2689	TCGA-READ	NA	s1960	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Rectal Adenocarcinoma	Stage IV	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bffa	58cfa830e4b0c9d6adf6bffa	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	360.61	1.9	0.15	58cfa830e4b0c9d6adf6bffa	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3878-01A	FDEEFF8E-1328-42A4-ACA0-A03B97421F1E	Primary Tumor	Illumina HiSeq	df3192f9-1041-4ef9-80aa-2f3e263fa968	Colorectal	64	D2F28259-87A7-4BD8-84BC-832E551C1ACE	8F233F73-550A-4708-9C2C-BEA9347969F7	TCGA-AG-3878-01A-02D-1167-02	HG18	TCGA-AG-3878	TCGA-READ	NA	s2127	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa831e4b0c9d6adf6c3ae	58cfa831e4b0c9d6adf6c3ae	TCGA-B6-A0X4-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_8_rg.sorted.filtered.	WGS	TCGA-B6-A0X4-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_8_rg.sorted	TCGA-B6-A0X4-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_8_rg.sorted.bam	56.99	1.97	0.14	58cfa831e4b0c9d6adf6c3ae	TCGA-B6-A0X4-10A-01D-A106_130719_SN1120_0270_AC2CVRACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0X4-10A	4E42FDC5-2A8B-49E9-87EF-6DB7A6692D08	Blood Derived Normal	Illumina HiSeq	b1fb31e5-69fe-4970-b9ab-98311778aa34	Breast	62	C437468C-9912-4AFB-99E6-1C9C7B566857	AB0347C3-AE35-4484-88A5-E545B27F5691	TCGA-B6-A0X4-10A-01D-A106-02	HG19_Broad_variant	TCGA-B6-A0X4	TCGA-BRCA	860	s6123	Harvard Medical School	Duke	United States	NO	T2	N1b	Infiltrating Ductal Carcinoma	Stage IIB	A106-02	FALSE
13722.58cfa831e4b0c9d6adf6c3c8	58cfa831e4b0c9d6adf6c3c8	TCGA-CG-4477-10A-01D-1154_130815_VM001_0007_VMR0007CXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4477-10A-01D-1154_130815_VM001_0007_VMR0007CXX_s_3_rg.sorted	TCGA-CG-4477-10A-01D-1154_130815_VM001_0007_VMR0007CXX_s_3_rg.sorted.bam	67.9	1.9	0.16	58cfa831e4b0c9d6adf6c3c8	TCGA-CG-4477-10A-01D-1154_130815_VM001_0007_VMR0007CXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4477-10A	18D0AAE7-9694-4252-B8FE-16E62DADAB07	Blood Derived Normal	Illumina HiSeq	c4ccf0ac-fcca-40dd-8c41-080f1d7c3e3f	Stomach	58	02F3A2F6-914C-4201-AB90-A7F2830F5CBA	B851171C-FDED-4A21-8766-A0AFD1B147B2	TCGA-CG-4477-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4477	TCGA-STAD	NA	s15460	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6c28a	58cfa830e4b0c9d6adf6c28a	TCGA-AF-3913-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AF-3913-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AF-3913-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	452.29	1.8	0.16	58cfa830e4b0c9d6adf6c28a	TCGA-AF-3913-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-3913-01A	03A9DD9D-62AE-4ACD-9272-389274858F3D	Primary Tumor	Illumina HiSeq	6b7624bc-5e74-4fd2-9475-f916cbe9bc5f	Colorectal	60	B01C6CD1-68DA-437F-90E4-9A645E8F3470	44A5F915-BADF-4521-8102-1B353E302E80	TCGA-AF-3913-01A-02D-1115-02	HG18	TCGA-AF-3913	TCGA-READ	316	s2147	Harvard Medical School	Christiana Healthcare	None	NO	T3	N1	Rectal Adenocarcinoma	Stage IV	1115-02	TRUE
13722.58cfa831e4b0c9d6adf6c42a	58cfa831e4b0c9d6adf6c42a	TCGA-BT-A2LA-01A-11D-A18D_120912_SN1222_0148_AC188PACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A2LA-01A-11D-A18D_120912_SN1222_0148_AC188PACXX_s_3_rg.sorted	TCGA-BT-A2LA-01A-11D-A18D_120912_SN1222_0148_AC188PACXX_s_3_rg.sorted.bam	80.43	NA	0.15	58cfa831e4b0c9d6adf6c42a	TCGA-BT-A2LA-01A-11D-A18D_120912_SN1222_0148_AC188PACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LA-01A	797A71EE-372D-41E5-AEEE-5AB3C4661110	Primary Tumor	Illumina HiSeq	587f05f3-8e6a-4a97-b59b-29371f2f8b74	Bladder	54	6ED52558-8039-4658-A245-78A29968CE2F	D08FDC4F-83B0-4885-A8CF-45F72E5E6BD2	TCGA-BT-A2LA-01A-11D-A18D-02	HG19_Broad_variant	TCGA-BT-A2LA	TCGA-BLCA	NA	s2860	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A18D-02	TRUE
13722.58cfa831e4b0c9d6adf6c4a6	58cfa831e4b0c9d6adf6c4a6	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted.bam	59.26	1.9	0.16	58cfa831e4b0c9d6adf6c4a6	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZJ-01A	8877B479-B62A-4794-B71E-418DE96DFF23	Primary Tumor	Illumina HiSeq	649e17cb-1adf-40a9-a837-4980acc1a108	Thyroid	36	C6D64D80-C8AA-494A-8C0E-8640BEEBDFC9	D54FCA2A-0B8E-4A33-8B52-3FBF0E47D799	TCGA-BJ-A0ZJ-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZJ	TCGA-THCA	NA	s12629	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c292	58cfa830e4b0c9d6adf6c292	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	504.59	1.9	0.15	58cfa830e4b0c9d6adf6c292	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AY-4071-01A	315EF7F6-CA21-4D87-8F19-40BD455885EC	Primary Tumor	Illumina HiSeq	0335df8b-3dec-4304-95e5-47210ed06ba3	Colorectal	63	7D09112D-53F5-4B72-993A-337C55A0C902	8DE6361C-E9B5-45FF-A328-67B0DED836B9	TCGA-AY-4071-01A-01D-1109-02	HG18	TCGA-AY-4071	TCGA-COAD	29	s12887	Harvard Medical School	UNC	None	NO	T1	N0	Not available	Stage I	1109-02	TRUE
13722.58cfa831e4b0c9d6adf6c46a	58cfa831e4b0c9d6adf6c46a	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	806.02	1.9	0.13	58cfa831e4b0c9d6adf6c46a	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	ASIAN	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-CA-5256-01A	17633A60-E12B-4A7C-BD8A-C16341DDC606	Primary Tumor	Illumina HiSeq	21c81645-36f0-4e4a-8f23-b589998bcb76	Colorectal	54	D4D5DEB6-6CFB-4E25-9824-8F7DC8D5B451	A8F8AAD6-F8C5-4133-A651-454C047A19D0	TCGA-CA-5256-01A-01D-1405-02	HG18	TCGA-CA-5256	TCGA-COAD	NA	s13544	Harvard Medical School	ILSbio	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c46c	58cfa831e4b0c9d6adf6c46c	TCGA-CA-5256-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CA-5256-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CA-5256-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	178.72	1.9	0.15	58cfa831e4b0c9d6adf6c46c	TCGA-CA-5256-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	ASIAN	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-CA-5256-10A	17633A60-E12B-4A7C-BD8A-C16341DDC606	Blood Derived Normal	Illumina HiSeq	1adb4258-b5bf-4496-a9fa-8f7a1ce8b667	Colorectal	54	8603228A-5F83-4B2E-A57B-DD3133CDE96E	2B29D3EE-2BBD-43FB-8262-86CB5B0CF0FA	TCGA-CA-5256-10A-01D-1405-02	HG18	TCGA-CA-5256	TCGA-COAD	NA	s12890	Harvard Medical School	ILSbio	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c5ab	58cfa831e4b0c9d6adf6c5ab	TCGA-CG-4462-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4462-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_7_rg.sorted	TCGA-CG-4462-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_7_rg.sorted.bam	57.2	1.9	0.14	58cfa831e4b0c9d6adf6c5ab	TCGA-CG-4462-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_7_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4462-01A	E9EA3687-0DB3-47F3-8099-B4FC054397F1	Primary Tumor	Illumina HiSeq	bd5f9f37-7032-427b-a031-8789066620ac	Stomach	72	D4F28131-D917-449B-95DC-DC6BA2EEE81B	8CB261D0-2AF0-4D1B-895C-9D7F2404DBDC	TCGA-CG-4462-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4462	TCGA-STAD	0	s14700	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c538	58cfa831e4b0c9d6adf6c538	TCGA-CN-4730-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CN-4730-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_6_rg.sorted	TCGA-CN-4730-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_6_rg.sorted.bam	928.4	1.9	0.16	58cfa831e4b0c9d6adf6c538	TCGA-CN-4730-10A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4730-10A	35C1F2C6-771C-4533-82DF-F8E2EC7107D7	Blood Derived Normal	Illumina HiSeq	2fecd58a-13da-4b74-ae07-237756d10f5c	Head and Neck	62	3D7DC830-42C8-4746-AA06-C5A58E6AD510	D7DBCD9B-1AF6-41AE-8C6F-420E6041E346	TCGA-CN-4730-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4730	TCGA-HNSC	NA	s16174	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c512	58cfa831e4b0c9d6adf6c512	TCGA-CM-4744-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4744-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4744-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	114.72	1.9	0.13	58cfa831e4b0c9d6adf6c512	TCGA-CM-4744-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4744-10A	CC15469C-7BAD-4E86-9DA3-AE0C72E9D380	Blood Derived Normal	Illumina HiSeq	e3c7b057-8313-444c-ad60-7fedc6f305a7	Colorectal	69	76B67785-5572-4167-B089-D142BD5A5EA7	253D4412-8761-475D-B845-25C45F12576C	TCGA-CM-4744-10A-01D-1405-02	HG18	TCGA-CM-4744	TCGA-COAD	NA	s13395	Harvard Medical School	MSKCC	None	NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c51e	58cfa831e4b0c9d6adf6c51e	TCGA-CM-4746-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4746-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4746-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	87.72	1.9	0.15	58cfa831e4b0c9d6adf6c51e	TCGA-CM-4746-10A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4746-10A	C0B8C55C-B993-481D-AEEA-9EBFA64EE20E	Blood Derived Normal	Illumina HiSeq	454e7afb-d46f-4230-bbf3-ee5844e29cdc	Colorectal	61	3ED6A50C-8AC3-49DB-9DC1-C2F8C49D78A1	850C3F5C-2CB7-465D-9254-BAC172442BAA	TCGA-CM-4746-10A-01D-1405-02	HG18	TCGA-CM-4746	TCGA-COAD	NA	s13846	Harvard Medical School	MSKCC	None	NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c5ae	58cfa831e4b0c9d6adf6c5ae	TCGA-CG-4455-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-4455-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_5_rg.sorted	TCGA-CG-4455-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_5_rg.sorted.bam	62.2	1.9	0.14	58cfa831e4b0c9d6adf6c5ae	TCGA-CG-4455-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4455-01A	8A173D98-20A1-4C84-86C1-97818E1C665A	Primary Tumor	Illumina HiSeq	97e101b8-16a4-4357-b26f-0bd6d14f9d6e	Stomach	72	4622DF2E-9B9E-4B17-ADE3-A602B50B1288	AFA14A3A-5E6B-4CBE-B660-65AA53E9D10F	TCGA-CG-4455-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4455	TCGA-STAD	NA	s14979	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c524	58cfa831e4b0c9d6adf6c524	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	471	1.9	0.14	58cfa831e4b0c9d6adf6c524	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4744-01A	CC15469C-7BAD-4E86-9DA3-AE0C72E9D380	Primary Tumor	Illumina HiSeq	e1403b52-6792-4d08-acad-95659ceeca82	Colorectal	69	A545FB9A-C386-4A80-9A25-660DC4F62904	6D073A6F-FB7B-4ED2-BD24-5233E019D64A	TCGA-CM-4744-01A-01D-1405-02	HG18	TCGA-CM-4744	TCGA-COAD	NA	s13689	Harvard Medical School	MSKCC	None	NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	TRUE
13722.58cfa831e4b0c9d6adf6c5c2	58cfa831e4b0c9d6adf6c5c2	TCGA-CG-4462-01A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4462-01A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_7_rg.sorted	TCGA-CG-4462-01A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_7_rg.sorted.bam	57.2	1.9	0.14	58cfa831e4b0c9d6adf6c5c2	TCGA-CG-4462-01A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_7_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4462-01A	E9EA3687-0DB3-47F3-8099-B4FC054397F1	Primary Tumor	Illumina HiSeq	1bcd6b3d-eeca-4c1e-bf6f-52c0a6b151ca	Stomach	72	D4F28131-D917-449B-95DC-DC6BA2EEE81B	8CB261D0-2AF0-4D1B-895C-9D7F2404DBDC	TCGA-CG-4462-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4462	TCGA-STAD	0	s15124	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c64c	58cfa831e4b0c9d6adf6c64c	TCGA-CG-4455-01A-01D-1154_120913_SN208_0429_AC187FACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4455-01A-01D-1154_120913_SN208_0429_AC187FACXX_s_7_rg.sorted	TCGA-CG-4455-01A-01D-1154_120913_SN208_0429_AC187FACXX_s_7_rg.sorted.bam	62.2	1.9	0.14	58cfa831e4b0c9d6adf6c64c	TCGA-CG-4455-01A-01D-1154_120913_SN208_0429_AC187FACXX_s_7_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4455-01A	8A173D98-20A1-4C84-86C1-97818E1C665A	Primary Tumor	Illumina HiSeq	002ff9b2-954c-4a9c-9f81-b5919872e770	Stomach	72	4622DF2E-9B9E-4B17-ADE3-A602B50B1288	AFA14A3A-5E6B-4CBE-B660-65AA53E9D10F	TCGA-CG-4455-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4455	TCGA-STAD	NA	s14978	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c6cc	58cfa831e4b0c9d6adf6c6cc	TCGA-CS-4938-10A-01D-1891_130912_SN590_0237_AC292LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CS-4938-10A-01D-1891_130912_SN590_0237_AC292LACXX_s_1_rg.sorted	TCGA-CS-4938-10A-01D-1891_130912_SN590_0237_AC292LACXX_s_1_rg.sorted.bam	1013	1.9	0.15	58cfa831e4b0c9d6adf6c6cc	TCGA-CS-4938-10A-01D-1891_130912_SN590_0237_AC292LACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-4938-10A	334F715E-08DC-4A29-B8E4-B010B829C478	Blood Derived Normal	Illumina HiSeq	d987c181-1947-486c-957f-c5bd782a1eba	Brain	31	1B19B2AB-F094-4B73-8AB7-E06F91AFE729	DDD29528-58AD-461F-8509-4E42F71B49FB	TCGA-CS-4938-10A-01D-1891-02	HG19_Broad_variant	TCGA-CS-4938	TCGA-LGG	NA	s8125	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6c6d8	58cfa831e4b0c9d6adf6c6d8	TCGA-CG-4460-01A-01D-1154_120913_SN208_0429_AC187FACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-4460-01A-01D-1154_120913_SN208_0429_AC187FACXX_s_8_rg.sorted	TCGA-CG-4460-01A-01D-1154_120913_SN208_0429_AC187FACXX_s_8_rg.sorted.bam	183.9	1.9	0.15	58cfa831e4b0c9d6adf6c6d8	TCGA-CG-4460-01A-01D-1154_120913_SN208_0429_AC187FACXX_s_8_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4460-01A	3C3D4EF0-019A-423E-89B2-4AC5A7B567AB	Primary Tumor	Illumina HiSeq	1d341d0a-b2f5-4f35-b60d-7c87f2a7dc78	Stomach	66	14FE3057-C82E-4D66-9798-BCD042CF64D6	1AE6944B-600D-40A8-ADD3-16F99982CDFE	TCGA-CG-4460-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4460	TCGA-STAD	669	s15396	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c722	58cfa831e4b0c9d6adf6c722	TCGA-CV-6938-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-6938-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_2_rg.sorted	TCGA-CV-6938-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_2_rg.sorted.bam	127.7	1.9	0.14	58cfa831e4b0c9d6adf6c722	TCGA-CV-6938-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6938-11A	FF9DB03D-F81C-4079-8B05-F5A8C05B8CFE	Solid Tissue Normal	Illumina HiSeq	f15c68cb-d7b4-4f77-9154-f6beb21ff1f1	Head and Neck	87	CF972FFA-A8F4-4DDF-AE83-F80E7C24DE3F	EF1B3760-3B55-4C1B-9952-4AD151738604	TCGA-CV-6938-11A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6938	TCGA-HNSC	144	s15645	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c64a	58cfa831e4b0c9d6adf6c64a	TCGA-CG-4466-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-4466-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_5_rg.sorted	TCGA-CG-4466-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_5_rg.sorted.bam	67.9	1.9	0.15	58cfa831e4b0c9d6adf6c64a	TCGA-CG-4466-10A-01D-1154_130815_VM001_0005_VMR0005CXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4466-10A	2F1B96B2-7031-4F7D-9490-14728D320F3E	Blood Derived Normal	Illumina HiSeq	f0d50aa8-d8a6-4d7d-bfa9-58c964a75540	Stomach	81	2775F741-265C-4B56-9D75-AF665CCBFC8A	45323803-2E2E-4A6F-B8C7-1D74C29E9C84	TCGA-CG-4466-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4466	TCGA-STAD	NA	s14416	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c92d	58cfa831e4b0c9d6adf6c92d	TCGA-D9-A1X3-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D9-A1X3-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_5_rg.sorted	TCGA-D9-A1X3-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_5_rg.sorted.bam	69.24	NA	0.18	58cfa831e4b0c9d6adf6c92d	TCGA-D9-A1X3-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D9-A1X3-10A	F0744FA2-DB4A-40DE-9FD2-F61863FD98D4	Blood Derived Normal	Illumina HiSeq	078e58c4-ac54-45b3-8a5e-9908be0db216	Skin	63	0DCEB511-4D42-4BE9-B6DA-F399F8D3C5B0	FAFD47F9-A673-4461-A8B3-B78A3EE989FE	TCGA-D9-A1X3-10A-01D-A190-02	HG19_Broad_variant	TCGA-D9-A1X3	TCGA-SKCM	NA	s7503	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T4b	N2b	Not available	Not available	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6c874	58cfa831e4b0c9d6adf6c874	TCGA-CV-6933-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-6933-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_1_rg.sorted	TCGA-CV-6933-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_1_rg.sorted.bam	215.7	1.9	0.16	58cfa831e4b0c9d6adf6c874	TCGA-CV-6933-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6933-11A	2A749317-0156-4213-8482-B2C2D6E52E9B	Solid Tissue Normal	Illumina HiSeq	8d4274cf-c829-4e6a-abf1-e3380c63ab8f	Head and Neck	53	EDD36B53-EB43-4ED6-9509-53A56CDCF80D	2E0F5A01-B6BF-4A04-9F70-05CAECA30B83	TCGA-CV-6933-11A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6933	TCGA-HNSC	2741	s16339	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c71a	58cfa831e4b0c9d6adf6c71a	TCGA-CV-6954-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-6954-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_7_rg.sorted	TCGA-CV-6954-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_7_rg.sorted.bam	99.7	1.9	0.14	58cfa831e4b0c9d6adf6c71a	TCGA-CV-6954-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_7_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	Not available	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6954-11A	402FD96C-76D3-4AC2-9F64-77BD34BE0ADB	Solid Tissue Normal	Illumina HiSeq	fa689d79-bedd-452e-935f-21bd4866b9d0	Head and Neck	59	9695FCED-AEF4-43ED-B1BE-026072DC4DDD	BDAFAD43-C3AE-4356-8B6F-DB08ACA4EDD1	TCGA-CV-6954-11A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6954	TCGA-HNSC	2002	s15521	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	NX	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c86c	58cfa831e4b0c9d6adf6c86c	TCGA-CV-6952-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CV-6952-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_5_rg.sorted	TCGA-CV-6952-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_5_rg.sorted.bam	203.7	1.9	0.15	58cfa831e4b0c9d6adf6c86c	TCGA-CV-6952-11A-01D-1911_120526_SN208_0303_BD12PWACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6952-11A	7ED006E8-461F-4664-BFFF-55FA6812743C	Solid Tissue Normal	Illumina HiSeq	48cd5e34-4d2c-4cb0-802c-1b4c2e7a44e1	Head and Neck	65	FE486AA7-B37A-4016-A71C-56D97BD73208	11CB737F-78D0-42B4-9800-C4D38EADAC88	TCGA-CV-6952-11A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6952	TCGA-HNSC	185	s15780	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6cadd	58cfa831e4b0c9d6adf6cadd	TCGA-E1-5305-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_3_rg.sorted.filtered.	WGS	TCGA-E1-5305-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_3_rg.sorted	TCGA-E1-5305-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_3_rg.sorted.bam	57.7	1.9	0.14	58cfa831e4b0c9d6adf6cadd	TCGA-E1-5305-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-E1-5305-01A	A0BC5147-D9B4-41FD-8DF3-A241D23722E8	Primary Tumor	Illumina HiSeq	0f660d53-1dae-499d-8a76-f591e1110acb	Brain	34	1B3185BF-9DEF-4B13-93F8-02CF3171464A	036EF90A-EACA-4105-9B7B-74C20BFA0BB9	TCGA-E1-5305-01A-01D-1891-02	HG19_Broad_variant	TCGA-E1-5305	TCGA-LGG	2433	s8354	Harvard Medical School	Duke	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6c970	58cfa831e4b0c9d6adf6c970	TCGA-DB-5280-10A-01D-1465_130808_SN208_0488_BC294YACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DB-5280-10A-01D-1465_130808_SN208_0488_BC294YACXX_s_4_rg.sorted	TCGA-DB-5280-10A-01D-1465_130808_SN208_0488_BC294YACXX_s_4_rg.sorted.bam	79.4	1.9	0.15	58cfa831e4b0c9d6adf6c970	TCGA-DB-5280-10A-01D-1465_130808_SN208_0488_BC294YACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5280-10A	4797C600-F024-42FE-B287-D919B24DCB79	Blood Derived Normal	Illumina HiSeq	c2968c6a-5afe-480e-a036-e3522ae763ec	Brain	43	B21973CB-382F-4B36-BAD8-973286C32FA8	F09CED0A-4EC8-4586-B8EF-B3B65DF18113	TCGA-DB-5280-10A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5280	TCGA-LGG	NA	s8558	Harvard Medical School	Mayo Clinic - Rochester	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6cb08	58cfa831e4b0c9d6adf6cb08	TCGA-DU-6542-10A-01D-1891_130912_SN590_0237_AC292LACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DU-6542-10A-01D-1891_130912_SN590_0237_AC292LACXX_s_2_rg.sorted	TCGA-DU-6542-10A-01D-1891_130912_SN590_0237_AC292LACXX_s_2_rg.sorted.bam	143	1.9	0.16	58cfa831e4b0c9d6adf6cb08	TCGA-DU-6542-10A-01D-1891_130912_SN590_0237_AC292LACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6542-10A	CD69D509-A652-4257-A8D3-767296BBB4EC	Blood Derived Normal	Illumina HiSeq	dda7afb5-9e07-42bd-b2e0-7499a263ebb5	Brain	25	28B425E6-57A6-432D-A995-D6B03D2094E4	3CD1E613-829B-40DD-AA6A-3460085EEC07	TCGA-DU-6542-10A-01D-1891-02	HG19_Broad_variant	TCGA-DU-6542	TCGA-LGG	NA	s8360	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6c93b	58cfa831e4b0c9d6adf6c93b	TCGA-DK-A2I1-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DK-A2I1-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_2_rg.sorted	TCGA-DK-A2I1-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_2_rg.sorted.bam	9.75	NA	0.2	58cfa831e4b0c9d6adf6c93b	TCGA-DK-A2I1-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2I1-10A	036B9681-AB58-4734-A8FD-E0D5D078BF5A	Blood Derived Normal	Illumina HiSeq	7f2d5952-2a08-48c4-b4c9-5773f777866e	Bladder	73	829A349C-E8DE-4D77-B7B9-5EA893FC583C	F360737A-DEB2-485E-A1D4-1A9C236B399F	TCGA-DK-A2I1-10A-01D-A17R-02	HG19_Broad_variant	TCGA-DK-A2I1	TCGA-BLCA	NA	s2714	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	TRUE
13722.58cfa831e4b0c9d6adf6cc6c	58cfa831e4b0c9d6adf6cc6c	TCGA-ER-A199-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-ER-A199-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_1_rg.sorted	TCGA-ER-A199-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_1_rg.sorted.bam	78.21	NA	0.16	58cfa831e4b0c9d6adf6cc6c	TCGA-ER-A199-06A-11D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A199-06A	E218FC54-1139-4944-82E2-742839E5553A	Metastatic	Illumina HiSeq	92b8625e-5129-4ea4-b59d-d35fa267eb87	Skin	86	7D2F3D83-95E7-4003-A2C8-3D986BB225EA	2A5E7859-8C9A-45B7-BD81-86DC3B6D5D20	TCGA-ER-A199-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A199	TCGA-SKCM	279	s8018	Harvard Medical School	University of Pittsburgh	United States	NO	T4b	N3	Not available	Stage IIIC	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cc33	58cfa831e4b0c9d6adf6cc33	TCGA-EE-A29N-06A-12D-A18Y_120729_SN1120_0180_BC1176ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EE-A29N-06A-12D-A18Y_120729_SN1120_0180_BC1176ACXX_s_5_rg.sorted	TCGA-EE-A29N-06A-12D-A18Y_120729_SN1120_0180_BC1176ACXX_s_5_rg.sorted.bam	55.63	NA	0.17	58cfa831e4b0c9d6adf6cc33	TCGA-EE-A29N-06A-12D-A18Y_120729_SN1120_0180_BC1176ACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29N-06A	8AAD9690-D1AD-424B-9A80-D7980760D093	Metastatic	Illumina HiSeq	1a8bfce8-1606-45e1-8da4-fbad852ec59c	Skin	78	1B381338-4AB1-4468-8042-2519061691E7	A2EF6B29-26E7-4BE0-A87B-122DC2D217A2	TCGA-EE-A29N-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29N	TCGA-SKCM	566	s7337	Harvard Medical School	University of Sydney	Australia	NO	TX	N0	Not available	I or II NOS	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb2a	58cfa831e4b0c9d6adf6cb2a	TCGA-E1-5307-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_4_rg.sorted.filtered.	WGS	TCGA-E1-5307-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_4_rg.sorted	TCGA-E1-5307-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_4_rg.sorted.bam	138.7	1.9	0.14	58cfa831e4b0c9d6adf6cb2a	TCGA-E1-5307-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-E1-5307-01A	A6EE311C-0A7B-4F47-86F1-F2164B128F9C	Primary Tumor	Illumina HiSeq	80d2e037-eb0e-4514-bdd4-caa1fc77176d	Brain	62	DED0F767-9CEE-4F1D-8E91-CB242D30B57E	A95622B9-01E0-4625-AAB8-2193C2594976	TCGA-E1-5307-01A-01D-1891-02	HG19_Broad_variant	TCGA-E1-5307	TCGA-LGG	1762	s8363	Harvard Medical School	Duke	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6ccac	58cfa831e4b0c9d6adf6ccac	TCGA-EE-A2MT-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EE-A2MT-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_2_rg.sorted	TCGA-EE-A2MT-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_2_rg.sorted.bam	50.87	NA	0.15	58cfa831e4b0c9d6adf6ccac	TCGA-EE-A2MT-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MT-06A	69A17647-493F-46D2-9CF0-6596E56289A0	Metastatic	Illumina HiSeq	5ccfc0fe-3cd9-4899-98f4-e668f12adcb1	Skin	45	9124FB58-5EB0-481C-B5A6-F2ED8114F887	528706E9-22D6-4A37-8E2D-2D945CD36F1F	TCGA-EE-A2MT-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2MT	TCGA-SKCM	NA	s7516	Harvard Medical School	University of Sydney	Australia	NO	T2a	N0	Not available	Stage IB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cd20	58cfa831e4b0c9d6adf6cd20	TCGA-EE-A2MQ-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EE-A2MQ-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_4_rg.sorted	TCGA-EE-A2MQ-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_4_rg.sorted.bam	46.6	NA	0.15	58cfa831e4b0c9d6adf6cd20	TCGA-EE-A2MQ-06A-11D-A18Y_120718_SN1222_0126_AC117AACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MQ-06A	C127FFB6-2CCF-4E90-B811-0AA40EBFAB17	Metastatic	Illumina HiSeq	55e99af5-5846-42c7-a272-5ff5cf525357	Skin	70	478A0B67-A1CF-456A-8D5F-12A1BF907AFB	80DE212A-5675-41C7-A79E-44E95D0B3C61	TCGA-EE-A2MQ-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2MQ	TCGA-SKCM	1315	s8011	Harvard Medical School	University of Sydney	Australia	NO	T3a	N2a	Not available	Stage IIIA	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cd22	58cfa831e4b0c9d6adf6cd22	TCGA-EE-A2MQ-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EE-A2MQ-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_8_rg.sorted	TCGA-EE-A2MQ-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_8_rg.sorted.bam	62.38	NA	0.16	58cfa831e4b0c9d6adf6cd22	TCGA-EE-A2MQ-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MQ-10A	C127FFB6-2CCF-4E90-B811-0AA40EBFAB17	Blood Derived Normal	Illumina HiSeq	379ff829-20a8-487f-a935-55656f3311b8	Skin	70	C1DCE764-F077-4696-B50A-3D778AE1E11C	3C4E786A-0441-4E99-BE3E-E840A7A5D529	TCGA-EE-A2MQ-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2MQ	TCGA-SKCM	1315	s7343	Harvard Medical School	University of Sydney	Australia	NO	T3a	N2a	Not available	Stage IIIA	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cd4b	58cfa831e4b0c9d6adf6cd4b	TCGA-ER-A197-06A-32D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-ER-A197-06A-32D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_2_rg.sorted	TCGA-ER-A197-06A-32D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_2_rg.sorted.bam	77.22	NA	0.17	58cfa831e4b0c9d6adf6cd4b	TCGA-ER-A197-06A-32D-A18Y_120729_SN1120_0179_AC11G3ACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A197-06A	3EBB2374-4518-4E19-9B65-9C3E66252C4C	Metastatic	Illumina HiSeq	63175366-aa4e-4f4a-99c8-5d6985a153a6	Skin	83	A0B189C0-996A-4A35-B8BF-EC1309B05603	E86E19FF-B225-4C87-9F16-4C931BEADC30	TCGA-ER-A197-06A-32D-A18Y-02	HG19_Broad_variant	TCGA-ER-A197	TCGA-SKCM	424	s7697	Harvard Medical School	University of Pittsburgh	United States	NO	T4b	N1a	Not available	Stage IIIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cda9	58cfa831e4b0c9d6adf6cda9	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted.bam	103.7	NA	0.15	58cfa831e4b0c9d6adf6cda9	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-7636-01A	B342E980-8383-4F1B-BF57-4098C37A536C	Primary Tumor	Illumina HiSeq	336bd48f-3c20-4a2f-a2ef-38bb94e30e11	Brain	48	BF70C0A6-CA2D-4355-B5BA-738094382E28	CE49A704-BECD-4A35-978B-4E21572CC5B2	TCGA-FG-7636-01A-11D-2088-02	HG19_Broad_variant	TCGA-FG-7636	TCGA-LGG	NA	s8573	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Astrocytoma	Not available	2088-02	FALSE
13722.58cfa831e4b0c9d6adf6cd65	58cfa831e4b0c9d6adf6cd65	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted.bam	72.56	2.05	0.18	58cfa831e4b0c9d6adf6cd65	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A232-01A	5EB0D577-223B-4409-89D1-5C5D196AFFC3	Primary Tumor	Illumina HiSeq	ca8aaa05-1546-46a2-aee9-1ad97cadf087	Thyroid	44	213BE6EE-1E61-4FA0-9B73-66B696086397	AD42DF5B-2665-4CA1-8049-943F684B6BFD	TCGA-FE-A232-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A232	TCGA-THCA	NA	s12530	Harvard Medical School	Ohio State University	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6ccae	58cfa831e4b0c9d6adf6ccae	TCGA-EE-A2MT-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EE-A2MT-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_6_rg.sorted	TCGA-EE-A2MT-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_6_rg.sorted.bam	21.98	NA	0.16	58cfa831e4b0c9d6adf6ccae	TCGA-EE-A2MT-10A-01D-A190_120718_SN1222_0126_AC117AACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MT-10A	69A17647-493F-46D2-9CF0-6596E56289A0	Blood Derived Normal	Illumina HiSeq	0484298e-529e-4cc4-bcca-4b0806922cd6	Skin	45	626AC5AE-EBF4-47E3-8019-8192FAA0D4FE	3C5D5E61-64B7-4D2C-B2D9-8F946A7482F3	TCGA-EE-A2MT-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2MT	TCGA-SKCM	NA	s7341	Harvard Medical School	University of Sydney	Australia	NO	T2a	N0	Not available	Stage IB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cd42	58cfa831e4b0c9d6adf6cd42	TCGA-ER-A2NC-06A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_2_rg.sorted.filtered.	WGS	TCGA-ER-A2NC-06A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_2_rg.sorted	TCGA-ER-A2NC-06A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_2_rg.sorted.bam	21.95	NA	0.16	58cfa831e4b0c9d6adf6cd42	TCGA-ER-A2NC-06A-11D-A18Y_120718_SN208_0415_AC116EACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A2NC-06A	B9607824-A8D3-4915-AB73-962CDCFD8DC3	Metastatic	Illumina HiSeq	903bc6ae-f6d5-44d0-afdf-0b93235b368b	Skin	50	F4967D10-95FD-4C8D-BCB5-19072D8D8DFA	7D63E49D-B427-499D-834A-D78B54B5713F	TCGA-ER-A2NC-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A2NC	TCGA-SKCM	1333	s7864	Harvard Medical School	University of Pittsburgh	United States	NO	T2a	N0	Not available	Stage IB	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6ce2a	58cfa832e4b0c9d6adf6ce2a	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted.bam	141.7	NA	0.14	58cfa832e4b0c9d6adf6ce2a	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FN-7833-01A	5B9D7565-A933-449D-8FFA-EC5F82DB2E77	Primary Tumor	Illumina HiSeq	91f0d100-c921-4319-9d82-98819189b525	Brain	25	CF2E4A0A-59C5-41DA-9F24-DE83EEB856E5	1C69F8E8-7D70-4BD1-8B42-7E93DC23DA7B	TCGA-FN-7833-01A-11D-2088-02	HG19_Broad_variant	TCGA-FN-7833	TCGA-LGG	NA	s8366	Harvard Medical School	International Genomics Consortium	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	2088-02	FALSE
13722.58cfa832e4b0c9d6adf6d0b4	58cfa832e4b0c9d6adf6d0b4	TCGA-FN-7833-10A-01D-2088_130923_SN1222_0220_BC2DUUACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FN-7833-10A-01D-2088_130923_SN1222_0220_BC2DUUACXX_s_8_rg.sorted	TCGA-FN-7833-10A-01D-2088_130923_SN1222_0220_BC2DUUACXX_s_8_rg.sorted.bam	1039	NA	0.14	58cfa832e4b0c9d6adf6d0b4	TCGA-FN-7833-10A-01D-2088_130923_SN1222_0220_BC2DUUACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FN-7833-10A	5B9D7565-A933-449D-8FFA-EC5F82DB2E77	Blood Derived Normal	Illumina HiSeq	8a4a2069-1e0c-4d49-a1eb-77f38954eed2	Brain	25	500D7019-6256-4698-BAAC-6F29E0B85AD7	A6D04659-D36D-433C-BFA9-B633C5BB206F	TCGA-FN-7833-10A-01D-2088-02	HG19_Broad_variant	TCGA-FN-7833	TCGA-LGG	NA	s8149	Harvard Medical School	International Genomics Consortium	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	2088-02	FALSE
13722.58cfa832e4b0c9d6adf6ceae	58cfa832e4b0c9d6adf6ceae	TCGA-EM-A1YD-11A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EM-A1YD-11A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_7_rg.sorted	TCGA-EM-A1YD-11A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_7_rg.sorted.bam	34.99	2.08	0.16	58cfa832e4b0c9d6adf6ceae	TCGA-EM-A1YD-11A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_7_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YD-11A	8A3659A8-2A85-4BAB-8BF3-55795922474C	Solid Tissue Normal	Illumina HiSeq	6c5fce85-3633-4842-af59-ac8edb797640	Thyroid	53	B5EFE349-B8D1-4B10-95D7-24B2233C1AFB	DCEFBF06-A42B-4AA6-B1C1-A321DE2BBE64	TCGA-EM-A1YD-11A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YD	TCGA-THCA	NA	s12522	Harvard Medical School	University Health Network	Canada	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6cf16	58cfa832e4b0c9d6adf6cf16	TCGA-FG-7636-10A-01D-2088_130923_SN1222_0220_BC2DUUACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FG-7636-10A-01D-2088_130923_SN1222_0220_BC2DUUACXX_s_7_rg.sorted	TCGA-FG-7636-10A-01D-2088_130923_SN1222_0220_BC2DUUACXX_s_7_rg.sorted.bam	66.3	NA	0.15	58cfa832e4b0c9d6adf6cf16	TCGA-FG-7636-10A-01D-2088_130923_SN1222_0220_BC2DUUACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-7636-10A	B342E980-8383-4F1B-BF57-4098C37A536C	Blood Derived Normal	Illumina HiSeq	3936d9e1-9fc2-4de3-9c2d-6bb41eecfcf5	Brain	48	3E8DB019-9057-49BD-8B3D-6B51A370C15F	CAB252B2-7534-44B2-894C-673368843642	TCGA-FG-7636-10A-01D-2088-02	HG19_Broad_variant	TCGA-FG-7636	TCGA-LGG	NA	s8150	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Astrocytoma	Not available	2088-02	FALSE
13722.58cfa832e4b0c9d6adf6d206	58cfa832e4b0c9d6adf6d206	TCGA-G2-A2EF-10A-01D-A18D_120912_SN1222_0148_AC188PACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G2-A2EF-10A-01D-A18D_120912_SN1222_0148_AC188PACXX_s_8_rg.sorted	TCGA-G2-A2EF-10A-01D-A18D_120912_SN1222_0148_AC188PACXX_s_8_rg.sorted.bam	21.13	NA	0.15	58cfa832e4b0c9d6adf6d206	TCGA-G2-A2EF-10A-01D-A18D_120912_SN1222_0148_AC188PACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EF-10A	2A142731-119C-495D-AD30-EB0B48BACB46	Blood Derived Normal	Illumina HiSeq	a641053d-d0ab-4204-a4c7-6fff5ed2ef4e	Bladder	50	7A1B6C6D-2E87-4DD7-B1EC-7871F8D24611	E7B17777-D064-43A5-9AFA-14891917BAC7	TCGA-G2-A2EF-10A-01D-A18D-02	HG19_Broad_variant	TCGA-G2-A2EF	TCGA-BLCA	NA	s3121	Harvard Medical School	MD Anderson	United States	NO	Not available	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A18D-02	TRUE
13722.58cfa832e4b0c9d6adf6d11a	58cfa832e4b0c9d6adf6d11a	TCGA-G2-A2EL-10A-01D-A18D_120912_SN1222_0148_AC188PACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G2-A2EL-10A-01D-A18D_120912_SN1222_0148_AC188PACXX_s_6_rg.sorted	TCGA-G2-A2EL-10A-01D-A18D_120912_SN1222_0148_AC188PACXX_s_6_rg.sorted.bam	17.24	NA	0.17	58cfa832e4b0c9d6adf6d11a	TCGA-G2-A2EL-10A-01D-A18D_120912_SN1222_0148_AC188PACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EL-10A	30C7445E-D0C4-4A0F-96A4-27E4259EE10B	Blood Derived Normal	Illumina HiSeq	9b81589b-68e2-4101-b77c-a356f255eb95	Bladder	77	C109058D-19C0-44B5-BFB5-5BD6C9D4E3B8	53F645F9-F8B0-46D6-B1FF-91042F47FA80	TCGA-G2-A2EL-10A-01D-A18D-02	HG19_Broad_variant	TCGA-G2-A2EL	TCGA-BLCA	819	s2915	Harvard Medical School	MD Anderson	United States	NO	Not available	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A18D-02	TRUE
13722.58cfa832e4b0c9d6adf6d2a8	58cfa832e4b0c9d6adf6d2a8	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted.bam	175	NA	0.13	58cfa832e4b0c9d6adf6d2a8	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7604-01A	019C5DE9-74FD-48B7-95A3-227532E16C5A	Primary Tumor	Illumina HiSeq	b3d0b563-b12d-4872-9a0c-f795ca13842f	Brain	50	9CA3488A-91F8-4EB2-8B03-24E8629757E1	31412731-7A51-4E73-BFC4-0098275D633B	TCGA-HT-7604-01A-11D-2088-02	HG19_Broad_variant	TCGA-HT-7604	TCGA-LGG	NA	s8575	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Astrocytoma	Not available	2088-02	FALSE
13722.58cfa832e4b0c9d6adf6d200	58cfa832e4b0c9d6adf6d200	TCGA-FS-A1Z0-06A-11D-A18Y_120718_SN1222_0127_BD147HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FS-A1Z0-06A-11D-A18Y_120718_SN1222_0127_BD147HACXX_s_1_rg.sorted	TCGA-FS-A1Z0-06A-11D-A18Y_120718_SN1222_0127_BD147HACXX_s_1_rg.sorted.bam	52.88	NA	0.16	58cfa832e4b0c9d6adf6d200	TCGA-FS-A1Z0-06A-11D-A18Y_120718_SN1222_0127_BD147HACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1Z0-06A	6A1966C3-7F01-4304-B4A1-C4EF683B179A	Metastatic	Illumina HiSeq	8f3ae468-0d68-4a91-ba8d-55ed86034e27	Skin	32	5B0F64D4-6052-4465-8AD9-058556EC9AA3	960ADBFE-F551-4DC6-95BA-5C1CE5D253AB	TCGA-FS-A1Z0-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1Z0	TCGA-SKCM	6164	s7866	Harvard Medical School	Essen	Germany	NO	T1a	N0	Not available	Stage IA	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d28b	58cfa832e4b0c9d6adf6d28b	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted.bam	56	NA	0.15	58cfa832e4b0c9d6adf6d28b	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7601-01A	E7FDF164-A85D-4FF5-9676-D2215CA35403	Primary Tumor	Illumina HiSeq	5faa261d-a169-4ab5-a52b-de3b50c46299	Brain	30	7F6B5679-49E1-498D-BD1F-A757CD7DB4CC	5F766AF5-08F5-4E10-AAED-4B582275CFC1	TCGA-HT-7601-01A-11D-2088-02	HG19_Broad_variant	TCGA-HT-7601	TCGA-LGG	NA	s8153	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Astrocytoma	Not available	2088-02	FALSE
13722.58cfa82ee4b0c9d6adf6afc4	58cfa82ee4b0c9d6adf6afc4	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	313.3	1.9	0.15	58cfa82ee4b0c9d6adf6afc4	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4418-01A	D2C1E896-6886-4122-BB48-5FBCD3F641F4	Primary Tumor	Illumina HiSeq	961e7ff2-7efc-46b6-9fe6-3f19366eeab8	Lung	69	C9E092B2-D6C3-4161-BD9E-0FA4015BEBBB	AA7559AC-F8C0-40E5-A313-3914A6E4559A	TCGA-05-4418-01A-01D-1203-02	GRCh37	TCGA-05-4418	TCGA-LUAD	274	s11440	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6afb2	58cfa82ee4b0c9d6adf6afb2	TCGA-05-4418-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4418-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4418-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	65.9	1.9	0.13	58cfa82ee4b0c9d6adf6afb2	TCGA-05-4418-10A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4418-10A	D2C1E896-6886-4122-BB48-5FBCD3F641F4	Blood Derived Normal	Illumina HiSeq	ba806a17-fb08-48cf-8ed8-069510bc4e50	Lung	69	5808A3F7-0876-4816-94D6-4DBE08257955	7D13B485-47B6-4326-BBA6-28C5E5014829	TCGA-05-4418-10A-01D-1203-02	GRCh37	TCGA-05-4418	TCGA-LUAD	274	s11330	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1203-02	TRUE
13722.58cfa830e4b0c9d6adf6c1f3	58cfa830e4b0c9d6adf6c1f3	TCGA-BG-A0LX-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0LX-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_8_rg.sorted	TCGA-BG-A0LX-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_8_rg.sorted.bam	21.13	2	0.15	58cfa830e4b0c9d6adf6c1f3	TCGA-BG-A0LX-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0LX-10A	AC1D3946-FE6C-4BD8-B02C-638799CB0F67	Blood Derived Normal	Illumina HiSeq	35dff020-7f96-4a7b-bb1e-57225beb9c83	Uterus	57	BB935FAB-8B12-4FDC-8A49-A03FD67CC014	6BD21A7A-30FC-4BD0-8ED7-F4ABE21ECBA8	TCGA-BG-A0LX-10A-01D-A043-02	HG19_Broad_variant	TCGA-BG-A0LX	TCGA-UCEC	NA	s5213	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba20	58cfa82fe4b0c9d6adf6ba20	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted.filtered.	WGS	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted.bam	338.96	1.9	0.16	58cfa82fe4b0c9d6adf6ba20	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3664-01A	A06C09A8-0951-49F4-A765-5147BBCAE109	Primary Tumor	Illumina HiSeq	9caec406-c1d9-43df-a730-7226fd5880b0	Colorectal	74	D448668C-90F3-40FA-9961-88407090DA31	4B4C0EDF-1012-4A6A-B01E-CDEB130FF2E6	TCGA-AA-3664-01A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3664	TCGA-COAD	NA	s13024	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	TRUE
13722.58cfa82fe4b0c9d6adf6ba35	58cfa82fe4b0c9d6adf6ba35	TCGA-A6-3810-11A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3810-11A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3810-11A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	469.86	1.9	0.15	58cfa82fe4b0c9d6adf6ba35	TCGA-A6-3810-11A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3810-11A	B728E6E8-A0E4-496B-904C-6F07C12E901F	Solid Tissue Normal	Illumina HiSeq	f725df5d-8fb1-4c7b-b4c6-828a349265d2	Colorectal	62	A692CCDA-F941-46A5-9AC4-28E300686929	F933A74E-5E70-45F7-95A1-CFC3039EE936	TCGA-A6-3810-11A-01D-1167-02	HG18	TCGA-A6-3810	TCGA-COAD	NA	s13653	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bc00	58cfa830e4b0c9d6adf6bc00	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	380	1.9	0.15	58cfa830e4b0c9d6adf6bc00	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3807-01A	5116E3B4-2BAC-40F5-8046-B9C1783FAAA5	Primary Tumor	Illumina HiSeq	d5f643a5-b69b-499a-8aab-7fc6520f2e55	Colorectal	53	1EB2A255-6EDD-4ADB-B52D-99DCEC590C5D	3A4293C1-0860-42F9-9D64-26B7298C2CDB	TCGA-A6-3807-01A-01D-1167-02	HG18	TCGA-A6-3807	TCGA-COAD	NA	s13505	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bc3a	58cfa830e4b0c9d6adf6bc3a	TCGA-AA-3968-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3968-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3968-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	259.56	1.9	0.15	58cfa830e4b0c9d6adf6bc3a	TCGA-AA-3968-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-3968-10A	CAB7BDBC-0A11-4901-97C3-26B884F79CB5	Blood Derived Normal	Illumina HiSeq	0cd10640-5672-427b-b9a7-d5acdef28f73	Colorectal	55	08FA1A76-022E-49E6-B416-314F7A02E2A4	10BF212B-35D2-453A-87C1-9A7D315DF220	TCGA-AA-3968-10A-01D-1167-02	HG18	TCGA-AA-3968	TCGA-COAD	NA	s13374	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa830e4b0c9d6adf6bca6	58cfa830e4b0c9d6adf6bca6	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	524.02	1.9	0.15	58cfa830e4b0c9d6adf6bca6	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4315-01A	DE287A25-981D-49F8-81AF-FE0300E4CD31	Primary Tumor	Illumina HiSeq	8b6a06d6-c15c-4491-996c-2a012440f8a2	Colorectal	61	BA9E5603-BB1D-4AA8-93E4-40043164F143	FBEA9F07-A969-4396-8A17-A269BF1F8A2A	TCGA-AZ-4315-01A-01D-1405-02	HG18	TCGA-AZ-4315	TCGA-COAD	NA	s13389	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	TRUE
13722.58cfa830e4b0c9d6adf6beac	58cfa830e4b0c9d6adf6beac	TCGA-AG-3898-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3898-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3898-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	24.59	1.9	0.15	58cfa830e4b0c9d6adf6beac	TCGA-AG-3898-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3898-10A	5A7D19F9-6BE2-45AC-9FFC-11E28594EEEE	Blood Derived Normal	Illumina HiSeq	bb8d9cc7-db6f-4290-b00e-c26297f8be6c	Colorectal	61	4328ABB7-6E1F-4DA9-A6A4-2F8FA32B4C30	B12A19E2-25CF-414F-BA42-396566C2A486	TCGA-AG-3898-10A-01D-1115-02	HG18	TCGA-AG-3898	TCGA-READ	NA	s1997	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6bff0	58cfa830e4b0c9d6adf6bff0	TCGA-AG-3878-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3878-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3878-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	68.61	1.9	0.15	58cfa830e4b0c9d6adf6bff0	TCGA-AG-3878-10A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3878-10A	FDEEFF8E-1328-42A4-ACA0-A03B97421F1E	Blood Derived Normal	Illumina HiSeq	d50f98e5-5a4a-4380-9f43-9add34b2e020	Colorectal	64	33490C7D-BDA5-4F34-9334-41FFEA509F86	3A5CB7A1-AB43-4C31-AFAE-98A3BF30F091	TCGA-AG-3878-10A-01D-1167-02	HG18	TCGA-AG-3878	TCGA-READ	NA	s1970	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1167-02	TRUE
13722.58cfa82ee4b0c9d6adf6b087	58cfa82ee4b0c9d6adf6b087	TCGA-05-4417-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_8_rg.sorted.filtered.	WGS	TCGA-05-4417-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_8_rg.sorted	TCGA-05-4417-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_8_rg.sorted.bam	39	1.9	0.15	58cfa82ee4b0c9d6adf6b087	TCGA-05-4417-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_8_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4417-10A	A244A99A-D7CC-4FB1-BC76-B66886481621	Blood Derived Normal	Illumina HiSeq	e22b68ac-9772-4665-b367-38eee8691898	Lung	51	655AD2E6-05FF-4A3F-9947-4F21DA1F4FDF	548CEAF3-3FC3-4A22-8BEB-E218DD47A2DA	TCGA-05-4417-10A-01D-1853-02	HG19_Broad_variant	TCGA-05-4417	TCGA-LUAD	NA	s11331	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae42	58cfa82ee4b0c9d6adf6ae42	TCGA-05-4250-10A-01D-1103_120228_SN1120_0116_AD0KRVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4250-10A-01D-1103_120228_SN1120_0116_AD0KRVACXX_s_1_rg.sorted	TCGA-05-4250-10A-01D-1103_120228_SN1120_0116_AD0KRVACXX_s_1_rg.sorted.bam	14.63	1.9	0.16	58cfa82ee4b0c9d6adf6ae42	TCGA-05-4250-10A-01D-1103_120228_SN1120_0116_AD0KRVACXX_s_1_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4250-10A	F98ECD8A-B878-4F53-B911-20CD8E17281C	Blood Derived Normal	Illumina HiSeq	e2b88393-7111-4c16-8b98-344fb8aa701f	Lung	79	6AE21FEA-41BE-4CD2-BFCB-EC138D42CFF3	6963DBCE-5E1F-419E-8997-1178CA90D733	TCGA-05-4250-10A-01D-1103-02	HG19_Broad_variant	TCGA-05-4250	TCGA-LUAD	121	s11116	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6d5	58cfa82fe4b0c9d6adf6b6d5	TCGA-55-6543-10A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_8_rg.sorted.filtered.	WGS	TCGA-55-6543-10A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_8_rg.sorted	TCGA-55-6543-10A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_8_rg.sorted.bam	225.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6d5	TCGA-55-6543-10A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-55-6543-10A	E68219B0-A9C2-49DF-8F0D-DB5EA97FD2DC	Blood Derived Normal	Illumina HiSeq	a66c52d0-6f85-4b19-aa52-97c7fd45d6f1	Lung	60	656A0565-869D-462E-899B-EB5DA57C75C7	DA1D674C-9EC2-4822-8CDE-9E4E655B3098	TCGA-55-6543-10A-01D-1751-02	HG19_Broad_variant	TCGA-55-6543	TCGA-LUAD	NA	s11240	Harvard Medical School	International Genomics Consortium	United States	NO	T1b	N0	Lung Bronchioloalveolar Carcinoma Mucinous	Stage IA	1751-02	TRUE
13722.58cfa82ee4b0c9d6adf6aefb	58cfa82ee4b0c9d6adf6aefb	TCGA-05-4415-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_6_rg.sorted.filtered.	WGS	TCGA-05-4415-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_6_rg.sorted	TCGA-05-4415-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_6_rg.sorted.bam	48	1.8	0.14	58cfa82ee4b0c9d6adf6aefb	TCGA-05-4415-10A-01D-1853_120228_SN1120_0116_AD0KRVACXX_s_6_rg.sorted.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4415-10A	D15B7B29-C5C5-41D8-B83B-7CC12FE92820	Blood Derived Normal	Illumina HiSeq	57cfe098-8cf8-4aab-ba84-1d57f4617af9	Lung	57	DD13F373-F9B3-4263-8E0C-C925B2AE5FD1	6D2948A0-4BB5-4959-971B-B98B8944FB0A	TCGA-05-4415-10A-01D-1853-02	HG19_Broad_variant	TCGA-05-4415	TCGA-LUAD	91	s10771	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1853-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae48	58cfa82ee4b0c9d6adf6ae48	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted.bam	486.4	1.9	0.15	58cfa82ee4b0c9d6adf6ae48	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4384-01A	9A50E7E4-831D-489F-87D2-979E987561CC	Primary Tumor	Illumina HiSeq	985192a3-1403-4393-895a-ca9a4d12268f	Lung	66	E4416303-50B0-4316-BFEE-030C7B29FAC6	5253B1A2-8C57-414A-8E19-6E8390A6C18D	TCGA-05-4384-01A-01D-1751-02	HG19_Broad_variant	TCGA-05-4384	TCGA-LUAD	NA	s10982	Harvard Medical School	Indivumed	Germany	NO	T2	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6fa	58cfa82fe4b0c9d6adf6b6fa	TCGA-50-5939-11A-01D-1623_120302_SN208_0271_BC0D91ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-50-5939-11A-01D-1623_120302_SN208_0271_BC0D91ACXX_s_4_rg.sorted	TCGA-50-5939-11A-01D-1623_120302_SN208_0271_BC0D91ACXX_s_4_rg.sorted.bam	38.7	2	0.14	58cfa82fe4b0c9d6adf6b6fa	TCGA-50-5939-11A-01D-1623_120302_SN208_0271_BC0D91ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5939-11A	12B79B4F-C28C-418E-A1E7-E622F33FDCC2	Solid Tissue Normal	Illumina HiSeq	67afa188-5949-4813-8056-994a819a72b5	Lung	85	1A762AC4-B6EF-4EA1-889A-0FDA1DF26765	B6DDA01B-CC15-4491-9623-AC2D9B9E92DC	TCGA-50-5939-11A-01D-1623-02	HG19_Broad_variant	TCGA-50-5939	TCGA-LUAD	460	s11349	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7de	58cfa82fe4b0c9d6adf6b7de	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted.bam	345.4	1.9	0.15	58cfa82fe4b0c9d6adf6b7de	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5931-01A	12CCD581-A921-41BC-BCEE-4E9BE54532CC	Primary Tumor	Illumina HiSeq	ba1d7028-7d97-4a0b-917e-b861a8656748	Lung	75	16A2D381-75A0-423B-AAC2-D5710AFB183B	5EA8E18D-2D34-4C6E-A89D-36DE5E91E80C	TCGA-50-5931-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5931	TCGA-LUAD	434	s11458	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82ee4b0c9d6adf6afec	58cfa82ee4b0c9d6adf6afec	TCGA-05-5715-10A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-5715-10A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_3_rg.sorted	TCGA-05-5715-10A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_3_rg.sorted.bam	160.4	1.9	0.16	58cfa82ee4b0c9d6adf6afec	TCGA-05-5715-10A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-5715-10A	E0A19099-5D25-40DF-AD73-6260DF3A1B32	Blood Derived Normal	Illumina HiSeq	93ca0971-dab1-4845-ad59-48fe54014068	Lung	69	8281B534-7B60-4FC6-BA0A-A711B0A19E64	057028CA-4A69-4003-825D-AAE09E0CE546	TCGA-05-5715-10A-01D-1623-02	HG19_Broad_variant	TCGA-05-5715	TCGA-LUAD	NA	s10776	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7fc	58cfa82fe4b0c9d6adf6b7fc	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.filtered.	WGS	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.bam	240.4	1.9	0.14	58cfa82fe4b0c9d6adf6b7fc	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-6178-01A	EDF80622-AEA2-4B50-BB69-691D6708AA83	Primary Tumor	Illumina HiSeq	f309d501-6d91-40ce-839c-bef9a434bae1	Lung	70	81FB5FA9-D901-4FAA-B909-376B8676D2BC	DE9A3263-6ACD-4BBB-9F91-D4E7FCBEFA04	TCGA-38-6178-01A-11D-1751-02	HG19_Broad_variant	TCGA-38-6178	TCGA-LUAD	NA	s11119	Harvard Medical School	UNC	United States	NO	T2b	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7f7	58cfa82fe4b0c9d6adf6b7f7	TCGA-38-4631-11A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_6_rg.sorted.filtered.	WGS	TCGA-38-4631-11A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_6_rg.sorted	TCGA-38-4631-11A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_6_rg.sorted.bam	61.4	1.8	0.15	58cfa82fe4b0c9d6adf6b7f7	TCGA-38-4631-11A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4631-11A	2483621A-4DB3-41AB-AA33-B9427EA8A0AF	Solid Tissue Normal	Illumina HiSeq	5ae01470-ac1e-459f-9598-e44be31e416a	Lung	72	FF565F35-43C7-4694-B7D0-70F440732B1C	C4C0A045-CC32-40F7-9B93-63214C946740	TCGA-38-4631-11A-01D-1751-02	HG19_Broad_variant	TCGA-38-4631	TCGA-LUAD	354	s11227	Harvard Medical School	UNC	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b943	58cfa82fe4b0c9d6adf6b943	TCGA-A5-A0GV-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_4_rg.sorted.filtered.	WGS	TCGA-A5-A0GV-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_4_rg.sorted	TCGA-A5-A0GV-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_4_rg.sorted.bam	10.97	1.94	0.17	58cfa82fe4b0c9d6adf6b943	TCGA-A5-A0GV-10A-01D-A043_120214_SN590_0139_BC0DYEACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GV-10A	5E3B981E-73FE-4CC9-8C89-B420E8E2F426	Blood Derived Normal	Illumina HiSeq	640286f9-ba4e-441b-baf8-e2ed40a65578	Uterus	67	4A3E6225-7149-4AC4-B104-C133B00F1B6D	BA20653D-7EF1-40D6-B86D-74C46B6D8BA7	TCGA-A5-A0GV-10A-01D-A043-02	HG19_Broad_variant	TCGA-A5-A0GV	TCGA-UCEC	NA	s4418	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b800	58cfa82fe4b0c9d6adf6b800	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted.bam	465.4	1.9	0.15	58cfa82fe4b0c9d6adf6b800	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4632-01A	875333AB-9048-462D-AAA2-693AD127E3CC	Primary Tumor	Illumina HiSeq	ee38fc59-2812-43a0-b6c0-ab684daab63d	Lung	42	D994817A-474E-4F92-8A78-7586CAA85D52	77D4D914-9C77-401B-BD71-9CF71A58DCE7	TCGA-38-4632-01A-01D-1751-02	HG19_Broad_variant	TCGA-38-4632	TCGA-LUAD	1357	s11449	Harvard Medical School	UNC	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b97c	58cfa82fe4b0c9d6adf6b97c	TCGA-91-6831-11A-02D-1853_120305_SN1120_0119_BD0REAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-91-6831-11A-02D-1853_120305_SN1120_0119_BD0REAACXX_s_5_rg.sorted	TCGA-91-6831-11A-02D-1853_120305_SN1120_0119_BD0REAACXX_s_5_rg.sorted.bam	184.7	1.9	0.14	58cfa82fe4b0c9d6adf6b97c	TCGA-91-6831-11A-02D-1853_120305_SN1120_0119_BD0REAACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6831-11A	DB0B9E63-4272-4F29-BF0E-1EC0FE79A9D7	Solid Tissue Normal	Illumina HiSeq	668cb7d1-0943-47c0-a4fa-a0b61974412a	Lung	66	41433A93-F941-40D7-BD47-CB6BEF90D289	C31BDC8D-4CA4-48F7-AF96-E9FBD02ABF99	TCGA-91-6831-11A-02D-1853-02	HG19_Broad_variant	TCGA-91-6831	TCGA-LUAD	NA	s10799	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b756	58cfa82fe4b0c9d6adf6b756	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.filtered.	WGS	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.bam	328.7	1.9	0.14	58cfa82fe4b0c9d6adf6b756	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6835-01A	2F09479F-87FC-4C34-8E2C-333E970A3681	Primary Tumor	Illumina HiSeq	8c5e1a0f-e9a8-4ce4-b066-97b2040c5327	Lung	81	EFD3F14F-F785-4AEC-9EFD-6DD8E9C41EBA	A4DC40A6-EE0F-4637-937F-406F5FC8579F	TCGA-91-6835-01A-11D-1853-02	HG19_Broad_variant	TCGA-91-6835	TCGA-LUAD	NA	s10913	Harvard Medical School	ABS - IUPUI	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9e2	58cfa82fe4b0c9d6adf6b9e2	TCGA-64-5815-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-64-5815-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_3_rg.sorted	TCGA-64-5815-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_3_rg.sorted.bam	132.7	1.9	0.14	58cfa82fe4b0c9d6adf6b9e2	TCGA-64-5815-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5815-01A	A65700C2-E58C-4FD4-AEB1-5686B8F4D212	Primary Tumor	Illumina HiSeq	d64bfa4e-ae37-494a-aabe-6787ac58054a	Lung	74	4420AAE3-3F44-4852-974D-74F155B99FE4	7DC45930-978E-42B5-8ECB-942F3C6DA727	TCGA-64-5815-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5815	TCGA-LUAD	NA	s11460	Harvard Medical School	Fox Chase	United States	NO	T2	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1623-02	TRUE
13722.58cfa830e4b0c9d6adf6bc60	58cfa830e4b0c9d6adf6bc60	TCGA-AP-A0LH-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_2_rg.sorted.filtered.	WGS	TCGA-AP-A0LH-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_2_rg.sorted	TCGA-AP-A0LH-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_2_rg.sorted.bam	31.83	1.72	0.15	58cfa830e4b0c9d6adf6bc60	TCGA-AP-A0LH-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LH-10A	7DCE4215-01F6-43E9-9378-9E22C26C23A2	Blood Derived Normal	Illumina HiSeq	265fdf19-e338-42d6-9032-162923c0a164	Uterus	60	6E5515FB-6252-4703-B7F4-B57E38121C5B	F7861538-BDB9-4C6B-820E-8184B2AA793F	TCGA-AP-A0LH-10A-01D-A043-02	HG19_Broad_variant	TCGA-AP-A0LH	TCGA-UCEC	1106	s4425	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Mixed serous and endometrioid	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bd86	58cfa830e4b0c9d6adf6bd86	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.bam	65.42	2.11	0.15	58cfa830e4b0c9d6adf6bd86	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0LX-01A	AC1D3946-FE6C-4BD8-B02C-638799CB0F67	Primary Tumor	Illumina HiSeq	182220ca-d437-40a2-adeb-d4cb1ce2f284	Uterus	57	99CDF3A0-90DC-4992-B75A-11DD41928D43	B294F25A-93D9-49A6-8FD3-6D2B0BBEF27C	TCGA-BG-A0LX-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0LX	TCGA-UCEC	NA	s5218	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bd8a	58cfa830e4b0c9d6adf6bd8a	TCGA-BG-A0LW-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0LW-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_6_rg.sorted	TCGA-BG-A0LW-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_6_rg.sorted.bam	13	2.1	0.13	58cfa830e4b0c9d6adf6bd8a	TCGA-BG-A0LW-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0LW-10A	68181BC9-AA8B-44EC-8601-564B30EA0561	Blood Derived Normal	Illumina HiSeq	1eb12505-9633-4851-9fc4-409b41c55970	Uterus	47	ADDF5D6E-5C42-400B-98BC-B44E48336953	D883C522-CED2-4540-9B2C-A3A6C56EDD25	TCGA-BG-A0LW-10A-01D-A043-02	HG19_Broad_variant	TCGA-BG-A0LW	TCGA-UCEC	NA	s4431	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bdd6	58cfa830e4b0c9d6adf6bdd6	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.bam	84.24	2.08	0.16	58cfa830e4b0c9d6adf6bdd6	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MC-01A	884FD57D-BD8E-40E7-82F6-0BA1C71101A9	Primary Tumor	Illumina HiSeq	db9c9c51-2c42-4a56-a87d-9c01038c4e6f	Uterus	74	46B48BF8-346B-4F25-916E-26A3CDDFA00D	9376C8CD-BD9D-4576-BBE3-7D771914AFA3	TCGA-BG-A0MC-01A-21D-A043-02	HG19_Broad_variant	TCGA-BG-A0MC	TCGA-UCEC	NA	s4601	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bc5a	58cfa830e4b0c9d6adf6bc5a	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted.bam	94.43	2	0.16	58cfa830e4b0c9d6adf6bc5a	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LH-01A	7DCE4215-01F6-43E9-9378-9E22C26C23A2	Primary Tumor	Illumina HiSeq	4334c333-7627-4949-90aa-55897232ec49	Uterus	60	4C657AD4-2C53-4EA9-82B5-52996E74E3FF	FCA1C7F5-E456-4574-9716-79770E6DAE8C	TCGA-AP-A0LH-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LH	TCGA-UCEC	1106	s5203	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Mixed serous and endometrioid	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9c0	58cfa82fe4b0c9d6adf6b9c0	TCGA-75-5147-10A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-75-5147-10A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_7_rg.sorted	TCGA-75-5147-10A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_7_rg.sorted.bam	46.4	1.9	0.15	58cfa82fe4b0c9d6adf6b9c0	TCGA-75-5147-10A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_7_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-5147-10A	D2824E6D-3784-45C2-9B0F-52B17356B5DA	Blood Derived Normal	Illumina HiSeq	1bbeacf6-d839-4656-a6ac-354d5ceae738	Lung	NA	C6EB2230-098B-4B50-85F5-1CDDFB1FB9A3	D20B4B63-2D12-4958-9BA8-E8B7538CA472	TCGA-75-5147-10A-01D-1623-02	HG19_Broad_variant	TCGA-75-5147	TCGA-LUAD	NA	s11250	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	TRUE
13722.58cfa830e4b0c9d6adf6bec7	58cfa830e4b0c9d6adf6bec7	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.bam	83.32	2.09	0.15	58cfa830e4b0c9d6adf6bec7	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LJ-01A	B4A520AE-F259-48C8-823E-C10B9B8A133A	Primary Tumor	Illumina HiSeq	c3705d55-9194-4d83-9162-41aae551e016	Uterus	42	BE3ED392-4D9F-4EAF-8A56-D251846DF4DA	2A88E054-E64F-4C5F-97F0-53F95D64FC04	TCGA-AP-A0LJ-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LJ	TCGA-UCEC	NA	s4996	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6be90	58cfa830e4b0c9d6adf6be90	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted.bam	92.87	2	0.15	58cfa830e4b0c9d6adf6be90	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A13I-01A	EBC094A6-CDC9-4C02-B8EC-A181B25A364D	Primary Tumor	Illumina HiSeq	b7cfe609-703a-4750-b9e7-5bda8e948cc4	Bladder	57	62C2BA8F-02E3-4100-86BC-5958038B4983	7C09CFF3-3162-4952-93AD-8A7D89F07266	TCGA-BL-A13I-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BL-A13I	TCGA-BLCA	223	s2689	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6beec	58cfa830e4b0c9d6adf6beec	TCGA-BL-A13J-10A-01D-A10R_120920_SN1222_0151_BD1D5CACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BL-A13J-10A-01D-A10R_120920_SN1222_0151_BD1D5CACXX_s_1_rg.sorted	TCGA-BL-A13J-10A-01D-A10R_120920_SN1222_0151_BD1D5CACXX_s_1_rg.sorted.bam	16.09	2.03	0.15	58cfa830e4b0c9d6adf6beec	TCGA-BL-A13J-10A-01D-A10R_120920_SN1222_0151_BD1D5CACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A13J-10A	556FCBC8-172A-4AF1-8822-AE036E8D68E8	Blood Derived Normal	Illumina HiSeq	db6e73ca-87ed-458b-9bd3-e274590e1b37	Bladder	65	C7348A4B-9360-4249-B1E2-CFD8647D3633	BE58C334-8842-4430-B763-D6186D19713C	TCGA-BL-A13J-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BL-A13J	TCGA-BLCA	81	s3264	Harvard Medical School	Christiana Healthcare	United States	NO	T4	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6be24	58cfa830e4b0c9d6adf6be24	TCGA-B7-5818-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_2_rg.sorted.filtered.	WGS	TCGA-B7-5818-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_2_rg.sorted	TCGA-B7-5818-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_2_rg.sorted.bam	299.7	1.9	0.16	58cfa830e4b0c9d6adf6be24	TCGA-B7-5818-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-B7-5818-10A	6E03B415-84A1-4B91-8717-1A41EDD4A255	Blood Derived Normal	Illumina HiSeq	144edb0d-1d38-420e-a1b5-ea974935bacf	Stomach	62	B55FF48A-8CD0-4B55-94AE-5537A956BF43	3505EFD5-D2CE-4FCC-9980-5FBF2522AF0D	TCGA-B7-5818-10A-01D-1598-02	HG19_Broad_variant	TCGA-B7-5818	TCGA-STAD	NA	s15447	Harvard Medical School	Cureline	Russia	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1598-02	TRUE
13722.58cfa830e4b0c9d6adf6bef8	58cfa830e4b0c9d6adf6bef8	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.bam	59.66	1.88	0.17	58cfa830e4b0c9d6adf6bef8	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28W-01A	A6D37F61-BECA-46EA-A59A-62257475AC77	Primary Tumor	Illumina HiSeq	32effbdc-7d3b-4ad8-9245-1a253cbe1ff3	Thyroid	32	32AEF736-82A4-4813-A272-86EF160E7D56	229AD821-4BB0-4046-B5E6-6193005D3C8A	TCGA-BJ-A28W-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28W	TCGA-THCA	NA	s12507	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6befa	58cfa830e4b0c9d6adf6befa	TCGA-BJ-A28W-10A-01D-A16N_120805_SN208_0421_AC11HPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A28W-10A-01D-A16N_120805_SN208_0421_AC11HPACXX_s_4_rg.sorted	TCGA-BJ-A28W-10A-01D-A16N_120805_SN208_0421_AC11HPACXX_s_4_rg.sorted.bam	62.61	1.87	0.17	58cfa830e4b0c9d6adf6befa	TCGA-BJ-A28W-10A-01D-A16N_120805_SN208_0421_AC11HPACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28W-10A	A6D37F61-BECA-46EA-A59A-62257475AC77	Blood Derived Normal	Illumina HiSeq	341f9656-c88d-4835-910f-e6e4ed9b7ad3	Thyroid	32	5961BC0B-0B25-426E-8318-6E04406630A1	1038A255-2A5F-4804-BCFB-F9E6701B5BFB	TCGA-BJ-A28W-10A-01D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28W	TCGA-THCA	NA	s12631	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6bf1c	58cfa830e4b0c9d6adf6bf1c	TCGA-BR-4267-11A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4267-11A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_7_rg.sorted	TCGA-BR-4267-11A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_7_rg.sorted.bam	273.9	1.9	0.15	58cfa830e4b0c9d6adf6bf1c	TCGA-BR-4267-11A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4267-11A	0D0F0200-25B8-483B-B04A-82A7833B4D30	Solid Tissue Normal	Illumina HiSeq	1ec7ecd8-69c7-4a5f-a296-4ebb9e591729	Stomach	51	5BD407C3-D3E1-44C1-8B1D-53951B497CF4	BC752F5C-8AC9-4DA9-A141-6DADD565B2EA	TCGA-BR-4267-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4267	TCGA-STAD	NA	s15045	Harvard Medical School	Asterand	None	NO	T2a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf60	58cfa830e4b0c9d6adf6bf60	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.bam	197.2	1.9	0.16	58cfa830e4b0c9d6adf6bf60	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4357-01A	BEC83DFF-2BBA-4467-92AA-5DC3DB9E0EAF	Primary Tumor	Illumina HiSeq	4bc9f55b-1edb-49c9-be1a-1d00a108b99b	Stomach	58	81C87C27-47C7-4DC7-BF92-E0037433DF30	93F60FA6-0D34-441E-8F61-80306E10D046	TCGA-BR-4357-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4357	TCGA-STAD	NA	s15301	Harvard Medical School	Asterand	Russia	NO	T3	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6bf68	58cfa830e4b0c9d6adf6bf68	TCGA-BR-4370-11A-01D-1154_130815_VM001_0003_VMR0003CXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-4370-11A-01D-1154_130815_VM001_0003_VMR0003CXX_s_2_rg.sorted	TCGA-BR-4370-11A-01D-1154_130815_VM001_0003_VMR0003CXX_s_2_rg.sorted.bam	93.3	1.9	0.15	58cfa830e4b0c9d6adf6bf68	TCGA-BR-4370-11A-01D-1154_130815_VM001_0003_VMR0003CXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4370-11A	A2A71CB0-9DBD-45CC-8867-DA84500515E7	Solid Tissue Normal	Illumina HiSeq	2d7a67d4-6bea-4ea5-a59c-edfc3adb7ed5	Stomach	74	A070F13B-EABC-4C8B-9587-E8BAA418B627	39E35101-5830-4EE4-88EE-63C559C10798	TCGA-BR-4370-11A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4370	TCGA-STAD	NA	s15107	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6bf8f	58cfa830e4b0c9d6adf6bf8f	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted.bam	106.93	1.95	0.16	58cfa830e4b0c9d6adf6bf8f	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K0-01A	29C8F468-5AC1-4D6C-8376-E36E6D246926	Primary Tumor	Illumina HiSeq	5de016ca-e694-4ebc-b06f-5d07f7523fda	Uterus	48	11C43948-E7C9-4436-A654-82FA8033B625	3296C785-7C20-487D-BAEC-C66022E77E53	TCGA-B5-A0K0-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K0	TCGA-UCEC	NA	s5204	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bf23	58cfa830e4b0c9d6adf6bf23	TCGA-B5-A0K1-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_4_rg.sorted.filtered.	WGS	TCGA-B5-A0K1-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_4_rg.sorted	TCGA-B5-A0K1-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_4_rg.sorted.bam	45.13	1.97	0.14	58cfa830e4b0c9d6adf6bf23	TCGA-B5-A0K1-10A-01D-A043_120214_SN590_0138_AC0E8HACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K1-10A	40A3ED98-3892-449C-B07E-7B7612BD997E	Blood Derived Normal	Illumina HiSeq	39f2c18d-e88e-4bae-a080-e0f971f99f99	Uterus	69	DCD30DE0-1752-4D6B-A20A-5054F63EC7C8	27572436-3466-419E-B630-67DCE18F6C6C	TCGA-B5-A0K1-10A-01D-A043-02	HG19_Broad_variant	TCGA-B5-A0K1	TCGA-UCEC	NA	s4597	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bfba	58cfa830e4b0c9d6adf6bfba	TCGA-BR-6707-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-6707-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_8_rg.sorted	TCGA-BR-6707-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_8_rg.sorted.bam	242	1.9	0.15	58cfa830e4b0c9d6adf6bfba	TCGA-BR-6707-10A-01D-1880_121220_SN1222_0163_AC1HA2ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6707-10A	DF3DF249-86C2-43D4-ABE1-796CD7DF653F	Blood Derived Normal	Illumina HiSeq	a99c1ab3-7b20-46dc-b74c-1866a6aaaf62	Stomach	75	40AA2161-2798-4CA5-ACE8-F6115E8BD86A	3957C639-FC9C-44C3-8256-27BA04BEF74E	TCGA-BR-6707-10A-01D-1880-02	HG19_Broad_variant	TCGA-BR-6707	TCGA-STAD	NA	s14621	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6bf95	58cfa830e4b0c9d6adf6bf95	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted.bam	29.7	1.9	0.13	58cfa830e4b0c9d6adf6bf95	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6564-01A	AF1086CC-B330-4AD6-AE1C-3B5C7259949A	Primary Tumor	Illumina HiSeq	6ee5a220-be0b-4909-bd37-5a6d8c53177d	Stomach	46	B8355E52-D7A7-4711-BBA7-BC4D201741F2	62E2C436-03DA-4B32-B43A-DF7AC992DD7C	TCGA-BR-6564-01A-12D-1880-02	HG19_Broad_variant	TCGA-BR-6564	TCGA-STAD	NA	s15051	Harvard Medical School	Asterand	Russia	NO	T3	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6c034	58cfa830e4b0c9d6adf6c034	TCGA-BR-6852-10A-01D-1880_130115_SN590_0207_AC1H8PACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-6852-10A-01D-1880_130115_SN590_0207_AC1H8PACXX_s_8_rg.sorted	TCGA-BR-6852-10A-01D-1880_130115_SN590_0207_AC1H8PACXX_s_8_rg.sorted.bam	312	1.8	0.16	58cfa830e4b0c9d6adf6c034	TCGA-BR-6852-10A-01D-1880_130115_SN590_0207_AC1H8PACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6852-10A	44799C67-61CD-4F3E-BDBC-423E2E0FD2E8	Blood Derived Normal	Illumina HiSeq	9f843373-3bfd-4a53-ba12-0a753b47d24d	Stomach	64	D97976AE-20EB-499F-ADAB-07CB854F1111	21A1C386-3D1A-40F2-854F-6BAF92BCB3AC	TCGA-BR-6852-10A-01D-1880-02	HG19_Broad_variant	TCGA-BR-6852	TCGA-STAD	NA	s15108	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6bf38	58cfa830e4b0c9d6adf6bf38	TCGA-AP-A0L8-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-AP-A0L8-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_6_rg.sorted	TCGA-AP-A0L8-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_6_rg.sorted.bam	35.69	1.84	0.17	58cfa830e4b0c9d6adf6bf38	TCGA-AP-A0L8-10A-01D-A043_120324_SN1120_0127_BC0L80ACXX_s_6_rg.sorted.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0L8-10A	9AA8C2B4-DB32-4899-BF0C-D578CB175E90	Blood Derived Normal	Illumina HiSeq	fa2fd6aa-d874-4777-b0af-20ce23f744ee	Uterus	70	6FFE937D-CB2E-49EA-9737-D2619A0EBB01	1ABAE462-1F01-44D5-8028-8F968E54FC72	TCGA-AP-A0L8-10A-01D-A043-02	HG19_Broad_variant	TCGA-AP-A0L8	TCGA-UCEC	1484	s4593	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c1f2	58cfa830e4b0c9d6adf6c1f2	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted.bam	70.31	1.91	0.17	58cfa830e4b0c9d6adf6c1f2	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted.bam	Dead	MALE	Not available	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20N-01A	EBEDAB7C-DD7C-448E-8324-78C86F13BE8B	Primary Tumor	Illumina HiSeq	c7de2a6f-d24f-4be6-98af-307070063116	Bladder	72	89EC2DFD-7A0C-4631-958D-D5492BC89F8D	CE801D11-240F-4510-8010-E3D7DA8247FC	TCGA-BT-A20N-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20N	TCGA-BLCA	795	s2697	Harvard Medical School	University of Pittsburgh	None	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	TRUE
13722.58cfa830e4b0c9d6adf6c1f8	58cfa830e4b0c9d6adf6c1f8	TCGA-BT-A20T-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BT-A20T-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_8_rg.sorted	TCGA-BT-A20T-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_8_rg.sorted.bam	10.21	1.76	0.18	58cfa830e4b0c9d6adf6c1f8	TCGA-BT-A20T-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20T-11A	096B4F32-10C1-4737-A0DD-CAE04C54EE33	Solid Tissue Normal	Illumina HiSeq	7205e655-2448-4a14-8a14-2a8a6a97c6ee	Bladder	63	27461A27-26EB-4C2C-9C54-E16FBD32C615	FF148CF3-AFB7-42F1-A137-AD7D6CB889C1	TCGA-BT-A20T-11A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20T	TCGA-BLCA	453	s2870	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A14U-02	TRUE
13722.58cfa830e4b0c9d6adf6c166	58cfa830e4b0c9d6adf6c166	TCGA-BS-A0TC-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0TC-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_1_rg.sorted	TCGA-BS-A0TC-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_1_rg.sorted.bam	15.3	1.98	0.17	58cfa830e4b0c9d6adf6c166	TCGA-BS-A0TC-10A-01D-A101_120409_SN1222_0095_AD0V1JACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TC-10A	7B7D2D2B-ABE6-4F32-ADD0-3715096995D1	Blood Derived Normal	Illumina HiSeq	dcd97c1e-7749-4903-ad55-e117ba95468d	Uterus	69	30B01B06-1614-43CA-86AE-204D55A40892	164DB1B3-6A8C-448E-B17E-0BD444F700B9	TCGA-BS-A0TC-10A-01D-A101-02	HG19_Broad_variant	TCGA-BS-A0TC	TCGA-UCEC	NA	s5013	Harvard Medical School	University of Hawaii	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bf14	58cfa830e4b0c9d6adf6bf14	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.bam	265.9	1.9	0.13	58cfa830e4b0c9d6adf6bf14	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4267-01A	0D0F0200-25B8-483B-B04A-82A7833B4D30	Primary Tumor	Illumina HiSeq	cd48e485-3a3f-4eec-92e7-f1c52c0866f1	Stomach	51	32D28ED3-2E33-4D83-8DE6-82E156B33211	F0DB5AF5-091F-4CDC-9917-BEFD658BF454	TCGA-BR-4267-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4267	TCGA-STAD	NA	s15044	Harvard Medical School	Asterand	None	NO	T2a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6c190	58cfa830e4b0c9d6adf6c190	TCGA-B7-5816-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_1_rg.sorted.filtered.	WGS	TCGA-B7-5816-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_1_rg.sorted	TCGA-B7-5816-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_1_rg.sorted.bam	459.7	1.9	0.16	58cfa830e4b0c9d6adf6c190	TCGA-B7-5816-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-B7-5816-10A	F07070C0-FD0A-4C19-BA1E-5F06B933CD7C	Blood Derived Normal	Illumina HiSeq	c42706d2-adb2-442e-a7d3-43fc52f02c43	Stomach	51	78BA755E-A4DA-4C45-B09A-250C815A85DB	0EB13C07-2B5D-4832-8BA0-A91D271FB5E6	TCGA-B7-5816-10A-01D-1598-02	HG19_Broad_variant	TCGA-B7-5816	TCGA-STAD	NA	s15178	Harvard Medical School	Cureline	Russia	NO	T4a	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IIB	1598-02	TRUE
13722.58cfa82ee4b0c9d6adf6afbe	58cfa82ee4b0c9d6adf6afbe	TCGA-05-4427-10A-01D-1853_120228_SN1120_0117_BC0DKWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-05-4427-10A-01D-1853_120228_SN1120_0117_BC0DKWACXX_s_2_rg.sorted	TCGA-05-4427-10A-01D-1853_120228_SN1120_0117_BC0DKWACXX_s_2_rg.sorted.bam	112	1.9	0.14	58cfa82ee4b0c9d6adf6afbe	TCGA-05-4427-10A-01D-1853_120228_SN1120_0117_BC0DKWACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4427-10A	78A24C56-576C-4245-BB42-6603B3D19897	Blood Derived Normal	Illumina HiSeq	9d47bafd-adc4-4120-b715-fe1ecbf86b82	Lung	65	3F3A0974-5AAD-4895-8153-B95D0D46595D	D161ED6B-FA73-4243-BFFD-921D92DB4E13	TCGA-05-4427-10A-01D-1853-02	HG19_Broad_variant	TCGA-05-4427	TCGA-LUAD	NA	s10985	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1853-02	TRUE
13722.58cfa830e4b0c9d6adf6c20a	58cfa830e4b0c9d6adf6c20a	TCGA-BT-A20N-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BT-A20N-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_2_rg.sorted	TCGA-BT-A20N-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_2_rg.sorted.bam	16.18	1.98	0.17	58cfa830e4b0c9d6adf6c20a	TCGA-BT-A20N-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_2_rg.sorted.bam	Dead	MALE	Not available	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20N-11A	EBEDAB7C-DD7C-448E-8324-78C86F13BE8B	Solid Tissue Normal	Illumina HiSeq	3a98735f-f5b6-4273-ac15-6d6f17971bcf	Bladder	72	753C9421-02BE-4ECD-9F8E-5DBB4FE72C38	0618C478-AD92-4BC0-A3F7-730181708653	TCGA-BT-A20N-11A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20N	TCGA-BLCA	795	s2869	Harvard Medical School	University of Pittsburgh	None	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	TRUE
13722.58cfa830e4b0c9d6adf6c1fa	58cfa830e4b0c9d6adf6c1fa	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.bam	476.7	1.9	0.16	58cfa830e4b0c9d6adf6c1fa	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5559-01A	17B17D91-C3DF-4B89-9C10-4DB069AFF656	Primary Tumor	Illumina HiSeq	a6749339-8b87-4219-84dd-8045857cbe79	Head and Neck	71	FBEA64F9-B46B-4AF1-BFB2-1791D93977B6	61532C84-EDD9-492D-AF89-99086F87381E	TCGA-BA-5559-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5559	TCGA-HNSC	NA	s16320	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1509-02	TRUE
13722.58cfa82fe4b0c9d6adf6b99a	58cfa82fe4b0c9d6adf6b99a	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.bam	877.7	1.9	0.15	58cfa82fe4b0c9d6adf6b99a	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5774-01A	FD3FC273-C035-40EA-A459-FF4806F5D592	Primary Tumor	Illumina HiSeq	b5b4f9c8-7044-4c76-ae48-241c8c4dd953	Lung	60	252C5D60-7033-44C3-8AB5-4604670A80F4	83902D13-5FD4-4640-B20F-3A8110F6D5EC	TCGA-64-5774-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5774	TCGA-LUAD	NA	s10910	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	TRUE
13722.58cfa830e4b0c9d6adf6c290	58cfa830e4b0c9d6adf6c290	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.bam	42.9	1.9	0.14	58cfa830e4b0c9d6adf6c290	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4294-01A	ACAB1362-C8A0-448B-8533-0CD84D97959C	Primary Tumor	Illumina HiSeq	23c036ca-ac6a-45dc-9100-558b2249f3bc	Stomach	65	CB5D3EDE-205D-43F6-A3E3-DB287FB1783B	97DB8928-FACC-4095-984F-07C52A759DB4	TCGA-BR-4294-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4294	TCGA-STAD	NA	s15374	Harvard Medical School	Asterand	Russia	NO	T2a	NX	Stomach  Intestinal Adenocarcinoma  Tubular Type	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6c216	58cfa830e4b0c9d6adf6c216	TCGA-BT-A20O-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BT-A20O-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_4_rg.sorted	TCGA-BT-A20O-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_4_rg.sorted.bam	10.13	1.84	0.17	58cfa830e4b0c9d6adf6c216	TCGA-BT-A20O-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20O-11A	C0E7FBE7-B9CB-4E65-941B-CD7D581C54EC	Solid Tissue Normal	Illumina HiSeq	d9764a1d-1e8f-47de-8916-e254751cd477	Bladder	75	F8846751-C6D7-4213-83BC-5A0382CBFFAE	F0DC405B-AFAB-4AE2-8585-295F6BC65243	TCGA-BT-A20O-11A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20O	TCGA-BLCA	370	s3086	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	TRUE
13722.58cfa830e4b0c9d6adf6c22c	58cfa830e4b0c9d6adf6c22c	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted.bam	12.85	1.87	0.15	58cfa830e4b0c9d6adf6c22c	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A0S7-01A	68BC786E-07C7-4964-BC88-5E2A8633626A	Primary Tumor	Illumina HiSeq	55a63ec5-a803-44ee-905f-c7bfff9162d6	Bladder	75	A9B73851-4609-4DF7-8EB8-45A56F4B2DD6	F415813D-F975-492B-9E4E-55CE47C967B9	TCGA-BT-A0S7-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BT-A0S7	TCGA-BLCA	200	s3269	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c2d0	58cfa830e4b0c9d6adf6c2d0	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.bam	52.72	1.93	0.17	58cfa830e4b0c9d6adf6c2d0	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-CE-A27D-01A	75A93F0E-CD41-43C6-A303-FF37E31395E9	Primary Tumor	Illumina HiSeq	c2d55126-05aa-44ef-97c3-ae2ac400c1b9	Thyroid	28	1807CEEE-28E1-4E8D-A1C4-6F6AD60EE310	CE991BB3-A63D-40C1-BFAF-3C4498D2C6EE	TCGA-CE-A27D-01A-11D-A16N-02	HG19_Broad_variant	TCGA-CE-A27D	TCGA-THCA	NA	s12362	Harvard Medical School	ILSbio	Vietnam	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6c24c	58cfa830e4b0c9d6adf6c24c	TCGA-BT-A20U-11A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BT-A20U-11A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_8_rg.sorted	TCGA-BT-A20U-11A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_8_rg.sorted.bam	50.51	2.1	0.16	58cfa830e4b0c9d6adf6c24c	TCGA-BT-A20U-11A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20U-11A	83B41D35-69B1-4218-BE1A-8821D8A6899C	Solid Tissue Normal	Illumina HiSeq	62a2b30e-c3e7-4831-8cda-b72f3d30157a	Bladder	70	996EE634-A7F1-4273-80D2-ADBD68D5A1CE	643C646C-1135-4636-9E12-67AED166780E	TCGA-BT-A20U-11A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20U	TCGA-BLCA	455	s2863	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	TRUE
13722.58cfa830e4b0c9d6adf6c312	58cfa830e4b0c9d6adf6c312	TCGA-BR-6706-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-6706-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_5_rg.sorted	TCGA-BR-6706-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_5_rg.sorted.bam	292.7	1.9	0.16	58cfa830e4b0c9d6adf6c312	TCGA-BR-6706-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6706-01A	93AEBBD4-19CF-495A-B8CE-3C4A3FEBA152	Primary Tumor	Illumina HiSeq	175293ed-2943-410e-8c01-a61c21354054	Stomach	63	C6BC78E9-87F1-4BE1-8EEB-17B2F59093E3	29893248-F981-4565-8754-AC75FB8C2586	TCGA-BR-6706-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6706	TCGA-STAD	NA	s15452	Harvard Medical School	Asterand	Ukraine	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6c2d6	58cfa830e4b0c9d6adf6c2d6	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.bam	333.7	1.9	0.15	58cfa830e4b0c9d6adf6c2d6	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6707-01A	DF3DF249-86C2-43D4-ABE1-796CD7DF653F	Primary Tumor	Illumina HiSeq	e2babdbd-1849-48ed-8726-1e3788be6064	Stomach	75	36F691AA-B737-4369-AD62-84F987F697A6	AA430360-2BE7-4C92-A10C-52588D8A6061	TCGA-BR-6707-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6707	TCGA-STAD	NA	s14890	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6c2ba	58cfa830e4b0c9d6adf6c2ba	TCGA-CE-A27D-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CE-A27D-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_2_rg.sorted	TCGA-CE-A27D-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_2_rg.sorted.bam	138.72	1.98	0.16	58cfa830e4b0c9d6adf6c2ba	TCGA-CE-A27D-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_2_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-CE-A27D-10A	75A93F0E-CD41-43C6-A303-FF37E31395E9	Blood Derived Normal	Illumina HiSeq	3bef8106-13f9-47e1-b775-aed6791c0d10	Thyroid	28	C850C70D-E86D-4F21-A6C3-62976A48033E	515713BB-0323-40A3-B2F0-52CA03F6860E	TCGA-CE-A27D-10A-01D-A16N-02	HG19_Broad_variant	TCGA-CE-A27D	TCGA-THCA	NA	s12510	Harvard Medical School	ILSbio	Vietnam	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6c2e4	58cfa830e4b0c9d6adf6c2e4	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.bam	487.7	1.9	0.14	58cfa830e4b0c9d6adf6c2e4	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6802-01A	7C831A1D-3253-4AF4-A0FF-7FE9FF9AF1CE	Primary Tumor	Illumina HiSeq	73cec875-41a5-40bd-9d13-9e1ed4dd64d0	Stomach	65	E3BF04C2-961F-4511-AF63-5A0E8AE6377B	0B4F4B0B-EF5C-4717-875A-7B8C5342DBC4	TCGA-BR-6802-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6802	TCGA-STAD	NA	s14885	Harvard Medical School	Asterand	Russia	NO	T3	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6c305	58cfa830e4b0c9d6adf6c305	TCGA-BR-6802-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-6802-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_8_rg.sorted	TCGA-BR-6802-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_8_rg.sorted.bam	249	1.9	0.15	58cfa830e4b0c9d6adf6c305	TCGA-BR-6802-10A-01D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6802-10A	7C831A1D-3253-4AF4-A0FF-7FE9FF9AF1CE	Blood Derived Normal	Illumina HiSeq	2c69e92d-3297-4add-a687-68ad89040c66	Stomach	65	4FD5B38F-5857-4E1F-86DE-BD44D1D80207	DEA0515B-71BD-4B14-9666-446C1E128F8B	TCGA-BR-6802-10A-01D-1880-02	HG19_Broad_variant	TCGA-BR-6802	TCGA-STAD	NA	s15238	Harvard Medical School	Asterand	Russia	NO	T3	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1880-02	TRUE
13722.58cfa830e4b0c9d6adf6c306	58cfa830e4b0c9d6adf6c306	TCGA-BR-6803-10A-01D-1880_130115_SN590_0207_AC1H8PACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-6803-10A-01D-1880_130115_SN590_0207_AC1H8PACXX_s_6_rg.sorted	TCGA-BR-6803-10A-01D-1880_130115_SN590_0207_AC1H8PACXX_s_6_rg.sorted.bam	188	1.9	0.15	58cfa830e4b0c9d6adf6c306	TCGA-BR-6803-10A-01D-1880_130115_SN590_0207_AC1H8PACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6803-10A	2F90209B-7464-4D7E-83D1-67850C263DED	Blood Derived Normal	Illumina HiSeq	8e0aa4a2-6371-4260-ac1c-249ff5c4f1f9	Stomach	54	68D1CB22-4E71-4187-943A-9984754C98A9	2252B273-50EA-45D3-A87D-F51D0C6547F7	TCGA-BR-6803-10A-01D-1880-02	HG19_Broad_variant	TCGA-BR-6803	TCGA-STAD	NA	s14401	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IIA	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c324	58cfa831e4b0c9d6adf6c324	TCGA-CG-4472-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4472-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_2_rg.sorted	TCGA-CG-4472-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_2_rg.sorted.bam	47.6	1.9	0.15	58cfa831e4b0c9d6adf6c324	TCGA-CG-4472-10A-01D-1154_130815_VM001_0006_VMR0006CXX_s_2_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4472-10A	306F0222-8734-44CA-9A31-86E4E62B0A1B	Blood Derived Normal	Illumina HiSeq	e9ebc1e2-3bf0-48b2-bfee-bff5a72097dd	Stomach	49	37B5833C-2E32-4077-A3E1-48735827FE29	6958B1D6-FCF8-4B38-A669-F0F834B1D02A	TCGA-CG-4472-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4472	TCGA-STAD	NA	s15193	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Not available	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c350	58cfa831e4b0c9d6adf6c350	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted.bam	152	1.9	0.15	58cfa831e4b0c9d6adf6c350	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5717-01A	BDC3899E-15AE-421F-829B-0E07FBD27C60	Primary Tumor	Illumina HiSeq	34ec4e75-2398-4904-adf0-34500892e1a5	Stomach	58	CEA37BBD-1BCC-4205-BE3D-DAFAC2E30256	64826993-D765-4895-BE39-BE5ECC72807B	TCGA-CG-5717-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5717	TCGA-STAD	212	s14488	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c336	58cfa831e4b0c9d6adf6c336	TCGA-CG-4472-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-4472-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_8_rg.sorted	TCGA-CG-4472-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_8_rg.sorted.bam	47.6	1.9	0.15	58cfa831e4b0c9d6adf6c336	TCGA-CG-4472-10A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_8_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4472-10A	306F0222-8734-44CA-9A31-86E4E62B0A1B	Blood Derived Normal	Illumina HiSeq	0f6fc60a-9288-4cc4-9b91-35bb56cbad3f	Stomach	49	37B5833C-2E32-4077-A3E1-48735827FE29	6958B1D6-FCF8-4B38-A669-F0F834B1D02A	TCGA-CG-4472-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4472	TCGA-STAD	NA	s14638	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Not available	Stage IV	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c3d7	58cfa831e4b0c9d6adf6c3d7	TCGA-CH-5741-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CH-5741-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_2_rg.sorted	TCGA-CH-5741-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_2_rg.sorted.bam	170.4	1.9	0.15	58cfa831e4b0c9d6adf6c3d7	TCGA-CH-5741-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5741-10A	B3BF57D4-E31A-4740-B438-FA826FB79550	Blood Derived Normal	Illumina HiSeq	b82ce0ca-281f-43c5-a79e-de66036ebf94	Prostate	56	CA3BC043-4D2E-4C95-88E8-94D61B8C9DA0	849BD756-7D8C-4739-B54E-FAC588C4A9B0	TCGA-CH-5741-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5741	TCGA-PRAD	NA	s3928	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c3f8	58cfa831e4b0c9d6adf6c3f8	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted.bam	30.7	1.9	0.14	58cfa831e4b0c9d6adf6c3f8	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5771-01A	3ACD8328-76F7-4F43-9660-394B95748C3D	Primary Tumor	Illumina HiSeq	93b110cf-3f4b-4f72-8025-320b77838b0a	Prostate	63	19C87DE2-7936-4277-8AA8-3942D36E7579	83F4BDB9-ED8B-4472-87BB-74C901B1A350	TCGA-CH-5771-01A-21D-1572-02	HG19_Broad_variant	TCGA-CH-5771	TCGA-PRAD	NA	s3931	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c37a	58cfa831e4b0c9d6adf6c37a	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.bam	46	1.9	0.17	58cfa831e4b0c9d6adf6c37a	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5813-01A	152B9D8A-19FD-4665-B9E4-4FEDFB1608CD	Primary Tumor	Illumina HiSeq	ccc0d204-3529-43aa-b108-62d12f6465bd	Stomach	60	09E42E33-D2EC-406C-9A42-36D9D2EBD6C6	2118F0C5-3178-40EA-850D-C3F6F8752DD9	TCGA-CD-5813-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5813	TCGA-STAD	NA	s14408	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3c4	58cfa831e4b0c9d6adf6c3c4	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted.bam	63.78	1.88	0.16	58cfa831e4b0c9d6adf6c3c4	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20O-01A	C0E7FBE7-B9CB-4E65-941B-CD7D581C54EC	Primary Tumor	Illumina HiSeq	c345a912-f3c8-4622-9793-88cf795fc964	Bladder	75	5ECD84AD-44FD-4599-BF3D-AB725E0404EC	13596E86-7CD8-4A07-941F-E936D0004F6B	TCGA-BT-A20O-01A-21D-A14U-02	HG19_Broad_variant	TCGA-BT-A20O	TCGA-BLCA	370	s3090	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c464	58cfa831e4b0c9d6adf6c464	TCGA-CH-5743-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CH-5743-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_4_rg.sorted	TCGA-CH-5743-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_4_rg.sorted.bam	26.4	1.9	0.15	58cfa831e4b0c9d6adf6c464	TCGA-CH-5743-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5743-10A	2DEE4BD8-B00E-4F8A-BFEA-5D8D1A068202	Blood Derived Normal	Illumina HiSeq	9e05f936-10ec-46a8-96d8-efc5c8510e51	Prostate	66	83AE9498-5808-4360-ACAD-E0C5948F27A4	43E22987-804C-496E-8011-BDB9340C4A33	TCGA-CH-5743-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5743	TCGA-PRAD	NA	s3587	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c465	58cfa831e4b0c9d6adf6c465	TCGA-CG-5733-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-5733-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_3_rg.sorted	TCGA-CG-5733-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_3_rg.sorted.bam	332	1.9	0.15	58cfa831e4b0c9d6adf6c465	TCGA-CG-5733-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_3_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5733-01A	8A9AFA5E-63CE-41EB-AAFB-B0B03653DA5A	Primary Tumor	Illumina HiSeq	4b31f837-59fa-48a7-bfbc-475e1251bd07	Stomach	83	315E485B-3069-4ADC-8AB5-BEDCC0642930	73EA65AA-3677-425F-B084-1FC3BEBA2D03	TCGA-CG-5733-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5733	TCGA-STAD	641	s14492	Harvard Medical School	Indivumed	Germany	NO	T2	N2	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c3ea	58cfa831e4b0c9d6adf6c3ea	TCGA-CH-5745-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CH-5745-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_8_rg.sorted	TCGA-CH-5745-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_8_rg.sorted.bam	128.4	1.9	0.15	58cfa831e4b0c9d6adf6c3ea	TCGA-CH-5745-10A-01D-1572_130104_SN1120_0209_BD1KP6ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5745-10A	AC67D0DF-7DC0-4A1A-8B47-BEEC9B94DE86	Blood Derived Normal	Illumina HiSeq	9ea9f797-df7f-4211-af54-30bb1c25941b	Prostate	68	690A7FAC-91CD-45C5-8DB7-69D7B9D1DBBF	D2F85EE6-E96F-42E5-86E4-2933E646D193	TCGA-CH-5745-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5745	TCGA-PRAD	NA	s3929	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c3f6	58cfa831e4b0c9d6adf6c3f6	TCGA-CH-5769-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CH-5769-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_6_rg.sorted	TCGA-CH-5769-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_6_rg.sorted.bam	175.7	2	0.13	58cfa831e4b0c9d6adf6c3f6	TCGA-CH-5769-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5769-11A	A7B76662-8380-4F35-9307-99C0ACACB904	Solid Tissue Normal	Illumina HiSeq	f2ed1ffa-45fe-4497-9137-3a7270cc913b	Prostate	48	B41D906B-2FEF-45C9-8B3A-C52B5856950E	7E331D74-AD6C-49D7-A9BD-7CFE657B5567	TCGA-CH-5769-11A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5769	TCGA-PRAD	NA	s3937	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c52e	58cfa831e4b0c9d6adf6c52e	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted.bam	75.7	1.9	0.15	58cfa831e4b0c9d6adf6c52e	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5769-01A	A7B76662-8380-4F35-9307-99C0ACACB904	Primary Tumor	Illumina HiSeq	2fe51267-827f-4ffb-8aa8-42352e2352d5	Prostate	48	18606532-21D5-40BF-92CF-A42B027449A1	5488DCD8-EC8B-4E14-8F62-5F9931580B87	TCGA-CH-5769-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5769	TCGA-PRAD	NA	s3424	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c534	58cfa831e4b0c9d6adf6c534	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted.bam	273.7	1.9	0.15	58cfa831e4b0c9d6adf6c534	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5766-01A	A5C77AB6-6E98-4A3D-81C8-F3D5FABD31D2	Primary Tumor	Illumina HiSeq	f778efd0-d2ed-48bc-ab57-e2bd12130169	Prostate	55	8477DA86-95BD-4B6D-A3E8-C16C9D61EA1F	ACAE8359-C2D0-4EB8-836B-D0BDF815F065	TCGA-CH-5766-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5766	TCGA-PRAD	NA	s3421	Harvard Medical School	Indivumed	Germany	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c428	58cfa831e4b0c9d6adf6c428	TCGA-BT-A20W-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BT-A20W-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_6_rg.sorted	TCGA-BT-A20W-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_6_rg.sorted.bam	21.45	2.03	0.15	58cfa831e4b0c9d6adf6c428	TCGA-BT-A20W-11A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20W-11A	4DC5CFFE-ED8C-47AB-B5FC-F9615B5414F7	Solid Tissue Normal	Illumina HiSeq	f3f37b3b-3755-4102-b654-abea4d035ed1	Bladder	71	5FF660D2-10DE-4D72-BDE0-93840309B5E5	47F326E8-52A3-43C8-BF5E-43358E0D13B9	TCGA-BT-A20W-11A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20W	TCGA-BLCA	254	s2695	Harvard Medical School	University of Pittsburgh	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c536	58cfa831e4b0c9d6adf6c536	TCGA-CH-5763-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5763-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_3_rg.sorted	TCGA-CH-5763-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_3_rg.sorted.bam	172.7	1.9	0.17	58cfa831e4b0c9d6adf6c536	TCGA-CH-5763-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5763-01A	18E79A01-07A2-4CD5-B700-71D41724E041	Primary Tumor	Illumina HiSeq	25246d22-8217-4900-8b3c-c63126974b5c	Prostate	66	F4192448-E5B3-4A9F-8354-9FE28503017A	0B812175-D56C-4407-9745-8DA5B8E531B4	TCGA-CH-5763-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5763	TCGA-PRAD	NA	s4126	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c492	58cfa831e4b0c9d6adf6c492	TCGA-CD-5813-10A-01D-1598_121026_SN1120_0198_BC188JACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CD-5813-10A-01D-1598_121026_SN1120_0198_BC188JACXX_s_6_rg.sorted	TCGA-CD-5813-10A-01D-1598_121026_SN1120_0198_BC188JACXX_s_6_rg.sorted.bam	125.7	1.9	0.14	58cfa831e4b0c9d6adf6c492	TCGA-CD-5813-10A-01D-1598_121026_SN1120_0198_BC188JACXX_s_6_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5813-10A	152B9D8A-19FD-4665-B9E4-4FEDFB1608CD	Blood Derived Normal	Illumina HiSeq	7cbca34e-4195-452d-84af-5ae9596c63af	Stomach	60	BDD59D7A-02EC-49A5-B797-5AC689AA00A5	021DAB66-2CCD-46F4-A889-C7B4D423453E	TCGA-CD-5813-10A-01D-1598-02	HG19_Broad_variant	TCGA-CD-5813	TCGA-STAD	NA	s15319	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c46d	58cfa831e4b0c9d6adf6c46d	TCGA-CD-5799-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CD-5799-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_4_rg.sorted	TCGA-CD-5799-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_4_rg.sorted.bam	79.4	1.9	0.16	58cfa831e4b0c9d6adf6c46d	TCGA-CD-5799-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5799-10A	C991697F-77F9-412A-9BD1-0E47F7387CB2	Blood Derived Normal	Illumina HiSeq	da9b3cb3-7284-4196-ae37-470689dcf5bd	Stomach	45	02A57E6D-BFA6-4A57-9C36-1292CAF91EB4	ED920586-15C8-4E14-8EDD-996771D6A569	TCGA-CD-5799-10A-01D-1598-02	HG19_Broad_variant	TCGA-CD-5799	TCGA-STAD	NA	s15117	Harvard Medical School	ILSbio	Vietnam	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c53b	58cfa831e4b0c9d6adf6c53b	TCGA-CH-5761-11A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CH-5761-11A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_8_rg.sorted	TCGA-CH-5761-11A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_8_rg.sorted.bam	215.7	1.9	0.13	58cfa831e4b0c9d6adf6c53b	TCGA-CH-5761-11A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5761-11A	854A481B-71A2-4F23-80AA-E91E9F4069B1	Solid Tissue Normal	Illumina HiSeq	ce8211c1-e866-447d-9c68-847d7d6d07f8	Prostate	61	2FC91628-6898-4D9D-931B-45D793450207	DEA1EF4F-6B51-4310-9E60-A9D9C27C1D41	TCGA-CH-5761-11A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5761	TCGA-PRAD	NA	s3939	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c540	58cfa831e4b0c9d6adf6c540	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted.bam	157.7	1.9	0.17	58cfa831e4b0c9d6adf6c540	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5764-01A	ED73F136-42E8-4100-B432-D10370D07E8B	Primary Tumor	Illumina HiSeq	036937fb-20a8-45df-a234-f7396aefb2d1	Prostate	66	48726D56-93A1-4730-A660-FCEEE0321084	F57D0D07-21B0-4901-9D81-C371C4673D4A	TCGA-CH-5764-01A-21D-1572-02	HG19_Broad_variant	TCGA-CH-5764	TCGA-PRAD	NA	s3777	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c54c	58cfa831e4b0c9d6adf6c54c	TCGA-CH-5766-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CH-5766-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_2_rg.sorted	TCGA-CH-5766-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_2_rg.sorted.bam	52.7	2	0.14	58cfa831e4b0c9d6adf6c54c	TCGA-CH-5766-11A-01D-1572_130104_SN208_0446_BD1KR5ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5766-11A	A5C77AB6-6E98-4A3D-81C8-F3D5FABD31D2	Solid Tissue Normal	Illumina HiSeq	3e827e6b-5861-47a6-9904-89cef9f94a0f	Prostate	55	09E15F2E-FC45-4ABA-86D6-2A5DD97AE173	536FED80-5729-4B83-93A0-FCFF2025B722	TCGA-CH-5766-11A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5766	TCGA-PRAD	NA	s4127	Harvard Medical School	Indivumed	Germany	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c3a0	58cfa831e4b0c9d6adf6c3a0	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted.bam	68.38	1.71	0.17	58cfa831e4b0c9d6adf6c3a0	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20U-01A	83B41D35-69B1-4218-BE1A-8821D8A6899C	Primary Tumor	Illumina HiSeq	9947c8cb-fa3d-4cc2-942e-b013f7a47faa	Bladder	70	D29E555F-8467-45C8-9124-0E6A757B1ADF	8D4442E9-3312-4607-A59F-49538B19FA71	TCGA-BT-A20U-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20U	TCGA-BLCA	455	s3270	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c54e	58cfa831e4b0c9d6adf6c54e	TCGA-CH-5765-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CH-5765-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_8_rg.sorted	TCGA-CH-5765-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_8_rg.sorted.bam	100.7	2	0.14	58cfa831e4b0c9d6adf6c54e	TCGA-CH-5765-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5765-11A	716EB429-D7AF-4D4F-BD8D-AFCFF1A323EE	Solid Tissue Normal	Illumina HiSeq	b2118b85-15e8-4468-ac1e-ae5862adf28d	Prostate	55	98DE6EDA-3A96-4CC1-9BF3-643F4BD6E87A	24C79143-DE2A-4834-92B2-C6F2421F7CF9	TCGA-CH-5765-11A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5765	TCGA-PRAD	NA	s3418	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c4b7	58cfa831e4b0c9d6adf6c4b7	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted.bam	201.9	1.9	0.14	58cfa831e4b0c9d6adf6c4b7	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4253-01A	411257A4-A148-4606-8C8B-F9F1240E40ED	Primary Tumor	Illumina HiSeq	90590609-4f3e-48b4-98e5-963c1c97f057	Stomach	80	C536B8DF-6FE3-425E-82E8-36299A6BA2B9	B7CE561B-B51B-4C85-822D-58DF663DE8EA	TCGA-BR-4253-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4253	TCGA-STAD	NA	s15104	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1128-02	TRUE
13722.58cfa831e4b0c9d6adf6c552	58cfa831e4b0c9d6adf6c552	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted.bam	211.7	1.9	0.15	58cfa831e4b0c9d6adf6c552	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5762-01A	D4FFAFDC-EE83-43DF-AA3B-7326503C6438	Primary Tumor	Illumina HiSeq	70b297c6-c1f6-4651-93c3-17888cf0b118	Prostate	60	6D1A2D44-72F3-4333-8506-E53CDC4E5185	25189A34-4C05-4D77-9A3B-212A475F66B1	TCGA-CH-5762-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5762	TCGA-PRAD	NA	s3594	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c564	58cfa831e4b0c9d6adf6c564	TCGA-CH-5752-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CH-5752-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_2_rg.sorted	TCGA-CH-5752-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_2_rg.sorted.bam	79.4	1.9	0.14	58cfa831e4b0c9d6adf6c564	TCGA-CH-5752-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5752-10A	D8F56D75-51AB-4A86-A502-C86E1DCD1EFF	Blood Derived Normal	Illumina HiSeq	78b4b6a6-b8b1-4499-8d0d-6f183072b505	Prostate	66	29DDF3D3-369B-4340-9B4F-338C23BE538A	5568CB77-E553-43F6-A320-3BF96A3E88B2	TCGA-CH-5752-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5752	TCGA-PRAD	NA	s3423	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c542	58cfa831e4b0c9d6adf6c542	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted.bam	197.7	1.9	0.16	58cfa831e4b0c9d6adf6c542	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5754-01A	0AAD0ABD-750A-400D-A34F-491DA996D46C	Primary Tumor	Illumina HiSeq	9b3dfe47-a8c3-4a73-8aa3-66af9d5001a2	Prostate	65	BE645D37-B3E1-4D09-91CB-6231E25ACEB8	2C0EF4A5-DC20-45E7-B8EE-7525D77128B6	TCGA-CH-5754-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5754	TCGA-PRAD	NA	s3596	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c55e	58cfa831e4b0c9d6adf6c55e	TCGA-CH-5753-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CH-5753-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_4_rg.sorted	TCGA-CH-5753-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_4_rg.sorted.bam	368.4	1.9	0.16	58cfa831e4b0c9d6adf6c55e	TCGA-CH-5753-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5753-10A	928C48A0-68EE-4E28-AE83-9832E52850CA	Blood Derived Normal	Illumina HiSeq	7244700c-38c6-43d7-8edd-8ffe49b8b04c	Prostate	70	075D2A08-79D0-4AA7-91D5-26BB3A1C3AB2	3E161E33-5110-47FF-ADC7-7F56DB149050	TCGA-CH-5753-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5753	TCGA-PRAD	NA	s3415	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c556	58cfa831e4b0c9d6adf6c556	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted.bam	191.7	1.9	0.16	58cfa831e4b0c9d6adf6c556	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5752-01A	D8F56D75-51AB-4A86-A502-C86E1DCD1EFF	Primary Tumor	Illumina HiSeq	d1bae4e7-eb79-4ede-abb5-19a328e4ad0c	Prostate	66	94A01526-7771-4A05-A9CE-9694B73DF3A7	490FC467-7E7E-40A1-98D0-ABA46EC71F53	TCGA-CH-5752-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5752	TCGA-PRAD	NA	s3427	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c562	58cfa831e4b0c9d6adf6c562	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted.bam	197.7	1.9	0.15	58cfa831e4b0c9d6adf6c562	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5761-01A	854A481B-71A2-4F23-80AA-E91E9F4069B1	Primary Tumor	Illumina HiSeq	4d316299-7958-45e8-93ab-2150e05d3210	Prostate	61	332A54B1-2DF4-4BAA-84AC-2D95ABEF4064	F2F787DA-691C-4E73-A8B1-8D662781953E	TCGA-CH-5761-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5761	TCGA-PRAD	NA	s3593	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c565	58cfa831e4b0c9d6adf6c565	TCGA-CH-5763-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CH-5763-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_4_rg.sorted	TCGA-CH-5763-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_4_rg.sorted.bam	116.7	1.9	0.13	58cfa831e4b0c9d6adf6c565	TCGA-CH-5763-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5763-11A	18E79A01-07A2-4CD5-B700-71D41724E041	Solid Tissue Normal	Illumina HiSeq	51855ca2-0a23-4f4a-8e63-5b34fcb33c98	Prostate	66	20F71991-0257-47C1-AE58-A64C83EAF8FE	913AAA7F-C6B7-47F7-B046-6548F217180D	TCGA-CH-5763-11A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5763	TCGA-PRAD	NA	s3778	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c56a	58cfa831e4b0c9d6adf6c56a	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted.bam	256.7	1.9	0.16	58cfa831e4b0c9d6adf6c56a	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5765-01A	716EB429-D7AF-4D4F-BD8D-AFCFF1A323EE	Primary Tumor	Illumina HiSeq	265ff01e-199b-4908-acaa-62aa8986967a	Prostate	55	E2359111-B056-4676-A8B6-C5CEA259B478	B7EFFFED-73EC-4139-A359-41B239F2978D	TCGA-CH-5765-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5765	TCGA-PRAD	NA	s3428	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c568	58cfa831e4b0c9d6adf6c568	TCGA-CH-5762-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CH-5762-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_2_rg.sorted	TCGA-CH-5762-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_2_rg.sorted.bam	91.7	2	0.13	58cfa831e4b0c9d6adf6c568	TCGA-CH-5762-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5762-11A	D4FFAFDC-EE83-43DF-AA3B-7326503C6438	Solid Tissue Normal	Illumina HiSeq	823dc639-947b-44e0-839b-882ab9437fac	Prostate	60	B95300F1-994C-4DE7-AC5B-964D7EA4E358	8897B262-39F8-492F-99A2-93C4012D6241	TCGA-CH-5762-11A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5762	TCGA-PRAD	NA	s3938	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c550	58cfa831e4b0c9d6adf6c550	TCGA-CH-5754-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CH-5754-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_6_rg.sorted	TCGA-CH-5754-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_6_rg.sorted.bam	104.4	1.9	0.14	58cfa831e4b0c9d6adf6c550	TCGA-CH-5754-10A-01D-1572_130103_SN1222_0166_BD1K7EACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5754-10A	0AAD0ABD-750A-400D-A34F-491DA996D46C	Blood Derived Normal	Illumina HiSeq	eff5ccea-5f74-449e-a9e6-4eb5a83e71c7	Prostate	65	C424E5E9-8E39-4C4B-A02D-37B6E7F11E38	76512EE5-8E1C-4A61-A662-AD9FF0DA8746	TCGA-CH-5754-10A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5754	TCGA-PRAD	NA	s3940	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c56e	58cfa831e4b0c9d6adf6c56e	TCGA-CH-5764-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CH-5764-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_6_rg.sorted	TCGA-CH-5764-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_6_rg.sorted.bam	52.7	2	0.16	58cfa831e4b0c9d6adf6c56e	TCGA-CH-5764-11A-01D-1572_130104_SN208_0445_AC1JWAACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5764-11A	ED73F136-42E8-4100-B432-D10370D07E8B	Solid Tissue Normal	Illumina HiSeq	2a2319bf-1c6c-4a8d-84e0-a9b256cb0903	Prostate	66	9A252640-7E22-42F9-917B-DD54A0EC8EAD	CDAA0E08-857F-47D2-A11B-196F56C5DE04	TCGA-CH-5764-11A-01D-1572-02	HG19_Broad_variant	TCGA-CH-5764	TCGA-PRAD	NA	s3419	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c632	58cfa831e4b0c9d6adf6c632	TCGA-CG-4441-01A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4441-01A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_1_rg.sorted	TCGA-CG-4441-01A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_1_rg.sorted.bam	250	1.9	0.15	58cfa831e4b0c9d6adf6c632	TCGA-CG-4441-01A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_1_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4441-01A	37E22429-EFD7-4D6A-B79A-9D8C7BE2170C	Primary Tumor	Illumina HiSeq	d3542e45-2b25-406d-976d-5d4c63e4839e	Stomach	83	60937697-57BA-4D03-9545-B0E321215448	DE856FF9-FEF4-4AA8-9418-F29EB79932B0	TCGA-CG-4441-01A-01D-1798-02	HG19_Broad_variant	TCGA-CG-4441	TCGA-STAD	426	s14699	Harvard Medical School	Indivumed	Germany	NO	T2	N2	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c636	58cfa831e4b0c9d6adf6c636	TCGA-CG-4441-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4441-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_2_rg.sorted	TCGA-CG-4441-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_2_rg.sorted.bam	30	1.9	0.15	58cfa831e4b0c9d6adf6c636	TCGA-CG-4441-10A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_2_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4441-10A	37E22429-EFD7-4D6A-B79A-9D8C7BE2170C	Blood Derived Normal	Illumina HiSeq	a450bc30-69de-4e0a-a561-2145c316b5f1	Stomach	83	869BA8D0-89C5-4753-8F7A-403EA5A7F20F	9F2622C7-461C-419B-B0F3-2AAAE488592C	TCGA-CG-4441-10A-01D-1798-02	HG19_Broad_variant	TCGA-CG-4441	TCGA-STAD	426	s15395	Harvard Medical School	Indivumed	Germany	NO	T2	N2	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c629	58cfa831e4b0c9d6adf6c629	TCGA-CQ-6219-10A-01D-1911_120504_SN1222_0101_AC0UMDACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CQ-6219-10A-01D-1911_120504_SN1222_0101_AC0UMDACXX_s_8_rg.sorted	TCGA-CQ-6219-10A-01D-1911_120504_SN1222_0101_AC0UMDACXX_s_8_rg.sorted.bam	54	NA	0.16	58cfa831e4b0c9d6adf6c629	TCGA-CQ-6219-10A-01D-1911_120504_SN1222_0101_AC0UMDACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6219-10A	0CA3D25A-22E9-4E40-834B-65F402535005	Blood Derived Normal	Illumina HiSeq	24f2b999-b137-4cd9-8d46-948ef995485d	Head and Neck	50	A10F3B24-FF67-48FB-9EB3-AFB10B3D36FB	008B9151-B9C9-42D8-AC2A-E2F3C4A62ABC	TCGA-CQ-6219-10A-01D-1911-02	HG19_Broad_variant	TCGA-CQ-6219	TCGA-HNSC	479	s15770	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N2a	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c6ce	58cfa831e4b0c9d6adf6c6ce	TCGA-CS-6290-01A-11D-1703_130808_SN208_0487_AC28U7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CS-6290-01A-11D-1703_130808_SN208_0487_AC28U7ACXX_s_7_rg.sorted	TCGA-CS-6290-01A-11D-1703_130808_SN208_0487_AC28U7ACXX_s_7_rg.sorted.bam	95.3	1.9	0.15	58cfa831e4b0c9d6adf6c6ce	TCGA-CS-6290-01A-11D-1703_130808_SN208_0487_AC28U7ACXX_s_7_rg.sorted.bam	Alive	MALE	Not available	Not available	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-6290-01A	42FE260F-520B-4FAC-8C09-D2B31AED59FB	Primary Tumor	Illumina HiSeq	dd2c0db0-5e68-43b9-a591-4efa9a782af1	Brain	31	6148F31E-CDBA-481B-BCD7-B3AEE05925B1	D31BD4D8-DF61-4B6B-9304-17B22FDD023B	TCGA-CS-6290-01A-11D-1703-02	HG19_Broad_variant	TCGA-CS-6290	TCGA-LGG	NA	s8555	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6c6b3	58cfa831e4b0c9d6adf6c6b3	TCGA-CV-5966-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-5966-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_7_rg.sorted	TCGA-CV-5966-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_7_rg.sorted.bam	62	1.8	0.14	58cfa831e4b0c9d6adf6c6b3	TCGA-CV-5966-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5966-10A	0D0731E2-8D82-4B6D-9258-2896A770A868	Blood Derived Normal	Illumina HiSeq	29536ca9-0a82-43fd-869c-1663c534daee	Head and Neck	63	BAD68BB8-4147-4981-959E-440AFC642F6E	154101FF-F8CF-4D61-BE7E-1DC04317799B	TCGA-CV-5966-10A-01D-1868-02	HG19_Broad_variant	TCGA-CV-5966	TCGA-HNSC	545	s16195	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6c6d6	58cfa831e4b0c9d6adf6c6d6	TCGA-CS-4944-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CS-4944-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_4_rg.sorted	TCGA-CS-4944-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_4_rg.sorted.bam	420.7	1.9	0.15	58cfa831e4b0c9d6adf6c6d6	TCGA-CS-4944-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	Not available	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-4944-10A	64CD17EB-C778-45E9-B994-02B68182E51B	Blood Derived Normal	Illumina HiSeq	4454284c-2c7d-48f0-8ddb-ee4896355ab4	Brain	50	7A4DC30F-0128-4BAF-B6CC-91773BF41E45	C1CB9060-2D95-4139-8881-6C4BB98AEEAD	TCGA-CS-4944-10A-01D-1465-02	HG19_Broad_variant	TCGA-CS-4944	TCGA-LGG	NA	s8554	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Astrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c67c	58cfa831e4b0c9d6adf6c67c	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted.bam	187.7	1.9	0.14	58cfa831e4b0c9d6adf6c67c	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4739-01A	7E3B90C1-8772-4E12-8050-A156558BEB82	Primary Tumor	Illumina HiSeq	796943be-2aa7-419f-801f-22c78459cc72	Head and Neck	71	F450DBE6-4972-4C49-AF97-963BCD0D0DA0	3B0BED92-ED76-451D-B605-A79FAE296DDE	TCGA-CN-4739-01A-02D-1509-02	HG19_Broad_variant	TCGA-CN-4739	TCGA-HNSC	NA	s15888	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa831e4b0c9d6adf6c6e4	58cfa831e4b0c9d6adf6c6e4	TCGA-CS-4941-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CS-4941-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_2_rg.sorted	TCGA-CS-4941-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_2_rg.sorted.bam	354.7	1.9	0.15	58cfa831e4b0c9d6adf6c6e4	TCGA-CS-4941-10A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-4941-10A	FC222F23-B3B2-4AC0-BC61-E8E8FA5CC160	Blood Derived Normal	Illumina HiSeq	76207c4c-20a5-4a76-aa64-df7b90201a78	Brain	67	FC331AA4-2641-4A1F-9AA2-64C8829438E0	82E2CAEA-0FD6-4C5F-A831-F7387621D603	TCGA-CS-4941-10A-01D-1465-02	HG19_Broad_variant	TCGA-CS-4941	TCGA-LGG	234	s8749	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Astrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c6d0	58cfa831e4b0c9d6adf6c6d0	TCGA-CS-4941-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CS-4941-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_1_rg.sorted	TCGA-CS-4941-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_1_rg.sorted.bam	157	1.9	0.15	58cfa831e4b0c9d6adf6c6d0	TCGA-CS-4941-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-4941-01A	FC222F23-B3B2-4AC0-BC61-E8E8FA5CC160	Primary Tumor	Illumina HiSeq	7df56317-1eca-4fb0-af19-36a4bfc5df00	Brain	67	4E5AEE62-DF39-4A74-917C-C3AB154F8D0E	8CA32F59-BA52-49E8-BA72-D2761ED47099	TCGA-CS-4941-01A-01D-1465-02	HG19_Broad_variant	TCGA-CS-4941	TCGA-LGG	234	s8126	Harvard Medical School	Thomas Jefferson University	United States	NO	Not available	Not available	Astrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c74c	58cfa831e4b0c9d6adf6c74c	TCGA-D7-6526-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D7-6526-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_2_rg.sorted	TCGA-D7-6526-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_2_rg.sorted.bam	274.7	1.9	0.15	58cfa831e4b0c9d6adf6c74c	TCGA-D7-6526-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6526-10A	A28E57E2-9071-4558-856A-162F7A837380	Blood Derived Normal	Illumina HiSeq	9470ad93-71f4-4d5d-a26b-8cec32d802dc	Stomach	67	79CEFAAA-0ED8-4BB9-BF61-47A835D9AE17	6713B663-75DF-4692-9B14-5B9746C206C1	TCGA-D7-6526-10A-01D-1798-02	HG19_Broad_variant	TCGA-D7-6526	TCGA-STAD	NA	s15408	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c665	58cfa831e4b0c9d6adf6c665	TCGA-CQ-6225-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CQ-6225-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_5_rg.sorted	TCGA-CQ-6225-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_5_rg.sorted.bam	38	NA	0.14	58cfa831e4b0c9d6adf6c665	TCGA-CQ-6225-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6225-10A	90F44998-3C05-44B2-9501-BBD0F43C5147	Blood Derived Normal	Illumina HiSeq	82431af8-972a-4db7-b424-bac44c375bc2	Head and Neck	65	D30CD5CB-D0DE-446A-8A57-4F8B69AB25FE	7F65174A-1AB8-492D-91B6-0C39F14243AF	TCGA-CQ-6225-10A-01D-1911-02	HG19_Broad_variant	TCGA-CQ-6225	TCGA-HNSC	403	s16326	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c6f4	58cfa831e4b0c9d6adf6c6f4	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted.bam	307	1.9	0.15	58cfa831e4b0c9d6adf6c6f4	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5977-01A	50239D1D-B3A4-4240-AB83-B24BA67B1299	Primary Tumor	Illumina HiSeq	ccdab134-2f40-4e7a-8b7c-ac1269321d3e	Head and Neck	66	84756AB5-9CB6-4DBD-848C-A85804F22AA1	140E6B2E-7EDD-417D-B720-58BEAB50AEA5	TCGA-CV-5977-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5977	TCGA-HNSC	NA	s15896	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c72e	58cfa831e4b0c9d6adf6c72e	TCGA-D6-6515-10A-01D-1868_120530_SN1222_0110_AC0VLAACXX_s_8_rg.sorted.filtered.	WGS	TCGA-D6-6515-10A-01D-1868_120530_SN1222_0110_AC0VLAACXX_s_8_rg.sorted	TCGA-D6-6515-10A-01D-1868_120530_SN1222_0110_AC0VLAACXX_s_8_rg.sorted.bam	566	1.9	0.14	58cfa831e4b0c9d6adf6c72e	TCGA-D6-6515-10A-01D-1868_120530_SN1222_0110_AC0VLAACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6515-10A	8E0E456E-85EE-4DE5-8F0B-72393D6ACDE0	Blood Derived Normal	Illumina HiSeq	9162c3e1-cccb-4dbd-8584-1ed07c67a6ae	Head and Neck	82	30F64CB6-602E-442B-A49C-AD7BA013582F	E0792BA6-84EE-48A7-8965-3EA79DED53A3	TCGA-D6-6515-10A-01D-1868-02	HG19_Broad_variant	TCGA-D6-6515	TCGA-HNSC	403	s15915	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6c72a	58cfa831e4b0c9d6adf6c72a	TCGA-D1-A17R-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A17R-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_2_rg.sorted	TCGA-D1-A17R-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_2_rg.sorted.bam	27.3	1.96	0.17	58cfa831e4b0c9d6adf6c72a	TCGA-D1-A17R-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17R-10A	73A0DD38-115D-48FB-B683-04AA5D612F2A	Blood Derived Normal	Illumina HiSeq	c8e63bfe-78b9-440d-bab8-d90db0329891	Uterus	58	3F4549BD-550F-4E11-B0F0-D08C43DB73D9	24FD6EF3-8975-4674-85CF-6593CBFA7129	TCGA-D1-A17R-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A17R	TCGA-UCEC	339	s4447	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c765	58cfa831e4b0c9d6adf6c765	TCGA-D7-6522-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D7-6522-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_4_rg.sorted	TCGA-D7-6522-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_4_rg.sorted.bam	169.7	1.9	0.15	58cfa831e4b0c9d6adf6c765	TCGA-D7-6522-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6522-10A	8BB3FACB-1933-4350-9F78-74537559E000	Blood Derived Normal	Illumina HiSeq	b268b352-4bb7-4b44-8367-f621ab6d372c	Stomach	58	0A5814D0-90A4-490E-A536-B423FCE6B5AA	0BC76B5E-0E98-4192-9801-2605243F425A	TCGA-D7-6522-10A-01D-1798-02	HG19_Broad_variant	TCGA-D7-6522	TCGA-STAD	NA	s15200	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c69e	58cfa831e4b0c9d6adf6c69e	TCGA-CQ-6220-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CQ-6220-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_5_rg.sorted	TCGA-CQ-6220-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_5_rg.sorted.bam	93	NA	0.14	58cfa831e4b0c9d6adf6c69e	TCGA-CQ-6220-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6220-10A	96D0CEFE-7949-4736-A7DC-1E4FA94765EC	Blood Derived Normal	Illumina HiSeq	7a4c76f2-7fac-4e3d-8651-0c74feb12abb	Head and Neck	69	67AD295F-426F-4761-90C3-448623D8EF37	59E0535C-BC9C-4584-A559-331C216EF4C9	TCGA-CQ-6220-10A-01D-1911-02	HG19_Broad_variant	TCGA-CQ-6220	TCGA-HNSC	985	s15771	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c761	58cfa831e4b0c9d6adf6c761	TCGA-CV-6952-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CV-6952-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_5_rg.sorted	TCGA-CV-6952-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_5_rg.sorted.bam	13	1.9	0.14	58cfa831e4b0c9d6adf6c761	TCGA-CV-6952-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6952-10A	7ED006E8-461F-4664-BFFF-55FA6812743C	Blood Derived Normal	Illumina HiSeq	0e2d0224-15cc-4ffb-b42d-300f4f08688a	Head and Neck	65	AA8A2097-2F73-4176-81C9-782F2C068DB9	B0D99166-225D-4BCA-910F-48754CE443A2	TCGA-CV-6952-10A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6952	TCGA-HNSC	185	s15519	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c7b0	58cfa831e4b0c9d6adf6c7b0	TCGA-D7-5578-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-5578-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_5_rg.sorted	TCGA-D7-5578-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_5_rg.sorted.bam	38.7	1.9	0.16	58cfa831e4b0c9d6adf6c7b0	TCGA-D7-5578-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-5578-10A	A3C1F9A2-9174-48CF-81DC-2AFCFDC4BA9C	Blood Derived Normal	Illumina HiSeq	a07d68ed-d63d-42c7-80dc-29e0c8cf5367	Stomach	80	51391BD9-2B63-47FB-888F-36F2F026F342	37CFFDEC-C98B-4657-AF4F-37C07C05EE16	TCGA-D7-5578-10A-01D-1598-02	HG19_Broad_variant	TCGA-D7-5578	TCGA-STAD	NA	s15196	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c7c2	58cfa831e4b0c9d6adf6c7c2	TCGA-D7-5579-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D7-5579-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_6_rg.sorted	TCGA-D7-5579-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_6_rg.sorted.bam	181.4	1.9	0.15	58cfa831e4b0c9d6adf6c7c2	TCGA-D7-5579-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-5579-10A	8B5746F9-DBEE-40BD-9141-1081960CF286	Blood Derived Normal	Illumina HiSeq	21ebfb93-aed0-454f-9a92-bd368dad175c	Stomach	74	A6AE07DC-A946-4D82-BF8D-F1837CFF3D1F	0865EF16-5B0E-4260-BE68-7C6B19EF7089	TCGA-D7-5579-10A-01D-1598-02	HG19_Broad_variant	TCGA-D7-5579	TCGA-STAD	NA	s14910	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N2	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c786	58cfa831e4b0c9d6adf6c786	TCGA-CV-5970-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-5970-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_8_rg.sorted	TCGA-CV-5970-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_8_rg.sorted.bam	4	1.8	0.15	58cfa831e4b0c9d6adf6c786	TCGA-CV-5970-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5970-10A	1F6167D9-C99D-4873-8D6E-E62A1C964135	Blood Derived Normal	Illumina HiSeq	509b8904-dfc6-4184-9e6c-1248a6280d9e	Head and Neck	59	156CC44B-397D-46D0-AF8C-2ECCF6F6CDC2	3222362E-0351-470B-82F3-EDEFBFA5B399	TCGA-CV-5970-10A-01D-1868-02	HG19_Broad_variant	TCGA-CV-5970	TCGA-HNSC	406	s16200	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6c752	58cfa831e4b0c9d6adf6c752	TCGA-CV-6939-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-6939-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_1_rg.sorted	TCGA-CV-6939-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_1_rg.sorted.bam	193.7	1.9	0.14	58cfa831e4b0c9d6adf6c752	TCGA-CV-6939-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	Not available	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6939-01A	E7D1F0DD-EEC0-4670-A2BA-00FFE38C6382	Primary Tumor	Illumina HiSeq	28dc7c63-6d80-4648-a356-07e8f846bc80	Head and Neck	60	1ED822F5-FEA5-46DE-9681-EC484DE734D8	8BB4510A-C148-4A9E-8ECF-6F8C8E9309CA	TCGA-CV-6939-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6939	TCGA-HNSC	666	s15515	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c7d6	58cfa831e4b0c9d6adf6c7d6	TCGA-D1-A168-10A-01D-A12F_120420_SN208_0286_BD0T87ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-D1-A168-10A-01D-A12F_120420_SN208_0286_BD0T87ACXX_s_8_rg.sorted	TCGA-D1-A168-10A-01D-A12F_120420_SN208_0286_BD0T87ACXX_s_8_rg.sorted.bam	13.52	1.97	0.14	58cfa831e4b0c9d6adf6c7d6	TCGA-D1-A168-10A-01D-A12F_120420_SN208_0286_BD0T87ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A168-10A	41893E97-7E90-4B03-B738-260F288ADE4C	Blood Derived Normal	Illumina HiSeq	274b9d8f-b7c4-4462-bea7-dc245a19a39b	Uterus	67	0E52377B-62A1-4B0C-A62C-4C4D2CE3F45E	7AD8CF50-EF3A-4E75-A691-9B10AB5CEF00	TCGA-D1-A168-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A168	TCGA-UCEC	NA	s4612	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c7dc	58cfa831e4b0c9d6adf6c7dc	TCGA-D1-A16E-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D1-A16E-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_7_rg.sorted	TCGA-D1-A16E-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_7_rg.sorted.bam	11.86	2	0.15	58cfa831e4b0c9d6adf6c7dc	TCGA-D1-A16E-10A-01D-A12F_120523_SN1222_0109_BD12MPACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16E-10A	E70465F6-1922-4EB7-B646-8B01AD3CE77B	Blood Derived Normal	Illumina HiSeq	8acc5ebb-d186-4dee-8bf1-22525966499f	Uterus	73	F4A2823E-A694-4036-88DC-8C27F7854DB4	43CE6A12-A5CA-479C-B1F8-7955BFCFFB4C	TCGA-D1-A16E-10A-01D-A12F-02	HG19_Broad_variant	TCGA-D1-A16E	TCGA-UCEC	NA	s4440	Harvard Medical School	Mayo Clinic	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A12F-02	TRUE
13722.58cfa831e4b0c9d6adf6c7d0	58cfa831e4b0c9d6adf6c7d0	TCGA-CV-6945-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-6945-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_2_rg.sorted	TCGA-CV-6945-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_2_rg.sorted.bam	155.7	1.9	0.14	58cfa831e4b0c9d6adf6c7d0	TCGA-CV-6945-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6945-01A	15714E69-E075-4688-8F51-C7102FE4CA07	Primary Tumor	Illumina HiSeq	50a2b9f7-d572-47c4-bf4b-3d6255512094	Head and Neck	41	55849997-67DE-4FC6-B7BF-9D02D15920C9	FC2ACD2E-751C-4252-85A1-6C5A8E980964	TCGA-CV-6945-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6945	TCGA-HNSC	366	s15775	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N2	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c84c	58cfa831e4b0c9d6adf6c84c	TCGA-D7-6527-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D7-6527-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_4_rg.sorted	TCGA-D7-6527-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_4_rg.sorted.bam	227.7	1.9	0.15	58cfa831e4b0c9d6adf6c84c	TCGA-D7-6527-10A-01D-1798_130218_SN208_0453_AC1T26ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6527-10A	CB622CD6-776D-4681-8A67-4ADDD61C66B8	Blood Derived Normal	Illumina HiSeq	7fda4d3c-8153-4107-b896-7b7967fdf926	Stomach	62	1C932E82-DF6F-4CE3-B691-46C0D5E9F893	DBB176B8-D56A-4B76-B4D0-B0763370AEE3	TCGA-D7-6527-10A-01D-1798-02	HG19_Broad_variant	TCGA-D7-6527	TCGA-STAD	NA	s15332	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach Intestinal Adenocarcinoma Papillary Type	Stage II	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c815	58cfa831e4b0c9d6adf6c815	TCGA-CV-6951-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-6951-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_8_rg.sorted	TCGA-CV-6951-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_8_rg.sorted.bam	6	1.9	0.16	58cfa831e4b0c9d6adf6c815	TCGA-CV-6951-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6951-10A	91728CD6-ED91-49DC-9279-FAEDBE211A9D	Blood Derived Normal	Illumina HiSeq	c7e5f6bc-d595-433f-89cc-cfd1cc99ff25	Head and Neck	57	16ECE3C5-7709-481C-A4BD-49ED6E6BDDA6	851E3F8F-6F52-4B1F-A439-7D08B7457276	TCGA-CV-6951-10A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6951	TCGA-HNSC	915	s15518	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c849	58cfa831e4b0c9d6adf6c849	TCGA-D7-6525-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-D7-6525-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_8_rg.sorted	TCGA-D7-6525-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_8_rg.sorted.bam	270	1.9	0.16	58cfa831e4b0c9d6adf6c849	TCGA-D7-6525-10A-01D-1798_130214_SN1120_0237_BD1TGLACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6525-10A	82F9A197-040D-4C5E-89D9-D87A7AA0168D	Blood Derived Normal	Illumina HiSeq	f95ec729-b7a8-4b1f-9c2c-ef00b3a74a77	Stomach	58	A523DD59-E6A8-4E71-AF54-E8064F3CDE61	11034761-0AB1-435A-A8A9-1F362E312403	TCGA-D7-6525-10A-01D-1798-02	HG19_Broad_variant	TCGA-D7-6525	TCGA-STAD	NA	s14558	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1798-02	TRUE
13722.58cfa831e4b0c9d6adf6c81c	58cfa831e4b0c9d6adf6c81c	TCGA-CV-6933-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-6933-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_7_rg.sorted	TCGA-CV-6933-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_7_rg.sorted.bam	34	1.9	0.16	58cfa831e4b0c9d6adf6c81c	TCGA-CV-6933-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6933-10A	2A749317-0156-4213-8482-B2C2D6E52E9B	Blood Derived Normal	Illumina HiSeq	983b388d-7527-45b1-bcc8-375b7f38e128	Head and Neck	53	6D7E5088-B49D-4182-90C2-79DF36F96E35	C74C03E1-2876-41E9-950D-6CB081DF559C	TCGA-CV-6933-10A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6933	TCGA-HNSC	2741	s15899	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c88c	58cfa831e4b0c9d6adf6c88c	TCGA-D7-6822-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-6822-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_5_rg.sorted	TCGA-D7-6822-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_5_rg.sorted.bam	442.7	1.9	0.14	58cfa831e4b0c9d6adf6c88c	TCGA-D7-6822-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6822-01A	E2AAABD9-F4BA-4763-A28A-C14D46A4BC5D	Primary Tumor	Illumina HiSeq	b8f8d06c-7bbf-4d0d-8f5a-e3012379df95	Stomach	77	C30AFDA8-FC63-4228-A9A9-42BCDB562ACE	586B20D4-917E-4344-BFBC-A21B12811C69	TCGA-D7-6822-01A-11D-1880-02	HG19_Broad_variant	TCGA-D7-6822	TCGA-STAD	NA	s14769	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IB	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c818	58cfa831e4b0c9d6adf6c818	TCGA-CV-6948-10A-01D-1911_120816_SN1222_0144_AD16PUACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-6948-10A-01D-1911_120816_SN1222_0144_AD16PUACXX_s_8_rg.sorted	TCGA-CV-6948-10A-01D-1911_120816_SN1222_0144_AD16PUACXX_s_8_rg.sorted.bam	23	1.8	0.13	58cfa831e4b0c9d6adf6c818	TCGA-CV-6948-10A-01D-1911_120816_SN1222_0144_AD16PUACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6948-10A	FCF0DC48-B889-4593-A15B-AA715AAE7BF5	Blood Derived Normal	Illumina HiSeq	44d87ab1-c19b-4411-8774-2f888600c978	Head and Neck	79	86696AE2-B67D-43B3-929B-C4BAB7417852	4291C3F6-447E-482F-ADB3-304D59F87F82	TCGA-CV-6948-10A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6948	TCGA-HNSC	1289	s15777	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N3	Head and Neck Squamous Cell Carcinoma	Stage IVB	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c850	58cfa831e4b0c9d6adf6c850	TCGA-CV-6948-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-6948-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_3_rg.sorted	TCGA-CV-6948-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_3_rg.sorted.bam	263.7	1.9	0.15	58cfa831e4b0c9d6adf6c850	TCGA-CV-6948-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6948-01A	FCF0DC48-B889-4593-A15B-AA715AAE7BF5	Primary Tumor	Illumina HiSeq	87c6cf32-e113-471b-86b3-cca360f47616	Head and Neck	79	21844F33-DD12-4940-B42D-2F9FABB2F7BA	8FEEA708-D971-4FD0-8542-1E31A9DFF8EA	TCGA-CV-6948-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6948	TCGA-HNSC	1289	s15650	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N3	Head and Neck Squamous Cell Carcinoma	Stage IVB	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c86a	58cfa831e4b0c9d6adf6c86a	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted.bam	223	1.9	0.14	58cfa831e4b0c9d6adf6c86a	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6003-01A	417B357E-C90E-4B63-AE7A-4B782038FFD3	Primary Tumor	Illumina HiSeq	b314312e-2a3f-45dd-a813-870344654395	Head and Neck	50	6892F7E3-630E-45B5-8C30-139161461A85	9DF426C5-E45E-428B-A63C-11D4C1BEB4B2	TCGA-CV-6003-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-6003	TCGA-HNSC	NA	s16197	Harvard Medical School	MD Anderson Cancer Center	None	NO	T2	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c8c0	58cfa831e4b0c9d6adf6c8c0	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted.bam	22	1.9	0.16	58cfa831e4b0c9d6adf6c8c0	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5971-01A	1465B7EC-8D2B-47DD-8387-977EED44CC86	Primary Tumor	Illumina HiSeq	03c22e39-15a9-4b8a-8db1-cf41d618b7fc	Head and Neck	60	82589B3F-BD41-4ABE-9469-7DD48447DDDC	5739D7DE-98D4-4591-B8B1-E0E9AA9B05DF	TCGA-CV-5971-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5971	TCGA-HNSC	NA	s16198	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N2a	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c898	58cfa831e4b0c9d6adf6c898	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted.bam	66.3	1.9	0.16	58cfa831e4b0c9d6adf6c898	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5854-01A	B95AFB1A-A1DF-4D85-AD34-191928E28A77	Primary Tumor	Illumina HiSeq	f499956c-7655-4be7-8a53-44403d30ea04	Brain	57	D5BAA53A-958C-4163-A388-D3C957C891F9	4716DB1C-94F8-40AE-B89B-EA41E6A7E8CE	TCGA-DU-5854-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5854	TCGA-LGG	NA	s8562	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6c90a	58cfa831e4b0c9d6adf6c90a	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted.bam	97.3	1.8	0.14	58cfa831e4b0c9d6adf6c90a	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5849-01A	5AF8ADA5-86B5-4832-8A8E-E975ECCA5515	Primary Tumor	Illumina HiSeq	d4f0a4e9-de7c-498f-89e7-aad71fb01915	Brain	48	9E0E239F-CED4-4CF3-BF3C-5EC8224D760B	7732E26C-3B82-4D03-A331-82D8088CEB44	TCGA-DU-5849-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5849	TCGA-LGG	NA	s8349	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6c8d8	58cfa831e4b0c9d6adf6c8d8	TCGA-CV-6951-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-6951-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_4_rg.sorted	TCGA-CV-6951-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_4_rg.sorted.bam	62.7	1.9	0.14	58cfa831e4b0c9d6adf6c8d8	TCGA-CV-6951-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6951-01A	91728CD6-ED91-49DC-9279-FAEDBE211A9D	Primary Tumor	Illumina HiSeq	ec458668-da73-4d3e-8ac6-08a0e974b879	Head and Neck	57	9EE0F161-0976-4697-BF69-7E42E7149FEB	90F9C6C1-B7E9-48E4-9A02-C5FAB56AFD95	TCGA-CV-6951-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6951	TCGA-HNSC	915	s15905	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c85e	58cfa831e4b0c9d6adf6c85e	TCGA-CV-6938-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-6938-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_8_rg.sorted	TCGA-CV-6938-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_8_rg.sorted.bam	75	1.8	0.13	58cfa831e4b0c9d6adf6c85e	TCGA-CV-6938-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6938-10A	FF9DB03D-F81C-4079-8B05-F5A8C05B8CFE	Blood Derived Normal	Illumina HiSeq	2bf8f074-cca1-41f9-88b4-32ba64d7990c	Head and Neck	87	1F925F99-1D41-4BDF-99AE-CA7B4D16A567	3A63D568-0924-4D11-BCA0-86DAB2D8C889	TCGA-CV-6938-10A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6938	TCGA-HNSC	144	s15906	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c923	58cfa831e4b0c9d6adf6c923	TCGA-DB-5276-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DB-5276-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_6_rg.sorted	TCGA-DB-5276-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_6_rg.sorted.bam	78.7	1.9	0.14	58cfa831e4b0c9d6adf6c923	TCGA-DB-5276-10A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5276-10A	9D0C1552-00A7-4F0A-A04A-A82E721EE4E3	Blood Derived Normal	Illumina HiSeq	c584cffe-856d-48a8-b1e6-95db5cb5f3de	Brain	32	BC639E06-8F9C-4759-B158-C03EC8E9DBF4	6F18CF36-A52F-4D38-9585-64DF0307BA29	TCGA-DB-5276-10A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5276	TCGA-LGG	NA	s8129	Harvard Medical School	Mayo Clinic - Rochester	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c8dc	58cfa831e4b0c9d6adf6c8dc	TCGA-CV-6945-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CV-6945-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_6_rg.sorted	TCGA-CV-6945-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_6_rg.sorted.bam	14	1.8	0.14	58cfa831e4b0c9d6adf6c8dc	TCGA-CV-6945-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6945-10A	15714E69-E075-4688-8F51-C7102FE4CA07	Blood Derived Normal	Illumina HiSeq	881094bd-54eb-4839-a62c-4abb208130cb	Head and Neck	41	974F0AEE-5BB9-4840-B141-A02B6A2FB65B	4DF4A64E-3543-4FF7-969F-49F5EB5EF877	TCGA-CV-6945-10A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6945	TCGA-HNSC	366	s16047	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N2	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c938	58cfa831e4b0c9d6adf6c938	TCGA-DH-5143-10A-01D-1465_130806_SN1222_0209_AD2AW0ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DH-5143-10A-01D-1465_130806_SN1222_0209_AD2AW0ACXX_s_2_rg.sorted	TCGA-DH-5143-10A-01D-1465_130806_SN1222_0209_AD2AW0ACXX_s_2_rg.sorted.bam	749.7	1.9	0.15	58cfa831e4b0c9d6adf6c938	TCGA-DH-5143-10A-01D-1465_130806_SN1222_0209_AD2AW0ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DH-5143-10A	DCD0856D-423A-40D7-8070-4C0988D61416	Blood Derived Normal	Illumina HiSeq	14764abf-abd2-4bc1-a8ee-79b07761338f	Brain	30	D5E50908-DDB0-4887-B6C3-63038AD511B8	15453F10-46D7-40AC-9B5E-5FB44E05FCE5	TCGA-DH-5143-10A-01D-1465-02	HG19_Broad_variant	TCGA-DH-5143	TCGA-LGG	NA	s8132	Harvard Medical School	University of Florida	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c950	58cfa831e4b0c9d6adf6c950	TCGA-D7-6818-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D7-6818-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_2_rg.sorted	TCGA-D7-6818-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_2_rg.sorted.bam	529	1.9	0.15	58cfa831e4b0c9d6adf6c950	TCGA-D7-6818-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6818-10A	AA2934F9-8783-428E-88A6-1D04B93FA1FD	Blood Derived Normal	Illumina HiSeq	327fce3d-289c-4d30-b812-d43fda314ac6	Stomach	53	5AB5F428-FB43-4C52-8E99-11574504065C	EF7F4439-A466-40B2-AEE2-1A2AEA45BDDD	TCGA-D7-6818-10A-01D-1880-02	HG19_Broad_variant	TCGA-D7-6818	TCGA-STAD	NA	s15463	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c8d2	58cfa831e4b0c9d6adf6c8d2	TCGA-CV-6939-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CV-6939-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_5_rg.sorted	TCGA-CV-6939-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_5_rg.sorted.bam	60	1.8	0.13	58cfa831e4b0c9d6adf6c8d2	TCGA-CV-6939-10A-01D-1911_120504_SN208_0297_BC0VJEACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	Not available	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6939-10A	E7D1F0DD-EEC0-4670-A2BA-00FFE38C6382	Blood Derived Normal	Illumina HiSeq	309581c5-c366-45cd-8989-49eb97775978	Head and Neck	60	65C69882-7AD5-4EA8-B8F6-CA17A0EA8E73	F5E8B5DB-1814-4D08-9D7D-3AD879EFD522	TCGA-CV-6939-10A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6939	TCGA-HNSC	666	s15901	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c96b	58cfa831e4b0c9d6adf6c96b	TCGA-DU-5849-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DU-5849-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_6_rg.sorted	TCGA-DU-5849-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_6_rg.sorted.bam	91	1.9	0.14	58cfa831e4b0c9d6adf6c96b	TCGA-DU-5849-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5849-10A	5AF8ADA5-86B5-4832-8A8E-E975ECCA5515	Blood Derived Normal	Illumina HiSeq	ce60dc42-d2f9-4eda-b08c-8e71133127b7	Brain	48	4D468A8E-04DA-4C51-AF1A-C0DC10E67F8D	FCEC83BA-6596-472D-9988-71092389A8ED	TCGA-DU-5849-10A-01D-1703-02	HG19_Broad_variant	TCGA-DU-5849	TCGA-LGG	NA	s8755	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6c9c4	58cfa831e4b0c9d6adf6c9c4	TCGA-DK-A1AG-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DK-A1AG-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_8_rg.sorted	TCGA-DK-A1AG-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_8_rg.sorted.bam	49.77	1.93	0.16	58cfa831e4b0c9d6adf6c9c4	TCGA-DK-A1AG-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AG-10A	F8C0A69C-DF53-4A0A-A30E-4424C0CE3DD5	Blood Derived Normal	Illumina HiSeq	90e16c1d-22cd-49d7-a4ff-546778f2adda	Bladder	65	A55072D2-EFF0-4B87-8330-55022E8D6F39	A40FB6BF-8D18-48E3-B5A3-2962C26C64F5	TCGA-DK-A1AG-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AG	TCGA-BLCA	NA	s3281	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c945	58cfa831e4b0c9d6adf6c945	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted.bam	113.7	1.9	0.14	58cfa831e4b0c9d6adf6c945	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6818-01A	AA2934F9-8783-428E-88A6-1D04B93FA1FD	Primary Tumor	Illumina HiSeq	5a217dfc-ada8-4dec-8f7c-06be0123b9ef	Stomach	53	953E155F-D9E1-41C8-BA12-351A38195D22	21E75BA4-E4C1-4D8A-BFA2-E4698B4FB46B	TCGA-D7-6818-01A-11D-1880-02	HG19_Broad_variant	TCGA-D7-6818	TCGA-STAD	NA	s15464	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c924	58cfa831e4b0c9d6adf6c924	TCGA-CN-6996-10A-01D-1911_120504_SN1222_0101_AC0UMDACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CN-6996-10A-01D-1911_120504_SN1222_0101_AC0UMDACXX_s_6_rg.sorted	TCGA-CN-6996-10A-01D-1911_120504_SN1222_0101_AC0UMDACXX_s_6_rg.sorted.bam	579	NA	0.15	58cfa831e4b0c9d6adf6c924	TCGA-CN-6996-10A-01D-1911_120504_SN1222_0101_AC0UMDACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6996-10A	49B94421-FE82-4F24-8EF2-820674142418	Blood Derived Normal	Illumina HiSeq	ca0120d2-68ba-4605-a647-eb86ed714611	Head and Neck	58	91A53555-ECB3-4FF6-B56F-8AC5021BB5A8	F268F2F5-1BE4-454B-809B-C509F1454D8E	TCGA-CN-6996-10A-01D-1911-02	HG19_Broad_variant	TCGA-CN-6996	TCGA-HNSC	NA	s15505	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c92f	58cfa831e4b0c9d6adf6c92f	TCGA-CQ-6229-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CQ-6229-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_6_rg.sorted	TCGA-CQ-6229-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_6_rg.sorted.bam	57	NA	0.14	58cfa831e4b0c9d6adf6c92f	TCGA-CQ-6229-10A-01D-1911_120504_SN208_0296_AC0V09ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6229-10A	A091822C-447A-49A5-8C20-E329DF79599C	Blood Derived Normal	Illumina HiSeq	16ed6dc6-b3ef-4721-a79d-db228afd20c2	Head and Neck	61	6C33C6D3-A5B8-47D2-8A20-66A54E46E272	7CA9E363-A5A7-4458-8015-6A72FB563F79	TCGA-CQ-6229-10A-01D-1911-02	HG19_Broad_variant	TCGA-CQ-6229	TCGA-HNSC	NA	s16189	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c9d2	58cfa831e4b0c9d6adf6c9d2	TCGA-DQ-5630-10A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DQ-5630-10A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_3_rg.sorted	TCGA-DQ-5630-10A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_3_rg.sorted.bam	134	1.9	0.15	58cfa831e4b0c9d6adf6c9d2	TCGA-DQ-5630-10A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5630-10A	91A712B5-A724-48D0-BA06-4F6857683463	Blood Derived Normal	Illumina HiSeq	1c95b304-0beb-462d-bb72-fe1946dfbc5f	Head and Neck	73	06BDB35A-E44C-4D86-AD0E-3BF74F567609	08A5D543-6FF9-402B-B86D-1A5ED0F0D75E	TCGA-DQ-5630-10A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5630	TCGA-HNSC	NA	s16208	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6ca50	58cfa831e4b0c9d6adf6ca50	TCGA-DK-A1AD-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DK-A1AD-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_6_rg.sorted	TCGA-DK-A1AD-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_6_rg.sorted.bam	50.25	1.92	0.15	58cfa831e4b0c9d6adf6ca50	TCGA-DK-A1AD-10A-01D-A13U_121025_SN590_0188_AC190CACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AD-10A	88A521CE-A5E9-4C6F-83D4-EC36A62FEDB6	Blood Derived Normal	Illumina HiSeq	02eda981-844a-4b1d-b9a6-fe1f173053e9	Bladder	69	836350C2-353D-462D-890B-8A471AFF9B4D	FFF392FF-6BD4-4155-9A69-3354F30FA6F4	TCGA-DK-A1AD-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AD	TCGA-BLCA	NA	s2709	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6ca14	58cfa831e4b0c9d6adf6ca14	TCGA-D7-6822-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D7-6822-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_6_rg.sorted	TCGA-D7-6822-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_6_rg.sorted.bam	413.3	1.9	0.15	58cfa831e4b0c9d6adf6ca14	TCGA-D7-6822-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6822-10A	E2AAABD9-F4BA-4763-A28A-C14D46A4BC5D	Blood Derived Normal	Illumina HiSeq	32163f63-f4dc-4d1a-bc93-3eff35bd1b5d	Stomach	77	B60B4A59-1064-4349-8942-375F7D0B4337	7D89EBA3-F7DE-43D9-A7BC-94FA4CEAEF67	TCGA-D7-6822-10A-01D-1880-02	HG19_Broad_variant	TCGA-D7-6822	TCGA-STAD	NA	s14710	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IB	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c9e2	58cfa831e4b0c9d6adf6c9e2	TCGA-DQ-5631-10A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DQ-5631-10A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_4_rg.sorted	TCGA-DQ-5631-10A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_4_rg.sorted.bam	135	1.9	0.15	58cfa831e4b0c9d6adf6c9e2	TCGA-DQ-5631-10A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5631-10A	10B3F56A-E61E-486B-8D3C-176668D5DC34	Blood Derived Normal	Illumina HiSeq	f614c1a4-6710-4035-bf2b-23679a3c3fd0	Head and Neck	52	730E5BDB-1E07-47A4-B708-3CC08C603017	5833C7BB-9FEE-4244-A533-36712BCF2444	TCGA-DQ-5631-10A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5631	TCGA-HNSC	548	s15533	Harvard Medical School	University Of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6cac8	58cfa831e4b0c9d6adf6cac8	TCGA-DA-A1IC-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DA-A1IC-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_2_rg.sorted	TCGA-DA-A1IC-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_2_rg.sorted.bam	32.66	NA	0.16	58cfa831e4b0c9d6adf6cac8	TCGA-DA-A1IC-10A-01D-A190_120730_SN208_0420_BC12YJACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1IC-10A	6625CE3F-3A1F-45F9-AA42-AB1931D6DAF4	Blood Derived Normal	Illumina HiSeq	615d39b9-8a2a-4712-87f9-40c1911e199c	Skin	81	564A6108-65B7-49D2-A8B9-02C32EE52CDD	4473278F-ED1D-4391-B15E-498F3F90D5CE	TCGA-DA-A1IC-10A-01D-A190-02	HG19_Broad_variant	TCGA-DA-A1IC	TCGA-SKCM	NA	s7500	Harvard Medical School	Yale	United States	NO	T3a	N2c	Not available	Stage IIIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ca62	58cfa831e4b0c9d6adf6ca62	TCGA-DQ-5625-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DQ-5625-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_2_rg.sorted	TCGA-DQ-5625-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_2_rg.sorted.bam	31	1.9	0.16	58cfa831e4b0c9d6adf6ca62	TCGA-DQ-5625-10A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5625-10A	53D9A130-4A3A-4491-85CD-9A44415A1632	Blood Derived Normal	Illumina HiSeq	faef45e3-26d8-4053-a1ff-b62774815392	Head and Neck	52	F3AD5B44-87B1-41AE-8CC1-42E158BC174C	EB9FB8DF-AD96-4EFF-8673-4D3DDB4BD6AB	TCGA-DQ-5625-10A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5625	TCGA-HNSC	NA	s16344	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6caee	58cfa831e4b0c9d6adf6caee	TCGA-E1-5303-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-E1-5303-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_3_rg.sorted	TCGA-E1-5303-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_3_rg.sorted.bam	46	1.9	0.14	58cfa831e4b0c9d6adf6caee	TCGA-E1-5303-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-E1-5303-01A	44A5C3B4-62A7-407B-B492-7069E1A43A26	Primary Tumor	Illumina HiSeq	e94ddca3-3117-4958-85a6-cde716b710dc	Brain	38	150856F7-77DA-4AA5-A28B-310A505AEA24	287AB664-A970-437E-A7F9-EF6C20D2266E	TCGA-E1-5303-01A-01D-1465-02	HG19_Broad_variant	TCGA-E1-5303	TCGA-LGG	2052	s8137	Harvard Medical School	Duke	United States	NO	Not available	Not available	Astrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6caec	58cfa831e4b0c9d6adf6caec	TCGA-DJ-A1QM-10A-01D-A14U_120629_SN1120_0167_AC0WMBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A1QM-10A-01D-A14U_120629_SN1120_0167_AC0WMBACXX_s_5_rg.sorted	TCGA-DJ-A1QM-10A-01D-A14U_120629_SN1120_0167_AC0WMBACXX_s_5_rg.sorted.bam	20.06	2.3	0.15	58cfa831e4b0c9d6adf6caec	TCGA-DJ-A1QM-10A-01D-A14U_120629_SN1120_0167_AC0WMBACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QM-10A	3597AF5E-65FF-40A7-95FC-DACC26CBCA14	Blood Derived Normal	Illumina HiSeq	e2866656-6032-4a62-a4f1-437b4fc38f62	Thyroid	42	03C149F0-A850-421E-B777-73A634A3FC82	C9A6DDA6-A5C6-42A6-B21C-A7E9EF57C238	TCGA-DJ-A1QM-10A-01D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QM	TCGA-THCA	NA	s12108	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1a	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cb1e	58cfa831e4b0c9d6adf6cb1e	TCGA-E5-A2PC-10B-01D-A204_120926_SN1222_0153_BD1D4MACXX_s_2_rg.sorted.filtered.	WGS	TCGA-E5-A2PC-10B-01D-A204_120926_SN1222_0153_BD1D4MACXX_s_2_rg.sorted	TCGA-E5-A2PC-10B-01D-A204_120926_SN1222_0153_BD1D4MACXX_s_2_rg.sorted.bam	12.14	NA	0.16	58cfa831e4b0c9d6adf6cb1e	TCGA-E5-A2PC-10B-01D-A204_120926_SN1222_0153_BD1D4MACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-E5-A2PC-10A	4107AE6F-502C-4BDC-BF14-E4B3711CBA38	Blood Derived Normal	Illumina HiSeq	d15f0d2c-94bd-40f7-8589-0087c2ec6339	Bladder	61	6408217A-386D-4B4E-8416-C61B37CA5FEE	11CC13C2-FBB5-43EF-9FBB-AA9468591AF9	TCGA-E5-A2PC-10B-01D-A204-02	HG19_Broad_variant	TCGA-E5-A2PC	TCGA-BLCA	NA	s3288	Harvard Medical School	Roswell Park	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A204-02	TRUE
13722.58cfa831e4b0c9d6adf6cb22	58cfa831e4b0c9d6adf6cb22	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted.filtered.	WGS	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted.bam	63.68	NA	0.16	58cfa831e4b0c9d6adf6cb22	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-E5-A2PC-01A	4107AE6F-502C-4BDC-BF14-E4B3711CBA38	Primary Tumor	Illumina HiSeq	496052c5-5ab2-4852-88e1-348116a86746	Bladder	61	2195B75E-157F-4547-9705-1E7E75666CA8	FABA82E6-FF3D-468C-91EC-A88794619697	TCGA-E5-A2PC-01A-11D-A204-02	HG19_Broad_variant	TCGA-E5-A2PC	TCGA-BLCA	NA	s3289	Harvard Medical School	Roswell Park	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A204-02	TRUE
13722.58cfa831e4b0c9d6adf6cb36	58cfa831e4b0c9d6adf6cb36	TCGA-EE-A2GP-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EE-A2GP-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_2_rg.sorted	TCGA-EE-A2GP-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_2_rg.sorted.bam	43.01	NA	0.15	58cfa831e4b0c9d6adf6cb36	TCGA-EE-A2GP-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GP-06A	06F09D1C-BA44-4CF9-A518-762D241A30DB	Metastatic	Illumina HiSeq	8b518870-b998-4d74-b43e-91c419614660	Skin	80	8F45D68C-D4D7-426D-87C4-03A74FADBEBB	D23C89BB-28C1-4320-9C82-B990849035E8	TCGA-EE-A2GP-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2GP	TCGA-SKCM	423	s7855	Harvard Medical School	University of Sydney	Australia	NO	T4b	N1a	Not available	Stage IIIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb56	58cfa831e4b0c9d6adf6cb56	TCGA-EE-A20H-06A-11D-A18Y_120730_SN1222_0141_BC115GACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EE-A20H-06A-11D-A18Y_120730_SN1222_0141_BC115GACXX_s_8_rg.sorted	TCGA-EE-A20H-06A-11D-A18Y_120730_SN1222_0141_BC115GACXX_s_8_rg.sorted.bam	55.78	NA	0.16	58cfa831e4b0c9d6adf6cb56	TCGA-EE-A20H-06A-11D-A18Y_120730_SN1222_0141_BC115GACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A20H-06A	267B98E7-708F-458A-82D1-5FAA415B9EE7	Metastatic	Illumina HiSeq	8a9e2a3c-228d-41b2-b1f5-a8242675c6e3	Skin	56	79AC8FFC-843B-4F1F-A681-8A507769DB19	609F4177-82C0-4E12-B1E9-291EBB381FF6	TCGA-EE-A20H-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A20H	TCGA-SKCM	5118	s8008	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb3a	58cfa831e4b0c9d6adf6cb3a	TCGA-EE-A2GR-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EE-A2GR-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_1_rg.sorted	TCGA-EE-A2GR-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_1_rg.sorted.bam	61.93	NA	0.16	58cfa831e4b0c9d6adf6cb3a	TCGA-EE-A2GR-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GR-06A	919DFC28-6B55-452E-884C-48CB86802AC2	Metastatic	Illumina HiSeq	9dea8dd3-8434-45ef-8b9b-1e397b099652	Skin	78	4F644FC3-191C-4B19-9FFC-D5BE630CEC93	7A5A39D0-F2D6-4158-8ED4-C76E62657738	TCGA-EE-A2GR-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2GR	TCGA-SKCM	NA	s7852	Harvard Medical School	University of Sydney	Australia	NO	T4	N0	Not available	Stage II	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb7a	58cfa831e4b0c9d6adf6cb7a	TCGA-EJ-7317-10A-01D-2111_130422_SN590_0225_BD23TLACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-7317-10A-01D-2111_130422_SN590_0225_BD23TLACXX_s_7_rg.sorted	TCGA-EJ-7317-10A-01D-2111_130422_SN590_0225_BD23TLACXX_s_7_rg.sorted.bam	293.6	NA	0.15	58cfa831e4b0c9d6adf6cb7a	TCGA-EJ-7317-10A-01D-2111_130422_SN590_0225_BD23TLACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7317-10A	68FC3693-0910-4EE8-8997-99C6333B65F4	Blood Derived Normal	Illumina HiSeq	15df0c4b-18fc-47ff-a394-3f998afafcbc	Prostate	71	251761C0-C419-4B44-973E-1D2BB89D26E2	DACE52C7-8DFA-4706-9E3C-A1141CC4E68B	TCGA-EJ-7317-10A-01D-2111-02	HG19_Broad_variant	TCGA-EJ-7317	TCGA-PRAD	NA	s3441	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cb81	58cfa831e4b0c9d6adf6cb81	TCGA-EJ-7782-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-7782-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_1_rg.sorted	TCGA-EJ-7782-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_1_rg.sorted.bam	74.6	NA	0.16	58cfa831e4b0c9d6adf6cb81	TCGA-EJ-7782-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_1_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7782-10A	1426B4BF-F4A5-477C-BBBB-E0E656549764	Blood Derived Normal	Illumina HiSeq	978aefd3-3013-45dc-a27f-b3b3a3352296	Prostate	71	71342824-DDD4-4A58-A005-E0D63CD36DA3	F9C1CBBE-F4C6-40B8-90B1-03D69590744A	TCGA-EJ-7782-10A-01D-2111-02	HG19_Broad_variant	TCGA-EJ-7782	TCGA-PRAD	NA	s4140	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cb9e	58cfa831e4b0c9d6adf6cb9e	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted.bam	282.3	NA	0.16	58cfa831e4b0c9d6adf6cb9e	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7328-01A	42B7D14F-09E5-4D91-BB98-5FE35907A6A9	Primary Tumor	Illumina HiSeq	09a1120f-21a6-48c2-a9e8-3b229a16fc7f	Prostate	70	4539A7C3-CCA2-4ED0-9310-92CD843AA1CD	C4D292D4-D001-4704-94C9-CC1674F6F16E	TCGA-EJ-7328-01A-31D-2111-02	HG19_Broad_variant	TCGA-EJ-7328	TCGA-PRAD	NA	s3960	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cb98	58cfa831e4b0c9d6adf6cb98	TCGA-EJ-5512-10A-01D-1573_130131_SN1120_0234_AD1PVUACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-5512-10A-01D-1573_130131_SN1120_0234_AD1PVUACXX_s_6_rg.sorted	TCGA-EJ-5512-10A-01D-1573_130131_SN1120_0234_AD1PVUACXX_s_6_rg.sorted.bam	544.4	1.9	0.17	58cfa831e4b0c9d6adf6cb98	TCGA-EJ-5512-10A-01D-1573_130131_SN1120_0234_AD1PVUACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5512-10A	C28F931F-5AB2-4899-9FE9-54024F082D92	Blood Derived Normal	Illumina HiSeq	e86e1bf3-6515-4cff-9811-7b19fe9b2d00	Prostate	46	9A0E8F46-D5E6-463C-B643-8CD35632B467	5FEA307B-0809-4D62-969E-0E8FEC5DED9C	TCGA-EJ-5512-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5512	TCGA-PRAD	NA	s4137	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cb60	58cfa831e4b0c9d6adf6cb60	TCGA-EE-A2GB-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EE-A2GB-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_4_rg.sorted	TCGA-EE-A2GB-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_4_rg.sorted.bam	55.16	NA	0.15	58cfa831e4b0c9d6adf6cb60	TCGA-EE-A2GB-06A-11D-A18Y_120726_SN590_0171_AD13PJACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GB-06A	E58BED18-503C-4182-BCF3-5AF6F20E1B8A	Metastatic	Illumina HiSeq	2dd72796-7cac-418d-a092-523f88e1dd64	Skin	51	EB4904DB-E9F4-4877-A429-A739562A2C86	BEA81FA6-A4BA-478B-9C37-5283A7F6748D	TCGA-EE-A2GB-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2GB	TCGA-SKCM	NA	s8007	Harvard Medical School	University of Sydney	Australia	NO	T2b	N1a	Not available	Stage IIIB	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb70	58cfa831e4b0c9d6adf6cb70	TCGA-EE-A29T-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EE-A29T-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_8_rg.sorted	TCGA-EE-A29T-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_8_rg.sorted.bam	20.36	NA	0.15	58cfa831e4b0c9d6adf6cb70	TCGA-EE-A29T-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29T-10A	9B99FFEE-FE9F-4BE5-A00A-EF86627282A4	Blood Derived Normal	Illumina HiSeq	83148501-88fd-4908-bad2-144b603a893c	Skin	51	CBE28A4D-8883-4EC4-B33D-5E7744C7978F	F0195AA4-9E9C-4B23-8FC7-4671385A687D	TCGA-EE-A29T-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29T	TCGA-SKCM	NA	s7676	Harvard Medical School	University of Sydney	Australia	NO	TX	NX	Not available	Not available	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cba6	58cfa831e4b0c9d6adf6cba6	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted.bam	456.3	NA	0.15	58cfa831e4b0c9d6adf6cba6	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7784-01A	4BC71292-60BB-4B63-86C1-0FE021083804	Primary Tumor	Illumina HiSeq	a2c5ffab-f279-44fb-a025-079de410f1c4	Prostate	63	0D3EC78C-3DA8-443F-BAA6-93CAED5B065C	2B122D7B-B5CE-44CE-B1EA-7E39E42B2A63	TCGA-EJ-7784-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7784	TCGA-PRAD	NA	s3958	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cba5	58cfa831e4b0c9d6adf6cba5	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted.bam	214.3	NA	0.15	58cfa831e4b0c9d6adf6cba5	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7331-01A	B424B73A-2DFA-473F-AB56-AB382CD1CDEF	Primary Tumor	Illumina HiSeq	a85ad241-998c-4d85-a63b-903ddeb62201	Prostate	64	5AA2E382-C8DF-44E3-8802-994188B11D55	F2DA114D-161B-46CD-BAA7-46E63DBC5D5C	TCGA-EJ-7331-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7331	TCGA-PRAD	NA	s4139	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cb63	58cfa831e4b0c9d6adf6cb63	TCGA-EE-A2A6-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EE-A2A6-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_2_rg.sorted	TCGA-EE-A2A6-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_2_rg.sorted.bam	24.47	NA	0.15	58cfa831e4b0c9d6adf6cb63	TCGA-EE-A2A6-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2A6-10A	CDCF4D91-98A1-4A65-98DD-C6FC80805A0C	Blood Derived Normal	Illumina HiSeq	944c7826-6e83-41b9-8b1a-bd058c415e96	Skin	43	C994DAF7-D84C-43BB-B40B-07AA57737E33	7B8E839F-740B-4BDE-98B8-44EA426D0F52	TCGA-EE-A2A6-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2A6	TCGA-SKCM	NA	s7843	Harvard Medical School	University of Sydney	Australia	NO	T1a	N0	Not available	Stage IA	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cbae	58cfa831e4b0c9d6adf6cbae	TCGA-EJ-5517-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-5517-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_6_rg.sorted	TCGA-EJ-5517-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_6_rg.sorted.bam	610.4	1.9	0.17	58cfa831e4b0c9d6adf6cbae	TCGA-EJ-5517-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5517-10A	4B9AA301-D2E3-47F3-B724-A34F420B2B6B	Blood Derived Normal	Illumina HiSeq	9b9eefbd-747b-48b2-9382-494a8c720a29	Prostate	55	96162A0B-A13A-43F8-8C78-FCE1B5A22938	A42F2DDC-EDDE-486D-BDDF-1A633CA32453	TCGA-EJ-5517-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5517	TCGA-PRAD	NA	s3432	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cb84	58cfa831e4b0c9d6adf6cb84	TCGA-EE-A29V-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EE-A29V-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_7_rg.sorted	TCGA-EE-A29V-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_7_rg.sorted.bam	24.23	NA	0.15	58cfa831e4b0c9d6adf6cb84	TCGA-EE-A29V-10A-01D-A190_120726_SN590_0172_BC0WN3ACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29V-10A	01CB0004-FC1E-4DA5-9D27-F458F8D711EE	Blood Derived Normal	Illumina HiSeq	fa59fd22-b903-473f-a799-3a3f6bcb8536	Skin	85	50459715-30F2-49A7-BE1F-9A54D61242A8	8965C2DB-BDE8-4C9B-84AA-6D2B55101415	TCGA-EE-A29V-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29V	TCGA-SKCM	787	s8005	Harvard Medical School	University of Sydney	Australia	NO	T3b	N1b	Not available	Stage IIIC	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cbc1	58cfa831e4b0c9d6adf6cbc1	TCGA-EJ-7784-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-7784-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_3_rg.sorted	TCGA-EJ-7784-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_3_rg.sorted.bam	304.6	NA	0.16	58cfa831e4b0c9d6adf6cbc1	TCGA-EJ-7784-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7784-10A	4BC71292-60BB-4B63-86C1-0FE021083804	Blood Derived Normal	Illumina HiSeq	9c78d3ff-5257-47e3-86d4-8c7bbdfc5130	Prostate	63	83FA44AA-DFC8-4A1F-9F87-09B0660C3F21	839085D9-2754-467B-AA09-E9558DCA5D88	TCGA-EJ-7784-10A-01D-2111-02	HG19_Broad_variant	TCGA-EJ-7784	TCGA-PRAD	NA	s3957	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cbc4	58cfa831e4b0c9d6adf6cbc4	TCGA-EJ-5532-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-5532-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_4_rg.sorted	TCGA-EJ-5532-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_4_rg.sorted.bam	665.4	1.9	0.16	58cfa831e4b0c9d6adf6cbc4	TCGA-EJ-5532-10A-01D-1573_130221_SN1120_0239_BD1V59ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5532-10A	AE3A0C92-148D-4F1C-8563-06AC1050F53E	Blood Derived Normal	Illumina HiSeq	eb3898c4-6098-4e04-b474-26ff917324b6	Prostate	57	BAAAF843-3E18-49D6-9CCC-21D8A025262C	F3516AED-A847-4F93-8B55-43FEA30563A4	TCGA-EJ-5532-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5532	TCGA-PRAD	NA	s3962	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cbb5	58cfa831e4b0c9d6adf6cbb5	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted.bam	347.7	1.9	0.15	58cfa831e4b0c9d6adf6cbb5	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5507-01A	607200F5-DF80-4F5D-90FB-FDC455A7415B	Primary Tumor	Illumina HiSeq	0dbb7308-269c-4ad8-97c7-e7475ae08189	Prostate	54	F93327F7-0290-4915-97BB-E31BAE2697DD	D2336094-05BD-4E89-84A3-91D641DC31D0	TCGA-EJ-5507-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5507	TCGA-PRAD	NA	s3787	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cbc3	58cfa831e4b0c9d6adf6cbc3	TCGA-EJ-7331-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-7331-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_5_rg.sorted	TCGA-EJ-7331-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_5_rg.sorted.bam	268.6	NA	0.16	58cfa831e4b0c9d6adf6cbc3	TCGA-EJ-7331-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7331-10A	B424B73A-2DFA-473F-AB56-AB382CD1CDEF	Blood Derived Normal	Illumina HiSeq	e78549aa-ba12-42c0-b788-639fb85774a8	Prostate	64	219983F4-DA82-4EA0-B9A0-257988E6C0F7	738A7AAD-026B-46B0-B10D-D1899AE297C1	TCGA-EJ-7331-10A-01D-2111-02	HG19_Broad_variant	TCGA-EJ-7331	TCGA-PRAD	NA	s3609	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cbd6	58cfa831e4b0c9d6adf6cbd6	TCGA-EJ-5525-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-5525-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_2_rg.sorted	TCGA-EJ-5525-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_2_rg.sorted.bam	477.4	1.9	0.16	58cfa831e4b0c9d6adf6cbd6	TCGA-EJ-5525-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5525-10A	554A7381-46FD-4301-B91B-5AF7F173C350	Blood Derived Normal	Illumina HiSeq	7a9972fa-ec25-4ba0-bfea-8a15187015dd	Prostate	67	B518D7C3-9F94-45BB-9DA5-F49BE6059853	A5B4A31F-190E-47A2-B1A7-A7D0A463BD66	TCGA-EJ-5525-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5525	TCGA-PRAD	NA	s3793	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cbc9	58cfa831e4b0c9d6adf6cbc9	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted.bam	271.7	1.9	0.15	58cfa831e4b0c9d6adf6cbc9	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5514-01A	F82D53B1-3DF8-4249-A615-464C9F4E0A32	Primary Tumor	Illumina HiSeq	581bee6a-6abe-4b55-8dc4-63bb242df1cf	Prostate	66	29AD80A4-B429-495C-885E-A92CFE2E4501	6F8F8AAC-C0DE-46F6-A7CF-502893CC57CB	TCGA-EJ-5514-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5514	TCGA-PRAD	NA	s3439	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cbe4	58cfa831e4b0c9d6adf6cbe4	TCGA-EJ-7327-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-7327-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_1_rg.sorted	TCGA-EJ-7327-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_1_rg.sorted.bam	403.6	NA	0.16	58cfa831e4b0c9d6adf6cbe4	TCGA-EJ-7327-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7327-10A	E90AB72A-4BBB-4C37-B48A-8A1A85D79D04	Blood Derived Normal	Illumina HiSeq	27f26a58-df63-4203-aea9-f907fc527c8c	Prostate	61	2B7212E7-C498-4CAA-A42C-78922CB118E4	B8EA6339-5F79-4E87-998F-C06E7799E32A	TCGA-EJ-7327-10A-01D-2111-02	HG19_Broad_variant	TCGA-EJ-7327	TCGA-PRAD	NA	s3608	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cbdf	58cfa831e4b0c9d6adf6cbdf	TCGA-EJ-5515-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-5515-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_2_rg.sorted	TCGA-EJ-5515-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_2_rg.sorted.bam	366.4	1.9	0.16	58cfa831e4b0c9d6adf6cbdf	TCGA-EJ-5515-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5515-10A	19CF56B2-A85B-43E7-971F-5680B9B1A67A	Blood Derived Normal	Illumina HiSeq	d2477eab-8dfa-47b7-9212-c2d294698767	Prostate	60	66E47792-74A2-4F8F-A7E5-602A8EC92DD8	14D2AE51-6008-4DE7-8A69-EA4CE0FC80BE	TCGA-EJ-5515-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5515	TCGA-PRAD	NA	s3955	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cc58	58cfa831e4b0c9d6adf6cc58	TCGA-EJ-5501-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-5501-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_4_rg.sorted	TCGA-EJ-5501-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_4_rg.sorted.bam	214.4	1.9	0.15	58cfa831e4b0c9d6adf6cc58	TCGA-EJ-5501-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5501-10A	8DF0C1E8-966C-4F46-AD15-FAE9E745A32E	Blood Derived Normal	Illumina HiSeq	91be46fe-3b96-4d1b-a7f4-229e972c32d1	Prostate	55	6A7ADCA9-9918-462D-8B8C-CB6A6AA8AD2D	1D371948-3DB6-4390-B576-6E4FDDD7C1FC	TCGA-EJ-5501-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5501	TCGA-PRAD	NA	s3604	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cbf4	58cfa831e4b0c9d6adf6cbf4	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted.bam	344.3	NA	0.16	58cfa831e4b0c9d6adf6cbf4	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7782-01A	1426B4BF-F4A5-477C-BBBB-E0E656549764	Primary Tumor	Illumina HiSeq	f92312ba-ec6b-477e-a08c-12c8af6d1775	Prostate	71	951C894E-9354-45AD-834A-FFC04441A3A9	47FB5E53-DD88-4B25-B6EF-C1ABE55FD5BA	TCGA-EJ-7782-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7782	TCGA-PRAD	NA	s3794	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cbf9	58cfa831e4b0c9d6adf6cbf9	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted.bam	160.3	NA	0.15	58cfa831e4b0c9d6adf6cbf9	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7785-01A	2DEF2A53-D2E8-46F0-8B07-F32DBF1833A4	Primary Tumor	Illumina HiSeq	dfbfaf44-ade6-4c48-88fb-a3898d878853	Prostate	54	63EBD9B1-F118-4315-8722-708F47A07063	196C6111-FF69-40F1-A7AA-973C5AC9106E	TCGA-EJ-7785-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7785	TCGA-PRAD	NA	s3966	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cc60	58cfa831e4b0c9d6adf6cc60	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted.bam	153.7	1.9	0.16	58cfa831e4b0c9d6adf6cc60	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5501-01A	8DF0C1E8-966C-4F46-AD15-FAE9E745A32E	Primary Tumor	Illumina HiSeq	6e2cf9a5-b8c5-4f44-8800-c95ad84bc9a8	Prostate	55	A1E37A0A-67F5-4A19-A540-A45CB89C4203	759BD886-73F1-4DEF-A446-98DAAC2C5B88	TCGA-EJ-5501-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5501	TCGA-PRAD	NA	s3790	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cbeb	58cfa831e4b0c9d6adf6cbeb	TCGA-EM-A1CW-01A-21D-A13U_120706_SN1222_0122_AC0WPYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EM-A1CW-01A-21D-A13U_120706_SN1222_0122_AC0WPYACXX_s_7_rg.sorted	TCGA-EM-A1CW-01A-21D-A13U_120706_SN1222_0122_AC0WPYACXX_s_7_rg.sorted.bam	29.55	2.05	0.18	58cfa831e4b0c9d6adf6cbeb	TCGA-EM-A1CW-01A-21D-A13U_120706_SN1222_0122_AC0WPYACXX_s_7_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CW-01A	22EB9F00-6869-4D8F-B657-DFD64F81E9E9	Primary Tumor	Illumina HiSeq	9c39283e-3646-4154-8265-d68a2f7de106	Thyroid	39	7045F3E1-5239-4159-9B38-31E4168853D0	2CC2002C-4F0A-47A6-AA0A-35FE1B545A7A	TCGA-EM-A1CW-01A-21D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CW	TCGA-THCA	NA	s12253	Harvard Medical School	University Health Network	Canada	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6cb7c	58cfa831e4b0c9d6adf6cb7c	TCGA-EE-A2GB-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EE-A2GB-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_8_rg.sorted	TCGA-EE-A2GB-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_8_rg.sorted.bam	35.83	NA	0.18	58cfa831e4b0c9d6adf6cb7c	TCGA-EE-A2GB-10A-01D-A190_120726_SN590_0171_AD13PJACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GB-10A	E58BED18-503C-4182-BCF3-5AF6F20E1B8A	Blood Derived Normal	Illumina HiSeq	310b2515-640a-417e-9a35-bee64f90ac1c	Skin	51	ACD1CECE-2851-4851-BB58-7DFD7441B9B6	BDAE7DA4-5F86-471E-8AD9-E5FDE3EBD0ED	TCGA-EE-A2GB-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2GB	TCGA-SKCM	NA	s7347	Harvard Medical School	University of Sydney	Australia	NO	T2b	N1a	Not available	Stage IIIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc90	58cfa831e4b0c9d6adf6cc90	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted.bam	131.7	1.9	0.15	58cfa831e4b0c9d6adf6cc90	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5518-01A	2B35C119-CDC1-49E2-8229-CA5CDE9E63D0	Primary Tumor	Illumina HiSeq	02ae3fcb-c1fe-400a-8172-0c62a8d4639c	Prostate	66	F12FA61C-FF1B-48E2-BE19-1D52D50DC261	BD026793-2032-4D13-9A6A-A189583A537C	TCGA-EJ-5518-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5518	TCGA-PRAD	NA	s3430	Harvard Medical School	University of Pittsburgh	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6ccbe	58cfa831e4b0c9d6adf6ccbe	TCGA-EJ-5507-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-5507-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_8_rg.sorted	TCGA-EJ-5507-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_8_rg.sorted.bam	138.4	1.8	0.15	58cfa831e4b0c9d6adf6ccbe	TCGA-EJ-5507-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5507-10A	607200F5-DF80-4F5D-90FB-FDC455A7415B	Blood Derived Normal	Illumina HiSeq	f6d132bc-c74a-4472-8e91-6d86e10f785e	Prostate	54	B4886477-D3F2-4C34-8104-0C379C64F38D	69C6307E-B897-4B90-BBA9-14DE96F14864	TCGA-EJ-5507-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5507	TCGA-PRAD	NA	s3431	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cc1a	58cfa831e4b0c9d6adf6cc1a	TCGA-EE-A29V-06A-12D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EE-A29V-06A-12D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_4_rg.sorted	TCGA-EE-A29V-06A-12D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_4_rg.sorted.bam	44.62	NA	0.17	58cfa831e4b0c9d6adf6cc1a	TCGA-EE-A29V-06A-12D-A18Y_120726_SN590_0172_BC0WN3ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29V-06A	01CB0004-FC1E-4DA5-9D27-F458F8D711EE	Metastatic	Illumina HiSeq	fea260c9-151c-4558-914f-1f9a5a20ef6a	Skin	85	08CD5F21-F1F6-4FFB-8587-2E13F6DED157	A974F839-A24A-4763-8E48-A3777AA7757F	TCGA-EE-A29V-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-EE-A29V	TCGA-SKCM	787	s7339	Harvard Medical School	University of Sydney	Australia	NO	T3b	N1b	Not available	Stage IIIC	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6ccbc	58cfa831e4b0c9d6adf6ccbc	TCGA-EJ-7328-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-7328-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_3_rg.sorted	TCGA-EJ-7328-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_3_rg.sorted.bam	211.6	NA	0.15	58cfa831e4b0c9d6adf6ccbc	TCGA-EJ-7328-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7328-10A	42B7D14F-09E5-4D91-BB98-5FE35907A6A9	Blood Derived Normal	Illumina HiSeq	ad1bcbc2-4111-46be-aa25-6f8222612d52	Prostate	70	562FB2D5-34A4-4AB3-A7C2-7FF5EDCAB189	C8679C7C-C1C9-4A07-A82B-AF7F768223E6	TCGA-EJ-7328-10A-01D-2111-02	HG19_Broad_variant	TCGA-EJ-7328	TCGA-PRAD	NA	s3444	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6ccc0	58cfa831e4b0c9d6adf6ccc0	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted.bam	81.7	1.9	0.15	58cfa831e4b0c9d6adf6ccc0	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5531-01A	ADF3C2F7-D5F9-41C3-BD8C-7F9F1F22FF73	Primary Tumor	Illumina HiSeq	0993d456-af78-4078-aa16-bd810177c278	Prostate	62	48F3A8B8-110C-49AB-BD85-CE33328C2CF6	90219925-E6E8-40BC-8DD0-BD76F942B48C	TCGA-EJ-5531-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5531	TCGA-PRAD	NA	s3445	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6ccd6	58cfa831e4b0c9d6adf6ccd6	TCGA-EJ-5506-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-5506-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_6_rg.sorted	TCGA-EJ-5506-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_6_rg.sorted.bam	277.4	1.9	0.15	58cfa831e4b0c9d6adf6ccd6	TCGA-EJ-5506-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5506-10A	E5E4D3B6-8E58-4DCF-8F67-A00E656A8E27	Blood Derived Normal	Illumina HiSeq	299c9fa9-0cc5-4e97-80d8-e0b7c60bd861	Prostate	67	89ABEFF0-3EE1-4E9C-A1F4-D8CC03A26F8A	380366C0-C2C1-4C13-9806-5270B7CF4824	TCGA-EJ-5506-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5506	TCGA-PRAD	NA	s3433	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6ccd4	58cfa831e4b0c9d6adf6ccd4	TCGA-EJ-5511-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-5511-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_8_rg.sorted	TCGA-EJ-5511-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_8_rg.sorted.bam	599.4	1.9	0.17	58cfa831e4b0c9d6adf6ccd4	TCGA-EJ-5511-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_8_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5511-10A	F8A42FEB-FBC9-4A13-BAD5-1DCEFCA2A9BF	Blood Derived Normal	Illumina HiSeq	22de66f2-6831-4ec8-8ee6-15de1605d466	Prostate	55	5D8C39A9-AC3C-46D2-97DE-DFC1F512EC40	FDDE3ED3-6525-4F34-B6E8-77A171410743	TCGA-EJ-5511-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5511	TCGA-PRAD	NA	s3791	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6ccf0	58cfa831e4b0c9d6adf6ccf0	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted.bam	100.7	1.9	0.13	58cfa831e4b0c9d6adf6ccf0	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5512-01A	C28F931F-5AB2-4899-9FE9-54024F082D92	Primary Tumor	Illumina HiSeq	1df8e29c-5be8-4dbf-abb8-f0ded9419a14	Prostate	46	D0B41403-8458-45E1-946E-21054FBA65B8	D5F126D6-7AAF-425A-BBEA-E7587A25529D	TCGA-EJ-5512-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5512	TCGA-PRAD	NA	s3954	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cc8d	58cfa831e4b0c9d6adf6cc8d	TCGA-ER-A19D-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ER-A19D-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_7_rg.sorted	TCGA-ER-A19D-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_7_rg.sorted.bam	15.61	NA	0.18	58cfa831e4b0c9d6adf6cc8d	TCGA-ER-A19D-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19D-10A	3409F118-1798-48D6-9556-12A5C77EBEFB	Blood Derived Normal	Illumina HiSeq	9f8626eb-9474-4d4f-8aaf-7f04869226d4	Skin	46	DF2B6EFB-3439-4A33-B905-47FD40CA30F5	B7AFB900-2269-4585-BE1F-A72F71499520	TCGA-ER-A19D-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A19D	TCGA-SKCM	383	s7352	Harvard Medical School	University of Pittsburgh	United States	NO	T2a	N0	Not available	Stage IB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ccb0	58cfa831e4b0c9d6adf6ccb0	TCGA-ER-A194-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-ER-A194-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_8_rg.sorted	TCGA-ER-A194-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_8_rg.sorted.bam	38.52	NA	0.16	58cfa831e4b0c9d6adf6ccb0	TCGA-ER-A194-10A-01D-A190_120723_SN1120_0178_BD1887ACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A194-10A	2BBF00F4-7798-4DAD-9894-96202C9132BE	Blood Derived Normal	Illumina HiSeq	ef0fa608-64aa-4fed-b93e-aeab3d012096	Skin	77	A2D0D9EA-35AC-416E-B5C2-768B69DC1372	E478F5FD-9C6D-4169-A023-B78D5F925EBD	TCGA-ER-A194-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A194	TCGA-SKCM	1354	s7351	Harvard Medical School	University of Pittsburgh	United States	NO	Not available	N0	Not available	Not available	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cce5	58cfa831e4b0c9d6adf6cce5	TCGA-EJ-5505-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-5505-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_4_rg.sorted	TCGA-EJ-5505-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_4_rg.sorted.bam	499.4	1.9	0.16	58cfa831e4b0c9d6adf6cce5	TCGA-EJ-5505-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5505-10A	1EA3B879-5451-49FB-B930-16E9B5627F18	Blood Derived Normal	Illumina HiSeq	b49d48cf-faee-4790-83ab-3920e77326b5	Prostate	57	466BD165-3778-4F22-9F3C-CAE696CDD633	813653EC-4D2B-4B69-B89D-9F6716542CE5	TCGA-EJ-5505-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5505	TCGA-PRAD	NA	s3436	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cd08	58cfa831e4b0c9d6adf6cd08	TCGA-EJ-5495-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-5495-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_2_rg.sorted	TCGA-EJ-5495-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_2_rg.sorted.bam	1161.4	1.9	0.16	58cfa831e4b0c9d6adf6cd08	TCGA-EJ-5495-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5495-10A	962DD3D5-8501-4658-8CB9-2424B476124C	Blood Derived Normal	Illumina HiSeq	c1976dc5-9458-46ad-a1a5-1db90aa4eb04	Prostate	68	36329281-238C-492A-B442-70182FFCB017	642519A5-9911-4355-A257-97288162AC53	TCGA-EJ-5495-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5495	TCGA-PRAD	NA	s3941	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cd06	58cfa831e4b0c9d6adf6cd06	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted.bam	253.7	1.9	0.14	58cfa831e4b0c9d6adf6cd06	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5496-01A	6755C231-355F-4CC3-85F1-6306C7F5D44B	Primary Tumor	Illumina HiSeq	00039222-b24d-4c86-b6ac-ffc00b3b6ece	Prostate	59	D0873929-EAC8-42E2-AF6F-DF3CB9CE698C	0A4FA030-2417-4F6F-8B86-5036FCA48F1E	TCGA-EJ-5496-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5496	TCGA-PRAD	NA	s3598	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cd2c	58cfa831e4b0c9d6adf6cd2c	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted.bam	176.7	1.9	0.15	58cfa831e4b0c9d6adf6cd2c	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5495-01A	962DD3D5-8501-4658-8CB9-2424B476124C	Primary Tumor	Illumina HiSeq	a2c14576-771c-460f-a71b-e25651274ca1	Prostate	68	8E53414F-455E-4665-AE0E-9E7405262A96	5644F0E3-3A3B-411A-B28D-C93C3BBD8F86	TCGA-EJ-5495-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5495	TCGA-PRAD	NA	s3597	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cd58	58cfa831e4b0c9d6adf6cd58	TCGA-EJ-5496-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-5496-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_4_rg.sorted	TCGA-EJ-5496-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_4_rg.sorted.bam	1010.4	1.9	0.16	58cfa831e4b0c9d6adf6cd58	TCGA-EJ-5496-10A-01D-1573_130125_SN1120_0233_AD1K3HACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5496-10A	6755C231-355F-4CC3-85F1-6306C7F5D44B	Blood Derived Normal	Illumina HiSeq	e93a13bd-c687-4275-9c7e-75b9b3c024b2	Prostate	59	276AE44F-7531-45B9-9372-5BBCC90B7CF6	7C73B237-4177-4966-8481-81ECC4ECDB61	TCGA-EJ-5496-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5496	TCGA-PRAD	NA	s3788	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cd23	58cfa831e4b0c9d6adf6cd23	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted.filtered.	WGS	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted.bam	373.7	1.9	0.14	58cfa831e4b0c9d6adf6cd23	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-F1-6874-01A	106F3344-F699-4B2C-8F62-4AC6C948DDE4	Primary Tumor	Illumina HiSeq	734d68fe-de19-4aef-8031-8ba255233eba	Stomach	79	C28FEBB9-E845-462F-B6A0-CB565EE6A049	273DDC2E-8E77-4F81-85C2-B9A8583D9E1D	TCGA-F1-6874-01A-11D-1880-02	HG19_Broad_variant	TCGA-F1-6874	TCGA-STAD	NA	s14773	Harvard Medical School	UNC	United States	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6cd5c	58cfa831e4b0c9d6adf6cd5c	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted.bam	107.7	1.9	0.15	58cfa831e4b0c9d6adf6cd5c	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5494-01A	E27C50E2-2A41-4F8C-9EF8-2BC51FB0C23E	Primary Tumor	Illumina HiSeq	01d186ab-6289-40da-9715-4f766da74b10	Prostate	50	37103479-02BD-45E8-95B3-7A4A78523999	9AA32D54-78ED-4DFC-ACA4-E1A88404F791	TCGA-EJ-5494-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5494	TCGA-PRAD	NA	s4131	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cd87	58cfa831e4b0c9d6adf6cd87	TCGA-EJ-7781-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-7781-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_7_rg.sorted	TCGA-EJ-7781-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_7_rg.sorted.bam	220.6	NA	0.17	58cfa831e4b0c9d6adf6cd87	TCGA-EJ-7781-10A-01D-2111_130502_SN590_0228_AD24A9ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7781-10A	33283111-9A2F-4D5E-92A5-3435846404F7	Blood Derived Normal	Illumina HiSeq	710510b5-d614-4a34-984a-0cb67724df03	Prostate	65	6839F951-8A1F-4023-8778-0EC40A6FF986	0CB2A252-8798-4883-9ADA-7AEEC9C4615C	TCGA-EJ-7781-10A-01D-2111-02	HG19_Broad_variant	TCGA-EJ-7781	TCGA-PRAD	NA	s3965	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cd8c	58cfa831e4b0c9d6adf6cd8c	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted.bam	168.3	NA	0.16	58cfa831e4b0c9d6adf6cd8c	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7781-01A	33283111-9A2F-4D5E-92A5-3435846404F7	Primary Tumor	Illumina HiSeq	bf6c4719-7b88-4975-9591-8bd34c19e3cf	Prostate	65	B5504343-6915-4D15-A81E-641B03C77F24	193083B4-B2E1-486C-A4F5-F62818AEBBC2	TCGA-EJ-7781-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7781	TCGA-PRAD	NA	s4141	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6cd4e	58cfa831e4b0c9d6adf6cd4e	TCGA-ET-A25R-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ET-A25R-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_7_rg.sorted	TCGA-ET-A25R-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_7_rg.sorted.bam	33.46	1.62	0.18	58cfa831e4b0c9d6adf6cd4e	TCGA-ET-A25R-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25R-10A	097B9CF1-EC0C-487C-9ADE-2BDAB12EB4CA	Blood Derived Normal	Illumina HiSeq	ff72e312-4484-403b-a19c-43c5dca61c5f	Thyroid	51	18E68337-FFFC-49E9-BAA5-0CA0948FDD5A	4A3F2DC0-834F-4D82-82CD-41BEC8AC61E6	TCGA-ET-A25R-10A-01D-A16N-02	HG19_Broad_variant	TCGA-ET-A25R	TCGA-THCA	NA	s12527	Harvard Medical School	Johns Hopkins	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A16N-02	TRUE
13722.58cfa831e4b0c9d6adf6cd28	58cfa831e4b0c9d6adf6cd28	TCGA-EE-A2MP-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EE-A2MP-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_5_rg.sorted	TCGA-EE-A2MP-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_5_rg.sorted.bam	37.32	NA	0.15	58cfa831e4b0c9d6adf6cd28	TCGA-EE-A2MP-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MP-10A	54782BD7-79BE-4E3C-BF99-844E7BB0E5D7	Blood Derived Normal	Illumina HiSeq	ae55062b-1a3c-407b-827e-7567130bf44e	Skin	34	DC48E514-D167-4252-8621-2D313D4B93CF	98D1F8A0-A931-4BEA-BE45-97C735FC47CD	TCGA-EE-A2MP-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2MP	TCGA-SKCM	NA	s7858	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6ce14	58cfa832e4b0c9d6adf6ce14	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted.bam	398.7	1.9	0.15	58cfa832e4b0c9d6adf6ce14	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5511-01A	F8A42FEB-FBC9-4A13-BAD5-1DCEFCA2A9BF	Primary Tumor	Illumina HiSeq	dfa7170d-3cc1-43b7-9d24-7be107cf2896	Prostate	55	1DA89009-5DBE-4D62-9406-36330F47B738	5D753860-8965-45E5-A919-C076B53334D4	TCGA-EJ-5511-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5511	TCGA-PRAD	NA	s3600	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cd6c	58cfa831e4b0c9d6adf6cd6c	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted.bam	101.84	1.93	0.17	58cfa831e4b0c9d6adf6cd6c	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25R-01A	097B9CF1-EC0C-487C-9ADE-2BDAB12EB4CA	Primary Tumor	Illumina HiSeq	442f6193-a979-40e4-89db-2e541d3ebdb7	Thyroid	51	C29162A3-F162-4D32-AB9A-421BE1FEB13C	77A80565-1BC9-4F0A-AFB3-23955FE283EB	TCGA-ET-A25R-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25R	TCGA-THCA	NA	s12003	Harvard Medical School	Johns Hopkins	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6ce46	58cfa832e4b0c9d6adf6ce46	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted.bam	125.7	1.9	0.15	58cfa832e4b0c9d6adf6ce46	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5504-01A	E1C3D1BD-CF8F-4FA4-AC8E-BF9E54F7AAD4	Primary Tumor	Illumina HiSeq	ea018935-4ded-4def-a204-bda7035ba32c	Prostate	65	7D0C0A85-8459-43A3-AC22-F447BB042149	FB332EAD-214E-4D76-BD3C-0774D906F68B	TCGA-EJ-5504-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5504	TCGA-PRAD	NA	s3953	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cdaf	58cfa831e4b0c9d6adf6cdaf	TCGA-FE-A22Z-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FE-A22Z-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_3_rg.sorted	TCGA-FE-A22Z-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_3_rg.sorted.bam	78.59	2.03	0.16	58cfa831e4b0c9d6adf6cdaf	TCGA-FE-A22Z-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A22Z-01A	78D14F86-896A-4F98-9274-B2E8E387ADD9	Primary Tumor	Illumina HiSeq	ae24ab9d-6983-466a-a7f4-50da56438303	Thyroid	61	D206D300-E0CE-4A40-AF1F-45A685346A6E	B7A31BAC-FD92-47AF-8C9C-E78E3FC1609A	TCGA-FE-A22Z-01A-11D-A16N-02	HG19_Broad_variant	TCGA-FE-A22Z	TCGA-THCA	NA	s12648	Harvard Medical School	Ohio State University	United States	NO	T4a	N1	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage IVA	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6ceb0	58cfa832e4b0c9d6adf6ceb0	TCGA-EJ-5530-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-5530-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_8_rg.sorted	TCGA-EJ-5530-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_8_rg.sorted.bam	696.4	1.9	0.16	58cfa832e4b0c9d6adf6ceb0	TCGA-EJ-5530-10A-01D-1573_130221_SN1120_0238_AC1TDEACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5530-10A	E4A755E3-4938-4321-B5A9-27A445036791	Blood Derived Normal	Illumina HiSeq	9722e61b-009b-4167-927d-68a6e13d0ead	Prostate	61	0D40DA59-0AF0-47ED-A4E3-42229D6F212F	842AF7DF-177C-4B4B-8EBD-7292D06BFC9F	TCGA-EJ-5530-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5530	TCGA-PRAD	NA	s4138	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa832e4b0c9d6adf6ce5c	58cfa832e4b0c9d6adf6ce5c	TCGA-GE-A2C6-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_8_rg.sorted.filtered.	WGS	TCGA-GE-A2C6-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_8_rg.sorted	TCGA-GE-A2C6-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_8_rg.sorted.bam	72.38	2.08	0.15	58cfa832e4b0c9d6adf6ce5c	TCGA-GE-A2C6-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-GE-A2C6-10A	7DEEDEBA-F05B-453C-9DF1-EEB20B0EC72E	Blood Derived Normal	Illumina HiSeq	b6bf2fbc-c57f-48cb-8fae-30e409afb4bb	Thyroid	33	DC7837F2-9B14-4E27-A7F8-08FE3CE27761	2E5F216C-704C-4AC0-A666-A164352BD22E	TCGA-GE-A2C6-10A-01D-A16N-02	HG19_Broad_variant	TCGA-GE-A2C6	TCGA-THCA	NA	s12122	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6ce83	58cfa832e4b0c9d6adf6ce83	TCGA-G2-A2EJ-10A-01D-A17R_120921_SN208_0430_AC18CWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-G2-A2EJ-10A-01D-A17R_120921_SN208_0430_AC18CWACXX_s_4_rg.sorted	TCGA-G2-A2EJ-10A-01D-A17R_120921_SN208_0430_AC18CWACXX_s_4_rg.sorted.bam	9.62	NA	0.16	58cfa832e4b0c9d6adf6ce83	TCGA-G2-A2EJ-10A-01D-A17R_120921_SN208_0430_AC18CWACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EJ-10A	C6227D39-D9E8-4E28-9E70-D7F720AB25E4	Blood Derived Normal	Illumina HiSeq	5ca74123-b721-4ec8-bade-785975c82891	Bladder	56	B695C910-8DA4-4F65-94E3-BB8463305582	39AE305E-B2CB-406E-B625-9DEDF1191A86	TCGA-G2-A2EJ-10A-01D-A17R-02	HG19_Broad_variant	TCGA-G2-A2EJ	TCGA-BLCA	NA	s2918	Harvard Medical School	MD Anderson	United States	NO	Not available	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	TRUE
13722.58cfa832e4b0c9d6adf6cf2a	58cfa832e4b0c9d6adf6cf2a	TCGA-H4-A2HQ-10A-01D-A17R_120921_SN208_0430_AC18CWACXX_s_6_rg.sorted.filtered.	WGS	TCGA-H4-A2HQ-10A-01D-A17R_120921_SN208_0430_AC18CWACXX_s_6_rg.sorted	TCGA-H4-A2HQ-10A-01D-A17R_120921_SN208_0430_AC18CWACXX_s_6_rg.sorted.bam	10.51	NA	0.18	58cfa832e4b0c9d6adf6cf2a	TCGA-H4-A2HQ-10A-01D-A17R_120921_SN208_0430_AC18CWACXX_s_6_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-H4-A2HQ-10A	CEDE5274-279D-4021-8ACA-5ECC4BF94D66	Blood Derived Normal	Illumina HiSeq	feb80610-46c5-490f-a029-9c6b401aeb25	Bladder	64	1650C0FB-03FF-45CB-93A6-A7544CEF346E	3A1438D1-7115-47FE-84AC-608C1DF101D5	TCGA-H4-A2HQ-10A-01D-A17R-02	HG19_Broad_variant	TCGA-H4-A2HQ	TCGA-BLCA	NA	s2930	Harvard Medical School	Medical College of Georgia	United States	NO	Not available	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17R-02	TRUE
13722.58cfa832e4b0c9d6adf6cf14	58cfa832e4b0c9d6adf6cf14	TCGA-FE-A22Z-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FE-A22Z-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_6_rg.sorted	TCGA-FE-A22Z-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_6_rg.sorted.bam	27.97	1.9	0.15	58cfa832e4b0c9d6adf6cf14	TCGA-FE-A22Z-10A-01D-A16N_120805_SN208_0422_BD16VPACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A22Z-10A	78D14F86-896A-4F98-9274-B2E8E387ADD9	Blood Derived Normal	Illumina HiSeq	c548c623-51dc-406f-8ce7-5589f31b53d7	Thyroid	61	7727F473-C83D-4CF2-B779-C4FDB6172AA7	0348769D-7455-4465-9154-45B4E677505B	TCGA-FE-A22Z-10A-01D-A16N-02	HG19_Broad_variant	TCGA-FE-A22Z	TCGA-THCA	NA	s12006	Harvard Medical School	Ohio State University	United States	NO	T4a	N1	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage IVA	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6cec6	58cfa832e4b0c9d6adf6cec6	TCGA-G2-A2EC-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G2-A2EC-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_6_rg.sorted	TCGA-G2-A2EC-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_6_rg.sorted.bam	39.61	NA	0.17	58cfa832e4b0c9d6adf6cec6	TCGA-G2-A2EC-10A-01D-A17R_120927_SN208_0433_BD1D5JACXX_s_6_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EC-10A	28E25FFB-8B0C-4839-A735-ED7B78E3213A	Blood Derived Normal	Illumina HiSeq	b2ae08c3-020a-401c-9a25-c937c153c403	Bladder	58	9F4EE11B-298A-4F1A-867A-86BBA1372476	87406693-CC45-41E6-94D2-0D6933577BCA	TCGA-G2-A2EC-10A-01D-A17R-02	HG19_Broad_variant	TCGA-G2-A2EC	TCGA-BLCA	NA	s2727	Harvard Medical School	MD Anderson	United States	NO	Not available	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	TRUE
13722.58cfa832e4b0c9d6adf6cfac	58cfa832e4b0c9d6adf6cfac	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted.bam	75.85	1.8	0.17	58cfa832e4b0c9d6adf6cfac	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-GE-A2C6-01A	7DEEDEBA-F05B-453C-9DF1-EEB20B0EC72E	Primary Tumor	Illumina HiSeq	4920d08d-433e-4371-8daa-641819a1e53f	Thyroid	33	D717EECF-11DC-4E15-851A-9EA18332A48B	A5FA44A2-8101-4A0C-982C-57337853BACA	TCGA-GE-A2C6-01A-11D-A16N-02	HG19_Broad_variant	TCGA-GE-A2C6	TCGA-THCA	NA	s12123	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	TRUE
13722.58cfa832e4b0c9d6adf6d01e	58cfa832e4b0c9d6adf6d01e	TCGA-FS-A1ZQ-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FS-A1ZQ-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_8_rg.sorted	TCGA-FS-A1ZQ-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_8_rg.sorted.bam	53.87	NA	0.16	58cfa832e4b0c9d6adf6d01e	TCGA-FS-A1ZQ-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZQ-10A	B91AF125-A024-4BA3-A5E8-99955FF9EFC5	Blood Derived Normal	Illumina HiSeq	3789dc51-ce06-41cd-9fe4-a60f3b49303a	Skin	31	567E5BB0-A080-43FD-87A4-94C5CCFF2148	0BFF6798-E967-424F-8B78-2875F6074F18	TCGA-FS-A1ZQ-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZQ	TCGA-SKCM	4062	s7534	Harvard Medical School	Essen	Germany	NO	TX	N0	Not available	I or II NOS	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6d082	58cfa832e4b0c9d6adf6d082	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted.bam	131.3	NA	0.15	58cfa832e4b0c9d6adf6d082	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7210-01A	6A5AF80E-07AD-4CD3-AAAB-5DB1090835D9	Primary Tumor	Illumina HiSeq	e6934494-d8e1-44c6-a343-30a6aa2e6cbc	Prostate	74	9069FC65-9BAE-49F3-9329-B78C8CC6CF1E	D414D851-0AF6-4C8F-8E40-CCA9FDF79488	TCGA-HC-7210-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7210	TCGA-PRAD	NA	s3983	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d0f5	58cfa832e4b0c9d6adf6d0f5	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted.bam	121.3	NA	0.15	58cfa832e4b0c9d6adf6d0f5	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7209-01A	582D1177-73B0-4A9C-8505-70D6B402BD01	Primary Tumor	Illumina HiSeq	d228a749-988a-4fcb-9f15-e334295216fb	Prostate	60	AA7850AC-FB78-433B-8D55-A24C05935DB5	3C59E423-E1A6-4C67-8A88-63A0817B856E	TCGA-HC-7209-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7209	TCGA-PRAD	NA	s3625	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6cf0e	58cfa832e4b0c9d6adf6cf0e	TCGA-FS-A1Z3-06A-11D-A18Y_120711_SN208_0414_BD13L5ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FS-A1Z3-06A-11D-A18Y_120711_SN208_0414_BD13L5ACXX_s_7_rg.sorted	TCGA-FS-A1Z3-06A-11D-A18Y_120711_SN208_0414_BD13L5ACXX_s_7_rg.sorted.bam	43.25	NA	0.17	58cfa832e4b0c9d6adf6cf0e	TCGA-FS-A1Z3-06A-11D-A18Y_120711_SN208_0414_BD13L5ACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1Z3-06A	29BCB876-5A91-4D56-AF47-7B4C856C151F	Metastatic	Illumina HiSeq	c18e2956-90d4-4a37-8841-e3b090936c2c	Skin	72	851FA9C8-97E5-40EE-8F48-7121F273AADE	9EAE9C8D-45FA-4A49-8F70-1AB43E6598F9	TCGA-FS-A1Z3-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1Z3	TCGA-SKCM	636	s7524	Harvard Medical School	Essen	Germany	NO	TX	N0	Not available	Stage IV	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d1ac	58cfa832e4b0c9d6adf6d1ac	TCGA-HC-7211-11A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-HC-7211-11A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_3_rg.sorted	TCGA-HC-7211-11A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_3_rg.sorted.bam	347.3	NA	0.16	58cfa832e4b0c9d6adf6d1ac	TCGA-HC-7211-11A-01D-2111_130517_SN590_0230_AD24B4ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7211-11A	EC3870C9-4930-4AF7-B2EB-1E16C9EC9F14	Solid Tissue Normal	Illumina HiSeq	05e04c32-8191-475a-9d50-3fa50aadb8d5	Prostate	62	710AADB2-1976-41F4-8A8A-BBB6B3283018	8C9CDD7B-FF6C-4D47-9306-E6AAF4C00790	TCGA-HC-7211-11A-01D-2111-02	HG19_Broad_variant	TCGA-HC-7211	TCGA-PRAD	NA	s3810	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d102	58cfa832e4b0c9d6adf6d102	TCGA-HC-7231-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-HC-7231-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_3_rg.sorted	TCGA-HC-7231-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_3_rg.sorted.bam	180.6	NA	0.14	58cfa832e4b0c9d6adf6d102	TCGA-HC-7231-10A-01D-2111_130517_SN590_0231_BC24V6ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	Not available	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7231-10A	B182BDA9-3D9F-4958-96EB-BD6CC441830C	Blood Derived Normal	Illumina HiSeq	9ad2873c-4fe1-4a32-9c57-921c2e4c87d2	Prostate	66	29687E3D-5220-42C8-BD92-7D0A85DB6B18	6AAE755F-02B5-4717-97B5-AF8937ACC4E7	TCGA-HC-7231-10A-01D-2111-02	HG19_Broad_variant	TCGA-HC-7231	TCGA-PRAD	NA	s3630	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d1bb	58cfa832e4b0c9d6adf6d1bb	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted.bam	116.7	1.9	0.14	58cfa832e4b0c9d6adf6d1bb	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5509-01A	13CE70A8-785C-4B59-B073-41922CB201F9	Primary Tumor	Illumina HiSeq	6fd44a89-a20c-4ecc-bafe-54da9b58cd9d	Prostate	63	99A7115E-046B-488E-95D2-48C35BD29867	4F3831BE-6C1C-4786-B953-2612753C1E5C	TCGA-EJ-5509-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5509	TCGA-PRAD	NA	s3440	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa832e4b0c9d6adf6d1d2	58cfa832e4b0c9d6adf6d1d2	TCGA-HQ-A2OE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HQ-A2OE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_5_rg.sorted	TCGA-HQ-A2OE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_5_rg.sorted.bam	71.88	NA	0.16	58cfa832e4b0c9d6adf6d1d2	TCGA-HQ-A2OE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-HQ-A2OE-01A	353C5FCC-9C6A-4AC6-99DC-FB4573B2AE6C	Primary Tumor	Illumina HiSeq	21c45d2f-f8bc-45dc-85d2-790ea5506bc4	Bladder	69	65DBBE08-4645-4552-9A1A-E6F79A621013	B04D2557-D084-4445-97BB-10A6CB59DC6B	TCGA-HQ-A2OE-01A-11D-A204-02	HG19_Broad_variant	TCGA-HQ-A2OE	TCGA-BLCA	NA	s2935	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Not available	A204-02	TRUE
13722.58cfa832e4b0c9d6adf6d114	58cfa832e4b0c9d6adf6d114	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted.bam	46.96	NA	0.16	58cfa832e4b0c9d6adf6d114	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2ES-01A	72D8EAE8-9EFB-45B2-ACBD-82C6B5732E38	Primary Tumor	Illumina HiSeq	5922785f-2336-403c-9cb6-0843df3383b5	Bladder	85	C2288290-F17A-435C-90E7-5A4913F0C076	52FA3B0A-B5C7-4A74-A798-0DB359029147	TCGA-G2-A2ES-01A-11D-A17R-02	HG19_Broad_variant	TCGA-G2-A2ES	TCGA-BLCA	NA	s2919	Harvard Medical School	MD Anderson	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	TRUE
13722.58cfa832e4b0c9d6adf6d1d8	58cfa832e4b0c9d6adf6d1d8	TCGA-HQ-A2OE-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HQ-A2OE-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_6_rg.sorted	TCGA-HQ-A2OE-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_6_rg.sorted.bam	20.82	NA	0.15	58cfa832e4b0c9d6adf6d1d8	TCGA-HQ-A2OE-10A-01D-A204_121002_SN1222_0155_BD1ERHACXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-HQ-A2OE-10A	353C5FCC-9C6A-4AC6-99DC-FB4573B2AE6C	Blood Derived Normal	Illumina HiSeq	2ff1fc67-2977-45d1-baca-e4098f7bca8d	Bladder	69	A360CC7F-D30B-48A5-AB63-3754E3A8C709	86227A84-351B-41F4-9915-FDA1049A6DCA	TCGA-HQ-A2OE-10A-01D-A204-02	HG19_Broad_variant	TCGA-HQ-A2OE	TCGA-BLCA	NA	s3310	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Not available	A204-02	TRUE
13722.58cfa832e4b0c9d6adf6d02c	58cfa832e4b0c9d6adf6d02c	TCGA-GD-A2C5-10A-01D-A17R_120927_SN208_0432_AC188LACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GD-A2C5-10A-01D-A17R_120927_SN208_0432_AC188LACXX_s_7_rg.sorted	TCGA-GD-A2C5-10A-01D-A17R_120927_SN208_0432_AC188LACXX_s_7_rg.sorted.bam	30.35	NA	0.11	58cfa832e4b0c9d6adf6d02c	TCGA-GD-A2C5-10A-01D-A17R_120927_SN208_0432_AC188LACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A2C5-10A	5D54C742-5A8E-4C40-8D62-95E75E210AB8	Blood Derived Normal	Illumina HiSeq	e5ea7215-cf70-453d-bf6d-64868d34d584	Bladder	53	68F5998D-53C5-4CC1-9249-2C24AE8579AD	33CF143A-29E5-40C1-8301-7A7A271BF4EF	TCGA-GD-A2C5-10A-01D-A17R-02	HG19_Broad_variant	TCGA-GD-A2C5	TCGA-BLCA	NA	s2732	Harvard Medical School	ABS - IUPUI	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17R-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5f0	58cfa82fe4b0c9d6adf6b5f0	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted.filtered.	WGS	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted.bam	168.4	2	0.15	58cfa82fe4b0c9d6adf6b5f0	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5933-01A	7A0EA814-F0DE-4BC4-A81A-DAA000559369	Primary Tumor	Illumina HiSeq	ca97b42b-d723-4c0a-8f71-819eca1bb805	Lung	72	D2355F3A-E2CE-4791-B1FB-B570850681DF	1D83B47D-66A8-4AE9-81BB-BDC03FA64AC6	TCGA-50-5933-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5933	TCGA-LUAD	2393	s11009	Harvard Medical School	University of Pittsburgh	United States	NO	T4	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIB	1751-02	TRUE
13722.58cfa82ee4b0c9d6adf6ae5c	58cfa82ee4b0c9d6adf6ae5c	TCGA-05-4397-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-05-4397-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_7_rg.sorted	TCGA-05-4397-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_7_rg.sorted.bam	573.23	1.9	0.14	58cfa82ee4b0c9d6adf6ae5c	TCGA-05-4397-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_7_rg.sorted.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4397-01A	6DFD47D2-831A-4386-9051-F78199A16BB5	Primary Tumor	Illumina HiSeq	09ccfcd9-4865-439b-9162-cf783f33f44d	Lung	65	C4C061CD-E926-400B-B18C-B47C234337CA	5D48DDB3-ED53-49CB-99B9-B75FCECCA1B4	TCGA-05-4397-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4397	TCGA-LUAD	731	s10643	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6af8a	58cfa82ee4b0c9d6adf6af8a	TCGA-05-4390-10A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_2_rg.sorted.filtered.	WGS	TCGA-05-4390-10A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_2_rg.sorted	TCGA-05-4390-10A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_2_rg.sorted.bam	27	1.9	0.15	58cfa82ee4b0c9d6adf6af8a	TCGA-05-4390-10A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4390-10A	B8475929-2D9D-4909-BD62-59684A140BD7	Blood Derived Normal	Illumina HiSeq	ad4b348b-351c-4edf-b95d-e49dfe7c5de7	Lung	58	B038C472-1AF2-45E1-81D8-B66FAE6FD66F	D3C7ABBD-591E-4F80-9A1C-046C2C4C1028	TCGA-05-4390-10A-01D-1751-02	HG19_Broad_variant	TCGA-05-4390	TCGA-LUAD	NA	s10899	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b5e6	58cfa82fe4b0c9d6adf6b5e6	TCGA-50-5935-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-5935-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_1_rg.sorted	TCGA-50-5935-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_1_rg.sorted.bam	32.4	2.1	0.13	58cfa82fe4b0c9d6adf6b5e6	TCGA-50-5935-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5935-11A	100430C8-1446-45C8-AF36-B6DBB3DDD0C1	Solid Tissue Normal	Illumina HiSeq	32fab0c6-8503-4996-a31a-4968a251eaa8	Lung	86	7D689C5F-365D-4E69-8AE6-971D96D56DF1	AD1E6112-B2F8-4871-BE0E-D073956C4A21	TCGA-50-5935-11A-01D-1751-02	HG19_Broad_variant	TCGA-50-5935	TCGA-LUAD	653	s11238	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	TRUE
13722.58cfa82ee4b0c9d6adf6afa6	58cfa82ee4b0c9d6adf6afa6	TCGA-05-4422-10A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-05-4422-10A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_6_rg.sorted	TCGA-05-4422-10A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_6_rg.sorted.bam	61.23	1.8	0.15	58cfa82ee4b0c9d6adf6afa6	TCGA-05-4422-10A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4422-10A	44DEC838-B653-42A7-A58B-A1FD232CD68C	Blood Derived Normal	Illumina HiSeq	8563e108-6248-4f9c-81ef-2c8118956385	Lung	68	FCE6E4CC-207C-4B2C-8387-6166D47565BB	6214FC0C-5B64-4611-B8F3-213A879615E7	TCGA-05-4422-10A-01D-1203-02	HG19_Broad_variant	TCGA-05-4422	TCGA-LUAD	NA	s11329	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	TRUE
13722.58cfa82ee4b0c9d6adf6b038	58cfa82ee4b0c9d6adf6b038	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted.bam	16.7	1.9	0.14	58cfa82ee4b0c9d6adf6b038	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4424-01A	66763A0C-6CDA-4832-A0CC-E7B496D78EAA	Primary Tumor	Illumina HiSeq	1e635509-6178-417e-9452-bc77482ee8ed	Lung	70	A4D06D63-8DA9-4C3C-A75D-4079C2238AA8	D1052F23-44EC-4C05-A164-6FBD72DFC9E2	TCGA-05-4424-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4424	TCGA-LUAD	NA	s11438	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6a2	58cfa82fe4b0c9d6adf6b6a2	TCGA-44-6776-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_1_rg.sorted.filtered.	WGS	TCGA-44-6776-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_1_rg.sorted	TCGA-44-6776-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_1_rg.sorted.bam	195.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6a2	TCGA-44-6776-11A-01D-1853_120123_SN590_0134_AC0DJKACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-44-6776-11A	C2A1DE2E-6451-4C95-8CE6-263F2B7E6EFF	Solid Tissue Normal	Illumina HiSeq	b7a6be76-449b-46fc-863f-1e1cb9498eae	Lung	60	DA9934B1-92AA-4A5F-B12D-EFE510FD7499	CD224998-3A69-4ECC-9EDE-893F793E7761	TCGA-44-6776-11A-01D-1853-02	HG19_Broad_variant	TCGA-44-6776	TCGA-LUAD	NA	s10657	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6a6	58cfa82fe4b0c9d6adf6b6a6	TCGA-44-6145-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_1_rg.sorted.filtered.	WGS	TCGA-44-6145-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_1_rg.sorted	TCGA-44-6145-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_1_rg.sorted.bam	305.7	1.8	0.16	58cfa82fe4b0c9d6adf6b6a6	TCGA-44-6145-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6145-10A	6144D666-8F77-4EFE-95F1-F9E5C4E5E056	Blood Derived Normal	Illumina HiSeq	b21d12d5-2762-46b6-bd9c-d2f3579c9779	Lung	62	FDD20655-0DB6-4ABB-BEC4-451BD3E5389E	04AD8606-F9CC-4067-821C-BB964D10F1B3	TCGA-44-6145-10A-01D-1751-02	HG19_Broad_variant	TCGA-44-6145	TCGA-LUAD	NA	s10649	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6af	58cfa82fe4b0c9d6adf6b6af	TCGA-44-6146-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_4_rg.sorted.filtered.	WGS	TCGA-44-6146-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_4_rg.sorted	TCGA-44-6146-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_4_rg.sorted.bam	191	1.9	0.15	58cfa82fe4b0c9d6adf6b6af	TCGA-44-6146-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6146-10A	0C0B610E-FE4C-406D-A5ED-5CC3B11DABF5	Blood Derived Normal	Illumina HiSeq	66abe87b-119e-4f15-822b-795e8ec2e60f	Lung	64	2640D6DC-15C7-405F-A348-6751393DEE6D	8D8C3FBF-204B-4A7A-942A-6A6CE2E0470C	TCGA-44-6146-10A-01D-1751-02	HG19_Broad_variant	TCGA-44-6146	TCGA-LUAD	NA	s10992	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Lung Mucinous Adenocarcinoma	Stage IIB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6be	58cfa82fe4b0c9d6adf6b6be	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.filtered.	WGS	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.bam	127.4	1.9	0.15	58cfa82fe4b0c9d6adf6b6be	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-55-6543-01A	E68219B0-A9C2-49DF-8F0D-DB5EA97FD2DC	Primary Tumor	Illumina HiSeq	0715b83e-fcd8-41e9-88ac-cfeb5fabd3de	Lung	60	8D9491E7-9B14-4988-8FA7-E6AF041120BD	1D88DA12-E71A-4F44-8D71-DA8957BDFCD4	TCGA-55-6543-01A-11D-1751-02	HG19_Broad_variant	TCGA-55-6543	TCGA-LUAD	NA	s10791	Harvard Medical School	International Genomics Consortium	United States	NO	T1b	N0	Lung Bronchioloalveolar Carcinoma Mucinous	Stage IA	1751-02	TRUE
13722.58cfa82ee4b0c9d6adf6b014	58cfa82ee4b0c9d6adf6b014	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted.bam	199.7	1.9	0.16	58cfa82ee4b0c9d6adf6b014	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-05-4433-01A	AEA68827-DC0F-484D-A00D-06DEEAA4B3CE	Primary Tumor	Illumina HiSeq	d1b6064d-6736-4aad-8ad3-70ab64c92e3d	Lung	82	1E9DAC94-1A10-47D0-AE92-81D38A264376	61B1812A-9455-437F-ACF7-D1AC3FA9F215	TCGA-05-4433-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4433	TCGA-LUAD	NA	s10986	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6dc	58cfa82fe4b0c9d6adf6b6dc	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted.filtered.	WGS	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted.bam	190.4	1.9	0.15	58cfa82fe4b0c9d6adf6b6dc	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5935-01A	100430C8-1446-45C8-AF36-B6DBB3DDD0C1	Primary Tumor	Illumina HiSeq	f4ad5c7d-a36e-4d9a-9c36-444e4b443953	Lung	86	98687ADB-F8E9-4E6E-BC1B-396A3DDFAC96	6F0D56B0-E246-4566-AFFB-B8DD5E88B5BA	TCGA-50-5935-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5935	TCGA-LUAD	653	s10908	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6d2	58cfa82fe4b0c9d6adf6b6d2	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.bam	472.3	1.9	0.15	58cfa82fe4b0c9d6adf6b6d2	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3396-01A	3BD6BADB-27FF-4D8D-B206-4D28DC264862	Primary Tumor	Illumina HiSeq	bf55243b-c7c6-46fc-9d54-e1916b0d7ea2	Lung	74	B560DF97-986B-4A88-A0F1-C38A30080EDB	ECCC6A5C-BB25-4591-996A-EE2A7507F771	TCGA-44-3396-01A-01D-1203-02	HG19_Broad_variant	TCGA-44-3396	TCGA-LUAD	NA	s10653	Harvard Medical School	Christiana Healthcare	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	TRUE
13722.58cfa82fe4b0c9d6adf6b6e4	58cfa82fe4b0c9d6adf6b6e4	TCGA-50-6593-11A-01D-1751_120105_SN1120_0107_AC054PACXX_s_4_rg.sorted.filtered.	WGS	TCGA-50-6593-11A-01D-1751_120105_SN1120_0107_AC054PACXX_s_4_rg.sorted	TCGA-50-6593-11A-01D-1751_120105_SN1120_0107_AC054PACXX_s_4_rg.sorted.bam	37.4	1.9	0.14	58cfa82fe4b0c9d6adf6b6e4	TCGA-50-6593-11A-01D-1751_120105_SN1120_0107_AC054PACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6593-11A	E10568FE-0436-43F2-9F0F-48F9903868C4	Solid Tissue Normal	Illumina HiSeq	d6164f86-2486-463f-897c-fa4c2934fd35	Lung	49	2EE7CF16-ECAC-4175-A280-C7C8C38CDCC9	9A45C8BD-B122-4E13-AD72-E9CE655FE37F	TCGA-50-6593-11A-01D-1751-02	HG19_Broad_variant	TCGA-50-6593	TCGA-LUAD	336	s10787	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b728	58cfa82fe4b0c9d6adf6b728	TCGA-44-6147-01A-11D-1751_111207_SN590_0112_D09CDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-44-6147-01A-11D-1751_111207_SN590_0112_D09CDACXX_s_1_rg.sorted	TCGA-44-6147-01A-11D-1751_111207_SN590_0112_D09CDACXX_s_1_rg.sorted.bam	219	1.9	0.17	58cfa82fe4b0c9d6adf6b728	TCGA-44-6147-01A-11D-1751_111207_SN590_0112_D09CDACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6147-01A	889AEC8E-14BA-48D9-8FE1-F2416E82B333	Primary Tumor	Illumina HiSeq	a9e60432-a9de-4497-b94d-5ead787d2de3	Lung	67	43F5270A-F2F2-4DD9-83B5-486B805E35B8	E9CE62EF-711E-4252-AC93-97B69C39041A	TCGA-44-6147-01A-11D-1751-02	HG19_Broad_variant	TCGA-44-6147	TCGA-LUAD	NA	s11447	Harvard Medical School	Christiana Healthcare	United States	NO	T1b	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b70a	58cfa82fe4b0c9d6adf6b70a	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.filtered.	WGS	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.bam	355.4	1.9	0.14	58cfa82fe4b0c9d6adf6b70a	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6216-01A	CCECCE70-DD54-4C5B-BF9F-CA87D290CB00	Primary Tumor	Illumina HiSeq	ae4aaef1-8b47-476b-933a-ff69761aa0a9	Lung	57	4EAA4B4A-E9DB-4E65-97D6-7FA1A205DA95	1003F495-01FE-47ED-A717-B8769F0FA3A3	TCGA-67-6216-01A-11D-1751-02	HG19_Broad_variant	TCGA-67-6216	TCGA-LUAD	NA	s11242	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T1a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b780	58cfa82fe4b0c9d6adf6b780	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted.bam	1032.7	1.9	0.17	58cfa82fe4b0c9d6adf6b780	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5045-01A	9EE20C0D-A1C3-47F3-ABDA-131B3F190F52	Primary Tumor	Illumina HiSeq	e3bc7a3f-c296-412c-8974-8c21cf01dbfb	Lung	57	BDD75BCA-6224-4743-A367-CB1FF01E8121	42839A7D-81DB-428A-AB3B-072ACD26CA91	TCGA-50-5045-01A-01D-1623-02	HG19_Broad_variant	TCGA-50-5045	TCGA-LUAD	2174	s11004	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b78c	58cfa82fe4b0c9d6adf6b78c	TCGA-49-6745-11A-01D-1853_111218_SN208_0258_C054RACXX_s_8_rg.sorted.filtered.	WGS	TCGA-49-6745-11A-01D-1853_111218_SN208_0258_C054RACXX_s_8_rg.sorted	TCGA-49-6745-11A-01D-1853_111218_SN208_0258_C054RACXX_s_8_rg.sorted.bam	117.7	1.9	0.14	58cfa82fe4b0c9d6adf6b78c	TCGA-49-6745-11A-01D-1853_111218_SN208_0258_C054RACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-49-6745-11A	9C7875AD-AB71-4D48-B2E3-E4C7A46393E9	Solid Tissue Normal	Illumina HiSeq	d9c97389-6652-4cde-82d7-7b8704ed1f0d	Lung	82	36BE2A07-E71C-4B12-83D8-506376DA8F5E	198687D4-99FD-4CA3-9BAE-603FAB00A5B4	TCGA-49-6745-11A-01D-1853-02	HG19_Broad_variant	TCGA-49-6745	TCGA-LUAD	NA	s11231	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7ac	58cfa82fe4b0c9d6adf6b7ac	TCGA-35-4123-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_4_rg.sorted.filtered.	WGS	TCGA-35-4123-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_4_rg.sorted	TCGA-35-4123-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_4_rg.sorted.bam	256.63	1.9	0.16	58cfa82fe4b0c9d6adf6b7ac	TCGA-35-4123-10A-01D-1103_110804_SN208_0217_BC03EKABXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-35-4123-10A	6CF49CF0-DE4C-4C90-8358-EAE19C6206B0	Blood Derived Normal	Illumina HiSeq	49076069-b689-4bbd-984c-7718df09a20e	Lung	38	1BBB46B1-7CEA-49F8-AAA9-C7E7994BB9F3	0F2760D3-4015-4E5E-AFD8-0325AE5A7D9A	TCGA-35-4123-10A-01D-1103-02	HG19_Broad_variant	TCGA-35-4123	TCGA-LUAD	NA	s10648	Harvard Medical School	Cureline	Russia	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7f2	58cfa82fe4b0c9d6adf6b7f2	TCGA-50-5055-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_6_rg.sorted.filtered.	WGS	TCGA-50-5055-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_6_rg.sorted	TCGA-50-5055-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_6_rg.sorted.bam	8.4	1.9	0.14	58cfa82fe4b0c9d6adf6b7f2	TCGA-50-5055-10A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5055-10A	CC3D9750-7CE0-489F-86D4-8017B7EBED29	Blood Derived Normal	Illumina HiSeq	d1b8082f-27b0-4a78-990a-3de7ee79daa3	Lung	79	7CF34EAB-C975-4CF2-ADA2-0AA156B533EA	C02CF895-93BD-4553-AD4D-9AC9D02A06C0	TCGA-50-5055-10A-01D-1623-02	HG19_Broad_variant	TCGA-50-5055	TCGA-LUAD	NA	s11346	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIA	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7d5	58cfa82fe4b0c9d6adf6b7d5	TCGA-50-5931-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5931-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_3_rg.sorted	TCGA-50-5931-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_3_rg.sorted.bam	12.4	1.9	0.14	58cfa82fe4b0c9d6adf6b7d5	TCGA-50-5931-11A-01D-1751_110928_SN590_0108_BB01CWACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5931-11A	12CCD581-A921-41BC-BCEE-4E9BE54532CC	Solid Tissue Normal	Illumina HiSeq	638da55f-beb6-4757-bcc1-bf1427cde1b8	Lung	75	0EBE60D2-3A5B-41A5-A3F2-8E50A72DC2D1	5C292720-2298-4865-B541-A4A822B0B768	TCGA-50-5931-11A-01D-1751-02	HG19_Broad_variant	TCGA-50-5931	TCGA-LUAD	434	s11237	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8a7	58cfa82fe4b0c9d6adf6b8a7	TCGA-44-6145-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_2_rg.sorted.filtered.	WGS	TCGA-44-6145-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_2_rg.sorted	TCGA-44-6145-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_2_rg.sorted.bam	59.4	1.9	0.14	58cfa82fe4b0c9d6adf6b8a7	TCGA-44-6145-11A-01D-1751_110927_SN208_0243_BC00TKACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6145-11A	6144D666-8F77-4EFE-95F1-F9E5C4E5E056	Solid Tissue Normal	Illumina HiSeq	6aee5e9f-1c40-44eb-a1a8-7ee785f62ee5	Lung	62	420FD4EB-E667-4F53-811C-B128D261ACF8	5856EED8-2D53-48F8-B43D-A5523422B632	TCGA-44-6145-11A-01D-1751-02	HG19_Broad_variant	TCGA-44-6145	TCGA-LUAD	NA	s10903	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b8ea	58cfa82fe4b0c9d6adf6b8ea	TCGA-49-6743-11A-01D-1853_111218_SN208_0258_C054RACXX_s_4_rg.sorted.filtered.	WGS	TCGA-49-6743-11A-01D-1853_111218_SN208_0258_C054RACXX_s_4_rg.sorted	TCGA-49-6743-11A-01D-1853_111218_SN208_0258_C054RACXX_s_4_rg.sorted.bam	16.7	1.9	0.13	58cfa82fe4b0c9d6adf6b8ea	TCGA-49-6743-11A-01D-1853_111218_SN208_0258_C054RACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-49-6743-11A	A391D49F-A822-460B-981C-6FBE1868EE38	Solid Tissue Normal	Illumina HiSeq	b26d0042-8fd0-41ca-8236-a6509446e036	Lung	81	4DA6A729-3CAE-47F9-8739-D4B614B8561D	2E932287-E4F8-444F-A78B-BD537EB8787B	TCGA-49-6743-11A-01D-1853-02	HG19_Broad_variant	TCGA-49-6743	TCGA-LUAD	NA	s10999	Harvard Medical School	Johns Hopkins	United States	NO	T1	N2	Lung Clear Cell Adenocarcinoma	Stage IIIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b82d	58cfa82fe4b0c9d6adf6b82d	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted.filtered.	WGS	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted.bam	62.7	1.9	0.15	58cfa82fe4b0c9d6adf6b82d	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-44-6779-01A	CBBEA9F1-396A-4BF3-B67C-2CAC3394DCEB	Primary Tumor	Illumina HiSeq	ab458a7b-afac-4c72-8db7-45994af6ceb8	Lung	50	5E04D394-7A40-4E89-BA20-892774DCB469	DB5F07FE-8DC0-4259-A6B1-E75B6F1188C5	TCGA-44-6779-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6779	TCGA-LUAD	500	s11344	Harvard Medical School	Christiana Healthcare	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9a2	58cfa82fe4b0c9d6adf6b9a2	TCGA-44-6148-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-6148-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_7_rg.sorted	TCGA-44-6148-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_7_rg.sorted.bam	315.7	1.9	0.15	58cfa82fe4b0c9d6adf6b9a2	TCGA-44-6148-10A-01D-1751_110927_SN208_0243_BC00TKACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6148-10A	8994C8C4-9EA0-46CB-B4A5-0055D7DA5BFA	Blood Derived Normal	Illumina HiSeq	14543816-c21e-496a-932b-67a41ac47e99	Lung	60	E221C1C3-71D5-424D-8D88-AC09C3140220	D46F0B7B-7D07-42BE-8C8B-7B74E46B4179	TCGA-44-6148-10A-01D-1751-02	HG19_Broad_variant	TCGA-44-6148	TCGA-LUAD	NA	s11235	Harvard Medical School	Christiana Healthcare	United States	NO	T1b	N0	Lung Mucinous Adenocarcinoma	Stage IA	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b762	58cfa82fe4b0c9d6adf6b762	TCGA-75-5125-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-75-5125-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_3_rg.sorted	TCGA-75-5125-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_3_rg.sorted.bam	628.4	1.9	0.15	58cfa82fe4b0c9d6adf6b762	TCGA-75-5125-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-5125-01A	205759A6-6391-491B-9857-0080C3A5871E	Primary Tumor	Illumina HiSeq	0a5ee83a-046b-41b4-9551-40372fa70b7d	Lung	NA	73A77977-FAB0-486F-8D15-BE8B30C8808A	02DE68CC-AD50-45FD-BB4D-819D6E0F55F5	TCGA-75-5125-01A-01D-1751-02	HG19_Broad_variant	TCGA-75-5125	TCGA-LUAD	NA	s11362	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b864	58cfa82fe4b0c9d6adf6b864	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.bam	101.03	2.18	0.17	58cfa82fe4b0c9d6adf6b864	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GU-01A	ADC22472-E31D-419F-AEAE-CB01B9423343	Primary Tumor	Illumina HiSeq	7666f932-cff3-4ea2-8650-8d4bdae72cac	Uterus	58	074D4466-E072-42CD-9A6C-A595DC9363E7	BB726D7A-6861-48AA-9BFD-5DF8DAAA1538	TCGA-A5-A0GU-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GU	TCGA-UCEC	NA	s4241	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa82fe4b0c9d6adf6b760	58cfa82fe4b0c9d6adf6b760	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted.bam	466.4	1.9	0.15	58cfa82fe4b0c9d6adf6b760	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted.bam	Dead	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-5122-01A	78AE716B-0CA5-4C01-A053-D41288385FCD	Primary Tumor	Illumina HiSeq	611aeb0f-3dbe-41c6-8b8e-b4a7c827ac1d	Lung	NA	DD9C2F71-145A-4F7F-8B64-095B1FC75C3D	4ADD8465-F06A-4752-8B9F-A6F790F727B1	TCGA-75-5122-01A-01D-1751-02	HG19_Broad_variant	TCGA-75-5122	TCGA-LUAD	NA	s11249	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9a8	58cfa82fe4b0c9d6adf6b9a8	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted.filtered.	WGS	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted.bam	292.4	1.9	0.14	58cfa82fe4b0c9d6adf6b9a8	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6215-01A	DBD5B0DE-94C9-45DD-AFB3-6820A7ECACA2	Primary Tumor	Illumina HiSeq	502bd59b-5e8d-4170-9a24-b18fa50a5dc1	Lung	52	3BA5F6B9-6458-44E2-A0AA-B5C7E5FCD632	483EF1DC-150E-4623-BA11-772ADE84E4E4	TCGA-67-6215-01A-11D-1751-02	HG19_Broad_variant	TCGA-67-6215	TCGA-LUAD	NA	s11555	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	TRUE
13722.58cfa830e4b0c9d6adf6bada	58cfa830e4b0c9d6adf6bada	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.bam	88.7	1.9	0.15	58cfa830e4b0c9d6adf6bada	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-49-6745-01A	9C7875AD-AB71-4D48-B2E3-E4C7A46393E9	Primary Tumor	Illumina HiSeq	b4eee7d7-a56c-4927-929e-ac66abe41408	Lung	82	357F3EFE-E2C9-432A-A2B6-75A5FDBAE3BE	A88D69EF-BE3C-4341-AD6C-0F035685862F	TCGA-49-6745-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6745	TCGA-LUAD	NA	s11451	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b9e8	58cfa82fe4b0c9d6adf6b9e8	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.bam	54.22	1.93	0.16	58cfa82fe4b0c9d6adf6b9e8	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G9-01A	45D58088-D3F4-4EB0-B75C-BCB98C0981DC	Primary Tumor	Illumina HiSeq	daffebdf-d935-425e-8576-3401ef583860	Uterus	79	117A5B33-42C5-4A52-BABE-D9712F3E7472	0DE57B60-95AF-48E2-85CA-58135A314355	TCGA-A5-A0G9-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G9	TCGA-UCEC	NA	s4778	Harvard Medical School	Cedars Sinai	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bc7c	58cfa830e4b0c9d6adf6bc7c	TCGA-AP-A0LQ-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AP-A0LQ-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_5_rg.sorted	TCGA-AP-A0LQ-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_5_rg.sorted.bam	63.33	2.03	0.16	58cfa830e4b0c9d6adf6bc7c	TCGA-AP-A0LQ-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LQ-01A	252500D2-86A3-4090-A57F-1E8C3D44C573	Primary Tumor	Illumina HiSeq	cf355e19-2857-4830-9be8-5053dc9c4d0a	Uterus	59	B75648DC-B25B-4EE6-850A-7D1F3A353E83	F8D9DE13-1935-483C-B2F4-B1CD8D61613F	TCGA-AP-A0LQ-01A-12D-A101-02	HG19_Broad_variant	TCGA-AP-A0LQ	TCGA-UCEC	NA	s5000	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bbaa	58cfa830e4b0c9d6adf6bbaa	TCGA-AA-A01X-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01X-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01X-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	47.22	2.09	0.14	58cfa830e4b0c9d6adf6bbaa	TCGA-AA-A01X-11A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01X-11A	2E386E48-B99B-4806-A3E3-081D72A606E7	Solid Tissue Normal	Illumina HiSeq	95a2f5a6-e084-4235-87c5-5b3a0605dcba	Colorectal	80	E3A8174D-358B-4367-BE5D-95FB8A2CE86F	CD4E760E-84CB-460F-9000-B3AF56756CCE	TCGA-AA-A01X-11A-11D-A079-02	HG18	TCGA-AA-A01X	TCGA-COAD	NA	s13380	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Colon Adenocarcinoma	Stage III	A079-02	TRUE
13722.58cfa830e4b0c9d6adf6bbd4	58cfa830e4b0c9d6adf6bbd4	TCGA-AG-A00C-10A-01D-A078_110405_SN590_0074_AB04EUABXX_s_4_rg.sorted.filtered.	WGS	TCGA-AG-A00C-10A-01D-A078_110405_SN590_0074_AB04EUABXX_s_4_rg.sorted	TCGA-AG-A00C-10A-01D-A078_110405_SN590_0074_AB04EUABXX_s_4_rg.sorted.bam	12.8	1.94	0.15	58cfa830e4b0c9d6adf6bbd4	TCGA-AG-A00C-10A-01D-A078_110405_SN590_0074_AB04EUABXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A00C-10A	FF004403-8CC5-43E6-BD1C-DDE4EB1E6193	Blood Derived Normal	Illumina HiSeq	364f941f-a9dd-4021-8c6d-fcdc069f3379	Colorectal	49	BB4FB9DC-E786-4FCF-8A1C-F5791BC900C3	096C7C19-C359-4B0D-859C-FB8A74921594	TCGA-AG-A00C-10A-01D-A078-02	HG18_Broad_variant	TCGA-AG-A00C	TCGA-READ	NA	s2166	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	A078-02	TRUE
13722.58cfa830e4b0c9d6adf6bd82	58cfa830e4b0c9d6adf6bd82	TCGA-BF-A1Q0-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BF-A1Q0-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_6_rg.sorted	TCGA-BF-A1Q0-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_6_rg.sorted.bam	56.81	NA	0.17	58cfa830e4b0c9d6adf6bd82	TCGA-BF-A1Q0-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1Q0-10A	633DDC04-C424-42C8-8E54-673968B130A7	Blood Derived Normal	Illumina HiSeq	6c5142a8-af0f-42a2-9924-fb42c095c0d9	Skin	80	5060B0AD-E07A-443E-8582-382C61AF81AC	F0A92AEC-2C16-4B97-85B4-019D30C9EFC9	TCGA-BF-A1Q0-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1Q0	TCGA-SKCM	NA	s7492	Harvard Medical School	Cureline	Russia	NO	T4b	N0	Not available	Stage IIC	A18Z-02	TRUE
13722.58cfa830e4b0c9d6adf6bc8a	58cfa830e4b0c9d6adf6bc8a	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted.bam	128.45	2.03	0.16	58cfa830e4b0c9d6adf6bc8a	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0L8-01A	9AA8C2B4-DB32-4899-BF0C-D578CB175E90	Primary Tumor	Illumina HiSeq	41360e8e-e9e9-402a-bd9e-a987e56c920e	Uterus	70	D1A7A58F-7A35-4A94-A337-051AE56DED00	2BE44D5B-CCD6-4DD5-B0C7-C7813B526B94	TCGA-AP-A0L8-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0L8	TCGA-UCEC	1484	s4244	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bd9a	58cfa830e4b0c9d6adf6bd9a	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.bam	71.62	1.94	0.14	58cfa830e4b0c9d6adf6bd9a	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M6-01A	002724FA-7051-49FA-9C58-4BCB7EBA4AC6	Primary Tumor	Illumina HiSeq	0db41cb8-f118-4d04-a002-22df953a0dec	Uterus	73	66E4B080-E6EF-4531-9B69-1B27F15C5669	61C058D9-E5DC-4D74-B378-28B8F0A2BF78	TCGA-BG-A0M6-01A-31D-A101-02	HG19_Broad_variant	TCGA-BG-A0M6	TCGA-UCEC	NA	s4249	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bd93	58cfa830e4b0c9d6adf6bd93	TCGA-BG-A0M6-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BG-A0M6-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_5_rg.sorted	TCGA-BG-A0M6-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_5_rg.sorted.bam	20.25	2.19	0.16	58cfa830e4b0c9d6adf6bd93	TCGA-BG-A0M6-10A-01D-A101_120406_SN1120_0130_AD0UKGACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M6-10A	002724FA-7051-49FA-9C58-4BCB7EBA4AC6	Blood Derived Normal	Illumina HiSeq	5884b987-20f3-49d4-adaa-3cde9f57adb8	Uterus	73	302D4FE2-E8F2-4C69-B767-6F01B4F42261	6D389072-9861-4CD5-BF7E-A389380F9FDF	TCGA-BG-A0M6-10A-01D-A101-02	HG19_Broad_variant	TCGA-BG-A0M6	TCGA-UCEC	NA	s4257	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bda9	58cfa830e4b0c9d6adf6bda9	TCGA-BF-A1PU-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BF-A1PU-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_8_rg.sorted	TCGA-BF-A1PU-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_8_rg.sorted.bam	38.15	NA	0.15	58cfa830e4b0c9d6adf6bda9	TCGA-BF-A1PU-10A-01D-A18Z_120517_SN208_0300_BC0VYMACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PU-10A	3DD5A206-D7F3-42F1-B9CC-4B31C76D495D	Blood Derived Normal	Illumina HiSeq	b11bd287-6ec9-4e17-97a9-0d9e09163409	Skin	46	A4D739D2-63A1-41FC-82C1-F1D027DB756D	04FD07BE-1E5D-48D0-8AE5-E21FDDCF797C	TCGA-BF-A1PU-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PU	TCGA-SKCM	NA	s7668	Harvard Medical School	Cureline	Russia	NO	T4b	N0	Not available	Stage IIC	A18Z-02	TRUE
13722.58cfa830e4b0c9d6adf6bc82	58cfa830e4b0c9d6adf6bc82	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted.bam	85.32	1.85	0.15	58cfa830e4b0c9d6adf6bc82	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LI-01A	E1E8DC66-467C-48A5-BE56-3DB4F665B9F1	Primary Tumor	Illumina HiSeq	9fe530df-5c54-45fa-a25d-65e1a7d0110b	Uterus	67	981D9E3B-63C5-41E9-827F-7F1D268D62F4	D80E9147-7A64-4AB0-891A-2D97D0634EAB	TCGA-AP-A0LI-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LI	TCGA-UCEC	NA	s5387	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6bdb3	58cfa830e4b0c9d6adf6bdb3	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.bam	57.94	1.87	0.14	58cfa830e4b0c9d6adf6bdb3	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MG-01A	9CDE90C8-2BE0-4328-A032-FF1DC19E66FD	Primary Tumor	Illumina HiSeq	30b3e5f5-4066-401d-9cf3-5ee64b9014ef	Uterus	73	96B6826D-8A4C-45F5-8CD3-B5988AA5FD0E	755BD772-9331-402B-832B-2933AAECFC71	TCGA-BG-A0MG-01A-21D-A101-02	HG19_Broad_variant	TCGA-BG-A0MG	TCGA-UCEC	NA	s4248	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bdca	58cfa830e4b0c9d6adf6bdca	TCGA-BH-A0DK-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BH-A0DK-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_6_rg.sorted	TCGA-BH-A0DK-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_6_rg.sorted.bam	14.3	1.95	0.15	58cfa830e4b0c9d6adf6bdca	TCGA-BH-A0DK-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0DK-10A	F2BBFA9D-9A9D-4F46-9FDE-378E4C44E2AD	Blood Derived Normal	Illumina HiSeq	70caaa1c-198e-4a38-9d77-d97bb89f7c65	Breast	49	0FBA2EFB-9EDE-4FD2-ABED-F18275A076DD	1CC19E5F-922B-4878-A0E9-546A8C3FC949	TCGA-BH-A0DK-10A-01D-A060-02	HG19_Broad_variant	TCGA-BH-A0DK	TCGA-BRCA	NA	s6465	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6be68	58cfa830e4b0c9d6adf6be68	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.bam	46.06	1.81	0.15	58cfa830e4b0c9d6adf6be68	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28Z-01A	6BA76174-620E-4851-857A-D0ADBFD6F3E6	Primary Tumor	Illumina HiSeq	3d2be877-3825-44b4-99b1-b3c314e68c0c	Thyroid	46	D9689254-AFE2-4544-AF54-E02670BD5EBD	F353E9F5-A869-4BE1-ACC4-A832D77285D4	TCGA-BJ-A28Z-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28Z	TCGA-THCA	NA	s12508	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	TRUE
13722.58cfa830e4b0c9d6adf6be55	58cfa830e4b0c9d6adf6be55	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.bam	118.49	2.07	0.17	58cfa830e4b0c9d6adf6be55	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LT-01A	43714E9A-E9C4-4206-AF92-1D00D2A8AE35	Primary Tumor	Illumina HiSeq	42ca121f-f3b0-4b47-acb4-f1294f88eb39	Uterus	57	C94DD7A5-DD58-4702-A7D1-8199D3F8C9CC	B057AD28-5D99-48BC-B642-7E548914F1B1	TCGA-AP-A0LT-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LT	TCGA-UCEC	NA	s4242	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6be38	58cfa830e4b0c9d6adf6be38	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.bam	80.24	1.95	0.16	58cfa830e4b0c9d6adf6be38	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JY-01A	61935424-44D0-4211-81C1-C925E436EAC5	Primary Tumor	Illumina HiSeq	e463dbb2-091a-4183-98b6-a90c2e55ffae	Uterus	50	95F418CE-FCD9-4402-BC24-1520F45CB6B7	88CE0037-F3F9-4F45-BF14-36A58FF61A3D	TCGA-B5-A0JY-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JY	TCGA-UCEC	NA	s4784	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6bf26	58cfa830e4b0c9d6adf6bf26	TCGA-BR-4201-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BR-4201-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_4_rg.sorted	TCGA-BR-4201-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_4_rg.sorted.bam	293.3	1.9	0.13	58cfa830e4b0c9d6adf6bf26	TCGA-BR-4201-11A-01D-1128_120816_SN590_0176_BD13T7ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4201-11A	8520654B-2192-46CF-9D72-1DDB885A7C55	Solid Tissue Normal	Illumina HiSeq	a6dc7c10-d45e-4f8a-a8fd-bd928d8f554c	Stomach	66	76438A23-27DF-4C9A-8ED9-3FA6CD0CE817	D4E9F0DD-A50B-47E8-97EC-C61EE7799884	TCGA-BR-4201-11A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4201	TCGA-STAD	NA	s14964	Harvard Medical School	Asterand	Russia	NO	T2a	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf3d	58cfa830e4b0c9d6adf6bf3d	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.bam	138.9	1.9	0.15	58cfa830e4b0c9d6adf6bf3d	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4187-01A	12071070-D06B-4C7B-A7B1-77C84963ABE6	Primary Tumor	Illumina HiSeq	1da3a244-39ae-4b4d-baed-e4d9b312f777	Stomach	56	144FB4ED-63BB-4908-B678-6026E09566A3	57CF858D-FF3F-4528-96DB-5A820C9B78DE	TCGA-BR-4187-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4187	TCGA-STAD	NA	s15046	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1128-02	TRUE
13722.58cfa830e4b0c9d6adf6bf7e	58cfa830e4b0c9d6adf6bf7e	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.bam	90.33	1.92	0.15	58cfa830e4b0c9d6adf6bf7e	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JV-01A	233E947A-D5E2-48E5-A8CE-5DA1ABB20681	Primary Tumor	Illumina HiSeq	2c99d5d5-1f92-452e-9370-59486a6d7bce	Uterus	63	42199E5A-9F4F-4445-9E6E-114D47BA67FA	7132C5C6-9DC5-42A8-863F-D82280266427	TCGA-B5-A0JV-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JV	TCGA-UCEC	NA	s4783	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c027	58cfa830e4b0c9d6adf6c027	TCGA-BJ-A0ZA-10A-02D-A10R_120616_SN1120_0154_BD142VACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZA-10A-02D-A10R_120616_SN1120_0154_BD142VACXX_s_7_rg.sorted	TCGA-BJ-A0ZA-10A-02D-A10R_120616_SN1120_0154_BD142VACXX_s_7_rg.sorted.bam	7.91	1.97	0.13	58cfa830e4b0c9d6adf6c027	TCGA-BJ-A0ZA-10A-02D-A10R_120616_SN1120_0154_BD142VACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZA-10A	4C513413-263E-4C7B-B997-7B688C47B698	Blood Derived Normal	Illumina HiSeq	b6543b80-1693-4e71-b213-e80b5a7c7e81	Thyroid	67	EAD7A19A-AF58-4B53-8091-A52C2221A4A9	6F261862-34AD-4C24-B71F-934B0762F5D8	TCGA-BJ-A0ZA-10A-02D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZA	TCGA-THCA	NA	s12626	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c12c	58cfa830e4b0c9d6adf6c12c	TCGA-B6-A0RE-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_8_rg.sorted.filtered.	WGS	TCGA-B6-A0RE-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_8_rg.sorted	TCGA-B6-A0RE-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_8_rg.sorted.bam	18.08	1.86	0.16	58cfa830e4b0c9d6adf6c12c	TCGA-B6-A0RE-10A-01D-A060_130725_SN590_0234_BC29HAACXX_s_8_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RE-10A	08DA7C4C-3067-4BCF-9D7A-78566DF72E69	Blood Derived Normal	Illumina HiSeq	67bd449b-7035-4a63-8e7e-e32f1f49e4f0	Breast	61	B515904E-B78D-41BB-A960-D8B26A384B16	F2DEE42D-9E1D-471D-BF3E-F1A0A27E16DF	TCGA-B6-A0RE-10A-01D-A060-02	HG19_Broad_variant	TCGA-B6-A0RE	TCGA-BRCA	NA	s6272	Harvard Medical School	Duke	United States	NO	TX	N0 (i-)	Infiltrating Ductal Carcinoma	Stage X	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6bfb6	58cfa830e4b0c9d6adf6bfb6	TCGA-B5-A0K0-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_8_rg.sorted.filtered.	WGS	TCGA-B5-A0K0-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_8_rg.sorted	TCGA-B5-A0K0-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_8_rg.sorted.bam	43.36	1.97	0.15	58cfa830e4b0c9d6adf6bfb6	TCGA-B5-A0K0-10A-01D-A043_120209_SN1120_0114_BC0DFVACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K0-10A	29C8F468-5AC1-4D6C-8376-E36E6D246926	Blood Derived Normal	Illumina HiSeq	967c5a49-ca2a-4d26-bd4a-840a16998e01	Uterus	48	1DF69E2E-F392-465F-8E61-4671BA2FCD35	3CB411F8-9308-4CED-822B-C94FE602AB73	TCGA-B5-A0K0-10A-01D-A043-02	HG19_Broad_variant	TCGA-B5-A0K0	TCGA-UCEC	NA	s5001	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c197	58cfa830e4b0c9d6adf6c197	TCGA-BH-A0H7-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BH-A0H7-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_8_rg.sorted	TCGA-BH-A0H7-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_8_rg.sorted.bam	6.8	1.96	0.17	58cfa830e4b0c9d6adf6c197	TCGA-BH-A0H7-10A-01D-A060_130725_SN590_0233_AD2B3HACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0H7-10A	2021ED1F-DC75-4701-B8B8-1386466E4802	Blood Derived Normal	Illumina HiSeq	a267b823-747c-4258-b5e8-9cb33834ff6a	Breast	65	F104689E-1DC6-412D-BFAA-D3203EAF095C	AA3E5150-7EFF-4837-9946-EFECBEE42E92	TCGA-BH-A0H7-10A-01D-A060-02	HG19_Broad_variant	TCGA-BH-A0H7	TCGA-BRCA	NA	s6773	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6c16e	58cfa830e4b0c9d6adf6c16e	TCGA-BJ-A0Z9-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z9-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_8_rg.sorted	TCGA-BJ-A0Z9-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_8_rg.sorted.bam	15.3	1.98	0.17	58cfa830e4b0c9d6adf6c16e	TCGA-BJ-A0Z9-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z9-10A	86F9ECA0-D1EA-4375-A6BC-055E44B3198A	Blood Derived Normal	Illumina HiSeq	3336e590-f910-4bf5-935b-509f5f84d860	Thyroid	57	C42D7353-3155-4F95-8557-1F0DD786B1C1	5FBB0F62-94C8-4F0F-BAB6-5F9DD79C3D43	TCGA-BJ-A0Z9-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z9	TCGA-THCA	NA	s12233	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A10R-02	TRUE
13722.58cfa830e4b0c9d6adf6c1aa	58cfa830e4b0c9d6adf6c1aa	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.bam	213.7	1.9	0.16	58cfa830e4b0c9d6adf6c1aa	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5555-01A	8970F713-4A7A-4125-892C-6A34139371D8	Primary Tumor	Illumina HiSeq	cd7725ec-bc8e-4c93-aba5-19dbdeb78b0d	Head and Neck	54	2920CA1C-6035-4350-ADA4-C60D485DBFFF	4AB42DF9-A215-4965-A125-CC0C4122FF06	TCGA-BA-5555-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5555	TCGA-HNSC	NA	s15609	Harvard Medical School	UNC	None	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa830e4b0c9d6adf6c1b6	58cfa830e4b0c9d6adf6c1b6	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted.bam	333.33	1.9	0.15	58cfa830e4b0c9d6adf6c1b6	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4076-01A	7DE19081-D5FD-468C-AD0D-F6E3E8B2AD70	Primary Tumor	Illumina HiSeq	f67d413c-c33d-4d97-9853-0b00f93f2304	Head and Neck	39	FD99FD83-4040-4738-8A5A-E42D36ECFE0E	54F77A3E-290A-4073-8012-4873579E95E9	TCGA-BA-4076-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4076	TCGA-HNSC	415	s15749	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6c036	58cfa830e4b0c9d6adf6c036	TCGA-AG-3999-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3999-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3999-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	13.59	1.9	0.15	58cfa830e4b0c9d6adf6c036	TCGA-AG-3999-10A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	Not available	Not available	Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3999-10A	60778DA8-D99E-4E51-96A2-3E900B3978D9	Blood Derived Normal	Illumina HiSeq	f639d084-d99e-4579-aeae-2edb77da3a8e	Colorectal	61	18262C9A-5015-4179-A10C-39149B47B13F	49016CD5-C461-45B4-8016-DDE0CD096173	TCGA-AG-3999-10A-01D-1115-02	HG18	TCGA-AG-3999	TCGA-READ	NA	s1980	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Rectal Adenocarcinoma	Stage IIIC	1115-02	TRUE
13722.58cfa830e4b0c9d6adf6c1f6	58cfa830e4b0c9d6adf6c1f6	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.bam	66.56	2.03	0.15	58cfa830e4b0c9d6adf6c1f6	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M4-01A	73E5310D-BA8C-4CBC-AA4F-E06206F898F4	Primary Tumor	Illumina HiSeq	6f34976e-c9a0-4b3f-afb6-d476e4d9f22d	Uterus	60	E6E7E411-45CF-47A1-BCF0-7AE800A61A8D	238A1E43-B716-479B-82C8-0E62A30F9BE9	TCGA-BG-A0M4-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M4	TCGA-UCEC	NA	s4429	Harvard Medical School	University of Pittsburgh	None	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa830e4b0c9d6adf6c1c0	58cfa830e4b0c9d6adf6c1c0	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted.bam	56.7	1.9	0.15	58cfa830e4b0c9d6adf6c1c0	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4225-01A	C1F50A22-38DF-41CC-A1F4-F7985504A7AC	Primary Tumor	Illumina HiSeq	4903ac5e-6fa0-41de-b272-c4139a3c0632	Head and Neck	73	AC42070B-F4D6-47BE-96AA-A713D66A0072	F7E6BD4D-3E7C-427E-8618-FAFB3731E597	TCGA-BB-4225-01A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4225	TCGA-HNSC	NA	s16024	Harvard Medical School	Johns Hopkins	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma	Not available	1431-02	TRUE
13722.58cfa82fe4b0c9d6adf6b84c	58cfa82fe4b0c9d6adf6b84c	TCGA-73-4676-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_8_rg.sorted.filtered.	WGS	TCGA-73-4676-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_8_rg.sorted	TCGA-73-4676-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_8_rg.sorted.bam	168.4	1.9	0.16	58cfa82fe4b0c9d6adf6b84c	TCGA-73-4676-11A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4676-11A	195A5AFB-B79F-44D2-9D12-884487630C2B	Solid Tissue Normal	Illumina HiSeq	a85b7af6-36cb-40db-9085-3d24b08100ea	Lung	45	D68673CD-08CA-404C-AD04-0774C51A6BFB	B3359F92-6D7F-4BF0-A8BF-4B17A50AF3BC	TCGA-73-4676-11A-01D-1751-02	HG19_Broad_variant	TCGA-73-4676	TCGA-LUAD	NA	s11557	Harvard Medical School	Roswell Park	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	TRUE
13722.58cfa830e4b0c9d6adf6c256	58cfa830e4b0c9d6adf6c256	TCGA-BH-A0HK-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BH-A0HK-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_2_rg.sorted	TCGA-BH-A0HK-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_2_rg.sorted.bam	20.06	2.07	0.17	58cfa830e4b0c9d6adf6c256	TCGA-BH-A0HK-10A-01D-A060_130807_SN590_0236_BC291KACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HK-10A	24334AC1-28A3-4B61-B590-3F51E375B247	Blood Derived Normal	Illumina HiSeq	c9ee059e-f157-47b4-a76b-64e57c14f01d	Breast	81	A67DC9C2-6D31-4B7D-99AD-C25CE2672E8C	AACC0421-E331-49E8-BA8F-AA7B091336C5	TCGA-BH-A0HK-10A-01D-A060-02	HG19_Broad_variant	TCGA-BH-A0HK	TCGA-BRCA	NA	s6124	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	TRUE
13722.58cfa830e4b0c9d6adf6c2c6	58cfa830e4b0c9d6adf6c2c6	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.bam	42.45	1.95	0.16	58cfa830e4b0c9d6adf6c2c6	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A1HS-01A	A73C0842-39C5-4C2C-AA6A-F31341A4F36E	Primary Tumor	Illumina HiSeq	ed90abf4-1d04-41ce-9de3-9dcf24c1e375	Bladder	75	0A01E5BA-5549-4027-9E84-1BBB163A8F07	B8F18CDA-053F-4E40-8978-7524A4C0B49A	TCGA-CF-A1HS-01A-11D-A13U-02	HG19_Broad_variant	TCGA-CF-A1HS	TCGA-BLCA	NA	s2875	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa830e4b0c9d6adf6c25d	58cfa830e4b0c9d6adf6c25d	TCGA-BJ-A0Z3-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z3-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_8_rg.sorted	TCGA-BJ-A0Z3-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_8_rg.sorted.bam	24.48	1.95	0.16	58cfa830e4b0c9d6adf6c25d	TCGA-BJ-A0Z3-10A-01D-A13U_120706_SN1120_0170_BD1422ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z3-10A	331CAE6E-2868-4C58-9302-709A9FF7D025	Blood Derived Normal	Illumina HiSeq	9033bf3e-9c80-4f03-9bcf-a63c9794ccff	Thyroid	33	CE23632D-EA12-422B-AA3A-78874E665E4D	A1FFA620-F821-4652-AF2E-0C629067F9A5	TCGA-BJ-A0Z3-10A-01D-A13U-02	HG19_Broad_variant	TCGA-BJ-A0Z3	TCGA-THCA	NA	s12746	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c368	58cfa831e4b0c9d6adf6c368	TCGA-CD-5802-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CD-5802-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_7_rg.sorted	TCGA-CD-5802-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_7_rg.sorted.bam	617.7	1.9	0.15	58cfa831e4b0c9d6adf6c368	TCGA-CD-5802-10A-01D-1598_121107_SN590_0199_AC179PACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5802-10A	0AECAC64-5982-4D76-8F31-958F6A00951D	Blood Derived Normal	Illumina HiSeq	7f21b1e4-76db-4eac-a757-f5497d930e2e	Stomach	58	602943B6-8FFC-4667-BE39-2E6A9FB3661A	82931E93-6809-4AF5-AEF9-6FAC2C21630D	TCGA-CD-5802-10A-01D-1598-02	HG19_Broad_variant	TCGA-CD-5802	TCGA-STAD	NA	s15391	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	TRUE
13722.58cfa830e4b0c9d6adf6c29a	58cfa830e4b0c9d6adf6c29a	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.filtered.	WGS	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.bam	91.47	2.12	0.14	58cfa830e4b0c9d6adf6c29a	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JR-01A	A766D113-BC3F-4448-A4E5-F391FB0C0E22	Primary Tumor	Illumina HiSeq	1e3ae5a0-6439-4dba-a151-f107d43c65cf	Uterus	73	07381A09-5CBD-4744-86EC-41A81E470204	E4F782AB-1668-4730-95D9-CB28E3CF61FD	TCGA-B5-A0JR-01A-13D-A043-02	HG19_Broad_variant	TCGA-B5-A0JR	TCGA-UCEC	NA	s4786	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa831e4b0c9d6adf6c36a	58cfa831e4b0c9d6adf6c36a	TCGA-CG-5720-11A-01D-1598_121029_SN208_0439_BD1KHKACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-5720-11A-01D-1598_121029_SN208_0439_BD1KHKACXX_s_4_rg.sorted	TCGA-CG-5720-11A-01D-1598_121029_SN208_0439_BD1KHKACXX_s_4_rg.sorted.bam	326	1.9	0.15	58cfa831e4b0c9d6adf6c36a	TCGA-CG-5720-11A-01D-1598_121029_SN208_0439_BD1KHKACXX_s_4_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5720-11A	7C9EA4FA-4CBC-4941-945A-E531E1D48304	Solid Tissue Normal	Illumina HiSeq	75fe7913-8432-492a-a33c-286c06164f35	Stomach	71	4D91E3D9-C9AC-487D-B617-295AF67176B0	EA5CD178-A2D6-4F23-8164-E5963541B835	TCGA-CG-5720-11A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5720	TCGA-STAD	30	s15458	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1598-02	TRUE
13722.58cfa830e4b0c9d6adf6c2ce	58cfa830e4b0c9d6adf6c2ce	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted.bam	73.22	2.09	0.15	58cfa830e4b0c9d6adf6c2ce	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JN-01A	B60F22AC-A659-4F33-B01D-820E86A9A5C9	Primary Tumor	Illumina HiSeq	19c2a28e-bdeb-46af-b33e-e9849fc553ed	Uterus	84	684C6894-FD49-4934-8962-9628ECE734FB	EB2131FF-4AE0-4814-81F3-A480A0DEBB2E	TCGA-B5-A0JN-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JN	TCGA-UCEC	NA	s4245	Harvard Medical School	Duke	United States	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A101-02	TRUE
13722.58cfa831e4b0c9d6adf6c401	58cfa831e4b0c9d6adf6c401	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.bam	145.7	2	0.17	58cfa831e4b0c9d6adf6c401	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5791-01A	829BED0C-C40D-44FD-AEE8-6C7589DB60F9	Primary Tumor	Illumina HiSeq	e2778c71-6feb-40df-8b1e-8d8f0e889beb	Prostate	72	C14B5C15-994B-4739-870B-A50984D274A1	500F071A-6697-4880-BBD0-9054CCAE108A	TCGA-CH-5791-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5791	TCGA-PRAD	NA	s3417	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6c43c	58cfa831e4b0c9d6adf6c43c	TCGA-CG-5732-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-5732-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_5_rg.sorted	TCGA-CG-5732-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_5_rg.sorted.bam	46	1.9	0.17	58cfa831e4b0c9d6adf6c43c	TCGA-CG-5732-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5732-11A	E62D5F3C-0A99-4932-A589-BFF4FA02B1D3	Solid Tissue Normal	Illumina HiSeq	c4e25e33-1ac2-427d-adeb-7d6cfc0269a6	Stomach	66	A3B99090-FED5-4A73-A2E8-12A4B51A4879	3F2916B7-2093-4A7B-8495-46C9EDEDA78D	TCGA-CG-5732-11A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5732	TCGA-STAD	NA	s14835	Harvard Medical School	Indivumed	Germany	NO	T2	N3	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c4da	58cfa831e4b0c9d6adf6c4da	TCGA-CG-4477-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4477-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_2_rg.sorted	TCGA-CG-4477-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_2_rg.sorted.bam	281.2	1.9	0.14	58cfa831e4b0c9d6adf6c4da	TCGA-CG-4477-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4477-01A	18D0AAE7-9694-4252-B8FE-16E62DADAB07	Primary Tumor	Illumina HiSeq	a2b4b066-6bb7-401c-9ff9-e88bee42884b	Stomach	58	6D7C7B4E-6913-487D-9DC3-DDA901434192	3AE56504-30EE-4C03-9F69-C5B415DE6738	TCGA-CG-4477-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4477	TCGA-STAD	NA	s14764	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c4f6	58cfa831e4b0c9d6adf6c4f6	TCGA-CG-5730-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-5730-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_1_rg.sorted	TCGA-CG-5730-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_1_rg.sorted.bam	326.3	1.9	0.15	58cfa831e4b0c9d6adf6c4f6	TCGA-CG-5730-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5730-01A	09587F1C-5C99-4102-BC49-84D50FA8D0CE	Primary Tumor	Illumina HiSeq	61f3e14a-530d-43c8-a795-a6aef7d031e4	Stomach	80	2986F11F-3C18-4621-8406-D46614537ED4	9E9AC3CA-F6EC-497E-938D-F6FEA03CC75C	TCGA-CG-5730-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5730	TCGA-STAD	NA	s14765	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c4be	58cfa831e4b0c9d6adf6c4be	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted.bam	65.9	1.9	0.14	58cfa831e4b0c9d6adf6c4be	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4367-01A	D139BD0C-2EEB-44EC-856B-E77CB03D294E	Primary Tumor	Illumina HiSeq	98785371-4af3-4d04-acc8-5c53c8076618	Stomach	78	1506E790-C21C-4419-B11B-14250C947FB5	174658D3-1933-47FD-A883-5F4AFA169778	TCGA-BR-4367-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4367	TCGA-STAD	NA	s14611	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Not available	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c426	58cfa831e4b0c9d6adf6c426	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.bam	81.7	1.9	0.14	58cfa831e4b0c9d6adf6c426	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4727-01A	12D05E8F-8D13-47C1-B713-2250F6ABCEF9	Primary Tumor	Illumina HiSeq	f26c4909-b285-4ca0-ac40-fe65ad4a6a1a	Head and Neck	56	F102AEF0-94B8-4D26-8055-35B76DA9DD5F	E42C764C-98DB-4E55-A625-B1443E6C4B3A	TCGA-CN-4727-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4727	TCGA-HNSC	NA	s15495	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa830e4b0c9d6adf6bec3	58cfa830e4b0c9d6adf6bec3	TCGA-AP-A0LI-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_8_rg.sorted.filtered.	WGS	TCGA-AP-A0LI-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_8_rg.sorted	TCGA-AP-A0LI-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_8_rg.sorted.bam	29.22	1.75	0.14	58cfa830e4b0c9d6adf6bec3	TCGA-AP-A0LI-10A-01D-A043_120301_SN590_0142_AD0LPVACXX_s_8_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LI-10A	E1E8DC66-467C-48A5-BE56-3DB4F665B9F1	Blood Derived Normal	Illumina HiSeq	8775e935-a82a-4dc0-9613-f331b1008811	Uterus	67	4B47A13D-1E13-47F0-AD67-6CB0AD02E3B1	A9E3D1B6-CC95-4AAC-B068-764F0814C9FF	TCGA-AP-A0LI-10A-01D-A043-02	HG19_Broad_variant	TCGA-AP-A0LI	TCGA-UCEC	NA	s4596	Harvard Medical School	MSKCC	None	NO	Not available	Not available	Serous endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa831e4b0c9d6adf6c459	58cfa831e4b0c9d6adf6c459	TCGA-CN-4727-10A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-4727-10A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_8_rg.sorted	TCGA-CN-4727-10A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_8_rg.sorted.bam	1116.4	1.9	0.15	58cfa831e4b0c9d6adf6c459	TCGA-CN-4727-10A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4727-10A	12D05E8F-8D13-47C1-B713-2250F6ABCEF9	Blood Derived Normal	Illumina HiSeq	03edf3dd-9b2f-4ef6-8846-5a0154eacc1e	Head and Neck	56	CC2D6CFA-7640-44DD-A200-68FD9F9EE69C	28CF8227-EDE2-470C-81C1-A11462070E9A	TCGA-CN-4727-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4727	TCGA-HNSC	NA	s15494	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c502	58cfa831e4b0c9d6adf6c502	TCGA-CG-5730-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-5730-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_4_rg.sorted	TCGA-CG-5730-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_4_rg.sorted.bam	82.3	1.9	0.15	58cfa831e4b0c9d6adf6c502	TCGA-CG-5730-11A-01D-1598_121023_SN208_0436_AC1CMBACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5730-11A	09587F1C-5C99-4102-BC49-84D50FA8D0CE	Solid Tissue Normal	Illumina HiSeq	bbd5bdf5-6935-4c46-ac56-be3e2c238528	Stomach	80	16225D9E-2074-42AE-91E5-4D0352916465	2CC66884-8812-464E-A232-6B90A028BD26	TCGA-CG-5730-11A-01D-1598-02	HG19_Broad_variant	TCGA-CG-5730	TCGA-STAD	NA	s15328	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c53e	58cfa831e4b0c9d6adf6c53e	TCGA-CH-5794-10A-01D-1573_130125_SN208_0451_BD1RB1ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CH-5794-10A-01D-1573_130125_SN208_0451_BD1RB1ACXX_s_6_rg.sorted	TCGA-CH-5794-10A-01D-1573_130125_SN208_0451_BD1RB1ACXX_s_6_rg.sorted.bam	79.4	1.9	0.13	58cfa831e4b0c9d6adf6c53e	TCGA-CH-5794-10A-01D-1573_130125_SN208_0451_BD1RB1ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5794-10A	A80D3EE7-60DD-49BB-B049-9335AFC035F5	Blood Derived Normal	Illumina HiSeq	3c58e5e5-3f65-4e72-8ec0-9975b3385833	Prostate	65	9BB98558-26D3-4887-8788-00518181BC3C	153DE8A8-5009-4408-BE9C-CAA1BF15A042	TCGA-CH-5794-10A-01D-1573-02	HG19_Broad_variant	TCGA-CH-5794	TCGA-PRAD	NA	s3935	Harvard Medical School	Indivumed	Germany	NO	T2b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6c580	58cfa831e4b0c9d6adf6c580	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted.bam	215.2	1.9	0.15	58cfa831e4b0c9d6adf6c580	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4368-01A	449BF2BE-B20E-4AD0-9FFB-910D83114018	Primary Tumor	Illumina HiSeq	138fe28f-1055-4872-99b0-71ca92e3494a	Stomach	78	87239062-9EA0-4987-AD13-5A2DDED4FF82	1AED45C5-BB15-43D4-9C04-291B7C5B4428	TCGA-BR-4368-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4368	TCGA-STAD	NA	s14469	Harvard Medical School	Asterand	Russia	NO	T4	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6c184	58cfa830e4b0c9d6adf6c184	TCGA-BA-4075-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BA-4075-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_3_rg.sorted	TCGA-BA-4075-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_3_rg.sorted.bam	430.33	1.9	0.16	58cfa830e4b0c9d6adf6c184	TCGA-BA-4075-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_3_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4075-01A	6FA62461-E721-415A-8B0F-363B84292B82	Primary Tumor	Illumina HiSeq	85bcc36c-7376-4108-ac13-c495a75d3e00	Head and Neck	49	4DC36C31-35D8-4263-B141-C734545540A9	4B0B38F4-AC21-4F3E-8A8E-A69FBA619629	TCGA-BA-4075-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4075	TCGA-HNSC	283	s16169	Harvard Medical School	UNC	None	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5eb	58cfa831e4b0c9d6adf6c5eb	TCGA-CG-4300-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4300-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_3_rg.sorted	TCGA-CG-4300-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_3_rg.sorted.bam	203.9	1.9	0.15	58cfa831e4b0c9d6adf6c5eb	TCGA-CG-4300-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_3_rg.sorted.bam	Dead	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4300-01A	8ED901F6-D1BC-48B1-8514-6E8C066DC160	Primary Tumor	Illumina HiSeq	56ae4dc6-1cf2-431b-a266-c26d18e12827	Stomach	79	95D00401-E891-414F-B748-BC746B233BCE	B4092131-14B4-474E-8129-A385D3ABAED6	TCGA-CG-4300-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4300	TCGA-STAD	609	s14754	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c54a	58cfa831e4b0c9d6adf6c54a	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted.bam	23.7	1.9	0.14	58cfa831e4b0c9d6adf6c54a	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4730-01A	35C1F2C6-771C-4533-82DF-F8E2EC7107D7	Primary Tumor	Illumina HiSeq	56942e06-fb67-4bf4-993e-16cb67f52239	Head and Neck	62	8270C53E-F2CF-4F57-A1AC-A8BA978CC1C8	094C2014-ABA2-4C11-B076-27EA61C7A48E	TCGA-CN-4730-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4730	TCGA-HNSC	NA	s15496	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5e7	58cfa831e4b0c9d6adf6c5e7	TCGA-CN-5367-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-5367-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_2_rg.sorted	TCGA-CN-5367-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_2_rg.sorted.bam	214.7	1.9	0.15	58cfa831e4b0c9d6adf6c5e7	TCGA-CN-5367-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5367-01A	61D0709C-D148-413B-A7B5-C0C82ED2F32F	Primary Tumor	Illumina HiSeq	9ab4b634-5191-4a97-b9df-f75528b90bae	Head and Neck	60	379F9E65-54F3-4566-B018-3F3EEE6A4DF4	1380173D-316F-4821-8B98-654AD1050A38	TCGA-CN-5367-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5367	TCGA-HNSC	352	s15762	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c600	58cfa831e4b0c9d6adf6c600	TCGA-CG-4466-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-4466-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_4_rg.sorted	TCGA-CG-4466-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_4_rg.sorted.bam	143.3	1.9	0.14	58cfa831e4b0c9d6adf6c600	TCGA-CG-4466-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4466-01A	2F1B96B2-7031-4F7D-9490-14728D320F3E	Primary Tumor	Illumina HiSeq	ca26b1dd-13f3-4f26-9cb8-922cb4b53a59	Stomach	81	0BC4ABB4-047B-4C8D-9F79-5B9EB32969E9	623D5E6A-A5D3-4580-BEF7-04673D42A1D0	TCGA-CG-4466-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4466	TCGA-STAD	NA	s14760	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c59a	58cfa831e4b0c9d6adf6c59a	TCGA-CN-4737-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-4737-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_4_rg.sorted	TCGA-CN-4737-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_4_rg.sorted.bam	142	1.9	0.15	58cfa831e4b0c9d6adf6c59a	TCGA-CN-4737-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4737-01A	1F744ADA-6DE1-446D-B62C-76A7FC8B40AF	Primary Tumor	Illumina HiSeq	db7d0f46-b4eb-4cad-8324-08d0a5781624	Head and Neck	19	BA5D40F5-56A2-438B-92B8-6EB7DB6D6AFA	43003723-9C58-4B5E-8F47-56B4BDA476A0	TCGA-CN-4737-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4737	TCGA-HNSC	NA	s15754	Harvard Medical School	University of Pittsburgh	None	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5f5	58cfa831e4b0c9d6adf6c5f5	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted.bam	322.7	1.9	0.16	58cfa831e4b0c9d6adf6c5f5	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5355-01A	45A10908-19E6-421A-8903-1440BFA57C9D	Primary Tumor	Illumina HiSeq	083daa5f-0e79-4402-94b2-48a892a5a4f1	Head and Neck	64	63535469-D402-4BA2-9AB5-986E6ED80F55	180BC055-9C10-4B84-80C4-3DF00742719D	TCGA-CN-5355-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5355	TCGA-HNSC	NA	s15501	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c5d4	58cfa831e4b0c9d6adf6c5d4	TCGA-CN-5367-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CN-5367-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_6_rg.sorted	TCGA-CN-5367-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_6_rg.sorted.bam	28.4	1.9	0.15	58cfa831e4b0c9d6adf6c5d4	TCGA-CN-5367-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5367-10A	61D0709C-D148-413B-A7B5-C0C82ED2F32F	Blood Derived Normal	Illumina HiSeq	b73d2b70-fbf3-440b-bf21-7a3ea5ebcdbd	Head and Neck	60	DA2FE372-D082-40B6-81AF-F895050AF58D	BA3EF724-B5F4-4DDF-BFD9-8928FB36BE7F	TCGA-CN-5367-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5367	TCGA-HNSC	352	s15887	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c640	58cfa831e4b0c9d6adf6c640	TCGA-CG-4466-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4466-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_1_rg.sorted	TCGA-CG-4466-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_1_rg.sorted.bam	143.3	1.9	0.14	58cfa831e4b0c9d6adf6c640	TCGA-CG-4466-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4466-01A	2F1B96B2-7031-4F7D-9490-14728D320F3E	Primary Tumor	Illumina HiSeq	a8cb52d3-64c6-4fca-a59c-b177968a7489	Stomach	81	0BC4ABB4-047B-4C8D-9F79-5B9EB32969E9	623D5E6A-A5D3-4580-BEF7-04673D42A1D0	TCGA-CG-4466-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4466	TCGA-STAD	NA	s14987	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	TRUE
13722.58cfa831e4b0c9d6adf6c634	58cfa831e4b0c9d6adf6c634	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted.bam	225.7	1.9	0.15	58cfa831e4b0c9d6adf6c634	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5361-01A	044579EF-16A6-4F00-B951-EDC423D8A14F	Primary Tumor	Illumina HiSeq	490cddf8-816a-45f5-acbf-3fd898eb3479	Head and Neck	80	C807171A-4433-4246-A454-C5CF768DA8AA	A4E6D494-865F-4F60-B9C6-13C9C0CEA6AB	TCGA-CN-5361-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5361	TCGA-HNSC	NA	s16184	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2a	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c619	58cfa831e4b0c9d6adf6c619	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted.bam	301.7	1.9	0.15	58cfa831e4b0c9d6adf6c619	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5356-01A	E1FED7AA-2BCE-45AE-B0C6-7F50EF97E425	Primary Tumor	Illumina HiSeq	c8e59618-fd16-4e8e-abe2-e3d5d674390c	Head and Neck	56	BCB5DA85-78D6-4519-9740-378587B1BD37	199B42E1-301A-49AD-A364-BBF4FAD8B049	TCGA-CN-5356-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5356	TCGA-HNSC	NA	s15885	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c63e	58cfa831e4b0c9d6adf6c63e	TCGA-CN-4733-10A-01D-1868_120530_SN1222_0110_AC0VLAACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CN-4733-10A-01D-1868_120530_SN1222_0110_AC0VLAACXX_s_6_rg.sorted	TCGA-CN-4733-10A-01D-1868_120530_SN1222_0110_AC0VLAACXX_s_6_rg.sorted.bam	195	1.9	0.16	58cfa831e4b0c9d6adf6c63e	TCGA-CN-4733-10A-01D-1868_120530_SN1222_0110_AC0VLAACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4733-10A	DEDD71B4-8537-4947-839E-90ACEDDD0893	Blood Derived Normal	Illumina HiSeq	42c2db46-32f6-476f-8c0a-eef25c7b64db	Head and Neck	61	7554FBBB-837F-4F9E-B7FE-B05AA1D76831	C4E4D614-B608-435A-B715-F2115D20AB3A	TCGA-CN-4733-10A-01D-1868-02	HG19_Broad_variant	TCGA-CN-4733	TCGA-HNSC	NA	s15757	Harvard Medical School	University of Pittsburgh	None	NO	T1	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1868-02	TRUE
13722.58cfa831e4b0c9d6adf6c64e	58cfa831e4b0c9d6adf6c64e	TCGA-CN-4741-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CN-4741-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_6_rg.sorted	TCGA-CN-4741-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_6_rg.sorted.bam	215.7	1.9	0.14	58cfa831e4b0c9d6adf6c64e	TCGA-CN-4741-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4741-01A	277B02E9-DED5-4980-845D-AF53690000AC	Primary Tumor	Illumina HiSeq	cd19ee2f-be9d-446a-9045-e7bfcafb49aa	Head and Neck	75	03C9108A-5139-4BAC-9641-C7DBBEDEF420	FAA30C0B-E008-4313-A2AB-1D641F98E2B9	TCGA-CN-4741-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4741	TCGA-HNSC	NA	s15760	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c642	58cfa831e4b0c9d6adf6c642	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted.bam	72.7	1.9	0.15	58cfa831e4b0c9d6adf6c642	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4734-01A	B80FDC9A-341D-4277-9664-8E8F770D9DDD	Primary Tumor	Illumina HiSeq	4b3be461-622d-492e-8465-1d0d1167701c	Head and Neck	70	20614787-1E55-40F0-88DE-080640EB8A03	EA9125C8-3F3B-47CE-AD79-802692B1FB4A	TCGA-CN-4734-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4734	TCGA-HNSC	NA	s15759	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c688	58cfa831e4b0c9d6adf6c688	TCGA-CU-A0YO-01A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CU-A0YO-01A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_5_rg.sorted	TCGA-CU-A0YO-01A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_5_rg.sorted.bam	30.08	1.91	0.16	58cfa831e4b0c9d6adf6c688	TCGA-CU-A0YO-01A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A0YO-01A	4A9EF220-922C-49CF-BBED-D173B214ED31	Primary Tumor	Illumina HiSeq	98d555c2-93ae-4db5-9b19-43655d10609d	Bladder	84	9E190462-39FC-41B2-B1D6-2DA150412FCF	A407711E-26FF-4C0C-9391-326A51614BB7	TCGA-CU-A0YO-01A-11D-A10R-02	HG19_Broad_variant	TCGA-CU-A0YO	TCGA-BLCA	149	s3097	Harvard Medical School	UNC	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c693	58cfa831e4b0c9d6adf6c693	TCGA-CU-A0YR-10A-01D-A10R_120926_SN590_0182_BD1EAGACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CU-A0YR-10A-01D-A10R_120926_SN590_0182_BD1EAGACXX_s_8_rg.sorted	TCGA-CU-A0YR-10A-01D-A10R_120926_SN590_0182_BD1EAGACXX_s_8_rg.sorted.bam	27.06	2.08	0.17	58cfa831e4b0c9d6adf6c693	TCGA-CU-A0YR-10A-01D-A10R_120926_SN590_0182_BD1EAGACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A0YR-10A	811B3950-36E7-485F-BC48-ACA1EEE2DDEF	Blood Derived Normal	Illumina HiSeq	d19696d2-2d27-4f0f-acfa-a934b3336215	Bladder	83	0810DD0F-204F-415E-B849-79C0AA43A030	34E801D2-2A81-4F1A-A0E3-799A7CD4EEB5	TCGA-CU-A0YR-10A-01D-A10R-02	HG19_Broad_variant	TCGA-CU-A0YR	TCGA-BLCA	NA	s2879	Harvard Medical School	UNC	United States	NO	T2	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c65f	58cfa831e4b0c9d6adf6c65f	TCGA-CQ-5325-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CQ-5325-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_5_rg.sorted	TCGA-CQ-5325-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_5_rg.sorted.bam	35.7	1.9	0.14	58cfa831e4b0c9d6adf6c65f	TCGA-CQ-5325-10A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5325-10A	408C5D54-7888-4955-8386-BF8819B48A6C	Blood Derived Normal	Illumina HiSeq	3fe557f8-8ca8-4e87-b083-a50b0c942824	Head and Neck	65	4F23D06D-E97A-44A6-A485-635E64FDFAB0	FDF04252-7092-4C2A-937F-A7ED2E15CED7	TCGA-CQ-5325-10A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5325	TCGA-HNSC	654	s16329	Harvard Medical School	University Health Network, Toronto	Canada	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c684	58cfa831e4b0c9d6adf6c684	TCGA-CN-4738-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4738-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_7_rg.sorted	TCGA-CN-4738-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_7_rg.sorted.bam	122.7	1.9	0.15	58cfa831e4b0c9d6adf6c684	TCGA-CN-4738-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4738-01A	97640EF0-0259-4244-95BA-48D28C60B372	Primary Tumor	Illumina HiSeq	142fc981-c09b-4d94-96d3-b0d48b4d59f2	Head and Neck	53	8277E744-0508-47D5-9CEA-11DCF7F56D35	0EABE3ED-367B-4055-8700-0036E6A0FB1D	TCGA-CN-4738-01A-02D-1509-02	HG19_Broad_variant	TCGA-CN-4738	TCGA-HNSC	436	s16176	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	TRUE
13722.58cfa831e4b0c9d6adf6c708	58cfa831e4b0c9d6adf6c708	TCGA-CU-A0YN-11A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CU-A0YN-11A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_4_rg.sorted	TCGA-CU-A0YN-11A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_4_rg.sorted.bam	8.8	2.09	0.14	58cfa831e4b0c9d6adf6c708	TCGA-CU-A0YN-11A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A0YN-11A	679A6869-2CE9-4472-8DB1-8869E2C1A440	Solid Tissue Normal	Illumina HiSeq	4f24b2d4-a63d-40e7-82c7-bc6e188fbb4a	Bladder	60	CAAC9355-9BAC-41D8-B7A7-8EEB775179FA	25F4133F-37D6-46DA-9405-03D506557044	TCGA-CU-A0YN-11A-11D-A10R-02	HG19_Broad_variant	TCGA-CU-A0YN	TCGA-BLCA	393	s3277	Harvard Medical School	UNC	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c6aa	58cfa831e4b0c9d6adf6c6aa	TCGA-CV-5966-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CV-5966-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_6_rg.sorted	TCGA-CV-5966-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_6_rg.sorted.bam	31	1.9	0.14	58cfa831e4b0c9d6adf6c6aa	TCGA-CV-5966-11A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5966-11A	0D0731E2-8D82-4B6D-9258-2896A770A868	Solid Tissue Normal	Illumina HiSeq	41d152b5-0e3b-4db4-a2b0-0f2a5276d6e8	Head and Neck	63	53D3B388-6F20-40E1-BA4B-B969F3E52E09	32059756-2F60-4B75-BDBC-72BE2CEE7259	TCGA-CV-5966-11A-01D-1681-02	HG19_Broad_variant	TCGA-CV-5966	TCGA-HNSC	545	s16045	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c756	58cfa831e4b0c9d6adf6c756	TCGA-D3-A1QB-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D3-A1QB-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_4_rg.sorted	TCGA-D3-A1QB-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_4_rg.sorted.bam	21.07	NA	0.16	58cfa831e4b0c9d6adf6c756	TCGA-D3-A1QB-10A-01D-A18Z_120626_SN590_0164_BC0VMVACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A1QB-10A	C59A5615-2DD1-4902-A62B-0E312EAB5484	Blood Derived Normal	Illumina HiSeq	3d27f6db-c1af-4fa8-87c5-3784e31cc9ca	Skin	75	EAE60575-D043-4D1A-9A51-FC785D9F75C4	863B524B-4438-4133-98C0-C03BACC092A2	TCGA-D3-A1QB-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A1QB	TCGA-SKCM	NA	s7497	Harvard Medical School	MD Anderson	United States	NO	T0	N2c	Not available	Stage III	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c7b5	58cfa831e4b0c9d6adf6c7b5	TCGA-CV-5973-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CV-5973-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_5_rg.sorted	TCGA-CV-5973-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_5_rg.sorted.bam	17	1.8	0.14	58cfa831e4b0c9d6adf6c7b5	TCGA-CV-5973-11A-01D-1681_120427_SN1120_0137_BD0T3FACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5973-11A	8FC1F1BE-D2D5-4B3A-9973-F4D964018BEB	Solid Tissue Normal	Illumina HiSeq	195bab19-b8a4-467b-b019-332843975246	Head and Neck	62	8ED1F8FB-095A-4E76-88A3-15CEE4B5B4BB	FE312A26-D94E-4AE0-962A-2372E061EECC	TCGA-CV-5973-11A-01D-1681-02	HG19_Broad_variant	TCGA-CV-5973	TCGA-HNSC	NA	s15898	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c7c0	58cfa831e4b0c9d6adf6c7c0	TCGA-CN-5369-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-5369-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_7_rg.sorted	TCGA-CN-5369-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_7_rg.sorted.bam	64.4	1.9	0.16	58cfa831e4b0c9d6adf6c7c0	TCGA-CN-5369-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5369-10A	B98867D7-7D5A-4C58-8878-37BEE6F2F4FA	Blood Derived Normal	Illumina HiSeq	054b3120-d8ab-44a6-93c2-a8a5ae1f7855	Head and Neck	90	8D31F35C-9178-447D-9A2B-ACC305FAB407	A8FA8446-39EF-4B2C-B42B-A6FFD39139E1	TCGA-CN-5369-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5369	TCGA-HNSC	380	s15502	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c801	58cfa831e4b0c9d6adf6c801	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted.bam	96	1.9	0.14	58cfa831e4b0c9d6adf6c801	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6018-01A	55838E1F-07E8-49CA-89D6-46216BABC6F7	Primary Tumor	Illumina HiSeq	ce9ca233-92c4-44b8-b97f-b56f1f73cb5a	Head and Neck	85	1A3E8C8B-9E99-499A-9BA7-4CDFC11B106D	7F0998E4-AF05-42C5-962C-5EA4D8993EB0	TCGA-CN-6018-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6018	TCGA-HNSC	NA	s15498	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c82a	58cfa831e4b0c9d6adf6c82a	TCGA-D3-A1Q8-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D3-A1Q8-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_2_rg.sorted	TCGA-D3-A1Q8-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_2_rg.sorted.bam	16.71	NA	0.17	58cfa831e4b0c9d6adf6c82a	TCGA-D3-A1Q8-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A1Q8-10A	7B7A49B5-5BE8-4966-8F3A-E6E01E694F86	Blood Derived Normal	Illumina HiSeq	9944e3cf-cf47-4a95-bb4f-b82804de4674	Skin	33	FBB400A5-4F92-4C9E-B44C-89110811E667	B69AFD53-07D1-49E8-9049-06D83D6458FF	TCGA-D3-A1Q8-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A1Q8	TCGA-SKCM	854	s7830	Harvard Medical School	MD Anderson	United States	NO	T0	N3	Not available	Stage IV	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c855	58cfa831e4b0c9d6adf6c855	TCGA-D7-5577-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D7-5577-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_4_rg.sorted	TCGA-D7-5577-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_4_rg.sorted.bam	72.7	1.9	0.17	58cfa831e4b0c9d6adf6c855	TCGA-D7-5577-10A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-5577-10A	2DC154AA-C478-404B-A92E-86ABCC8DBDB7	Blood Derived Normal	Illumina HiSeq	9f188367-53c1-43c9-a6bb-c59e0546fb91	Stomach	53	52FE54DA-9C54-49F6-89D3-7039B86A7D7D	EB4BEB73-DFEC-4A76-A41C-3266B9DBB17C	TCGA-D7-5577-10A-01D-1598-02	HG19_Broad_variant	TCGA-D7-5577	TCGA-STAD	NA	s14709	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N3	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c83e	58cfa831e4b0c9d6adf6c83e	TCGA-D3-A1Q9-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D3-A1Q9-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_4_rg.sorted	TCGA-D3-A1Q9-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_4_rg.sorted.bam	16.46	NA	0.16	58cfa831e4b0c9d6adf6c83e	TCGA-D3-A1Q9-10A-01D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A1Q9-10A	798074D3-0B84-4DD5-AA88-91FEDA9AC8C6	Blood Derived Normal	Illumina HiSeq	9bdfcf04-e0e9-42e7-b757-5b5e6020d85a	Skin	72	8AAB08F4-76AD-4862-B09D-BAF412BBBB6A	9F418C93-5A97-41D5-B69F-EB581C967390	TCGA-D3-A1Q9-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A1Q9	TCGA-SKCM	961	s7494	Harvard Medical School	MD Anderson	United States	NO	T4b	N2a	Not available	Stage IIIB	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c84d	58cfa831e4b0c9d6adf6c84d	TCGA-D3-A2JP-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D3-A2JP-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_3_rg.sorted	TCGA-D3-A2JP-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_3_rg.sorted.bam	52.77	NA	0.16	58cfa831e4b0c9d6adf6c84d	TCGA-D3-A2JP-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A2JP-06A	E9A42A85-9513-41B2-A71D-6D62F70B00E4	Metastatic	Illumina HiSeq	ed56a64c-9f71-4163-bdda-c3d36448943e	Skin	37	922EA7D7-2F0F-47B3-BC8C-6A55203EBECB	D3A9DE23-92A7-401A-B49B-5CA3B97F8F9D	TCGA-D3-A2JP-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D3-A2JP	TCGA-SKCM	NA	s7670	Harvard Medical School	MD Anderson	United States	NO	T0	N3	Not available	Stage IIIC	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c85c	58cfa831e4b0c9d6adf6c85c	TCGA-D3-A1Q8-06A-11D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D3-A1Q8-06A-11D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_1_rg.sorted	TCGA-D3-A1Q8-06A-11D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_1_rg.sorted.bam	45.79	NA	0.17	58cfa831e4b0c9d6adf6c85c	TCGA-D3-A1Q8-06A-11D-A18Z_120626_SN590_0163_AC0VU5ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A1Q8-06A	7B7A49B5-5BE8-4966-8F3A-E6E01E694F86	Metastatic	Illumina HiSeq	0f0ce208-c694-4ce1-9864-0eef3d792bb5	Skin	33	5AA5BBF1-9369-42CE-AB77-4FB0CDC57F39	CE0BE99D-0C07-4338-96A6-799D8F5A6C38	TCGA-D3-A1Q8-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-D3-A1Q8	TCGA-SKCM	854	s7829	Harvard Medical School	MD Anderson	United States	NO	T0	N3	Not available	Stage IV	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c900	58cfa831e4b0c9d6adf6c900	TCGA-DU-6399-01A-12D-1703_130813_SN1440_0160_AD2B87ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DU-6399-01A-12D-1703_130813_SN1440_0160_AD2B87ACXX_s_3_rg.sorted	TCGA-DU-6399-01A-12D-1703_130813_SN1440_0160_AD2B87ACXX_s_3_rg.sorted.bam	39.3	1.9	0.17	58cfa831e4b0c9d6adf6c900	TCGA-DU-6399-01A-12D-1703_130813_SN1440_0160_AD2B87ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6399-01A	4EF429BE-C345-4258-9B42-B56E215E1A2C	Primary Tumor	Illumina HiSeq	bcd63f96-cd75-4e38-826d-5304bd0d18db	Brain	54	41555F97-0269-4F3D-AB13-6B0AE08D1FF5	329097BC-E434-4EA7-B0AC-EFF202C58C6F	TCGA-DU-6399-01A-12D-1703-02	HG19_Broad_variant	TCGA-DU-6399	TCGA-LGG	2000	s8754	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6c8f8	58cfa831e4b0c9d6adf6c8f8	TCGA-CN-5373-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-5373-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_8_rg.sorted	TCGA-CN-5373-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_8_rg.sorted.bam	50.4	1.9	0.15	58cfa831e4b0c9d6adf6c8f8	TCGA-CN-5373-10A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5373-10A	546F01D5-AED5-4FB8-91C0-0FD5E0FDE935	Blood Derived Normal	Illumina HiSeq	166276f6-82c3-4536-bce5-6e520be8554c	Head and Neck	55	629A4D66-6FD4-4619-B949-362860B276CB	08C37803-59E9-44B8-BC72-C4D512312537	TCGA-CN-5373-10A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5373	TCGA-HNSC	NA	s15765	Harvard Medical School	University of Pittsburgh	None	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1431-02	TRUE
13722.58cfa831e4b0c9d6adf6c8fc	58cfa831e4b0c9d6adf6c8fc	TCGA-CN-6018-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-6018-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_7_rg.sorted	TCGA-CN-6018-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_7_rg.sorted.bam	523.7	1.9	0.16	58cfa831e4b0c9d6adf6c8fc	TCGA-CN-6018-10A-01D-1681_120425_SN1222_0099_AC0JCEACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6018-10A	55838E1F-07E8-49CA-89D6-46216BABC6F7	Blood Derived Normal	Illumina HiSeq	c73af9fc-fb38-4307-955a-8e275bdab29f	Head and Neck	85	DD41FBB4-0AB7-469D-BF71-44017FEB05E1	CEB9ED62-B029-4AFD-8D10-EA5EA35F24F5	TCGA-CN-6018-10A-01D-1681-02	HG19_Broad_variant	TCGA-CN-6018	TCGA-HNSC	NA	s15625	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	TRUE
13722.58cfa831e4b0c9d6adf6c914	58cfa831e4b0c9d6adf6c914	TCGA-DK-A1AA-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A1AA-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_3_rg.sorted	TCGA-DK-A1AA-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_3_rg.sorted.bam	72.54	1.95	0.16	58cfa831e4b0c9d6adf6c914	TCGA-DK-A1AA-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AA-01A	56D8A1B8-1268-4362-A7F1-77B76FBF1B59	Primary Tumor	Illumina HiSeq	006c1498-f327-4fff-8936-7d7cb06639f4	Bladder	57	577700D1-C366-41EF-8A0D-E50DEEFB5E3C	6482BD80-A3F1-4169-A9F2-B45A9445035C	TCGA-DK-A1AA-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AA	TCGA-BLCA	NA	s3107	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c94c	58cfa831e4b0c9d6adf6c94c	TCGA-DU-6392-10A-01D-1703_130813_SN1440_0160_AD2B87ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DU-6392-10A-01D-1703_130813_SN1440_0160_AD2B87ACXX_s_2_rg.sorted	TCGA-DU-6392-10A-01D-1703_130813_SN1440_0160_AD2B87ACXX_s_2_rg.sorted.bam	65.7	1.9	0.15	58cfa831e4b0c9d6adf6c94c	TCGA-DU-6392-10A-01D-1703_130813_SN1440_0160_AD2B87ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6392-10A	FCD9E1C4-BDDB-4856-844C-03DF48FBA499	Blood Derived Normal	Illumina HiSeq	743888e9-97f5-42de-bb8b-acf4ade0af5e	Brain	35	24654746-1EA4-4FDB-83B8-5096F86C5509	C0870844-1918-4DCF-BE7C-010C6BEFF20C	TCGA-DU-6392-10A-01D-1703-02	HG19_Broad_variant	TCGA-DU-6392	TCGA-LGG	NA	s8134	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6ca0d	58cfa831e4b0c9d6adf6ca0d	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted.bam	55.51	1.93	0.17	58cfa831e4b0c9d6adf6ca0d	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AD-01A	88A521CE-A5E9-4C6F-83D4-EC36A62FEDB6	Primary Tumor	Illumina HiSeq	26694fc3-c6e4-45f9-82f0-57b6f4955b4b	Bladder	69	C79F4327-675D-4651-994D-E683096DF9C3	86DF29FD-B5F6-4316-BC89-DC9386D177C6	TCGA-DK-A1AD-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AD	TCGA-BLCA	NA	s2711	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c94f	58cfa831e4b0c9d6adf6c94f	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted.bam	331	1.88	0.15	58cfa831e4b0c9d6adf6c94f	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-5578-01A	A3C1F9A2-9174-48CF-81DC-2AFCFDC4BA9C	Primary Tumor	Illumina HiSeq	306aee2b-5fac-4825-952b-d838746530a5	Stomach	80	E88D8673-C0BE-4549-8DAF-100187608F17	A00E8607-F965-421B-B0ED-57C09488F514	TCGA-D7-5578-01A-01D-1598-02	HG19_Broad_variant	TCGA-D7-5578	TCGA-STAD	NA	s15401	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1598-02	TRUE
13722.58cfa831e4b0c9d6adf6c985	58cfa831e4b0c9d6adf6c985	TCGA-DJ-A13W-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A13W-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_1_rg.sorted	TCGA-DJ-A13W-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_1_rg.sorted.bam	50.62	1.95	0.15	58cfa831e4b0c9d6adf6c985	TCGA-DJ-A13W-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13W-01A	3B48CC5E-3396-4DD5-893D-54B75B98B016	Primary Tumor	Illumina HiSeq	ab5fa454-36a6-4d10-bfda-443dd6709cd8	Thyroid	45	4DCA97A5-B0E5-4383-8CC5-B6FF07741647	8A15A4FE-F286-422D-9D50-33ABBD885250	TCGA-DJ-A13W-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13W	TCGA-THCA	NA	s11992	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c976	58cfa831e4b0c9d6adf6c976	TCGA-DK-A1A6-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A1A6-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_7_rg.sorted	TCGA-DK-A1A6-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_7_rg.sorted.bam	85.12	1.95	0.15	58cfa831e4b0c9d6adf6c976	TCGA-DK-A1A6-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A6-01A	9C274536-3CA1-4F0E-93A8-1688074D862F	Primary Tumor	Illumina HiSeq	66e30a9a-052c-40b8-ac7c-a241a6b87d6e	Bladder	53	7AD1CD01-0EA2-4FA4-9B05-C280BD256546	CACE3242-E727-4E1F-9427-B952E10C9B12	TCGA-DK-A1A6-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A6	TCGA-BLCA	NA	s2892	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6c9af	58cfa831e4b0c9d6adf6c9af	TCGA-DJ-A13W-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DJ-A13W-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_2_rg.sorted	TCGA-DJ-A13W-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_2_rg.sorted.bam	38.59	1.95	0.14	58cfa831e4b0c9d6adf6c9af	TCGA-DJ-A13W-10A-01D-A10R_120617_SN1222_0116_AC0WMMACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13W-10A	3B48CC5E-3396-4DD5-893D-54B75B98B016	Blood Derived Normal	Illumina HiSeq	8ac86520-440a-4302-b185-5f222e1f75ef	Thyroid	45	C6EAF3F8-DD7D-4B38-BF42-8A53AAFAB259	BCB946CF-8A80-41B4-BD03-3A3255FA1C83	TCGA-DJ-A13W-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13W	TCGA-THCA	NA	s12107	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6ca21	58cfa831e4b0c9d6adf6ca21	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted.bam	61.38	2	0.18	58cfa831e4b0c9d6adf6ca21	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QD-01A	DA201150-748E-4B74-BB35-10C995E26079	Primary Tumor	Illumina HiSeq	df7bafb3-c992-479d-be29-dae220124025	Thyroid	20	A8307181-67CE-4A79-8D23-76CEEE1D2761	781162AA-AAFA-4C44-B9AF-727917E8C9F4	TCGA-DJ-A1QD-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QD	TCGA-THCA	NA	s12367	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6ca84	58cfa831e4b0c9d6adf6ca84	TCGA-DU-5872-10A-01D-1703_130813_SN1440_0160_AD2B87ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DU-5872-10A-01D-1703_130813_SN1440_0160_AD2B87ACXX_s_1_rg.sorted	TCGA-DU-5872-10A-01D-1703_130813_SN1440_0160_AD2B87ACXX_s_1_rg.sorted.bam	168.4	1.9	0.14	58cfa831e4b0c9d6adf6ca84	TCGA-DU-5872-10A-01D-1703_130813_SN1440_0160_AD2B87ACXX_s_1_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5872-10A	48607130-C09A-491D-882F-7D2591D13182	Blood Derived Normal	Illumina HiSeq	31f28101-11ef-411d-baa5-15d1a1618d2d	Brain	43	274BE2B2-3354-4E96-B871-F2722D7DE04D	25EC883D-0C94-4A6E-8F94-E865111831B1	TCGA-DU-5872-10A-01D-1703-02	HG19_Broad_variant	TCGA-DU-5872	TCGA-LGG	NA	s8345	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6ca77	58cfa831e4b0c9d6adf6ca77	TCGA-DJ-A13U-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A13U-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_6_rg.sorted	TCGA-DJ-A13U-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_6_rg.sorted.bam	33.29	1.92	0.15	58cfa831e4b0c9d6adf6ca77	TCGA-DJ-A13U-10A-01D-A10R_120616_SN1120_0153_AC0WMJACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13U-10A	8C5AEF43-341E-4A37-84EB-FD730EB957C7	Blood Derived Normal	Illumina HiSeq	6b567a7f-04e1-4dfb-97cc-0c569f787f04	Thyroid	60	544D494E-88F5-4B2E-8170-CD4595ACD592	D40518AF-D226-45D0-8FD0-56ADB4A4AF25	TCGA-DJ-A13U-10A-01D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13U	TCGA-THCA	NA	s12106	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6ca90	58cfa831e4b0c9d6adf6ca90	TCGA-DU-5872-01A-11D-1703_130808_SN208_0488_BC294YACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DU-5872-01A-11D-1703_130808_SN208_0488_BC294YACXX_s_6_rg.sorted	TCGA-DU-5872-01A-11D-1703_130808_SN208_0488_BC294YACXX_s_6_rg.sorted.bam	31.7	1.8	0.17	58cfa831e4b0c9d6adf6ca90	TCGA-DU-5872-01A-11D-1703_130808_SN208_0488_BC294YACXX_s_6_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5872-01A	48607130-C09A-491D-882F-7D2591D13182	Primary Tumor	Illumina HiSeq	ed7bb33a-0d4e-4215-b4c5-2dc1250d882b	Brain	43	048550EE-189D-483D-B07F-B77F10278420	CF245938-DD0C-42FE-9A39-09F29FF12F23	TCGA-DU-5872-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5872	TCGA-LGG	NA	s8350	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6ca7f	58cfa831e4b0c9d6adf6ca7f	TCGA-DK-A1A5-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A1A5-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_1_rg.sorted	TCGA-DK-A1A5-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_1_rg.sorted.bam	59.04	1.91	0.16	58cfa831e4b0c9d6adf6ca7f	TCGA-DK-A1A5-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A5-01A	904A8757-E0C5-41EF-B583-C8F170CAAAC1	Primary Tumor	Illumina HiSeq	3aa26bad-446a-4391-a584-27b78fc638e8	Bladder	79	A9EF3EC5-B1C1-481F-89CF-1729FAB50173	C4A751AF-E8CC-452A-9B5B-99D4B0AC585D	TCGA-DK-A1A5-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A5	TCGA-BLCA	65	s2889	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6ca8c	58cfa831e4b0c9d6adf6ca8c	TCGA-DJ-A1QF-10A-01D-A14U_120629_SN1120_0167_AC0WMBACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A1QF-10A-01D-A14U_120629_SN1120_0167_AC0WMBACXX_s_6_rg.sorted	TCGA-DJ-A1QF-10A-01D-A14U_120629_SN1120_0167_AC0WMBACXX_s_6_rg.sorted.bam	45.48	1.84	0.17	58cfa831e4b0c9d6adf6ca8c	TCGA-DJ-A1QF-10A-01D-A14U_120629_SN1120_0167_AC0WMBACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QF-10A	FCA0C7D9-5E6F-4AA7-BA04-5DF2EB8BA398	Blood Derived Normal	Illumina HiSeq	f9c3adcc-b52e-4ce1-bede-54362599ed2f	Thyroid	61	11ECEDEE-9701-4923-B899-EC553D73B7B0	165ED3A5-FE7D-473C-9877-AC901C36D97E	TCGA-DJ-A1QF-10A-01D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QF	TCGA-THCA	NA	s12371	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6cab8	58cfa831e4b0c9d6adf6cab8	TCGA-DA-A1HY-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DA-A1HY-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_1_rg.sorted	TCGA-DA-A1HY-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_1_rg.sorted.bam	38.32	NA	0.17	58cfa831e4b0c9d6adf6cab8	TCGA-DA-A1HY-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1HY-06A	40E17BF8-6C19-4E5E-B60D-AD54F504A970	Metastatic	Illumina HiSeq	8aae7183-1c94-4dda-a586-c65451a782cb	Skin	42	12590302-AB64-4652-88DD-CBBF5091E1C1	538AFAF8-22F1-4E4D-A83D-5DE08B257EDC	TCGA-DA-A1HY-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-DA-A1HY	TCGA-SKCM	NA	s7674	Harvard Medical School	Yale	United States	NO	T2b	N1	Not available	Stage III	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6caba	58cfa831e4b0c9d6adf6caba	TCGA-DA-A1HW-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DA-A1HW-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_7_rg.sorted	TCGA-DA-A1HW-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_7_rg.sorted.bam	44.61	NA	0.16	58cfa831e4b0c9d6adf6caba	TCGA-DA-A1HW-06A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1HW-06A	800D3A17-269F-4D97-94FF-8585F20038D8	Metastatic	Illumina HiSeq	fc79df1a-6c0c-45d1-96da-6463d1b33fe9	Skin	37	0CB9BC8F-475B-4FED-9CC0-D1B29E9F178B	BA059B4A-D1BF-4DBD-87DD-B0F7DD234917	TCGA-DA-A1HW-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-DA-A1HW	TCGA-SKCM	NA	s7504	Harvard Medical School	Yale	United States	NO	T1a	N1b	Not available	Stage IIIB	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6cacc	58cfa831e4b0c9d6adf6cacc	TCGA-DA-A1I2-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DA-A1I2-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_2_rg.sorted	TCGA-DA-A1I2-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_2_rg.sorted.bam	37.33	NA	0.16	58cfa831e4b0c9d6adf6cacc	TCGA-DA-A1I2-10A-01D-A18Z_120520_SN590_0158_AC0J99ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1I2-10A	01AD975D-C2ED-4E4D-BD3B-C9512FC9073C	Blood Derived Normal	Illumina HiSeq	e0b5bd2d-5be5-428e-8560-0623991eaa7c	Skin	45	346BA3E2-73E0-4ACC-961E-13D258A286DA	E498CB49-0DF9-4FB6-A426-4B09202C16D6	TCGA-DA-A1I2-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-DA-A1I2	TCGA-SKCM	NA	s8001	Harvard Medical School	Yale	United States	NO	T4b	N2b	Not available	Stage III	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6caf2	58cfa831e4b0c9d6adf6caf2	TCGA-E1-5305-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-E1-5305-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_1_rg.sorted	TCGA-E1-5305-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_1_rg.sorted.bam	19	1.9	0.16	58cfa831e4b0c9d6adf6caf2	TCGA-E1-5305-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-E1-5305-10A	A0BC5147-D9B4-41FD-8DF3-A241D23722E8	Blood Derived Normal	Illumina HiSeq	69689ca9-e4c2-440e-9e41-961f4b548891	Brain	34	CA30BB7E-5171-4C32-9D2E-BBB8DBA00832	18C43302-644E-4786-8BB6-0FE155B00DC2	TCGA-E1-5305-10A-01D-1891-02	HG19_Broad_variant	TCGA-E1-5305	TCGA-LGG	2433	s8569	Harvard Medical School	Duke	United States	NO	Not available	Not available	Astrocytoma	Not available	1891-02	TRUE
13722.58cfa831e4b0c9d6adf6cad4	58cfa831e4b0c9d6adf6cad4	TCGA-DA-A1I2-06A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DA-A1I2-06A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_1_rg.sorted	TCGA-DA-A1I2-06A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_1_rg.sorted.bam	65.65	NA	0.18	58cfa831e4b0c9d6adf6cad4	TCGA-DA-A1I2-06A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1I2-06A	01AD975D-C2ED-4E4D-BD3B-C9512FC9073C	Metastatic	Illumina HiSeq	01864b7d-181e-4599-9dd4-31fca5173ddd	Skin	45	1E373C9C-DDB0-4C77-87AF-468EE586F998	FFBDE34F-A8F9-458A-9022-EC29D8EC6277	TCGA-DA-A1I2-06A-21D-A18Z-02	HG19_Broad_variant	TCGA-DA-A1I2	TCGA-SKCM	NA	s7328	Harvard Medical School	Yale	United States	NO	T4b	N2b	Not available	Stage III	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6cb5c	58cfa831e4b0c9d6adf6cb5c	TCGA-EE-A2MD-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EE-A2MD-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_4_rg.sorted	TCGA-EE-A2MD-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_4_rg.sorted.bam	46.36	NA	0.16	58cfa831e4b0c9d6adf6cb5c	TCGA-EE-A2MD-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MD-06A	D28B2D64-2399-4CE1-9C9A-7538DABAB862	Metastatic	Illumina HiSeq	d129b319-ccf2-4715-9abd-3890ff13945f	Skin	52	FE5CCE9F-6DBD-4532-8926-BBF6BD850E71	5A62986F-DA0F-41F6-A848-4AD44A3E7885	TCGA-EE-A2MD-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2MD	TCGA-SKCM	1438	s7517	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage II	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb76	58cfa831e4b0c9d6adf6cb76	TCGA-EE-A2MC-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EE-A2MC-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_6_rg.sorted	TCGA-EE-A2MC-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_6_rg.sorted.bam	53.6	NA	0.18	58cfa831e4b0c9d6adf6cb76	TCGA-EE-A2MC-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MC-10A	3791BD88-C61E-46C3-AAA4-942C2169887C	Blood Derived Normal	Illumina HiSeq	a6801df2-863b-49c3-8b02-52bbb3536e41	Skin	73	7243ECA7-7101-4963-821E-0F2676CD42E9	CDD2EA14-07C6-40F9-846A-B28DAF3762E3	TCGA-EE-A2MC-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2MC	TCGA-SKCM	1871	s7342	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb66	58cfa831e4b0c9d6adf6cb66	TCGA-EE-A2GS-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EE-A2GS-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_6_rg.sorted	TCGA-EE-A2GS-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_6_rg.sorted.bam	19.44	NA	0.15	58cfa831e4b0c9d6adf6cb66	TCGA-EE-A2GS-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GS-10A	880BB701-F1D3-4BF2-BFC8-143AD8D07B6A	Blood Derived Normal	Illumina HiSeq	49f9daa4-da67-4d32-9183-82c94e8344b4	Skin	28	DA45B6F7-4C97-4614-BE20-3BD10F785476	C21B6ECB-F70F-4E2E-964B-CBA7E8EBAEE9	TCGA-EE-A2GS-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2GS	TCGA-SKCM	NA	s7350	Harvard Medical School	University of Sydney	Australia	NO	T2a	N0	Not available	Stage IB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb8c	58cfa831e4b0c9d6adf6cb8c	TCGA-EE-A2M6-06A-12D-A18Y_120724_SN208_0417_AC117BACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EE-A2M6-06A-12D-A18Y_120724_SN208_0417_AC117BACXX_s_5_rg.sorted	TCGA-EE-A2M6-06A-12D-A18Y_120724_SN208_0417_AC117BACXX_s_5_rg.sorted.bam	43.63	NA	0.16	58cfa831e4b0c9d6adf6cb8c	TCGA-EE-A2M6-06A-12D-A18Y_120724_SN208_0417_AC117BACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2M6-06A	58F0AE89-E277-4DFF-BB73-777CDF602DC7	Metastatic	Illumina HiSeq	73c366ca-675a-4a91-b0e1-63b111e2cfd6	Skin	61	7381FB99-0C06-416B-A503-F2570172B894	F5E09CF4-DC1D-49AF-AD66-DCC9BE52FB34	TCGA-EE-A2M6-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2M6	TCGA-SKCM	NA	s7851	Harvard Medical School	University of Sydney	Australia	NO	T1	N0	Not available	Stage I	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cb80	58cfa831e4b0c9d6adf6cb80	TCGA-EE-A2ME-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EE-A2ME-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_7_rg.sorted	TCGA-EE-A2ME-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_7_rg.sorted.bam	18.96	NA	0.16	58cfa831e4b0c9d6adf6cb80	TCGA-EE-A2ME-10A-01D-A190_120724_SN1222_0139_BD13UNACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2ME-10A	D70E0D27-7F27-4807-A36E-9FB7B00F0A70	Blood Derived Normal	Illumina HiSeq	18ac5a1c-5e50-4962-ab78-94e561021d0c	Skin	51	C51882CD-DAC8-4FB1-973A-1287195E7CBF	F92F171E-3442-4EF7-B30A-B4A11C86AA47	TCGA-EE-A2ME-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2ME	TCGA-SKCM	3141	s8012	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cb88	58cfa831e4b0c9d6adf6cb88	TCGA-EE-A2M5-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EE-A2M5-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_4_rg.sorted	TCGA-EE-A2M5-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_4_rg.sorted.bam	52.28	NA	0.18	58cfa831e4b0c9d6adf6cb88	TCGA-EE-A2M5-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2M5-10A	B5E37B9B-6264-4CC8-9B44-1D8AC0692D6C	Blood Derived Normal	Illumina HiSeq	711839e5-5f9c-40f0-9927-79435679cb77	Skin	49	0F5E478D-C3FA-44B6-8A17-BA0991516D60	CE036245-08C0-4D4E-B64A-810A1B7ACF40	TCGA-EE-A2M5-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2M5	TCGA-SKCM	659	s7340	Harvard Medical School	University of Sydney	Australia	NO	T2	N0	Not available	Stage I	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6c9f1	58cfa831e4b0c9d6adf6c9f1	TCGA-DA-A1HY-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DA-A1HY-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_2_rg.sorted	TCGA-DA-A1HY-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_2_rg.sorted.bam	27.75	NA	0.15	58cfa831e4b0c9d6adf6c9f1	TCGA-DA-A1HY-10A-01D-A18Z_120612_SN590_0162_BC0VNGACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-DA-A1HY-10A	40E17BF8-6C19-4E5E-B60D-AD54F504A970	Blood Derived Normal	Illumina HiSeq	cd19c1ed-65ae-412e-8d09-572a87a53517	Skin	42	06A02194-D705-401A-B6E4-FA2DF9958CF1	60ADADDE-D83B-4427-9AE8-AEA0544B4B34	TCGA-DA-A1HY-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-DA-A1HY	TCGA-SKCM	NA	s7507	Harvard Medical School	Yale	United States	NO	T2b	N1	Not available	Stage III	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6c916	58cfa831e4b0c9d6adf6c916	TCGA-D3-A1Q7-10A-01D-A18Z_120516_SN1222_0107_BD12HYACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D3-A1Q7-10A-01D-A18Z_120516_SN1222_0107_BD12HYACXX_s_3_rg.sorted	TCGA-D3-A1Q7-10A-01D-A18Z_120516_SN1222_0107_BD12HYACXX_s_3_rg.sorted.bam	16.63	NA	0.17	58cfa831e4b0c9d6adf6c916	TCGA-D3-A1Q7-10A-01D-A18Z_120516_SN1222_0107_BD12HYACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A1Q7-10A	DF6303CD-FFB5-422F-9865-B09029A6D54F	Blood Derived Normal	Illumina HiSeq	e3e0036b-8e9b-4e50-87ac-5b77b6295bd6	Skin	42	D1621C19-7370-49B7-B5B8-A97A98874857	B4F4D3D6-D548-40B8-A155-44D9E4A3E655	TCGA-D3-A1Q7-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A1Q7	TCGA-SKCM	NA	s7496	Harvard Medical School	MD Anderson	United States	NO	T1b	N0	Not available	Stage IB	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6cb95	58cfa831e4b0c9d6adf6cb95	TCGA-EE-A2GT-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EE-A2GT-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_5_rg.sorted	TCGA-EE-A2GT-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_5_rg.sorted.bam	20.12	NA	0.17	58cfa831e4b0c9d6adf6cb95	TCGA-EE-A2GT-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2GT-10A	97D9DFC9-C937-48B4-B453-DF081950419F	Blood Derived Normal	Illumina HiSeq	4798cb67-a102-4a3f-b036-caa4d5ff6bb1	Skin	77	0A095191-727B-45FF-9E30-E6CC490326A4	90DBCC2C-71AB-4ABF-8A1D-7587305E9435	TCGA-EE-A2GT-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2GT	TCGA-SKCM	NA	s7509	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage IIA	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cbfe	58cfa831e4b0c9d6adf6cbfe	TCGA-DU-6405-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DU-6405-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_6_rg.sorted	TCGA-DU-6405-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_6_rg.sorted.bam	241.3	1.9	0.14	58cfa831e4b0c9d6adf6cbfe	TCGA-DU-6405-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6405-01A	9239A22E-80B1-49A2-B0D5-CBAB7E415254	Primary Tumor	Illumina HiSeq	2d1d4000-347f-44e4-8ff3-b61fea3daeb3	Brain	51	54BFF4F3-312D-4E1A-8327-F08F5A270EAC	9593D4DE-0DAB-4D1E-B86C-AF91CAC938E6	TCGA-DU-6405-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-6405	TCGA-LGG	605	s8359	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6cc03	58cfa831e4b0c9d6adf6cc03	TCGA-DU-7010-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DU-7010-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_3_rg.sorted	TCGA-DU-7010-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_3_rg.sorted.bam	193	NA	0.16	58cfa831e4b0c9d6adf6cc03	TCGA-DU-7010-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7010-01A	834E560A-A506-456D-BAF2-A206CA058153	Primary Tumor	Illumina HiSeq	61859b0d-b4a7-4c67-bf02-21422618f2f2	Brain	58	A6DA348E-A70C-4620-BFCB-2AFBE893284B	3EF3E4F1-9B47-4F11-9024-85242ECEE397	TCGA-DU-7010-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7010	TCGA-LGG	456	s8355	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cc13	58cfa831e4b0c9d6adf6cc13	TCGA-DU-6402-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DU-6402-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_4_rg.sorted	TCGA-DU-6402-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_4_rg.sorted.bam	234.3	1.9	0.15	58cfa831e4b0c9d6adf6cc13	TCGA-DU-6402-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6402-01A	152F028E-EE29-40E0-8E75-5CAFFFACBD45	Primary Tumor	Illumina HiSeq	d556f16a-ad20-42eb-8e92-57114d46e174	Brain	52	0E594B0A-05E4-40C8-80BA-0D4BB08E437D	A60A9995-6A02-4035-9C3E-2FEE0E6E87C5	TCGA-DU-6402-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-6402	TCGA-LGG	214	s8563	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6cc00	58cfa831e4b0c9d6adf6cc00	TCGA-EE-A29C-10A-01D-A190_120807_SN590_0173_AC0VN5ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EE-A29C-10A-01D-A190_120807_SN590_0173_AC0VN5ACXX_s_4_rg.sorted	TCGA-EE-A29C-10A-01D-A190_120807_SN590_0173_AC0VN5ACXX_s_4_rg.sorted.bam	28.26	NA	0.18	58cfa831e4b0c9d6adf6cc00	TCGA-EE-A29C-10A-01D-A190_120807_SN590_0173_AC0VN5ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A29C-10A	FC5B5D2F-0D03-45C2-B7A0-BA6EC108FE51	Blood Derived Normal	Illumina HiSeq	dc2f1c6e-824c-4c84-8733-8ec69a47d878	Skin	20	27C69419-2272-46E8-AE91-5A441A29BDB1	FA3B6B80-3EAC-4AFB-865C-DA8B0CB10C9B	TCGA-EE-A29C-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A29C	TCGA-SKCM	NA	s7681	Harvard Medical School	University of Sydney	Australia	NO	T2a	N0	Not available	Stage IB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cc24	58cfa831e4b0c9d6adf6cc24	TCGA-DU-7292-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DU-7292-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_1_rg.sorted	TCGA-DU-7292-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_1_rg.sorted.bam	28	NA	0.14	58cfa831e4b0c9d6adf6cc24	TCGA-DU-7292-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7292-01A	145F87A3-5E86-4A87-8E49-B166A2271D02	Primary Tumor	Illumina HiSeq	06fe9cf9-6572-4026-9990-7ec39cd21278	Brain	69	BD3011C5-FCF0-4B28-8D82-1175F69B118B	A3B00BDD-7250-4E6F-8F83-6CC01D672EF4	TCGA-DU-7292-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7292	TCGA-LGG	242	s8361	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cc2b	58cfa831e4b0c9d6adf6cc2b	TCGA-DU-7007-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DU-7007-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_8_rg.sorted	TCGA-DU-7007-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_8_rg.sorted.bam	81	NA	0.15	58cfa831e4b0c9d6adf6cc2b	TCGA-DU-7007-10A-01D-2022_130910_SN208_0494_AC2A1DACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7007-10A	8E2DCC00-9F7E-4DEE-B24D-43C8B30294C5	Blood Derived Normal	Illumina HiSeq	df044351-b6ec-40c5-befc-9a76d30cd84c	Brain	33	D801113A-0DB4-4C93-960F-6870AB10435F	5424DC10-3749-49F8-8972-69C24AF94AA4	TCGA-DU-7007-10A-01D-2022-02	HG19_Broad_variant	TCGA-DU-7007	TCGA-LGG	1915	s8141	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cc0b	58cfa831e4b0c9d6adf6cc0b	TCGA-DU-6403-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DU-6403-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_5_rg.sorted	TCGA-DU-6403-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_5_rg.sorted.bam	180.3	1.9	0.14	58cfa831e4b0c9d6adf6cc0b	TCGA-DU-6403-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6403-01A	8DAA29C0-F652-4130-A004-5183BBE30C63	Primary Tumor	Illumina HiSeq	d17b6f47-d1c9-4916-8722-8b6908f8552a	Brain	60	664226B3-6C8B-4E0A-A75B-955D65E62DA9	97CFB7E8-82E2-43BD-A458-376AD3CD7CFE	TCGA-DU-6403-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-6403	TCGA-LGG	354	s8135	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6cc2f	58cfa831e4b0c9d6adf6cc2f	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted.bam	111	NA	0.15	58cfa831e4b0c9d6adf6cc2f	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7008-01A	427C40F6-D1BD-49F2-B303-A975793B937E	Primary Tumor	Illumina HiSeq	3a51e8e7-621e-4d62-bb3d-cb6700af6a43	Brain	41	7A0C3571-4265-4D36-AFBC-FA234970F94B	7602BA72-B5E0-49C7-940A-6E9EFBDB5C58	TCGA-DU-7008-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7008	TCGA-LGG	NA	s8566	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa831e4b0c9d6adf6cc52	58cfa831e4b0c9d6adf6cc52	TCGA-EJ-5499-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-5499-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_2_rg.sorted	TCGA-EJ-5499-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_2_rg.sorted.bam	289.4	1.9	0.16	58cfa831e4b0c9d6adf6cc52	TCGA-EJ-5499-10A-01D-1573_130223_SN590_0214_BC1UJ3ACXX_s_2_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5499-10A	FD1AA612-DF86-4D48-892D-2ACEBD76EA96	Blood Derived Normal	Illumina HiSeq	3635d2b0-fde1-42b9-8831-c429d8b8e864	Prostate	61	CF9C48D8-C21F-408D-8E2C-4F93DA7ADA73	FF5F777F-4C0B-4A02-8E24-2748D02154CB	TCGA-EJ-5499-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5499	TCGA-PRAD	NA	s3950	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cc78	58cfa831e4b0c9d6adf6cc78	TCGA-EM-A1CV-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EM-A1CV-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_5_rg.sorted	TCGA-EM-A1CV-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_5_rg.sorted.bam	54.35	1.98	0.16	58cfa831e4b0c9d6adf6cc78	TCGA-EM-A1CV-10A-01D-A13U_120706_SN1222_0122_AC0WPYACXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CV-10A	762EDDB5-1B47-4B79-B20A-1EDFB07C0705	Blood Derived Normal	Illumina HiSeq	c32dd2f8-7551-4307-aa32-932cfa20250a	Thyroid	32	449B0789-B12B-43EB-AB63-960CA4B24122	04EBB1B4-E7FC-4A7F-8159-0B763306E991	TCGA-EM-A1CV-10A-01D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CV	TCGA-THCA	NA	s12113	Harvard Medical School	University Health Network	Canada	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6cca7	58cfa831e4b0c9d6adf6cca7	TCGA-EE-A2MJ-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EE-A2MJ-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_3_rg.sorted	TCGA-EE-A2MJ-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_3_rg.sorted.bam	76.88	NA	0.17	58cfa831e4b0c9d6adf6cca7	TCGA-EE-A2MJ-10A-01D-A190_120729_SN1120_0179_AC11G3ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MJ-10A	8509F10A-C454-45A5-9C22-853FDA423B9F	Blood Derived Normal	Illumina HiSeq	ef89481c-65ce-4d5e-8f55-3544d9b1be29	Skin	60	A76B218B-2CE8-43D9-8E5E-9BF7561F6AF9	53494B17-8D69-4F26-B944-7FFEB5B95524	TCGA-EE-A2MJ-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2MJ	TCGA-SKCM	2927	s7518	Harvard Medical School	University of Sydney	Australia	NO	T4b	N0	Not available	Stage III	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ccce	58cfa831e4b0c9d6adf6ccce	TCGA-EE-A2M7-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EE-A2M7-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_7_rg.sorted	TCGA-EE-A2M7-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_7_rg.sorted.bam	24.33	NA	0.17	58cfa831e4b0c9d6adf6ccce	TCGA-EE-A2M7-10A-01D-A190_120724_SN208_0417_AC117BACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2M7-10A	7B4BCF0E-EC55-489B-870F-A4360A6BEA2F	Blood Derived Normal	Illumina HiSeq	42bab265-08ca-4684-a949-bfbfe42eedc1	Skin	66	9D059E5A-B61B-40B9-B66F-0733A0DE6208	C3FF18F0-682B-426E-9885-7DD12B1AA703	TCGA-EE-A2M7-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2M7	TCGA-SKCM	877	s7344	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage II	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ccde	58cfa831e4b0c9d6adf6ccde	TCGA-EM-A1CV-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EM-A1CV-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_4_rg.sorted	TCGA-EM-A1CV-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_4_rg.sorted.bam	104.75	1.89	0.17	58cfa831e4b0c9d6adf6ccde	TCGA-EM-A1CV-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CV-01A	762EDDB5-1B47-4B79-B20A-1EDFB07C0705	Primary Tumor	Illumina HiSeq	54060b82-ddf3-4449-aa9c-baaa4d66f1b7	Thyroid	32	95D077B1-E4F3-48EA-84BC-F663FD438693	DEC98438-085F-40C3-8751-D50BA12C8584	TCGA-EM-A1CV-01A-11D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CV	TCGA-THCA	NA	s12521	Harvard Medical School	University Health Network	Canada	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6ccb2	58cfa831e4b0c9d6adf6ccb2	TCGA-EE-A2MH-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EE-A2MH-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_1_rg.sorted	TCGA-EE-A2MH-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_1_rg.sorted.bam	67.86	NA	0.16	58cfa831e4b0c9d6adf6ccb2	TCGA-EE-A2MH-06A-11D-A18Y_120724_SN1222_0139_BD13UNACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MH-06A	BD2345ED-33B8-4010-8479-4D6C67E29561	Metastatic	Illumina HiSeq	559cf449-1385-4c18-ae67-8723edf24857	Skin	66	BB992A35-5C82-4B27-99B6-A39B5C6501FF	F0C1AB78-7825-4CF4-B4D7-E7A1A8A17C0F	TCGA-EE-A2MH-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-EE-A2MH	TCGA-SKCM	516	s7691	Harvard Medical School	University of Sydney	Australia	NO	T4a	N0	Not available	Stage III	A18Y-02	TRUE
13722.58cfa831e4b0c9d6adf6cd24	58cfa831e4b0c9d6adf6cd24	TCGA-EE-A2ML-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EE-A2ML-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_7_rg.sorted	TCGA-EE-A2ML-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_7_rg.sorted.bam	23.1	NA	0.16	58cfa831e4b0c9d6adf6cd24	TCGA-EE-A2ML-10A-01D-A190_120724_SN1222_0138_AC1168ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2ML-10A	01CFBFAE-F344-439D-AEAB-A9E15D636325	Blood Derived Normal	Illumina HiSeq	2eb86a50-3721-4e6d-9fac-46ce15804128	Skin	35	9F14A724-08E5-4861-8F83-DFDD5832387D	B84CE7BC-4FA4-40E5-A103-B6957623CC2C	TCGA-EE-A2ML-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2ML	TCGA-SKCM	NA	s7512	Harvard Medical School	University of Sydney	Australia	NO	T3a	N0	Not available	Stage II	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cd2d	58cfa831e4b0c9d6adf6cd2d	TCGA-ER-A19Q-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_5_rg.sorted.filtered.	WGS	TCGA-ER-A19Q-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_5_rg.sorted	TCGA-ER-A19Q-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_5_rg.sorted.bam	35.12	NA	0.15	58cfa831e4b0c9d6adf6cd2d	TCGA-ER-A19Q-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19Q-10A	391EAB51-B140-4BC2-BC8C-99400FBA9066	Blood Derived Normal	Illumina HiSeq	34899f85-566b-41ea-a927-a0707757d97f	Skin	37	9A2863AB-9C6C-4A1C-9405-D18063553DD6	97955976-6F7E-4890-A478-C205EEEA7277	TCGA-ER-A19Q-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A19Q	TCGA-SKCM	1548	s7520	Harvard Medical School	University of Pittsburgh	United States	NO	Not available	N0	Not available	Not available	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cd52	58cfa831e4b0c9d6adf6cd52	TCGA-ER-A19O-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_6_rg.sorted.filtered.	WGS	TCGA-ER-A19O-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_6_rg.sorted	TCGA-ER-A19O-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_6_rg.sorted.bam	45.99	NA	0.17	58cfa831e4b0c9d6adf6cd52	TCGA-ER-A19O-10A-01D-A190_120718_SN208_0416_BD140PACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19O-10A	69C0EF46-3117-46F3-B36E-581EB03EB829	Blood Derived Normal	Illumina HiSeq	e63520a0-e72d-453b-ac6c-6a1a491fac19	Skin	56	AD02F0ED-FBB4-49AE-9315-7D42D2C5F628	8AC49AAE-2C7C-4426-9FAA-B4652A8D51A8	TCGA-ER-A19O-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A19O	TCGA-SKCM	NA	s7695	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1b	Not available	Stage IIIB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6cdce	58cfa831e4b0c9d6adf6cdce	TCGA-FI-A2CY-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FI-A2CY-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_2_rg.sorted	TCGA-FI-A2CY-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_2_rg.sorted.bam	82.11	NA	0.16	58cfa831e4b0c9d6adf6cdce	TCGA-FI-A2CY-10A-01D-A17E_120511_SN1120_0140_AD12J0ACXX_s_2_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-FI-A2CY-10A	B9AB4AB9-BA9C-4A01-9F61-55C82B924936	Blood Derived Normal	Illumina HiSeq	77b11597-ba2d-483b-b654-69ed9c5924d2	Uterus	60	B09A76E3-73B7-4192-B3DD-E37C42C8D271	A1CABC1F-6CD8-48F6-80FC-0D153932CF6E	TCGA-FI-A2CY-10A-01D-A17E-02	HG19_Broad_variant	TCGA-FI-A2CY	TCGA-UCEC	NA	s5231	Harvard Medical School	Washington University	United States	NO	Not available	Not available	Mixed serous and endometrioid	Not available	A17E-02	TRUE
13722.58cfa831e4b0c9d6adf6cd3e	58cfa831e4b0c9d6adf6cd3e	TCGA-ER-A19D-06A-11D-A18Y_120723_SN1120_0177_AC11GTACXX_s_3_rg.sorted.filtered.	WGS	TCGA-ER-A19D-06A-11D-A18Y_120723_SN1120_0177_AC11GTACXX_s_3_rg.sorted	TCGA-ER-A19D-06A-11D-A18Y_120723_SN1120_0177_AC11GTACXX_s_3_rg.sorted.bam	60.84	NA	0.16	58cfa831e4b0c9d6adf6cd3e	TCGA-ER-A19D-06A-11D-A18Y_120723_SN1120_0177_AC11GTACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19D-06A	3409F118-1798-48D6-9556-12A5C77EBEFB	Metastatic	Illumina HiSeq	051dd55e-0c45-4fb7-a1c0-4da4438e9078	Skin	46	ECCBE1D5-33F3-443B-8C12-57276C552238	6778B87E-33A9-4382-9493-07215A7F4447	TCGA-ER-A19D-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A19D	TCGA-SKCM	383	s8019	Harvard Medical School	University of Pittsburgh	United States	NO	T2a	N0	Not available	Stage IB	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6ce3c	58cfa832e4b0c9d6adf6ce3c	TCGA-ER-A19T-06A-11D-A18Z_120520_SN590_0158_AC0J99ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ER-A19T-06A-11D-A18Z_120520_SN590_0158_AC0J99ACXX_s_7_rg.sorted	TCGA-ER-A19T-06A-11D-A18Z_120520_SN590_0158_AC0J99ACXX_s_7_rg.sorted.bam	21.29	NA	0.16	58cfa832e4b0c9d6adf6ce3c	TCGA-ER-A19T-06A-11D-A18Z_120520_SN590_0158_AC0J99ACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19T-06A	B85B14D7-3B5A-4800-AF12-622EC03B9FE5	Metastatic	Illumina HiSeq	0a570c18-b47d-4029-b8d7-68764071be02	Skin	51	D3EBC18D-E94B-4991-ABB0-5324B67CD8CE	E3E60482-506A-4226-A44D-DD0062514CD1	TCGA-ER-A19T-06A-11D-A18Z-02	HG19_Broad_variant	TCGA-ER-A19T	TCGA-SKCM	270	s7355	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N3	Not available	Stage IV	A18Z-02	TRUE
13722.58cfa832e4b0c9d6adf6ce38	58cfa832e4b0c9d6adf6ce38	TCGA-ER-A2NC-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_6_rg.sorted.filtered.	WGS	TCGA-ER-A2NC-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_6_rg.sorted	TCGA-ER-A2NC-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_6_rg.sorted.bam	18.45	NA	0.18	58cfa832e4b0c9d6adf6ce38	TCGA-ER-A2NC-10A-01D-A190_120718_SN208_0415_AC116EACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A2NC-10A	B9607824-A8D3-4915-AB73-962CDCFD8DC3	Blood Derived Normal	Illumina HiSeq	d8753ce7-f69f-4ba8-8838-f059baaaf786	Skin	50	C1263982-3881-4D2D-AF77-D238E78A1417	238F6B9D-5469-4510-8FAD-6C83D7652DFE	TCGA-ER-A2NC-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A2NC	TCGA-SKCM	1333	s7357	Harvard Medical School	University of Pittsburgh	United States	NO	T2a	N0	Not available	Stage IB	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6ce71	58cfa832e4b0c9d6adf6ce71	TCGA-FS-A1ZK-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FS-A1ZK-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_8_rg.sorted	TCGA-FS-A1ZK-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_8_rg.sorted.bam	50.13	NA	0.16	58cfa832e4b0c9d6adf6ce71	TCGA-FS-A1ZK-10A-01D-A190_120605_SN1222_0112_AC0WJJACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZK-10A	1404791B-86BF-4DFD-85B4-C8FF356F109C	Blood Derived Normal	Illumina HiSeq	2e15541d-4e6a-4d69-aace-9b16fdce059f	Skin	68	9F006B7F-4BE8-423E-86C6-36EF71215C9F	A5BA51BF-D226-4FB9-A0E2-D154461F4858	TCGA-FS-A1ZK-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZK	TCGA-SKCM	728	s7870	Harvard Medical School	Essen	Germany	NO	T4	N0	Not available	Stage II	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf22	58cfa832e4b0c9d6adf6cf22	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted.bam	79.4	1.9	0.13	58cfa832e4b0c9d6adf6cf22	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6364-01A	F8D8B417-5945-42A5-850A-FBC04B4F0E61	Primary Tumor	Illumina HiSeq	01dfbaf5-2c53-4f89-97c0-f845932cfde5	Prostate	72	242C8BCB-F8D3-4D3A-ABB1-0AB5D74D3BCB	6E0AAA4D-9ACC-4E63-AC7E-5B478D6406B5	TCGA-G9-6364-01A-21D-1784-02	HG19_Broad_variant	TCGA-G9-6364	TCGA-PRAD	NA	s4147	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cebb	58cfa832e4b0c9d6adf6cebb	TCGA-EM-A1YB-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EM-A1YB-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_3_rg.sorted	TCGA-EM-A1YB-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_3_rg.sorted.bam	54.54	1.7	0.18	58cfa832e4b0c9d6adf6cebb	TCGA-EM-A1YB-10A-01D-A14U_120717_SN1120_0175_AC1179ACXX_s_3_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YB-10A	B43A4F92-7A13-4558-A97E-7B3FEB2D70C9	Blood Derived Normal	Illumina HiSeq	ebadd853-06ca-4a12-b3b8-43a03254305a	Thyroid	73	D4C2816C-B09F-49A4-9FB8-0CABFA72553E	B5299B6D-EF3E-487F-8115-F46E0DBA1E4D	TCGA-EM-A1YB-10A-01D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YB	TCGA-THCA	NA	s12643	Harvard Medical School	University Health Network	Canada	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6cec4	58cfa832e4b0c9d6adf6cec4	TCGA-EM-A1YB-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EM-A1YB-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_1_rg.sorted	TCGA-EM-A1YB-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_1_rg.sorted.bam	31.49	1.93	0.17	58cfa832e4b0c9d6adf6cec4	TCGA-EM-A1YB-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YB-01A	B43A4F92-7A13-4558-A97E-7B3FEB2D70C9	Primary Tumor	Illumina HiSeq	13add68c-df0c-4f19-8032-d084a8cedcab	Thyroid	73	13C7182D-EF93-48A7-9569-EED7714CEC40	59B09269-9CB6-4AD9-874D-5237896747A1	TCGA-EM-A1YB-01A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YB	TCGA-THCA	NA	s12751	Harvard Medical School	University Health Network	Canada	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6cf35	58cfa832e4b0c9d6adf6cf35	TCGA-G9-6356-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-G9-6356-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_2_rg.sorted	TCGA-G9-6356-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_2_rg.sorted.bam	39.7	1.8	0.14	58cfa832e4b0c9d6adf6cf35	TCGA-G9-6356-10A-01D-1784_130215_SN590_0211_AC1UJWACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6356-10A	1D7FFBE7-6139-412B-8739-8082A63A2B33	Blood Derived Normal	Illumina HiSeq	c966ad1f-2ded-40de-950e-0b9ee42a5923	Prostate	60	6E069287-0274-4F2E-A996-0C27F81C9329	FA765A2B-44EA-4964-8135-3648FE153E05	TCGA-G9-6356-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6356	TCGA-PRAD	NA	s3971	Harvard Medical School	Roswell Park	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cebc	58cfa832e4b0c9d6adf6cebc	TCGA-FE-A233-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FE-A233-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_6_rg.sorted	TCGA-FE-A233-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_6_rg.sorted.bam	21.67	2	0.18	58cfa832e4b0c9d6adf6cebc	TCGA-FE-A233-10A-01D-A14U_120629_SN1222_0121_BD143UACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A233-10A	E70FEAFD-1390-4F4C-A635-DA65C1A7DAEB	Blood Derived Normal	Illumina HiSeq	42951f67-0d38-478d-8f8d-86556244b29d	Thyroid	18	B9FD4BE0-F412-494D-8837-BEB45B0A3B03	CFCCBE24-737D-4CDE-B74F-D319C3723974	TCGA-FE-A233-10A-01D-A14U-02	HG19_Broad_variant	TCGA-FE-A233	TCGA-THCA	NA	s12117	Harvard Medical School	Ohio State University	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	TRUE
13722.58cfa832e4b0c9d6adf6cf4a	58cfa832e4b0c9d6adf6cf4a	TCGA-FS-A1ZT-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FS-A1ZT-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_4_rg.sorted	TCGA-FS-A1ZT-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_4_rg.sorted.bam	57.99	NA	0.17	58cfa832e4b0c9d6adf6cf4a	TCGA-FS-A1ZT-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZT-10A	57882F61-4A32-49F1-AFD4-61C70B184D8B	Blood Derived Normal	Illumina HiSeq	174a6efc-f288-454f-97ae-e05d238bb3d9	Skin	55	138B9456-4B6D-43BA-AB95-F0E1408A5C15	09813947-8BFD-48A8-B0C9-E2FD7699BEBA	TCGA-FS-A1ZT-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZT	TCGA-SKCM	NA	s7703	Harvard Medical School	Essen	Germany	NO	T2	N1b	Not available	Stage III	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf64	58cfa832e4b0c9d6adf6cf64	TCGA-FS-A1ZW-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FS-A1ZW-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_3_rg.sorted	TCGA-FS-A1ZW-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_3_rg.sorted.bam	66.18	NA	0.16	58cfa832e4b0c9d6adf6cf64	TCGA-FS-A1ZW-10A-01D-A190_120602_SN1120_0147_BD13TBACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZW-10A	49A6F6A6-BF6F-45CF-93DC-B006B4A0637D	Blood Derived Normal	Illumina HiSeq	7453f952-2bcf-495f-a111-5064baf2d40a	Skin	65	B7772DDC-6155-409A-B672-F61861CB4268	42C7AAC2-EA71-4E4C-81CD-1BEAD1D3DA9D	TCGA-FS-A1ZW-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZW	TCGA-SKCM	NA	s7869	Harvard Medical School	Essen	Germany	NO	T2b	N1a	Not available	Stage IIIB	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf96	58cfa832e4b0c9d6adf6cf96	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted.filtered.	WGS	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted.bam	149.7	1.9	0.15	58cfa832e4b0c9d6adf6cf96	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6351-01A	F59B9C65-46E8-4CC3-AA71-8844F6C2273C	Primary Tumor	Illumina HiSeq	ddf40c8c-cec5-4f4b-853a-1541566f51b5	Prostate	51	92436584-12D6-4CF2-9AB1-CDF98E4E8260	DE6145E0-8D30-4CA1-A169-0BDC7E5BC57A	TCGA-G9-6351-01A-21D-1957-02	HG19_Broad_variant	TCGA-G9-6351	TCGA-PRAD	NA	s3618	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1957-02	TRUE
13722.58cfa832e4b0c9d6adf6cf7b	58cfa832e4b0c9d6adf6cf7b	TCGA-FS-A1ZZ-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FS-A1ZZ-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_7_rg.sorted	TCGA-FS-A1ZZ-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_7_rg.sorted.bam	45.06	NA	0.16	58cfa832e4b0c9d6adf6cf7b	TCGA-FS-A1ZZ-10A-01D-A190_120602_SN1120_0146_AC0WLVACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZZ-10A	F6FF5E77-60D8-4987-9A92-654FD4DB81F1	Blood Derived Normal	Illumina HiSeq	23022644-31a1-40a0-b7eb-97e14bec2d3f	Skin	54	16756720-FA90-435C-94CD-6D68458BF096	17A12A35-5A02-4F8D-BC01-C5FAA35A2790	TCGA-FS-A1ZZ-10A-01D-A190-02	HG19_Broad_variant	TCGA-FS-A1ZZ	TCGA-SKCM	822	s7540	Harvard Medical School	Essen	Germany	NO	T3b	N0	Not available	Stage IIB	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6cf84	58cfa832e4b0c9d6adf6cf84	TCGA-FS-A1ZM-06A-12D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FS-A1ZM-06A-12D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_3_rg.sorted	TCGA-FS-A1ZM-06A-12D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_3_rg.sorted.bam	50.9	NA	0.15	58cfa832e4b0c9d6adf6cf84	TCGA-FS-A1ZM-06A-12D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZM-06A	9937259A-9D47-483C-8773-B3C60E02A653	Metastatic	Illumina HiSeq	3f7ff4ec-1e07-4f3c-a649-4819d0db712c	Skin	74	838AB0DA-14FA-481D-8EE9-B15463EBB62D	BF915DAD-C627-4A13-84AB-4BFD5DFF76BE	TCGA-FS-A1ZM-06A-12D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZM	TCGA-SKCM	NA	s8032	Harvard Medical School	Essen	Germany	NO	T2	N2c	Not available	Stage III	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cfa6	58cfa832e4b0c9d6adf6cfa6	TCGA-FS-A1ZZ-06A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FS-A1ZZ-06A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_5_rg.sorted	TCGA-FS-A1ZZ-06A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_5_rg.sorted.bam	76.94	NA	0.18	58cfa832e4b0c9d6adf6cfa6	TCGA-FS-A1ZZ-06A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZZ-06A	F6FF5E77-60D8-4987-9A92-654FD4DB81F1	Metastatic	Illumina HiSeq	a063d15d-a203-4c9c-ba64-60b38c6876fa	Skin	54	6FCB5378-D9E3-460E-9409-4298EA610BB6	45F0846F-66B7-49B9-A950-CBCD1D5ABA94	TCGA-FS-A1ZZ-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZZ	TCGA-SKCM	822	s7538	Harvard Medical School	Essen	Germany	NO	T3b	N0	Not available	Stage IIB	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6cfb9	58cfa832e4b0c9d6adf6cfb9	TCGA-G9-6365-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-G9-6365-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_2_rg.sorted	TCGA-G9-6365-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_2_rg.sorted.bam	27.7	1.8	0.14	58cfa832e4b0c9d6adf6cfb9	TCGA-G9-6365-10A-01D-1784_130215_SN590_0212_BC1NP2ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6365-10A	6845076E-E940-4437-8618-81DB4A447544	Blood Derived Normal	Illumina HiSeq	cc8dcea7-b44b-4a7d-a9ef-f98a23c37e9a	Prostate	71	1668E387-F9EB-4301-9E72-9FDBDC521D45	CE08011F-F42E-46C6-8565-B825EB960B1D	TCGA-G9-6365-10A-01D-1784-02	HG19_Broad_variant	TCGA-G9-6365	TCGA-PRAD	NA	s3614	Harvard Medical School	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6cfbe	58cfa832e4b0c9d6adf6cfbe	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted.bam	249.4	1.9	0.14	58cfa832e4b0c9d6adf6cfbe	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6385-01A	E82A04CF-E81E-43C6-9CD9-0E29FA0F00AE	Primary Tumor	Illumina HiSeq	53da3cf6-b29e-4b1f-9d51-c1f9648b6634	Prostate	66	CFE4B1FA-B658-49D3-87AD-6DF7D75A58DF	00D3CD80-E6C2-4408-8F10-3656BD371157	TCGA-G9-6385-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6385	TCGA-PRAD	NA	s3456	Harvard Medical School	Roswell Park	United States	NO	T2c	Not available	Prostate Adenocarcinoma Acinar Type	Not available	1784-02	TRUE
13722.58cfa832e4b0c9d6adf6d03e	58cfa832e4b0c9d6adf6d03e	TCGA-FS-A1ZT-06A-11D-A18Y_120602_SN1120_0147_BD13TBACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FS-A1ZT-06A-11D-A18Y_120602_SN1120_0147_BD13TBACXX_s_2_rg.sorted	TCGA-FS-A1ZT-06A-11D-A18Y_120602_SN1120_0147_BD13TBACXX_s_2_rg.sorted.bam	56.66	NA	0.15	58cfa832e4b0c9d6adf6d03e	TCGA-FS-A1ZT-06A-11D-A18Y_120602_SN1120_0147_BD13TBACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZT-06A	57882F61-4A32-49F1-AFD4-61C70B184D8B	Metastatic	Illumina HiSeq	0a573a63-c701-4756-9f53-242b32237d44	Skin	55	2812580B-D88A-4141-BC61-92A08C292C5F	89EAE08E-6977-4C47-95DE-354EB7F787E9	TCGA-FS-A1ZT-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZT	TCGA-SKCM	NA	s7533	Harvard Medical School	Essen	Germany	NO	T2	N1b	Not available	Stage III	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d0dd	58cfa832e4b0c9d6adf6d0dd	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted.filtered.	WGS	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted.bam	107	NA	0.15	58cfa832e4b0c9d6adf6d0dd	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HW-7495-01A	49967A57-7C12-46BB-8D71-CEBBB17C9935	Primary Tumor	Illumina HiSeq	10d85d7f-6926-453a-bfef-d1b9d129d9d1	Brain	45	1CCC7965-99A5-420A-B5AB-F9853B50E3B1	07DDE76E-E126-4D66-BA85-059F076B7D04	TCGA-HW-7495-01A-11D-2022-02	HG19_Broad_variant	TCGA-HW-7495	TCGA-LGG	NA	s8577	Harvard Medical School	MSKCC	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d0da	58cfa832e4b0c9d6adf6d0da	TCGA-FS-A1ZE-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FS-A1ZE-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_1_rg.sorted	TCGA-FS-A1ZE-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_1_rg.sorted.bam	65.82	NA	0.17	58cfa832e4b0c9d6adf6d0da	TCGA-FS-A1ZE-06A-11D-A18Y_120609_SN208_0343_BC0WVWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZE-06A	2C79ADD1-8093-4E81-8F80-069AF7B7C2FA	Metastatic	Illumina HiSeq	7e15422f-a494-44e1-a671-0b2ec886c3e2	Skin	40	A6FF4B8A-BCD0-4925-9638-AA4DA7388BED	387CCD51-0985-414E-B10B-ABAA3FB068D6	TCGA-FS-A1ZE-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZE	TCGA-SKCM	NA	s7532	Harvard Medical School	Essen	Germany	NO	T4b	N0	Not available	Stage IIC	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d1b7	58cfa832e4b0c9d6adf6d1b7	TCGA-HI-7169-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HI-7169-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_4_rg.sorted	TCGA-HI-7169-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_4_rg.sorted.bam	162	NA	0.14	58cfa832e4b0c9d6adf6d1b7	TCGA-HI-7169-10A-01D-2111_130607_SN590_0232_BD26R5ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7169-10A	11FB5853-8EEB-4AD8-825D-3EAAF3FA08D6	Blood Derived Normal	Illumina HiSeq	a13e9b9b-1033-4ccd-8d15-9040610834b3	Prostate	55	BC487EB7-6A06-467B-9D26-DE09895879D8	3884E13B-ACA5-4878-84F6-7C19DF94BA80	TCGA-HI-7169-10A-01D-2111-02	HG19_Broad_variant	TCGA-HI-7169	TCGA-PRAD	NA	s3462	Harvard Medical School	Fox Chase	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d1b4	58cfa832e4b0c9d6adf6d1b4	TCGA-HT-7468-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HT-7468-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_6_rg.sorted	TCGA-HT-7468-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_6_rg.sorted.bam	141	NA	0.13	58cfa832e4b0c9d6adf6d1b4	TCGA-HT-7468-10A-01D-2022_130911_SN1222_0218_BC2A1NACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7468-10A	E6C55BA6-4C8A-4EA4-8DDE-74D01915DB02	Blood Derived Normal	Illumina HiSeq	dd94727e-cce1-407e-99ce-89064229b3e8	Brain	30	F5491D55-E07E-45FE-B0BA-85DCAC4E3BE3	47B970F3-550E-4358-9099-1F74287DC96B	TCGA-HT-7468-10A-01D-2022-02	HG19_Broad_variant	TCGA-HT-7468	TCGA-LGG	NA	s8758	Harvard Medical School	Case Western - St Joes	United States	NO	Not available	Not available	Oligodendroglioma	Not available	2022-02	TRUE
13722.58cfa832e4b0c9d6adf6d1e5	58cfa832e4b0c9d6adf6d1e5	TCGA-FG-6690-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FG-6690-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_5_rg.sorted	TCGA-FG-6690-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_5_rg.sorted.bam	113	1.9	0.14	58cfa832e4b0c9d6adf6d1e5	TCGA-FG-6690-10A-01D-1891_130919_SN590_0239_BC2N06ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6690-10A	AD202887-88B3-4E0F-A4C3-7E135D4CB258	Blood Derived Normal	Illumina HiSeq	a570edf3-b9eb-4c0f-b0d3-cb958f070979	Brain	70	8CBF4DDC-A8CF-4AA2-ABB2-E793853E28EF	FEE715CF-4D4E-49B0-A8DC-DAD81F1C0117	TCGA-FG-6690-10A-01D-1891-02	HG19_Broad_variant	TCGA-FG-6690	TCGA-LGG	NA	s8365	Harvard Medical School	Case Western	United States	NO	Not available	Not available	Oligodendroglioma	Not available	1891-02	TRUE
13722.58cfa832e4b0c9d6adf6d1da	58cfa832e4b0c9d6adf6d1da	TCGA-HI-7169-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-HI-7169-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_3_rg.sorted	TCGA-HI-7169-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_3_rg.sorted.bam	54.6	NA	0.13	58cfa832e4b0c9d6adf6d1da	TCGA-HI-7169-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7169-01A	11FB5853-8EEB-4AD8-825D-3EAAF3FA08D6	Primary Tumor	Illumina HiSeq	9537d469-d484-46ee-a6e8-6bb3461148c5	Prostate	55	AEEF0836-305C-465C-A9CA-6C1825353AE7	58543208-CB10-466F-A0FC-6C5202B8F13D	TCGA-HI-7169-01A-11D-2111-02	HG19_Broad_variant	TCGA-HI-7169	TCGA-PRAD	NA	s4155	Harvard Medical School	Fox Chase	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa832e4b0c9d6adf6d1ba	58cfa832e4b0c9d6adf6d1ba	TCGA-HR-A2OH-01A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-HR-A2OH-01A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_1_rg.sorted	TCGA-HR-A2OH-01A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_1_rg.sorted.bam	42.28	NA	0.15	58cfa832e4b0c9d6adf6d1ba	TCGA-HR-A2OH-01A-11D-A18Y_120602_SN1120_0146_AC0WLVACXX_s_1_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Skin Cutaneous Melanoma	Aligned reads	TCGA-HR-A2OH-06A	6668ACFE-1594-42C0-B839-8A592702675F	Metastatic	Illumina HiSeq	e5833102-da03-41b2-8042-99e9d2c36758	Skin	46	0E839C8C-39B3-4DFB-8798-4AAAB5F20460	CC15F1D0-36E1-44E6-8FEE-0A6DEB3FA407	TCGA-HR-A2OH-06A-11D-A18Y-02	HG19_Broad_variant	TCGA-HR-A2OH	TCGA-SKCM	2004	s7705	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T3b	N2a	Not available	Stage IIIB	A18Y-02	TRUE
13722.58cfa832e4b0c9d6adf6d1c5	58cfa832e4b0c9d6adf6d1c5	TCGA-HI-7171-01A-12D-2111_130607_SN590_0232_BD26R5ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-HI-7171-01A-12D-2111_130607_SN590_0232_BD26R5ACXX_s_7_rg.sorted	TCGA-HI-7171-01A-12D-2111_130607_SN590_0232_BD26R5ACXX_s_7_rg.sorted.bam	127.3	NA	0.14	58cfa832e4b0c9d6adf6d1c5	TCGA-HI-7171-01A-12D-2111_130607_SN590_0232_BD26R5ACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7171-01A	931FEB14-3F69-41C1-8435-5FD4FB775BDF	Primary Tumor	Illumina HiSeq	0dc8ef7a-58a8-4b25-ad57-4c31592151e2	Prostate	56	B9D6C505-4D71-4189-925F-36914241B831	5A0710CB-B515-48F7-94B1-5DCD72B30F3F	TCGA-HI-7171-01A-12D-2111-02	HG19_Broad_variant	TCGA-HI-7171	TCGA-PRAD	1329	s3814	Harvard Medical School	Fox Chase	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa82fe4b0c9d6adf6b61e	58cfa82fe4b0c9d6adf6b61e	TCGA-75-5146-10A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-75-5146-10A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_5_rg.sorted	TCGA-75-5146-10A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_5_rg.sorted.bam	300.4	1.9	0.16	58cfa82fe4b0c9d6adf6b61e	TCGA-75-5146-10A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-75-5146-10A	1D276B62-5E64-48FB-B2CE-5192B511FE37	Blood Derived Normal	Illumina HiSeq	22cccb1d-1901-4369-8c11-24895005a4df	Lung	NA	5F68BDF1-1348-483B-8595-A8DB4044BF1F	0FB64824-EACC-4E60-B834-21E990B18FC5	TCGA-75-5146-10A-01D-1623-02	HG19_Broad_variant	TCGA-75-5146	TCGA-LUAD	NA	s10798	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7ee	58cfa82fe4b0c9d6adf6b7ee	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted.filtered.	WGS	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted.bam	62.7	1.9	0.15	58cfa82fe4b0c9d6adf6b7ee	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6829-01A	1427CD18-5AD3-491A-9981-908E31AE49DB	Primary Tumor	Illumina HiSeq	be9bb40c-b149-4b91-b271-b8881bb90d6f	Lung	78	9B416640-9AEC-4B0D-AA88-B94287375950	E6E4F55E-8C3A-45E9-8F3B-9FDFE9D2965D	TCGA-91-6829-01A-21D-1853-02	HG19_Broad_variant	TCGA-91-6829	TCGA-LUAD	1258	s11361	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N0	Lung Bronchioloalveolar Carcinoma Nonmucinous	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b668	58cfa82fe4b0c9d6adf6b668	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.filtered.	WGS	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.bam	245.7	1.9	0.14	58cfa82fe4b0c9d6adf6b668	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	Not available	Lung Adenocarcinoma	Aligned reads	TCGA-55-6642-01A	474B86D9-D897-467D-85D4-51DFA26EA107	Primary Tumor	Illumina HiSeq	9b12800d-6911-4d3f-a25e-4d1b686b63aa	Lung	63	08D8F333-08F9-4268-99B7-61F7B057F542	93AF51CC-26FF-4904-84BC-2DFFB317D86A	TCGA-55-6642-01A-11D-1853-02	HG19_Broad_variant	TCGA-55-6642	TCGA-LUAD	NA	s11552	Harvard Medical School	International Genomics Consortium	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	TRUE
13722.58cfa82fe4b0c9d6adf6b7fe	58cfa82fe4b0c9d6adf6b7fe	TCGA-38-4632-11A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_8_rg.sorted.filtered.	WGS	TCGA-38-4632-11A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_8_rg.sorted	TCGA-38-4632-11A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_8_rg.sorted.bam	153.4	1.9	0.16	58cfa82fe4b0c9d6adf6b7fe	TCGA-38-4632-11A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_8_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4632-11A	875333AB-9048-462D-AAA2-693AD127E3CC	Solid Tissue Normal	Illumina HiSeq	64c992dd-605a-4f70-b4a2-240b669c9e61	Lung	42	84F43782-7249-46C3-9241-51E8933FA720	E25A6DC8-7BE3-4559-BD22-6493E08BAE91	TCGA-38-4632-11A-01D-1751-02	HG19_Broad_variant	TCGA-38-4632	TCGA-LUAD	1357	s11448	Harvard Medical School	UNC	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1751-02	TRUE
13722.58cfa830e4b0c9d6adf6c032	58cfa830e4b0c9d6adf6c032	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.bam	385.7	1.9	0.15	58cfa830e4b0c9d6adf6c032	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6852-01A	44799C67-61CD-4F3E-BDBC-423E2E0FD2E8	Primary Tumor	Illumina HiSeq	bff2f642-516a-4072-95aa-f213a4555f79	Stomach	64	F230ED0B-8D08-4546-9762-923097B4BF02	20F8131D-3F7E-47C5-AE84-A3886A387514	TCGA-BR-6852-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6852	TCGA-STAD	NA	s15387	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c348	58cfa831e4b0c9d6adf6c348	TCGA-CG-4462-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-4462-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_8_rg.sorted	TCGA-CG-4462-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_8_rg.sorted.bam	112.9	1.8	0.14	58cfa831e4b0c9d6adf6c348	TCGA-CG-4462-10A-01D-1154_130815_VM001_0004_VMR0004CXX_s_8_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4462-10A	E9EA3687-0DB3-47F3-8099-B4FC054397F1	Blood Derived Normal	Illumina HiSeq	5451c12f-c4fc-4e74-93da-2db445659914	Stomach	72	1A413F5F-C3C1-4249-A9C9-627798B6483A	F13DC305-E466-4C6E-9E69-F18A26DD2AB8	TCGA-CG-4462-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4462	TCGA-STAD	0	s14482	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6c2f5	58cfa830e4b0c9d6adf6c2f5	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.bam	91.7	1.9	0.14	58cfa830e4b0c9d6adf6c2f5	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6803-01A	2F90209B-7464-4D7E-83D1-67850C263DED	Primary Tumor	Illumina HiSeq	af361f62-8dd0-4336-9fa9-41cdc800b18e	Stomach	54	E56FE72A-760A-4A60-9013-EA611080BA3F	D2F16739-9EAA-465D-95BA-D13C3AEB9A40	TCGA-BR-6803-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6803	TCGA-STAD	NA	s15308	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IIA	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6c48a	58cfa831e4b0c9d6adf6c48a	TCGA-CG-4462-10A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CG-4462-10A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_8_rg.sorted	TCGA-CG-4462-10A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_8_rg.sorted.bam	112.9	1.8	0.14	58cfa831e4b0c9d6adf6c48a	TCGA-CG-4462-10A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_8_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4462-10A	E9EA3687-0DB3-47F3-8099-B4FC054397F1	Blood Derived Normal	Illumina HiSeq	c1ec8c57-0cf2-4bfe-b6d3-a7ed77f918c4	Stomach	72	1A413F5F-C3C1-4249-A9C9-627798B6483A	F13DC305-E466-4C6E-9E69-F18A26DD2AB8	TCGA-CG-4462-10A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4462	TCGA-STAD	0	s14703	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	TRUE
13722.58cfa830e4b0c9d6adf6bf7c	58cfa830e4b0c9d6adf6bf7c	TCGA-B5-A0K0-10A-01D-A043_120322_SN208_0278_BD0RB0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-B5-A0K0-10A-01D-A043_120322_SN208_0278_BD0RB0ACXX_s_5_rg.sorted	TCGA-B5-A0K0-10A-01D-A043_120322_SN208_0278_BD0RB0ACXX_s_5_rg.sorted.bam	43.36	1.97	0.15	58cfa830e4b0c9d6adf6bf7c	TCGA-B5-A0K0-10A-01D-A043_120322_SN208_0278_BD0RB0ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K0-10A	29C8F468-5AC1-4D6C-8376-E36E6D246926	Blood Derived Normal	Illumina HiSeq	6391c247-10cf-4199-a09a-ff94a9633944	Uterus	48	1DF69E2E-F392-465F-8E61-4671BA2FCD35	3CB411F8-9308-4CED-822B-C94FE602AB73	TCGA-B5-A0K0-10A-01D-A043-02	HG19_Broad_variant	TCGA-B5-A0K0	TCGA-UCEC	NA	s4246	Harvard Medical School	Duke	United States	NO	Not available	Not available	Endometrioid endometrial adenocarcinoma	Not available	A043-02	TRUE
13722.58cfa830e4b0c9d6adf6c1e4	58cfa830e4b0c9d6adf6c1e4	TCGA-BT-A0S7-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BT-A0S7-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_2_rg.sorted	TCGA-BT-A0S7-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_2_rg.sorted.bam	22.85	1.94	0.14	58cfa830e4b0c9d6adf6c1e4	TCGA-BT-A0S7-10A-01D-A10R_120920_SN1222_0150_AC1927ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A0S7-10A	68BC786E-07C7-4964-BC88-5E2A8633626A	Blood Derived Normal	Illumina HiSeq	2414eb9d-53e3-403c-87e5-dcb81ae001db	Bladder	75	584B35EF-DECB-4A5D-AA61-C83BCB2D15B2	3D48F5A7-07A3-4283-88A1-05C5E58B4B9B	TCGA-BT-A0S7-10A-01D-A10R-02	HG19_Broad_variant	TCGA-BT-A0S7	TCGA-BLCA	200	s2693	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c6ac	58cfa831e4b0c9d6adf6c6ac	TCGA-CQ-6223-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CQ-6223-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_7_rg.sorted	TCGA-CQ-6223-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_7_rg.sorted.bam	55	NA	0.14	58cfa831e4b0c9d6adf6c6ac	TCGA-CQ-6223-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6223-10A	D9E8C707-E61A-4813-8DC0-2472E9CCF12B	Blood Derived Normal	Illumina HiSeq	e392e96d-65fa-489f-829d-9a222f0ff650	Head and Neck	69	2AE7FBDA-7434-4105-9FED-C5F650BF10DB	4189A43B-649F-4495-B4FB-3B452E53BCFC	TCGA-CQ-6223-10A-01D-1911-02	HG19_Broad_variant	TCGA-CQ-6223	TCGA-HNSC	NA	s15630	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	TRUE
13722.58cfa830e4b0c9d6adf6c21e	58cfa830e4b0c9d6adf6c21e	TCGA-BT-A20P-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BT-A20P-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_4_rg.sorted	TCGA-BT-A20P-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_4_rg.sorted.bam	11.99	2.03	0.16	58cfa830e4b0c9d6adf6c21e	TCGA-BT-A20P-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20P-11A	F48937ED-E294-41F0-8872-7010391167A9	Solid Tissue Normal	Illumina HiSeq	84bd8301-5869-4245-a3cc-3781508f00c5	Bladder	81	2A07DBF4-D44C-4643-8A37-80E013DBE20B	327826B3-DDC6-4478-A28D-9688B58F279F	TCGA-BT-A20P-11A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20P	TCGA-BLCA	544	s2859	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	TRUE
13722.58cfa830e4b0c9d6adf6c238	58cfa830e4b0c9d6adf6c238	TCGA-BT-A20Q-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BT-A20Q-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_6_rg.sorted	TCGA-BT-A20Q-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_6_rg.sorted.bam	7	1.89	0.14	58cfa830e4b0c9d6adf6c238	TCGA-BT-A20Q-11A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20Q-11A	419DEAAC-EA45-4BDD-9FA0-B5CD8429B44F	Solid Tissue Normal	Illumina HiSeq	6669a6f9-a976-4716-a57d-7b08ef6afd14	Bladder	73	DF346965-B972-445D-9AAC-35605B908F4D	51F7BC24-EEEB-407E-BCB0-531A5092067A	TCGA-BT-A20Q-11A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20Q	TCGA-BLCA	593	s2694	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A14U-02	TRUE
13722.58cfa831e4b0c9d6adf6c6c9	58cfa831e4b0c9d6adf6c6c9	TCGA-CQ-6224-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CQ-6224-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_8_rg.sorted	TCGA-CQ-6224-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_8_rg.sorted.bam	67	NA	0.16	58cfa831e4b0c9d6adf6c6c9	TCGA-CQ-6224-10A-01D-1911_120504_SN1222_0102_BC0VHDACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6224-10A	D86FD392-FA5C-4142-A647-440E6C32D478	Blood Derived Normal	Illumina HiSeq	532aa1c3-e7a0-4117-9718-2accf1ab0fd5	Head and Neck	52	737605E7-E6DC-4A82-A244-61B6AEFE392B	DC395D99-027E-4997-B75B-6E17E066FB3E	TCGA-CQ-6224-10A-01D-1911-02	HG19_Broad_variant	TCGA-CQ-6224	TCGA-HNSC	NA	s16190	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c48e	58cfa831e4b0c9d6adf6c48e	TCGA-C4-A0F6-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C4-A0F6-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_1_rg.sorted	TCGA-C4-A0F6-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_1_rg.sorted.bam	74.36	1.93	0.16	58cfa831e4b0c9d6adf6c48e	TCGA-C4-A0F6-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Bladder Urothelial Carcinoma	Aligned reads	TCGA-C4-A0F6-01A	4FF9B4F2-6D04-4FED-8796-155902A8BF28	Primary Tumor	Illumina HiSeq	2332be3a-c2a5-446a-ae60-b8f873fe1866	Bladder	82	905D2BF1-08CB-4260-8188-00B60D881CF2	1765E178-12BD-4682-AB4A-368C4DCB5AEE	TCGA-C4-A0F6-01A-11D-A10R-02	HG19_Broad_variant	TCGA-C4-A0F6	TCGA-BLCA	NA	s3084	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	TRUE
13722.58cfa831e4b0c9d6adf6c782	58cfa831e4b0c9d6adf6c782	TCGA-CV-6959-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-6959-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_8_rg.sorted	TCGA-CV-6959-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_8_rg.sorted.bam	16	1.9	0.15	58cfa831e4b0c9d6adf6c782	TCGA-CV-6959-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6959-10A	EF3CE0E5-D2E8-4616-8B1A-A78C591CF235	Blood Derived Normal	Illumina HiSeq	4eee28c3-7d03-46c8-99b8-b3b17fce88d8	Head and Neck	48	854B6BC0-3318-4D35-A6F5-6F598E47870C	8862CE4E-8AA5-4542-8750-67B26759B7D1	TCGA-CV-6959-10A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6959	TCGA-HNSC	256	s16340	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6c95b	58cfa831e4b0c9d6adf6c95b	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted.bam	173.3	1.9	0.14	58cfa831e4b0c9d6adf6c95b	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5847-01A	92A7C445-2217-400A-BDCD-DF41502416B6	Primary Tumor	Illumina HiSeq	a76674c6-34c4-4c06-b7e4-eb602b3bc5fa	Brain	34	C68FC12C-C538-4A89-9F6E-C0800A5A6B53	F83FB674-A46C-47DE-BAD8-36605068D2E2	TCGA-DU-5847-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5847	TCGA-LGG	NA	s8136	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6c9d0	58cfa831e4b0c9d6adf6c9d0	TCGA-D7-6820-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D7-6820-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_3_rg.sorted	TCGA-D7-6820-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_3_rg.sorted.bam	160.7	1.9	0.14	58cfa831e4b0c9d6adf6c9d0	TCGA-D7-6820-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6820-01A	1142251C-28EB-48BF-9C54-7126D4557605	Primary Tumor	Illumina HiSeq	8b99bd62-c3d1-40c5-af7c-b1976df9622c	Stomach	64	490660D7-5512-4DBF-893A-B6B8C27CA407	B53083C4-6000-4B71-92CE-B2299D0EA2D3	TCGA-D7-6820-01A-11D-1880-02	HG19_Broad_variant	TCGA-D7-6820	TCGA-STAD	NA	s15331	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIB	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6ca10	58cfa831e4b0c9d6adf6ca10	TCGA-DU-5847-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DU-5847-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_4_rg.sorted	TCGA-DU-5847-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_4_rg.sorted.bam	74	1.9	0.14	58cfa831e4b0c9d6adf6ca10	TCGA-DU-5847-10A-01D-1703_130806_SN1222_0209_AD2AW0ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5847-10A	92A7C445-2217-400A-BDCD-DF41502416B6	Blood Derived Normal	Illumina HiSeq	d565f96e-c548-46a5-8dd2-341da735c3d8	Brain	34	1047FE18-DF48-4043-9D62-3B0FB0F6A1D0	00321B81-7463-4F1A-AB82-3B74FFF43F44	TCGA-DU-5847-10A-01D-1703-02	HG19_Broad_variant	TCGA-DU-5847	TCGA-LGG	NA	s8348	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Astrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6c87d	58cfa831e4b0c9d6adf6c87d	TCGA-D3-A2JD-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D3-A2JD-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_3_rg.sorted	TCGA-D3-A2JD-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_3_rg.sorted.bam	18	NA	0.18	58cfa831e4b0c9d6adf6c87d	TCGA-D3-A2JD-10A-01D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-D3-A2JD-10A	A5F95C6C-E25A-4AD8-BD5D-FCFD8A31933C	Blood Derived Normal	Illumina HiSeq	28a73c15-1674-4322-94fc-ecf6ca914d51	Skin	58	FC0F052A-C6DE-4AD4-852A-5BF7FE83ABB2	626E455C-5340-4095-8D27-D1D83615D201	TCGA-D3-A2JD-10A-01D-A18Z-02	HG19_Broad_variant	TCGA-D3-A2JD	TCGA-SKCM	361	s7321	Harvard Medical School	MD Anderson	United States	NO	T4b	N1b	Not available	Stage IIIC	A18Z-02	TRUE
13722.58cfa831e4b0c9d6adf6ca3c	58cfa831e4b0c9d6adf6ca3c	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted.bam	48	1.9	0.16	58cfa831e4b0c9d6adf6ca3c	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DH-5143-01A	DCD0856D-423A-40D7-8070-4C0988D61416	Primary Tumor	Illumina HiSeq	9e2bca97-d504-4863-b306-8f559a2cc8a1	Brain	30	570101B6-3670-4D1A-A94D-0DDC8DF42061	55952783-8C2C-4528-A544-B4C962AB634A	TCGA-DH-5143-01A-01D-1465-02	HG19_Broad_variant	TCGA-DH-5143	TCGA-LGG	NA	s8753	Harvard Medical School	University of Florida	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1465-02	TRUE
13722.58cfa831e4b0c9d6adf6c832	58cfa831e4b0c9d6adf6c832	TCGA-CV-6954-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-6954-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_7_rg.sorted	TCGA-CV-6954-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_7_rg.sorted.bam	16	1.8	0.14	58cfa831e4b0c9d6adf6c832	TCGA-CV-6954-10A-01D-1911_120505_SN1120_0138_AD11NHACXX_s_7_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	Not available	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6954-10A	402FD96C-76D3-4AC2-9F64-77BD34BE0ADB	Blood Derived Normal	Illumina HiSeq	90995f22-7f27-483b-9410-bfd068cdbc20	Head and Neck	59	EAA7EA4D-7F53-4107-B147-EA87EFA8B954	2B5419A2-9E0E-40AF-9FC7-EA3A56780E87	TCGA-CV-6954-10A-01D-1911-02	HG19_Broad_variant	TCGA-CV-6954	TCGA-HNSC	2002	s16202	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	NX	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	TRUE
13722.58cfa831e4b0c9d6adf6ca0c	58cfa831e4b0c9d6adf6ca0c	TCGA-DK-A1AE-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A1AE-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_7_rg.sorted	TCGA-DK-A1AE-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_7_rg.sorted.bam	76.27	1.91	0.17	58cfa831e4b0c9d6adf6ca0c	TCGA-DK-A1AE-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AE-01A	493A4FF2-37A5-4B79-928D-83DBFE534556	Primary Tumor	Illumina HiSeq	31314a75-c671-479c-aff0-437d0965f1fc	Bladder	84	67865453-D515-4D63-84E8-CFB2686A211D	885B8E06-182F-437B-9183-B454643A64EC	TCGA-DK-A1AE-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AE	TCGA-BLCA	NA	s2710	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6ca56	58cfa831e4b0c9d6adf6ca56	TCGA-DU-5852-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DU-5852-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_7_rg.sorted	TCGA-DU-5852-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_7_rg.sorted.bam	172.3	1.9	0.16	58cfa831e4b0c9d6adf6ca56	TCGA-DU-5852-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5852-01A	9ED5AF0E-C87F-46FF-81E7-9D3041B4034E	Primary Tumor	Illumina HiSeq	9dd03595-2a2f-4fc1-9cd1-52a490696f01	Brain	61	101AAA90-FE0A-42B7-BCC7-4F44E29883EC	E5AF958A-0014-4259-970D-5E0EA3CAE376	TCGA-DU-5852-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5852	TCGA-LGG	205	s8347	Harvard Medical School	Henry Ford Hospital	United States	NO	Not available	Not available	Oligoastrocytoma	Not available	1703-02	TRUE
13722.58cfa831e4b0c9d6adf6c9cc	58cfa831e4b0c9d6adf6c9cc	TCGA-DO-A1JZ-11A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DO-A1JZ-11A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_5_rg.sorted	TCGA-DO-A1JZ-11A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_5_rg.sorted.bam	34.85	1.87	0.18	58cfa831e4b0c9d6adf6c9cc	TCGA-DO-A1JZ-11A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DO-A1JZ-11A	169F045F-1739-4B0B-9BDC-028AACA420F8	Solid Tissue Normal	Illumina HiSeq	30bf8f15-68fe-456b-b8e4-ea373602a809	Thyroid	23	36232F2E-9DA5-42D2-90F2-3D1589133229	D913E31C-92E9-43C1-B21A-D36F62BB3446	TCGA-DO-A1JZ-11A-11D-A13U-02	HG19_Broad_variant	TCGA-DO-A1JZ	TCGA-THCA	NA	s12109	Harvard Medical School	Medical College of Georgia	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6cb90	58cfa831e4b0c9d6adf6cb90	TCGA-EJ-5508-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-5508-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_2_rg.sorted	TCGA-EJ-5508-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_2_rg.sorted.bam	1081.4	1.9	0.17	58cfa831e4b0c9d6adf6cb90	TCGA-EJ-5508-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5508-10A	BD18DD01-D894-4BDD-9CE2-E25705A52A57	Blood Derived Normal	Illumina HiSeq	0d2993b7-024f-4363-9ff1-9d3ce308eca0	Prostate	65	8E8F4F4E-5BE8-4372-8DC0-19B70A671E24	40F79B17-FF1D-4EF6-A784-2D6B3952C371	TCGA-EJ-5508-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5508	TCGA-PRAD	NA	s3434	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cbdb	58cfa831e4b0c9d6adf6cbdb	TCGA-EJ-5514-10A-01D-1573_130131_SN1120_0234_AD1PVUACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-5514-10A-01D-1573_130131_SN1120_0234_AD1PVUACXX_s_8_rg.sorted	TCGA-EJ-5514-10A-01D-1573_130131_SN1120_0234_AD1PVUACXX_s_8_rg.sorted.bam	484.4	1.9	0.16	58cfa831e4b0c9d6adf6cbdb	TCGA-EJ-5514-10A-01D-1573_130131_SN1120_0234_AD1PVUACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5514-10A	F82D53B1-3DF8-4249-A615-464C9F4E0A32	Blood Derived Normal	Illumina HiSeq	eb55f146-90ca-458a-a1ae-b7e8347c700c	Prostate	66	EC2C8B2F-9FB0-49CB-B42F-ED7F03A3AF56	6EEFB25F-0E21-401F-8D8E-3F4305D40565	TCGA-EJ-5514-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5514	TCGA-PRAD	NA	s3943	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6ca31	58cfa831e4b0c9d6adf6ca31	TCGA-DK-A2I6-10A-01D-A18D_121005_SN1120_0195_AC13RHACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A2I6-10A-01D-A18D_121005_SN1120_0195_AC13RHACXX_s_1_rg.sorted	TCGA-DK-A2I6-10A-01D-A18D_121005_SN1120_0195_AC13RHACXX_s_1_rg.sorted.bam	11.91	NA	0.15	58cfa831e4b0c9d6adf6ca31	TCGA-DK-A2I6-10A-01D-A18D_121005_SN1120_0195_AC13RHACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2I6-10A	DE810AF0-4C18-4E8F-9836-F8ABC425E3EB	Blood Derived Normal	Illumina HiSeq	4456fd98-e15f-406d-a4be-d8e3ec851888	Bladder	81	E68C90DA-B63A-4D90-9D2B-C0FFC796C9CC	6CAB2D7F-8E6A-4F30-9A04-34C29C7417D5	TCGA-DK-A2I6-10A-01D-A18D-02	HG19_Broad_variant	TCGA-DK-A2I6	TCGA-BLCA	NA	s2883	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A18D-02	TRUE
13722.58cfa831e4b0c9d6adf6ca3e	58cfa831e4b0c9d6adf6ca3e	TCGA-DK-A1AE-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DK-A1AE-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_8_rg.sorted	TCGA-DK-A1AE-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_8_rg.sorted.bam	43.92	1.98	0.16	58cfa831e4b0c9d6adf6ca3e	TCGA-DK-A1AE-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AE-10A	493A4FF2-37A5-4B79-928D-83DBFE534556	Blood Derived Normal	Illumina HiSeq	bd5c0062-f4b4-40fd-abd7-657e17170eca	Bladder	84	FDE77852-768F-4949-9CCC-4FAA7BDBC6F3	4206AC09-4332-4A08-AAED-36512D313A52	TCGA-DK-A1AE-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AE	TCGA-BLCA	NA	s3104	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	TRUE
13722.58cfa831e4b0c9d6adf6cc92	58cfa831e4b0c9d6adf6cc92	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted.bam	52.7	1.9	0.15	58cfa831e4b0c9d6adf6cc92	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5510-01A	4A3D9EFE-F24E-4135-8A70-E202651E7A81	Primary Tumor	Illumina HiSeq	95ce00b3-cfc9-4400-ab07-de043b39cccf	Prostate	48	3EAE6B68-D333-4B36-9E70-D2BED19C1DFA	495CB006-3042-4F8A-9AFA-9C10415DBB26	TCGA-EJ-5510-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5510	TCGA-PRAD	NA	s3603	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6ccba	58cfa831e4b0c9d6adf6ccba	TCGA-EJ-7785-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-7785-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_5_rg.sorted	TCGA-EJ-7785-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_5_rg.sorted.bam	282.6	NA	0.15	58cfa831e4b0c9d6adf6ccba	TCGA-EJ-7785-10A-01D-2111_130502_SN590_0229_BD2459ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7785-10A	2DEF2A53-D2E8-46F0-8B07-F32DBF1833A4	Blood Derived Normal	Illumina HiSeq	138e80f6-23a0-459a-9177-6dd8c1ce4b69	Prostate	54	8922B439-8133-4337-B4A3-1B46AE61B8D5	806ADA5A-32C9-43F2-BE24-8A563C07DB1E	TCGA-EJ-7785-10A-01D-2111-02	HG19_Broad_variant	TCGA-EJ-7785	TCGA-PRAD	NA	s4142	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	2111-02	TRUE
13722.58cfa831e4b0c9d6adf6ccda	58cfa831e4b0c9d6adf6ccda	TCGA-EJ-5504-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-5504-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_2_rg.sorted	TCGA-EJ-5504-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_2_rg.sorted.bam	178.4	1.9	0.15	58cfa831e4b0c9d6adf6ccda	TCGA-EJ-5504-10A-01D-1573_130315_SN590_0220_BD1WFMACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5504-10A	E1C3D1BD-CF8F-4FA4-AC8E-BF9E54F7AAD4	Blood Derived Normal	Illumina HiSeq	fdf14dea-7dab-403e-9c85-8b16dcf88d2c	Prostate	65	EFA8FC5E-04B7-47D0-8861-A36B500E0764	7EE9D6AF-14EE-4475-9D16-DD8252FE8410	TCGA-EJ-5504-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5504	TCGA-PRAD	NA	s4135	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6ccee	58cfa831e4b0c9d6adf6ccee	TCGA-EJ-5518-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-5518-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_8_rg.sorted	TCGA-EJ-5518-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_8_rg.sorted.bam	610.4	1.9	0.16	58cfa831e4b0c9d6adf6ccee	TCGA-EJ-5518-10A-01D-1573_130131_SN1120_0235_BD1TAFACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5518-10A	2B35C119-CDC1-49E2-8229-CA5CDE9E63D0	Blood Derived Normal	Illumina HiSeq	048d94f9-66cb-4acc-9246-166201f39dab	Prostate	66	DA203181-CD7A-44FD-85D9-9A7E7D8E9778	98CE8C9E-8F01-466B-92B5-EE4FA7E7AFF7	TCGA-EJ-5518-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5518	TCGA-PRAD	NA	s3786	Harvard Medical School	University of Pittsburgh	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa831e4b0c9d6adf6cd30	58cfa831e4b0c9d6adf6cd30	TCGA-F1-6874-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_8_rg.sorted.filtered.	WGS	TCGA-F1-6874-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_8_rg.sorted	TCGA-F1-6874-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_8_rg.sorted.bam	82	1.9	0.13	58cfa831e4b0c9d6adf6cd30	TCGA-F1-6874-10A-01D-1880_121220_SN1120_0207_BC1JALACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-F1-6874-10A	106F3344-F699-4B2C-8F62-4AC6C948DDE4	Blood Derived Normal	Illumina HiSeq	478d46a8-c228-4b0d-9d5b-c433514e64d3	Stomach	79	76368D40-D8B0-453A-82B6-F45C61C124D3	A132AFF7-EF8D-4844-B2EF-F3A4CE6BE7B0	TCGA-F1-6874-10A-01D-1880-02	HG19_Broad_variant	TCGA-F1-6874	TCGA-STAD	NA	s14425	Harvard Medical School	UNC	United States	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1880-02	TRUE
13722.58cfa831e4b0c9d6adf6ccea	58cfa831e4b0c9d6adf6ccea	TCGA-EJ-5509-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-5509-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_4_rg.sorted	TCGA-EJ-5509-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_4_rg.sorted.bam	132.4	1.9	0.15	58cfa831e4b0c9d6adf6ccea	TCGA-EJ-5509-10A-01D-1573_130308_SN590_0219_BC1UVPACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5509-10A	13CE70A8-785C-4B59-B073-41922CB201F9	Blood Derived Normal	Illumina HiSeq	47e80516-5fba-4339-88e2-fbf8f7c524af	Prostate	63	1BD3E76B-3C7D-4143-A4BB-2356B18848B2	FDF3FF32-0919-4AF4-9BA3-E5907B77F134	TCGA-EJ-5509-10A-01D-1573-02	HG19_Broad_variant	TCGA-EJ-5509	TCGA-PRAD	NA	s3781	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1573-02	TRUE
13722.58cfa832e4b0c9d6adf6ceda	58cfa832e4b0c9d6adf6ceda	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted.bam	164.7	1.9	0.14	58cfa832e4b0c9d6adf6ceda	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5505-01A	1EA3B879-5451-49FB-B930-16E9B5627F18	Primary Tumor	Illumina HiSeq	156ad547-dfb8-48c9-88b9-6842c81fead1	Prostate	57	A31147E1-4A52-4233-BC27-B0DFA6708DC6	3AB7712C-40E4-4752-AC1D-0CB9D7345413	TCGA-EJ-5505-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5505	TCGA-PRAD	NA	s3605	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa832e4b0c9d6adf6cedd	58cfa832e4b0c9d6adf6cedd	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted.bam	256.7	1.9	0.15	58cfa832e4b0c9d6adf6cedd	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5508-01A	BD18DD01-D894-4BDD-9CE2-E25705A52A57	Primary Tumor	Illumina HiSeq	69098ac9-e4d2-44cd-ae04-e179d90a749e	Prostate	65	E3969BF5-B0CC-49E3-B8CB-3D9E98F1676D	706963B3-03D9-4990-AE75-09F8781D79B7	TCGA-EJ-5508-01A-02D-1572-02	HG19_Broad_variant	TCGA-EJ-5508	TCGA-PRAD	NA	s3784	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type	Not available	1572-02	TRUE
13722.58cfa831e4b0c9d6adf6cc9a	58cfa831e4b0c9d6adf6cc9a	TCGA-EE-A2MI-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EE-A2MI-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_8_rg.sorted	TCGA-EE-A2MI-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_8_rg.sorted.bam	26.57	NA	0.15	58cfa831e4b0c9d6adf6cc9a	TCGA-EE-A2MI-10A-01D-A190_120724_SN208_0418_BD13N7ACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EE-A2MI-10A	C061AE6C-7A02-47C3-AECD-A56487C01603	Blood Derived Normal	Illumina HiSeq	270078f3-9359-471b-99e5-0c398664d8ef	Skin	43	A0DABFDB-1FCF-47E3-B822-7E4B54D9B38E	B1AE52DE-36C5-4F03-9302-B226F153B066	TCGA-EE-A2MI-10A-01D-A190-02	HG19_Broad_variant	TCGA-EE-A2MI	TCGA-SKCM	6225	s7345	Harvard Medical School	University of Sydney	Australia	NO	T4	N0	Not available	Stage IIB	A190-02	TRUE
13722.58cfa832e4b0c9d6adf6ce50	58cfa832e4b0c9d6adf6ce50	TCGA-ER-A19E-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_6_rg.sorted.filtered.	WGS	TCGA-ER-A19E-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_6_rg.sorted	TCGA-ER-A19E-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_6_rg.sorted.bam	21.01	NA	0.16	58cfa832e4b0c9d6adf6ce50	TCGA-ER-A19E-10A-01D-A190_120723_SN1120_0177_AC11GTACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19E-10A	3FEA3F02-2DB3-44E0-984E-C61130D92C9B	Blood Derived Normal	Illumina HiSeq	ddd1871b-91a1-4f2f-acd5-a69ecf18c07e	Skin	36	D88BD93A-7ACE-4247-B36E-D434583D31BC	341315CF-D88D-4153-AC84-7243D4D1BC04	TCGA-ER-A19E-10A-01D-A190-02	HG19_Broad_variant	TCGA-ER-A19E	TCGA-SKCM	396	s7358	Harvard Medical School	University of Pittsburgh	United States	NO	T2a	N0	Not available	Stage IB	A190-02	TRUE
13722.58cfa831e4b0c9d6adf6ca70	58cfa831e4b0c9d6adf6ca70	TCGA-DK-A1AB-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DK-A1AB-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_4_rg.sorted	TCGA-DK-A1AB-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_4_rg.sorted.bam	31.2	1.94	0.18	58cfa831e4b0c9d6adf6ca70	TCGA-DK-A1AB-10A-01D-A13U_121002_SN1222_0154_AC1A3DACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AB-10A	F027D254-EC01-4882-A8A7-964AE90B7D49	Blood Derived Normal	Illumina HiSeq	9eaeaeec-3d40-4c27-8e58-b9aa313a628f	Bladder	74	8A3DABE6-85A3-43E6-9223-654B16A7180B	DD644B8E-4BFF-4511-82CF-251EED30CD3E	TCGA-DK-A1AB-10A-01D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AB	TCGA-BLCA	NA	s2705	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	TRUE
